WCLC 2017 Program PDF

Onsite Program
IASLC 18TH WORLD CONFERENCEON LUNG CANCER
CONFERENCE HASHTAG:
#WCLC2017
FOLLOW US ON TWITTER @IASLC #WCLC2017
BECOME A MEMBER OF IASLC
FOLLOW US ON FACEBOOK.COM/IASLC
FOLLOW US ON INSTAGRAM IASLC.LUNG WWW.IASLC.ORG
Bristol-Myers Squibb: At the Forefront of Immuno-Oncology Research
Immuno-Oncology (I-O) research is the investigation of

innovative approaches that aim to harness the body’s
natural immune response to fight cancer.
Bristol-Myers Squibb has been committed to advancing
this fundamentally different approach to cancer research
and continues to build upon our past discoveries to
advance our current research.
© 2017 Bristol-Myers Squibb Company. All rights reserved. 17A719

IASLC 18TH WORLD CONFERENCE ON LUNG CANCER
TABLE OF CONTENTS
1 | WELCOME 2 | IASLC AND WCLC 3 | GENERAL

COMMITTEES CONFERENCE
Welcome Messages 4
INFORMATION
Conference Sponsors 6 International Association for the
Study of Lung Cancer (IASLC) 10 Registration 20
Conference Summary 7
IASLC Board of Directors 11 Press and Media 23
IASLC Foundation 11 Information for Invited Faculty
WCLC 2017 Committees 13 and Abstract Presenters 26
Regional Organizing CME Accreditation Information 28

Committee 13 Onsite Services and
International Program General Information 31
Committee 13
International Abstract
Review Committee 16
4 | EXHIBIT 5 | IASLC AND 6 | CONFERENCE

INFORMATION CONFERENCE PROGRAM
AWARDS
Exhibit Information 38 Program at a Glance 56
Exhibitor Listing 39 IASLC Distinguished Sessions at a Glance | By Day 58
Award Winners 46
Exhibit Floor Plan 40 Sessions at a Glance | By Track 64
IASLC Fellowship Award Winners 49
Exhibitor Company
Descriptions 41 IASLC Academy Award Winners 49
IASLC International
Mentorship Award Winners 50
WCLC 2017 Young Investigator
Award Winners 51
WCLC 2017 Developing Nation
Award Winners 52
IASLC/WCLC 2017 Patient
Advocacy Award Winners 53
2017 Nurse and Allied Health
Professional Award Winners 53
WCLC 2017 Lectureship
Award Winners 54
WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 1

IASLC 18TH WORLD CONFERENCE ON LUNG CANCER
TABLE OF CONTENTS
7 | DAILY SCIENTIFIC 8 | POSTER 9 | AUTHOR INDEX

PROGRAM SESSIONS
Author Index 170
Saturday, October 14, 2017 74 Poster Session 1
Monday, October 16
Sunday, October 15, 2017 77
At a Glance 124
Monday, October 16, 2017 82 In Detail 125
10 | MAPS AND
Tuesday, October 15, 2017 96
Poster Session 2 FLOOR PLANS
Wednesday, October 18, 2017 111 Tuesday, October 17
At a Glance 139 PACIFICO Yokohama
In Detail 140 Maps and Floor Plans 206
Poster Session 3
Wednesday, October 18
At a Glance 154
In Detail 155
CONFERENCE SECRETARIAT
International Conference Services Ltd. (ICS)
Suite 300, 1201 West Pender Street

Vancouver, BC, Canada V6E 2V2
Phone +1 604 681 2153

Fax +1 604 681 1049
Email wclc2017@icsevents.com
www.icsevents.com
2 IASLC 18th World Conference on Lung Cancer / Onsite Program WWW.IASLC.ORG

SECTION 1
WELCOME
Welcome Messages 4
Conference Sponsors 6
Conference Summary 7

WELCOME MESSAGES
WELCOME MESSAGE FROM YOUR IASLC WCLC 2017 CO-PRESIDENTS
Dear Colleagues,
On behalf of the International Association for the Study of Lung Cancer (IASLC) and the Regional Organizing Committee, it is a
great pleasure to welcome you to the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.
With WCLC now being an annual Conference and with delegates from more than 100 countries attending, WCLC has become the
premier international meeting to discuss the latest findings in the field of lung cancer and thoracic malignancies. In more than 150 ses-
sions the scientific program will cover a variety of groundbreaking topics that illustrate the latest scientific and clinical developments
but also provide the ideal forum to discuss and really understand how they can affect your practice day to day.
The program includes stimulating presentations from more than 350 world renowned keynote speakers as well as more than 2,000
oral, mini oral and poster abstract presentations. Please note that each day a different set of posters will be displayed in the Exhibit
Hall, so make sure to visit the Exhibit Hall each day. Posters will be on display for the entire day with presenters being asked to stand
by their poster during the morning and afternoon networking breaks.
We encourage you to participate actively in the discussions and hope the meeting helps in the exchange of information and devel-
opment of new collaborations. Take advantage of the various networking opportunities the Conference provides. Seating areas will
be placed throughout the Exhibition Hall and refreshments will be provided throughout each day in the Exhibit Hall, allowing you to
network with friends, colleagues, exhibitors and sponsors.
We also would like to extend our gratitude and thanks to all spon-
sors and exhibitors for their continued support to WCLC and
IASLC. Without them this Conference wouldn’t be possible.
WCLC 2017 PROGRAM HIGHLIGHTS We hope that, despite an intense Conference program, you also
will be able to get some glimpses of Yokohama, Japan.
More than 400 world renowned experts as speakers, Yokohama has developed as an outer part of Tokyo for the last
session chairs and abstract discussants 150 years, therefore creating unique cultures making Yokohama
a unique city among Japan’s biggest cities. Because of this,
Yokohama has also played host to many international organiza-
More than 350 oral and mini oral abstract presentations
tions and conferences. Yokohama is a city rich in history, archi-
tecture and culture!
More than 1,700 poster presentations
Thank you for joining us in Yokohama for WCLC 2017.
We can’t wait to see you.
Young Investigator and First Time Attendee Session
Yours sincerely,
Joint IASLC - Chinese Society for Clinical Oncology -
Chinese Alliance Against Lung Cancer Session
Industry Supported Symposia
Dr. Hisao Asamura, MD and Dr. Keunchil Park, MD, PhD

IASLC WCLC 2017 Co-Presidents

WELCOME MESSAGES
WELCOME MESSAGE FROM THE MAYOR OF YOKOHAMA
We feel privileged to be hosting the 18th World Conference on Lung Cancer (WCLC 2017). It is an
honor to have such a meaningful event here in Yokohama.
We feel privileged to be hosting the 18th World Conference on Lung Cancer (WCLC 2017). It is an
As the representative for the people of Yokohama, I am pleased to welcome International Association
honor to have such a meaningful event here in Yokohama.
for the Study of Lung Cancer (IASLC) President David Carbone and other distinguished guests from
various countries. I would also
As the representative forlike
the to extend
people my heartfeltI am
of Yokohama, gratitude
pleasedtotoProf. HisaoInternational
welcome Asamura and Prof.
Association
Keunchilfor
Park
the (who
Studywill serveCancer
of Lung as IASLC WCLC
(IASLC) 2017 David
President Conference Co-Presidents
Carbone ), and to allguests
and other distinguished othersfrom
whose dedicated efforts brought
various countries. I wouldso many
also likeparticipants
to extend mytoheartfelt
WCLCgratitude
2017. to Prof. Hisao Asamura and Prof.
Keunchil Park (who will serve as IASLC WCLC 2017 Conference Co-Presidents ), and to all others
With more than 3.7 million citizens, Yokohama is Japan's largest single municipality, and we strive
whose dedicated efforts brought so many participants to WCLC 2017.
every day to provide healthier lives and improved healthcare for those living in our city. Particularly
With
in the area more than 3.7
of treatments for million
cancer, citizens,
which isYokohama is Japan's
said to affect one in largest single
every two municipality,
Japanese andwe
citizens, weare
strive
pursuingevery day to provide
comprehensive healthier
measures livesonand
based theimproved
Yokohamahealthcare for thosefor
City Ordinance living in our city.
Measures Particularly
to Eliminate
Cancer. inIn the area of treatments for cancer, which is said to affect one in every two Japanese citizens, we are
addition to promoting cancer prevention and early detection and making appropriate
pursuing comprehensive measures based on the Yokohama City Ordinance for Measures to Eliminate
treatments available, we work to support cancer patients, their families, and cancer-related research
Cancer. In addition to promoting cancer prevention and early detection and making appropriate
in the field of medicine as well as a wide array of other areas such as welfare and employment.
treatments available, we work to support cancer patients, their families, and cancer-related research
In Yokohama's bayside
in the field region, as
of medicine which hasa been
well as designated
wide array asareas
of other "Lifesuch
Innovation Keihin
as welfare Coastal Area
and employment.
Comprehensive Special Zones for International Competitiveness Development" by the Japanese
In Yokohama's bayside region, which has been designated as "Life Innovation Keihin Coastal Area
government, we actively promote and support efforts in areas including development of medical
Comprehensive Special Zones for International Competitiveness Development" by the Japanese
diagnostic technologies
government, and development
we actively promote andofsupport
pharmaceutical drugsincluding
efforts in areas in response to increasingly
development of medical
personalized treatment approaches. Additionally, in the field of drug development, we are involved
diagnostic technologies and development of pharmaceutical drugs in response to increasingly
in the creation of newtreatment
personalized cancer drugs.
approaches. Additionally, in the field of drug development, we are involved
in the creation of new cancer drugs.
During the WCLC 2017 period, we will be lighting up various locations around Yokohama in lavender,
the colorDuring
used to
thepromote
WCLC 2017cancer awareness.
period, We
we will be plan to
lighting up utilize
various the opportunity
locations presented by
around Yokohama this
in lavender,
Conference
the to encourage
color all citizens
used to promote of Yokohama
cancer awareness. toWetake
plangreater notice
to utilize the of and interest
opportunity in cancer-
presented by this
Conference to encourage all citizens of Yokohama to take greater notice of and interest in cancer-
related issues.
related issues.
I hope that all who attend WCLC 2017 will enjoy their stay in our city. With gorgeous waterfront
scenery, Ia hope
good that all who
selection of attend
places WCLC 2017
to eat and willand
shop, enjoy their
other stayattractions,
such in our city.visitors
With gorgeous
can trulywaterfront
enjoy
scenery,
themselves after aConference
good selection of places to eat and shop, and other such attractions, visitors can truly enjoy
sessions.
themselves after Conference sessions.
In closing, I would like to express my sincere hope that WCLC 2017 will provide opportunities for
In closing, I would like to express my sincere hope that WCLC 2017 will provide opportunities for
its many participants to engage in fruitful discussions and lively exchanges.
its many participants to engage in fruitful discussions and lively exchanges.

CONFERENCE SPONSORS
IASLC AND THE 18TH WORLD CONFERENCE ON LUNG CANCER

GRATEFULLY ACKNOWLEDGE THE GENEROUS SUPPORT OF ITS OFFICIAL SPONSORS:
DIAMOND SPONSORS
PLATINUM SPONSORS
SILVER SPONSORS
BRONZE SPONSORS
SUPPORTERS CONTRIBUTORS
IASLC AND THE 18TH WORLD CONFERENCE ON LUNG CANCER WOULD ALSO LIKE TO
SINCERELY THANK THE FOLLOWING ORGANIZATIONS FOR PROVIDING MEDICAL EDUCATIONAL GRANTS:

CONFERENCE SUMMARY
CONFERENCE VENUE
PACIFICO YOKOHAMA
ONSITE REGISTRATION SPEAKER PREVIEW CENTER MEDIA ROOM
PACIFICO CONFERENCE CENTER, PACIFICO CONFERENCE CENTER, PACIFICO CONFERENCE CENTER,

LEVEL 2F LEVEL 3F ROOM 421, LEVEL 4F
Saturday, October 14 14:00 – 18:00 Saturday, October 14 14:00 – 18:00 Sunday, October 15 15:00 – 19:00
Sunday, October 15 07:00 – 20:00 Sunday, October 15 07:00 – 20:00 Monday, October 16 08:00 – 19:00
Monday, October 16 06:30 – 16:00 Monday, October 16 06:30 – 17:30 Tuesday, October 17 08:00 – 19:00
Tuesday, October 17 06:30 – 16:00 Tuesday, October 17 06:30 – 17:30 Wednesday, October 18 08:00 – 18:00
Wednesday, October 18 06:30 – 16:00 Wednesday, October 18 06:30 – 16:30
EXHIBIT HALL COAT AND BAGGAGE CHECK POSTER PICK UP
PACIFICO EXHIBITION HALL, PACIFICO CONFERENCE CENTER, PACIFICO EXHIBITION HALL,

HALL B + C LEVEL 1F EXHIBIT HALL (HALL B + C)
Monday, October 16 09:30 – 16:00 Saturday, October 14 07:30 – 19:30 Monday, October 16 08:00 – 16:00
Tuesday, October 17 09:30 – 16:00 Sunday, October 15 07:00 – 21:00 Tuesday, October 17 08:00 – 16:00
Wednesday, October 18 09:30 – 16:00 Monday, October 16 06:30 – 19:30 Wednesday, October 18 08:00 – 10:30
Tuesday, October 17 06:30 – 19:30
All day refreshments and light snacks will Wednesday, October 18 06:30 – 18:00
be served in the Exhibit Hall throughout
opening hours.
IASLC BUSINESS MEETING
PACIFICO ANNEX HALL, F201 + F202,

LEVEL 2F
Monday, October 16 14:30 – 15:30
Light Refreshments will be provided.

SECTION 2
IASLC AND
COMMITTEES
International Association for the
Study of Lung Cancer (IASLC) 10
IASLC Board of Directors 11
IASLC Foundation 11
WCLC 2017 Committees 13
Regional Organizing
Committee 13
International Program
Committee 13
International Abstract
Review Committee 16

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)
13100 East Colfax Avenue, Unit 10

Aurora, Colorado 80011 USA
IASLC STAFF
Phone 1-855-GO-IASLC (1-855-464-2752)
Fax Membership 720-505-2176 Fred R. Hirsch, MD, PhD Kristin Schultz
Pia Hirsch 720-325-2848 Chief Executive Officer Advocacy Specialist
fred.hirsch@ucdenver.edu kristin.schultz@iaslc.org
Pia Hirsch Karen Muth

The International Asso- Senior Director of Education, Executive Assistant to the CEO
ciation for the Study of Corporate Relations and karen.muth@iaslc.org
Lung Cancer (IASLC) is Governance
the only global organi- pia.hirsch@iaslc.org Mary Todd
Managing Editor JTO
zation dedicated to the
Kristin M. Richeimer mary.todd@iaslc.org
study of lung cancer. Director of Membership
Founded in 1974, the kristin.richeimer@iaslc.org Paul Silvey
association’s membership Education Programs Coordinator
includes nearly 7,000 Murry Wynes, PhD paul.silvey@iaslc.org
Director of Scientific Affairs
lung cancer specialists
Department Kelsey Wood
in over 100 countries. murry.wynes@iaslc.org Membership Coordinator
kelsey.wood@iaslc.org
IASLC members work to enhance the understanding John Skadow
of lung cancer among scientists, members of the Director of Finance Jenna Gentry
john.skadow@iaslc.org Project Coordinator
medical community and the public. IASLC publishes
jenna.gentry@iaslc.org
the Journal of Thoracic Oncology, a valuable resource
Colleen Miller
for medical specialists and scientists who focus on Director of Communications Debra Clements
the detection, prevention, diagnosis and treatment colleen.miller@iaslc.org Conference Coordinator
of lung cancer. debra.clements@iaslc.org
Jacinta Wiens, PhD
Scientific Affairs Project Manager Vengie Lau
jacinta.wiens@iaslc.org Asia Support
vengie.lau@iaslc.org
Becky Bunn
THE IASLC MISSION IS: Public Relations Manager
becky.bunn@iaslc.org
To embrace the study of the etiology, epidemiology,
Michelle Martinez
prevention, diagnosis, treatment and all other aspects
Data and Technical Analyst
of lung cancer and other thoracic malignancies michelle.martinez@iaslc.org
Adam Mohrbacher
To provide education and information about lung
Content Specialist
cancer and other thoracic malignancies to IASLC adam.mohrbacher@iaslc.org
members, to the medical community at large, and
to the public Carlos Ferreira
Continuing Medical Education
Compliance Specialist
To use all available means to eliminate lung cancer carlos.ferreira@iaslc.org
and other thoracic malignancies as a health threat
Michelle Gruver
for the individual patient and throughout the world
Fellowship Coordinator
michelle.gruver@iaslc.org

IASLC BOARD OF DIRECTORS 2015 – 2017
OFFICERS
President David P. Carbone, USA
President Elect Giorgio Scagliotti, Italy
Past President Tony Mok, Hong Kong
Chief Executive Officer Fred R. Hirsch, USA
Treasurer David R. Gandara, USA
BOARD OF DIRECTORS IASLC FOUNDATION BOARD
Michael Boyer, Solange Peters, Marc Braunstein, Tony Mok,

Australia Switzerland USA Hong Kong
Laurie Gaspar, Robert Pirker, David P. Carbone, Giorgio Scagliotti,
USA Austria USA Italy
David Harpole, Martin Reck, Ivar Samren,
USA Germany Lauren Fisher, USA
USA
Norihiko Ikeda, Miyako Satouchi, Kathy Weber,
Japan Japan David R. Gandara, USA
USA
Pasi A. Janne, William D. Travis,
USA USA Fred R. Hirsch,
USA
Keith Kerr, Heather Wakelee,
UK USA
Francoise Mornex, Yi-Long Wu,
France China
Yuichiro Ohe,
Japan
Support the IASLC Foundation by attending

the Joint IASLC Foundation – JLCS Concert
Monday, October 16, 2017, 19:30 – 20:30
(See next page for details.)

IASLC FOUNDATION
VIOLINIST
THE TOK YO CIT Y PHILH A R MONIC ORCHESTR A

KEN TAKASEKI, CONDUCTOR
JOINT IASLC FOUNDATION

JLCS CONCERT
VIOLIN CONCERTO IN
D MAJOR, OP. 35 (TCHAIKOVSKY)
MONDAY, OCTOBER 16, 2017

19:30 – 20:30
Minatomirai Hall, Yokohama

Across from PACIFICO Yokohama
Join us for a benefit concert in

support of the IASLC Foundation.
This performance is given in honor of
those who have been afflicted by lung
cancer and those who have dedicated
their lives to research, diagnoses, and
treatment of the disease.
Ticket Price: 50 USD

Tickets can be purchased at Registration.
Limited seats available.

WCLC 2017 COMMITTEES
REGIONAL ORGANIZING COMMITTEE
PRESIDENTS
INTERNATIONAL PROGRAM COMMITTEE
Hisao Asamura, Japan & Keunchil Park, Korea
EPIDEMIOLOGY/ RADIOLOGY/STAGING/
MEMBERS PRIMARY PREVENTION/ SCREENING
TOBACCO CONTROL
Myung-Ju Ahn, Korea Yuko Nakayama, Japan AND CESSATION CHAIR
Shuji Sakai, Japan

CHAIR
Akihiko Gemma, Japan Young Taek Oh, Korea CO-CHAIR
Tomotaka Sobue, Japan
Ramon Rami-Porta, Spain
Norihiko Ikeda, Japan Yuichiro Ohe, Japan CO-CHAIR
Nise Yamaguchi, Brazil
Sergi Call, Spain
Young Tae Kim, Korea Jeong-Seon Ryu, Korea
Carolyn Dresler, USA John Field, UK
Kaoru Kubota, Japan Ikuo Sekine, Japan Haruyuki Kawai, Japan Edward F. Patz, USA
Gabor Kovacs, Hungary Helmut Prosch, Austria

Tetsuya Mitsudomi, Japan Shun-ichi Watanabe, Japan Motoyasu Sagawa, Japan
Manfred Neuberger, Austria
Martina Pötschke-Langer, Kenji Suzuki, Japan
Kazuhiko Nakagawa, Japan Yasushi Yatabe, Japan
Germany Ignacio Wistuba, USA
Javier Zulueta, Spain
BIOLOGY/PATHOLOGY
CHAIR EARLY STAGE NSCLC
Takashi Kohno, Japan CHAIR

CO-CHAIRS
Young Tae Kim, Korea
Yasushi Yatabe, Japan
CO-CHAIR
Pan-Chyr Yang, Taiwan Ichiro Yoshino, Japan
Jin-Haeng Chung, Taiwan
Thomas D’Amico, USA
Montse Sanchez-Cespedes, Elie Fadel, France
Spain
Glenwood Goss, Canada
Sanja Dacic, USA
Jang-Ming Lee, Taiwan
Martin Filipits, USA
Eric Lim, UK
Ramaswamy Govindan, USA
Heather Wakelee, USA
Fred R. Hirsch, USA
Kazuhiro Yasufuku, Canada
Ryohei Katayama, Japan
Keith Kerr, UK
Luis Montuenga, Spain
Andrew Nicholson, UK
Iver Petersen, Germany
Helmut Popper, Austria
Benjamin Solomon, Australia
Roman Thomas, Germany
William Travis, USA

WCLC 2017 COMMITTEES
INTERNATIONAL PROGRAM COMMITTEE (CONTINUED)
LOCALLY ADVANCED NSCLC SCLC/NEUROENDOCRINE THYMIC MALIGNANCIES/ RADIOTHERAPY

TUMORS ESOPHAGEAL CANCER/OTHER
CHAIR THORACIC MALIGNANCIES CHAIR
CHAIR
Young-Taek Oh, Korea Kazushige Hayakawa, Japan
CHAIRS
Sumitra Thongprasert, Thailand
CO-CHAIR CO-CHAIR
Meinoshin Okumura, Japan
Yi-Long Wu, China CO-CHAIR
Hak Choy, USA
Akihiko Gemma, Japan Mir Ali Reza Hoda, Austria
CO-CHAIRS
Philip Bonomi, USA Yong Chan Ahn, Korea
James C. Yao, USA Jhingook Kim, Korea
Wilfried Eberhardt, Germany Jeffery Bradley, USA
Hiroaki Akamatsu, Japan Frank Detterbeck, USA
Hans Hoffmann, Germany Karin Dieckmann, Austria
Hideo Kunitoh, Japan
Francoise Mornex, France Wentao Fang, China Corinne Faivre-Finn, UK
Nirush Lertprasertsook,
Yuichiro Ohe, Japan Joseph S. Friedberg, USA Jacek Jassem, Poland
Thailand
Everett Vokes, USA Nicolas Girard, France Billy Loo, USA
Pieter E. Postmus, UK
Milada Zemanova, Keiko Shibuya, Japan Yasushi Nagata, Japan
Jens Benn Sorensen, Denmark
Czech Republic
Nico van Zandwijk, Australia Yuko Nakayama, Japan
Sabine Zöchbauer-Müller,
Austria David Waller, UK Jinming Yu, China
ADVANCED NSCLC
CHAIR MESOTHELIOMA
SURGERY CHEMOTHERAPY/
Michael Boyer, Australia TARGETED THERAPY
CHAIR
CHAIR
CO-CHAIRS CHAIR
Kwun Fong, Australia Norihiko Ikeda, Japan
Li Zhang, China Yuichiro Ohe, Japan
CO-CHAIR
CO-CHAIR
Ikuo Sekine, Japan CO-CHAIR
Seiki Hasegawa, Japan Wentao Fang, China
Myung-Jun Ahn, Korea
Lucio Crinò, Italy
Paul Baas, Netherlands Alessandro Brunelli, UK
Peter Ellis, Canada Benjamin Besse, France
Dean Fennell, UK Dominique Grunenwald, France
David R. Gandara, USA Federico Cappuzzo, Italy
Hedy Lee Kindler, USA Walter Klepetko, Austria
Glenwood Goss, Canada Byoung Chul Cho, Korea
Pyng Lee, Singapore Eric Vallieres, USA
Christian Manegold, Germany Oliver Gautschi, Switzerland
Takashi Nakano, Japan Giulia Veronesi, Italy
Mary O’Brien, UK Roy Herbst, USA
Anna Nowak, Australia Shun-ichi Watanabe, Japan
Nir Peled, Israel Pasi A. Jänne, USA
Harvey Pass, USA
Robert Pirker, Austria Julian Molina, USA
Yoshitaka Sekido, Japan
Elisabeth Quoix, France Sai-Hong Ou, USA
Jan van Meerbeeck, Belgium
Martin Schuler, Germany Robert Pirker, Austria
Walter Weder, Switzerland
Daniel Shao Weng Tan, Martin Sebastian, Germany
Singapore
Lecia Sequist, USA
Konstantinos N. Syrigos, Greece
Rolf Stahel, Switzerland
James Chih-Hsin Yang, Taiwan
Caicun Zhou, China

IMMUNOLOGY AND REGIONAL ASPECTS/ PATIENTS SUPPORT PULMONARY/ENDOSCOPY
IMMUNOTHERAPY HEALTH POLICY/ AND ADVOCACY GROUP
PUBLIC HEALTH CHAIR
CHAIR CHAIR
Jeong-Seon Ryu, Korea
CHAIRS
Tony Mok, Hong Kong Yoichi Nakanishi, Japan
CO-CHAIR
Anna Nowak, Australia
CO-CHAIR CO-CHAIR
Kazuhiro Yasufuku, Canada
Kazuhiko Nakagawa, Japan Purvish Parikh, India Christina Ng, Malaysia
CO-CHAIRS
Yoon Soo Chang, Korea
Charles Butts, Canada Christoph Zielinski, Austria Bonnie Addario, USA
Eric Edell, USA
Raffit Hassan, USA Digambar Behera, India Ingeborg Beunders, Austria
Felix Herth, Germany
Clarissa Mathias, Brazil Kazuo Hasegawa, Japan
Paul A. Bunn Jr., USA Te-Chun Hsia, USA
Martin Reck, Germany Rudolf Huber, Germany
Nagahiro Saijo, Japan Akira Inoue, Japan
Naiyer Rizvi, USA Laksmi Sita Andarini, Indonesia
Gyula Ostoros, Hungary
Christian Rolfo, Belgium Emily Stone, Australia
Anne-Pascale Meert, Belgium
David Spigel, USA Stefania Vallone, Italy
Momen Wahidi, USA
YOUNG INVESTIGATORS
CHAIR
Miyako Satouchi, Japan

PALLIATIVE CARE/ EDUCATION/PUBLICATION/
CLINICAL DESIGN
ETHICS/NURSES CO-CHAIR CAREER DEVELOPMENT
AND STATISTICS
Thanyanan Reungwetwattana,
CHAIR CHAIR
Thailand CHAIR
Kaoru Kubota, Japan Sanghoon Jheon, Korea
Daniel Shao Weng Tan, Singapore
CO-CHAIRS Yasushi Goto, Japan CO-CHAIR
CO-CHAIR
Chong-Kin Liam, Malaysia Maximilian Hochmair, Austria Masayuki Noguchi, Japan
Mary Redman, USA
In Gak Kwon, Korea Sukhmani Padda, USA
Alex Adjei, USA
Naiyarat Prasongsook, Thailand Stefan Michiels, France
Jean Klastersky, Belgium Peter Berzinec, Slovakia
Wang Shuhang, China Lothar Pilz, Germany
Jeffrey Crawford, USA Ednin Hamzah, Malaysia
Amanda Tufman, Germany
Richard Lim, Malaysia Pierre Massion, USA
Stefan Zimmermann,
Phichai Chansriwong, Thailand Switzerland Barbara Melosky, Canada
Richard Gralla, USA Mari Mino-Kenudson, USA
Enrico Ruffini, Italy
Navneet Singh, India
Erik Thunnissen, Netherlands
Yi-Long Wu, China

INTERNATIONAL ABSTRACT REVIEW COMMITTEE
Alex Adjei, USA Kwun Fong, Australia Gilberto Lopes, USA Shuji Sakai, Japan
Myung-Ju Ahn, Korea Patrick Forde, USA Philip Mack, USA Montse Sanchez-Cespedes, Spain
Yong Chan Ahn, Korea Joseph Friedberg, USA Nishio Makoto, Japan Miyako Satouchi, Japan
Hiroaki Akamatsu, Japan David R. Gandara, USA Céline Mascaux, France Martin Schuler, Germany
Sita Andarini, Indonesia Edward Garon, USA Pierre Massion, USA Martin Sebastian, Germany
Hisao Asamura, Japan Oliver Gautschi, Switzerland Clarissa Mathias, Brazil Yoshitaka Sekido, Japan
Paul Baas, Netherlands Akihiko Gemma, Japan Fiona McDonald, UK Ikuo Sekine, Japan
David Ball, Australia Scott Gettinger, USA Barbara Melosky, Canada Lecia Sequist, USA
Fabrice Barlesi, France Ignacio Gil-Bazo, Spain Stefan Michiels, France Keiko Shibuya, Japan
Mary Beth Beasley, USA Nicolas Girard, France Mari Mino-Kenudson, USA Navneet Singh, India
Digambar Behera, India Yasushi Goto, Japan Tetsuya Mitsudomi, Japan Tomotaka Sobue, Japan
Peter Berzinec, Slovak Republic Ramaswamy Govindan, USA Tony Mok, Hong Kong Ben Solomon, Australia
Benjamin Besse, France Richard Gralla, USA Julian Molina, USA Jens Benn Sørensen, Denmark
Ingeborg Beunders, Austria Dominique Grunenwald, France Luis Montuenga, Spain Virote Sriuranpong, Thailand
Stella Bialous, USA Georgia Hardavella, UK Francoise Mornex, France Rolf Stahel, Switzerland
Philip Bonomi, USA Kazuo Hasegawa, Japan Yasushi Nagata, Japan Matthew Steliga, USA
Hossein Borghaei, USA Seiki Hasegawa, Japan Yoichi Nakanishi, Japan Emily Stone, Australia
Michael Boyer, Australia Raffit Hassan, USA Takashi Nakano, Japan Kostas Syrigos, Greece
Jeffrey Bradley, USA Kazushige Hayakawa, Japan Yuko Nakayama, Japan Daniel Tan, Singapore
Alessandro Brunelli, UK Felix JF Herth, Germany Andrew Nicholson, USA Erik Thunnissen, Netherlands
Lukas Bubendorf, Switzerland Fred R. Hirsch, USA Masayuki Noguchi, Japan William Travis, USA
Charles Butts, Canada Mir Hoda, Austria Anna Nowak, Australia Amanda Tufman, Germany
Vera Capelozzi, Brazil Hans Hoffmann, Germany Mary O’Brien, UK Eric Vallieres, USA
Frederico Cappuzzo, Italy Te-Chun Hsia, USA Young-Taek Oh, Korea Stefania Vallone, Italy
David P. Carbone, USA Rudolf Huber, Germany Yuichiro Ohe, Japan Jan Van Meerbeeck, Belgium
Yoon Soo Chang, Korea Norihiko Ikeda, Japan Yoshiharu Ohno, Japan Nico Van Zandwijk, Australia
Phichai Chansriwong, Thailand Akira Inoue, Japan Meinoshin Okumura, Japan Giulia Veronesi, Italy
Sukki Cho, Korea Jacek Jassem, Poland Gyula Ostoros, Hungary Everett Vokes, USA
Hak Choy, USA Sanghoon Jheon, Korea Sai-Hong Ou, USA Momen Wahidi, USA
Jin-Haeng Chung, Korea Ryohei Katayama, Japan Sukhmani Padda, USA Heather Wakelee, USA
Jeffrey Crawford, USA Haruyuki Kawai, Japan Keunchil Park, Korea David Waller, USA
Lucio Crinò, Italy Jhingook Kim, Korea Harvey Pass, USA Shuhang Wang, China
Sanja Dacic, USA Tae Jung Kim, USA Nir Peled, Israel Shun-ichi Watanabe, Japan
Thomas D’Amico, USA Young Kim, USA Iver Petersen, Germany Ignacio Wistuba, USA
Dirk De Ruysscher, Netherlands Hedy Lee Kindler, USA Lothar Pilz, Germany Yi-Long Wu, China
Karin Dieckmann, Austria Walter Klepetko, Austria Robert Pirker, Austria Murry Wynes, USA
Robert Doebele, USA Takashi Kohno, Japan Naiyarat Prasongsook, Thailand Nise Yamaguchi, Brazil
Carolyn Dresler, USA Ritsuko Komaki, USA Helmut Prosch, Austria James Chih-Hsin Yang, Taiwan
Rafal Dziadziuszko, Poland Kaoru Kubota, Japan Elisabeth Quoix, France Pan-Chyr Yang, Taiwan
Wilfried Eberhardt, Germany Hideo Kunitoh, Japan Luis Raez, USA Kazuhiro Yasufuku, Canada
Eric Edell, USA In Gak Kwon, Korea Ramon Rami-Porta, Spain Yasushi Yatabe, Japan
Peter Ellis, Canada Primo Lara, USA Martin Reck, Germany Ichiro Yoshino, Japan
William Evans, Canada David LeDuc, USA Thanyanan Reungwetwattana, Jinming Yu, China
Thailand
Elie Fadel, France Jang-Ming Lee, Taiwan Milada Zemanová, Czech Republic
Christian Rolfo, Belgium
Corinne Faivre-Finn, UK Jin Soo Lee, Korea Li Zhang, China
Charles Rudin, USA
Wentao Fang, China Pyng Lee, Singapore Caicun Zhou, China
Enrico Ruffini, Italy
Enriqueta Felip, Spain Nirush Lertprasertsuke, Thailand Stefan Zimmermann, Switzerland
Prudence Russell, Australia
Dean Fennell, UK Chong-Kin Liam, Malaysia Sabine Zöchbauer-Müller, Austria
Jeong-Seon Ryu, Korea
John Field, UK Eric Lim, UK Javier Zulueta, Spain
Motoyasu Sagawa, Japan
Martin Filipits, Austria Richard Lim, Malaysia
Nagahiro Saijo, Japan
Pier Luigi Filosso, Italy Billy Loo, USA

SC
LC
20
17
SCLC BIOMARKER
TESTING SYMPOSIUM
18TH WORLD CONFERENCE ON LUNG CANCER
YOKOHAMA, JAPAN | OCTOBER 18, 2017
The objectives of this Symposium are to:
Discuss key unmet needs in the management of patients with SCLC
Discuss emerging therapeutics for the management of SCLC
Evaluate emerging biomarker testing in SCLC
AGENDA | MAIN HALL, LEVEL 1F

TIME TOPIC PRESENTER
12:45 – 12:50 Welcome & Introductions Dr. Koichi Goto (Chair)

12:50 – 13:15 Opportunities & Challenges in SCLC Patients Care Dr. Benjamin Besse
13:15 – 13:45 Novel Therapeutics in SCLC & the Changing Treatment Landscape Dr. Maya Gottfried
13:45 – 14:10 Incorporating Biomarker Testing & Targeted Therapies into Dr. Wilfried Eberhardt
the SCLC Treatment Paradigm
14:10 – 14:15 Closing Remarks Dr. Koichi Goto (Chair)
14:15 Adjourn
This program was approved by the IASLC 18th World Conference on Lung Cancer Program Committee as an independent activity
held in conjunction with the IASLC 18th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.
SECTION 3
GENERAL
CONFERENCE
INFORMATION
Registration 20
Press and Media 23
Information for Invited Faculty
and Abstract Presenters 26
CME Accreditation Information 28
Onsite Services and
General Information 31

REGISTRATION
REGISTRATION LOCATION AND HOURS
PACIFCO CONFERENCE CENTER,

LEVEL 2F
HOURS OF OPERATION
Saturday, October 14 14:00 – 18:00

Sunday, October 15 07:00 – 20:00
Wednesday, October 18 06:30 – 16:00
REGISTRATION MATERIALS
REGISTRATION MATERIALS INCLUDE: NAME BADGES
`` Name Badge including barcode which will provide access Delegates and guests are requested to wear their name badge
for any signed up scientific sessions and Opening Ceremony at all times in order to participate in the Scientific Sessions,
and Welcome Reception Networking Events and Exhibition.
`` Tickets for IASLC Foundation Concert and
Conference Dinner (if applicable)
DELEGATE HELP DESK
`` Ribbons (if applicable)
PACIFCO CONFERENCE CENTER,
`` Program at a Glance LEVEL 2F
(not included in Accompanying Person Registration)
SUPPORTED BY
`` Abstract USB Stick
(not included in Accompanying Person Registration)
DELEGATE BAGS INCLUDE: Sunday, October 15 09:00 – 17:00

SUPPORTED BY
`` Printed Onsite Program Wednesday, October 18 09:00 – 17:00
(only if printed version selected at time of registration)
`` Printed Abstract Book
(only if printed version selected at time of registration) TOURS AND ACCOMMODATION DESK
`` Abstract USB Stick PACIFCO CONFERENCE CENTER,

LEVEL 2F
`` Invitation Flyers for Industry Supported Symposia
`` Additional Promotional Flyers from Sponsors and Exhibitors Saturday, October 14 14:00 – 18:00
`` 2016 Scientific Advance Article Sunday, October 15 09:00 – 17:00

`` IASLC EGFR Atlas
`` IASLC Information/Folder
`` IASLC Lung Cancer News


ADVANCING CANCER
CARE THROUGH
INNOVATION
AREA OF RESEARCH: For more than 5 decades, Lilly
CANCER ANGIOGENESIS AND Oncology has been dedicated to
delivering innovative treatment
TUMOR MICROENVIRONMENT
approaches with the goal of
improving the outcomes of people
AREA OF RESEARCH: living with cancer. We are driven to
accelerate the pace and progress
CANCER CELL SIGNALING of cancer care by developing a
broad portfolio of therapies,
including those tailored to unique
AREA OF RESEARCH:
patients and those that modulate
IMMUNO-ONCOLOGY the immune system.
For more information on all our clinical trials, visit Lilly.com.
Eli Lilly and Company. © All Rights Reserved. July 2017
49373_elonmr_wclc17_ab_184x271_fa.indd 1 7/31/17 4:40 PM

The IASLC Foundation supports the education of
fellows and young investigators who will be the next
generation of lung cancer physicians and scientists.
Help others succeed
For more information visit:

www.iaslc.org/foundation
PRESS AND MEDIA
PRESS AND MEDIA REGISTRATION AND ACCESS MEDIA ROOM

Press and Media passes are issued to journalists, including photographers and
PACIFICO CONFERENCE CENTER,
freelance journalists, after providing proof of accreditation. Pre-registered Press
ROOM 421, LEVEL 4F
and Media representatives are required to check in at the regular Registration
Counters. Non-registered Press and Media representatives should proceed to the
New Registration counter. Sunday, October 15 15:00 – 19:00
INTERVIEW POLICY
All interviews outside of press conferences must be arranged in advance with Tuesday, October 17 08:00 – 19:00
interviewees and must take place in IASLC approved and designated rooms. No
last-minute or hallway interviews are permitted anywhere inside the conference
facility. The IASLC provides designated complimentary interview rooms (Room
416 and 417) for up to two hours. Sign up is required (online via wclc2017.iaslc.
org/press-media/press-media/ or onsite in the Media Room, Room 421). For Wireless internet access, power bars
questions, please see the IASLC staff in the Media Room. and a copier are available in the Media
Room to assist credentialed media
USE OF THE IASLC WCLC SCIENTIFIC PROGRAM CONTENT
representatives.
Please be aware that the information and materials displayed and/or presented
at all sessions of this meeting are the property of the IASLC World Conference on
Lung Cancer. Members of the media are permitted to photograph or record and
transmit/share any presentation’s slides without approval from the presenter and/
or the IASLC unless explicitly forbidden. All information distributed must adhere to INTERVIEW ROOMS
the IASLC’s embargo policy. Commercial firms cannot copy, photocopy, transform (SIGN UP REQUIRED – MAX. 2 HOURS)
to electronic format, reproduce or distribute information or materials displayed at
this meeting without the written permission of the International Association for the PACIFICO CONFERENCE CENTER,
Study of Lung Cancer. Use of the WCLC/IASLC name and/or logo in any fashion by ROOM 416 AND 417, LEVEL 4F
any commercial entity for any purpose is expressly prohibited without the express
written permission of the International Association for the Study of Lung Cancer.
Interviews conducted through photography, videotaping and audio recording are Tuesday, October 17 08:00 – 18:00
allowed for news coverage only in the following areas/events:
· Press Conferences
· Interview rooms
· Other designated locations
· Recording in common areas requires permission and/or an IASLC staff escort
PRESS CONFERENCES
COPYRIGHT
Reproduction of materials such as abstract data, posters, presentation slides, etc., ROOM 418, LEVEL 4F
requires first obtaining permission from the listed author(s) and/or presenter(s).
Photography of sessions, trade show booths, event setup, etc. is prohibited by
IASLC/WCLC. The WCLC has a designated staff photographer and can provide Sunday, October 15 13:30 – 14:30
WCLC 2017 event photography for journalists who wish to run photos of the event
in their given media. Please contact Becky Bunn, IASLC Public Relations Manager Monday, October 16 10:00 – 10:45
at Becky.Bunn@iaslc.org for any press and media related questions. Tuesday, October 17 10:00 – 10:45
SOCIAL MEDIA POLICY Wednesday, October 18 10:00 – 10:45

Organizations may use social media to disseminate news and information regard-
ing abstracts being presented at the WCLC. All information distributed through
social media channels must adhere to the IASLC’s embargo policy. Press releases will be posted on the
Organizations promoting their research through Twitter are welcome to include Conference website at the conclusion
the IASLC’s World Conference hashtag, #WCLC2017. of each Conference day. Press
Members of the media are permitted to photograph or record and transmit/share conferences will be lived streamed.
on any social media platform any presentation’s slides without approval from the
presenter and/or the IASLC unless explicitly forbidden. Representatives from aca-
demic institutions are permitted to share slides, but not for the media to re-trans-
mit. Only non-flash photography is allowed of slide presentations.
For complete guidelines and media policies please refer to the Conference website
at wclc2017.iaslc.org/press-media/press-media/

INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS
SPEAKER PREVIEW CENTER DISCLOSURE INFORMATION
All invited speakers as well as oral and mini oral abstract presenters must
All invited speakers as well as oral include a slide with their financial disclosure information.
and mini oral abstract presenters Without a disclosure slide you will not be allowed to present!
are required to report to the Speaker
Preview Center at least 24 hours prior
to their scheduled presentation in order
to upload their presentation slides or to PRESENTATION SLIDE TEMPLATE
check their previously uploaded slides.
All invited speakers as well as oral and mini oral abstract presenters
are asked to use the IASLC/WCLC presentation slide template for their
presentation.
NO FILE SUBMISSIONS WILL BE
ACCEPTED IN THE SESSION ROOMS.
REGISTRATION
Computers are available to preview and
upload presentations. Presenters should INVITED FACULTY ‘Invited Faculty’ Registration Counter
make sure all fonts appear as expected (Session Chairs, Invited Speakers,
and all sound/video clips are working Abstract Discussants)
properly. The final version must be
submitted to the Speaker Preview Center, ABSTRACT PRESENTERS ‘Registered Delegate’ Counter
no presentation submissions will be
accepted in the Session Rooms.
SPEAKER PREVIEW CENTER

LEVEL 3F


POSTER PRESENTERS
ALL POSTER PRESENTATIONS/BOARDS

ARE LOCATED IN THE EXHIBIT HALL
(HALL B + C)
Each Poster Board is identified by a

sign with the assigned Poster Num-
ber. The Poster Number corresponds
with the pre-assigned Poster Number
provided in your confirmation letter and
printed in the Abstract Book and this
Onsite Program.
SUPPORTED BY
P1: Poster Session 1

Monday, October 16

Tuesday, October 17

ORAL ABSTRACT PRESENTERS
`` You will have a total of 10 minutes; 8 minutes of presentation,

followed by 2 minutes time for questions from the audience. POSTER DISPLAY TIME
Time limits will be strictly enforced.
Monday – Wednesday 09:30 – 16:00
`` You are asked to prepare a PPT Presentation with maximum 10 slides
(not including title and disclosure slide).
`` Please be in room for your session 10 minutes before the start time PRESENTERS IN ATTENDANCE
of the session. The Session Chairs will start and end strictly on time.
Monday – Wednesday 10:00 – 10:45
`` All presenters MUST include statement disclosing any conflict of
interest related to your abstract as the first slide of your presentation. 14:30 – 15:30
MINI ORAL PRESENTERS POSTER PRINTING SERVICE
`` You will have a total of 5 minutes (no Q&A). If you have ordered to have your poster
Time limits will be strictly enforced. printed by the Conference at an addi-
tional charge, you may pick up your
`` Please be in room for your session 10 minutes before the start time poster onsite.
of the session. The Session Chairs will start and end strictly on time.
`` You are asked to prepare a PPT Presentation with maximum 6 slides
(not including title and disclosure slide). POSTER PICK UP
`` All presenters MUST include statement disclosing any conflict of PACIFICO EXHIBITION HALL,
interest related to your abstract as the first slide of your presentation. EXHIBIT HALL (HALL B + C)


HOW TO RECEIVE CME CREDIT
CME ACCREDITATION INFORMATION A Conference electronic evaluation form will be emailed to learners
after the Conference. Participants that wish to receive CME credits
will have to complete the online evaluation form in order to receive
their CME certificate. CME credits will only be provided for the
sessions that learners are scanned in for. The CME certificate will
be ready for you to print or save upon completion.
FINANCIAL/COMMERCIAL This information is used not only to evaluate the present activity,
but also to plan for future programs.
RELATIONSHIPS & COI DISCLOSURES
All official Conference sessions will be accredited Your opinion is very valuable! Thank you for your participation.
except for the Poster Sessions, Hands-On Train-
ing Sessions, and Industry Supported Symposia.
All individuals able to influence or control content
of any CME certified activity that will be pre-
sented were required to complete an electronic The Conference will provide lectures on accurate `` Integrate clinical data on maintenance therapy
Financial Relationships/Conflicts of Interest diagnosis, including molecular diagnosis, state- in NSCLC to determine which patients would
Disclosure Form prior to the Conference. In of-the-art treatment of thoracic malignancies, benefit most from a maintenance regimen.
addition, abstract submitters provided disclosure and recent diagnostic and therapeutic advances. `` Review the clinical significance of optimal
information for all co-authors at the time of Participants will learn about palliative care and its biopsy, specimen flow and molecular testing
abstract submission. implementation in daily practice. for personalized medicine in non-academic
Participants will be informed about the possi- settings.
Individuals who refused to disclose relevant
financial relationships were eliminated from bilities for continuous medical education. They `` Illustrate the molecular pathways that hold
presenting at the Conference. will learn about clinical trial designs and how to promise for therapeutic intervention.
become successful investigators of co-operative `` Outline current therapeutic approaches for
Definition of Conflicts of Interest: www.accme. research groups. The Conference will also allow limited and extensive small cell lung cancer
org/requirements/accreditation-require- participants to be better informed about patient (SCLC).
ments-cme-providers/policies-and-definitions/ support and advocacy groups.
definition-commercial-interest `` Describe current therapeutic approaches for
Overall, the participants of the WCLC will benefit patients with mesothelioma and thymoma.
All commercial relationships and conflicts of in regard to learning the best clinical practice `` Predict optimal and best practice approaches
interest were identified and thoroughly vetted by in the area of lung cancer and other thoracic for supportive and palliative care of patients
the IASLC Ethics Committee, CME Subcommittee, malignancies. with thoracic cancers.
Education Committee and/or an independent
reviewer. COI was evaluated by the Board of `` Evaluate the support and survivorship
Directors of the IASLC for fair balance, scientific resources available for lung cancer patients
TARGET AUDIENCE and their families.
objectivity of studies utilized in this activity, and
patient care recommendations. IASLC CME `` Illustrate important aspects of clinical trial
This CME live Conference is designed to meet the
is committed to providing its learners with design and master protocols.
educational needs of healthcare professionals
high-quality CME activities and related materials `` Explain to more junior investigators and stu-
who diagnose and treat patients with lung cancer,
that promote improvements or quality in health dents on research and technology advances,
including medical oncologists, thoracic surgeons,
care and not a specific proprietary business and encourage them to initiate investigations
pulmonologists, radiation oncologists, radiolo-
interest of a commercial entity. in lung cancer research.
gists, pathologists, advanced practice nurses, and
All non-FDA approved uses of products must physician assistants.
be clearly identified. Disclosures may be made
in form of a slide, printed material, or oral OFFICIAL LANGUAGE
statement. Each presenter should reveal his/her LEARNING OBJECTIVES
disclosure information during his/her presenta- The official language of the IASLC 18th World
tion with the visual aid of a slide. Conference on Lung Cancer is English.
At the end of the Conference the attendee will
be able to:
`` Identify effective global lung cancer preven-
CREDIT STATEMENT tion strategies.
`` Improve their ability to participate in tobacco DISCLAMER
IASLC is accredited by the Accreditation Council
for Continuing Medical Education (ACCME) control and smoking cessation programs.
The information presented at the IASLC 18th World
to provide continuing medical education for `` Recognize the current approaches and Conference on Lung Cancer is that of the contrib-
physicians. strategies for early detection and screening of uting faculty and does not necessarily represent
lung cancer. the views of the International Association for the
IASLC designates this live activity for a maximum
`` Demonstrate the best methods to implement Study of Lung Cancer and/or any named commercial
of 21 AMA PRA Category 1 Credit(s)™. Physicians
multi-disciplinary tumor boards into commu- entity providing financial support. Specific therapies
will receive credits based on the sessions they discussed may not be approved and/or specified
attended and were scanned for. Ensure that nity practices.
for use as indicated by the faculty presenters.
you get your badge scanned when going into a `` Examine evidence-based therapeutic regi- Therefore, before prescribing any medication,
session! mens for early stage and locally advanced please review the complete prescribing information,
NSCLC. including indications, contraindications, warnings,
`` Distinguish evidence-based therapeutic precautions, and adverse effects.
GOAL & PURPOSE regimens for metastatic NSCLC based on Participants have an implied responsibility to use the
biomarker status and patient/tumor charac- newly acquired information to enhance patient out-
The WCLC is an educational and scientific event teristics. comes and their own professional development. The
which, due to its multidisciplinary nature, will `` Define best practices regarding the appli- information presented in this activity is not meant
cover all aspects of the management of lung can- cation of targeted therapies for metastatic to serve as a guideline for patient management.
cers, mesothelioma, thymic and other thoracic NSCLC in frontline and then subsequent Any procedures, medications, or other courses of
malignancies. settings following acquired resistance to the diagnosis or treatment discussed or suggested in
this activity should not be used by clinicians without
Participants will learn about tobacco control and targeted therapy.
evaluation of their patient’s conditions and possible
smoking cessation programs and how to imple- `` Describe current and emerging immunother- contraindications on dangers in use, review of any
ment them in their daily practice. Participants will apy strategies in the context of clinical trials applicable manufacturer’s product information,
update their knowledge on early detection and findings and patient selection in metastatic and comparison with recommendations of other
screening. NSCLC. authorities.

Visit the IASLC’s Social Media
Corner on Level 3F of the
Conference Center &
Join the Conversation!
• View live feeds from Twitter,
Facebook and Instagram
• Take your photo in
front of our special #WCLC2017
Mt. Fuji backdrop
• Pin your country on
our world map
• Learn how to post
on social media
• Get your free gift
RESEARCH GRANT
US$200,000 (US $100,000 per year for two years)
APPLICATION DEADLINE
OCTOBER 31, 2017
ONSITE SERVICES AND GENERAL INFORMATION
IASLC WCLC 2017 IASLC WCLC 2017 JOIN THE

OFFICIAL MOBILE APP VIRTUAL MEETING CONVERSATION!
#WCLC2017
SUPPORTED BY All audio and webcast recordings
including presentations, abstracts and For the first time, the IASLC will have
electronic versions of most posters will a Social Media Corner to assist and
Download the free IASLC WCLC 2017 be available in the Virtual Meeting within encourage attendees to use and follow
mobile app for a convenient way to stay 24 hours. Check your name badge for social media throughout the Conference.
up-to-date via your phone or tablet. View login details.
the full scientific schedule, abstracts, Plan to stop by the IASLC Social Media
exhibit information including floor plan Corner on Level 3F of the PACIFICO
iaslc.library.org
and exhibitor company descriptions, and Conference Center (at the top of the
general Conference and venue informa- escalators) as often as you like during
tion on our easy to use app! the Conference — there will always be
something going on. Not social media
The app is compatible with all iOS savvy? No problem. We’re here to help!
devices (iPhone, iTouch and iPad) and all
Android mobile devices. Timely updates
Here’s what’s happening:
on program or room changes will be
distributed through the mobile app via `` View live feeds from Twitter, Instagram
and Facebook
notification alerts.
`` Take your photo in front of our special
Mt. Fuji backdrop
`` Pin your country on our world map
`` Learn how to post on social media
`` Get your free gift
IASLC SOCIAL MEDIA ACCOUNTS TO FOLLOW:
@iaslc
facebook.com/iaslc
Iaslc.lung
CONFERENCE HASHTAG:
#WCLC2017

ABSTRACTS ATM
SUPPORTED BY 7-ELEVEN STORE, LEVEL 2F PACIFICO EXHIBITION HALL
An ATM is located in the 7-Eleven store on Level 2F in the

Abstracts selected for IASLC WCLC are presented in Oral, PACIFICO Exhibition Hall.
Mini Oral and Poster Sessions. The top 3 abstracts are pre-
sented in the Presidential Symposium on Tuesday, October 17,
08:15–09:45.
BAGGAGE CHECK
All accepted and confirmed abstracts are published in a supple-

PACIFICO CONFERENCE CENTER, LEVEL 1F
ment of the Journal of Thoracic Oncology, which will be posted
online on the JTO website in December 2017.
See Coat and Baggage Check
All accepted and confirmed abstracts except for those included
in Press Releases and/or Press Conferences are also available
on the Abstract USB Stick which is handed out along with your
BREAKFAST
delegate bag. If you requested a printed version of the Abstract
Book, please pick it up along with your delegate bag.
The Conference does NOT provide breakfast unless otherwise
indicated in the program.
ABSTRACTS ONLINE
BUSINESS CENTER
Attendees are invited to view the abstracts in the virtual meet-
ing available on the Conference website. The virtual meeting
Delegates may use the two Business Centers, located at
allows searching for abstracts, topics, presenters, sessions and
PACIFICO.
keywords, selecting abstracts of interest and building your own
personal conference calendar. It is free for all WCLC delegates.
Opening Hours 09:00 – 18:00
GET THE WCLC 2017 VIRTUAL MEETING AT

Exhibition Hall
library.iaslc.org
LEVEL 2F (OUTSIDE HALL B, ROOM B14)
All accepted abstracts are also included in the WCLC 2017

Conference Center
Mobile App.
LEVEL 1F (SELF SERVICE CENTER)
ACCREDITATION
CELL PHONES
See CME Accreditation and CME Certificate
As a courtesy to fellow attendees, please turn off cell phones
during scientific sessions.
ATTIRE
Business casual is appropriate for all sessions and network-

ing events. Room temperature can vary in session rooms.
We encourage attendees to dress in layers for their personal
comfort.

CERTIFICATE OF ATTENDANCE COAT AND BAGGAGE CHECK
International attendees can request a ‘Certificate of Attendance’ PACIFICO CONFERENCE CENTER, LEVEL 1F
by completing the Conference evaluation form available on the

Conference website at the conclusion of the Conference. After A coat and baggage check will be available at
completing the evaluation form you will be able to download PACIFICO Conference Center.

your Certificate of Attendance.
CHARGING STATIONS Monday, October 16 06:30 – 19:30

CHARGING STATIONS IN THE
EXHIBIT HALL SUPPORTED BY Wednesday, October 18 06:30 – 18:00
EXHIBIT HALL (HALL B + C)
Charging Stations are located in the Exhibit Hall (Hall B + C) CONVENIENCE STORES
allowing delegates to power up their cell phones, laptops and
other electronic devices for free. 7-Eleven Store
EXHIBITION HALL, LEVEL 2F | 07:00–21:00
CME ACCREDITATION AND CME CERTIFICATE Daily YAMAZAKAI
EXHIBITION HALL, LEVEL 1F | 07:00–23:00

This activity is planned for 21 AMA PRA Category 1 Credit(s)™.
Please see page 28 in this book for further information. English speaking staff are available at both stores.
International attendees can request a ‘CME Certificate’ by

completing the Conference evaluation form available on the
Conference website website at the conclusion of the Confer- DELEGATE LOUNGES
ence. After completing the evaluation form you will be able to
download your CME Certificate. EXHIBIT HALL (HALL B + C)
Delegates will only receive credits for the sessions they actually Delegate Lounges are available and located in the Exhibit Hall
attended and were scanned for. Ensure that you get your badge (Hall B + C). These lounges are specifically designed to provide
scanned when going into a session! a comfortable seating area for delegates to rest, conduct brief
meetings or network with colleagues.

FOREIGN CURRENCY EXCHANGE LOCKERS
7-ELEVEN, DAILY YAMAZAKAI | EXHIBITION HALL LEVEL 2F Coin operated lockers (small, medium, large) are available
INTERCONTINENTAL HOTEL | 2ND FLOOR
and located in seven places at PACIFICO Yokohama.
You can withdraw Japanese Yen with international credit cards CONFERENCE CENTER, LEVEL 1F ENTRANCE
at the ATM in the 7-Eleven and the Daily YAMAZAKI store. SMALL | JPY300/DAY
There is also a foreign currency exchange machine on the
CONFERENCE CENTER, LEVEL 2F ENTRANCE
2nd floor of the Intercontinental Hotel.
SMALL, MEDIUM, LARGE | JPY300-600/DAY
EXHIBITION HALL, LEVEL 1F, IN FRONT OF EXHIBIT HALL (HALL B)

MEDIUM, LARGE, VERY LARGE | JPY400-600/DAY
IASLC
EXHIBITION HALL, LEVEL 1F, IN FRONT OF EXHIBIT HALL
(BETWEEN HALL B AND C)
Business Meeting SMALL, MEDIUM, LARGE | JPY300-500/DAY
ANNEX HALL F201 + F202 EXHIBITION HALL, LEVEL 1F, IN FRONT OF PLENARY HALL (HALL D)
SMALL, LARGE | JPY300-500/DAY
Monday, October 16 14:30 – 15:30 EXHIBITION HALL, LEVEL 2F, IN FRONT OF GATE 1
SMALL, LARGE | JPY300-500/DAY
All IASLC Members are invited to attend the IASLC Business
ANNEX HALL, LEVEL 2F
Meeting. Light refreshments will be provided. IASLC WCLC SMALL, LARGE | JPY300-500/DAY
Travel and Advocacy Award Winners will be presented with
their awards.
IASLC Booth LOST AND FOUND

Please visit the IASLC Booth (#2404) in the Exhibit Hall
(Hall B + C) for updates on membership, society-sponsored PACIFICO CONFERENCE CENTER, LEVEL 2F
meetings and events, the IASLC Foundation, JTO and general

information. Lost and found items should be returned/claimed at the
Delegate Help Desk.
For membership inquiries you can also visit the IASLC mem-
bership counter in the registration area on Level 2F of the
Conference Center.
MEDIA ROOM
IASLC Social Media Corner
PACIFICO CONFERENCE CENTER LEVEL 4F, ROOM 421
Please visit the IASLC Social Media Corner on Level 3F of the
Conference Center and share your WCLC experience with us. Wireless internet and a copier are available.
Please see page 23 in this book for further information.
INTERNET CAFÉ
SUPPORTED BY
Keep in touch with home and office! The Internet Café is located
in the Exhibit Hall (Hall B + C) adjacent to the Exhibit Showcase
Theater. Computers with internet and printers are available to
delegates on a complimentary basis. The Internet Café is open
during Exhibit Hall Hours. Internet sessions are limited to 15
minute per delegate.

NEWSPAPER RESTAURANTS
SUNDAY AND MONDAY

There are plenty of restaurants choices in Yokohama and Tokyo.
EDITIONS SUPPORTED BY
The staff at the Delegate Help Desk will be happy to assist with
recommendations and bookings.
A daily Conference Newspaper will be available from Sunday
to Wednesday at no charge to Conference delegates. The The mall across from PACIFICO and the Intercontinental Hotel
Newspaper will be distributed at various points at PACIFICO. provides a great variety of restaurants and food courts.
A PDF version of each edition will also be available on the
Conference website and the Mobile App.
SHIPPING
PARKING PACIFICO LOGISTICS CENTER,

LOCATED ON LEVEL 2F IN THE PACIFICO EXHIBITION HALL
MINATO MIRAI PARKING LOT (PACIFICO EXHIBITION HALL)
The PACIFICO Logistics Center can assist with shipping needs
The cost of Minato Mirai Parking Lot (PACIFICO Exhibition Hall) and baggage deposit services.
is as follows:
WEEKDAY PARKING | JPY1,350, FROM 07:00–24:00
SMOKING
WEEKEND PARKING | JPY1,850, FROM 07:00–24:00
Smoking is prohibited in all areas of the PACIFICO Yokohama.
POSTERS ONLINE

All abstracts accepted for poster presentation will be presented
as traditional printed posters to be displayed on poster boards
in the Exhibit Hall (Hall B + C). In addition to the printed poster, All Presenters are required to submit and/or preview their
each presenter is required to submit an electronic version of slides at least 24 hours prior to their scheduled presentation
their poster to be made available in the Virtual Meeting to ensure compatibility with the Conference AV Equipment.
(library.iaslc.org), which is free of charge to all delegates. PACIFICO CONFERENCE CENTER, LEVEL 3F

PRESS
Please see page 23 in this book for further information. Monday, October 16 06:30 – 17:30
PUBLIC TRANSPORTATION
We strongly recommend that you take public transportation

whenever possible. Yokohama/Tokyo has one of the most mod-
ern and efficient public transportation networks. For assistance,
please visit the Delegate Help Desk in the PACIFICO Conference
Center, Level 2F.

VIRTUAL MEETING WIRELESS INTERNET
All oral sessions are recorded (slides and audio) and will be
SUPPORTED BY
made available as a Virtual Meeting through the IASLC Virtual
Library within 24 hours.
WCLC is providing free Wi-Fi throughout the PACIFICO Yoko-
hama. To ensure a positive Wi-Fi experience for all users please
The WCLC 2017 Virtual Meeting is included in your
do not use your own wireless Hotspot device. These additional
registration and can be accessed through library.iaslc.org.
Wi-Fi devices create significant RF interference which can
interfere with all Wi-Fi networks. Please turn these devices off
Your personal Virtual Meeting Access Code is the same as
and connect to the Wi-Fi network WCLC and open your web
your Delegate ID Number and can be found on your badge or
browser to connect to the Internet.
through your WCLC 2017 confirmation email. After you enter
your Access Code and confirm your account details, you’ll be
To connect to the Wi-Fi, connect to the network
able to view any presentations that have been marked as “Now
FREE-PACIFICO Wi-Fi and open the browser for internet
Available”.
access.
To start viewing, please visit: library.iaslc.org.
WATER STATIONS
SUPPORTED BY
Water stations will be placed throughout PACIFICO Yokohama.
DISCLAIMER
The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program
or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although
every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.

SECTION 4
EXHIBIT
INFORMATION
Exhibit Information 38
Exhibitor Listing 39
Exhibit Floor Plan 40
Exhibitor Company
Descriptions 41

EXHIBIT INFORMATION
PACIFICO EXHIBITION HALL, HALL B + C
All day refreshments and light snacks

will be served in the Exhibit Hall
throughout opening hours.
EXHIBIT SHOWCASE SESSIONS
Monday, October 16 13:00 - 14:00
EXH 01: THERMO FISHER: NEXT GENERATION SEQUENCING – CHANGING
Wednesday, October 18 09:30 – 16:00 PARADIGM IN NSCLC PATIENT MANAGEMENT
As number of targeted therapies in NSCLC is rapidly increasing, simultaneous testing for mul-
tiple biomarkers is becoming progressively important to ensure a timely diagnosis and start
of treatment. 1Next Generation Sequencing (NGS) technology has been significantly advanc-
ing cancer research for some time and now is finally ready for a daily routine patient testing
EXHIBIT FEATURES
Objective of this session is to
`` Exhibit Information Booth with `` Explain basic science and principle of NGS and its application in NSCLC patient testing
- Information Desk `` Introduce the first NGS in vitro diagnostic (IVD) test for NSCLC, simultaneously delivering
- Show Service Provider Desk multiple biomarker results for multiple targeted therapies – Oncomine Dx Target Test
`` Give forum for multiple stakeholders – clinicians, laboratories and patients - discussion
- Poster Pick Up Counter
``
`` Publication table for promotional Tuesday, October 17 10:00 - 10:30
materials or related events and EXH 02: ASTRAZENECA: THE ROLE OF PD-L1 IN TREATMENT DECISION MAKING
organizations FOR NSCLC PATIENTS
`` Internet Stations Agenda

(attached to Showcase Theater) 1. Current Therapy Landscape in NSCLC
2. Identifying The Right Patient For IO: The Choice of Test | The Importance of the Algorithm
`` Charging Stations 3. Optimising the Sample Testing Journey
`` Food & Beverage Stations 4. What’s Next for Precision Medicine in NSCLC
`` Barista Coffee Stations

POSTER SESSIONS POSTER PICK UP COUNTER
`` Delegate Lounges
`` Patient Advocacy Lounge All poster presentations have Poster Presenters who had their poster
`` Exhibit Showcase Theater been assigned a consecutive printed by the Conference, can pick
publication number for locating up their poster at the Poster Pick Up
`` Not for Profit Pavilion the abstract/poster in this Counter at the Exhibit Information
`` Publisher’s Corner brochure, the Abstract Book Booth in the Exhibit Hall during the
and the Poster Boards in the following times:
Exhibit Hall (Hall B + C).
P1: Poster Session 1 Tuesday, October 17 08:00 – 16:00
Monday, October 16 Wednesday, October 18 08:00 – 10:30

Tuesday, October 17

POSTERS ONLINE
All abstracts accepted for poster presentation will be presented as traditional

printed posters to be displayed on poster boards in the Exhibit Hall (Hall B +
C). In addition to the printed poster, each presenter is required to submit an
electronic version of their poster to be made available in the Virtual Meeting
(library.iaslc.org), which is free of charge to all delegates.

EXHIBITOR LISTING
BY EXHIBITOR BY BOOTH NUMBER
COMPANY NAME BOOTH # BOOTH # COMPANY NAME
AbbVie 1304 100 Lilly Oncology

AME Publishing Company 1212 105 AstraZeneca
Amoy Diagnostics Co., Ltd. 2010 615 International Thoracic Oncology Nursing
Forum (ITONF)
AstraZeneca 105
616 Polish Lung Cancer Group -
Boehringer Ingelheim International GmbH 1300
Polska Grupa Raka Pluca
Bristol-Myers Squibb (BMS) 804
800 Novartis
Bruker 1713
804 Bristol-Myers Squibb (BMS)
Celgene Corporation 808
808 Celgene Corporation
EIT Health LUCINDA: AI & Lung Cancer 1114
1112 Global Lung Cancer Coalition (GLCC)
F. Hoffmann - La Roche 2400
1113 Korean Association for Lung Cancer (KALC)
Global Lung Cancer Coalition (GLCC) 1112
1114 EIT Health LUCINDA: AI & Lung Cancer
Guardant Health, Inc. 2008
1212 AME Publishing Company
IASLC 2404
1300 Boehringer Ingelheim International GmbH
International Thoracic Oncology 615
1304 Abbvie
Nursing Forum (ITONF)
1308 Pfizer Oncology
Korean Association for Lung Cancer (KALC) 1113
1704 MSD
Lilly Oncology 100
1712 Peregrine Pharmaceuticals
Median Technologies 2009
1713 Bruker
MSD 1704
1812 PANAGENE Inc.
Novartis 800
1813 Sanomics Limited
PANAGENE Inc. 1812
1900 Takeda Oncology
Peregrine Pharmaceuticals 1712
2008 Guardant Health, Inc.
Pfizer Oncology 1308
2009 Median Technologies
Polish Lung Cancer Group - 616
Polska Grupa Raka Pluca 2010 Amoy Diagnostics Co., Ltd.
Sanomics Limited 1813 2308 Scanlan International, Inc.
Scanlan International, Inc. 2308 2400 F. Hoffmann - La Roche
Takeda Oncology 1900 2404 IASLC
Thermo Fisher Scientific 2411 2411 Thermo Fisher Scientific

EXHIBIT FLOOR PLAN
POSTERS
EXHIBIT
DELEGATE
INTERNET CAFÉ
INFORMATION
BOOTH
616
LOUNGE
&
POSTER SHOWCASE
615
PICK UP
THEATER
DELEGATE
1114
1113 1212 LOUNGE 1713 1813

ADVOCACY
INTERNET CAFÉ
LOUNGE
PATIENT
1112 1712 1812

2411
POSTERS 2010
808 1308 2009
2008 2308
105
804 1304 1704
2404
100
800 1300 1900 2400

EXHIBITOR COMPANY DESCRIPTIONS
1304 1300
AbbVie is a global, research-driven biopharmaceutical company

committed to developing innovative advanced therapies for Through scientific innovation and collaboration, Boehringer
some of the world’s most complex and critical conditions. The Ingelheim is committed to discovering and developing novel
company’s mission is to use its expertise, dedicated people and anti-cancer agents that address unmet needs across a broad
unique approach to innovation to markedly improve treatments range of solid and hematological malignancies. Approved
across four primary therapeutic areas: immunology, oncology, agents are for specific NSCLC sub-types and the oncology
virology and neuroscience. In more than 75 countries, AbbVie portfolio is supported by a strong early pipeline. As part of our
employees are working every day to advance health solutions unique research approach, we seek out strong partnerships and
for people around the world. For more information about remain dedicated to delivering treatments that improve cancer
AbbVie, please visit us at www.abbvie.com. Follow @abbvie patients’ lives.
on Twitter, Facebook or LinkedIn.
804
1212
Bristol-Myers Squibb is a global BioPharma company whose
mission is to discover, develop and deliver innovative medi-
AME publishes over 40 peer-reviewed journals, including Jour-
cines that help patients prevail over serious diseases. Around
nal of Thoracic Disease (JTD), Translational Cancer Research
the world, our medicines help millions of people in their fight
(TCR), Translational Lung Cancer Research (TLCR), Annals
against such diseases as cancer, cardiovascular disease,
of Translational Medicine (ATM), as well as a series of books
hepatitis B and hepatitis C, HIV/AIDS and rheumatoid arthritis.
including Lung Cancer, Lung Cancer Precision Medicine, Art of
The Bristol-Myers Squibb Foundation’s philanthropic programs
Operative Techniques, Video-Assisted Thoracic Surgery, The
seek to promote health equity and improve the health outcomes
Robotic Thoracic Surgery. During this period, AME has estab-
among populations disproportionately affected by serious dis-
lished editorial offices in Hong Kong, Guangzhou, Changsha,
eases and conditions, giving new hope to some of the world’s
Nanjing, Shanghai, Beijing, Chengdu, Taipei, and Sydney. AME
most vulnerable people.
represents “Academic Made Easy, Excellent and Enthusiastic”.
“Patients come first” is the core value of AME.
1713
2010
Offering the largest range of Preclinical Imaging systems,
Bruker is committed to supporting the scientific community
Amoy Diagnostics Co., Ltd. is an R&D based provider of state- with high-end instruments dedicated to disease research,
of-the-art diagnostic products and services in area of human translational science and Molecular Imaging. Our non-invasive
oncology personalized healthcare. We have a rich portfolio of in-vivo imaging modalities are designed to deliver greater scien-
tests that focuses on detecting mutations and measuring gene tific insight based on animal-centric solutions.
expression in various samples including FFPE cancer tissue,
body fluids & whole blood. Bruker offers advanced preclinical imaging solutions for a
broad spectrum of application areas, such as oncology, neu-
rology, cardiology, inflammation, infectious diseases, functional
and anatomical neuroimaging, orthopedics, cardiac imaging
105 and stroke models. Our range of imaging modalities includes
PET/SPECT/CT Imaging, MRI, PET/MRI Imaging and microCT
imaging.
AstraZeneca is a global, science-led biopharmaceutical com-
pany that focuses on the discovery, development and commer-
cialisation of prescription medicines, primarily in three main
therapy areas - Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide.

808 2404
Celgene Corporation is a global biopharmaceutical company The International Association for the Study of Lung Cancer
that is helping healthcare providers turn incurable cancers (IASLC) is the only global organization dedicated to the study
into chronic, manageable diseases, as well as manage serious of lung cancer. Founded in 1974, the association’s member-
inflammatory conditions through innovative therapies. This ship includes nearly 7,000 lung cancer specialists in over 100
dedication to medical progress goes hand-in-hand with our countries. IASLC members work to enhance the understand-
industry-leading patient support and access programs. ing of lung cancer among scientists, members of the medical
community and the public. IASLC publishes the Journal of
Thoracic Oncology, a valuable resource for medical specialists
and scientists who focus on the detection, prevention, diagnosis
and treatment of lung cancer.
1114
LUCINDA project (Oxford, Groningen, Heidelberg & Optellum)

is developing the world’s first image-based risk stratification 615
software for incidental and screen detected nodules for CT.
Visit our exhibit to:

International Thoracic Oncology Nursing Forum is a global
· Learn about image-based nodule risk stratification
group of nurses with a mission to promote and support excel-
· Understand the real benefit of Deep Learning
lence in Thoracic Oncology Nursing. ITONF leads the Interna-
· See the prototype & get involved in product development
tional Thoracic Oncology Nursing community in evidence-based
and trials.
thoracic cancer care in an effort to improve outcomes for
thoracic oncology patients and reduce the burden of thoracic
For more information, visit: www.optellum.com/eit-health-lucinda.
cancers globally.
1112
1113
The Global Lung Cancer Coalition promotes global understand-

The Korean Association for Lung Cancer (KALC) is the only
ing of the burden of lung cancer and the right of patients to
academic association in Korea dedicated to the study of lung
effective early detection, better treatment and supportive care.
cancer. KALC promotes multi-disciplinary approach and collab-
Serving as the international voice of lung cancer patients, the
oration among physicians and scientists, and advocates for the
Global Lung Cancer Coalition is committed to improving disease
rights of lung cancer patients.
outcomes for all.
100
2008
For more than 50 years, Lilly has been dedicated to deliver-
Guardant Health is focused on conquering cancer by using its ing life-changing medicines and support to people living with
breakthrough blood-based assays, vast data sets, and advanced cancer and those who care for them. Lilly is determined to build
analytics. Using both molecular and digital tools, Guardant on this heritage and continue making life better for all those
Health is addressing challenges across the cancer care con- affected by cancer around the world. To learn more about
tinuum. The company has raised more than $500 million from Lilly’s commitment to people with cancer, please visit
leading investors. Its first product, the Guardant360 assay, www.LillyOncology.com.
came to market in 2014, and is now the most widely ordered
comprehensive liquid biopsy commercially available.

1712
2009
Since 2002, Median has been doing one thing and one thing Peregrine Pharmaceuticals is committed to improving the lives
only — expanding the boundaries of the identification, inter- of patients by manufacturing high quality products for biotech-
pretation, analysis and reporting of imaging data in the medical nology and pharmaceutical companies, as well as advancing
world. Median is at the heart of innovative imaging solutions and licensing investigational immunotherapy and related prod-
with our oncology-focused Lesion Management Solution ucts. The company is evaluating its lead clinical immunomodu-
(LMS) software and iBiopsy® for imaging phenotyping. These latory candidate, bavituximab, in multiple combination therapy
software, together with our global team of imaging experts, are oncology trials.
advancing development of treatments and the monitoring and
diagnosing of patients with cancer — it’s a smart blend of tech-
nology, science and service. We empower healthcare, pharma,
biotech and medical device companies with the most meaning- 1308
ful information about their patients and treatments so we can
all help people with their health challenges. This is how we are
helping to create a healthier world. Pfizer Oncology is committed to pursuing innovative treatments
that are helping to redefine life with cancer. As an oncology
leader with one of the most robust oncology pipelines in the
industry, we are focused on translating scientific breakthroughs
1704 into clinical application. Additionally, we are dedicated to
working collaboratively with the community to make a positive
impact on people’s lives. www.pfizer.com
For 125 years, MSD has been a global health care leader
working to help the world be well. MSD is a tradename of
Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescrip-
tion medicines, vaccines, biologic therapies, and animal health
products, we work with customers and operate in more than 616
140 countries to deliver innovative health solutions. We also
demonstrate our commitment to increasing access to health-
care through far-reaching policies, programs and partnerships. Polish Lung Cancer Group – PolGRP multidisciplinary asso-
For more information, visit www.msd.com. ciation established in 2002. Its primary role is didactic and
educational equally spreading lung cancer knowledge in Poland.
Every year in November organizes annual conference with
IASLC accreditation also awarded to “Best of WCLC“ meeting.
800 Its Lung Cancer Registry contains above 30,000 records.
Novartis Oncology is a global leader in transforming outcomes

for people with cancer. Our research is driven by a distinctive
scientific and clinical strategy focused on precision oncol-
2400
ogy–understanding how cancer develops on a genomic level
and developing drugs that hone in on those targets. For more
information, visit www.novartisoncology.com.
Roche is a global pioneer in pharmaceuticals and diagnostics
focused on advancing science to improve people’s lives. The
combined strengths of pharmaceuticals and diagnostics under
one roof have made Roche the leader in personalized health-
1812
care — a strategy that aims to fit the right treatment to each
patient in the best way possible.
PANAGENE is the exclusive PNA and PNA based molecular
diagnostic reagent provider. Real-time PCR based PANAGENE
kits facilitate more reliable MDx tests in short time in your
site directly. PANAGEN’s EGFR, KRAS, EML4-ALK, ROS1 kits
provide the diagnostic solution for the patients in lung cancer in
high sensitivity and specificity.

1813 1900
Sanomics is a pioneering genomics technology company based

in Hong Kong. Using a new generation of proprietary technol- Located in Osaka, Japan, Takeda is a research-based global
ogies, Sanomics offers blood-based liquid biopsy for cancer company with its main focus on pharmaceuticals. As the largest
patients. Genomics biomarker is essential to personalized man- pharmaceutical company in Japan and one of the global leaders
agement of cancer. Presence or absence of the abnormal muta- of the industry, Takeda is committed to strive towards better
tions will help physicians to determine the treatment strategy. health for people worldwide through leading innovation in medi-
cine. Additional information about Takeda is available through
its corporate website, www.takeda.com.
2308
2411
Highest quality surgical products designed and manufactured
by the Scanlan family since 1921. Titanium and stainless steel
instrument designs including Scanlan® LEGACY needle holders Thermo Fisher Scientific Inc. is the world leader in serving sci-
and forceps, and Super Cut™ Scissors. Full line Scanlan® ence. Our mission is to enable our customers to make the world
VATS instruments including D’Amico Clamps, Suctions, Biopsy healthier, cleaner and safer. We help our customers accelerate
Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps and life sciences research, solve complex analytical challenges,
Khan Decortication Grasper. improve patient diagnostics and increase laboratory productiv-
ity. For more information, please visit www.thermofisher.com.

SECTION 5
IASLC AND
CONFERENCE
AWARDS
IASLC Distinguished
Award Winners 46
IASLC Fellowship Award Winners 49
IASLC Academy Award Winners 49
IASLC International
Mentorship Award Winners 50
WCLC 2017 Young Investigator
Award Winners 51
WCLC 2017 Developing Nation
Award Winners 52
IASLC/WCLC 2017 Patient
Advocacy Award Winners 53
2017 Nurse and Allied Health
Professional Award Winners 53
WCLC 2017 Lectureship
Award Winners 54

The IASLC Distinguished Award Winners
will receive their awards during the
IASLC AND CONFERENCE AWARDS Opening Ceremony on Sunday, October 15,
18:30 – 20:00.
IASLC DISTINGUISHED AWARDS
Tony Mok Ramon Rami-Porta

IASLC PAUL A. BUNN, JR. IASLC MERIT AWARD
SCIENTIFIC AWARD
THE IASLC MERIT AWARD IS GIVEN TO A MEMBER OF IASLC WHO HAS
MADE AN EXTRAORDINARY CONTRIBUTION TO THE ORGANIZATION’S
(FORMERLY IASLC SCIENTIFIC AWARD)
DEVELOPMENT.
THE IASLC PAUL A. BUNN, JR. SCIENTIFIC AWARD IS GIVEN TO AN IASLC SCIEN-
TIST FOR LIFETIME SCIENTIFIC CONTRIBUTIONS IN THORACIC MALIGNANCY
Ramon Rami-Porta graduated from Barcelona University Medical
RESEARCH AND WHO HAS ALSO CONTRIBUTED TO THE ORGANIZATION’S School in 1980. He followed specialty training in thoracic surgery at the
DEVELOPMENT. Jimenez Diaz Foundation, Madrid, and was board-certified in thoracic
surgery in 1985.
Prof. Tony S. K. Mok was trained at the University of Alberta, Canada
and he subsequently completed a fellowship in medical oncology at the During his residency he also worked on a research project on malig-
Princess Margaret Hospital in Canada. After working as a community nant pleural effusion for his PhD degree that he received in 1986 from
oncologist in Toronto, Canada for seven years, he returned to Hong the Autonomous University of Madrid. In the last years of his medical
Kong in 1996 to pursue an academic career. training and during his residency, he visited several institutions in
the United States of America for further training, and, as a certified
He is Li Shu Fan Medical Foundation Named Professor of Clinical thoracic surgeon, he was an overseas trainee at the National Cancer
Oncology and Chairman of Clinical Oncology at The Chinese University Centre in Tokyo. As a thoracic surgeon he worked in Barcelona and in
of Hong Kong, Hong Kong. His main research interest focuses on bio- Santiago de Compostela; he was attending thoracic surgeon at Hospital
marker and molecular targeted therapy in lung cancer. He co-founded Universitari Mutua Terrassa, in Terrassa (Barcelona), from 1989 to
the Lung Cancer Research Group, and has led a number of important 2016; and in 2017 he was appointed Clinical Chief of the Department of
multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Thoracic Surgery at the same hospital.
Study), a landmark study that established the role of first-line gefitinib
in patients with EGFR mutation. His major interests are lung cancer staging, surgical treatment of lung
cancer, and thoracic oncology in general. He is a member of several
Prof. Mok has contributed to over 200 articles in international peer-re- national and international medical societies. In the Spanish Society of
viewed journals, including the New England Journal of Medicine, Pneumology and Thoracic Surgery (SEPAR), he was a member of the
Science, Lancet and Journal of Clinical Oncology, and contributed to group of coordinators of the Bronchogenic Carcinoma Cooperative
multiple editorials and textbooks. He is active and experienced in serv- Group (GCCB-S), a multicentre group whose project was to study lung
ing the academic societies. He is now Fellow of American Society of cancer staging. He has been member of the International Association
Clinical Oncology (FASCO), Past Chair of the ASCO International Affairs for the Study of Lung Cancer since 1990, is a member of its Staging
Committee, Treasurer and Past President of the International Asso- and Prognostic Factors Committee, and was appointed Chair of this
ciation for the Study of Lung Cancer (IASLC), a member of the ASCO Committee in 2009, ending his term in 2016. He also is a member of
Publications Committee and Vice Secretary of the Chinese Society of Network for Biomedical Research Centers in Respiratory Diseases (CI-
Clinical Oncology (CSCO). BERES) Lung Cancer Group, a government-supported network study
group on lung cancer.
He is closely affiliated with the oncology community in China, and has
received an Honorary Professorship at Guang Dong Province People’s His other interests are travelling, reading and the life and works of
Hospital, Guest Professorship at Peking University School of Oncology, Graham Greene.
Visiting Professorship at Shanghai Jiao Tong University and West China
School of Medicine/West China Hospital, Sichuan University. He is an
Associate Editor on Thoracic Oncology for Journal of Clinical Oncol-
ogy. He has also authored eight books in Chinese and hosted three
television series in Hong Kong.

IASLC AND CONFERENCE AWARDS
Carolyn Dresler Yasushi Yatabe

JOSEPH W. CULLEN MARY J. MATTHEWS
PREVENTION/EARLY DETECTION AWARD PATHOLOGY/TRANSLATIONAL RESEARCH AWARD
THE JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD IS THE MARY J. MATTHEWS PATHOLOGY/TRANSLATIONAL RESEARCH AWARD
GIVEN TO AN IASLC SCIENTIST FOR LIFETIME SCIENTIFIC ACHIEVEMENTS IS GIVEN TO AN IASLC SCIENTIST FOR LIFETIME SCIENTIFIC ACHIEVEMENTS
IN PREVENTION RESEARCH OF THORACIC MALIGNANCIES. IN PATHOLOGY-TRANSLATIONAL RESEARCH OF THORACIC MALIGNANCIES.
Carolyn Dresler, MD, MPA, by day, is the Associate Director for Med- Yasushi Yatabe, MD, PhD, is Chief of the Department of Pathology and
ical and Health Sciences for the Office of Science at the Center for Molecular Diagnostics at the Aichi Cancer Center Hospital, Chikusa-ku
Tobacco Products within the FDA. Prior to this she was the Director Nagoya, Japan. He is a surgical and molecular pathologist, and is
for the Arkansas Department of Health Tobacco Prevention and recognized as one of the leading experts in lung cancer research. In
Cessation Program. Before Arkansas, she was the Head of the Group addition, Dr. Yatabe is active in a number of professional societies,
for Tobacco and Cancer at the International Agency for Research on holding positions in a chair, Pathology Committee of the International
Cancer in Lyon, France. Association for the Study of Lung Cancer (2015-2017), a chapter editor
of the WHO classification of tumors of lung, pleura, thymus and heart
In 2002-2003 she completed a Master in Public Administration at (2015) and a co-chair of the revised CAP/IASLC/AMP Molecular Test-
the Kennedy School of Government at Harvard University. She is a ing Guidelines. He is also an editor for several oncology and pathology
USA Board Certified Thoracic Surgeon (University of Toronto) with journals, including an associate editor of the Journal of Thoracic
Surgical Oncology training (Memorial Sloan Kettering), with a specific Oncology.
interest in the diagnosis, treatment and most of all, prevention of lung
cancer. She is a former Board member for the International Associa- Dr. Yatabe received his medical degree from Tsukuba University,
tion for the Study of Lung Cancer. School of Medicine in 1991, and subsequently completed his PhD in
1995 at Nagoya University in Japan. He then began work as a Senior
Her academic practices of thoracic surgery were at Washington Uni- Pathologist at the Aichi Cancer Center Hospital until 1998. After spend-
versity in St. Louis, Missouri and then at Fox Chase Cancer Center in ing 2 years of post-doctoral fellowship at the Norris Comprehensive
Philadelphia, Pennsylvania. Cancer Center, University of Southern California, Los Angeles, CA,
USA, Dr. Yatabe returned to the Aichi Cancer Center Hospital in 2000.
Her passion is utilizing the human rights framework to improve
tobacco control and is the founding President of the Human Rights and Dedicated to research, Dr. Yatabe has published more than 400 articles
Tobacco Control Network. Her goal is to have fewer people dying from in peer-reviewed journals, and presented his work at many national
tobacco, specifically from tobacco-caused lung cancer. and international conferences. His research is focused on the molecu-
lar pathogenesis of the clonal evolution of cancer and lung cancer, with
contributions to the expansion and integration of molecular oncology
and pathology, as seen in the representive work (reference #8, and
#10). Due to his diligence, Dr. Yatabe has earned a number of awards
throughout his career, including the Japanese Society of Pathology
“Pathology Research Award” in 2001 and the Japanese Lung Cancer
Society “Shinonoi-Kawai Award” in 2009.

PREVIOUS IASLC DISTINGUISHED AWARD WINNERS
IASLC IASLC
IASLC
MARY J. MATTHEWS PAUL A. BUNN, JR.
IASLC JOSEPH W. CULLEN
YEAR PATHOLOGY/ SCIENTIFIC AWARD
MERIT AWARD PREVENTION/EARLY
TRANSLATIONAL (FORMERLY
DETECTION AWARD
RESEARCH AWARD IASLC SCIENTIFIC AWARD)
1991 Clifton Mountain
Y. Shimosato
1994 Geno Saccamanno Jesse Steinfeld Robert Ginsberg
N. Bleehen
1997 Heine H. Hansen William Travis Clifford Douglas John D. Minna
2000 Desmond Carney Yokio Shimosato Daniel C. Ihde
2003 Paul A. Bunn, Jr. Adi Gazdar Paul van Houtte
2005 Harubumi Kato Elisabeth Brambilla Nigel Gray Thierry LeChevalier
2007 Peter Goldstraw Fred R. Hirsch James Mulshine Frances Shepherd
Bruce Johnson
2009 Giorgio Scagliotti Masayuki Noguchi Stephen Lam
Tom Lynch
2011 David Ball Philip Hasleton John Field Nagahiro Saijo
2013 James Jett Tetsuya Mitsudomi Pieter Postmus David Gandara
2015 Harvey Pass Ming Tsao Jacek Jassem Yi-Long Wu
Sumitra Thongprasert
2016 Keith Kerr Ugo Pastorino Roy Herbst
Keunchil Park

IASLC FELLOWSHIP AWARD WINNERS | 2016 – 2017
ESRA AKBAY PUEY LING CHIA ROBIN MJELLE
UT Southwestern Medical Center, Olivia Newton-John Cancer Research Department of Cancer Research
Dallas, Texas, USA Institute, Austin Health, Victoria, Australia and Molecular Medicine, Norwegian
University of Science and Technology
NTNU, Norway
VALSAMO ANAGNOSTOU SIDDHARTHA DEVARAKONDA
Sidney Kimmel Comprehensive Cancer Washington University School of

Center at Johns Hopkins University, Medicine, St. Louis, Michigan, USA NICOLAS REYNOIRD
Baltimore, Maryland, USA Institute Albert Bonnoit, Centre
Recherche INSERM U1209 - CNRS -
JULIE GEORGE UGA, Grenoble, France
LUIZ HENRIQUE ARAUJO Department of Translational Genomics,
Brazilian National Cancer Institute, University of Cologne, Cologne, Germany
INCA, Brazil APICHAT TANTRAWORASIN
Department of Thoracic Surgery,

Icahn School of Medicine at Mount Sinai,
New York, USA
The IASLC Academy Award Winners will

IASLC ACADEMY AWARD WINNERS be recognized and presented with their
award during the IASLC Business Meeting,
SUPPORTED BY
Monday, October 16, 14:30 – 15:30, F201 +
F202 (Annex Hall).
SUREIN ARULANANDA TAN LING PABLO MUNOZ
Olivia Newton-John Cancer Research National Cancer Centre Singapore, Princess Margaret Cancer Centre,
Institute, Australia Singapore Canada
AHMED BADAWY BENJAMIN LOK FRANCESCO PASSIGLIA
Alexandria University, Egypt Princess Margaret Cancer Centre, Palermo University Hospital, Italy
Canada
MARTA HONORIO ERIN SCHENK

ALEXANDER LOUIE
Hospital Prof. Doutor Fernando Fonseca Mayo Clinic, USA
(HFF), Portugal London Regional Cancer Program,
Canada
JENNIFER LEWIS
DEEBYA MISHRA
Vanderbilt University Medical Center,
USA B P Koirala Institute of Health Sciences,
Nepal
JESSICA LIN
FABIO MORAES
Dana-Farber Cancer Institute/
Massachusetts General Hospital, USA Princess Margaret Cancer Centre,
Canada

IASLC WCLC 2017 CONFERENCE AWARDS
IASLC INTERNATIONAL MENTORSHIP JIN KANG WENHUA LIANG

AWARD WINNERS Division of Pulmonary Oncology, Cancer The First Affiliated Hospital of Guang-
Center, Guangdong Lung Cancer Institute zhou Medical University, China State
The IASLC International Mentorship (GLCI), Guangdong General Hospital Key Laboratory of Respiratory Disease,
Award Winners will receive their award (GGH), China National Clinical Research Center for
during the IASLC Business Meeting on Respiratory Disease, Guangzhou, China
Monday, October 16, 14:30 – 15:30, P1.01–009: Clinically Primary and Sec-
F201 + F202 (Annex Hall). ondary Resistance to ALK Inhibitors in P3.02–008: Non-Invasive Diagnosis
ALK-Positive Advanced Non-Small-Cell of Solitary Pulmonary Nodules Using
Lung Cancer High-Throughput Targeted DNA Methyla-
SUPPORTED BY
tion Sequencing of Circulating Tumor DNA
MADIHA KANWAL
Kunming Institute of Zoology, University FARIZ NURWIDYA
NOOR ALSAADOUN of Chinese Academy of Sciences, Department of Pulmonology and
University of Calgary, Canada Kunming, China Respiratory Medicine, Universitas
Indonesia, Indonesia
P1.06–005: Sex-Based Disparities in P1.02–040: Genetic Risk Evaluation in
NSCLC: An Evidence-Based Study Families with Lung Cancer History in P1.02–065: Histone Deacetylase Inhi-
High Lung Cancer Mortality Region of bition Alters Stem Cell Phenotype in
Xuanwei, China Gefitinib-Resistant Lung Cancer Cells
with EGFR Mutation
ASEEM RAI BHATNAGAR
Linear Accelerator Center, SMS Hospital,
Jaipur, India SZE SHYANG KHO
Respiratory Medicine Unit, Sarawak ABHISHEK SHANKAR
P2.10–007: Quality of Life across Various General Hospital, Malaysia All India Institute of Medical Sciences,
Treatment Lines in Metastatic Lung Delhi, India
Cancer Patients P2.12–001: Early Experience with Radial
Endobronchial Ultrasound with Guide P3.06–007: Level of Awareness of
Sheath for Diagnosis of Peripheral Pul- Various Aspects of Lung Cancer Among
monary Lesion College Students in India: Impact of
WANDEE CHANPRASERTPINYO Cancer Awareness Programme
Ramathibodi Hospital, Mahidol University,
Thailand
MILICA KONTIC
OA 11.04: Effect of Early Palliative Care Clinic for Pulmonology, Clinical Center VORALAK VICHAPAT
on Aggressiveness of Cancer Care near of Serbia, Serbia Mahidol University, Thailand
End of Life in Lung Cancer Patient
P3.05–005: Hypermethylation of the P2.01–009: The Efficacy of Bevacizumab
RASSF1A and SOX1 Genes in Tumor Adding in Standard First Line Chemo-
DNA Predicts Unfavorable Overall therapy and Maintenance Treatment in
VALERIA DENNINGHOFF Survival in Surgically Resected NSCLC Advanced NSCLC: A Network Meta-
CEMIC, Argentina Patients Analysis
P2.02–071: Prospective Molecular Study

of 22 Genes by NGS in Patients with
Non-Small Cell Lung Cancer (NSCLC) MIAN XIE
in Argentina: A Single Institution The First Affiliated Hospital of
Experience Guangzhou Medical University, China
MA 16.11: Alterations of Notch Pathway

among Patients with Adenoid Cystic
Carcinoma of the Trachea and Its Impact
on Survival

WCLC 2017 YOUNG INVESTIGATOR BHAGIRATHBHAI DHOLARIA GILLIANNE LAI

AWARD WINNERS Mayo Clinic, USA National Cancer Centre Singapore,
Singapore
The WCLC 2017 Young Investigator OA 06.07: Survival Trends Among Non-
Award Winners will receive their award Small Cell Lung Cancer (NSCLC) Patients OA 09.07: Clonality of c-MET Copy Num-
during the IASLC Business Meeting on Over a Decade: Impact of Initial Therapy ber Gain as a Determinant of Primary
Monday, October 16, 14:30 – 15:30, at Academic Centers TKI Resistance in EGFR-Mutant NSCLC
F201 + F202 (Annex Hall).
SUPPORTED BY MARCIN NICOŚ

KATEY ENFIELD
British Columbia Cancer Research Medical University of Lublin, Poland
Centre, Canada
OA 08.03: Effect of TOP2A and ERCC1
Genes Polymorphism on the Efficacy
OA 07.07: Inhibition of the Novel Onco-
HAVAL BALATA and Toxicity of Cisplatin and Etoposide
gene ELF3 Abolishes Lung Adenocarci-
University Hospital of South Manchester, Therapy in SCLC Patients
noma Growth
UK
OA 15.04: Community-Based Lung Can- JI SOO PARK

cer Screening, Targeting High-Risk Ever ROBERTO FERRARA
Yonsei Cancer Centre, Korea
Smokers in Deprived Areas of Manches- Medical Oncology Gustave Roussy,
ter: an NHS Implementation Project France
MA 12.01: A Phase Ib Study of the
Combination of Afatinib and Ruxolitinib
MA 10.11: Hyperprogressive Disease
in EGFR Mutant NSCLC Progressed on
(HPD) Is Frequent in Non-Small Cell
JOSHUA BAUMI EGFR-TKI: An Updated Analysis
Lung Cancer (NSCLC) Patients (Pts)
Perelman School of Medicine at the Treated with Anti PD1/PD-L1 Agents (IO)
University of Pennsylvania, USA
ALEXANDRE REUBEN
OA 17.08: Phase II Study of Pembroli- The University of Texas MD Anderson
zumab for Oligometastatic Non-Small MEREDITH GIULIANI
Cancer Center, USA
Cell Lung Cancer (NSCLC) Following University of Toronto and Princess
Completion of Locally Ablative Therapy Margaret Cancer Center, Canada
OA 13.05: Immune, Molecular and T Cell
(LAT)
Repertoire Landscape of 235 Resected
MA 13.09: Toxicity and Second Primary
Non-Small Cell Lung Cancers and Paired
Lung Cancers in Late Survivors Follow-
Normal Lung Tissues
ing Lung SBRT
KEZHONG CHEN
Peking University People’s Hospital,
China SARA RICCIARDI
FRANCESCO GUERRERA
Division of Thoracic Surgery,
OA 07.01: A Prospective Study of Periop- University of Torino, Italy
University Hospital of Pisa, Italy
erative Rapid Clearance of Circulating
Tumor DNA in R0 Resected Non-Small OA 16.02: Risk of Recurrence in Stage I
MA 17.01: Skip N2, an Independent Prog-
Cell Lung Cancer Patients Adenocarcinoma of the Lung: A Multi-In-
nostic Factor of Survival: Analysis of a
stitutional Study on Interaction with Type
Favourable N2 Subgroup
of Surgery and Type of Nodal Staging
HANBO CHEN
London Health Sciences Centre, Canada KATHARINE SEE
TOMONARI KINOSHITA
Royal Melbourne Hospital, Australia
OA 16.01: Stereotactic Ablative Radio- Keio University School of Medicine,
therapy Verses Surgery in Early Lung Japan
MA 14.09: Impact of Lung Cancer
Cancer: A Meta-analysis of Propensity
Perceived Risk, Screening Eligibility and
Score-Adjusted Studies MA 05.04: Distinct Immunosuppressive
Worry on LDCT Screening Preference –
Microenvironment Determines Poor
Challenges for Engaging Patients at High
Prognosis of Nonsmokers with Ade-
Risk
nocarcinoma of Non-Small Cell Lung
Cancer

MICHAEL SHARPNACK WCLC 2017 DEVELOPING NATION GULRUKH BOTIRALIEVA

The Ohio State University Comprehen- AWARD WINNERS National Cancer Research Center,
sive Cancer Center, USA Uzbekistan
The WCLC 2017 Developing Nation
OA 18.02: The Landscape of Alteration of Award Winners will receive their award P2.02–049: Immunohistochemical
DNA Integrity-Related Genes and Their during the IASLC Business Meeting on Approach in Predicting Primary Lung
Association with Tumor Mutation Burden Monday, October 16, 14:30 – 15:30, Cancer Outcome: A Single Center Study
Non-Small Cell Lung Cancer F201 + F202 (Annex Hall).
SUPPORTED BY
GAMZE ÇETINKAYA
YAAKOV TOLWIN
Uludag University, Turkey
Tel Aviv University, Israel
P2.14–016: Pulomonary Resection After
MA 18.11: High Incidence of Lung Cancer
Curative Intent Chemoradiation of NSCLC
in Early Stage TCC Patients PEDRO AGUIAR JR
Faculdade de Medicina do ABC, Brazil
JOAN ELIAS WALTER

P2.07–054: Cost-Effectiveness of TATIANA IONOVA
Pembrolizumab as First-Line Therapy for Multinational Center for Quality of Life
University of Groningen, University Medi-
Advanced Non-Small Cell Lung Cancer
cal Center Groningen, The Netherlands Research, Russia
OA 15.06: Management of Nonresolving P1.01–056: Quality of Life and Clinical

New Solid Nodules after Initial Detection Outcomes of Nivolumab as 2+ Line Treat-
SHARIF AHMED
in Incidence Rounds of CT Lung Cancer ment in Advanced Refractory NSCLC
Screening United Hospital Limited, Bangladesh Pts: Interim Analysis
P1.06–011: Hyponatremia – Evaluation of

Prevalence in Hospitalized Lung Cancer
MARISSA WILLIAMS Patients and Its Prognostic Significance AKHIL KAPOOR
Asbestos Diseases Research Institute, Tata Memorial Hospital, India
Australia
P1.01–021: FISH and IHC Discordance
MA 19.06: Multiple Mechanisms Contrib- MARISOL ARROYO HERNANDEZ
in ALK Rearranged Non Small Cell Lung
ute to Downregulation of Tumour Sup- Instituto Nacional de Cancerologia, Cancer
pressor microRNAs in Malignant Pleural Mexico
Mesothelioma
MA 20.12: Longitudinal Evaluation of
Pulmonary Function in Patients with SZE SHYANG KHO
Advanced NSCLC Treated with Concur- Sarawak General Hospital, Myanmar
rent Chemo-Radiotherapy
P2.12–002: Radial Probe Endobronchial
Ultrasound (R-EBUS) Guided Transbron-
chial Cryobiopsy In The Diagnosis of
FELICIANO BARRON Peripheral Lung Mass
Instituto Nacional de Cancerologia,
Mexico
P3.14–012: Risk Developing Pneumonitis HENGRUI LIANG

Increases in Patients Receiving Immuno- The First Affiliated Hospital of Guang-
therapy with a History of Lung Irradiation zhou Medical University, National Clinical
Research Center for Respiratory Disease,
China State Key Laboratory of Respira-
tory Disease, China
MA 12.11: The Alteration of T790M Prev-

alence Between 19 Deletions and L858R
in NSCLC After EGFR-TKIs Therapy, a
Meta-Analysis

QIANWEN LIU LIN TONG IASLC PATIENT ADVOCACY AWARD

Sun Yat-sen University Cancer Center, Shanghai Respiratory Research Institute, WINNERS
China China
The IASLC Patient Advocacy Award
OA 03.07: Developing Prognostic Nomo- MA 20.13: etDNA: Tumor-Derived DNA Winners will receive their award during
gram and Evaluating Its Role in Personal- from Pleural Effusion Supernatant as a the IASLC Business Meeting on Monday,
ized Adjuvant Chemotherapy for Patients Promising Source for NGS-Based Muta- October 16, 14:30 – 15:30, F201 + F202
with ESCC tion Profiling in Lung Cancer (Annex Hall).
ANNE MARIE CERATO

HÜSEYIN MELEK NATTHAYA TRIPHURIDET Canada
Uludag University, Turkey Chulabhorn Hospital, Thailand
ANNIE CACCIATO
MA 17.08: The Validity of TNM Classifica- P2.06–006: Screening Values for CEA USA
tion After Induction Treatment in Patients and Cyfra 21-1 for Lung Cancer in Com-
with NSCLC: Pulmonary Resection with bination with Low Dose CT (LDCT) in ADITYA MANNA
or Without Induction Treatment High-Risk Populations India
ANDREA PRIAS
Peru
MANGESH PATIL DONGSHENG YUE
CSABA LÁSZLÓ DÉGI
Tata Memorial Hospital, India Tianjin Medical University Cancer
Romania
Institute and Hospital, China
P2.14–005: Determination of Optimal Cut
off SUV Threshold for Auto-Contouring OA 16.04: Efficacy and Safety of Erlotinib
of GTV Using PETCT for Early Stage vs Vinorelbine/Cisplatin as Adjuvant
NSCLC WCLC 2017 NURSE AND ALLIED HEALTH
Therapy for Stage IIIA EGFR Mutant
PROFESSIONAL AWARD WINNERS
NSCLC Patients
The IASLC Nurse and Allied Health

AMRITA SINGH Professional Award Winners will
Thapar University, India FEI ZHOU receive their award during the IASLC
Department of Medical Oncology, Business Meeting on Monday, October
P2.06–004: Role of Polymorphic Vari- Shanghai Pulmonary Hospital, Tongji 16, 14:30 – 15:30, F201 + F202
ants of BER and DSBR Pathway Genes University School of Medicine, China (Annex Hall).
in Modulating Lung Cancer Susceptibility
and Prognosis of North Indian Population P3.15–015: LCNEC Tumor Location,
Divided into Central and Peripheral Type, LAERKE WINTHER
Has Distinct Clinicopathologic Feature, University of Copenhagen, Denmark
Genomic Characteristics and Survival
APICHAT TANTRAWORASIN
P2.10–003: The Deterioration and Prog-
Chiang Mai University, Thailand
nostic Value of Functional Capacity in
Patients with Lung Cancer: A Systematic
OA 04.08: Is Lobe-Specific Lymph Node Review
Dissection in Clinical N0-1 Non-Small
Cell Lung Cancer Adequate for Patholog-
ical Nodal Staging
ZHI XUAN LIN
Chi Mei Medical Center, Taiwan
ANA PAULA TEIXEIRA
P1.10–006: Adverse Events After First-
National Cancer Institute - Ministry of
Line Target Therapy for Non-Small Cell
Health, Brazil Lung Cancer Patients in a Case Manage-
ment Model
P3.06–006: The Government Willing-
ness to Legislate Tobacco Control and
Changes on Individual Behavior in Brazil

HEINE HANSEN LECTURESHIP AWARD ADI GAZDAR LECTURESHIP AWARD

WCLC 2017 LECTURESHIP AWARDS - SMALL CELL LUNG CANCER - TRANSLATIONAL RESEARCH
WCLC 2017 Lectureship Award Winners

will receive their award before their TAOFEEK OWONIKOKO KATEY ENFIELD
presentation in the Abstract Session. Emory University, USA BC Cancer Research Centre, Canada
OA 08.06: Exploratory Analysis for OA 07.07: Inhibition of the Novel Onco-

Predictors of Benefit of PARP Inhibitor gene ELF3 Abolishes Lung Adenocarci-
NEW Therapy in Extensive Stage Small Cell noma Growth
JAMES COX LECTURESHIP AWARD Lung Cancer: ECOG-ACRIN 2511 Study
IN RADIATION ONCOLOGY
IASLC is introducing the James Cox NURSE & ALLIED HEALTH

Lectureship Award for Radiation Oncol- CLIFTON MOUNTAIN LECTURESHIP LECTURESHIP AWARD
ogy. In the future the award will be pre- AWARD - SURGERY/STAGING
sented to the best abstract in Radiation
Oncology. MORTEN QUIST
HERBERT DECALUWE Rigshospitalet, University of Copenhagen,
James Cox will give his award presen- University Hospitals KU Leuven, Belgium Denmark
tation during the Presidential Sym-
posium, Tuesday, October 17, 08:15 OA 16.06: Mediastinal Staging by Video- OA 11.02: Exercise Improves Functional
mediastinoscopy in Clinical N1 Non-Small Capacity in Patients with Advance Stage
– 09:45.
Cell Lung Cancer: a Prospective Multi- Lung Cancer
centre Study
DANIEL C. IDHE LECTURESHIP AWARD

- COMBINED MODALITY
TSUGUO NARUKE LECTURESHIP

DIRK DE RUYSSCHER AWARD - STAGING
Maastricht University Medical Center,
Netherlands
MATTHEW SMELTZER
MA 17.10: Toxicity Results from the University of Memphis School of Public
Randomized Phase III NVALT-11 Study Health, USA
of Prophylactic Cranial Irradiation vs.
Observation in Stage III NSCLC OA 15.08: Thoroughness of Staging and
the Outcomes of Surgical Resection Out-
comes in Potentially Curable Non-Small
Cell Lung Cancer (NSCLC)
ROBERT J. GINSBERG LECTURESHIP

AWARD - SURGERY
FRANCESCO GUERRERA
University of Torino, Italy
OA 16.02: Risk of Recurrence in Stage I

Adenocarcinoma of the Lung: A Multi-In-
stitutional Study on Interaction with Type
of Surgery and Type of Nodal Staging

SECTION 6
CONFERENCE
PROGRAM
Program at a Glance 56
Sessions at a Glance | By Day 58
Sessions at a Glance | By Track 64

PROGRAM AT A GLANCE
SATURDAY SUNDAY MONDAY

OCTOBER 14, 2017 OCTOBER 15, 2017 OCTOBER 16, 2017
07:00
Meet the Expert Opposed Industry
Sessions
07:30 Sign Up Required
Symposia
(07:00–08:00) (07:00–08:00)
08:00
08:30 Joint Plenary Session PL 01:
Young IASLC- Prevention, Screening, and Management
09:00 CSCO- Scientific
Invest- of Screen-Detected Lung Cancer
igator CAALC Symposium
09:30 (08:15–09:45)
Session Session Roche
10:00 Breakfast Sign Up
Breakfast Poster Session P1 with Press Conference
Provided Required Presenters Present
Provided
10:30 (07:30–11:30) (08:15–12:00) (10:00–10:45) (10:00–10:45)
(08:00–11:30)
11:00
Educational Sessions
11:30 Oral and Mini Oral *Includes Mini Symposia,
Abstract Sessions Educational Session, Pro-Con
12:00 Unopposed Industry Symposium (11:00–12:30)
Sessions, Grand Rounds Sessions
- Takeda Oncology (11:00–12:30)
12:30 (11:30–13:00)
Symposium
13:00 on the Advances Unopposed Industry Supported
13:30 in Lung Cancer Symposium
CT Screening - Boehringer Ingelheim GmbH & Co. KG
14:00 [Ticketed Event]
Press Conference (12:45–14:15)
(13:30–14:30)
(09:00–18:00)
14:30
Poster Session P1 with IASLC Business
15:00 Presenters Present Meeting
(14:30–15:30) (14:30–15:30)
15:30 Unopposed Industry Symposium
- Lilly Oncology
16:00 (15:00–16:30)
Oral and Mini Oral
16:30 *Includes Mini Symposia,
17:00 Unopposed Industry Supported (15:45–17:30)
(15:45–17:30)
Symposium
17:30 Medscape - Supported by Independent Educational
Grant from AstraZeneca Pharmaceuticals LP
18:00 (16:45–18:15) Unopposed Industry Supported
18:30 Symposium
Opening Ceremony (18:30–20:00) - Bristol-Myers Squibb
19:00 - ARRIVE EARLY - (17:45–19:15)
ADDITIONAL SECURITY IN PLACE!
19:30 DOORS WILL BE CLOSED AT 18:25
Badge required for all attendees including Concert with Ms. Suwanai and the Tokyo City
Industry
those only attending as a paid guest of a delegate. Workshop
Philharmonic Orchestra [Ticketed Event]
20:00 Minatomira Concert Hall (across from
- Medtronic
PACIFICO Yokohama) (19:30–20:30) (19:15–20:30)
20:30
Welcome Reception
(20:00–21:00)
21:00 Faculty Dinner
[by Invitation Only]
21:30
YOKOHAMA BAY HOTEL TOKYU
22:00 (20:30–23:00)
22:30
14:00–18:00 Registration open 07:00–20:00 Registration open 06:30–16:00 Registration open
14:00–18:00 Speaker Preview Center open 07:00–20:00 Speaker Preview Center open 06:30–17:30 Speaker Preview Center open
09:30–16:00 Exhibit Hall open | Posters on Display

PROGRAM AT A GLANCE
TUESDAY WEDNESDAY
OCTOBER 17, 2017 OCTOBER 18, 2017
07:00
Meet the Expert Opposed Industry Highlights of the Meet the Expert Sessions Highlights of the Previous
Sessions
Sign Up Required
Symposia Previous Day Sessions Sign Up Required Day Sessions 07:30
(07:00–08:00) (07:00–08:00) (07:00–08:00) (07:00–08:00)
(07:00–08:00)
08:00
Presidential Symposium 08:30

Plenary Session PL 03:
Including James Cox Lectureship and
Immunology in Lung Cancer Update 2017 09:00
Top 3 Abstract Presentations
(08:15–09:45)
(08:15–09:45) 09:30
10:00
Poster Session P2 with Press Conference Poster Session P3 with Press Conference
Presenters Present Presenters Present
(10:00–10:45) (10:00–10:45) (10:00–10:45) (10:00–10:45) 10:30
11:00
Educational Sessions Educational Sessions
Oral and Mini Oral *Includes Mini Symposia,
Oral and Mini Oral *Includes Mini Symposia, 11:30
Abstract Sessions Educational Session, Pro-Con Abstract Sessions Educational Session, Pro-Con
(11:00–12:30)
(11:00–12:30)
Sessions, Grand Rounds Sessions 12:00
(11:00–12:30) (11:00–12:30)
12:30
Unopposed Industry Supported Symposium 13:00

Medscape - Supported by an Independent Educational
Unopposed Industry Supported Symposium
Grant from AstraZeneca Pharmaceuticals LP - AbbVie 13:30
(12:45–14:15)
(12:45–14:15) 14:00
14:30
Poster Session P2 Poster Session P3 with Oral and Educational
with Presenters Present Presenters Present
Mini Oral Sessions 15:00
(14:30–15:30) *Includes Mini Symposia,
(14:30–15:30) Abstract Educational Session,
15:30
Sessions Pro-Con Sessions,
Grand Rounds Sessions
(14:30–16:15) (14:30–16:15) 16:00
Oral and Mini Oral *Includes Mini Symposia, 16:30
(15:45–17:30)
(15:45–17:30)
Closing Plenary Session 17:00
(16:30–17:45)
17:30
18:00
Unopposed Industry Supported Symposium
- MSD 18:30
(17:45–19:15)
19:00
19:30
20:00
Conference Dinner 20:30

[Ticketed Event]
21:00
PLENARY HALL (HALL D)
(19:30–22:30) 21:30
22:00
22:30
06:30–16:00 Registration open 06:30–16:00 Registration open
06:30–17:30 Speaker Preview Center open 06:30–16:30 Speaker Preview Center open
09:30–16:00 Exhibit Hall open | Posters on Display 09:30–16:00 Exhibit Hall open | Posters on Display

SESSIONS AT A GLANCE | BY DAY
SATURDAY | OCTOBER 14, 2017
TOPIC # SESSION TITLE ROOM TIME

RADIOLOGY/STAGING/ WS 01 IASLC Supporting the Implementation of Quality Assured Global CT Screening F203 08:30 – 21:00
SCREENING
Workshop (By Invitation Only) (Annex Hall)
RADIOLOGY/STAGING/ WS 02 IASLC Symposium on the Advances in Lung Cancer CT Screening (Ticketed Session) F201 + F202 09:00 – 18:15
SCREENING
(Annex Hall)
SUNDAY | OCTOBER 15, 2017

ADVANCED NSCLC JCSE 01 Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: F203 07:30 – 11:30
SCLC/NEUROENDOCRINE Ongoing Research from East and West (Annex Hall)
TUMORS
SURGERY
IMMUNOLOGY AND
IMMUNOTHERAPY
CHEMOTHERAPY/
TARGETED THERAPY
EDUCATION/ YI 01 Young Investigator and First Time Attendee Session F201 + F202 08:00 – 11:30
PUBLICATION/CAREER
DEVELOPMENT
(Annex Hall)
SCIENTIFIC SYMPOSIUM SS 01 Supporting the Clinical Management of Lung Cancer Patients through Innovation in Room 315 08:15 – 12:00
Diagnostics – Roche
ISS ISS 01 Treatment Options for Patients with ALK+ NSCLC: How is the Paradigm Changing? Room 11:30 – 13:00
– Takeda Oncology 303 + 304
MESOTHELIOMA WS 03 ITONF Lung Cancer and Mesothelioma Workshop (Ticketed Session) Room 313 12:15 – 17:55
NURSING/PALLIATIVE
CARE/ETHICS
PULMONOLOGY/ WS 04 Minimally Invasive Diagnosis and Staging of Lung Cancer - Interventional Pulmonology Room 13:00 – 17:00
ENDOSCOPY
Hands-On Workshop (Ticketed Session) 416 + 417
Press Conference Room 418 13:30 – 14:30
ISS ISS 02 Treatment Selection Strategies in Advanced NSCLC – Implications and Global Room 15:00 – 16:30
Perspectives – Lilly Oncology 303 + 304
ISS ISS 03 Management of Advanced NSCLC: Where Do Immune Checkpoint Inhibitors Fit In? Room 16:45 – 18:15
– Medscape – Supported by an Independent Educational Grant from AstraZeneca 301 + 302
Pharmaceuticals LP
Opening Ceremony National Convention 18:30 – 20:00
ARRIVE EARLY – ADDITIONAL SECURITY IN PLACE! DOORS WILL BE CLOSED AT 18:25 Hall
Badge required for all attendees including those only attending as a paid guest of a delegate.
Welcome Reception National Convention 20:00 – 21:00

Hall
MONDAY | OCTOBER 16, 2017

ISS ISS 04 Integrating Liquid Biopsy into Clinical Care: Common Questions and Challenges F201 + F202 07:00 – 08:00
– Guardant Health (Annex Hall)
ISS ISS 05 What’s New in SCLC? Assessing Emerging Therapeutic Options – Medscape F203 + F204 07:00 – 08:00
– Supported by an Independent Educational Grant from AbbVie (Annex Hall)
RADIOLOGY/STAGING/ MTE 01 Management of Small Nodules Detected by CT Screening (Sign Up Required) Room 07:00 – 08:00
SCREENING
301 + 302
BIOLOGY/PATHOLOGY MTE 02 Appropriate and Optimized Handling of Specimens (Sign Up Required) Room 316 07:00 – 08:00
SURGERY MTE 03 Surgery for T4 Lung Cancer (Sign Up Required) Room 07:00 – 08:00
303 + 304
RADIOTHERAPY MTE 04 Radiotherapy for SCLC (Sign Up Required) Room 07:00 – 08:00
311 + 312
BIOLOGY/PATHOLOGY MTE 05 Neuroendocrine Tumors: Pathology and Genetic Update (Sign Up Required) Room 07:00 – 08:00
313 + 314
ES EDUCATIONAL SESSION JCSE JOINT IASLC/CSCO/CAALC SESSION PC PRO-CON SESSION

EXH EXHIBIT SHOWCASE SESSION MA MINI ORAL ABSTRACT SESSION PL PLENARY SESSION
GR GRAND ROUNDS SESSION MS MINI SYMPOSIUM SH HIGHLIGHT OF THE PREVIOUS DAY SESSION
ISS INDUSTRY SUPPORTED SYMPOSIUM MTE MEET THE EXPERT SESSION (SIGN UP REQUIRED) SS SCIENTIFIC SYMPOSIUM
OA ORAL ABSTRACT SESSION WS WORKSHOP

BY DAY | SESSIONS AT A GLANCE
BIOLOGY/PATHOLOGY MTE 06 Lung Cancer Pathology Update (Sign Up Required) Room 315 07:00 – 08:00
CHEMOTHERAPY/ MTE 07 Molecular Biology: Minimum Requirement for Clinicians (Sign Up Required) Room 501 07:00 – 08:00
TARGETED THERAPY
PULMONOLOGY/ MTE 08 Technical Details of EBUS and EUS (Sign Up Required) Room 502 07:00 – 08:00
ENDOSCOPY
NURSING/PALLIATIVE MTE 09 Management of Difficult Symptoms (Sign Up Required) Room 503 07:00 – 08:00
CARE/ETHICS
CHEMOTHERAPY/ MTE 10 Bridging the Gap between Genomics and Clinics (Sign Up Required) Room 07:00 – 08:00
TARGETED THERAPY
511 + 512
RADIOLOGY/STAGING/ PL 01 Prevention, Screening, and Management of Screen-Detected Lung Cancer Plenary Hall 08:15 – 09:45
SCREENING
(Hall D)
Poster Viewing with Presenters Present - Poster Session P1 Exhibit Hall 10:00 – 10:45
(Hall B + C)
CLINICAL DESIGN, MS 01 Clinical Development of Novel Agents Main Hall 11:00 – 12:30
STATISTICS AND
CLINICAL TRIALS
REGIONAL ASPECTS/ MS 02 Ethnic Differences: Biology or Myth Room 501 11:00 – 12:30
HEALTH POLICY/PUBLIC
HEALTH
EARLY STAGE NSCLC MS 03 Best Practice for Small-Sized Early Stage Lung Cancer: Standard Surgery, F203 + F204 11:00 – 12:30
Limited Resection, SBRT (Annex Hall)
PATIENT ADVOCACY MS 04 Joint IASLC/GLCC Session Current Issues in Lung Cancer Advocacy Room 316 11:00 – 12:30
RADIOLOGY/STAGING/ ES 01 New TNM and WHO Classification Room 11:00 – 12:30
SCREENING
301 + 302
RADIOLOGY/STAGING/ ES 02 Diagnostic and Interventional Radiology in Lung Cancer: Update 2017 Room 315 11:00 – 12:30
SCREENING
CHEMOTHERAPY/ GR 01 What to Do at the Time of Progression on Targeted Therapy Room 11:00 – 12:30
TARGETED THERAPY
303 + 304
RADIOTHERAPY OA 01 The New Aspect of Radiation Therapy F201 + F202 11:00 – 12:30
(Annex Hall)
MESOTHELIOMA OA 02 Mesothelioma: Challenges For New Treatment F205 + F206 11:00 – 12:30
(Annex Hall)
THYMIC MALIGNANCIES/ OA 03 Mediastinal and Esophageal Tumor: Insight and New Treatment Room 11:00 – 12:30
ESOPHAGEAL CANCER/
OTHER THORACIC
311 + 312
MALIGNANCIES
SCLC/NEUROENDOCRINE MA 01 SCLC: Research Perspectives Room 503 11:00 – 12:30

TUMORS
CLINICAL DESIGN, MA 02 Emerging Targets Room 11:00 – 12:30

STATISTICS AND
CLINICAL TRIALS
511 + 512
ADVANCED NSCLC MA 03 Chemotherapy Room 502 11:00 – 12:30

CHEMOTHERAPY/
TARGETED THERAPY
PATIENT ADVOCACY MA 04 Advocacy: Listen to the Patients Room 11:00 – 12:30

313 + 314
ISS ISS 06 Maximizing Clinical Benefit from TKIs in the Treatment of Advanced NSCLC Main Hall 12:45 – 14:15
– Boehringer Ingelheim Pharma GmbH & Co. KG
EXH 01 Thermo Fisher: Next Generation Sequencing – Changing Paradigm in NSCLC Patient Exhibit Showcase 13:00 – 14:00
Management Theater (Hall B + C)
IASLC Business Meeting F201 + F202 14:30 – 15:30
(Annex Hall)
(Hall B + C)
IMMUNOLOGY AND MS 05 Clinical Issues of Immune Checkpoint Inhibitors Main Hall 15:45 – 17:30
IMMUNOTHERAPY
THYMIC MALIGNANCIES/ MS 06 Combined Modality Treatment for Thymic and Pleural Malignancy F201 + F202 15:45 – 17:30
ESOPHAGEAL CANCER/
OTHER THORACIC
(Annex Hall)
MALIGNANCIES
SCLC/NEUROENDOCRINE MS 07 Neuroendocrine Tumors other than SCLC: Pathology to Patient Management F203 + F204 15:45 – 17:30
TUMORS
(Annex Hall)
MESOTHELIOMA MS 08 Novel Treatment for Mesothelioma Room 316 15:45 – 17:30
EPIDEMIOLOGY/ MS 09 Global Perspectives in Eliminating the Major Cause of Lung Cancer Room 315 15:45 – 17:30
PRIMARY PREVENTION/
TOBACCO CONTROL AND
CESSATION
NURSING/PALLIATIVE MS 10 Evidence Based Care: Interpreting the Research and Enhancing Practice F205 + F206 15:45 – 17:30
CARE/ETHICS
(Annex Hall)
NURSING/PALLIATIVE ES 03 Current Topics for Nurses & Allied Health Room 15:45 – 17:30
CARE/ETHICS
313 + 314

EARLY STAGE NSCLC PC 01 1-1. Surgery vs Non-Surgical Local Treatment for Small-Sized NSCLC Room 502 15:45 – 17:30
ADVANCED NSCLC 1-2. What is the role of Local Therapy in Non-CNS Oligometastatic NSCLC?
SURGERY OA 04 Surgery from Minimal to Radical Room 15:45 – 17:30
311 + 312
ADVANCED NSCLC OA 05 Next Generation TKI Room 15:45 – 17:30
CHEMOTHERAPY/ 301 + 302
TARGETED THERAPY
EPIDEMIOLOGY/ OA 06 Global Tobacco Control and Epidemiology I Room 15:45 – 17:30

PRIMARY PREVENTION/
TOBACCO CONTROL AND
511 + 512
CESSATION
BIOLOGY/PATHOLOGY OA 07 Biomarker for Lung Cancer Room 503 15:45 – 17:30

IMMUNOLOGY AND MA 05 Immuno-Oncology: Novel Biomarker Candidates Room 15:45 – 17:30
IMMUNOTHERAPY
303 + 304
BIOLOGY/PATHOLOGY MA 06 Lung Cancer Biology I Room 501 15:45 – 17:30
ISS ISS 07 The Evolving I-O Treatment Landscape in Thoracic Cancers: Clinical Updates and Main Hall 17:45 – 19:15
Future Directions – Bristol-Myers Squibb
PULMONOLOGY/ WS 05 superDimension™ Electromagnetic Navigation Bronchoscopy - Bridging the Diagnostic Room 315 19:15 – 20:30
ENDOSCOPY
and Therapeutic Domains in Lung Cancer - Medtronic
Joint IASLC Foundation - JLCS Concert (Ticketed Event) Minatomirai Hall 19:30 – 20:30
Faculty Dinner (By Invitation Only) Yokohama Bay 20:30 – 23:00
Hotel Tokyu
TUESDAY | OCTOBER 17, 2017

ISS ISS 08 Optimising the Continuum of Care for Patients with Oncogenic-Driven NSCLC F201 + F202 07:00 – 08:00
– Pfizer Oncology (Annex Hall)
ISS ISS 09 The Evolution of Targetable Oncogenic Drivers in NSCLC: Novel Treatment Paradigms F203 + F204 07:00 – 08:00
– Novartis (Annex Hall)
ADVANCED NSCLC SH 01 WCLC 2017 Highlights of the Previous Day Room 502 07:00 – 08:00
CLINICAL DESIGN,
STATISTICS AND
CLINICAL TRIALS
IMMUNOLOGY AND
IMMUNOTHERAPY
PATIENT ADVOCACY
SURGERY
BIOLOGY/PATHOLOGY
EPIDEMIOLOGY/
PRIMARY PREVENTION/
TOBACCO CONTROL AND
CESSATION
CHEMOTHERAPY/ SH 02 WCLC 2017 Highlights of the Previous Day Room 503 07:00 – 08:00
TARGETED THERAPY
SCLC/NEUROENDOCRINE
TUMORS
RADIOTHERAPY
BIOLOGY/PATHOLOGY
MESOTHELIOMA
THYMIC MALIGNANCIES/
ESOPHAGEAL CANCER/
OTHER THORACIC
MALIGNANCIES
EDUCATION/ MTE 11 How to Write a Scientific Paper (Sign Up Required) Room 07:00 – 08:00
PUBLICATION/CAREER
DEVELOPMENT
511 + 512
NURSING/PALLIATIVE MTE 12 Oncology Nursing (Sign Up Required) Room 316 07:00 – 08:00
CARE/ETHICS
MESOTHELIOMA MTE 13 Malignant Pleural Mesothelioma: State of the Art (Sign Up Required) Room 501 07:00 – 08:00
RADIOLOGY/STAGING/ MTE 14 Imaging of Lung Cancer (Sign Up Required) F205 + F206 07:00 – 08:00
SCREENING
(Annex Hall)
IMMUNOLOGY AND MTE 15 Biomarkers for Immune Checkpoint Inhibitors (Sign Up Required) Room 07:00 – 08:00
IMMUNOTHERAPY
301 + 302


SURGERY MTE 16 Technical Issues after Neoadjuvant Chemoradiation – Surgeon’s Perspective (Sign Up Room 07:00 – 08:00
Required) 311 + 312
SCLC/NEUROENDOCRINE MTE 17 Neuroendocrine Tumor (Sign Up Required) Room 418 07:00 – 08:00
TUMORS
ADVANCED NSCLC MTE 18 Treatment for Squamous Cell Carcinoma (Sign Up Required) Room 07:00 – 08:00
313 + 314
PULMONOLOGY/ MTE 19 Laser Therapy for Early Stage and Airway Obstruction (Sign Up Required) Room 317 07:00 – 08:00
ENDOSCOPY
BIOLOGY/PATHOLOGY MTE 20 Liquid Biopsy (Sign Up Required) Room 07:00 – 08:00

303 + 304
CHEMOTHERAPY/ MTE 21 Search for Novel Driver Mutations (Sign Up Required) Room 315 07:00 – 08:00
TARGETED THERAPY
EARLY STAGE NSCLC PL 02 Presidential Symposium including Top 3 Abstracts and James Cox Lectureship Award Plenary Hall 08:15 – 09:45
IMMUNOLOGY AND Presentation (Hall D)
IMMUNOTHERAPY
SURGERY
EXH 02 AstraZeneca: The Role of PD-L1 in Treatment Decision Making for NSCLC Patients Exhibit Showcase 10:00 – 10:30
Theater (Hall B + C)
(Hall B + C)
LOCALLY ADVANCED MS 11 Combined Modality Treatment for Superior Sulcus Tumors Room 503 11:00 – 12:30
NSCLC
REGIONAL ASPECTS/ MS 12 Sustainable Care System in Each Region Room 501 11:00 – 12:30
HEALTH
ADVANCED NSCLC MS 13 How to Deal with CNS Metastases Room 502 11:00 – 12:30
NURSING/PALLIATIVE MS 14 QOL Evaluation in Practice from the Viewpoint of Physicians and Nurses Room 315 11:00 – 12:30
CARE/ETHICS
BIOLOGY/PATHOLOGY ES 04 Biology of Lung Cancer F201 + F202 11:00 – 12:30

(Annex Hall)
IMMUNOLOGY AND GR 02 Management of Immunotherapy-Related Adverse Events Main Hall 11:00 – 12:30
IMMUNOTHERAPY
SCLC/NEUROENDOCRINE PC 02 Is Radiotherapy Necessary for Extensive SCLC? (Thoracic Radiation/PCI) F203 + F204 11:00 – 12:30
TUMORS
(Annex Hall)
SCLC/NEUROENDOCRINE OA 08 Neuroendocrine Carcinoma: Translational Room 11:00 – 12:30
TUMORS
311 + 312
ADVANCED NSCLC OA 09 EGFR TKI Resistance Room 11:00 – 12:30
TARGETED THERAPY
NURSING/PALLIATIVE MA 08 Supportive Care and Communication Room 11:00 – 12:30

CARE/ETHICS
511 + 512
LOCALLY ADVANCED MA 09 The Current Status of Radiation Oncology Room 316 11:00 – 12:30
NSCLC
RADIOTHERAPY
ADVANCED NSCLC MA 10 Immunotherapy I Room 11:00 – 12:30

IMMUNOLOGY AND 303 + 304
IMMUNOTHERAPY
ADVANCED NSCLC MA 11 Emerging Diagnostic/Biomarkers in NSCLC Room 11:00 – 12:30

TARGETED THERAPY
ADVANCED NSCLC MA 12 Circumventing EGFR Resistance F205 + F206 11:00 – 12:30

CHEMOTHERAPY/ (Annex Hall)
TARGETED THERAPY
ISS ISS 10 Evolving Decisions and Best Practices: Management of EGFR-Mutated NSCLC Main Hall 12:45 – 14:15
– Medscape – Supported by an Independent Educational Grant from AstraZeneca
Pharmaceuticals LP
JTO Meet the JTO Editor Room 14:30 – 15:30
511 + 512
(Hall B + C)
BIOLOGY/PATHOLOGY MS 15 Molecular Testing Room 15:45 – 17:30
301 + 302
RADIOTHERAPY MS 16 Future Direction of Chemoradiotherapy for Inoperable Non-Small Cell Lung Cancer Room 502 15:45 – 17:30
CHEMOTHERAPY/
TARGETED THERAPY
CLINICAL DESIGN, MS 17 Lessons Learned from Negative Trials Room 15:45 – 17:30
STATISTICS AND
CLINICAL TRIALS
303 + 304
IMMUNOLOGY AND MS 18 Biomarker for Anti-PD-L1 Therapy Main Hall 15:45 – 17:30
IMMUNOTHERAPY
PATIENT ADVOCACY MS 19 Elevating the Lung Cancer Voice: Raising Awareness and Creating Community Room 315 15:45 – 17:30

SURGERY ES 05 Surgical Skills Room 503 15:45 – 17:30

NURSING/PALLIATIVE ES 06 Communication Skills in the End of Life/ Symptom Management in Lung Cancer F201 + F202 15:45 – 17:30
CARE/ETHICS
(Annex Hall)
ADVANCED NSCLC MA 07 ALK, ROS and HER2 Room 316 15:45 – 17:30
CHEMOTHERAPY/
TARGETED THERAPY
EARLY STAGE NSCLC MA 13 New Insights of Diagnosis and Update of Treatment Room 15:45 – 17:30
311 + 312
RADIOLOGY/STAGING/ MA 14 Diagnostic Radiology, Staging and Screening for Lung Cancer I F205 + F206 15:45 – 17:30
SCREENING
(Annex Hall)
BIOLOGY/PATHOLOGY MA 15 Lung Cancer Biology II Room 501 15:45 – 17:30
THYMIC MALIGNANCIES/ MA 16 Mediastinal, Tracheal and Esophageal Tumor: Multimodality Approaches Room 15:45 – 17:30
ESOPHAGEAL CANCER/
OTHER THORACIC
313 + 314
MALIGNANCIES
LOCALLY ADVANCED MA 17 Locally Advanced NSCLC F203 + F204 15:45 – 17:30

NSCLC
(Annex Hall)
EPIDEMIOLOGY/ MA 18 Global Tobacco Control and Epidemiology II Room 15:45 – 17:30
PRIMARY PREVENTION/
TOBACCO CONTROL AND
511 + 512
CESSATION
ISS ISS 11 Pembrolizumab: The New Standard of Care in Advanced Lung Cancer – MSD Main Hall 17:45 – 19:15
Conference Dinner (Ticketed Event) Plenary Hall 19:30 – 22:30
(Hall D)
WEDNESDAY | OCTOBER 18, 2017

ADVANCED NSCLC SH 03 WCLC 2017 Highlights of the Previous Day F201 + F202 07:00 – 08:00
IMMUNOLOGY AND (Annex Hall)
IMMUNOTHERAPY
EARLY STAGE NSCLC
RADIOLOGY/STAGING/
SCREENING
BIOLOGY/PATHOLOGY
EPIDEMIOLOGY/
PRIMARY PREVENTION/
TOBACCO CONTROL AND
CESSATION
CHEMOTHERAPY/ SH 04 WCLC 2017 Highlights of the Previous Day F203 + F204 07:00 – 08:00
TARGETED THERAPY
NURSING/PALLIATIVE (Annex Hall)
CARE/ETHICS
SCLC/NEUROENDOCRINE
TUMORS
LOCALLY ADVANCED
NSCLC
RADIOTHERAPY
BIOLOGY/PATHOLOGY
THYMIC MALIGNANCIES/
ESOPHAGEAL CANCER/
OTHER THORACIC
MALIGNANCIES
NURSING/PALLIATIVE MTE 22 Management of Elderly Patients with Lung Cancer (Sign Up Required) Room 07:00 – 08:00
CARE/ETHICS
303 + 304
THYMIC MALIGNANCIES/ MTE 23 Mediastinal Tumors including Thymic Tumors, Lymphoma, Germ Cell Tumors: Room 07:00 – 08:00
ESOPHAGEAL CANCER/
OTHER THORACIC
Biopsy, Diagnosis and Treatment (Sign Up Required) 311 + 312
MALIGNANCIES
BIOLOGY/PATHOLOGY MTE 24 Basic Cytology for Clinicians (Sign Up Required) Room 07:00 – 08:00
313 + 314
EPIDEMIOLOGY/ MTE 25 Tobacco Control – Practical Issues (Sign Up Required) Room 316 07:00 – 08:00
PRIMARY PREVENTION/
TOBACCO CONTROL AND
CESSATION
CLINICAL DESIGN, MTE 26 Clinical Trial Design for Novel Treatment (Sign Up Required) Room 315 07:00 – 08:00
STATISTICS AND
CLINICAL TRIALS
RADIOLOGY/STAGING/ MTE 27 CT Screening for Lung Cancer (Sign Up Required) Room 501 07:00 – 08:00
SCREENING
IMMUNOLOGY AND MTE 28 Immunotherapy for Earlier Stage NSCLC (Sign Up Required) Room 07:00 – 08:00
IMMUNOTHERAPY
301 + 302


RADIOTHERAPY MTE 29 Stereotactic Body Radiation Therapy for Early Stage Lung Cancer Room 502 07:00 – 08:00
(Sign Up Required)
SURGERY MTE 30 Surgery after Concurrent Chemoradiotherapy (Sign Up Required) Room 503 07:00 – 08:00
CHEMOTHERAPY/ MTE 31 Perspectives of Anti-Angiogenesis (Sign Up Required) Room 418 07:00 – 08:00
TARGETED THERAPY
IMMUNOLOGY AND PL 03 Immunology in Lung Cancer Update 2017 Plenary Hall 08:15 – 09:45
IMMUNOTHERAPY
(Hall D)
(Hall B + C)
NURSING/PALLIATIVE MS 20 Value-based Management for Special Populations Room 501 11:00 – 12:30
CARE/ETHICS
NURSING/PALLIATIVE MS 21 Being Mortal: Learning from ZEN Room 316 11:00 – 12:30
CARE/ETHICS
EPIDEMIOLOGY/ MS 22 The Cost of Lung Cancer Room 502 11:00 – 12:30

PRIMARY PREVENTION/
TOBACCO CONTROL AND
CESSATION
PULMONOLOGY/ ES 07 Recent Advances in Diagnostics and Interventional Bronchoscopy Room 503 11:00 – 12:30
ENDOSCOPY
CHEMOTHERAPY/ ES 08 Molecular Diagnostics and Targeted Therapy Main Hall 11:00 – 12:30
TARGETED THERAPY
EARLY STAGE NSCLC GR 03 Treatment Options for Early Stage Lung Cancer Patients with Limited Pulmonary F205 + F206 11:00 – 12:30
Reserve (Annex Hall)
CHEMOTHERAPY/ PC 03 3-1 What is the Optimal Sequence of ALK-TKI for ALK-Positive Lung Cancer? Room 11:00 – 12:30
TARGETED THERAPY
(Alectinib First or Crizotinib First) 303 + 304
3-2 Which Do you Prefer: Liquid Biopsy or Tissues Biopsy for Molecular Diagnosis?
ADVANCED NSCLC OA 10 Liquid Biopsy for Genomic Alterations F201 + F202 11:00 – 12:30
(Annex Hall)
NURSING/PALLIATIVE OA 11 Reducing Burden: Patient-Centered Care Room 11:00 – 12:30
CARE/ETHICS
313 + 314
PATIENT ADVOCACY
ADVANCED NSCLC OA 12 Emerging Genomic Targets F203 + F204 11:00 – 12:30

CHEMOTHERAPY/ (Annex Hall)
TARGETED THERAPY
IMMUNOLOGY AND OA 13 Immuno-Biology Room 11:00 – 12:30

IMMUNOTHERAPY
301 + 302
CLINICAL DESIGN, OA 14 New Paradigms in Clinical Trials Room 11:00 – 12:30
STATISTICS AND
CLINICAL TRIALS
311 + 312
MESOTHELIOMA MA 19 Mesothelioma: Bench to Bedside Room 315 11:00 – 12:30

ISS ISS 12 SCLC Biomarker Testing Symposium – AbbVie Main Hall 12:45 – 14:15
(Hall B + C)
LOCALLY ADVANCED MS 23 Management of N2 NSCLC: What “Operable” Means? F203 + F204 14:30 – 16:15
NSCLC
(Annex Hall)
RADIOLOGY/STAGING/ MS 24 Management of GGO-Containing Nodule Room 503 14:30 – 16:15
SCREENING
CHEMOTHERAPY/
TARGETED THERAPY
SURGERY
CHEMOTHERAPY/ MS 25 Novel Molecular Targets (KRAS/MET/Novel Fusions): Druggable or Not? Main Hall 14:30 – 16:15
TARGETED THERAPY
BIOLOGY/PATHOLOGY MS 26 Re-Modeling Microenvironment Mimicking Human Cancer Room 502 14:30 – 16:15
PATIENT ADVOCACY MS 27 Engaging Patients in Research: Best Practices Room 14:30 – 16:15
311 + 312
SCLC/NEUROENDOCRINE ES 09 Recent Progress in the Management of Small Cell Lung Cancer Room 501 14:30 – 16:15
TUMORS
RADIOTHERAPY ES 10 Radiation Treatment Update F201 + F202 14:30 – 16:15

(Annex Hall)
RADIOLOGY/STAGING/ OA 15 Diagnostic Radiology, Staging and Screening for Lung Cancer II Room 14:30 – 16:15
SCREENING
303 + 304
EARLY STAGE NSCLC OA 16 Treatment Strategies and Follow Up Room 315 14:30 – 16:15
ADVANCED NSCLC OA 17 Immunotherapy II Room 14:30 – 16:15
IMMUNOLOGY AND 301 + 302
IMMUNOTHERAPY
BIOLOGY/PATHOLOGY OA 18 Lung Cancer Pathology and Genetics Room 316 14:30 – 16:15
PULMONOLOGY/ MA 20 Recent Advances in Pulmonology/Endoscopy F205 + F206 14:30 – 16:15
ENDOSCOPY
(Annex Hall)
PL 04 Closing Plenary: Where We Are Now, and Where We Will Be in 10 Years Main Hall 16:30 – 17:45

SESSIONS AT A GLANCE | BY TRACK
ADVANCED NSCLC
TOPIC # SESSION TITLE DATE ROOM TIME

ADVANCED NSCLC JCSE 01 Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Sunday, F203 07:30 – 11:30
Cancer: Ongoing Research from East and West October 15 (Annex Hall)
ADVANCED NSCLC MA 03 Chemotherapy Monday, Room 502 11:00 – 12:30
October 16
ADVANCED NSCLC OA 05 Next Generation TKI Monday, Room 15:45 – 17:30
October 16 301 + 302
ADVANCED NSCLC PC 01 1-1. Surgery vs Non-Surgical Local Treatment for Small-Sized NSCLC Monday, Room 502 15:45 – 17:30
1-2. What is the role of Local Therapy in Non-CNS Oligometastatic NSCLC? October 16
ADVANCED NSCLC MTE 18 Treatment for Squamous Cell Carcinoma (Sign Up Required) Tuesday, Room 07:00 – 08:00
October 17 313 + 314
ADVANCED NSCLC SH 01 WCLC 2017 Highlights of the Previous Day Tuesday, Room 502 07:00 – 08:00
October 17
ADVANCED NSCLC MS 13 How to Deal with CNS Metastases Tuesday, Room 502 11:00 – 12:30
October 17
ADVANCED NSCLC OA 09 EGFR TKI Resistance Tuesday, Room 11:00 – 12:30
October 17 301 + 302
ADVANCED NSCLC MA 10 Immunotherapy I Tuesday, Room 11:00 – 12:30
October 17 303 + 304
ADVANCED NSCLC MA 11 Emerging Diagnostic/Biomarkers in NSCLC Tuesday, Room 11:00 – 12:30
October 17 313 + 314
ADVANCED NSCLC MA 12 Circumventing EGFR Resistance Tuesday, F205 + F206 11:00 – 12:30
October 17 (Annex Hall)
ADVANCED NSCLC MA 07 ALK, ROS and HER2 Tuesday, Room 316 15:45 – 17:30
October 17
ADVANCED NSCLC SH 03 WCLC 2017 Highlights of the Previous Day Wednesday, F201 + F202 07:00 – 08:00
ADVANCED NSCLC OA 10 Liquid Biopsy for Genomic Alterations Wednesday, F201 + F202 11:00 – 12:30
ADVANCED NSCLC OA 12 Emerging Genomic Targets Wednesday, F203 + F204 11:00 – 12:30
ADVANCED NSCLC OA 17 Immunotherapy II Wednesday, Room 14:30 – 16:15
October 18 301 + 302
BIOLOGY / PATHOLOGY

BIOLOGY/PATHOLOGY MTE 02 Appropriate and Optimized Handling of Specimens (Sign Up Required) Monday, Room 316 07:00 – 08:00
October 16
BIOLOGY/PATHOLOGY MTE 05 Neuroendocrine Tumors: Pathology and Genetic Update (Sign Up Required) Monday, Room 07:00 – 08:00
October 16 313 + 314
BIOLOGY/PATHOLOGY MTE 06 Lung Cancer Pathology Update (Sign Up Required) Monday, Room 315 07:00 – 08:00
October 16
BIOLOGY/PATHOLOGY OA 07 Biomarker for Lung Cancer Monday, Room 503 15:45 – 17:30
October 16
BIOLOGY/PATHOLOGY MA 06 Lung Cancer Biology I Monday, Room 501 15:45 – 17:30
October 16
BIOLOGY/PATHOLOGY SH 01 WCLC 2017 Highlights of the Previous Day Tuesday, Room 502 07:00 – 08:00
October 17
BIOLOGY/PATHOLOGY SH 02 WCLC 2017 Highlights of the Previous Day Tuesday, Room 503 07:00 – 08:00
October 17
BIOLOGY/PATHOLOGY MTE 20 Liquid Biopsy (Sign Up Required) Tuesday, Room 07:00 – 08:00
October 17 303 + 304
BIOLOGY/PATHOLOGY ES 04 Biology of Lung Cancer Tuesday, F201 + F202 11:00 – 12:30


BY TRACK | SESSIONS AT A GLANCE
BIOLOGY/PATHOLOGY MS 15 Molecular Testing Tuesday, Room 15:45 – 17:30

October 17 301 + 302
BIOLOGY/PATHOLOGY MA 15 Lung Cancer Biology II Tuesday, Room 501 15:45 – 17:30
October 17
BIOLOGY/PATHOLOGY MTE 24 Basic Cytology for Clinicians (Sign Up Required) Wednesday, Room 07:00 – 08:00
October 18 313 + 314
BIOLOGY/PATHOLOGY SH 03 WCLC 2017 Highlights of the Previous Day Wednesday, F201 + F202 07:00 – 08:00
BIOLOGY/PATHOLOGY SH 04 WCLC 2017 Highlights of the Previous Day Wednesday, F203 + F204 07:00 – 08:00
BIOLOGY/PATHOLOGY OA 18 Lung Cancer Pathology and Genetics Wednesday, Room 316 14:30 – 16:15
October 18
BIOLOGY/PATHOLOGY MS 26 Re-Modeling Microenvironment Mimicking Human Cancer Wednesday, Room 502 14:30 – 16:15
October 18
CHEMOTHERAPY / TARGETED THERAPY

CHEMOTHERAPY/ JCSE 01 Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Sunday, F203 07:30 – 11:30
TARGETED THERAPY
CHEMOTHERAPY/ MTE 07 Molecular Biology: Minimum Requirement for Clinicians (Sign Up Required) Monday, Room 501 07:00 – 08:00
TARGETED THERAPY
October 16
CHEMOTHERAPY/ MTE 10 Bridging the Gap between Genomics and Clinics (Sign Up Required) Monday, Room 07:00 – 08:00
TARGETED THERAPY
October 16 511 + 512
CHEMOTHERAPY/ GR 01 What to Do at the Time of Progression on Targeted Therapy Monday, Room 11:00 – 12:30
TARGETED THERAPY
October 16 303 + 304
CHEMOTHERAPY/ MA 03 Chemotherapy Monday, Room 502 11:00 – 12:30
TARGETED THERAPY
October 16
CHEMOTHERAPY/ OA 05 Next Generation TKI Monday, Room 15:45 – 17:30
TARGETED THERAPY
October 16 301 + 302
CHEMOTHERAPY/ MTE 21 Search for Novel Driver Mutations (Sign Up Required) Tuesday, Room 315 07:00 – 08:00
TARGETED THERAPY
October 17
CHEMOTHERAPY/ SH 02 WCLC 2017 Highlights of the Previous Day Tuesday, Room 503 07:00 – 08:00
TARGETED THERAPY
October 17
CHEMOTHERAPY/ OA 09 EGFR TKI Resistance Tuesday, Room 11:00 – 12:30
TARGETED THERAPY
October 17 301 + 302
CHEMOTHERAPY/ MA 11 Emerging Diagnostic/Biomarkers in NSCLC Tuesday, Room 11:00 – 12:30
TARGETED THERAPY
October 17 313 + 314
CHEMOTHERAPY/ MA 12 Circumventing EGFR Resistance Tuesday, F205 + F206 11:00 – 12:30
TARGETED THERAPY
CHEMOTHERAPY/ MA 07 ALK, ROS and HER2 Tuesday, Room 316 15:45 – 17:30
TARGETED THERAPY
October 17
RADIOTHERAPY MS 16 Future Direction of Chemoradiotherapy for Inoperable Non-Small Cell Lung Tuesday, Room 502 15:45 – 17:30
CHEMOTHERAPY/ October 17
TARGETED THERAPY
CHEMOTHERAPY/ SH 04 WCLC 2017 Highlights of the Previous Day Wednesday, F203 + F204 07:00 – 08:00
TARGETED THERAPY
CHEMOTHERAPY/ MTE 31 Perspectives of Anti-Angiogenesis (Sign Up Required) Wednesday, Room 418 07:00 – 08:00
TARGETED THERAPY
October 18
CHEMOTHERAPY/ ES 08 Molecular Diagnostics and Targeted Therapy Wednesday, Main Hall 11:00 – 12:30
TARGETED THERAPY
October 18
CHEMOTHERAPY/ PC 03 3-1 What is the Optimal Sequence of ALK-TKI for ALK-Positive Lung Cancer? Wednesday, Room 11:00 – 12:30
TARGETED THERAPY
(Alectinib First or Crizotinib First) October 18 303 + 304
3-2 Which Do you Prefer: Liquid Biopsy or Tissues Biopsy for Molecular
Diagnosis?
CHEMOTHERAPY/ OA 12 Emerging Genomic Targets Wednesday, F203 + F204 11:00 – 12:30
TARGETED THERAPY
RADIOLOGY/STAGING/ MS 24 Management of GGO-Containing Nodule Wednesday, Room 503 14:30 – 16:15
SCREENING
October 18
CHEMOTHERAPY/
TARGETED THERAPY
SURGERY
CHEMOTHERAPY/ MS 25 Novel Molecular Targets (KRAS/MET/Novel Fusions): Druggable or Not? Wednesday, Main Hall 14:30 – 16:15
TARGETED THERAPY
October 18

CLINICAL DESIGN / STATISTICS AND CLINICAL TRIALS

CLINICAL DESIGN, MS 01 Clinical Development of Novel Agents Monday, Main Hall 11:00 – 12:30
STATISTICS AND
CLINICAL TRIALS
October 16
CLINICAL DESIGN, MA 02 Emerging Targets Monday, Room 11:00 – 12:30

STATISTICS AND
CLINICAL TRIALS
October 16 511 + 512
CLINICAL DESIGN, SH 01 WCLC 2017 Highlights of the Previous Day Tuesday, Room 502 07:00 – 08:00
STATISTICS AND
CLINICAL TRIALS
October 17
CLINICAL DESIGN, MS 17 Lessons Learned from Negative Trials Tuesday, Room 15:45 – 17:30
STATISTICS AND
CLINICAL TRIALS
October 17 303 + 304
CLINICAL DESIGN, MTE 26 Clinical Trial Design for Novel Treatment (Sign Up Required) Wednesday, Room 315 07:00 – 08:00
STATISTICS AND
CLINICAL TRIALS
October 18
CLINICAL DESIGN, OA 14 New Paradigms in Clinical Trials Wednesday, Room 11:00 – 12:30
STATISTICS AND
CLINICAL TRIALS
October 18 311 + 312
EARLY STAGE NSCLC

EARLY STAGE NSCLC MS 03 Best Practice for Small-Sized Early Stage Lung Cancer: Standard Surgery, Monday, F203 + F204 11:00 – 12:30
Limited Resection, SBRT October 16 (Annex Hall)
EARLY STAGE NSCLC PC 01 1-1. Surgery vs Non-Surgical Local Treatment for Small-Sized NSCLC Monday, Room 502 15:45 – 17:30
1-2. What is the role of Local Therapy in Non-CNS Oligometastatic NSCLC? October 16
EARLY STAGE NSCLC PL 02 Presidential Symposium (incl. Top 3 Rated Abstracts) Tuesday, Plenary Hall 08:15 – 09:45
October 17 (Hall D)
EARLY STAGE NSCLC MA 13 New Insights of Diagnosis and Update of Treatment Tuesday, Room 15:45 – 17:30
October 17 311 + 312
EARLY STAGE NSCLC SH 03 WCLC 2017 Highlights of the Previous Day Wednesday, F201 + F202 07:00 – 08:00
EARLY STAGE NSCLC GR 03 Treatment Options for Early Stage Lung Cancer Patients with Limited Pulmonary Wednesday, F205 + F206 11:00 – 12:30
Reserve October 18 (Annex Hall)
EARLY STAGE NSCLC OA 16 Treatment Strategies and Follow Up Wednesday, Room 315 14:30 – 16:15
October 18
EDUCATION / PUBLICATION / CAREER DEVELOPMENT

EDUCATION/ YI 01 Young Investigator and First Time Attendee Session Sunday, F201 + F202 08:00 – 11:30
PUBLICATION/CAREER
DEVELOPMENT
EDUCATION/ MTE 11 How to Write a Scientific Paper (Sign Up Required) Tuesday, Room 07:00 – 08:00
PUBLICATION/CAREER
DEVELOPMENT
October 17 511 + 512
EDUCATION / JTO Meet the JTO Editor Tuesday, Room 14:30 – 15:30
PUBLICATION / CAREER
DEVELOPMENT
October 17 511 + 512


EPIDEMIOLOGY / PRIMARY PREVENTION / TOBACCO CONTROL AND CESSATION

EPIDEMIOLOGY/ MS 09 Global Perspectives in Eliminating the Major Cause of Lung Cancer Monday, Room 315 15:45 – 17:30
PRIMARY PREVENTION/
TOBACCO CONTROL AND
October 16
CESSATION
EPIDEMIOLOGY/ OA 06 Global Tobacco Control and Epidemiology I Monday, Room 15:45 – 17:30
PRIMARY PREVENTION/
TOBACCO CONTROL AND
October 16 511 + 512
CESSATION
EPIDEMIOLOGY/ SH 01 WCLC 2017 Highlights of the Previous Day Tuesday, Room 502 07:00 – 08:00
PRIMARY PREVENTION/
TOBACCO CONTROL AND
October 17
CESSATION
EPIDEMIOLOGY/ MA 18 Global Tobacco Control and Epidemiology II Tuesday, Room 15:45 – 17:30
PRIMARY PREVENTION/
TOBACCO CONTROL AND
October 17 511 + 512
CESSATION
EPIDEMIOLOGY/ SH 03 WCLC 2017 Highlights of the Previous Day Wednesday, F201 + F202 07:00 – 08:00
PRIMARY PREVENTION/
TOBACCO CONTROL AND
CESSATION
EPIDEMIOLOGY/ MTE 25 Tobacco Control – Practical Issues (Sign Up Required) Wednesday, Room 316 07:00 – 08:00
PRIMARY PREVENTION/
TOBACCO CONTROL AND
October 18
CESSATION
EPIDEMIOLOGY/ MS 22 The Cost of Lung Cancer Wednesday, Room 502 11:00 – 12:30
PRIMARY PREVENTION/
TOBACCO CONTROL AND
October 18
CESSATION
IMMUNOLOGY AND IMMUNOTHERAPY

IMMUNOLOGY AND JCSE 01 Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Sunday, F203 07:30 – 11:30
IMMUNOTHERAPY
IMMUNOLOGY AND MS 05 Clinical Issues of Immune Checkpoint Inhibitors Monday, Main Hall 15:45 – 17:30
IMMUNOTHERAPY
October 16
IMMUNOLOGY AND MA 05 Immuno-Oncology: Novel Biomarker Candidates Monday, Room 15:45 – 17:30
IMMUNOTHERAPY
October 16 303 + 304
IMMUNOLOGY AND SH 01 WCLC 2017 Highlights of the Previous Day Tuesday, Room 502 07:00 – 08:00
IMMUNOTHERAPY
October 17
IMMUNOLOGY AND MTE 15 Biomarkers for Immune Checkpoint Inhibitors (Sign Up Required) Tuesday, Room 07:00 – 08:00
IMMUNOTHERAPY
October 17 301 + 302
IMMUNOLOGY AND PL 02 Presidential Symposium (incl. Top 3 Rated Abstracts) Tuesday, Plenary Hall 08:15 – 09:45
IMMUNOTHERAPY
October 17 (Hall D)
IMMUNOLOGY AND GR 02 Management of Immunotherapy-Related Adverse Events Tuesday, Main Hall 11:00 – 12:30
IMMUNOTHERAPY
October 17
IMMUNOLOGY AND MA 10 Immunotherapy I Tuesday, Room 11:00 – 12:30
IMMUNOTHERAPY
October 17 303 + 304
IMMUNOLOGY AND MS 18 Biomarker for Anti-PD-L1 Therapy Tuesday, Main Hall 15:45 – 17:30
IMMUNOTHERAPY
October 17
IMMUNOLOGY AND SH 03 WCLC 2017 Highlights of the Previous Day Wednesday, F201 + F202 07:00 – 08:00
IMMUNOTHERAPY
IMMUNOLOGY AND MTE 28 Immunotherapy for Earlier Stage NSCLC (Sign Up Required) Wednesday, Room 07:00 – 08:00
IMMUNOTHERAPY
October 18 301 + 302
IMMUNOLOGY AND PL 03 Immunology in Lung Cancer Update 2017 Wednesday, Plenary Hall 08:15 – 09:45
IMMUNOTHERAPY
October 18 (Hall D)
IMMUNOLOGY AND OA 13 Immuno-Biology Wednesday, Room 11:00 – 12:30
IMMUNOTHERAPY
October 18 301 + 302
IMMUNOLOGY AND OA 17 Immunotherapy II Wednesday, Room 14:30 – 16:15
IMMUNOTHERAPY
October 18 301 + 302

LOCALLY ADVANCED NSCLC

LOCALLY ADVANCED MS 11 Combined Modality Treatment for Superior Sulcus Tumors Tuesday, Room 503 11:00 – 12:30
NSCLC
October 17
LOCALLY ADVANCED MA 09 The Current Status of Radiation Oncology Tuesday, Room 316 11:00 – 12:30
NSCLC
October 17
LOCALLY ADVANCED MA 17 Locally Advanced NSCLC Tuesday, F203 + F204 15:45 – 17:30
NSCLC
LOCALLY ADVANCED SH 04 WCLC 2017 Highlights of the Previous Day Wednesday, F203 + F204 07:00 – 08:00
NSCLC
LOCALLY ADVANCED MS 23 Management of N2 NSCLC: What “Operable” Means? Wednesday, F203 + F204 14:30 – 16:15
NSCLC
MESOTHELIOMA

MESOTHELIOMA WS 03 ITONF Lung Cancer and Mesothelioma Workshop (Ticketed Session) Sunday, Room 313 12:15 – 17:55
October 15
MESOTHELIOMA OA 02 Mesothelioma: Challenges For New Treatment Monday, F205 + F206 11:00 – 12:30
MESOTHELIOMA MS 08 Novel Treatment for Mesothelioma Monday, Room 316 15:45 – 17:30
October 16
MESOTHELIOMA SH 02 WCLC 2017 Highlights of the Previous Day Tuesday, Room 503 07:00 – 08:00
October 17
MESOTHELIOMA MTE 13 Malignant Pleural Mesothelioma: State of the Art (Sign Up Required) Tuesday, Room 501 07:00 – 08:00
October 17
MESOTHELIOMA MA 19 Mesothelioma: Bench to Bedside Wednesday, Room 315 11:00 – 12:30
October 18
NURSING / PALLIATIVE CARE / ETHICS

NURSING/PALLIATIVE WS 03 ITONF Lung Cancer and Mesothelioma Workshop (Ticketed Session) Sunday, Room 313 12:15 – 17:55
CARE/ETHICS
October 15
NURSING/PALLIATIVE MTE 09 Management of Difficult Symptoms (Sign Up Required) Monday, Room 503 07:00 – 08:00
CARE/ETHICS
October 16
NURSING/PALLIATIVE ES 03 Current Topics for Nurses & Allied Health Monday, Room 15:45 – 17:30
CARE/ETHICS
October 16 313 + 314
NURSING/PALLIATIVE MS 10 Evidence Based Care: Interpreting the Research and Enhancing Practice Monday, F205 + F206 15:45 – 17:30
CARE/ETHICS
NURSING/PALLIATIVE MTE 12 Oncology Nursing (Sign Up Required) Tuesday, Room 316 07:00 – 08:00
CARE/ETHICS
October 17
NURSING/PALLIATIVE MS 14 QOL Evaluation in Practice from the Viewpoint of Physicians and Nurses Tuesday, Room 315 11:00 – 12:30
CARE/ETHICS
October 17
NURSING/PALLIATIVE MA 08 Supportive Care and Communication Tuesday, Room 11:00 – 12:30
CARE/ETHICS
October 17 511 + 512
NURSING/PALLIATIVE ES 06 Communication Skills in the End of Life/ Symptom Management in Lung Cancer Tuesday, F201 + F202 15:45 – 17:30
CARE/ETHICS
NURSING/PALLIATIVE SH 04 WCLC 2017 Highlights of the Previous Day Wednesday, F203 + F204 07:00 – 08:00
CARE/ETHICS
NURSING/PALLIATIVE MTE 22 Management of Elderly Patients with Lung Cancer (Sign Up Required) Wednesday, Room 07:00 – 08:00
CARE/ETHICS
October 18 303 + 304
NURSING/PALLIATIVE MS 20 Value-based Management for Special Populations Wednesday, Room 501 11:00 – 12:30
CARE/ETHICS
October 18


NURSING/PALLIATIVE MS 21 Being Mortal: Learning from ZEN Wednesday, Room 316 11:00 – 12:30
CARE/ETHICS
October 18
NURSING/PALLIATIVE OA 11 Reducing Burden: Patient-Centered Care Wednesday, Room 11:00 – 12:30
CARE/ETHICS
October 18 313 + 314
PATIENT ADVOCACY

PATIENT ADVOCACY MA 04 Advocacy: Listen to the Patients Monday, Room 11:00 – 12:30
October 16 313 + 314
PATIENT ADVOCACY MS 04 Joint IASLC/GLCC Session Current Issues in Lung Cancer Advocacy Monday, Room 316 11:00 – 12:30
October 16
PATIENT ADVOCACY SH 01 WCLC 2017 Highlights of the Previous Day Tuesday, Room 502 07:00 – 08:00
October 17
PATIENT ADVOCACY MS 19 Elevating the Lung Cancer Voice: Raising Awareness and Creating Community Tuesday, Room 315 15:45 – 17:30
October 17
PATIENT ADVOCACY OA 11 Reducing Burden: Patient-Centered Care Wednesday, Room 11:00 – 12:30
October 18 313 + 314
PATIENT ADVOCACY MS 27 Engaging Patients in Research: Best Practices Wednesday, Room 14:30 – 16:15
October 18 311 + 312
PULMONOLOGY / ENDOSCOPY

PULMONOLOGY/ WS 04 Minimally Invasive Diagnosis and Staging of Lung Cancer – Interventional Sunday, Room 13:00 – 17:00
ENDOSCOPY
Pulmonology Hands-On Workshop October 15 416 + 417
PULMONOLOGY/ MTE 08 Technical Details of EBUS and EUS (Sign Up Required) Monday, Room 502 07:00 – 08:00
ENDOSCOPY
October 16
PULMONOLOGY/ WS 05 superDimension™ Electromagnetic Navigation Bronchoscopy - Bridging the Monday, Room 315 19:15 – 20:30
ENDOSCOPY
Diagnostic and Therapeutic Domains in Lung Cancer - Medtronic October 16
PULMONOLOGY/ MTE 19 Laser Therapy for Early Stage and Airway Obstruction (Sign Up Required) Tuesday, Room 317 07:00 – 08:00
ENDOSCOPY
October 17
PULMONOLOGY/ ES 07 Recent Advances in Diagnostics and Interventional Bronchoscopy Wednesday, Room 503 11:00 – 12:30
ENDOSCOPY
October 18
PULMONOLOGY/ MA 20 Recent Advances in Pulmonology/Endoscopy Wednesday, F205 + F206 14:30 – 16:15
ENDOSCOPY
RADIOLOGY / STAGING / SCREENING

RADIOLOGY/STAGING/ WS 01 IASLC Supporting the Implementation of Quality Assured Global CT Screening Saturday, F203 08:30 – 21:00
SCREENING
Workshop (By Invitation Only) October 14 (Annex Hall)
RADIOLOGY/STAGING/ WS 02 IASLC Symposium on the Advances in Lung Cancer CT Screening Saturday, F201 + F202 09:00 – 18:15
SCREENING
(Ticketed Session) October 14 (Annex Hall)
RADIOLOGY/STAGING/ SS 01 Supporting the Clinical Management of Lung Cancer Patients through Innovation Sunday, Room 315 08:15 – 12:00
SCREENING
in Diagnostics – Roche October 15
RADIOLOGY/STAGING/ MTE 01 Management of Small Nodules Detected by CT Screening (Sign Up Required) Monday, Room 07:00 – 08:00
SCREENING
October 16 301 + 302
RADIOLOGY/STAGING/ PL 01 Prevention, Screening, and Management of Screen-Detected Lung Cancer Monday, Plenary Hall 08:15 – 09:45
SCREENING
October 16 (Hall D)
RADIOLOGY/STAGING/ ES 01 New TNM and WHO Classification Monday, Room 11:00 – 12:30
SCREENING
October 16 301 + 302
RADIOLOGY/STAGING/ ES 02 Diagnostic and Interventional Radiology in Lung Cancer: Update 2017 Monday, Room 315 11:00 – 12:30
SCREENING
October 16
RADIOLOGY/STAGING/ MTE 14 Imaging of Lung Cancer (Sign Up Required) Tuesday, F205 + F206 07:00 – 08:00
SCREENING
RADIOLOGY/STAGING/ MA 14 Diagnostic Radiology, Staging and Screening for Lung Cancer I Tuesday, F205 + F206 15:45 – 17:30
SCREENING
RADIOLOGY/STAGING/ SH 03 WCLC 2017 Highlights of the Previous Day Wednesday, F201 + F202 07:00 – 08:00
SCREENING

RADIOLOGY/STAGING/ MTE 27 CT Screening for Lung Cancer (Sign Up Required) Wednesday, Room 501 07:00 – 08:00
SCREENING
October 18
RADIOLOGY/STAGING/ MS 24 Management of GGO-Containing Nodule Wednesday, Room 503 14:30 – 16:15
SCREENING
October 18
RADIOLOGY/STAGING/ OA 15 Diagnostic Radiology, Staging and Screening for Lung Cancer II Wednesday, Room 14:30 – 16:15
SCREENING
October 18 303 + 304
RADIOTHERAPY

RADIOTHERAPY MTE 04 Radiotherapy for SCLC (Sign Up Required) Monday, Room 07:00 – 08:00
October 16 311 + 312
RADIOTHERAPY OA 01 The New Aspect of Radiation Therapy Monday, F201 + F202 11:00 – 12:30
RADIOTHERAPY SH 02 WCLC 2017 Highlights of the Previous Day Tuesday, Room 503 07:00 – 08:00
October 17
RADIOTHERAPY MA 09 The Current Status of Radiation Oncology Tuesday, Room 316 11:00 – 12:30
October 17
RADIOTHERAPY MS 16 Future Direction of Chemoradiotherapy for Inoperable Non-Small Cell Lung Tuesday, Room 502 15:45 – 17:30
Cancer October 17
RADIOTHERAPY SH 04 WCLC 2017 Highlights of the Previous Day Wednesday, F203 + F204 07:00 – 08:00
RADIOTHERAPY MTE 29 Stereotactic Body Radiation Therapy for Early Stage Lung Cancer Wednesday, Room 502 07:00 – 08:00
(Sign Up Required) October 18
RADIOTHERAPY ES 10 Radiation Treatment Update Wednesday, F201 + F202 14:30 – 16:15
REGIONAL ASPECTS / HEALTH POLICY / PUBLIC HEALTH

REGIONAL ASPECTS/ MS 02 Ethnic Differences: Biology or Myth Monday, Room 501 11:00 – 12:30
HEALTH
October 16
REGIONAL ASPECTS/ MS 12 Sustainable Care System in Each Region Tuesday, Room 501 11:00 – 12:30
HEALTH
October 17
SCLC / NEUROENDOCRINE TUMORS

SCLC/NEUROENDOCRINE JCSE 01 Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Sunday, F203 07:30 – 11:30
TUMORS
SCLC/NEUROENDOCRINE MA 01 SCLC: Research Perspectives Monday, Room 503 11:00 – 12:30
TUMORS
October 16
SCLC/NEUROENDOCRINE MS 07 Neuroendocrine Tumors other than SCLC: Pathology to Patient Management Monday, F203 + F204 15:45 – 17:30
TUMORS
SCLC/NEUROENDOCRINE SH 02 WCLC 2017 Highlights of the Previous Day Tuesday, Room 503 07:00 – 08:00
TUMORS
October 17
SCLC/NEUROENDOCRINE MTE 17 Neuroendocrine Tumor (Sign Up Required) Tuesday, Room 418 07:00 – 08:00
TUMORS
October 17
SCLC/NEUROENDOCRINE PC 02 Is Radiotherapy Necessary for Extensive SCLC? (Thoracic Radiation/PCI) Tuesday, F203 + F204 11:00 – 12:30
TUMORS
SCLC/NEUROENDOCRINE OA 08 Neuroendocrine Carcinoma: Translational Tuesday, Room 11:00 – 12:30
TUMORS
October 17 311 + 312


SCLC/NEUROENDOCRINE SH 04 WCLC 2017 Highlights of the Previous Day Wednesday, F203 + F204 07:00 – 08:00
TUMORS
SCLC/NEUROENDOCRINE ES 09 Recent Progress in the Management of Small Cell Lung Cancer Wednesday, Room 501 14:30 – 16:15
TUMORS
October 18
SURGERY

SURGERY JCSE 01 Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Sunday, F203 07:30 – 11:30
RADIOLOGY/STAGING/ MTE 01 Management of Small Nodules Detected by CT Screening (Sign Up Required) Monday, Room 07:00 – 08:00
SCREENING
October 16 301 + 302
SURGERY MTE 03 Surgery for T4 Lung Cancer (Sign Up Required) Monday, Room 07:00 – 08:00
October 16 303 + 304
SURGERY OA 04 Surgery from Minimal to Radical Monday, Room 15:45 – 17:30
October 16 311 + 312
SURGERY SH 01 WCLC 2017 Highlights of the Previous Day Tuesday, Room 502 07:00 – 08:00
October 17
SURGERY MTE 16 Technical Issues after Neoadjuvant Chemoradiation – Surgeon’s Perspective Tuesday, Room 07:00 – 08:00
(Sign Up Required) October 17 311 + 312
SURGERY PL 02 Presidential Symposium (incl. Top 3 Rated Abstracts) Tuesday, Plenary Hall 08:15 – 09:45
October 17 (Hall D)
SURGERY ES 05 Surgical Skills Tuesday, Room 503 15:45 – 17:30
October 17
SURGERY MTE 30 Surgery after Concurrent Chemoradiotherapy (Sign Up Required) Wednesday, Room 503 07:00 – 08:00
October 18
SURGERY MS 24 Management of GGO-Containing Nodule Wednesday, Room 503 14:30 – 16:15
October 18
THYMIC MALIGNANCIES / ESOPHAGEAL CANCER / OTHER THORACIC MALIGNANCIES

THYMIC MALIGNANCIES/ OA 03 Mediastinal and Esophageal Tumor: Insight and New Treatment Monday, Room 11:00 – 12:30
ESOPHAGEAL CANCER/
OTHER THORACIC
October 16 311 + 312
MALIGNANCIES
THYMIC MALIGNANCIES/ MS 06 Combined Modality Treatment for Thymic and Pleural Malignancy Monday, F201 + F202 15:45 – 17:30
ESOPHAGEAL CANCER/
OTHER THORACIC
MALIGNANCIES
THYMIC MALIGNANCIES/ SH 02 WCLC 2017 Highlights of the Previous Day Tuesday, Room 503 07:00 – 08:00
ESOPHAGEAL CANCER/
OTHER THORACIC
October 17
MALIGNANCIES
THYMIC MALIGNANCIES/ MA 16 Mediastinal, Tracheal and Esophageal Tumor: Multimodality Approaches Tuesday, Room 15:45 – 17:30
ESOPHAGEAL CANCER/
OTHER THORACIC
October 17 313 + 314
MALIGNANCIES
THYMIC MALIGNANCIES/ SH 04 WCLC 2017 Highlights of the Previous Day Wednesday, F203 + F204 07:00 – 08:00
ESOPHAGEAL CANCER/
OTHER THORACIC
MALIGNANCIES
THYMIC MALIGNANCIES/ MTE 23 Mediastinal Tumors including Thymic Tumors, Lymphoma, Germ Cell Tumors: Wednesday, Room 07:00 – 08:00
ESOPHAGEAL CANCER/
OTHER THORACIC
Biopsy, Diagnosis and Treatment (Sign Up Required) October 18 311 + 312
MALIGNANCIES
INDUSTRY SUPPORTED SYMPOSIA

INDUSTRY SUPPORTED ISS 01 Treatment Options for Patients with ALK+ NSCLC: How is the Paradigm Sunday, Room 11:30 – 13:00
SYMPOSIUM
Changing? – Takeda Oncology October 15 303 + 304
INDUSTRY SUPPORTED ISS 02 Treatment Selection Strategies in Advanced NSCLC – Implications and Global Sunday, Room 15:00 – 16:30
SYMPOSIUM
Perspectives – Lilly Oncology October 15 303 + 304
INDUSTRY SUPPORTED ISS 03 Management of Advanced NSCLC: Where Do Immune Checkpoint Inhibitors Sunday, Room 16:45 – 18:15
SYMPOSIUM
Fit In? – Medscape – Supported by Independent Educational Grant from October 15 301 + 302
AstraZeneca Pharmaceuticals LP

INDUSTRY SUPPORTED ISS 04 Integrating Liquid Biopsy into Clinical Care: Common Questions and Challenges Monday, F201 + F202 07:00 – 08:00
SYMPOSIUM
– Guardant Health October 16 (Annex Hall)
INDUSTRY SUPPORTED ISS 05 What’s New in SCLC? Assessing Emerging Therapeutic Options – Medscape Monday, F203 + F204 07:00 – 08:00
SYMPOSIUM
– Supported by Independent Educational Grant from AbbVie October 16 (Annex Hall)
INDUSTRY SUPPORTED ISS 06 Maximizing Clinical Benefit from TKIs in the Treatment of Advanced NSCLC Monday, Main Hall 12:45 – 14:15
SYMPOSIUM
– Boehringer Ingelheim Pharma GmbH & Co. KG October 16
INDUSTRY SUPPORTED ISS 07 The Evolving I-O Treatment Landscape in Thoracic Cancers: Clinical Updates Monday, Main Hall 17:45 – 19:15
SYMPOSIUM
and Future Directions – Bristol-Myers Squibb October 16
INDUSTRY SUPPORTED ISS 08 Optimising the Continuum of Care for Patients with Oncogenic-Driven NSCLC Tuesday, F201 + F202 07:00 – 08:00
SYMPOSIUM
– Pfizer Oncology October 17 (Annex Hall)
INDUSTRY SUPPORTED ISS 09 The Evolution of Targetable Oncogenic Drivers in NSCLC: Novel Treatment Tuesday, F203 + F204 07:00 – 08:00
SYMPOSIUM
Paradigms – Novartis October 17 (Annex Hall)
INDUSTRY SUPPORTED ISS 10 Evolving Decisions and Best Practices: Management of EGFR-Mutated NSCLC Tuesday, Main Hall 12:45 – 14:15
SYMPOSIUM
– Medscape – Supported by an Independent Educational Grant from October 17
AstraZeneca Pharmaceuticals LP
INDUSTRY SUPPORTED ISS 11 Pembrolizumab: The New Standard of Care in Advanced Lung Cancer Tuesday, Main Hall 17:45 – 19:15
SYMPOSIUM
– MSD October 17
INDUSTRY SUPPORTED ISS 12 SCLC Biomarker Testing Symposium – AbbVie Wednesday, Main Hall 12:45 – 14:15
SYMPOSIUM
October 18
SCIENTIFIC SYMPOSIUM

SCIENTIFIC SYMPOSIUM SS 01 Supporting the Clinical Management of Lung Cancer Patients through Innovation Sunday, Room 315 08:15 – 12:00
in Diagnostics – Roche October 15


SECTION 7
DAILY
SCIENTIFIC
PROGRAM
Saturday, October 14, 2017 74
Sunday, October 15, 2017 77
Monday, October 16, 2017 82
Tuesday, October 15, 2017 96
Wednesday, October 18, 2017 111

SCIENTIFIC PROGRAM | SATURDAY, OCTOBER 14, 2017
SATURDAY, OCTOBER 14, 2017 | SCIENTIFIC PROGRAM
07:30 – 19:30 COAT AND BAGGAGE CHECK OPEN PL PLENARY SESSION OA ORAL ABSTRACT SESSION
ES EDUCATIONAL SESSION MA MINI ORAL ABSTRACT

PACIFICO CONFERENCE CENTER, SESSION
GR GRAND ROUND SESSION
LEVEL 1F SH HIGHLIGHTS OF
MS MINI SYMPOSIUM THE PREVIOUS DAY
MTE MEET THE EXPERT SESSION ISS INDUSTRY SUPPORTED
14:00 – 18:00 REGISTRATION OPEN (SIGN UP REQUIRED) SYMPOSIUM
PACIFICO CONFERENCE CENTER, PC PRO-CON SESSION EXH EXHIBIT SHOWCASE
WS WORKSHOP SESSION
LEVEL 2F
YI YOUNG INVESTIGATOR JCSE JOINT IASLC/CSCO/
SESSION CAALC SESSION
14:00 – 18:00 SPEAKER PREVIEW CENTER OPEN SS SCIENTIFIC SYMPOSIUM

LEVEL 3F
SESSION 2
08:30 – 21:00 WS 01: IASLC Supporting the Implementation of
Quality Assured Global CT Screening Workshop Radiological Imaging – Quality Assurance and Training
(By Invitation Only) CHAIRS: NING WU, CHINA,
TRACK: RADIOLOGY/STAGING/SCREENING DAVID BALDWIN, UK,
& MATTHIJS OUDKERK, NETHERLANDS
ROOM: F203 (ANNEX HALL)
09:50 WS 01.10: Reviews of International Guidelines for

08:30 WS 01.01: Welcome and Aims of Workshop
Management of Pulmonary Nodules (i.e. NCCN/ LUNG-
James L. Mulshine, USA & John Field, UK
RADS, BTS, Fleischner IELCAP, etc.)
David F. Yankelevitz, Icahn School of Medicine at Mount
Sinai, USA
SESSION 1
10:05 WS 01.11: Planning for European Registries for CT
CHAIRS: HARRY J. DE KONING, NETHERLANDS Screened Images – What Are Their Objectives?
& JOHN FIELD, UK Matthijs Oudkerk, University of Groningen, Netherlands
10:20 WS 01.12: Planning for USA Registries for CT Screened

08:40 WS 01.03: CT Screened Lung Cancer Survivor:
Images – What Are Their Objectives?
A Patient’s Prospective on Lung Cancer Screening
Ricardo S. Avila, Accumetra, LLC, USA
Andrea Katalin Borondy Kitts, Lahey Hospital & Medical
Center, USA 10:35 WS 01.13: Next Generation CT Scanners for Lung
Cancer Screening – Way Forward
08:55 WS 01.04: Tobacco Cessation in the CT Screening
Sebastian Schmidt, Siemens Healthcare GmbH, Germany
Setting – Is It Working?
Jamie Ostroff, SomaLogic, Inc., USA 10:50 Discussion
09:10 WS 01.05: How Do We Engage the High Risk Population
in Lung Cancer Screening? – Primary Care Perspective 11:00 Tea/Coffee Break
in the UK
Martin Ledson, Liverpool Heart & Chest, UK
SESSION 3
09:17 WS 01.06: How Do We Engage the High Risk Population
in Lung Cancer Screening? – Strategy for Engaging
Added Value to Lung Cancer CT Screening Programs
Participants
Angela Meredith Criswell, Lung Cancer Alliance, USA CHAIRS: NIR PELED, ISRAEL
& KWUN FONG, AUSTRALIA
09:25 WS 01.07: Modeling Smoking Trends and CT Screening
to 2060
11:30 WS 01.17: The Potential of Radio-omics and Deep
Rafael Meza, University of Michigan, USA
Learning
09:40 Discussion Anthony Reeves, Cornell University, USA
11:45 WS 01.18: Lung Cancer Indicator Detection Trial (LuCID)

Marc Phillipe Van Der Schee, Owlstone Medical Ltd, UK
12:00 Discussion
12:05 Lunch

SESSION 4:
16:00 Tea/Coffee Break
The Concept of Collaboration in CT Screening Programs
CHAIRS: ANGELA MEREDITH CRISWELL, USA

& DAVID YANKELEVITZ, USA SESSION 6

16:20 What Priorities and Recommendations Should the IASLC
13:25 WS 01.22: Quality Control Throughout Lung Cancer
Executive Focus On: How They Can Support Leadership
Management
in this Area of Lung Cancer (Round Table Discussion)
David Gierada, Washington University School of Medicine,
USA CHAIRS: JAMES L. MULSHINE, USA
& JOHN FIELD, UK
13:33 WS 01.23: Radiology Leading But Integrated?
David F. Yankelevitz, Icahn School of Medicine at Mount
Sinai, USA 1. How Do We Ensure Smoking Cessation is Integrated
into Best Practice Screening?
13:41 WS 01.24: Designs of Possible Biomarkers for Future Angela Meredith Criswell, Lung Cancer Alliance, USA
Screening Programs?
John Field, The University of Liverpool, UK 2. How Do We Optimise an International Approach to
Pulmonary Nodules Management?
13:49 WS 01.25: Smoking Cessation – How to Integrate? Matthijs Oudkerk, University of Groningen, University
Jamie Ostroff, SomaLogic, Inc., USA Medical Center Groningen, Netherlands
13:57 WS 01.26: COPD Integration into CT Screening – Patient 3. How to Talk About Lung Cancer Screening Which is
Benefit? More Appropriate to the Public?
Javier Zulueta, Clinica Universidad de Navarra, Spain Sam M. Janes, University College London, UK
14:05 WS 01.27: Surgical Integration at the Earliest Stages 4. Can We Implement International Standards for
Planned CT Screening? Quantitative CT Imaging within Lung Cancer?
Jesper Holst Pedersen, Rigshospitalet, Copenhagen David F. Yankelevitz, Icahn School of Medicine at Mount
University, Denmark Sinai, USA
14:13 Discussion 5. How Can IASLC Lead Global Lung Cancer Progress
Over the Next 10 Years?
Kwun M. Fong, University of Queensland Thoracic
Research Centre at The Prince Charles Hospital, Australia
SESSION 5
18:00 Networking Dinner
The Current Global Implementation of CT Lung Cancer
Screening Programs
CHAIRS: ROBERT SMITH, USA

& SHUJI SAKAI, JAPAN
09:00 – 18:15 WS 02: IASLC Symposium on the Advances in
Lung Cancer CT Screening (Ticketed Session)
14:30 WS 01.30.01 China - Overview of Lung Cancer
Screening in China from 2000 TRACK: RADIOLOGY/STAGING/SCREENING
Matthijs Oudkerk, University of Groningen, University ROOM: F201 + F202 (ANNEX HALL)
Medical Center Groningen, Netherlands
14:40 WS 01.30.02: China - The Beijing University - CT 09:00 WS 02.01: Welcome to the Special Symposium
Screening Trial Giulia Veronesi, Italy & Claudia Henschke, USA
Ning Wu, Chinese Academy of Medical Sciences & Peking
Union Medical College, China
SESSION 1
14:50 WS 01.31: Japan
Kazuto Ashizawa, Nagasaki University Graduate School Status of Lung Cancer Screening in USA and Europe
of Biomedical Sciences, Japan
CHAIRS: ROBERT SMITH, USA
& GIULIA VERONESI, ITALY
15:00 WS 01.32: Canada & Australia
Kwun M. Fong, The Prince Charles Hospital, Australia
09:10 WS 02.03: Lung Cancer Screening – IELCAP
15:20 WS 01.33: EU Commission Recommendations on Contribution to CT Screening Implementation
Screening Claudia I. Henschke, Icahn School of Medicine at Mount
Denis Horgan, European Alliance for Personalised Sinai, USA
Medicine, Belgium
10:10 WS 02.04: Lung Cancer Screening Status in Europe
15:30 WS 01.34: CT Screening in USA – Current Issues Giulia Veronesi, Humanitas Research Hospital, Italy
around Implementation – Lessons to be Learnt
James L. Mulshine, Rush University, USA 10:40 WS 02.05: The European Commission
Recommendations on Lung Cancer Screening
15:40 WS 01.35: USA Roundtable Update Denis Horgan, European Alliance for Personalized
Ella Kazerooni, University of Michigan, USA Medicine, Belgium
15:50 WS 01.36: NELSON – Update 11:00 Group Discussion

Harry J. De Koning, Erasmus MC, Netherlands

SESSION 2
Current Lung Cancer Screening Guidelines

(Panel Discussion)
CHAIRS: JAVIER ZULUETA, SPAIN

& CLAUDIA HENSCHKE, USA
12:00 WS 02.09: Lung Cancer Guidelines

David Yankelevitz, Icahn School of Medicine at Mount
Sinai, USA
Matthew Callister, Leeds Teaching Hospitals, UK
Stephen Lam, British Columbia Cancer Agency, Canada,
Sadayuki Murayama, Graduate School of Medical Science,
University of the Ryukyus, Japan
Nasser Altorki, Cornell University, USA
John Field, The University of Liverpool, UK
13:00 Lunch
SESSION 3
Early Detection Biomarkers
CHAIRS: NIR PELED, ISRAEL

& LUIS MONTUENGA, SPAIN
14:00 WS 02.12: Lung Cancer Biomarkers – Do We Have Good

Candidates for Early Detection?
Pierre P. Massion, Vanderbilt Ingram Cancer Center, USA
14:30 WS 02.13: New Approaches to Interventional

Pulmonology for Lung Cancer Screening
Nir Peled, Soroka Medical Center, Israel
15:00 WS 02.14: The Airway Transcriptome

Avrum Spira, Boston University School of Medicine, USA
15:30 WS 02.15: Quality Control for Lung Imaging Biomarkers

Ricardo S. Avila, Accumetra, LLC, USA
SESSION 4
Lung Cancer Screening’s Impact on COPD

and Smoking Cessation
CHAIRS: ANDREA BORONDY KITSS, USA

& KAZUTO ASHIZAWA, JAPAN
16:15 WS 02.18: Lung Cancer Screening and COPD –

A Pneumologist’s Viewpoint
Javier Zulueta, Clinica Universidad de Navarra, Spain
16:45 WS 02.19: Tobacco Cessation in the CT Screening

Setting – The Way Forward?
Jamie Ostroff, SomaLogic, Inc., USA
17:15 WS 02.20: Communicating Complex Issues Simply:

Pivotal Role of Nursing in Lung Cancer Screening
Joelle Thirsk Fathi, University of Washington, USA
18:00 Final Discussion

SCIENTIFIC PROGRAM | SUNDAY, OCTOBER 15, 2017
SUNDAY, OCTOBER 15, 2017 | SCIENTIFIC PROGRAM

PL PLENARY SESSION OA ORAL ABSTRACT SESSION
07:00 – 21:00 COAT AND BAGGAGE CHECK OPEN
WS WORKSHOP SESSION
LEVEL 2F

LEVEL 3F
10:20 JCSE 01.11: A Multicenter, Non-Interventional Study on

07:30 – 11:30 JCSE 01: Joint IASLC/CSCO/CAALC Session: Real World EGFR Testing and in Patients with IIIB/IV
Immunotherapy for Management of Lung NSCLC in Northern China
Cancer: Ongoing Research from East and West Ying Cheng, Jilin Provincial Cancer Hospital, China
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY 10:35 JCSE 01.12: A Phase II Study of Fruquintinib in
CHEMOTHERAPY/TARGETED THERAPY Combination with Gefitinib in Stage IIIb/IV NSCLC
ADVANCED NSCLC
SCLC/NEUROENDOCRINE TUMORS
Patients Harboring EGFR Activating Mutations
SURGERY Shun Lu, Shanghai Chest Hospital, Shanghai Jiaotong
ROOM: F203 (ANNEX HALL)
University School of Medicine, China
CHAIRS: CHUNXUE BAI, CHINA,
10:50 JCSE 01.13: Discussant Oral Abstracts JCSE 01.10,
FRED R. HIRSCH, USA,
TONY MOK, HONG KONG, JCSE 01.11 and JCSE 01.12
& YI-LONG WU, CHINA Joel W. Neal, Stanford Cancer Institute/Stanford
University, USA
Breakfast and Coffee Breaks provided 11:10 JCSE 01.14: Discussant Poster Abstracts JCSE 01.15 –
JCSE 01.28
07:30 JCSE 01.01: Breakfast and Poster Viewing Bob T. Li, Memorial Sloan Kettering Cancer Center, USA
Jonathan W. Riess, University of California Davis Cancer
07:55 JCSE 01.02: Welcome and Introduction Center, USA
08:00 JCSE 01.03: The Science of Immunotherapy

Roy S. Herbst, Yale School of Medicine | Yale Cancer
Center | Smilow Cancer Hospital at Yale-New Haven, USA Posters On Display in Room
08:20 JCSE 01.05: PD-1+CD8+ T and iNKT Cell Based JCSE 01.15: Next Generation Sequencing of Large-Cell
Immunotherapy on Lung Cancer Neuroendocrine Carcinoma Reveals an Association of PIK3CA
Jianqing Xu, Shanghai Public Health Clinical Center, Fudan Mutations with Brain Metastases
University, China Mian Xie, The First Affiliated Hospital of Guangzhou Medical
University, China
08:40 JCSE 01.06: ctDNA Based Tumor Mutation Burden
Evaluation for Predicting Immunotherapy Effect JCSE 01.16: Altered Expression of Programmed Death-1
Jie Hu, Zhongshan Hospital Fudan University, China Receptor(PD-1) and Its Ligand PD-L1, PD-L2 after Neo-Adjuvant
Chemotherapy in Lung Cancer
09:00 JCSE 01.07: Ongoing Trials in China on Checkpoint Wenyu Sun, The First Hospital of Jinlin University, China
Inhibitors and Other Immunotherapies
Qing Zhou, Guangdong Lung Cancer Institute, Guangdong JCSE 01.17: The Correlation of DLL3 Expression with High-
General Hospital and Guangdong Academy of Medical Grade Pulmonary Neuroendocrine Carcinoma Clinicopathologic
Sciences, China Features and Prognose
Li-Xu Yan, Guangdong General Hospital, Guangdong Academy of
09:20 Coffee Break and Poster Viewing Medical Sciences, China
JCSE 01.18: Uncommon Mutation Types of EGFR and Response

09:45 JCSE 01.09: Therapeutic Practices in Europe for to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell
Immunotherapy, including Biomarkers Lung Cancer Patients
Solange Peters, Lausanne University Hospital CHUV, Yun Fan, Zhejiang Cancer Hospital, China
Switzerland
JCSE 01.19: EGFR Mutation Correlates with Uninflamed
10:05 JCSE 01.10: The Main Treatment Failure Pattern for Phenotype and Weak Immunogenicity, Causing Impaired
Completely Resected Stage II–IIIA (N1–N2) EGFR- Response to PD-1 Blockade in NSCLC
Mutation Positive Lung Cancer Zhong-Yi Dong, Guangdong Lung Cancer Institute, Guangdong
Songtao Xu, Zhongshan Hospital Fudan University, China General Hospital, China

JCSE 01.20: Primary Tumor Resection versus Maintenance 08:40 YI 01.04: Clinical Trials 101
Therapy for Patients with Oligometastatic Non-Small Cell Lung Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer
Cancer Center at Johns Hopkins, USA
Xiaozheng Kang, Peking University Cancer Hospital, China
08:55 YI 01.05: Investigator Initiated Trials
JCSE 01.21: Combination of Biomarker and Clinicopathologic Daniel Shao Weng Tan, National Cancer Centre Singapore,
Characters May Circle out Beneficiaries through Second-Line Singapore

Immunotherapy: A Meta Analyse
Si-Yang Liu, Guangdong Lung Cancer Institute; Guangdong General 09:10 Coffee Break
Hospita & Guangdong Academy of Medical Sciences, China
JCSE 01.22: Is Preoperative EGFR-TKI Comparable with 09:40 YI 01.07: How to Get Your Paper Published
Chemotherapy for Stage II-IIIA Lung Adenocarcinoma? Alex Adjei, Roswell Park Cancer Institute, USA
Chao Lyu, Peking University Cancer Hospital, China
09:55 YI 01.08: Why Should I Publish? An Overview of the
JCSE 01.23: The Feasibility of Osimertinib Treatment on Brain Manuscript Cycle: From Submission to Publication
Metastases in NSCLC Patients After 1st Generation EGFR-TKI Jim Jett, Mayo Clinic, USA
Resistance: A Preliminary Study
Lucheng Zhu, Hangzhou Cancer Hospital, China 10:10 YI 01.09: How to Prepare an Abstract for an
International Conference and How to Prepare Your
JCSE 01.24: Detection of EGFR, ALK and Other Driver Presentation for the Conference (Tips and Tricks)
Oncogenes from Plasma cfDNA by Single Molecule Amplification Michael Boyer, Chris O’Brien Lifehouse, Australia
and Re-sequencing Technology (cSMART)
Tony Mok, The Chinese University of Hong Kong, Hong Kong 10:25 YI 01.10: How to Write a Grant Application for Young
Investigators
JCSE 01.25: Detection of EGFR T790M Mutations by Four Heather A. Wakelee, Stanford Cancer Institute/Stanford
Testing Platforms in ctDNA from Chinese Patients with Advanced University, USA
NSCLC
Xu-Chao Zhang, Guangdong Lung Cancer Institute, Gunagdong 10:40 YI 01.11: The Young Investigator Travel Award
General Hospital and Guangdong Academy of Medical, China Experience – A Report from a Previous Award Winner
Takahiro Karasaki, Graduate School of Medicine, The
JCSE 01.26: Circulating Cell-Free DNA of Cerebrospinal Fluid University of Tokyo, Japan
May Function as Liquid Biopsy for Leptomeningeal Metastases of
ALK Rearrangement NSCLC 10:45 YI 01.12: Making the Most of the WCLC: A Guide for First
Yangsi Li, Guangdong Lung Cancer Institute, Guangdong Provincial Time Attendee – From an Expert Perspective
Key Laboratory of Translational Medicine in Lung Cancer, Suresh Senan, VU University Medical Center, Netherlands
Guangdong General Hospital & Guangdong Academy of Medical
Sciences, China 11:00 YI 01.13: Making the Most of the WCLC: A Guide for First
Time Attendee – From a Second Time Attendee
JCSE 01.27: Patients with ALK IHC-Positive/FISH-Negative Deepali Jain, All India Institute of Medical Sciences, India
NSCLC Benefit from ALK TKI Treatment: Response Data from the
Global ALEX Trial 11:05 Question and Answer Session
Tony Mok, State Key Laboratory of South China, Hong Kong Cancer
Institute, The Chinese University of Hong Kong, Hong Kong
JCSE 01.28: NGS Sequencing Based Liquid / Tissue Biopsy 08:15 – 12:00 SS 01: Supporting the Clinical Management
Identified Coexistence of HER2 Amplification and Mutation in of Lung Cancer Patients through Innovation
Advanced NSCLC Patients in Diagnostics - Roche (Sign Up Required)
Rongrong Chen, Geneplus-Beijing, China
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: 315
11:30 JCSE 01.29: Closing Remarks
08:15 SS 01.01: Welcome & Opening
08:30 SS 01.02: Unmet Medical Needs and Challenges in

Lung Cancer Patient Management - A Pulmonologists
08:00 – 11:30 YI 01: Young Investigator and First Time
Perspective
Attendee Session
Ramon Marrades, Hospital Clínic de Barcelona, Spain
TRACK: EDUCATION/PUBLICATION/CAREER DEVELOPMENT
ROOM: F201 + F202 (ANNEX HALL) 08:47 SS 01.03: Protein-based Biomarkers as Tools to
Support Clinical Decision Making with Results from the
CHAIRS: PETER GOLDSTRAW, UK
& GIORGIO SCAGLIOTTI, ITALY Laboratory
Rafael Molina, University of Barcelona, Spain
Breakfast and Coffee Breaks provided 09:05 SS 01.04: Panel - Question and Answer Session
08:00 YI 01.01: Introduction to IASLC: What It Can Do For You 09:20 Break
Silvia Novello, University of Turin, Italy
09:35 SS 01.05: Integrated Tissue and Molecular Diagnostics
08:10 YI 01.02: Planning an Academic Career in Lung Cancer
for Optimal Lung Cancer Patient Care
Navneet Singh, Postgraduate Institute of Medical Education
Stephen Finn, St James’s Hospital, Ireland
and Research (PGIMER), India
08:25 YI 01.03: Community versus Academic Oncology

Philip Bonomi, Rush University Medical Center, USA

10:10 SS 01.06: The Evolution of Lung Cancer Treatment SESSION 1
- Clinical Impact of Genomic Alterations Detected in
Tissue and Plasma Local Therapies for Lung Cancer and Mesothelioma
Alice Shaw, Massachusetts General Hospital, USA
CHAIR: CAITLIN BRODERICK, AUSTRALIA
10:45 SS 01.07: Clinical Utility of Liquid Biopsy in Managing

NSCLC Patients - Performance and Impact on Clinical 13:00 WS 03.03: Welcome Address
Decisions Beth Ivimey, Chris O’Brien Lifehouse, Australia
Shobhit Baijal, Heartlands Hospital, UK
13:05 WS 03.04: The Oncology Nurse Role in the Treatment of
11:20 SS 01.08: Panel - Question and Answer Session Lung Cancer and Mesothelioma: The Recent Practice in
Japan
11:50 SS 01.09: Wrap-up & Closing Miki Hosoya, National Cancer Center Japan, Japan
13:30 WS 03.05: Explaining Radiation Treatments in Lung

Cancer
Mary Duffy, Peter MacCallum Cancer Centre, Australia
11:30 – 13:00 ISS 01: Treatment Options for Patients with
ALK+ NSCLC: How is the Paradigm Changing? 13:50 WS 03.06: Local Treatments for Lung Cancer – Blade vs
– Takeda Oncology Beam: A Debate
David L. Ball, Peter MacCallum Cancer Centre, Australia
TRACK: INDUSTRY SUPPORTED SYMPOSIUM
Melissa Culligan, University of Maryland Medical Center –
ROOM: 303 + 304
Thoracic Surgery, USA
CHAIRS: D. ROSS CAMIDGE, USA
& TONY MOK, HONG KONG
SESSION 2
Lunch boxes provided Wellness and Supportive Care for Lung Cancer and
Mesothelioma Patients
11:30 ISS 01.01: Welcome and Introduction CHAIR: KATHLEEN ANN GAMBLIN, USA
D. Ross Camidge, University of Colorado, USA &
Tony Mok, Chinese University of Hong Kong, Hong Kong 14:20 WS 03.08: Acute Thoracic Oncology Nursing
Philippa Jones, NIHR Clinical Research Network, UK
11:35 ISS 01.02: Long-term Survival for Patients with ALK+
NSCLC: An Achievable Aim? 14:40 WS 03.09: Living Well with Lung Cancer and
Tony Mok, Chinese University of Hong Kong, Hong Kong Mesothelioma
Pippa Labuc, Guy’s & St Thomas’ NHS Foundation Trust, UK
11:55 ISS 01.03: Treating Patients with ALK+ NSCLC: What
Are the Unmet Needs? 15:00 Panel Discussion
D. Ross Camidge, University of Colorado, USA
12:15 ISS 01.04: Testing Resistant ALK+ NSCLC: Can 15:10 Break
Treatment Be Personalised?
Maurice Pérol, Centre Léon Bérard, France
SESSION 3
12:35 ISS 01.05: Panel Discussion and Questions from the
Systemic Treatments for Lung Cancer and Mesothelioma
Audience
D. Ross Camidge, University of Colorado, USA, CHAIR: MASSEY NEMATOLLAHI, CANADA
Tony Mok, Chinese University of Hong Kong, Hong Kong,
Maurice Perol, Centre Leon Berard, France 15:25 WS 03.13: Targeted Therapies: Toxicities Management
and Care
12:50 ISS 01.06: Summary and Conclusions
Alexandre Chan, National University of Singapore, Singapore
D. Ross Camidge, University of Colorado, USA &
Tony Mok, Chinese University of Hong Kong, Hong Kong 15:50 WS 03.14: Targeted Therapies: Case Studies and
Experience from Different Regions Q&A
Facilitator: Beth Ivimey, Chris O’Brien Lifehouse, Australia
Alexandre Chan, National University of Singapore,
Singapore
12:15 – 17:55 WS 03: ITONF Lung Cancer and Mesothelioma Caitlin Broderick, W A Cancer and Palliative Care Network,
Workshop (Ticketed Session) Australia
TRACK: MESOTHELIOMA Beth Eaby-Sandy, University of Pennsylvania Health
NURSING/PALLIATIVE CARE/ETHICS System, USA
ROOM: ROOM 313 John McPhelim , Hairmyres Hospital, UK
Lunch provided 16:15 WS 03.15: Immuno-oncology Overview

Marianne Davies, Yale Cancer Center, USA
12:15 ITONF Members Meeting (with Lunch) 16:35 WS 03.16: Japan’s Challenges in Immunotherapy for
Lung Cancer as a Pioneer: The Nurses View
Kimura Yasutaka, Meio University, Japan
16:55 WS 03.17: Latest Advances in the Treatment of

Malignant Pleural Mesothelioma
Mary Hesdorffer, Mesothelioma Applied Research
Foundation, USA

17:20 WS 03.18: Mesothelioma Online Educational
Programs, ITONF Nurse Education Programs & N&AH 15:00 – 16:30 ISS 02: Treatment Selection Strategies in
Immunotherapy Guidelines Launch Advanced NSCLC – Implications and Global
Facilitator: Melissa Culligan, University of Maryland Perspectives – Lilly Onoclogy
Medical Center – Thoracic Surgery, USA
Kathleen Ann Gamblin, Northside Hospital Cancer Institute,

ROOM: 303 + 304
USA
CHAIRS: NICK THATCHER,UK
Liz Darlison, University Hospitals of Leicester NHS Trust, UK & KAZUHIKO NAKAGAWA, JAPAN
Anne Fraser, ADHB, New Zealand
Snacks and Refreshments provided
17:55 WS 03.19: Close
Melissa Culligan, University of Maryland Medical Center –
Thoracic Surgery, USA 15:00 ISS 02.01: Welcome & Introduction
Kazuhiko Nakagawa, Kindai University Faculty of Medicine,
Japan
Nick Thatcher, The Christie Hospital, UK
13:00 – 17:00 WS 04: Minimally Invasive Diagnosis and Staging 15:05 ISS 02.02: Increasing Complexity of Therapeutic
of Lung Cancer – Interventional Pulmonology Decision-Making for Advanced NSCLC
Hands-On Workshop (Ticketed Session) David R. Gandara, UC Davis Comprehensive Cancer
Center, USA
TRACK: PULMONOLOGY/ENDOSCOPY
ROOM: 416 + 417
15:25 ISS 02.03: How Long Do I Treat? When to Stop?
Implications for Clinical Practice
Silvia Novello, University of Turin, Italy
13:00 WS 04.01: Welcome and Introduction
Kazuhiro Yasufuku, Division of Thoracic Surgery, Toronto 15:40 ISS 02.04: Illustrative and Interactive Case Study
General Hospital, University Health Network, Canada Discussions
Hidehito Horinouchi, National Cancer Center Hospital, Japan,
13:10 WS 04.02: EBUS-TBNA – Role in Invasive Mediastinal Myung-Ju Ahn, Samsung Medical Center, Korea,
Staging
Oscar Arrieta, Instituto Nacional de Cancerologia, Mexico
Kazuhiro Yasufuku, Division of Thoracic Surgery, Toronto
General Hospital, University Health Network, Canada 16:10 ISS 02.05: Global Perspectives on the Changing
Treatment Paradigm in Advanced NSCLC
13:30 WS 04.03: Specimen Acquisition and Processing
James Chih-Hsin Yang, National Taiwan University, Taiwan
Takahiro Nakajima, Department of Thoracic Surgery, Chiba
University School of Medicine, Japan 16:20 ISS 02.06: Panel Discussion
13:50 WS 04.04: Radial Probe EBUS – Methods and Results
Japan, Nick Thatcher, The Christie Hospital, UK
Takehiro Izumo, Respiratory Endoscopy Division, National
Cancer Center, Japan 16:30 ISS 02.07: Symposium Closes
14:10 WS 04.05: Navigational Bronchoscopy
Laura Donahoe, Division of Thoracic Surgery, Toronto
General Hospital, University Health Network, Canada
16:45 – 18:15 ISS 03: Management of Advanced NSCLC:
14:30 WS 04.06: Hands-On Session (5 work stations): Where Do Immune Checkpoint Inhibitors Fit In? -
1. EBUS-TBNA Medscape - Supported by Independent Educational
2. Radial Probe EBUS Grant from AstraZeneca Pharmaceuticals LP
3. Specimen Handling TRACK: INDUSTRY SUPPORTED SYMPOSIUM
4. Navigational Bronchoscopy (superDimension) ROOM: 301 + 302
5. Navigational Bronchoscopy (BF Navi)
CHAIR: HOSSEIN BORGHAEI, USA
Refreshments provided
13:30 – 14:30 Press Conference

16:45 ISS 03.01: Welcome and Introductions
ROOM: 418 Hossein Borghaei, Fox Chase Cancer Center, USA
 For information on topics and speakers, please visit the
Press & Media page on the Conference website at: 16:50 ISS 03.02: Where Do Checkpoint Inhibitors Fit in
wclc2017.iaslc.org/press-media/press-media/ Second-Line Therapy?
Fabrice Barlesi, Aix-Marseille University, France
17:05 ISS 03.03: Where Do Checkpoint Inhibitors Fit in First-

Line Therapy?
Edward B. Garon, UCLA Medical Center, USA
17:20 ISS 03.04: The Immune Effects of Immune Checkpoint

Inhibitors: ir-AEs
Hossein Borghaei, Fox Chase Cancer Center, USA
17:35 ISS 03.05: Double, Double, Toil and Trouble With

Combination Therapy?
Edward B. Garon, UCLA Medical Center, USA

17:50 ISS 03.06: The Future of Checkpoint Inhibitors in Your
Practice
18:00 ISS 03.07: Concluding Remarks

Hossein Borghaei, Fox Chase Cancer Center, USA,

Fabrice Barlesi, Aix-Marseille University, France, Edward
B. Garon, UCLA Medical Center, USA
18:05 ISS 03.08: Question and Answer Session
18:30 – 20:00 Opening Ceremony
ROOM: NATIONAL CONVENTION HALL
IMPORTANT NOTE
Increased security will be in place and doors will be
closed at 18:25. No further entrance after 18:25.
Please ensure to arrive at least 30 minutes early.
Badges are required for ALL attendees including
those attending as paid guests of delegates
Taiko Drummer Performances

Welcome Addresses by IASLC and Local Dignitaries
Distinguished Award Winner Presentations
20:00 – 21:00 Welcome Reception
ROOM: NATIONAL CONVENTION HALL
Food & Beverages provided

SCIENTIFIC PROGRAM | MONDAY, OCTOBER 16, 2017
MONDAY, OCTOBER 16, 2017 | SCIENTIFIC PROGRAM

WS WORKSHOP SESSION
LEVEL 2F

LEVEL 3F
09:30 – 16:00 EXHIBIT HALL OPEN

HALL B + C
SNACKS AND BEVERAGES PROVIDED

ALL DAY DURING EXHIBIT OPENING HOURS
07:00 – 08:00 ISS 04: Integrating Liquid Biopsy into Clinical 07:00 – 08:00 ISS 05: What’s New in SCLC? Assessing
Care: Common Questions and Challenges – Emerging Therapeutic Options - Medscape -
Guardant Health Supported by an Independent Educational Grant
from AbbVie
ROOM: F201 + F202 (ANNEX HALL) TRACK: INDUSTRY SUPPORTED SYMPOSIUM
CHAIRS: RAFAEL ROSELL, SPAIN ROOM: F203 + F204 (ANNEX HALL)
& GEOFFREY R. OXNARD, USA CHAIR: CHARLES M. RUDIN, USA
07:00 ISS 04.01: Welcome and Clinical NSCLC Overview Continental Breakfast provided
Rafael Rosell, Catalan Institute of Oncology, Germans Trias
i Pujol Health Sciences Institute and Hospital, Spain 07:00 ISS 05.01: Welcome and Introduction
Charles M. Rudin, Memorial Sloan Kettering Cancer Center,
07:15 ISS 04.02: Considerations When Choosing a Liquid
USA
Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA
07:05 ISS 05.02: Why Is SCLC Such a Hard Nut to Crack?
07:30 ISS 04.03: Clinical Application of Liquid Biopsy
Jeffrey Crawford, Duke Cancer Institute, USA
Luis E. Raez, Memorial Cancer Institute, USA
07:15 ISS 05.03: What’s in the Phase 3 Pipeline for SCLC?
07:37 ISS 04.04: When Tissue and Plasma Are Discordant:
Immunotherapies
Why This Can Occur and What Next?
Antonio Rossi, S.G. Moscati Hospital, Italy
07:25 ISS 05.04: What’s in the Phase 3 Pipeline for SCLC?
07:45 ISS 04.05: What is the Number and Can I Treat When
Novel Biological Targets
it’s Low?
Enriqueta Felip, Hospital Universitari Vall d’Hebron, Spain
07:35 ISS 05.05: Panel Discussion: What is the Likely Impact
on Clinical Practice and the SCLC Landscape?
USA,
Jeffrey Crawford, Duke Cancer Institute, USA,
Enriqueta Felip, Hospital Universitari Vall d’Hebron, Spain,
Antonio Rossi, S.G. Moscati Hospital, Italy
07:50 ISS 05.06: Summary and Conclusion

USA

07:00 – 08:00 MTE 01: Management of Small Nodules 07:00 – 08:00 MTE 05: Neuroendocrine Tumors: Pathology
Detected by CT Screening (Sign Up Required) and Genetic Update (Sign Up Required)
TRACK: RADIOLOGY/STAGING/SCREENING TRACK: BIOLOGY/PATHOLOGY
SURGERY ROOM: 313 + 314

ROOM: 301 + 302
07:00 MTE 05.01: Neuroendocrine Tumors: Pathology and

07:00 MTE 01.01: Management of Small Nodules Detected by Genetic Update
CT Screening; A Surgeon’s Perspective Elisabeth Brambilla, Institut Albert Bonniot, Hopital Albert
Jun Nakajima, The University of Tokyo Hospital, Japan Michallon, France
07:00 – 08:00 MTE 02: Appropriate and Optimized Handling 07:00 – 08:00 MTE 06: Lung Cancer Pathology Update
of Specimens (Sign Up Required) (Sign Up Required)
TRACK: BIOLOGY/PATHOLOGY TRACK: BIOLOGY/PATHOLOGY
ROOM: 316 ROOM: 315
07:00 MTE 02.01: Appropriate and Optimized Handling of 07:00 MTE 06.01: Lung Cancer Pathology Update
Surgically Resected Specimens Prudence Russell, St. Vincent’s Hospital / University of
Erik Thunnissen, VU University Medical Center, Melbourne, Australia
Netherlands Andre L. Moreira, New York University School of Medicine,
USA
07:30 MTE 02.02: Appropriate and Optimized Handling of
Biopsy or Cytology Specimens
Mari Mino-Kenudson, Massachusetts General Hospital &
Harvard Medical School, USA
07:00 – 08:00 MTE 07: Molecular Biology: Minimum
Requirement for Clinicians (Sign Up Required)
TRACK: CHEMOTHERAPY/TARGETED THERAPY
07:00 – 08:00 MTE 03: Surgery for T4 Lung Cancer ROOM: 501
(Sign Up Required)
TRACK: SURGERY 07:00 MTE 07.01: Molecular Biology that Clinicians Should
ROOM: 303 + 304 Know: From a Clinical Viewpoint
Prasad S. Adusumilli, Memorial Sloan Kettering Cancer
Center, USA
07:00 MTE 03.01: Do Extended Resections Improve T4 Lung
Cancer Outcomes? 07:30 MTE 07.02: Molecular Biology that Clinicians Should
Dominique H. Grunenwald, Pierre & Marie Curie Know: From a Basic Viewpoint
University, France Martin Filipits, Medical University of Vienna, Austria
07:00 – 08:00 MTE 04: Radiotherapy for SCLC 07:00 – 08:00 MTE 08: Technical Details of EBUS and EUS
(Sign Up Required) (Sign Up Required)
TRACK: RADIOTHERAPY TRACK: PULMONOLOGY/ENDOSCOPY
ROOM: 311 + 312 ROOM: 502
07:00 MTE 04.01: Role of Radiotherapy in Multimodality 07:00 MTE 08.01: Technical Aspects of EBUS-TBNA for
Treatment for SCLC Clinicians
Corinne Faivre-Finn, Univ. of Manchester, UK Takahiro Nakajima, Chiba University Graduate School of
Medicine, Japan
07:30 MTE 04.02: General Principles of PCI in the Treatment
of SCLC 07:30 MTE 08.02: Clinical Aspects of EUS(B)-FNA
David L. Ball, Peter MacCallum Cancer Centre, Australia Bin Hwangbo, National Cancer Center, Korea

07:00 – 08:00 MTE 09: Management of Difficult Symptoms 10:00 – 10:45 Networking Opportunity
(Sign Up Required) & Poster Presenters Present for
TRACK: NURSING/PALLIATIVE CARE/ETHICS P1 Posters
ROOM: 503
07:00 MTE 09.01: Management of Difficult Symptoms Refreshments provided

Richard J. Gralla, Albert Einstein College of Medicine, USA
07:30 MTE 09.02: Symptom Experiences and Symptom P1.01 Advanced NSCLC
Clusters in Advanced Lung Cancer
Sanjay Popat, Royal Marsden Hospital, UK P1.02 Biology/Pathology
P1.03 Chemotherapy/Targeted Therapy
P1.04 Clinical Design, Statistics and Clinical Trials

07:00 – 08:00 MTE 10: Bridging the Gap between Genomics
P1.05 Early Stage NSCLC
and Clinics (Sign Up Required)
TRACK: CHEMOTHERAPY/TARGETED THERAPY P1.06 Epidemiology/Primary Prevention/
ROOM: 511 + 512 Tobacco Control and Cessation
P1.07 Immunology and Immunotherapy

07:00 MTE 10.01: Bridging the Gap between Genomics and
Clinics P1.08 Locally Advanced NSCLC
Frederico Cappuzzo, Department of Oncology-Hematology,
AUSL Romagna, Italy P1.09 Mesothelioma
07:30 MTE 10.02: Bridging the Gap between Genomics and P1.10 Nursing/Palliative Care/Ethics
Clinics
P1.11 Patient Advocacy
Julien Sage, Stanford University, USA
P1.12 Pulmonology/Endoscopy
P1.13 Radiology/Staging/Screening
08:15 – 09:45 PL 01: Prevention, Screening,
and Management of Screen-Detected P1.14 Radiotherapy
Lung Cancer
P1.15 SCLC/Neuroendocrine Tumors
TRACK: RADIOLOGY/STAGING/SCREENING P1.16 Surgery
ROOM: PLENARY HALL (HALL D)
CHAIRS: MICHAEL BOYER, AUSTRALIA P1.17 Thymic Malignancies/Esophageal Cancer/
& MATTHIJS OUDKERK, NETHERLANDS Other Thoracic Malignancies
08:15 PL 01.01: Current Status of Smoking Cesession

Program (Tobacco Control)
Carolyn Dresler, Human Rights and Tobacco Control
11:00 – 12:30 MS 01: Clinical Development of Novel Agents
Network, USA
TRACK: CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS
08:35 PL 01.02: Major Advances in CT Screening: ROOM: MAIN HALL
A Radiologist’s Perspective
CHAIRS: SUMITHRA MANDREKAR, USA
Claudia I. Henschke, Icahn School of Medicine at Mount & MOTOMI MORI, USA
Sinai, USA
08:55 PL 01.03: Changing Epidemiology in Lung Cancer 11:00 MS 01.01: Expansion Cohorts in Phase I Trials: Non
Mary Reid, Roswell Park Cancer Institute, USA Controlled Phase II or Translational Science?
Benjamin Besse, Gustave Roussy, France
09:15 PL 01.04: What is the Optimal Management of Screen-
Detected Lung Cancers 11:20 MS 01.02: Are We Categorizing Biomarkers Too
Shun-ichi Watanabe, National Cancer Center Hospital, Quickly?
Japan Jack Lee, MD Anderson Cancer Center, USA
09:35 Question and Answer Session 11:40 MS 01.03: Innovative Trial Designs: What is the Minimal
Burden of Proof for Drug Approval?
Giuseppe Giaccone, Georgetown University, USA
12:00 MS 01.04: Is “Big Data” the Solution to the Complex

10:00 – 10:45 Press Conference Therapeutic Landscape?
Yu Shyr, Vanderbilt University Medical Center, USA
ROOM: 418
 For information on topics and speakers, please visit the 12:20 Question and Answer Session
Press & Media page on the Conference website at:
wclc2017.iaslc.org/press-media/press-media/

11:00 – 12:30 MS 02: Ethnic Differences: Biology or Myth 11:00 – 12:30 MS 04: Joint IASLC/GLCC Session Current
Issues in Lung Cancer Advocacy
TRACK: REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH
ROOM: 501 TRACK: PATIENT ADVOCACY
ROOM: 316

CHAIRS: RONALD NATALE, USA
& JEONG-SEON RYU, KOREA CHAIRS: NATASHA B. LEIGHL, CANADA
& MAUREEN RIGNEY, USA
11:00 MS 02.01: Lung Cancer Genomics

Ramaswamy Govindan, Washington University School of 11:00 MS 04.01: Lung Cancer Advocacy Tools for Everyone –
Medicine, USA The Use of GLCC Data
Jesme Fox, Roy Castle Lung Cancer Foundation, UK
11:15 MS 02.02: Molecular Epidemiology
Tomoya Kawaguchi, Graduate school of Medicine, Osaka 11:15 MS 04.02: Lung Cancer Advocates and Measuring Value
City University, Japan in Healthcare
Carolyn Aldige, Prevent Cancer Foundation, USA
11:30 MS 02.03: Chemotherapy: Efficacy and Toxicity
Difference According to Ethnicity 11:30 MS 04.03: Accessing New Lung Cancer Therapies –
Martin Edelman, Fox Chase Cancer Center, USA Challenges & Experience in Latin America
Patricia Mondragon, Respirando con Valor AC, Mexico
11:45 MS 02.04: Targeted Agents and Immunotherapy:
Efficacy and Toxicity Difference According to Ethnicity 11:45 MS 04.04: Patient Advocacy – Making a Difference for
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain Lung Cancer Patients in Japan
Toshiyuki Sawa, Gifu Municipal Hospital, Japan
12:00 MS 02.05: Is Ethnicity a Prognostic Factor in Lung
Cancer 12:00 MS 04.05: Lung Cancer Patients and Stopping Smoking
Viola Zhu, Chao Family Comprehensive Cancer Center, – What Advocates Need to Know
UC Irvine, USA Aoife McNamara, Irish Cancer Society, Ireland
12:15 Question and Answer Session 12:15 Question and Answer Session
11:00 – 12:30 MS 03: Best Practice for Small-Sized Early 11:00 – 12:30 ES 01: New TNM and WHO Classification
Stage Lung Cancer: Standard Surgery, Limited
Resection, SBRT
ROOM: 301 + 302
TRACK: EARLY STAGE NSCLC CHAIRS: MASAYUKI NOGUCHI, JAPAN
ROOM: F203 + F204 (ANNEX HALL) & PETER GOLDSTRAW, UK
CHAIRS: RICARDO BEYRUTI, BRAZIL
& HO YUN LEE, KOREA
11:00 ES 01.01: New TNM Classification
Ramon Rami-Porta, Hospital Universitari Mutua Terrassa,
11:00 MS 03.01: Limited vs. Standard Surgical Resection: and CIBERES Lung Cancer Group, Spain
North American Experience
Nasser Altorki, Cornell University, USA 11:20 ES 01.02: New Histological Classification
William D. Travis, Memorial Sloan Kettering Cancer Center,
11:15 MS 03.02: Limited vs. Standard Surgical Resection: USA
Japanese Experience
Hisao Asamura, Keio University School of Medicine, Japan 11:40 ES 01.03: Immunohistochemistry, Chromosomal and
DNA Analysis, and Molecular Testing
11:30 MS 03.03: Limited vs. Standard Surgical Resection: Yasushi Yatabe, Aichi Cancer Center, Japan
European Experience
Paul Emile Van Schil, Antwerp University Hospital, 12:00 ES 01.04: Staging and Pathology of Multiple Nodules
Belgium Presenting in the Lungs
Andrew G. Nicholson, Royal Brompton and Harefield NHS
11:45 MS 03.04: Technical Aspects of Limited Resection Foundation Trust and National Heart and Lung Institute, UK
Harvey I. Pass, NYU Langone Medical Center, USA
12:20 Question and Answer Session
12:00 MS 03.05: SBRT Experience
Joe Y. Chang, MD Anderson Cancer Center, USA

11:00 – 12:30 ES 02: Diagnostic and Interventional Radiology
in Lung Cancer: Update 2017
ROOM: 315
CHAIRS: DAVID F. YANKELEVITZ, USA
& SHUJI SAKAI, JAPAN
11:00 ES 02.01: The Dutch-Belgian Lung Cancer Screening

Trial (NELSON)
Harry J. De Koning, Erasmus MC, Netherlands

11:15 ES 02.02: The Fleischner Guideline / Lung-RADs 11:20 OA 01.03: Patterns of Change in High-Risk Radiological
Matthew Eric Callister, Leeds Teaching Hospitals, UK Features in Patients without Local Recurrence after
SABR for Early-Stage NSCLC
11:30 ES 02.03: Radiologic Implications of the WHO Merle Ilona Ronden, VU Medical Center, Netherlands
Classification for Lung Cancer
Kavita Garg, University of Colorado Anschutz Medical 11:30 OA 01.04: Discussant – OA 01.01, OA 01.02, OA 01.03
Campus, USA Jin Hee Kim, Keimyung University Dongsan Medical

Center, Korea
11:45 ES 02.04: Interventional Radiology on Personalized
Medicine for Lung Cancer 11:45 OA 01.05: Analysis of Radiotherapy Quality Assurance
Tae Jung Kim, Samsung Medical Center, Korea Data for the Convert Trial – Does Non-Compliance to
Protocol Affect Survival?
12:00 ES 02.05: MRI and Advanced Applications for Lung Elena Wilson, 2University College London Hospitals NHS
Cancer Foundation Trust, London, UK, UK
Yoshiharu Ohno, Kobe University Graduate School of
Medicine, Japan 11:55 OA 01.06: Radiation Therapy is Associated with an
Increased Incidence of Cardiac Events in Small Cell Lung
12:15 Question and Answer Session Cancer Patients
Matthew Jeffrey Ferris, Winship Cancer Institute at Emory
University, USA
12:05 OA 01.07: Tracking Major Symptom Burden from

11:00 – 12:30 GR 01: What to Do at the Time of Progression Chemotherapy Concurrent with 3D vs. IMRT vs. Proton
on Targeted Therapy Beam Radiotherapy for NSCLC
Qiuling Shi, University of Texas MD Anderson Cancer
TRACK: CHEMOTHERAPY/TARGETED THERAPY Center, USA
ROOM: 303 + 304
CHAIRS: DONG-WAN KIM, KOREA 12:15 OA 01.08: Discussant – OA 01.05, OA 01.06, OA 01.07
& LECIA V. SEQUIST, USA Yukinori Matsuo, Kyoto University, Japan
11:00 GR 01.01: Case Study

Dong-Wan Kim, Seoul National University Hospital, Korea
11:05 GR 01.02: Case Study 11:00 – 12:30 OA 02: Mesothelioma: Challenges For New
Lecia V. Sequist, Massachusetts General Hospital, USA Treatment
TRACK: MESOTHELIOMA
11:10 GR 01.03: First-Line Management of EGFR Mutant
ROOM: F205 + F206 (ANNEX HALL)
NSCLC
Li Zhang, Sun Yat-sen University Cancer Center, China CHAIRS: SEIKI HASEGAWA, JAPAN
& ANNA NOWAK, AUSTRALIA
11:30 GR 01.04: EGFR-Positive NSCLC Cases Who Failed
Previous EGFR-TKI 11:00 OA 02.01: Randomized Phase II Study of Anetumab
Gregory J. Riely, Memorial Sloan Kettering Cancer Center, Ravtansine or Vinorelbine in Patients with Metastatic
USA Pleural Mesothelioma
Hedy Lee Kindler, University of Chicago, USA
11:50 GR 01.05: First-Line Management of ALK Mutant NSCLC
Silvia Novello, University of Turin, Department of Oncology, 11:10 OA 02.02: Ipilimumab and Nivolumab in the Treatment
S. Luigi Hospital, Italy of Recurrent Malignant Pleural Mesothelioma: A Phase II
Study
12:10 GR 01.06: ALK-Positive NSCLC Cases who Failed
Paul Baas, Netherlands Cancer Institute, Netherlands
Previous ALK Inhibitors
Jürgen Wolf, Universitätsklinikum Köln, Germany 11:20 OA 02.03: Prophylactic Irradiation of Tracts (PIT)
in Patients with Pleural Mesothelioma: Results of a
Multicentre Phase III Trial
Neil Bayman, The Christie NHS Foundation Trust, UK
Daniel H. Sterman, NYU Langone Medical Center, USA
11:00 – 12:30 OA 01: The New Aspect of Radiation Therapy
TRACK: RADIOTHERAPY 11:30 OA 02.04: Discussant – OA 02.01, OA 02.02, OA 02.03
Daniel H. Sterman, NYU Langone Medical Center, USA
CHAIRS: MASAHIRO HIRAOKA, JAPAN 11:45 OA 02.05: RESPECT-MESO: An International
& SUNG HWAN KIM, KOREA
Randomised Controlled Trial to Assess Early Specialist
Palliative Care in Malignant Pleural Mesothelioma
11:00 11:00 OA 01.01: A Randomized Trial of SABR vs Fraser Brims, Curtin University, Australia
Conventional Radiotherapy for Inoperable Stage I Non-
Small Cell Lung Cancer: TROG 09.02 (CHISEL) 11:55 OA 02.06: Radioimmunotherapy Combining CTLA-4
David L. Ball, Peter MacCallum Cancer Centre, Australia Blockade or Low-Dose Cyclophosphamide with Local
Radiation in Murine Malignant Mesothelioma
11:10 OA 01.02: Stereotactic Radiotherapy as Salvage Mikihiro Kohno, Toronto General Research Institute,
Treatment After Surgery and Curative Intended Canada
Radiotherapy for Patients with NSCLC
Olfred Hansen, Odense University Hospital, Denmark 12:05 OA 02.07: Surgical Selection in Pleurectomy
Decortication for Mesothelioma – an Overview from
Screening and Selection from MARS 2 Pilot
Eric Lim, Royal Brompton Hospital, UK

12:15 Discussant – OA 02.05, OA 02.06, OA 02.07 11:10 MA 01.03: The Potential of ctDNA Sequencing in
Prasad S. Adusumilli, Memorial Sloan-Kettering Cancer Disease Monitoring and Depicting Genomic Evolution of
Center, USA Small-Cell Lung Cancer Under Therapy
Jianjun Zhang, The University of Texas MD Anderson
Cancer Center, USA

11:15 MA 01.04: Discussant – MA 01.01, MA 01.02, MA 01.03
11:00 – 12:30 OA 03: Mediastinal and Esophageal Tumor: Charles Andrew Butts, Cross Cancer Institute, Canada
Insight and New Treatment
11:30 MA 01.05: Activity and Safety of the Combination of
TRACK: THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/ PM01183 and Doxorubicin in Relapsed SCLC. Final
OTHER THORACIC MALIGNANCIES Results of a Phase Ib Trial
ROOM: 311 + 312 Emiliano Calvo, START Madrid – HM CIOCC, Hospital
CHAIRS: MASAYUKI CHIDA, JAPAN Madrid Norte Sanchinarro, Spain
& JHINGOOK KIM, KOREA
11:35 MA 01.06: A Phase II Study of Etirinotecan Pegol
(NKTR-102) in Patients with Chemotherapy-Resistant
11:00 OA 03.01: Prevalence of Autoimmune Diseases in Small Cell Lung Cancer
Thymic Epithelial Tumors (TET) Insights from RYTHMIC Hongbin Chen, Roswell Park Cancer Institute, USA
Marie-Eve Boucher, Institut Gustave Roussy, France
11:40 MA 01.07: Lanreotide Maintenance in SCLC Expressing
11:10 OA 03.02: Comprehensive Characterization of Thymic Somatostatine Receptors: Efficacy Results of
Epithelial Tumour Subtypes Through an Analysis of Multicenter Randomized G04.2011 Trial
Somatic Mutations and Copy Number Alterations Sara Pilotto, University of Verona, Azienda Ospedaliera
Spyridon Gennatas, Imperial College, London, UK Universitaria Integrata (AOUI), Italy
11:20 OA 03.03: Phase II Trial of Cetuximab and 11:45 MA 01.08: Discussant – MA 01.05, MA 01.06, MA 01.07
Chemotherapy Followed by Surgical Resection for Anne Tsao, University of Texas M.D. Anderson Cancer
Locally Advanced Thymoma Center, USA
James Huang, Memorial Sloan-Kettering Cancer Center,
USA 12:00 MA 01.09: Treatment Patterns in Extensive Disease
Small Cell Lung Cancer Across the United States,
11:30 OA 03.04: A Phase II Study of Pembrolizumab for Europe, and Japan
Patients with Refractory or Relapsed Thymic Epithelial Yong Yuan, Bristol-Myers Squibb, USA
Tumor
Jinhyun Cho, Inha University Hospital, Korea 12:05 MA 01.10: Outcome Based on Baseline Total Lymphocyte
Count & Neutrophil-To-Lymphocyte Ratio in Extensive
11:40 OA 03.05: Discussant – OA 03.01, OA 03.02, OA 03.03, Stage Small-Cell Lung Cancer
OA 03.04 Ryoko Suzuki, The University of Texas MD Anderson
Masanori Tsuchida, Niigata University Graduate School of Cancer Center, USA
Medical and Dental Sciences, Japan
12:10 MA 01.11: Timing of Thoracic Radiotherapy Is More
11:55 OA 03.06: Clinicopathologic, Immunophenotypic and Important Than Dose Escalation in Patients with
Genetic Studies of Mediastinal Paragangliomas Limited-Stage Small Cell Lung Cancer
Anja C. Roden, Mayo Clinic, USA Xiao Hu, Zhejiang Cancer Hospital, Zhejiang Key
Laboratory of Radiation Oncology, China
12:05 OA 03.07: Developing Prognostic Nomogram
and Evaluating Its Role in Personalized Adjuvant 12:15 MA 01.12: Discussant – MA 01.09, MA 01.10, MA 01.11
Chemotherapy for Patients with ESCC Anand Swaminath, McMaster University, Canada
Qianwen Liu, Sun Yat-sen University Cancer Center, China
12:15 OA 03.08: Discussant – OA 03.06, OA 03.07

Nicolas Girard, Hospices Civils de Lyon, France
11:00 – 12:30 MA 02: Emerging Targets
ROOM: 511 + 512
11:00 – 12:30 MA 01: SCLC: Research Perspectives CHAIRS: RAVI SALGIA, USA
& SHUN LU, CHINA
TRACK: SCLC/NEUROENDOCRINE TUMORS
ROOM: 503
CHAIRS: JOHN V. HEYMACH, USA 11:00 MA 02.01: Evidence of Clinical Activity of Sitravatinib
& EUN KYUNG CHO, KOREA in Combination with Nivolumab in NSCLC Patients
Progressing on Prior Checkpoint Inhibitors
Ticiana A. Leal, University of Wisconsin Carbone Cancer
11:00 MA 01.01: Metastatic Behavior of Pulmonary
Center, USA
Neuroendocrine Carcinomas Is Associated with
Epithelial to Mesenchymal Transition Gene Profile 11:05 MA 02.02: Phase 2 Study of Pembrolizumab Plus
Tabatha Gutierrez Prieto, Faculdade de Medicina da USP, CC-486 vs Pembrolizumab Plus Placebo in Previously
Brazil Treated Patients with Advanced NSCLC
Luis Paz-Ares, Hospital Universitario Doce de Octubre,
11:05 MA 01.02: Multigene Mutation Profiling and Clinical
Spain
Characteristics of Small-Cell Lung Cancer in Never-
Smokers Versus Heavy Smokers 11:10 MA 02.03: Selective Histone Deacetylase Inhibitor ACY-
Andrés F. Cardona, Foundation for Clinical and Applied 241 Plus Nivolumab for Refractory Advanced NSCLC:
Cancer Research – FICMAC, Colombia Results From a Phase 1b Study
Mark Awad, Dana- Farber Cancer Institute, USA

11:15 MA 02.04: Discussant – MA 02.01, MA 02.02, MA 11:30 MA 03.05: Bevacizumab Combined with Chemotherapy
02.03 for Patients with Advanced NSCLC and Brain
Grace K. Dy, Roswell Park Cancer Institute, USA Metastasis. A French Cohort Study
Jaafar Bennouna, University Hospital, France
11:30 MA 02.05: Nivolumab in Advanced Non-Squamous
NSCLC Patients with KRAS Mutations: Results from the 11:35 MA 03.06: Effect of 2L Ramucirumab after Rapid Time
Italian Expanded Access Program (EAP) to Progression on 1L Therapy: Subgroup Analysis of

Domenico Galetta, Istituto Tumori “Giovanni Paolo II”, Italy REVEL in Advanced NSCLC
Martin Reck, LungClinic Grosshansdorf, Germany
11:35 MA 02.06: BRAF Mutant NSCLC: Correlation with PD-L1
Expression,TMB, MSI and Response to ICPi and Anti- 11:40 MA 03.07: The Predictive Value of Interferon-? Release
BRAF Therapy Assays (IGRA) for Chemotherapy Response in Advanced
Elizabeth Dudnik, Rabin Medical Center, Israel Non-Small-Cell Lung Cancer Patients
Hsu-Ching Huang, Taipei Veterans General Hospital,
11:40 MA 02.07: A Phase II Study of Pembrolizumab in EGFR Taiwan
Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve
Patients with Advanced NSCLC 11:45 MA 03.08: Discussant – MA 03.05, MA 03.06, MA
Aaron Lisberg, University of California, USA 03.07
Ikuo Sekine, Faculty of Medicine, University of Tsukuba,
11:45 MA 02.08: Discussant – MA 02.05, MA 02.06, MA Japan
02.07
Barbara Melosky, British Columbia Cancer Agency, Canada 12:00 MA 03.09: The Cost and the Benefit: Front-Line
Immunotherapy for Non-Small Cell Lung Cancer
12:00 MA 02.09: A Ph I/II Study of BGB324, a Selective Christine M. Bestvina, University of Chicago Medicine, USA
AXL Inhibitor as Monotherapy and in Combination with
Erlotinib in Advanced NSCLC 12:05 MA 03.10: Prognostic Factors in NSCLC Patients
Don Lynn Gibbons, MD Anderson Cancer Center, USA Treated with a Fourth-Line Therapy
Vincent Leroy, Lille University Hospital, France
12:05 MA 02.10: Phase I Study of ABBV-399 (Telisotuzumab
Vedotin) as Monotherapy and in Combination with 12:10 MA 03.11: Targeting CDCA3 Enhances Sensitivity to
Erlotinib in NSCLC Platinum-Based Chemotherapy in Non-Small Cell Lung
Jonathan Wade Goldman, UCLA, USA Cancer
Mark N. Adams, Institute of Health and Biomedical
12:10 MA 02.11: A Phase I Trial of Erlotinib and Onalespib Innovation, Australia
in EGFR-mutant NSCLC: Focus on EGFR Exon 20
Insertions 12:15 MA 03.12: Discussant – MA 03.09, MA 03.10, MA 03.11
Jonathan W. Riess, University of California Davis Cancer Mary O’Brien, Royal Marsden Hospital, UK
Center, USA

Dean A. Fennell, University of Leicester & Leicester
University Hospitals, UK 11:00 – 12:30 MA 04: Advocacy: Listen to the Patients
TRACK: PATIENT ADVOCACY
ROOM: 313 + 314
CHAIRS: RUDOLF M. HUBER, AUSTRIA
11:00 – 12:30 MA 03: Chemotherapy & CSABA L. DÉGI, ROMANIA
TRACK: ADVANCED NSCLC

CHEMOTHERAPY/TARGETED THERAPY 11:00 MA 04.01: Prospective Comparative Evaluation
ROOM: 502 of Patient and Caregiver Perspectives on a
CHAIRS: JIN-HYOUNG KANG, KOREA Multidisciplinary Model of Lung Cancer Care
& WU-CHOU SU, TAIWAN Matthew P. Smeltzer, University of Memphis School of
Public Health, USA
11:00 MA 03.01: Nab-Paclitaxel ± CC-486 as Second-Line 11:05 MA 04.02: Assessing the Psychosocial Needs of Newly
Treatment of Advanced NSCLC: Results from the Diagnosed NSCLC Patients: Identifying the Population
ABOUND.2L+ Study Most At-Risk
Ramaswamy Govindan, Washington University School of Bonnie Leung, British Columbia Cancer Agency, Canada
Medicine, USA
11:10 MA 04.03: Physician Empathy and Sensitivity to a
11:05 MA 03.02: Timing of B12/Folate Supplementation in Patient’s Emotional Journey Can Be Critical to Patient
NSCLC Patients on Pemetrexed Based Chemotherapy: Optimism and Empowerment
Final Results of the PEMVITASTART Randomized Trial Danielle Hicks, Lung Cancer Foundation, USA
Navneet Singh, Postgraduate Institute of Medical Education
and Research (PGIMER), India 11:15 MA 04.04: Discussant – MA 04.01, MA 04.02, MA
04.03
11:10 MA 03.03: Nedaplatin plus Docetaxel versus Cisplatin Kathy Weber, Mednax, Inc, USA
plus Docetaxel as First-Line Chemotherapy for
Advanced Squamous Cell Carcinoma of the Lung 11:30 MA 04.05: The Impact of the Meso Foundation on
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong Advocacy Efforts for Funding Mesothelioma Research
University, China Melinda Kotizan, Mesothelioma Applied Research
Foundation, USA
11:15 MA 03.04: Discussant – MA 03.01, MA 03.02, MA
03.03
Adrian G. Sacher, Dana-Farber Cancer Institute, USA

11:35 MA 04.06: Developing a Lung Cancer Clinical Quality
Registry Framework to Collect Longitudinal Patient- 13:00 – 14:00 EXH 01: Thermo Fisher: Next Generation
Reported Outcomes Sequencing – Changing Paradigm in NSCLC
Mary Duffy, Peter MacCallum Cancer Centre, Australia Patient Management
11:40 MA 04.07: Understanding Patient Barriers to Utilization TRACK: EXHIBIT SHOWCASE SESSION

of Low Dose CT Lung Cancer Screening ROOM: EXHIBIT SHOWCASE THEATER,
Cherie Parungo Erkmen, Temple University Hospital, USA EXHIBIT HALL (HALL B + C)

As number of targeted therapies in NSCLC is rapidly increasing,
04.07
simultaneous testing for multiple biomarkers is becoming progres-
Andrea Katalin Borondy Kitts, Lahey Hospital & Medical
sively important to ensure a timely diagnosis and start of treatment.1
Center, USA
Next Generation Sequencing (NGS) technology has been significantly
advancing cancer research for some time and now is finally ready for
12:00 MA 04.09: A Study on the Damage of Passive Smoking
a daily routine patient testing. Objective of this session is to:
to Japanese Lung Cancer Patients
Kazuo Hasegawa, Japan Lung Cancer Alliance, Japan
`` Explain basic science and principle of NGS and its application in
12:05 MA 04.10: An Assessment of the Willingness to Provide NSCLC patient testing
Serial Bio-Specimens: Experience from an Irish Tertiary
`` Introduce the first NGS in vitro diagnostic (IVD) test for NSCLC,
Cancer Centre
simultaneously delivering multiple biomarker results for multiple
Anne-Marie Baird, St. James’s Hospital & Trinity College
targeted therapies – Oncomine Dx Target Test
Dublin, Ireland
`` Give forum for multiple stakeholders – clinicians, laboratories and
12:10 MA 04.11: A Comprehensive Vision to Reduce Lung patients – discussion
Cancer Stigma: Changing Cultural Perspectives on Lung
Cancer
Angela Meredith Criswell, Lung Cancer Alliance, USA
14:30 – 15:30 IASLC Business Meeting
12:15 MA 04.12: Discussant – MA 04.09, MA 04.10, MA 04.11 (Including Travel Award Presentations)
Sita Andarini, Faculty of Medicine, Universitas Indonesia,
Persahabatan Hospital, Indonesia ROOM: F201 + F202 (ANNEX HALL)
Refreshments will be provided

12:45 – 14:15 ISS 06: Maximizing Clinical Benefit from
TKIs in the Treatment of Advanced NSCLC –
Boehringer Ingelheim Pharma GmbH & Co. KG
ROOM: MAIN HALL 14:30 – 15:30 Networking Opportunity
CHAIRS: TETSUYA MITSUDOMI, JAPAN & Poster Presenters Present for
P1 Posters
Lunch boxes provided
12:45 ISS 06.01: Meeting Welcome and Introductions

Tetsuya Mitsudomi, Kindai University Faculty of Medicine,
Japan
P1.01 Advanced NSCLC
12:50 ISS 06.02: Efficacy of EGFR TKIs in NSCLC Patients
With Uncommon EGFR Mutations P1.02 Biology/Pathology
Terufumi Kato, Kanagawa Cancer Center, Japan
13:10 ISS 06.03: Considerations for Choosing TKIs for
Squamous NSCLC in the Era of Immunotherapy: Which P1.04 Clinical Design, Statistics and Clinical Trials
Patients Could Benefit?
Glenwood Goss, Ottawa Regional Cancer Centre, Canada P1.05 Early Stage NSCLC
13:30 ISS 06.04: Emerging Algorithm for Optimal Sequencing P1.06 Epidemiology/Primary Prevention/
of EGFR TKIs in EGFR Mutation-Positive NSCLC Tobacco Control and Cessation
Keunchil Park, Samsung Med Ctr, Sungkyunkwan
University School of Medicine, Korea P1.07 Immunology and Immunotherapy
13:50 ISS 06.05: Panel Discussion: Carrying the Data into the P1.08 Locally Advanced NSCLC
Clinic: TKI Sequencing Decisions for EGFR Mutation-
Positive NSCLC Patients P1.09 Mesothelioma
Terufumi Kato, Kanagawa Cancer Center, Japan,
P1.10 Nursing/Palliative Care/Ethics
Glenwood Goss, Ottawa Regional Cancer Centre, Canada,
Keunchil Park, Samsung Med Ctr, Sungkyunkwan P1.11 Patient Advocacy
University School of Medicine, Korea
14:10 ISS 06.06: Meeting Close
Tetsuya Mitsudomi, Kindai University Faculty of Medicine, P1.13 Radiology/Staging/Screening
Japan

16:45 MS 06.05: The Use of Adjuvant IMRT after
P1.14 Radiotherapy Pleurectomy/Decortication
Andreas Rimner, Memorial Sloan-Kettering Cancer Center,
USA
P1.16 Surgery
17:00 MS 06.06: Chemotherapy for Thymic and Mesothelial
P1.17 Thymic Malignancies/Esophageal Cancer/ Tumors

Other Thoracic Malignancies Miyako Satouchi, Hyogo Cancer Center, Japan
15:45 – 17:30 MS 05: Clinical Issues of Immune Checkpoint

Inhibitors
15:45 – 17:30 MS 07: Neuroendocrine Tumors other than
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY SCLC: Pathology to Patient Management
ROOM: MAIN HALL
CHAIRS: LUISE. RAEZ, USA
& NICO VAN ZANDWIJK, AUSTRALIA
CHAIRS: CARLOS BARRIOS, BRAZIL
& SANG-WE KIM, KOREA
15:45 MS 05.01: How to Evaluate the Efficacy of IO?
Frances A. Shepherd, Princess Margaret Cancer Centre,
15:45 MS 07.01: Pathology of Neuroendocrine Tumors other
Canada
than SCLC
16:00 MS 05.02: First-line versus Second-Line Anti-PD-(L)1 Mary Beth Beasley, Mount Sinai Medical Center, USA
Therapy for Patients with Positive PD-L1 Expression
16:00 MS 07.02: Novel Chemotherapy for LCNEC
Fabrice Barlesi, Aix Marseille University, France
Seiji Niho, National Cancer Center Hospital East, Japan
16:15 MS 05.03: Rational IO/IO Combinations
16:15 MS 07.03: Novel Systemic Therapy for Carcinoid of the
Tony Mok, Chinese University of Hong Kong, Hong Kong
Lung
16:30 MS 05.04: Practical Approach to Combination of Primo Lara, University of California Davis Comprehensive
Chemotherapy with IO Cancer Center, USA
Yuichiro Ohe, National Cancer Center Hospital, Japan
16:30 MS 07.04: Surgical Treatment for Neuroendocrine
16:45 MS 05.05: Continuation of Immunotherapy in Post- Tumors other than SCLC
Progressive Disease Akira Iyoda, Toho University School of Medicine, Japan
David R. Gandara, UC Davis Comprehensive Cancer
16:45 MS 07.05: ESTS Registration for Neuroendocrine
Center, USA
Tumors
17:00 MS 05.06: Brain Metastasis: Rationale and Efficacy Pier Luigi Filosso, University of Torino Italy, Italy
with IO
17:00 MS 07.06: Which Chemotherapy or Targeted Therapy
Ignacio Gil-Bazo, Clinica Universidad de Navarra, Spain
is Better for Treatment of LCNEC Patients: SCLC-based
17:15 Question and Answer Session versus Non-SCLC-based Regimens?
Sumitra Thongprasert, Bangkok Hospital Chiang Mai,
Thailand

15:45 – 17:30 MS 06: Combined Modality Treatment for
Thymic and Pleural Malignancy
TRACK: THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/
OTHER THORACIC MALIGNANCIES 15:45 – 17:30 MS 08: Novel Treatment for Mesothelioma
TRACK: MESOTHELIOMA
CHAIRS: OSCAR ARRIETA, MEXICO
& SCOTT SWANSON, USA ROOM: 316
CHAIRS: PAUL BAAS, NETHERLANDS
& TAKASHI NAKANO, JAPAN
15:45 MS 06.01: Proposal of Change for Future Staging
System for Thymic Tumor
Meinoshin Okumura, Osaka Univeristy Graduate School of 15:45 MS 08.01: Today’s Challenges in MPM Care
Medicine, Japan Walter Weder, University Hospital Zurich, Switzerland
16:00 MS 06.02: Is There a Role for Minimally Invasive 16:00 MS 08.02: Current Role of RT in MPM
Surgery in Locally Advanced Thymic Tumors? Anna Wrona, Medical University of Gdansk, Poland
Wentao Fang, Shanghai Chest Hospital, China
16:15 MS 08.03: Basic Science and Surgical Advances in MPM
16:15 MS 06.03: PD vs. EPP in the Treatment of MPM Raphael Bueno, Brigham and Women’s Hospital, USA
David Rice, UT MD Anderson Cancer Center, USA
16:30 MS 08.04: Immunotherapy in MPM
16:30 MS 06.04: The Effect of the Timing of Chemotherapy: Anna Nowak, University of Western Australia, Australia
Induction vs Adjuvant after PD or EPP
16:45 MS 08.05: New Biological Insights
David Waller, St Bartholomew’s Hospital, London, UK
Yoshitaka Sekido, Aichi Cancer Center Research Institute,
Japan

17:00 MS 08.06: Molecularly Stratified Therapy 17:05 MS 10.05: Immunotherapy: The Latest
Hedy Lee Kindler, University of Chicago, USA Beth Eaby-Sandy, Abramson Cancer Center, University of
Pennsylvania, USA
17:15 MS 08.07: Achieving Equitable Access to Novel
Treatments for all Patients 17:25 Question and Answer Session
Liz Darlison, University Hospitals of Leicester, UK

15:45 – 17:30 PC 01: 1-1. Surgery vs Non-Surgical Local

Treatment for Small-Sized NSCLC
15:45 – 17:30 MS 09: Global Perspectives in Eliminating the PC 01: 1-2. What is the Role of Local Therapy
Major Cause of Lung Cancer in Non-CNS Oligometastatic NSCLC?
TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO TRACK: EARLY STAGE NSCLC

CONTROL AND CESSATION ADVANCED NSCLC
ROOM: 315 ROOM: 502
CHAIRS: CAROLYN DRESLER, USA CHAIRS: DAVID L. BALL, AUSTRALIA
& WILLIAM K. EVANS, USA & HIROSHI DATE, JAPAN
15:45 MS 09.01: Global Tobacco Control 15:45 PC 01.01: SABR as First Line Treatment Option
Emily Stone, St Vincent’s Hospital Sydney, Australia Hak Choy, UT Southwestern Medical Center, USA
16:00 MS 09.02: FCTC Implementation around the World 16:05 PC 01.02: Surgery as First Line Treatment Option
Geoffrey Fong, University of Waterloo, Canada Robert John Downey, Memorial Sloan Kettering Cancer
Center, USA
16:15 MS 09.03: Cost Effectiveness of Smoking Cessation
Hong Gwan Seo, National Cancer Center, Korea 16:25 PC 01.03: Other First Line Treatment Options
Hiran Fernando, Inova Fairfax Hospital,Inova Schar Cancer
16:30 MS 09.04: Nicotine Dependence and Cessation in Lung Institute, USA
Cancer Patients
Matthew A. Steliga, University of Arkansas for Medical 16:45 PC 01.04: There is a Role of Surgery in Non-CNS
Sciences, USA Oligometastatic Disease
Young Tae Kim, Seoul National University Hospital, Korea
16:45 MS 09.05: Holding the Tobacco Industry Accountable;
Discussion about iQOS 17:05 PC 01.05: There is No Role of Surgery in Non-CNS
Yumiko Mochizuki, National Cancer Center, Japan Oligometastatic Disease
Egbert F. Smit, Netherlands Cancer Institute, Netherlands
17:00 MS 09.06: Tobacco Industry Interference in Low and
Middle Income Countries 17:25 Question and Answer Session
Nise Yamaguchi, Hospital Albert Einstein, Brazil
17:15 MS 09.07: Implementation of Smoking Cessation

Strategies
Stella Bialous, UCSF School of Nursing, USA 15:45 – 17:30 ES 03: Current Topics for Nurses & Allied
Health
TRACK: NURSING/PALLIATIVE CARE/ETHICS
ROOM: 313 + 314
15:45 – 17:30 MS 10: Evidence Based Care: Interpreting the CHAIRS: ANNE FRASER, NEW ZEALAND
Research and Enhancing Practice & SUE KIM, KOREA

15:45 ES 03.01: IASLC Immunotherapy Guidelines
Kimberly Ann Rohan, Edward Cancer Center, USA
CHAIRS: CAITLIN BRODERICK, AUSTRALIA
& PIPPA LABUC, UK
16:05 ES 03.02: Pulmonary Rehabilitation
Catherine L. Granger, The University of Melbourne,
15:45 MS 10.01: Radiotherapy Management Australia
Mary Duffy, Peter MacCallum Cancer Centre, Australia
16:25 ES 03.03: Allied Health: The Missing Link in
16:05 MS 10.02: Interpreting Published Research Comprehensive Cancer Care
Angela Mary Tod, University of Sheffield, UK Kahren White, Private Practice, Australia
16:25 MS 10.03: Community Outreach – Engaging in Primary 16:45 ES 03.04: Mesothelioma: Beyond the Basics
Care Mary Hesdorffer, Mesothelioma Applied Research
Lavinia Dobrea, St. Joseph Hospital, USA Foundation, USA
16:45 MS 10.04: Pre-Operative Support 17:05 ES 03.05: Case Presentation

Melissa Culligan, University of Maryland Medical Center – Yun Hee Ham, Samsung Medical Center, Korea
Thoracic Surgery, USA

16:05 OA 05.03: Clinical Activity of ASP8273 in Asian Non-
15:45 – 17:30 OA 04: Surgery from Minimal to Radical Small Cell Lung Cancer Patients with EGFR Activating
and T790M Mutations
TRACK: SURGERY Keunchil Park, Samsung Medical Center, Sungkyunkwan
ROOM: 311 + 312 University School of Medicine, Korea
CHAIRS: JANG-MING LEE, TAIWAN

& ANDREW CHANG, USA 16:15 OA 05.04: Discussant – OA 05.01, OA 05.02, OA 05.03
Mark G. Kris, Memorial Sloan Kettering Cancer Center,
USA
15:45 OA 04.01: Randomised Trial of Systematic Lymph
Node Dissection versus Bilateral Mediastinal 16:30 OA 05.05: Brigatinib in Crizotinib-Refractory ALK+
Lymphadenectomy in Patients with Non-Small Cell NSCLC: Updated Efficacy and Safety Results From
Carcinoma ALTA, a Randomized Phase 2 Trial
Jaroslaw Kuzdzal, Jagiellonian University, John Paul II Myung-Ju Ahn, Samsung Medical Center, Korea
Hospital, Poland
16:40 OA 05.06: Phase 2 Study of Lorlatinib in Patients with
15:55 OA 04.02: Feasibility of Pulmonary Resection Following Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer
Definitive Chemoradiotherapy for Primary Lung Ben J. Solomon, Peter MacCallum Cancer Centre,
Carcinoma Australia
Yasuhiro Hida, Hokkaido University Hospital, Japan
16:50 OA 05.07: Efficacy and Updated Safety of Ceritinib (450
16:05 OA 04.03: Primary Tumor Resection versus Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in
Maintenance Therapy for Patients with Oligometastatic ALK+ Metastatic NSCLC
Non-Small Cell Lung Cancer Byoung Chul Cho, Yonsei Cancer Center, Yonsei University
Xiaozheng Kang, Peking University Cancer Hospital, China College of Medicine, Korea
16:15 OA 04.04: Discussant – OA 04.01, OA 04.02, OA 04.03 17:00 OA 05.08: Final Result of Phase I/II Study (AF-001JP)
Hiroyasu Yokomise, Kagawa University Hospital, Japan of Alectinib, a Selective CNS-Active ALK Inhibitor, in
ALK+ NSCLC Patients (Pts)
16:30 OA 04.05: Intermediate Results of ICG Anatomical
Makoto Nishio, The Cancer Institute Hospital of Japanese
Segmentectomy Based on the Virtual Segmentectomy
Foundation for Cancer Research, Japan
Simulation
Yasuo Sekine, Tokyo Women’s Medical University Yachiyo 17:10 OA 05.09: Discussant- OA 05.05, OA 05.06, OA 05.07,
Medical Center, Japan OA 05.08
Kentaro Tanaka, Kyushu University Hospital, Japan
16:40 OA 04.06: Surgeon Practices for Post Resection Lung
Cancer Surveillance: Comparisons of STS and ESTS
Members
Leah Backhus, Stanford University School of Medicine,
USA
15:45 – 17:30 OA 06: Global Tobacco Control and
16:50 OA 04.07: Initial Results of Tubeless Single-Port Epidemiology I
Thoracoscopic Surgery for Pulmonary Tumor TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO
Chao-Yu Liu, Far Eastern Memorial Hospital, Taiwan CONTROL AND CESSATION
ROOM: 511 + 512
17:00 OA 04.08: Is Lobe-Specific Lymph Node Dissection in
CHAIRS: GÁBOR KOVÁCS, HUNGARY
Clinical N0-1 Non-Small Cell Lung Cancer Adequate for
& YUN FAN, CHINA
Pathological Nodal Staging
Apichat Tantraworasin, Chiang Mai University, Thailand
15:45 OA 06.01: Costs and Cost-Effectiveness of Smoking
17:10 OA 04.09: Discussant – OA 04.05, OA 04.06, OA Cessation Within an Organized CT Lung Cancer (LC)
04.07, OA 04.08 Screening Program
Anthony Kim, University of Cincinnati, USA William Kenneth Evans, McMaster University, Canada
15:55 OA 06.02: Final Report of the INHERIT EGFR Study

– 33 Unrelated Kindreds Carrying Germline EGFR
Mutations
15:45 – 17:30 OA 05: Next Generation TKI Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA
TRACK: ADVANCED NSCLC 16:05 OA 06.03: Comorbidity and Competing Causes of Death
CHEMOTHERAPY/TARGETED THERAPY attenuate outcomes in the NLST.
ROOM: 301 + 302 Robert P. Young, University of Auckland, New Zealand
CHAIRS: JAMES CHIH-HSIN YANG, TAIWAN
& FIONA BLACKHALL, UK 16:15 OA 06.04: Discussant – OA 06.01, OA 06.02, OA 06.03
Anthonie Van Der Wekken, University Medical Centre
Groningen, Netherlands
15:45 OA 05.01: First-Line Dacomitinib versus Gefitinib in
Advanced Non-Small-Cell Lung Cancer with EGFR 16:30 OA 06.05: Socioeconomic Factors Affecting Outcomes
Mutation Subgroups in Non-Small Cell Lung Cancer (NSCLC): A Large
Yi-Long Wu, Guangdong General Hospital & Guangdong Population-Based Analysis
Academy of Medical Sciences, China Yanyan Lou, Mayo Clinic, USA
15:55 OA 05.02: Osimertinib vs SoC EGFR-TKI as First-Line 16:40 OA 06.06: Chr15q25 Locus Confers Risk of Lung
Treatment in Patients with EGFRm Advanced NSCLC Cancer, COPD and Smoking: Triple Whammy Effect in
(FLAURA): Plasma ctDNA Analysis the ACRIN NLST Sub-Study (N=9,270)
Jhanelle Elaine Gray, H. Lee Moffitt Cancer Center & Raewyn J. Hopkins, University of Auckland, New Zealand
Research Institute, USA

16:50 OA 06.07: Survival Trends Among Non-Small Cell Lung
Cancer (NSCLC) Patients Over A Decade: Impact of 15:45 – 17:30 MA 05: Immuno-Oncology: Novel Biomarker
Initial Therapy at Academic Centers Candidates
Bhagirathbhai Dholaria, Mayo Clinic, USA
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY
17:00 OA 06.08: Is Lung Cancer Screening Associated with a ROOM: 303 + 304

Negative Psychological Impact? CHAIR: YOICHI NAKANISHI, JAPAN
Ben Young, University of Nottingham, UK
17:10 OA 06.09: Discussant – OA 06.05, OA 06.06, OA 06.07, 15:45 MA 05.01: Integrating INDEL Mutations into Neoantigen
OA 06.08 Prediction in Lung Cancer: Developing Personalized
Norihiko Ikeda, Tokyo Medical University, Japan Cancer Vaccines
Yanyan Lou, Mayo Clinic, USA
15:50 MA 05.02: STK11/LKB1 Loss of Function Genomic

Alterations Predict Primary Resistance to PD-1/PD-L1
Axis Blockade in KRAS-Mutant NSCLC
15:45 – 17:30 OA 07: Biomarker for Lung Cancer
Ferdinandos Skoulidis, The University of Texas M. D.
TRACK: BIOLOGY/PATHOLOGY Anderson Cancer Center, USA
ROOM: 503
15:55 MA 05.03: The Early Monitoring of Derived Neutrophil-
CHAIRS: PHILIP C. MACK, USA
& SHINICHI TOYOOKA, JAPAN To Lymphocyte Ratio (dNLR) Could Be a Surrogate
Marker of Benefit of Immunotherapy in NSCLC
Laura Mezquita, Gustave Roussy, France
15:45 OA 07.01: A Prospective Study of Perioperative Rapid
Clearance of Circulating Tumor DNA in R0 Resected 16:00 MA 05.04: Distinct Immunosuppressive
Non-Small Cell Lung Cancer Patients Microenvironment Determines Poor Prognosis of
Kezhong Chen, Peking University People’s Hospital, China Nonsmokers with Adenocarcinoma of Non-Small Cell
Lung Cancer
15:55 OA 07.02: Characteristics of Lung Cancer Cell-Free Tomonari Kinoshita, Keio University School of Medicine,
Tumor DNA (CfDNA) Shedding and Correlation with Japan
Tumor Burden as Measured by RECIST
Vincent K. Lam, The University of Texas MD Anderson 16:05 MA 05.05: Discussant – MA 05.01, MA 05.02, MA
Cancer Center, USA 05.03, MA 05.04
Laura Q. Chow, University of Washington, USA
16:05 OA 07.03: Circulating Tumor DNA Mutant Allele
Frequency and Tumor Burden as Biomarkers for 16:20 MA 05.06: Comparison Study of PD-L1
Response to Immune Checkpoint Blockade Immunohistochemistry Assays with 22C3 and 28-8:
Young Kwang Chae, Developmental Therapeutics Program Analysis on Surgical Specimens of NSCLC.
of the Division of Hematology Oncology Robert H. Lurie Tomohito Saito, Kansai Medical University Hospital, Japan
Comprehensive Cancer Center of Northwestern University,
USA 16:25 MA 05.07: Whole Body PD-1 and PD-L1 PET in Pts with
NSCLC
16:15 OA 07.04: Discussant – OA 07.01, OA 07.02, OA 07.03 Anna-Larissa Nadia Niemeijer, VU University Medical
Balazs Halmos, Albert Einstein/Montefiore Cancer Center, Center, Netherlands
USA
16:30 MA 05.08: Very Early Response of Circulating Tumor
16:30 OA 07.05: Serial Biopsies in Patients with EGFR-Mutant Derived DNA Predict the Efficacy of Treatment by
NSCLC Highlight the Spatial and Temporal Heterogeneity Nivolumab in Patients with Non-Small Cell Lung Cancer
of Resistance Mechanisms Yuki Iijima, Yamanashi Prefectural Central Hospital, Japan
Zofia Piotrowska, Massachusetts General Hospital, USA
16:35 MA 05.09: Pre-Existing Immunity Measured by Teff
16:40 OA 07.06: Innate Genetic Evolution of Lung Cancers Gene Expression in Tumor Tissue is Associated with
and Spatial Heterogeneity: Analysis of Treatment-Naïve Atezolizumad Efficacy in NSCLC
Lesions Marcin Kowanetz, Genentech, Inc., USA
Kenichi Suda, University of Colorado Anschutz Medical
Campus, USA 16:40 MA 05.10: Discussant – MA 05.06, MA 05.07, MA
05.08, MA 05.09
16:50 OA 07.07: Inhibition of the Novel Oncogene ELF3 David Rimm, Yale University School of Medicine, USA
Abolishes Lung Adenocarcinoma Growth
Katey S.S. Enfield, British Columbia Cancer Research 16:55 MA 05.11: Endothelial Adhesion Molecule
Centre, Canada Overexpression Correlates to Decreased CD8 T Cells
and Increased B/Treg Cells in Lung Cancer
17:00 OA 07.08: Clinical Potential of Sputum in Detecting Young Kwang Chae, Robert H Lurie Comprehensive
Driver Mutations in Patients with Non-Small Cell Lung Cancer Center of Northwestern University, USA
Cancer: A Preliminary Study
Vanessa Karen De Sá, AC Camargo Cancer Center, Brazil 17:00 MA 05.12: Oncogenic Drivers Induce Production of CCL5
to Recruit Regulatory T-Cells Early in Lung Cancer
17:10 OA 07.09: Discussant – OA 07.05, OA 07.06, OA 07.07, Progression
OA 07.08 William W. Lockwood, British Columbia Cancer Research
Iver Petersen, SRH Wald-Klinikum, Germany Centre, Canada
17:05 MA 05.13: Scavenger Receptor MARCO Defines a

Targetable Tumor-Associated Macrophage Subset in
Lung Cancer
Linnea La Fleur, Uppsala University, Sweden

17:10 MA 05.14: Differential Expression of IFN-Stimulating 16:55 MA 06.11: Distinct Mutational Landscape and
DNA Sensors STING and cGAS in Lung Cancer Evolutionary Trajectories of Brain Metastasis and Liver
Subtypes Metastasis in Lung Adenocarcinoma
Charles Caldwell Jr, University of Colorado, USA Tao Jiang, Shanghai Pulmonary Hospital, Tongji University
School of Medicine, China
17:15 MA 05.15: Discussant – MA 05.11, MA 05.12, MA 05.13,
MA 05.14 17:00 MA 06.12: Genomic Rearrangements of Lung

Hiroyuki Suzuki, Fukushima Medical University, Japan Adenocarcinomas with Fusion Driver Gene
Seongyeol Park, Korea Advanced Institute of Science and
Technology, Korea
17:05 MA 06.13: Direct Metabolomic Profiling of Lung Cancers

15:45 – 17:30 MA 06: Lung Cancer Biology I Elizabeth Starren, Imperial College London and the Royal
Brompton and Harefield NHS Trust, UK
TRACK: BIOLOGY/PATHOLOGY
ROOM: 501 17:10 MA 06.14: Oncogenic SOS1 Mutations in Lung
CHAIRS: NORIKO MOTOI, JAPAN Adenocarcinoma
& KEITH M. KERR, UK Diana Cai, Dana-Farber Cancer Institute, USA

15:45 MA 06.01: Cancer Testis Antigens and Mutational Load MA 06.14
in Relation to the Immune Landscape of Non-Small Cell Akihiko Yoshida, National Cancer Center, Japan
Lung Cancer
Patrick Micke, Uppsala University, Sweden
15:50 MA 06.02: Cytology and Surgical Pathology Specimens

are Comparable Testing Substrates for PD-L1
17:45 – 19:15 ISS 07: The Evolving I-O Treatment Landscape
Immunohistochemistry in Lung Cancer
in Thoracic Cancers: Clinical Updates and
Paul Andrew Vanderlaan, Beth Israel Deaconess Medical
Future Directions – Bristol-Myers Squibb
Center, Harvard Medical School, USA
15:55 MA 06.03: Programmed Death-Ligand 1 (PD-L1) ROOM: MAIN HALL
Expression in Clinical Practice: Comparison of
CHAIRS: DANIEL TAN, SINGAPORE
Temporally or Spatially Separated Test Results
Charuhas Deshpande, University of Pennsylvania, USA
16:00 MA 06.04: Development of Next-Generation Sequencing
Based Cancer Panel and Its Clinical Implications in Lung
Cancer
Daniel Tan, National Cancer Centre Singapore, Singapore
Yoohwa Hwang, Seoul National University Borame
Hospital, Korea 17:50 ISS 07.02: Current and Evolving Research Landscape in
NSCLC
Daniel Tan, National Cancer Centre Singapore, Singapore
06.03, MA 06.04
Giuseppe Giaccone, Georgetown University, USA 18:15 ISS 07.03: Emerging Data in SCLC and Mesothelioma
Anne-Marie C. Dingemans, Maastricht University Medical
16:20 MA 06.06: Assessment of RANK Prevalence and Clinical
Center, Netherlands
Significance in the NSCLC European Thoracic Oncology
Platform Lungscape Cohort 18:35 ISS 07.04: The Role of Emerging Biomarkers in Lung
Erik Thunnissen, VU University Medical Center,, Cancer
Netherlands David P. Carbone, The Ohio State Wexner Medical Center,
USA
16:25 MA 06.07: JAK Pseudokinase Domain Variants
Highlight nRTK nsSNPs Identified with Next-Generation 19:00 ISS 07.05: Closing and Audience Question and Answer
Sequencing in NSCLC Patients Session
Matthew K. Stein, West Cancer Center, University of Daniel Tan, National Cancer Centre Singapore, Singapore,
Tennessee Health Science Center, USA
Anne-Marie C. Dingemans, Maastricht University Medical
16:30 MA 06.08: Lung Cancer Patients with Germline Center, Netherlands,
Mutation: A Retrospective Study David P. Carbone, The Ohio State Wexner Medical Center,
Sandipkumar Patel, Ohio State University Comprehensive USA
Cancer Center, USA
16:35 MA 06.09: Detection of EGFR T790M Mutations by Four

Testing Platforms in ctDNA from Chinese Patients with
Advanced NSCLC
Xu-Chao Zhang, Guangdong Lung Cancer Institute,
Medical Research Center of Guangdong General Hospital,
Guangdong Academy of Medical Sciences, China

06.08, MA 06.09
Kenzo Soejima, Keio University School of Medicine, Japan

19:15 – 20:30 WS 05: superDimension™ Electromagnetic 20:30 – 23:00 Faculty Dinner
Navigation Bronchoscopy - Bridging the (By Invitation Only)
Diagnostic and Therapeutic Domains in Lung
Cancer - Medtronic (Sign Up Required)
VENUE: YOKOHAMA BAY HOTEL TOKYO,

TRACK: PULMONOLOGY/ENDOSCOPY QUEENS BALLROOM
ROOM: 315
19:15 WS 05.01: Update on Global NAVIGATE Trial (first 1000

patients)
19:30 WS 05.02: Optimizing the Diagnostic Procedure

Christopher W. Towe, University Hospitals Cleveland
Medical Center and Case Western Reserve School of
Medicine, USA
19:50 WS 05.03: superDimension™ Beyond the Diagnosis

Mark R. Bowling, East Carolina University, USA
20:10 WS 05.04: Question and Answer Session
19:30 – 20:30 Joint IASLC Foundation – JLCS Concert

with Ms. Suwanai and the Tokyo City
Philharmonic Orchestra (Ticketed Event)
IASLC FOUNDATION
V IOLINIST
T HE TOK YO CIT Y
PHILH A R MON IC
ORCHE STR A
KEN TAK ASEKI,
CONDUCTOR
JOINT IASLC FOUNDATION

JLCS CONCERT
VIOLIN CONCERTO IN
D MAJOR, OP. 35 (TCHAIKOVSKY)

SCIENTIFIC PROGRAM | TUESDAY, OCTOBER 15, 2017
TUESDAY, OCTOBER 17, 2017 | SCIENTIFIC PROGRAM

WS WORKSHOP SESSION
LEVEL 2F

LEVEL 3F

HALL B + C

07:00 ISS 09.01: Welcome and Introduction

07:00 – 08:00 ISS 08: Optimising the Continuum of Care Solange Peters, Lausanne University Hospital CHUV,
for Patients with Oncogenic Driven NSCLC Switzerland
– Pfizer Oncology
07:05 ISS 09.02: NSCLC as a Model for Precision Oncology
TRACK: INDUSTRY SUPPORTED SYMPOSIUM Ben J. Solomon, Peter MacCallum Cancer Centre,
ROOM: F201 + F202 (ANNEX HALL) Australia
CHAIR: YASUSHI GOTO, JAPAN
07:20 ISS 09.03: Management of ALK+ NSCLC: A Rapidly-
changing Landscape
Continental Breakfast provided Solange Peters, Lausanne University Hospital CHUV,
Switzerland
Yasushi Goto, National Cancer Center Japan, Japan 07:35 ISS 09.04: Progress in the Treatment of BRAF-Mutated
NSCLC: Where Are We Now?
07:10 ISS 08.02: Building on Experience and Driving Precision David Planchard, Gustave Roussy, France
Medicine in ALK+ & ROS1+ NSCLC
Nicolas Girard, Hospices Civils de Lyon, France 07:50 ISS 09.05: Expert Panel Q&A (Including Brief Summary
and Close)
07:35 ISS 08.03: Resistance to ALK and ROS1 Inhibitors: Solange Peters, Lausanne University Hospital CHUV,
Addressing the Clinical Impact Switzerland,
Justin F. Gainor, Massachusetts General Hospital, USA Ben J. Solomon, Peter MacCallum Cancer Centre, Australia,
David Planchard, Gustave Roussy, France
07:50 ISS 08.04: Panel Discussion
Yasushi Goto, National Cancer Center Japan, Japan,
Nicolas Girard, Hospices Civils de Lyon, France,
Justin F. Gainor, Massachusetts General Hospital, USA
07:00 – 08:00 SH 01: WCLC 2017 Highlights of the
08:00 ISS 08.05 Meeting Close Previous Day
TRACK: ADVANCED NSCLC,
CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS,
IMMUNOLOGY AND IMMUNOTHERAPY,
PATIENT ADVOCACY,
07:00 – 08:00 ISS 09: The Evolution of Targetable Oncogenic SURGERY,
Drivers in NSCLC: Novel Treatment Paradigms BIOLOGY/PATHOLOGY,
– Novartis EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO
CONTROL AND CESSATION
TRACK: INDUSTRY SUPPORTED SYMPOSIUM ROOM: 502
CHAIR: SOLANGE PETERS, SWITZERLAND
07:00 SH 01.01: Advanced NSCLC, Clinical Design, Statistics
and Clinical Trials, Immunology and Immunotherapy and
Continental Breakfast provided Patient Advocacy
Suresh S. Ramalingam, Winship Cancer Institute of Emory
University, USA

07:20 SH 01.02: Surgery
Masafumi Kawamura, Teikyo University, School of 07:00 – 08:00 MTE 13: Malignant Pleural Mesothelioma:
Medicine, Japan State of the Art (Sign Up Required)
07:40 SH 01.03: Biology/Pathology and Epidemiology/Primary TRACK: MESOTHELIOMA

Prevention/Tobacco Control and Cessation ROOM: 501

Yuichi Takiguchi, Chiba University Hospital, Japan
07:00 MTE 13.01: Surgery for Malignant Pleural Mesothelioma
Scott Swanson, Brigham and Women’s Hospital, Harvard
Medical School, USA
07:00 – 08:00 SH 02: WCLC 2017 Highlights of the 07:30 MTE 13.02: Systemic Treatments for Malignant Pleural
Previous Day Mesothelioma
TRACK: CHEMOTHERAPY/TARGETED THERAPY, Shirish M. Gadgeel, Karmanos Cancer Institute/Wayne
SCLC/NEUROENDOCRINE TUMORS, State University, USA
RADIOTHERAPY,
BIOLOGY/PATHOLOGY,
MESOTHELIOMA,
THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/
OTHER THORACIC MALIGNANCIES
ROOM: 503
07:00 – 08:00 MTE 14: Imaging of Lung Cancer
(Sign Up Required)
07:00 SH 02.01: Chemotherapy/Targeted Therapy and SCLC/
Neuroendocrine Tumors ROOM: F205 + F206 (ANNEX HALL)
Robert Pirker, Medical University of Vienna, Austria
07:00 MTE 14.01: Computed Tomographic Features of Small
07:20 SH 02.02: Radiotherapy Pulmonary Nodules: A Follow-Up Study
Sung-Ja Ahn, Chonnam National University Hwasun Masahiko Kusumoto, National Cancer Center Hospital East,
Hospital, Korea Japan
07:40 SH 02.03: Biology/Pathology, Mesothelioma and Thymic 07:30 MTE 14.02: Diagnostic Intervention for Lung Cancer
Malignancies/Esophageal Cancer/Other Thoracic David F. Yankelevitz, Icahn School of Medicine at Mount
Malignancies Sinai, USA
Yuko Minami, National Hospital Organization Ibarakihigashi
National Hospital The Center of Chest Diseases and
Severe Motor & Intelectual Disabilities, Japan
07:00 – 08:00 MTE 15: Biomarkers for Immune Checkpoint

Inhibitors (Sign Up Required)
07:00 – 08:00 MTE 11: How to Write a Scientific Paper TRACK: IMMUNOLOGY AND IMMUNOTHERAPY
(Sign Up Required) ROOM: 301 + 302

ROOM: 511 + 512 07:00 MTE 15.01: Mechanisms of Resistance in IO
Roy S. Herbst, Yale School of Medicine, Yale Cancer
Center, Smilow Cancer Hospital at Yale-New Haven, USA
07:00 MTE 11.01: How to Write a Scientific Paper that will be
Accepted 07:30 MTE 15.02: Fast and Deeper Responders with IO: How
Alex Adjei, Roswell Park Cancer Institute, USA to Select Them?
07:00 – 08:00 MTE 12: Oncology Nursing (Sign Up Required)

TRACK: NURSING/PALLIATIVE CARE/ETHICS 07:00 – 08:00 MTE 16: Technical Issues after Neoadjuvant
ROOM: 316
Chemoradiation – Surgeon’s Perspective
(Sign Up Required)
TRACK: SURGERY
07:00 MTE 12.01: Peripheral Neuropathy in Lung Cancer
Patients ROOM: 311 + 312
Alex Molassiotis, The Hong Kong Polytechnic University,
Hong Kong 07:00 MTE 16.01: Difficulties of Surgery After Induction of
Chemoradiotherapy
07:30 MTE 12.02: Advance Care Planning: The Pros and Cons Eric Vallieres, Swedish Medical Center and Cancer
Patsy Yates, QLD University of Technology, School of Institute, USA
Nursing, Australia
07:30 MTE 16.02: Surgery for Stage IIIA NSCLC – Surgeon’s
Perspective
Gail Elizabeth Darling, University of Toronto, Canada

07:30 MTE 21.02: New Molecular Diagnosis Platforms for
07:00 – 08:00 MTE 17: Neuroendocrine Tumor Clinicians
(Sign Up Required) Marc Ladanyi, MSKCC, USA
ROOM: 418
08:15 – 09:45 PL 02: Presidential Symposium

07:00 MTE 17.01: Pathological Features of Neuroendocrine (incl. Top 3 Abstracts)
Tumors
Yuichi Ishikawa, Japanese Foundation for Cancer TRACK: EARLY STAGE NSCLC
Research, Japan IMMUNOLOGY AND IMMUNOTHERAPY
SURGERY
07:30 MTE 17.02: Surgical Strategy for the Treatment of ROOM: PLENARY HALL (HALL D)
Neuroendocrine Tumors CHAIRS: HISAO ASAMURA, JAPAN
Enrico Ruffini, University of Torino, Italy & KEUNCHIL PARK, KOREA
08:15 PL 02.01: Introduction and Welcome
08:20 PL 02.02: Patient-Reported Outcomes with

07:00 – 08:00 MTE 18: Treatment for Squamous Cell Durvalumab after Chemoradiation in Locally Advanced,
Carcinoma (Sign Up Required) Unresectable NSCLC: Data from PACIFIC
TRACK: ADVANCED NSCLC Rina Hui, Westmead Hospital and the University of Sydney,
Australia
ROOM: 313 + 314
08:30 PL 02.03: Discussant - PL 02.02

07:00 MTE 18.01: Treatment for Squamous Cell Carcinoma Michael Boyer, Chris O’Brien Lifehouse, Australia
Paul K. Paik, Memorial Sloan Kettering Cancer Center, USA
08:40 PL 02.04: SCAT Ph III Trial: Adjuvant CT Based on
BRCA1 Levels in NSCLC N+ Resected Patients. Final
Survival Results a Spanish Lung Cancer Group Trial
Bartomeu Massuti, Alicante University Hospital, Spain
07:00 – 08:00 MTE 19: Laser Therapy for Early Stage and
08:50 PL 02.05: Discussant - PL 02.04
Airway Obstruction (Sign Up Required)
Joan Schiller, Inova Schar Cancer Institute, USA
TRACK: PULMONOLOGY/ENDOSCOPY
ROOM: 317
09:00 PL 02.06: The IASLC Lung Cancer Staging Project:
Analysis of Resection Margin Status and Proposals for
R Status Descriptors for Non-Small Cell Lung Cancer
07:00 MTE 19.01: Laser Therapy for Airway Obstruction John G. Edwards, University of Sheffield, UK
Kenneth Kazuto Sakata, Mayo Clinic, USA
09:10 PL 02.07: Discussant - PL 02.06
07:30 MTE 19.02: Ablative Therapy for Early Stage Lung Kemp Kernstine, University of Texas Southwestern, USA
Cancer
Antoni Rosell, Hospital Universitari de Bellvitge, Spain 09:20 PL 02.08: James Cox Lectureship Award Presentation
James D. Cox, The University of Texas MD Anderson
Cancer Center, USA
07:00 – 08:00 MTE 20: Liquid Biopsy (Sign Up Required)

TRACK: BIOLOGY/PATHOLOGY 10:00 – 10:45 Press Conference
ROOM: 303 + 304
ROOM: 418
 For information on topics and speakers, please visit the
07:00 MTE 20.01: Recent Advances in Liquid Biopsy
Press & Media page on the Conference website at:
Daniel Shao Weng Tan, National Cancer Centre Singapore,
Singapore wclc2017.iaslc.org/press-media/press-media/
07:30 MTE 20.02: Recent Advances in Liquid Biopsy

Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA
10:00 – 10:45 Networking Opportunity
& Poster Presenters Present for
P2 Posters
07:00 – 08:00 MTE 21: Search for Novel Driver Mutations EXHIBIT HALL (HALL B + C)
(Sign Up Required)
ROOM: 315

07:00 MTE 21.01: Novel Driver Mutations for Lung Cancer
Koichi Goto, National Cancer Center Hospital East, Japan P2.02 Biology/Pathology

11:45 MS 11.04: Radiation Therapy for Superior Sulcus Tumor
Suresh Senan, VU University Medical Center, Netherlands
P2.06 Epidemiology/Primary Prevention/
12:00 MS 11.05: Definitive Chemoradiotherapy in Superior
Tobacco Control and Cessation
Sulcus Tumor
Everett E. Vokes, University of Chicago Medicine &

Biological Sciences, USA
P2.08 Locally Advanced NSCLC
P2.09 Mesothelioma
P2.11 Patient Advocacy 11:00 – 12:30 MS 12: Sustainable Care System in Each Region
P2.12 Pulmonology/Endoscopy TRACK: REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH
ROOM: 501
P2.13 Radiology/Staging/Screening CHAIRS: YASUSHI GOTO, JAPAN
& MARY ELLEN HAND, USA
P2.14 Radiotherapy
P2.15 SCLC/Neuroendocrine Tumors 11:00 MS 12.01: Sustainable Care System in North America
Glenwood Goss, Ottawa Regional Cancer Centre, Canada
P2.16 Surgery
11:15 MS 12.02: Sustainable Care System in Europe
P2.17 Thymic Malignancies/Esophageal Cancer/ Solange Peters, Lausanne University Hospital CHUV,
Other Thoracic Malignancies Switzerland
11:30 MS 12.03: Sustainable Care System in China

Yi-Long Wu, Guangdong General Hospital, China
10:00 – 10:30 EX 02: AstraZeneca Exhibit 11:45 MS 12.04: Sustainable Care System in Philippines
Showcase Session Gerardo de Hitta Cornelio, Philippine General Hospital / St.
Lukes Global City, Philippines
ROOM: EXHIBIT SHOWCASE THEATER,
EXHIBIT HALL (HALL B + C) 12:00 MS 12.05: Sustainable Care System in South America
Eduardo Richardet, IONC (Instituto Oncologico de
The Role of PD-L1 in Treatment Decision Making for Cordoba), Argentina
NSCLC Patients
Agenda
1. Current Therapy Landscape in NSCLC
2. Identifying The Right Patient For IO

11:00 – 12:30 MS 13: How to Deal with CNS Metastases
· The Choice of Test
· The Importance of the Algorithm TRACK: ADVANCED NSCLC
ROOM: 502
3. Optimising the Sample Testing Journey
CHAIRS: MARTIN SCHULER, GERMANY
& NIR PELED, ISRAEL
4. What’s Next for Precision Medicine in NSCLC
11:00 MS 13.01: Strategic Approach to CNS Metastasis

Maurice Pérol, Léon-Bérard Cancer Center, France
11:00 – 12:30 MS 11: Combined Modality Treatment for 11:15 MS 13.02: SBRT vs. WBRT
Superior Sulcus Tumors Paul Van Houtte, Institut Jules Bordet, Belgium
TRACK: LOCALLY ADVANCED NSCLC 11:30 MS 13.03: Target Therapy for ALK/ROS1 + NSCLC with
ROOM: 503 CNS Metastasis
CHAIRS: GILBERTO D. CASTRO, BRAZIL Alice Shaw, Massachusetts General Hospital, USA
& PHILIP BONOMI, USA
11:45 MS 13.04: The Role of Chemotherapy in the Management
of CNS Metastasis
11:00 MS 11.01: Preoperative Chemoradiotherapy Followed by Chong-Kin Liam, University of Malaya, Malaysia
Surgical Resection
Hideo Kunitoh, Japanese Red Cross Medical Center, Japan 12:00 MS 13.05: Targeted Therapy for EGFR Positive Mutant
NSCLC with CNS Metastasis
11:15 MS 11.02: Problems in the Management of Superior Myung-Ju Ahn, Samsung Medical Center, Korea
Sulcus Tumor
Georgios Stamatis, Ruhrlandklinik/Universityclinik Essen, 12:15 Question and Answer Session
Germany
11:30 MS 11.03: Surgical Approaches in Superior Sulcus

Tumor
Elie Fadel, Hopital Marie Lannelongue, France

11:20 PC 02.02: Thoracic Radiation – NO
11:00 – 12:30 MS 14: QOL Evaluation in Practice from the Sue S. Yom, UCSF, USA
Viewpoint of Physicians and Nurses
11:40 PC 02.03: PCI---YES
TRACK: NURSING/PALLIATIVE CARE/ETHICS Andrea Bezjak, Princess Margaret Cancer Centre, Canada
ROOM: 315
CHAIRS: QING ZHOU, CHINA 12:00 PC 02.04: PCI---NO

& BETH EABY-SANDY, USA Takashi Seto, National Kyushu Cancer Center, Japan

11:00 MS 14.01: Elements to Reach the Treatment Goal of
Palliation
Christian Klaus Manegold, Medical Faculty Mannheim,
University of Heidelberg, Germany
11:00 – 12:30 GR 02: Management of Immunotherapy-Related
11:15 MS 14.02: Dimensions of Quality of Life in Lung Cancer
Adverse Events
Marianne Davies, Yale University, USA
11:30 MS 14.03: Estimating Prognosis – How Accurate Can ROOM: MAIN HALL
We Be?
CHAIRS: EDWARD B. GARON, USA
Kunihiko Kobayashi, Saitama Medical University & MAKOTO NISHIO, JAPAN
International Medical Center, Japan
11:45 MS 14.04: Whole Person Care 11:00 GR 02.01: Case Study

Caitlin Broderick, W A Cancer and Palliative Care Network, Edward Brian Garon, UCLA Medical Center, USA
Australia
12:00 MS 14.05: Quality of Life in Women with Lung Cancer Makoto Nishio, The Cancer Institute Hospital of Japanese
and Effect of Inner Strength in Mood and QOL Foundation for Cancer Research, Japan
Eunjung Ryu, Chung-Ang University, Korea
11:10 GR 02.03: Pathophysiology of Immunotherapy-related
12:15 Question and Answer Session Toxicity
Ji-Youn Han, National Cancer Center, Korea
11:25 GR 02.04: Current Standard in Monitoring of

Immunotherapy-related Toxicity
11:00 – 12:30 ES 04: Biology of Lung Cancer Clarissa Mathias, Nucleo de Oncologia da Bahia, Brazil
TRACK: BIOLOGY/PATHOLOGY 11:40 GR 02.05: Practical Management of Immunotherapy-

ROOM: F201 + F202 (ANNEX HALL) related Toxicity
CHAIRS: VERA L. CAPELOZZI, BRAZIL Scott N. Gettinger, Yale Cancer Center, USA
& AKIHIKO GEMMA, JAPAN
11:55 GR 02.06: Who Should Not Receive Immunotherapy?
Terufumi Kato, Kanagawa Cancer Center, Japan
11:00 ES 04.01: Novel Targetable Oncogenes in Lung Cancer
Takashi Kohno, National Cancer Center Research Institute, 12:10 GR 02.07: Toxicity of Induction Immunotherapy
Japan Followed by Radiotherapy: How to Minimize It?
Dirk K. De Ruysscher, Maastricht University Medical
11:20 ES 04.02: Resistance Mechanism in TKI Center, Netherlands
Jürgen Wolf, Center for Integrated Oncology Koeln,
University Hospital Cologne, Germany 12:25 Question and Answer Session
11:40 ES 04.03: Tumor Heterogeneity

Jianjun Zhang, The University of Texas MD Anderson
Cancer Center, USA
11:00 – 12:30 OA 08: Neuroendocrine Carcinoma:
12:00 ES 04.04: Exploiting Synthetic Lethality in Lung Cancer
Translational
Therapy
David P. Carbone, The Ohio State Wexner Medical Center, TRACK: SCLC/NEUROENDOCRINE TUMORS
USA ROOM: 311 + 312
CHAIRS: DAVID S. ETTINGER, USA
12:20 Question and Answer Session & SABINE ZÖCHBAUER-MÜLLER, AUSTRIA
11:00 OA 08.01: Next Generation Sequencing of Large-Cell

Neuroendocrine Carcinoma Reveals an Association of
11:00 – 12:30 PC 02: Is Radiotherapy Necessary for PIK3CA Mutations with Brain Metastases
Extensive SCLC? (Thoracic Radiation/PCI) Mian Xie, The First Affiliated Hospital of Guangzhou
Medical University, China
ROOM: F203 + F204 (ANNEX HALL) 11:10 OA 08.02: The Correlation of DLL3 Expression with
CHAIRS: JENS BENN SØRENSEN, DENMARK High-Grade Pulmonary Neuroendocrine Carcinoma
& YOUNG-TAEK OH, KOREA Clinicopathologic Features and Prognoses
Li-Xu Yan, Guangdong General Hospital, Guangdong
Academy of Medical Sciences, China
11:00 PC 02.01: Thoracic Radiation – YES
Ritsuko Komaki, MD Anderson Cancer Center, USA
11:20 OA 08.03: Effect of TOP2A and ERCC1 Genes
Polymorphism on the Efficacy and Toxicity of Cisplatin 11:00 – 12:30 MA 08: Supportive Care and Communication
and Etoposide Therapy in SCLC Patients
Marcin Nicos, Medical University of Lublin, Poland TRACK: NURSING/PALLIATIVE CARE/ETHICS
ROOM: 511 + 512
11:30 OA 08.04: Discussant – OA 08.01, OA 08.02, OA 08.03

CHAIRS: ENZA ESPOSITO-NGUYEN, USA
Ikuo Sekine, Faculty of Medicine, University of Tsukuba, & JOHN MCPHELIM, UK
Japan
11:45 OA 08.05: Major Drivers of Chemotherapy and Radiation 11:00 MA 08.01: Incorporating the Review of Patients on
Utilization for Limited-Stage Small Cell Lung Cancer in Immunotherapy into an Established Lung CNS Nurse Led
the United States Review Clinic
Stephen G. Chun, MD Anderson Cancer Center, USA Louise Rae Gilham, Maidstone and Tunbridge Wells NHS
Trust, UK
11:55 OA 08.06: Exploratory Analysis for Predictors of
Benefit of PARP Inhibitor Therapy in Extensive Stage 11:05 MA 08.02: Efficacy of Single-Dose NEPA versus 3-Day
Small Cell Lung Cancer: ECOG-ACRIN 2511 Study Aprepitant Regimen for Prevention of CINV: A Phase 3
Taofeek K. Owonikoko, Emory University, USA Lung Cancer Subset Analysis
Shun Lu, Shanghai Lung Cancer Center, Shanghai Chest
12:05 OA 08.07: Pazopanib Maintenance for Extensive Disease Hospital, Shanghai Jiao Tong University, China
Small Cell Lung Cancer: a Randomized, Placebo-
Controlled Phase II study (KCSG-LU12-07) 11:10 MA 08.03: Discussing Potential Recurrence after Lung
Jong-Mu Sun, Samsung Medical Center, Korea Cancer Surgery: Complexity and Challenges
Matthew Johnson, Royal Brompton and Harefield NHS
12:15 OA 08.08: Discussant – OA 08.05, OA 08.06, OA 08.07 Foundation Trust, UK
Karen L. Reckamp, City of Hope, USA
08.03
Jeffrey Crawford, Duke Cancer Institute, USA
11:30 MA 08.05: Surviving Lung Cancer, an Analysis of the

11:00 – 12:30 OA 09: EGFR TKI Resistance Patient Concerns Identified in a Nurse-Led Follow-Up
TRACK: ADVANCED NSCLC Clinic after Thoracic Surgery
CHEMOTHERAPY/TARGETED THERAPY Jenny Mitchell, Oxford University Hospitals NHS
ROOM: 301 + 302 Foundation Trust, UK
CHAIRS: THANYANAN REUNGWETWATTANA, THAILAND
& LECIA V. SEQUIST, USA 11:35 MA 08.06: Assessment to Programming: Responding to
the Needs of the US Lung Cancer Community
Maureen Rigney, Lung Cancer Alliance, USA
11:00 OA 09.01: Characterizing the Genomic Landscape
of EGFR C797S in Lung Cancer Using ctDNA Next- 11:40 MA 08.07: Can the Early Intervention of the
Generation Sequencing Lung Cancer CNS Reduce the Length of Stay for
Zofia Piotrowska, Massachusetts General Hospital, USA Patients Admitted via the Emergency Route on First
Presentation?
11:10 OA 09.02: Osimertinib Resistance Mediated by Loss of Jeanette Draffen, North Tees & Hartlepool NHS
EGFR T790M Is Associated with Early Resistance and Foundation Trust, UK
Competing Resistance Mechanisms
Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA 11:45 MA 08.08: Discussant – MA 08.05, MA 08.06, MA
08.07
11:20 OA 09.03: TATTON Ph Ib Expansion Cohort: Osimertinib Beth Ivimey, Chris O’Brien Lifehouse, Australia
plus Savolitinib for Pts with EGFR-Mutant MET-
Amplified NSCLC after Progression on Prior EGFR-TKI 12:00 MA 08.09: Postoperative Mobilisation and Rehabilitation
Myung-Ju Ahn, Samsung Medical Center, Korea Requirements for Lung Cancer Patients Undergoing
Minimally Invasive Surgery
11:30 OA 09.04: Discussant – OA 09.01, OA 09.02, OA 09.03 Paula Jane Agostini, Heart of England NHS Foundation
Hatim Husain, University of California San Diego, USA Trust, UK
11:45 OA 09.05: Identification of Novel Potentially Targetable 12:05 MA 08.10: Favorable Clinical Status Predicts Benefit
Genomic Alterations in Paired Tumors with Acquired From Early-Palliative Cares & OS Improvement in
EGFR TKI Resistance by NGS NSCLC: A Randomized Clinical Study
Jacqulyne Ponville Robichaux, University of Texas MD Oscar Arrieta, Instituto Nacional de Cancerologia, Mexico
Anderson Cancer Center, USA
12:10 MA 08.11: Do Patients Treated with Chemotherapy for
11:55 OA 09.06: A Phase Ib Trial of Savolitinib plus Gefitinib Advanced NSCLC Regret Having Received Treatment?
for Chinese Patients with EGFR-Mutant MET-Amplified A Prospective Evaluation in 164 Patients
Advanced NSCLC Patricia J. Hollen, University of Virginia, USA
Jin -Ji Yang, Guangdong Lung Cancer Institute, Guangdong
General Hospital and Guangdong Academy of Medical 12:15 MA 08.12: Discussant – MA 08.09, MA 08.10, MA 08.11
Sciences, China Bonnie Leung, British Columbia Cancer Agency, Canada
12:05 OA 09.07: Clonality of c-MET Copy Number Gain as a

Determinant of Primary TKI Resistance in EGFR-Mutant
NSCLC
Gillianne Lai, National Cancer Centre Singapore, Singapore

Howard L. West, Swedish Cancer Institute, USA
11:00 – 12:30 MA 09: The Current Status of Radiation 11:00 – 12:30 MA 10: Immunotherapy I
Oncology
TRACK: RADIOTHERAPY ADVANCED NSCLC
LOCALLY ADVANCED NSCLC ROOM: 303 + 304
ROOM: 316 CHAIRS: SHUHANG WANG, CHINA

CHAIRS: TOMOKI KIMURA, JAPAN & ROBERT PIRKER, AUSTRIA
& YONG CHAN AHN, KOREA
11:00 MA 10.01: Durvalumab ± Tremelimumab with Platinum-

11:00 MA 09.01: A Propensity-Matched Analysis of Lobectomy Doublets in Non-Small Cell Lung Cancer: Canadian
and Stereotactic Body Radiotherapy for Early Stage Cancer Trials Group Study IND.226
Non-Small Cell Lung Cancer Desiree Hao, University of Calgary & Tom Baker Cancer
Yaping Xu, Zhejiang Cancer Hospital, China Centre, Canada
11:05 MA 09.02: Ultra-Central Tumours Treated with 11:05 MA 10.02: Nab-Paclitaxel + Durvalumab as Second- or
Stereotactic Body Radiotherapy: A Single Institutional Third-Line Treatment of Advanced NSCLC: Results from
Experience ABOUND.2L+
Meredith Elana Giuliani, University of Toronto and Princess Ramaswamy Govindan, Washington University School of
Margaret Cancer Center, Canada Medicine, USA
11:10 MA 09.03: Discussant – MA 09.01, MA 09.02 11:10 MA 10.03: 3-Year Survival and Duration of Response
Takafumi Komiyama, University of Yamanashi School of in Randomized Phase II Study of Atezolizumab vs
Medicine, Japan Docetaxel in 2L/3L NSCLC (POPLAR)
Keunchil Park, Samsung Medical Center, Sungkyunkwan
11:25 MA 09.04: Increasingly Abnormal Pre-Treatment University School of Medicine, Korea
Diffusion Capacity Is Associated with Greater Local
Failure After Lung SBRT 11:15 MA 10.04: Discussant – MA 10.01, MA 10.02, MA 10.03
Gregory M.M. Videtic, Cleveland Clinic, USA Wan-Teck Lim, National Cancer Centre, Singapore
11:30 MA 09.05: Evidence in Favor of or against the Use of 11:30 MA 10.05: Improved Outcome for Immune Checkpoint
TKIs with Concurrent Cranial Radiotherapy in Patients Inhibitors (ICI) in Patients Previously Treated with
with NSCLC and CNS Involvement Bavituximab in the SUNRISE Trial
Giannis Mountzios, University of Athens School of Michael Boyer, Chris O’Brien Lifehouse, Australia
Medicine, Greece
11:35 MA 10.06: Real-World Results in Non-Squamous Non-
11:35 MA 09.06: Pulmonary Oligometastases Treated by Small Cell Lung Cancer Patients: Italian Nivolumab
Stereotactic Body Radiation Therapy (SBRT): A Expanded Access Programme
Nationwide Survey of 1,378 Patients Francesco Grossi, Ospedale Policlinico San Martino, Italy
Yuzuru Niibe, Toho University Omori Medical Center,
Japan 11:40 MA 10.07: Elderly Lung Cancer Patients on
Immunotherapy: Preliminary Results from the ELDERS
11:40 MA 09.07: Discussant – MA 09.04, MA 09.05, MA Study
09.06 Fabio Gomes, The Christie NHS Foundation Trust, UK
Gerard G. Hanna, Queen’s University of Belfast, UK
11:55 MA 09.08: Receipt of Chest Radiation and Immune- Hidehito Horinouchi, National Cancer Center Hospital,
Related Pneumonitis in Patients with NSCLC Treated Japan
with Anti-PD-1/PD-L1
Jarushka Naidoo, Sidney Kimmel Comprehensive Cancer 12:00 MA 10.09: Increased T Follicular Helper Cell Infiltration
Center at Johns Hopkins University, USA in Lung Adenocarcinoma Tertiary Lymphoid Organs
Erin Anne Marshall, BC Cancer Research Centre, Canada
12:00 MA 09.09: Isotoxic Dose-Escalated Radiotherapy (RT)
in Non-Small Cell Lung Cancer (NSCLC) with Deep 12:05 MA 10.10: Tumor Draining Lymph Node Immuno-
Inspiration Breath Hold (DIBH) phenotype Corresponds with Primary Tumor Character-
Hannah Bainbridge, The Royal Marsden Hospital, NHS istics in Patients with Non-Small Cell Lung Cancer
Foundation Trust, UK Daniel H. Sterman, NYU Langone Medical Center, USA
12:05 MA 09.10: Toward a Radiological Scoring System of 12:10 MA 10.11: Hyperprogressive Disease (HPD) Is Frequent
Radiotherapy-Induced Lung Damage in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts)
Catarina Veiga, University College London, UK Treated with Anti PD1/PD-L1 Agents (IO)
Roberto Ferrara, Medical Oncology Gustave Roussy,
12:10 MA 09.11: Isotoxic Intensity Modulated Radiotherapy France
(IMRT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
– a Feasibility Study 12:15 MA 10.12: Discussant – MA 10.09, MA 10.10, MA 10.11
Kate Haslett, The Christie NHS Foundation Trust, UK David E. Gerber, UT Southwestern, USA

MA 09.11
Cecile Le Pechoux, Gustave Roussy, France
11:00 – 12:30 MA 11: Emerging Diagnostic/Biomarkers in 11:00 – 12:30 MA 12: Circumventing EGFR Resistance
NSCLC
TRACK: ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY
CHEMOTHERAPY/TARGETED THERAPY ROOM: F205 + F206 (ANNEX HALL)

ROOM: 313 + 314 CHAIR: WAN LING TAN, SINGAPORE
CHAIRS: MOHAMED IBRAHIM ABDUL WAHID, MALAYSIA
& MARTIN RECK, GERMANY
11:00 MA 12.01: A Phase Ib Study of the Combination of
Afatinib and Ruxolitinib in EGFR Mutant NSCLC
11:00 MA 11.01: Liquid Biopsies for Monitoring BRAF Mutation Progressed on EGFR-TKI: An Updated Analysis
(V600E) in Advanced BRAF (V600E) Non-Small Cell Ji Soo Park, Yonsei Cancer Center, Korea
Lung Cancer (NSCLC)
Laura Mezquita, Gustave Roussy, France 11:05 MA 12.02: Phase I/II Study of S49076, a MET/AXL/
FGFR Inhibitor, Combined with Gefitinib in NSCLC
11:05 MA 11.02: Circulating Tumour DNA in Early Stage Patients Progressing on EGFR TKI
NSCLC: High Sensitivity Analysis in Low Burden Gee-Chen Chang, Taichung Veterans General Hospital,
Disease. LUCID Study Update Taiwan
Robert Campbell Rintoul, Papworth Hospital NHS
Foundation Trust, UK 11:10 MA 12.03: Kinase Fusions as Recurrent Mechanisms of
Acquired Resistance in EGFR-Mutated Non-Small Cell
11:10 MA 11.03: Gefitinib as First-Line Treatment of Plasma Lung Cancer (NSCLC)
CtDNA EGFR Mutation-Positive NSCLC Detected by Sai-Hong Ignatius Ou, University of California at Irvine
DdPCR: BENEFIT Study (CTONG1405) School of Medicine, Chao Comprehensive Cancer Center,
Jie Wang, Cancer Institute/Hospital, Chinese Academy of USA
Medical Sciences, China
11:15 MA 11.04: Discussant – MA 11.01, MA 11.02, MA 11.03 Miguel-Angel Molina-Vila, Pangaea Oncology, Spain
Hye Ryun Kim, Yonsei Cancer Center, Korea
11:30 MA 12.05: Genomic Profiling of EGFR T790M Mutated
11:30 MA 11.05: Targeted DNA- and RNA-Based Next- Non-Small Cell Lung Cancer to Evaluate the Mechanisms
Generation Sequencing for Identifying MET Exon 14 of Resistance to Osimertinib
Alterations in Pulmonary Sarcomatoid Carcinoma Sonam Puri, H.Lee Moffitt Cancer Center/University of
Gang Cheng, Novogene Co., Ltd., China South Florida, USA
11:35 MA 11.06: Retrospective Analysis of NSCLC Testing in 11:35 MA 12.06: Using Population Dynamics Mathematical
Low Tumor Content Samples: Single-Gene Tests, NGS, Modeling to Optimize an Intermittent Dosing Regimen for
& the Oncomine™ Dx Target Test Osimertinib in EGFR-Mutant NSCLC
Tiffany M. Yu, Quorum Consulting, Inc., USA Xiuning Le, Beth Israel Deaconess Medical Center, USA
11:40 MA 11.07: Exosomes-Transmitted MicroRNAs Promote 11:40 MA 12.07: Adjusted Indirect Comparison of Osimertinib
EGFR-TKIs Resistance in NSCLC by Activating PI3K/ to Chemotherapy in NSCLC Patients with EGFRm
AKT Signaling Pathway T790M Who Progressed after EGFR-TKI
Xiaozhen Liu, Shanghai Pulmonary Hospital, Tongji Christopher Hoyle, AstraZeneca, UK
11:45 MA 11.08: Discussant – MA 11.05, MA 11.06, MA 11.07 Dae Ho Lee, University of Ulsan College of Medicine, Asan
Justin F. Gainor, Massachusetts General Hospital, USA Medical Center, Korea
12:00 MA 11.09: Real World Data of Rebiopsy, Mutation Status, 12:00 MA 12.09: EGFR T790M Co-Exist with Sensitive
and Its Association with Plasma Genotyping after EGFR Mutation in the Same Cell Group in Lung
TKI Failure in NSCLC Adenocarcinoma Patients
Min Hee Hong, Yonsei Cancer Center, Korea Xiaohua Shi, Peking Union Medical College Hospital, China
12:05 MA 11.10: EGFR TKI Treatment Induces Active 12:05 MA 12.10: Clinical Utility of Plasma EGFR T790M
Deamination of 5-Methylcytosine and Leads to Acquired Mutation Detection in Advanced Non-Small Cell Lung
T790M Resistant Mutation Cancer Patients According to RECIST Criteria
Khaled A. Hassan, University of Michigan, USA Lourdes Barrera, AstraZeneca, USA
12:10 MA 11.11: Italian Nivolumab Expanded Access Program 12:10 MA 12.11: The Alteration of T790M Prevalence Between
in Non-Squamous NSCLC Patients: Results in Never 19 Deletions and L858R in NSCLC After EGFR-TKIs
Smokers and EGFR Positive Patients Therapy, a Meta-Analysis
Marina Chiara Garassino, 1Fondazione IRCCS Istituto Hengrui Liang, The First Affiliated Hospital of Guangzhou
Nazionale dei Tumori, Italy Medical University, China
12:15 MA 11.12: Discussant – MA 11.09, MA 11.10, MA 11.11 12:15 MA 12.12: Discussant – MA 12.09, MA 12.10, MA 12.11
Nicolas Girard, Hospices Civils de Lyon, France Kenneth O’Byrne, Princess Alexandra Hospital, Australia
12:45 – 14:15 ISS 10: Evolving Decisions and Best Practices:
Management of EGFR-Mutated NSCLC - P2.06 Epidemiology/Primary Prevention/
Medscape - Supported by an Independent Tobacco Control and Cessation
Educational Grant from AstraZeneca
Pharmaceuticals LP P2.07 Immunology and Immunotherapy

P2.08 Locally Advanced NSCLC
ROOM: MAIN HALL
CHAIR: SURESH S. RAMALINGAM, USA P2.09 Mesothelioma

P2.11 Patient Advocacy
Suresh S. Ramalingam, Winship Cancer Institute of Emory P2.12 Pulmonology/Endoscopy
University, USA
P2.13 Radiology/Staging/Screening
12:50 ISS 10.02: The Evolving Treatment Algorithm in EGFR-
Mutated NSCLC P2.14 Radiotherapy
Rolf A. Stahel, University Hospital Zurich, Switzerland
13:05 ISS 10.03: Diagnosis and Management on the Frontline
P2.16 Surgery
University, USA P2.17 Thymic Malignancies/Esophageal Cancer/
Other Thoracic Malignancies
13:20 ISS 10.04: Case Examples of Second-Line Management
Heather A. Wakelee, Stanford Cancer Center, USA
13:35 ISS 10.05: Sequencing Therapy to Improve Outcomes

Lecia V. Sequist, Massachusetts General Hospital, USA
15:45 – 17:30 MS 15: Molecular Testing
13:50 ISS 10.06: Concluding Remarks
TRACK: BIOLOGY/PATHOLOGY
ROOM: 301 + 302
University, USA
CHAIRS: JIN SOO LEE, KOREA
13:55 ISS 10.07: Question and Answer Session & IVER PETERSEN, GERMANY
University, USA 15:45 MS 15.01: Overview of Updated CAP/IASLC/AMP
Rolf A. Stahel, University Hospital Zurich, Switzerland Molecular Testing Guideline
Heather A. Wakelee, Stanford Cancer Center, USA Neal Lindeman, Brigham and Women’s Hospital, USA
Lecia V. Sequist, Massachusetts General Hospital, USA
16:05 MS 15.02: Molecular Testing Using NGS
Ignacio I. Wistuba, The University of Texas MD Anderson
Cancer Center, USA
16:25 MS 15.03: Molecular Testing Using Blood (Liquid Biopsy)

14:30 – 15:30 JTO: Meet the JTO Editor Caroline Dive, CRUK Manchester Institute, UK
16:45 MS 15.04: Molecular Testing Using Cytology Specimens
ROOM: 511 + 512
Lukas Bubendorf, University Hospital Basel, Switzerland
14:30 JTO 01: Meet the JTO Editor 17:05 MS 15.05: Clinical Samples for Molecular Testing
Alex Adjei, Roswell Park Cancer Institute, USA Philip Christopher Mack, UC Davis Comprehensive Cancer
Center, USA

P2 Posters 15:45 – 17:30 MS 16: Future Direction of Chemoradiotherapy
for Inoperable Non-Small Cell Lung Cancer
EXHIBIT HALL (HALL B + C) TRACK: RADIOTHERAPY
CHEMOTHERAPY/TARGETED THERAPY
Refreshments provided ROOM: 502
CHAIRS: YUKO NAKAYAMA, JAPAN
& CECILE LE PECHOUX, FRANCE
P2.02 Biology/Pathology 15:45 MS 16.01: Is the Dose Escalation Possible?

Jeffrey Bradley, Washington University School of Medicine,
P2.03 Chemotherapy/Targeted Therapy USA
P2.04 Clinical Design, Statistics and Clinical Trials 16:05 MS 16.02: Selection of Chemotherapeutic Agents
Nobuyuki Yamamoto, Wakayama Medical University, Japan
16:25 MS 16.03: Management According to the Histologic 16:45 MS 18.05: Liquid Biopsy Biomarkers in IO: Is There
Subtypes Room?
Kazushige Hayakawa, Kitasato Univ. School of Medicine, Christian Rolfo, Antwerp University Hospital, Belgium
Japan
17:00 MS 18.06: Future Perspectives of Biomarkers for Anti
16:45 MS 16.04: Future Direction of Immuno-Radiotherapy PD-1/PD-L1 Therapy

Wilfried Eberhardt, University of Duisburg-Essen, Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer
Germany Center at Johns Hopkins, USA
17:05 MS 16.05: High-Dose Boost Radiation Using SBRT/ 17:15 Question and Answer Session
IMRT
James D. Cox, The University of Texas MD Anderson
Cancer Center, USA
17:25 Question and Answer Session 15:45 – 17:30 MS 19: Elevating the Lung Cancer Voice:
Raising Awareness and Creating Community
TRACK: PATIENT ADVOCACY
ROOM: 315
15:45 – 17:30 MS 17: Lessons Learned from Negative Trials CHAIRS: TOSHIYUKI SAWA, JAPAN
& ANDREJA CIRILA ŠKUFCA SMRDEL, SLOVENIA
ROOM: 303 + 304
15:45 MS 19.01: Transformative Science in the Community
CHAIRS: VIROTE SRIURANPONG, THAILAND
& JOHAN F. VANSTEENKISTE, BELGIUM Jim Baranski, Lung Cancer Foundation of America, USA
16:05 MS 19.02: Lung Cancer Awareness Month: Unity through

15:45 MS 17.01: PROCLAIM IASLC – Organizer Perspective
Anthony Brade, Princess Margaret Hospital, Canada Kristin Richeimer, IASLC, USA
15:55 MS 17.02: MAGRIT 16:25 MS 19.03: The ROS1der Story: How a Group of Patients,
Johan F. Vansteenkiste, University Hospital KU Leuven, Doctors and Advocates Launched an International
Belgium Research Effort
Lisa Goldman, Patient Advocate/Self, USA
16:05 MS 17.03: Is There Such a Thing as a ‘Negative’ Trial?
Lucinda Jane Billingham, University of Birmingham, UK 16:45 MS 19.04: Shine a Light on Lung Cancer: The Evolution
Alana Shea Boyd, Lung Cancer Alliance, USA
16:30 MS 17.04: MET-Lung: A Phase III Trial of Onartuzumab
(METMab) Plus Erlotinib vs Erlotinib in Previously 17:05 MS 19.05: “How to Beauty Your Day”: Looking Good,
Treated Stage IIIB or IV NSCLC Feeling Better – An Italian Approach
Karen Kelly, UC Davis Comprehensive Cancer Center, USA Stefania Vallone, Women Against Lung Cancer in Europe
(WALCE Onlus), Italy
16:40 MS 17.05: CheckMate026
David P. Carbone, The Ohio State Wexner Medical Center, 17:25 Question and Answer Session
USA
16:50 MS 17.06: Avoiding Phase II-III Attrition: Enhanced

Biomarkers, Better Drugs or Improved Trial Design?
John Crowley, Cancer Research And Biostatistics, USA 15:45 – 17:30 ES 05: Surgical Skills
17:15 Question and Answer Session TRACK: SURGERY
ROOM: 503
CHAIRS: KOHEI YOKOI, JAPAN
& YOUNG MOG SHIM, KOREA
15:45 – 17:30 MS 18: Biomarker for Anti-PD-L1 Therapy

15:45 ES 05.01: Strategy for N2 NSCLC
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY Joe B. Putnam, Baptist MD Anderson Cancer Center, USA
ROOM: MAIN HALL
16:00 ES 05.02: Superior Sulcus Tumor
CHAIRS: YUICHI ISHIKAWA, JAPAN
& SANJA DACIC, USA Valerie W. Rusch, Memorial Sloan-Kettering Cancer Center,
USA
15:45 MS 18.01: How to Select and Set up a IHC Platform for 16:15 ES 05.03: Management of Early Stage Lung Cancer
PD-L1 Expression Norihiko Ikeda, Tokyo Medical University, Japan
Reinhard Büttner, University Hospital Cologne, Germany
16:30 ES 05.04: Minimally Invasive Surgery for Lung Cancer,
16:00 MS 18.02: An Update on the BLUEPRINT and Related including Robotics
Projects Giulia Veronesi, Humanitas Research Hospital, Italy
Fred R. Hirsch, Univ. of Colorado Cancer Center, USA
16:45 ES 05.05: Lung Cancer Surgery for High Risk Patients
16:15 MS 18.03: Potential Application of Molecular Genomic Claudio Suarez Cruzat, Clínica Santa María, Chile
for Immunotherapy
Rolf A. Stahel, University Hospital Zurich, Switzerland 17:00 ES 05.06: Salvage Surgery
Hans Hoffmann, Thoraxklinik, University of Heidelberg,
16:30 MS 18.04: PD-L1 Expression in Early Stage Lung Cancer Germany
Jin-Haeng Chung, Seoul National University Bundang
Hospital, Korea 17:15 Question and Answer Session
16:20 MA 07.06: Detection of Mechanisms of Resistance to
15:45 – 17:30 ES 06: Communication Skills in the End of Life/ ALK Inhibitors in Routine Practice: A Retrospective
Symptom Management in Lung Cancer Study
Philippe Jamme, Institut de biologie, France
ROOM: F201 + F202 (ANNEX HALL) 16:25 MA 07.07: Clinical Outcomes and ALK Resistance
CHAIRS: KAORU KUBOTA, JAPAN Mutations in ALK+ Non-Small Cell Lung Cancer
& JIN -JI YANG, CHINA According to EML4-ALK Variant
Jessica Jiyeong Lin, Massachusetts General Hospital, USA
15:45 ES 06.01: Advanced Directives – Are They Useful? 16:30 MA 07.08: Clinical Implications of ALK Resistance
Maiko Fujimori, National Center for Neurology & Mutations: Institutional Experience and Launch of
Psychiatry, Japan Remote Participation Study
Pablo Martinez, Dana-Farber Cancer Institute, USA
16:00 ES 06.02: Discussing Advance Care Plans – What Do
You Say? 16:35 MA 07.09: ALK/ROS1/TRK Inhibitor TPX-0005
Florian Strasser, Cantonal Hospital, Switzerland Effectively Overcomes Clinical Resistance Solvent Front
Mutations
16:15 ES 06.03: Palliative Management of Dyspnea
J. Jean Cui, TP Therapeutics, Inc., USA
Keiko Tanaka, Tokyo Metropolitan Cancer and Infectious
Diseases Center Komagome Hospital, Japan 16:40 MA 07.10: Discussant – MA 07.06, MA 07.07, MA 07.08,
MA 07.09
16:30 ES 06.04: The Lung Cancer Patient, the Nurse and the
Takashi Seto, National Kyushu Cancer Center, Japan
Rehabilitation Opportunities in Denmark
Marianne Cumberland, University of Copenhagen, 16:55 MA 07.11: A Phase II Study of Trastuzumab Emtansine in
RigsHospitalet, Denmark HER2-positive Non-Small-Cell-Lung Cancer
Daijiro Harada, Shikoku Cancer Center, Japan
16:45 ES 06.05: Approach to Malignant Pleural Effusions
Peter Goldstraw, National Heart and Lung Institute, 17:00 MA 07.12: Short-Term Culture of Patient Derived
Imperial College, UK Tumor Organoids Identify Neratinib/Trastuzumab as an
Effective Combination in HER2 Mutant Lung Cancer
17:00 ES 06.06: Dignity Conserving Therapy
Elena Ivanova, Belfer Center for Applied Cancer Science,
Natasha B. Leighl, Princess Margaret Cancer Centre,
Dana-Farber Cancer Institute, USA
Canada
17:05 MA 07.13: NGS Sequencing Based Liquid / Tissue
Biopsy Identified Coexistence of HER2 Amplification and
Mutation in Advanced NSCLC Patients
Rongrong Chen, Geneplus-Beijing, China
17:10 MA 07.14: Change in Practice Patterns from an Online

15:45 – 17:30 MA 07: ALK, ROS and HER2 NSCLC Treatment Decision Support Tool
TRACK: ADVANCED NSCLC David R. Gandara, UC Davis Comprehensive Cancer
CHEMOTHERAPY/TARGETED THERAPY Center, USA
ROOM: 316
CHAIRS: ROBERT C. DOEBELE, USA
MA 07.14
& JAMES CHUNG-MAN HO, HONG KONG
Chia-Chi Lin, National Taiwan University Hospital, Taiwan
15:45 MA 07.01: Patients with ALK IHC-Positive/FISH-

Negative NSCLC Benefit from ALK TKI Treatment:
Response Data from the Global ALEX Trial
Tony Mok, State Key Laboratory of South China, Hong 15:45 – 17:30 MA 13: New Insights of Diagnosis and Update
Kong Cancer Institute, The Chinese University of Hong of Treatment
Kong, Hong Kong
TRACK: EARLY STAGE NSCLC
15:50 MA 07.02: Response to Ensartinib in TKI Naïve ALK+ ROOM: 311 + 312
NSCLC Patients CHAIRS: SATOSHI ISHIKURA, JAPAN
Heather A. Wakelee, Stanford University School of & HARUHIKO NAKAYAMA, JAPAN
Medicine, USA
15:55 MA 07.03: Incidence, Predictors and Prognostic 15:45 MA 13.01: Clinical and Pathological Variables Influencing
Significance of Thromboembolic Events in Patients with Noninvasive Detection of Early Stage Lung Cancer Using
Advanced Alk-Rearranged NSCLCs Circulating Tumor DNA
Jon Zugazagoitia, Hospital U. 12 Octubre, Spain Jacob John Chabon, Stanford University, USA
16:00 MA 07.04: Clinical Impact of Crizotinib on Brain 15:50 MA 13.02: Comprehensive Genetic Analysis Related to
Metastases in Patients with Advanced ROS1-Rearranged PD-L1 Expression in Early-stage Lung Squamous Cell
Non-Small Cell Lung Cancer Carcinoma
Shun Lu, Shanghai Chest Hospital, China Hui Yu, University of Colorado Anschutz Medical Campus,
USA
MA 07.04 15:55 MA 13.03: Quantitative Spatial Profiling of PD-1/
Neal Ready, Duke University Medical Center, USA PD-L1 Interaction Predicts Response to Adjuvant
Chemotherapy Non–Small-Cell Lung Cancer
Vamsidhar Velcheti, Cleveland Clinic, USA
16:00 MA 13.04: Adjuvant Systemic Therapy in Patients with
Early-Stage Non-Small Cell Lung Cancer (NSCLC) 15:45 – 17:30 MA 14: Diagnostic Radiology, Staging and
Treated with Stereotactic Body Radiation Therapy Screening for Lung Cancer I
Vinicius Ernani, Fred and Pamela Buffett Cancer Center-
University of Nebraska Medical Center, USA TRACK: RADIOLOGY/STAGING/SCREENING

16:05 MA 13.05: Discussant – MA 13.01, MA 13.02, MA 13.03, CHAIRS: HARUHIKO KONDO, JAPAN
MA 13.04 & HONG KWAN KIM, KOREA
Shinichi Toyooka, Okayama University Graduate School of
Medicine, Japan
15:45 MA 14.01: Influence of Early Lung Cancer Screening
16:20 MA 13.06: New Risk Factors for Overall Survival Programme on Treated Patients’ Profile and Activity of
After SBRT in Early Stage NSCLC: A Role of RT Plan Thoracic Surgery Department
Optimization Bartosz Kubisa, Pomeranian Medical University of
Feng-Ming (Spring) Kong, Indiana University School of Szczecin, Poland
Medicine, USA
15:50 MA 14.02: Simulation of the Four Rounds of NELSON
16:25 MA 13.08: Long Term Follow-up on NRG Oncology Lung Cancer Screening Triage Algorithm
RTOG 0915 (NCCTG N0927): a Randomized Phase II Takashi Hayashi, Median Technologies, France
Study of 2 SBRT Schedules for Lung Cancer
15:55 MA 14.03: Lung Cancer Risk Score Analysis Using
Gregory M.M. Videtic, Cleveland Clinic, USA
Plasma microRNA Profiles
16:30 MA 13.09: Toxicity and Second Primary Lung Cancers in Jennifer Eve Gyoba, University of Alberta, Canada
Late Survivors Following Lung SBRT
16:00 MA 14.04: Therapeutic Response Assessment of NSCLC
Meredith Elana Giuliani, University of Toronto and Princess
Patients Treated with Apatinib: A Radiomics Approach
Margaret Cancer Center, Canada
Based on CT Texture Features
16:35 MA 13.10: Discussant – MA 13.06, MA 13.08, MA 13.09 Qiong Zhao, First Affiliated Hospital, Zhejiang University,
Hong-Gyun Wu, Seoul National University College of China
Medicine, Korea
16:50 MA 13.11: Clinical Significance of Lobar and MA 14.04
Segmental Lymph Node Metastasis in cT1N0M0 Lung Edward F. Patz, Duke University, USA
Adenocarcinoma
16:20 MA 14.06: Population Based Cohort Study to Evaluate
Fei Xiao, National Clinical Research Center for Respiratory
Lung Cancer Screening Using Low Dose CT in Hitachi
Diseases, Center for Respiratory Diseases, China-Japan
City
Friendship Hospital, China
Takeshi Nawa, Hitachi General Hospital, Hitachi, Ltd, Japan
16:55 MA 13.12: Wedge Resection and Segmentectomy Are
16:25 MA 14.07: Randomized Lung Cancer Screening with
Associated with Comparable Outcomes for Patients with
Low-Dose CT in China: A Specific Risk-Based Screening
Less Than 2cm Non-Small Cell Lung Cancer
for Chinese Population
Kamran Ali, Seoul National University Bundang Hospital,
Baohui Han, Shanghai Chest Hospital, China
Korea
16:30 MA 14.08: Hematology/Oncology Providers’ Practices
17:00 MA 13.13: Spread through Air Spaces Is a Prognostic
and Attitudes of Lung Cancer Screening And Tobacco
Factor in Wedge Resection of Non-Small Cell Lung
Cessation at an Academic Medical Center and VA
Cancer
Jennifer Lewis, Vanderbilt University Medical Center, USA
Satoshi Shiono, Yamagata Prefectural Central Hospital,
Japan 16:35 MA 14.09: Impact of Lung Cancer Perceived Risk,
Screening Eligibility and Worry on LDCT Screening
17:05 MA 13.14: Surgical Outcomes and Survival Analysis
Preference – Challenges for Engaging Patients at High
Following Second Pulmonary Resection for Non-Small
Risk
Cell Lung Cancer
Katharine See, Royal Melbourne Hospital, Australia
Yusuke Takahashi, Memorial Sloan Kettering Cancer
Center, USA 16:40 MA 14.10: Discussant – MA 14.06, MA 14.07, MA 14.08,
MA 14.09
Helmut Prosch, Medical University of Vienna, Austria
MA 13.14
Taichiro Goto, Yamanashi Central Hospital, Japan 16:55 MA 14.11: Malignancy Risk Prediction of Pulmonary
Nodule in Lung Cancer Screening – Diameter Or
Volumetric Measurement
Ren Yuan, BC Cancer Agency, Canada
17:00 MA 14.12: Detecting Epidermal Growth Factor Receptor

Mutation Status in Patients with Lung Adenocarcinoma
Using Radiomics and Random Forest
Tianying Jia, Shanghai Chest Hospital, Shanghai Jiao Tong
University, China
17:05 MA 14.13: Nodule Size Isn’t Everything: Imaging

Features Other Than Size Contribute to AI Based Risk
Stratification of Solid Nodules
Timor Kadir, Optellum Ltd., UK
17:10 MA 14.14: The First 100 Days: Early findings from the 17:00 MA 15.12: Expanding the Lung Small RNA
Lung Cancer Screening Pilot for People at High Risk in Transcriptome: Discovery of Unannotated microRNAs
Ontario, Canada with Roles in Development and Tumourigenesis
Gail Elizabeth Darling, University of Toronto, Canada Brenda C. Minatel, British Columbia Cancer Research
Centre, Canada
MA 14.14 17:05 MA 15.13: The Transfer of Exogenous UCHL-1 via

Ugo Pastorino, Fondazione IRCCS Istituto Nazionale Mesenchymal Lung Cancer Exosomes to Mediate
Tumori, Italy Phenotypic Alterations of Recipients
Yoshihisa Shimada, UT Southwestern Medical Center, USA
17:10 MA 15.14: Long Non-Coding RNA Disruption in Lung

Adenocarcinoma Reveals Novel Mechanisms of
15:45 – 17:30 MA 15: Lung Cancer Biology II Metastasis
Adam Patrick Sage, British Columbia Cancer Research
TRACK: BIOLOGY/PATHOLOGY Centre, Canada
ROOM: 501
CHAIRS: HIROTOSHI AKITA, JAPAN 17:15 MA 15.15: Discussant – MA 15.11, MA 15.12, MA 15.13,
& LUCIANO MUTTI, UK MA 15.14
David Rimm, Yale University School of Medicine, USA
15:45 MA 15.01: LungBEAM: A Prospective Multicenter Trial to
Monitor EGFR Mutations Using BEAMing Technology in
Stage IV NSCLC Patients
Pilar Garrido, Hospital Universitario Ramón y Cajal, Spain
15:45 – 17:30 MA 16: Mediastinal, Tracheal and Esophageal
15:50 MA 15.02: Plasma CfDNA next Generation Sequencing Tumor: Multimodality Approaches
in Non-Small Cell Lung Cancer: Clinical Outcomes and TRACK: THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/
Comparison to Tissue OTHER THORACIC MALIGNANCIES
Luis E. Raez, Memorial Cancer Institute, USA ROOM: 313 + 314
CHAIRS: KEIKO SHIBUYA, JAPAN
15:55 MA 15.03: Distribution of Circulating Tumor DNA in & FRANCOISE MORNEX, FRANCE
Lung Cancer: Analysis of Primary Lesion, Pulmonary
Vein, Bone Marrow and Pripheral Blood
Taichiro Goto, Yamanashi Central Hospital, Japan 15:45 MA 16.01: Characterization of Autoantibody Responses
in Thymoma with Myasthenia Gravis by Single-Cell
16:00 MA 15.04: Detection of ALK Rearrangements in Non- Sequencing of B-cells
Small-Cell Lung Cancer (NSCLC) Patients by Liquid Sukhmani Kaur Padda, Department of Medicine, Division
Biopsy of Oncology, Stanford Cancer Institute/Stanford University
Dongmei Lin, Beijing Cancer Hospital, China School of Medicine, USA
16:05 MA 15.05: Discussant – MA 15.01, MA 15.02, MA 15.03, 15:50 MA 16.02: Different Pattern and Prognostic Role of PD-
MA 15.04 L1, IDO, and Foxp3 Treg Expression in Thymoma and
Montse Sanchez-Cespedes, Bellvitge Biomedical Research Thymic Carcinoma
Institute, Spain Yi-Ting Yen, National Cheng Kung University Hospital,
Taiwan
16:20 MA 15.06: ERBB Receptor Feedback Inhibitor-1
Alterations in Non-Small Cell Lung Cancer 15:55 MA 16.03: Health Utility Scores in Patients with Thymic
Jeffrey G. Schneider, NYU Winthrop Hospital, USA Malignancies Treated with Multimodality Therapy
Sara Victoria Soldera, Princess Margaret Cancer Center,
16:25 MA 15.07: Consistency Analysis of Mutations in Tumor Canada
Tissue and Circulating Cell-Free DNA in Lung Cancer
Patients Through next Generation Sequencing 16:00 MA 16.04: Phase II Trial of S-1 Treatment as Palliative-
Geng Tian, Shenzhen Second People’s Hospital, China Intent Chemotherapy for Previously Treated Advanced
Thymic Carcinoma
16:30 MA 15.08: Safety and Efficacy of Osimertinib in Treating Fumiyoshi Ohyanagi, The Cancer Institute Hospital of
an EGFR-Mutant Lung Cancer Patient with a Germline Japanese Foundation for Cancer Research, Japan
EGFR T790M Mutation
Tianhong Li, University of California Davis Comprehensive 16:05 MA 16.05: Discussant – MA 16.01, MA 16.02, MA 16.03,
Cancer Center, USA MA 16.04
Mir Ali Reza Hoda, Medical University Vienna, Austria
16:35 MA 15.09: Circumferential Distribution and Distance
from Main Tumor of Tumor Spread Through Air Spaces 16:20 MA 16.06: Minimally Invasive Thoracoscopic
(STAS) Are Prognostic Thymectomy for Early-Stage Thymomas: Modified
Koji Kameda, Memorial Sloan Kettering Cancer Center, Subxiphoid Approach Versus Unilateral Approach
USA Jian-Yong Ding, Zhongshan Hospital, Fudan University,
China
MA 15.09 16:25 MA 16.07: Appropriate Time to Adjuvant Radiotherapy
Natasha Rekhtman, Memorial Sloan Kettering Cancer for Thymoma with MG after Extended Thymectomy
Center, USA Lei Yu, Beijing Tongren Hospital, Capital Medical University,
China
16:55 MA 15.11: CCNE1, PTGS2, TGFA and WISP2 Predict
Benefit from Bevacizumab and Chemotherapy in 16:30 MA 16.08: Surgery for Pleural Dissemination of
Patients with Advanced Non-Small Cell Lung Cancer Thymoma; A 20-Year Experience
(SAKK19/09) Kenji Kimura, Osaka University Graduate School of
Sacha I. Rothschild, University Hospital Basel, Switzerland Medicine, Japan
16:35 MA 16.09: Discussant – MA 16.06, MA 16.07, MA 16.08 16:25 MA 17.07: Veliparib in Combination with Paclitaxel/
Takashi Ohtsuka, Keio University, Japan Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in
Patients with Stage III NSCLC
16:50 MA 16.10: Treatment Outcomes of Primary Malignant Thomas E. Stinchcombe, Duke University, USA
Germ Cell Tumors of the Mediastinum
Tadashi Sakane, Nagoya City University Graduate School 16:30 MA 17.08: The Validity of TNM Classification After

of Medical Sciences, Japan Induction Treatment in Patients with NSCLC: Pulmonary
Resection with or Without Induction Treatment
16:55 MA 16.11: Alterations of Notch Pathway among Patients Huseyin Melek, Uludag University, Turkey
with Adenoid Cystic Carcinoma of the Trachea and Its
Impact on Survival 16:35 MA 17.09: Discussant – MA 17.06, MA 17.07, MA 17.08
Mian Xie, The First Affiliated Hospital of Guangzhou Clarissa Mathias, Núcleo de Oncologia da Bahia, Brazil
16:50 MA 17.10: Toxicity Results from the Randomized Phase
17:00 MA 16.12: Prolonged Survival after Pulmonary III NVALT-11 Study of Prophylactic Cranial Irradiation vs.
Metastasectomy for Testicular Germ-cell Tumors in a Observation in Stage III NSCLC
Single Institution Dirk K. De Ruysscher, Maastricht University Medical
Jose Francisco Corona-Cruz, Instituto Nacional de Center, Netherlands
Cancerologia Mexico, Mexico
16:55 MA 17.11: Prediction of Response to Trimodality Therapy
17:05 MA 16.13: PD-L1 Expression Is a Prognostic Factor in Using CT-Derived Radiomic Features in Stage III Non-
Patients with Esophageal Squamous Cell Carcinoma Small Cell Lung Cancer (NSCLC)
Treated with Postoperative Adjuvant Radiotherapy Vamsidhar Velcheti, Cleveland Clinic, USA
Yaping Xu, Zhejiang Cancer Hospital, China
17:00 MA 17.12: Comparison of EORTC, PERCIST, PeterMac &
17:10 MA 16.14: c-Met in Esophageal Squamous Cell Deauville PET Response Criteria after Radical ChemoRT
Carcinoma: An Independent Prognostic Factor and in Non-Small-Cell Lung Cancer
Potential Therapeutic Target Guy-Anne Turgeon, Peter MacCallum Cancer Centre,
Yaping Xu, Zhejiang Cancer Hospital, China Australia
17:15 MA 16.15: Discussant – MA 16.10, MA 16.11, MA 16.12, 17:05 MA 17.13: Impact of Histologic Subtype of Locally
MA 16.13, MA 16.14 Advanced Lung Adenocarcinoma on Outcomes After
Chang Hyun Kang, Seoul National University Hospital, Definitive Chemoradiation
Korea Abraham J. Wu, Memorial Sloan Kettering Cancer Center,
USA
17:10 MA 17.14: Phase I Trial Evaluating MEK Inhibitor

Selumetinib with Concomitant Thoracic Radiotherapy in
15:45 – 17:30 MA 17: Locally Advanced NSCLC Non-Small-Cell Lung Cancer
Kate Haslett, The University of Manchester, UK
TRACK: LOCALLY ADVANCED NSCLC
ROOM: F203 + F204 (ANNEX HALL) 17:15 MA 17.15: Discussant – MA 17.10, MA 17.11, MA 17.12, MA
CHAIRS: SANGHOON JHEON, KOREA 17.13, MA 17.14
& GEORGIOS STAMATIS, GERMANY Olfred Hansen, Odense University Hospital, Denmark
15:45 MA 17.01: Skip N2, an Independent Prognostic Factor of

Survival: Analysis of a Favourable N2 Subgroup
Sara Ricciardi, Divison of Thoracic Surgery, University
15:45 – 17:30 MA 18: Global Tobacco Control and
Hospital of Pisa, Italy
Epidemiology II
15:50 MA 17.02: Clinical Impact of the Tumor Immune TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO
Microenvironment and Immunoscore in Completely CONTROL AND CESSATION
Resected Stage IIIA(N2) Non-Small Cell Lung Cancer ROOM: 511 + 512
Wen Feng, Shanghai Chest Hospital, Shanghai Jiao Tong CHAIRS: HARUYUKI KAWAI, JAPAN
University, China & CHRISTIAN K. MANEGOLD, GERMANY
15:55 MA 17.03: Prognostic Value of the New IASLC/ATS/

ERS Lung Adenocarcinoma Classification in Completely 15:45 MA 18.01: Driving Improvements in Cancer Care
Resected Stage IIIA(N2) NSCLC Ontario’s Smoking Cessation Initiative for Cancer
Qin Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong Patients in Ontario, Canada
University, China Meredith Elana Giuliani, University of Toronto and Princess
Margaret Cancer Center, Canada
16:00 MA 17.04: Initial Surgery in Patients with Clinical
N2 Non-Small Cell Lung Cancer: A Multi-Institution 15:50 MA 18.02: Outcomes of Integrating Smoking Cessation
Retrospective Study Counseling in a Lung Screening Program
Tomohiro Maniwa, Yao Municipal Hospital, Japan Matthew A. Steliga, University of Arkansas for Medical
Sciences, USA
MA 17.04 15:55 MA 18.03: Role of Electronic Cigarettes in Lung Cancer
Jin Seok Ahn, Samsung Medical Center, Korea Prevention Among Smokers
Maciej Lukasz Goniewicz, Roswell Park Cancer Institute,
16:20 MA 17.06: Safety Data from Randomized Phase II Study USA
of CDDP+S-1 vs CDDP+PEM Combined with TRT for
Locally Advanced Non-Squamous NSCLC
Akira Ono, Shizuoka Cancer Center, Japan
16:00 MA 18.04: Changes in Smoking Behaviour in the Early 17:50 ISS 11.02: Anti-PD-1 in NSCLC: A Critical Look at the
Cancer Detection Test Lung Cancer Scotland (ECLS) Landscape
Study Frances A. Shepherd, Princess Margaret Cancer Centre,
Ben Young, University of Nottingham, UK Canada
16:05 MA 18.05: Discussant – MA 18.01, MA 18.02, MA 18.03, 18:05 ISS 11.03: PD-1 in Combination or As Monotherapy?
MA 18.04 Martin Reck, LungClinic Grosshansdorf, Germany

Emily Stone, St Vincent’s Hospital Sydney, Australia
18:20 ISS 11.04: Future Role for PD-1/L1 in Early-Stage (Non-
16:20 MA 18.06: Clinical Prognostic Model for Older Patients Metastatic) NSCLC and Other Thoracic Malignancies
with Advanced Non-Small Cell Lung Cancer Giorgio Scagliotti, University of Torino, Italy
Apar Kishor Ganti, VA-Nebraska Western Iowa Health Care
System; University of Nebraska Medical Center, USA 18:45 ISS 11.05: Panel Discussion
16:25 MA 18.07: Disparity in Prognostic Factors After Canada,
Pulmonary Resection in Non-Small Cell Lung Cancer Martin Reck, LungClinic Grosshansdorf, Germany,
Between Asian and White Patients Giorgio Scagliotti, University of Torino, Italy
Apichat Tantraworasin, Chiang Mai University, Thailand
19:10 ISS 11.06: Closing Remarks
16:30 MA 18.08: Assessment of Baseline Symptom Burden in Frances A. Shepherd, Princess Margaret Cancer Centre,
Treatment-Naïve Patients with Lung Cancer Canada
George R. Simon, The University of Texas MD Anderson
Cancer Center, USA
16:35 MA 18.09: Enrollment of Minorities, the Elderly, and

19:30 – 22:30 Conference Dinner
Women in Lung Cancer Clinical Trials
Narjust Duma, Mayo Clinic, USA (Ticketed Event)
16:40 MA 18.10: Discussant – MA 18.06, MA 18.07, MA 18.08, ROOM: PLENARY HALL (HALL D)
MA 18.09
Manfred Neuberger, Medical University of Vienna, Austrian
Academy of Science, Austria
16:55 MA 18.11: High Incidence of Lung Cancer in Early Stage

TCC Patients
Yaakov Tolwin, Tel Aviv University, Israel
17:00 MA 18.12: Quality of Data Informing Epidemiological

Studies in Patients with Lung Cancer
Marliese Alexander, Peter MacCallum Cancer Centre,
Australia
17:05 MA 18.13: Mutation Profile of EGFR Gene in Chinese

Patients with Non-Small-Cell Lung Cancer (NSCLC): An
Analysis of 2,666 Cases
Dongmei Lin, Beijing Cancer Hospital, China
17:10 MA 18.14: Non-Small Cell Lung Cancer (NSCLC)

Treatment and Survival in Scandinavia: The SCAN-
LEAF Study
Simon Ekman, Karolinska University Hospital, Sweden

MA 18.14
Konstantinos Arnaoutakis, University of Arkansas for
Medical Sciences, USA
17:45 – 19:15 ISS 11: Pembrolizumab: The New Standard

of Care in Advanced Lung Cancer – MSD
ROOM: MAIN HALL
CHAIRS: FRANCES A. SHEPHERD, CANADA

Canada
SCIENTIFIC PROGRAM | WEDNESDAY, OCTOBER 18, 2017
WEDNESDAY, OCTOBER 18, 2017 | SCIENTIFIC PROGRAM

WS WORKSHOP SESSION
LEVEL 2F

LEVEL 3F

HALL B + C

07:20 SH 04.02: Locally Advanced NSCLC and Radiotherapy

07:00 – 08:00 SH 03: WCLC 2017 Highlights of the Fumihiro Tanaka, University of Occupational and
Previous Day Environmental Health, Japan
TRACK: ADVANCED NSCLC, 07:40 SH 04.03: Biology/Pathology and Thymic Malignancies/
IMMUNOLOGY AND IMMUNOTHERAPY, Esophageal Cancer/Other Thoracic Malignancies
EARLY STAGE NSCLC,
RADIOLOGY/STAGING/SCREENING,
Kenzo Hiroshima, Tokyo Women’s Medical University,
BIOLOGY/PATHOLOGY, Japan
EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO
07:00 – 08:00 MTE 22: Management of Elderly Patients with

07:00 SH 03.01: Advanced NSCLC and Immunology and
Lung Cancer (Sign Up Required)
Immunotherapy
Nico Van Zandwijk, University of Sydney, Australia TRACK: NURSING/PALLIATIVE CARE/ETHICS
ROOM: 303 + 304
07:20 SH 03.02: Early Stage NSCLC and Radiology/Staging/
Screening
Jaroslaw Kuzdzal, Jagiellonian University, Poland 07:00 MTE 22.01: Any Differences in the Management of
Elderly Patients with Lung Cancer between East and
07:40 SH 03.03: Biology/Pathology and Epidemiology/Primary West?
Prevention/Tobacco Control and Cessation Kwun M. Fong, The Prince Charles Hospital UQ Thoracic
Anja C. Roden, Mayo Clinic, USA Research Centre, Australia
07:30 MTE 22.02: Treatment Options in Advanced Non-Small

Cell Lung Cancer (NSCLC) in the Elderly: An Evolving
Landscape
07:00 – 08:00 SH 04: WCLC 2017 Highlights of the Corey J. Langer, Abramson Cancer Center, University of
Previous Day Pennsylvania, USA
TRACK: CHEMOTHERAPY/TARGETED THERAPY,

NURSING/PALLIATIVE CARE/ETHICS,
SCLC/NEUROENDOCRINE TUMORS,
LOCALLY ADVANCED NSCLC,
RADIOTHERAPY, 07:00 – 08:00 MTE 23: Mediastinal Tumors including Thymic
BIOLOGY/PATHOLOGY, Tumors, Lymphoma, Germ Cell Tumors: Biopsy,
THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/ Diagnosis and Treatment (Sign Up Required)
ROOM: F203 + F204 (ANNEX HALL) TRACK: THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/
ROOM: 311 + 312
07:00 SH 04.01: Chemotherapy/Targeted Therapy, Nursing/
Palliative Care/Ethics, and SCLC/Neuroendocrine Tumors
Paul Baas, Netherlands Cancer Institute, Netherlands 07:00 MTE 23.01: Thymic Neoplasms
Frank Detterbeck, Yale University School of Medicine, USA
07:30 MTE 23.02: Mediastinal Germ Cell Tumor
Lawrence Einhorn, Indiana University, USA 07:00 – 08:00 MTE 28: Immunotherapy for Earlier Stage
NSCLC (Sign Up Required)
ROOM: 301 + 302
07:00 – 08:00 MTE 24: Basic Cytology for Clinicians

(Sign Up Required) 07:00 MTE 28.01: Rationale for IO in Treatment of Early Stage
TRACK: BIOLOGY/PATHOLOGY NSCLC
Patrick M. Forde, Johns Hopkins University, USA
ROOM: 313 + 314
07:30 MTE 28.02: Pros and Cons of IO in Early Stage NSCLC

07:00 MTE 24.01: Diagnostic Value and Limitation of Cytology Edward Brian Garon, UCLA Medical Center, USA
Kim Geisinger, The University of Mississippi Medical
Center, USA
07:30 MTE 24.02: Novel Techniques of Cytological Diagnosis

Spasenija Savic, Universitatsspital Basel, Switzerland 07:00 – 08:00 MTE 29: Stereotactic Body Radiation Therapy
for Early Stage Lung Cancer (Sign Up Required)
TRACK: RADIOTHERAPY
ROOM: 502
07:00 – 08:00 MTE 25: Tobacco Control – Practical Issues
(Sign Up Required) 07:00 MTE 29.01: Update and Overview of SBRT for Early
TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO Stage Lung Cancer
CONTROL AND CESSATION Yasushi Nagata, Hiroshima University, Graduate School of
ROOM: 316 Medical Sciences, Japan
07:00 MTE 25.01: Smoking after Diagnosis of Cancer

Jacek Jassem, Medical University of Gdansk, Poland
07:00 – 08:00 MTE 30: Surgery after Concurrent
07:30 MTE 25.02: What Physicians and Scientists Can Do in Chemoradiotherapy (Sign Up Required)
Tobacco Control Action
Yumiko Mochizuki, National Cancer Center, Japan TRACK: SURGERY
ROOM: 503
07:00 MTE 30.01: Surgery after Concurrent

Chemoradiotherapy
07:00 – 08:00 MTE 26: Clinical Trial Design for Novel
Gustavo Lyons, Buenos Aires British Hospital, Argentina
Treatment (Sign Up Required)
ROOM: 315
07:00 – 08:00 MTE 31: Perspectives of Anti-Angiogenesis

07:00 MTE 26.01: Contemporary Trial Design Considerations in (Sign Up Required)
the Era of Immuno-oncology
Mary Redman, Fred Hutchinson Cancer Research Center, TRACK: CHEMOTHERAPY/TARGETED THERAPY
USA ROOM: 418
07:00 MTE 31.01: Perspectives of Anti-Angiogenesis

John V. Heymach, The University of Texas MD Anderson
Cancer Center, USA
07:00 – 08:00 MTE 27: CT Screening for Lung Cancer
(Sign Up Required)
ROOM: 501
07:00 MTE 27.01: Who Should be Screened for Lung Cancer?

Jim Jett, National Jewish Health, USA
07:30 MTE 27.02: Pulmonary Nodule Guidelines: How Do We

Decide Between the IELCAP, ACCP, NCCN, Fleischner
Society, BTS, and Lung-RADS?
Jin Mo Goo, Seoul National Univ Hospital, Korea
08:15 – 09:45 PL 03: Immunology in Lung P3.15 SCLC/Neuroendocrine Tumors
Cancer Update 2017 P3.16 Surgery
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY P3.17 Thymic Malignancies/Esophageal Cancer/

ROOM: PLENARY HALL (HALL D) Other Thoracic Malignancies
CHAIRS: DAVID P. CARBONE, USA
& KEUNCHIL PARK, KOREA
08:15 PL 03.01: Serendipities of Acquired Immunity

11:00 – 12:30 MS 20: Value-based Management for Special
Tasuku Honjo, Graduate School of Medicine Kyoto
Populations
University, Japan
08:45 PL 03.02: Biomarkers in Immunooncology Therapy ROOM: 501
Naiyer Rizvi, Columbia University Medical Center, USA CHAIRS: JIE WANG, CHINA
& ELISABETH QUOIX, FRANCE
09:05 PL 03.03: Blueprint 2: PD-L1 Immunohistochemistry
Comparability Study in Real-Life, Clinical Samples
Ming Sound Tsao, University Health Network and 11:00 MS 20.01: When is a Treatment Considered Futile?
Princess Margaret Cancer Centre, Canada Vera Hirsh, McGill University, Royal Victoria Hospital,
Canada
09:25 PL 03.04: Current Status and Future of
Immunotherapy in Lung Cancer 11:20 MS 20.02: Value-Based Judgment in Advanced NSCLC:
Martin Reck, LungenClinic Grosshansdorf, Germany The European Perspective
Robert Pirker, Medical University of Vienna, Austria
11:40 MS 20.03: What Do Patients Want at the End of Life? –

East vs West
10:00 – 10:45 Press Conference Hiroaki Okamoto, Yokohama Municipal Citizen’s Hospital,
Japan
ROOM: 418
 For information on topics and speakers, please visit the 12:00 MS 20.04: Treatment of Fragile Patients with Advanced
Press & Media page on the Conference website at: NSCLC: Futile or Fertile?
wclc2017.iaslc.org/press-media/press-media/ Byoung Chul Cho, Yonsei Cancer Center, Korea

P3 Posters 11:00 – 12:30 MS 21: Being Mortal: Learning from ZEN
EXHIBIT HALL (HALL B + C) TRACK: NURSING/PALLIATIVE CARE/ETHICS

ROOM: 316
Refreshments provided CHAIRS: MEREDITH CUMMINS, AUSTRALIA
& KAORU KUBOTA, JAPAN

11:00 MS 21.01: Spirituality in Asia
P3.02 Biology/Pathology Nanrei Yokota, Engakuji Temple, Japan
P3.03 Chemotherapy/Targeted Therapy 11:40 MS 21.02: Meditation: From the Temples to the Clinic
Alejandro Chaoul, MD Anderson Cancer Center, USA
12:00 MS 21.03: Self-Care: “Provider, Heal Thyself”
P3.05 Early Stage NSCLC Maria Ftanou, Peter MacCallum Cancer Insititue, Australia
P3.06 Epidemiology/Primary Prevention/ 12:20 Question and Answer Session

Tobacco Control and Cessation
P3.08 Locally Advanced NSCLC 11:00 – 12:30 MS 22: The Cost of Lung Cancer
P3.09 Mesothelioma TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO

P3.10 Nursing/Palliative Care/Ethics ROOM: 502
CHAIRS: RONAN J. KELLY, USA
P3.11 Patient Advocacy & TOMOTAKA SOBUE, JAPAN
11:00 MS 22.01: The Economic Burden of Lung Cancer
P3.13 Radiology/Staging/Screening Natasha B. Leighl, Princess Margaret Cancer Centre,
Canada
P3.14 Radiotherapy
11:20 MS 22.02: The Cost-Benefit of Lung Cancer Care from a
Patient’s Perspective 11:00 – 12:30 ES 08: Molecular Diagnostics and Targeted
Danielle Hicks, Bonnie J. Addario Lung Cancer Foundation, Therapy
USA
11:40 MS 22.03: Health Disparities and the Costs of Tobacco ROOM: MAIN HALL
Related Diseases CHAIRS: KWUN M. FONG, AUSTRALIA

Peter Boyle, International Prevention Research Institute, & DAVID PLANCHARD, FRANCE
France
12:00 MS 22.04: The Economic World of Tobacco Free 11:00 ES 08.01: Overview of Diagnostics and Pathology
Investments Tetsuya Mitsudomi, Kindai University Faculty of Medicine,
Bronwyn King, Peter MacCallum Cancer Centre, Australia Japan
12:20 Question and Answer Session 11:15 ES 08.02: Update of the Management of EGFR-Positive
NSCLC
James Chih-Hsin Yang, National Taiwan University, Taiwan
11:30 ES 08.03: Update of the Management of ALK-Positive

NSCLC
11:00 – 12:30 PC 03: 3-1 What is the Optimal Sequence D. Ross Camidge, University of Colorado, USA
of ALK-TKI for ALK-Positive Lung Cancer?
(Alectinib First or Crizotinib First) 11:45 ES 08.04: Emerging Target Therapy in NSCLC
PC 03: 3-2 Which Do you Prefer: Liquid Biopsy Enriqueta Felip, Hospital Universitari Vall d’Hebron, Spain
or Tissues Biopsy for Molecular Diagnosis?
12:00 ES 08.05: Oncogenomics for Clinicians
TRACK: CHEMOTHERAPY/TARGETED THERAPY Matthew Meyerson, Dana Farber Cancer Institute, Broad
ROOM: 303 + 304 Institute of Harvard and MIT, and Massachusetts General
CHAIRS: RAFAL DZIADZIUSZKO, POLAND Hospital, USA
& YEW OO TAN, SINGAPORE
11:00 PC 03.01: Crizotinib First

Sai-Hong Ignatius Ou, University of California at Irvine, USA
11:20 PC 03.02: Alectinib First

11:00 – 12:30 GR 03: Treatment Options for Early Stage
Lung Cancer Patients with Limited Pulmonary
Japan
Reserve
11:40 PC 03.03: Liquid Biopsy TRACK: EARLY STAGE NSCLC
Heather A. Wakelee, Stanford University, USA ROOM: F205 + F206 (ANNEX HALL)
CHAIRS: ALEXANDER V. LOUIE, CANADA
12:00 PC 03.04: Tissues Biopsy
& ICHIRO YOSHINO, JAPAN
Keith M. Kerr, University of Aberdeen, School of Medicine
and Dentistry, USA
12:20 Question and Answer Session Alexander Vincent Louie, London Regional Cancer
Program, Canada

Ichiro Yoshino, Chiba University Graduate School of
11:00 – 12:30 ES 07: Recent Advances in Diagnostics and Medicine, Japan
Interventional Bronchoscopy
11:10 GR 03.03: Minimally Invasive Surgery for Early Stage
TRACK: PULMONOLOGY/ENDOSCOPY NSCLC
ROOM: 503 Thomas D’Amico, Duke University, USA
CHAIRS: STEPHEN LAM, CANADA
& NORIAKI KURIMOTO, JAPAN 11:30 GR 03.04: Merit and Demerit of Minimally Invasive
Approach
Eric Lim, Royal Brompton Hospital, UK
11:00 ES 07.01: Endoscopic Staging of Lung Cancer
Kazuhiro Yasufuku, University Health Network, Canada 11:50 GR 03.05: Any Roles of Systemic Therapy
(Chemotherapy, Targeted Therapy, Immunotherapy) for
11:20 ES 07.02: Guided Bronchoscopy for Peripheral Lung Early Stage NSCLC with Limited Pulmonary Reserve?
Nodules Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong
Takehiro Izumo, Japanese Red Cross Medical Center, University, China
Japan
12:10 GR 03.06: Possibility of Radiotherapy (SBRT) for Early
11:40 ES 07.03: Bronchoscopic Management of Central Stage NSCLC
Airway Obstruction Laurie E. Gaspar, University of Colorado Denver Health
Hojoong Kim, Samsung Medical Center, Korea Science Center, USA
12:00 ES 07.04: Endoscopic Options for Solitary Pulmonary
Nodules
Stephen Lam, British Columbia Cancer Agency, Canada
11:30 OA 11.04: Effect of Early Palliative Care on
11:00 – 12:30 OA 10: Liquid Biopsy for Genomic Alterations Aggressiveness of Cancer Care near End of Life in Lung
Cancer Patient
TRACK: ADVANCED NSCLC Wandee Chanprasertpinyo, Ramathibodi Hospital, Mahidol
ROOM: F201 + F202 (ANNEX HALL) University, Thailand

CHAIRS: PASI A. JÄNNE, USA
& ADRIAN G. SACHER, USA 11:40 OA 11.05: Discussant – OA 11.01, OA 11.02, OA 11.03, OA
11.04
Jin Soo Lee, National Cancer Center, Korea
11:00 OA 10.01: Detection of EGFR Mutations From Plasma
ctDNA in the Osimertinib Phase III trial (AURA3): 11:55 OA 11.06: Lung Cancer Diagnosis and Assessment as
Comparison of Three Plasma Assays a System Design Problem: Creating an Award Winning
Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan Program with Patient Advocates as Co-Designers
University School of Medicine, Korea Jason Pantarotto, University of Ottawa / The Ottawa
Hospital, Canada
11:10 OA 10.02: Unique Genetic Profiles from Circulating
Cell-Free DNA of Cerebrospinal Fluid in Leptomeningeal 12:05 OA 11.07: Enhancing Lung Cancer (LC) Care in the
Metastases of EGFR Mutant NSCLC Community Setting Through a Patient Advocacy
Benyuan Jiang, Guangdong Lung Cancer Institute, China ‘Centers of Excellence’ (COE) Program
Luis E. Raez, Memorial Cancer Institute, USA
11:20 OA 10.03: Liquid Biopsy in the Lung Cancer Clinic: A
Prospective Study of Plasma DNA next Generation 12:15 OA 11.08: Discussant – OA 11.06, OA 11.07
Sequencing to Guide Matched Therapy Kazuo Hasegawa, Japan Lung Cancer Alliance, Japan
Joshua K. Sabari, Memorial Sloan Kettering Cancer Center,
USA

Rina Hui, Westmead Hospital and the University of Sydney,
Australia 11:00 – 12:30 OA 12: Emerging Genomic Targets
11:45 OA 10.05: Non-Invasive Molecular Profiling in NSCLC by CHEMOTHERAPY/TARGETED THERAPY
Targeted and Whole Exome Analysis of Plasma cfDNA ROOM: F203 + F204 (ANNEX HALL)
Dana W.Y. Tsui, Memorial Sloan Kettering Cancer Center,
CHAIRS: HIROTOSHI AKITA, JAPAN
USA & MAURICE PÉROL, FRANCE
11:55 OA 10.06: Longitudinal Mutation Monitoring in Plasma

by Deep Sequencing as a Potential Predictor of Disease 11:00 OA 12.01: The Preclinical and Clinical Activity of
Progression in NSCLC Poziotinib, a Potent, Selective Inhibitor of EGFR Exon
John Jiang, Roche Sequencing Solutions, USA 20 Mutant NSCLC
John V. Heymach, The University of Texas MD Anderson
12:05 OA 10.07: Genomic Profile of Cell-Free DNA from Cancer Center, USA
Sputum, Plasma, Urine and Tumor Tissue and
Correlation with Clinical Effect in Advanced NSCLC 11:10 OA 12.02: Final Results of a Phase 2 Study of the hsp90
Zhen Wu, Department of Respiratory medicine ,Chinese Inhibitor Luminespib (AUY922) in NSCLC Patients
PLA General Hospital, China Harboring EGFR Exon 20 Insertions
Zofia Piotrowska, Massachusetts General Hospital, USA
Naoko Aragane, Saga University, Japan 11:20 OA 12.03: Clinical Features of Advanced Lung Cancer
Harboring HER2 Aberrations: A Large Prospective
Cohort Study (HER2-CS STUDY)
Shinobu Hosokawa, Japanese Red Cross Okayama
Hospital, Japan
11:00 – 12:30 OA 11: Reducing Burden: Patient-Centered Care
TRACK: NURSING/PALLIATIVE CARE/ETHICS Christina S. Baik, University of Washington, Seattle Cancer
PATIENT ADVOCACY Care Alliance, USA
ROOM: 313 + 314
CHAIRS: BETH IVIMEY, AUSTRALIA 11:40 OA 12.05: Spectrum of 1,014 Somatic BRAF Alterations
& ERIC BERNICKER, USA Detected in Cell-Free DNA of Patients with Advanced
Non-Small Cell Lung Cancer
Trever G. Bivona, UC San Francisco, USA
11:00 OA 11.01: Impact of Tobacco Smoking on the Humanistic
and Financial Burden of Advanced Non-Small Cell Lung 11:50 OA 12.06: Plasma Genomic Profiling and Outcomes of
Cancer (A-NSCLC) Patients with MET Exon 14-Altered NSCLCs Treated
Oana Chirita, Bristol-Myers Squibb, UK with Crizotinib on PROFILE 1001
Alexander Drilon, Memorial Sloan Kettering Cancer Center,
11:10 OA 11.02: Exercise Improves Functional Capacity in
USA
Patients with Advance Stage Lung Cancer
Morten Quist, Rigshospitalet, University of Copenhagen, 12:00 OA 12.07: LOXO-292, a Potent, Highly Selective RET
Denmark Inhibitor, in MKI-Resistant RET Fusion-Positive Lung
Cancer Patients with and without Brain Metastases
11:20 OA 11.03: Reducing Lung Cancer Mortality in Disparate
Populations through Cancer-Community Awareness
Access Research and Education (C-CARE)
Lovoria B. Williams, Augusta University, USA
12:10 OA 12.08: Genomic Analysis of Non-Small Cell Lung 11:10 OA 14.02: Rethinking Progression-Free Survival (PFS)
Cancer (NSCLC) Cases with Focal and Non-Focal MET as a Clinical Trials Surrogate for Overall Survival (OS)
Amplification David James Stewart, University of Ottawa, Canada
Sai-Hong Ignatius Ou, University of California at Irvine
School of Medicine, Chao Family Comprehensive Cancer 11:20 OA 14.03: Ontario’s Bundled Payment System for
Center, USA Systemic Therapy Supports Lung Cancer Trials
William Kenneth Evans, Cancer Care Ontario, Canada

12:20 OA 12.09: Discussant – OA 12.05, OA 12.06, OA 12.07,
OA 12.08 11:30 OA 14.04: Discussant – OA 14.01, OA 14.02, OA 14.03
Julien Mazieres, Toulouse University Hospital, France George R. Simon, MD Anderson Cancer Center, USA
11:45 OA 14.05: Phase 2 Basket Trial of Ado-Trastuzumab

Emtansine in Patients with HER2 Mutant or Amplified
Lung Cancers
11:00 – 12:30 OA 13: Immuno-Biology Bob T. Li, Memorial Sloan Kettering Cancer Center, USA
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY 11:55 OA 14.06: Entrectinib in Patients with Locally Advanced
ROOM: 301 + 302 or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung
CHAIRS: HIROYUKI SUZUKI, JAPAN
Cancer (NSCLC)
& SCOTT N. GETTINGER, USA Myung-Ju Ahn, Samsung Medical Center, Korea
12:05 OA 14.07: Progress in Lung Squamous Cell Carcinoma

11:00 OA 13.01: CD38-Mediated Immunometabolic from the Lung-MAP Master Protocol (S1400) Sub-
Suppression as a Mechanism of Resistance to PD-1/ Studies S1400A, S1400B, S1400C and S1400D
PD-L1 Axis Blockade Roy S. Herbst, Yale University, USA
Don Lynn Gibbons, MD Anderson, USA
11:10 OA 13.02: Distribution of PD-L1 Tumor Expression Fiona Blackhall, Christie Hospital NHS Foundation Trust,
by Assay Type in Patients with Metastatic NSCLC UK
(MNSCLC)
11:20 OA 13.03: Wide Expression of Alternative Immune

Checkpoint Molecules, B7x and HHLA2, in PD-L1 11:00 – 12:30 MA 19: Mesothelioma: Bench to Bedside
Negative Human Lung Cancers
Haiying Cheng, Albert Einstein College of Medicine/ TRACK: MESOTHELIOMA
Montefiore Medical Center, USA ROOM: 315
CHAIRS: DEAN A. FENNELL, UK
11:30 OA 13.04: Discussant – OA 13.01, OA 13.02, OA 13.03 & HEDY LEE KINDLER, USA
Charles Andrew Butts, Cross Cancer Institute, Canada
11:45 OA 13.05: Immune, Molecular and T Cell Repertoire 11:00 MA 19.01: A Phase II Study of Nivolumab: A Multicenter,
Landscape of 235 Resected Non-Small Cell Lung Open-Label, Single Arm Study in Malignant Pleural
Cancers and Paired Normal Lung Tissues Mesothelioma (MERIT)
Alexandre Reuben, The University of Texas MD Anderson Yasushi Goto, National Cancer Center Hospital, Japan
Cancer Center, USA
11:05 MA 19.02: Tremelimumab plus Durvalumab in First- or
11:55 OA 13.06: Co-Expression of IDO1 and PD-L1 Indicates Second-Line Mesothelioma Patients: Final Analysis of
More Aggressive Features of Lung Adenocarcinoma the NIBIT-MESO-1 Study
Yuka Kozuma, Graduate School of Medical Sciences, Luana Calabro, Center for Immuno-Oncology, University
Kyushu University, Japan Hospital of Siena, Italy
12:05 OA 13.07: Contraction of T Cell Clonality in Lung Cancer 11:10 MA 19.03: Nintedanib + Pemetrexed/Cisplatin in
Metastases Malignant Pleural Mesothelioma (MPM): Phase II
Aaron S. Mansfield, Mayo Clinic, USA Biomarker Data from the LUME? Meso Study
Anna Nowak, School of Medicine, Faculty of Medicine and
12:15 OA 13.08: Discussant – OA 13.05, OA 13.06, OA 13.07 Health Sciences, University of Western Australia, Crawley,
Hiroshi Kagamu, Saitama University International Medical Australia
Center, Japan
Glen Reid, Asbestos Diseases Research Institute, Australia
11:30 MA 19.05: Pegylated Arginine Deiminase Potentiates

11:00 – 12:30 OA 14: New Paradigms in Clinical Trials PD-1/PD-L1 Immune Checkpoint Blockade in Malignant
Mesothelioma
TRACK: CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS Peter Szlosarek, St. Bartholomew’s Hospital, UK
ROOM: 311 + 312
CHAIRS: ALEX ADJEI, USA
11:35 MA 19.06: Multiple Mechanisms Contribute to
& EUN KYUNG CHO, KOREA Downregulation of Tumour Suppressor microRNAs in
Malignant Pleural Mesothelioma
Marissa Williams, Asbestos Diseases Research Institute,
11:00 OA 14.01: The Impact of Measurement Variability on Australia
Response Categorization in Oncology Trials
Soon Ho Yoon, Seoul National University College of 11:40 MA 19.07: Does Loss of Smad7 Lead to Increased
Medicine, Korea Aggressiveness of Malignant Pleural Mesothelioma?
Michael Grusch, Medical University Vienna, Austria
Yoshitaka Sekido, Aichi Cancer Center Research Institute, P3.08 Locally Advanced NSCLC
Japan
P3.09 Mesothelioma
12:00 MA 19.09: The Role of Neoadjuvant Chemotherapy in
Patients with Malignant Pleural Mesothelioma

David Harpole, Duke Medical Center, USA P3.11 Patient Advocacy
12:05 MA 19.10: Comparative Value of MR and CT for Tumor P3.12 Pulmonology/Endoscopy
Volumetric and Clinical Staging of Malignant Pleural
Mesothelioma P3.13 Radiology/Staging/Screening
Ritu R. Gill, Brigham and Women’s Hospital, USA
P3.14 Radiotherapy
12:10 MA 19.11: Discussant – MA 19.09, MA 19.10
Walter Weder, University Hospital Zurich, Switzerland P3.15 SCLC/Neuroendocrine Tumors
12:25 Question and Answer Session P3.16 Surgery
P3.17 Thymic Malignancies/Esophageal Cancer/

Other Thoracic Malignancies
12:45 – 14:15 ISS 12: SCLC Biomarker Testing Symposium –

AbbVie
TRACK: INDUSTRY SUPPORTED SYMPOSIUM 14:30 – 16:15 MS 23: Management of N2 NSCLC: What
ROOM: MAIN HALL “Operable” Means?
CHAIRS: KOICHI GOTO, JAPAN
TRACK: LOCALLY ADVANCED NSCLC
CHAIRS: DAVID JABLONS, USA
& GUSTAVO LYONS, ARGENTINA
12:45 ISS 12.01: Welcome & Introductions
Koichi Goto, National Cancer Center Hospital East, Japan 14:30 MS 23.01: What Type of Lung Cancer Cannot be
Resected?
12:55 ISS 12.02: Opportunities & Challenges in SCLC Patient
Marc De Perrot, University Health Network, Canada
Care
Benjamin Besse, Gustave Roussy, France 14:50 MS 23.02: When Do Surgeons Quit Resection During
Surgery?
13:15 ISS 12.03: Novel Therapeutics in SCLC & the Changing
Jessica Donington, NYU Langone Medical Center, USA
Treatment Landscape
Maya Gottfried, Meir Medical Center, Israel 15:10 MS 23.03: What is Resectable N2 Disease, and What
is Unresectable N2 Disease: A Medical Oncologist’s
13:45 ISS 12.04: Incorporating Biomarker Testing & Targeted
Viewpoint
Therapies into the SCLC Treatment Paradigm
Hidehito Horinouchi, National Cancer Center Hospital,
Wilfried Eberhardt, University of Essen, Germany
Japan
14:10 ISS 12.05: Closing Remarks
15:30 MS 23.04: What is Resectable N2 Disease, and What
Koichi Goto, National Cancer Center Hospital East, Japan
is Unresectable N2 Disease: A Radiation Oncologist’s
14:15 ISS 12.06: Adjourn Viewpoint
Walter John Curran, Jr., Winship Cancer Institute, USA
15:50 MS 23.05: What is Resectable N2 Disease, and What is

Unresectable N2 Disease: A Surgeon’s Viewpoint
Jhingook Kim, Samsung Medical Center, Sungkyunkwan
& Poster Presenters Present for University School of Medicine, Korea
P3 Posters
14:30 – 16:15 MS 24: Management of GGO-Containing Nodule
P3.01 Advanced NSCLC TRACK: RADIOLOGY/STAGING/SCREENING
CHEMOTHERAPY/TARGETED THERAPY
P3.02 Biology/Pathology SURGERY
ROOM: 503
CHAIRS: HARVEY I. PASS, USA
& YOUNG WHAN KIM, KOREA
P3.05 Early Stage NSCLC 14:30 MS 24.01: Natural History of GGO-Containing Tumors
Ryutaro Kakinuma, Tokyo General Hospital, Japan
P3.06 Epidemiology/Primary Prevention/
Tobacco Control and Cessation 14:50 MS 24.02: What Type of Surgery Should be Selected for
GGO-Containing Tumors?
P3.07 Immunology and Immunotherapy Paul De Leyn, University Hospitals Leuven, Belgium
15:10 MS 24.03: When to Operate GGO-Containing Tumors?
David Harpole, Duke University, USA 14:30 – 16:15 MS 27: Engaging Patients in Research:
Best Practices
15:30 MS 24.04: Possibility of Radiotherapy for GGO-
Containing Tumors TRACK: PATIENT ADVOCACY
Hiroshi Onishi, University of Yamanashi, Japan ROOM: 311 + 312
CHAIRS: SHANI SHILO, ISRAEL

15:50 MS 24.05: Possibility of Chemotherapy for GGO- & JANE KERR, AUSTRALIA
Containing Tumors
Pieter E. Postmus, Clatterbridge Cancer Centre, UK
14:30 MS 27.01: The Multi-Centre Clinical Trials Network
16:10 Question and Answer Session (MCTN): Matching Lung Cancer Patients to Trials in
Australia
Nick Pavlakis, Royak North Shore Hospital, Australia
14:50 MS 27.02: LungMATCH: Developing a Patient-Friendly,

14:30 – 16:15 MS 25: Novel Molecular Targets (KRAS/MET/ Personalized Education and Navigation Program to
Novel Fusions): Druggable or Not? Increase Participation in Clinical Research
Jennifer C. King, Lung Cancer Alliance, USA
ROOM: MAIN HALL 15:10 MS 27.03: Lung Cancer Registry: Using Patient Data to
CHAIRS: RAFAEL ROSELL, SPAIN Improve Outcomes and Quality of Life
& ISAMU OKAMOTO, JAPAN David LeDuc, Addario Lung Cancer Foundation, USA
15:30 MS 27.04: Approaches to Patient-Centric Clinical Trials:

14:30 MS 25.01: Discovery of Novel Molecular Targets
Sharing Challenges and Lessons Learned
Pasi A. Jänne, Dana-Farber Cancer Institute, USA
Ingeborg Beunders, Focus Patient Ltd., Austria
14:50 MS 25.02: KRAS-Targeted Therapy or Angiogenesis:
15:50 MS 27.05: Screening Veterans: Opportunity and
Still a Viable Target?
Challenge
Ravi Salgia, City of Hope National Medical Center, USA
Chris Draft, The Chris Draft Family Foundation, USA
15:10 MS 25.03: MET-Related Molecular Targets
Alexander Drilon, Memorial Sloan Kettering Cancer Center,
USA
15:30 MS 25.04: FGFR-Related Novel Molecular Targets

Kazuto Nishio, Kinkai University School of Medicine, Japan
14:30 – 16:15 ES 09: Recent Progress in the Management
15:50 MS 25.05: Novel Fusions of Small Cell Lung Cancer
Robert C. Doebele, University of Colorado Anschutz
Medical Campus, USA
ROOM: 501
16:10 Question and Answer Session CHAIRS: DAVID S. ETTINGER, USA
& KENNETH O’BYRNE, AUSTRALIA
14:30 ES 09.01: Genomics and Translational Research

14:30 – 16:15 MS 26: Re-Modeling Microenvironment Charles M. Rudin, Memorial Sloan Kettering Cancer Center,
Mimicking Human Cancer USA
TRACK: BIOLOGY/PATHOLOGY 14:45 ES 09.02: Cytotoxic Chemotherapy

ROOM: 502 Yoichi Nakanishi, Kyushu University, Japan
CHAIRS: PAN CHYR YANG, TAIWAN
& CÉLINE MASCAUX, FRANCE 15:00 ES 09.03: Immunotherapy
Caicun Zhou, Shanghai Pulmonary Hospital, Tongji
University, China
14:30 MS 26.01: Cancer Stem Cell
Hideyuki Saya, Institute for Advanced Medical Research, 15:15 ES 09.04: Novel Agents for SCLC
School of Medicine, Keio University, Japan Se-Hoon Lee, Samsung Medical Center, Korea
14:50 MS 26.02: Innate Immune Microenvironment 15:30 ES 09.05: Management of Paraneoplastic Syndromes in
Ruben Pio, CIMA-University of Navarra, Spain SCLC
Lucio Crinò, Medical Oncology- Istituto Scientifico
15:10 MS 26.03: Animal Model Romagnolo per lo Studio e la Cura dei Tumori (IRST)
Kwok-Kin Wong, NYU Langone Health Perlmutter Cancer IRCCS, Italy
Center, USA
15:45 ES 09.06: NCI’s Small Cell Lung Cancer Consortium:
15:30 MS 26.04: PDx Model New Answers to Old Questions
John Poirier, Memorial Sloan Kettering Cancer Center, Peter Ujhazy, National Cancer Institute, USA
USA
15:50 MS 26.05: In Vitro Model of Early Progression in SCLC
Kwon-Sik Park, University of Virginia, USA
15:45 OA 15.08: Thoroughness of Staging and the Outcomes
14:30 – 16:15 ES 10: Radiation Treatment Update of Surgical Resection Outcomes in Potentially Curable
Non-Small Cell Lung Cancer (NSCLC)
TRACK: RADIOTHERAPY Matthew P. Smeltzer, University of Memphis School of
ROOM: F201 + F202 (ANNEX HALL) Public Health, USA

CHAIRS: ZHONGXING LIAO, USA
& FIONA MCDONALD, UK 15:55 OA 15.09: Discussant – OA 15.06, OA 15.07, OA 15.08
John Field, The University of Liverpool, UK
14:30 ES 10.01: SBRT
Billy Loo, Stanford University, USA
14:50 ES 10.02: IMRT

Francoise Mornex, Centre Hospitalier Lyon-Sud, France 14:30 – 16:15 OA 16: Treatment Strategies and Follow Up
TRACK: EARLY STAGE NSCLC
15:10 ES 10.03: Proton Therapy
ROOM: 315
Yong Chan Ahn, Samsung Medical Center, Korea
CHAIRS: JUN NAKAJIMA, JAPAN
15:30 ES 10.04: Carbon-ion Therapy & TODD DEMMY, USA
Yuko Nakayama, National Cancer Center Hospital, Japan
14:30 OA 16.01: Stereotactic Ablative Radiotherapy Versus
15:50 ES 10.05: RT and Targeted Therapies
Surgery in Early Lung Cancer: A Meta-analysis of
Rafal Dziadziuszko, Medical University of Gdansk, Poland
Propensity Score-Adjusted Studies
16:10 Question and Answer Session Hanbo Chen, London Health Sciences Centre, Canada
14:40 OA 16.02: Risk of Recurrence in Stage I

Adenocarcinoma of the Lung: A Multi-Institutional Study
on Interaction with Type of Surgery and Type of Nodal
Staging
14:30 – 16:15 OA 15: Diagnostic Radiology, Staging and Francesco Guerrera, University of Torino, Italy
Screening for Lung Cancer II
14:50 OA 16.03: Recurrences and 2Nd Primary Cancers in the
IFCT-0302 Trial Assessing a CT-Scan-Based Follow-Up
ROOM: 303 + 304
after Lung Cancer Surgery
CHAIRS: YUKITOSHI SATOH, JAPAN
Virginie Westeel, Centre Hospitalier Universitaire de
& JIN MO GOO, KOREA
Besançon, Hôpital Minjoz, France
14:30 OA 15.01: Lung Cancer Screening: Participant Selection 15:00 OA 16.04: Efficacy and Safety of Erlotinib vs
by Risk Model – the Pan-Canadian Study Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA
Stephen Lam, BC Cancer Agency, Canada EGFR Mutant NSCLC Patients
Dongsheng Yue, Tianjin Medical University Cancer Institute
14:40 OA 15.02: Benefits, Harms, and Economic Efficiency of and Hospital, China
Low-Dose CT Lung Cancer Screening Strategies in a
Population-Based Setting 15:10 OA 16.05: Discussant – OA 16.01, OA 16.02, OA 16.03,
Alexander Kuhlmann, Leibniz Universität Hannover, OA 16.04
Germany In Kyu Park, Seoul National University Hospital, Korea
14:50 OA 15.03: Gene-Based Risk Stratification of NLST- 15:25 OA 16.06: Mediastinal Staging by Videomediastinoscopy
ACRIN Screening Participants Identifies The “Sweet in Clinical N1 Non-Small Cell Lung Cancer: A
Spot” of Screening (N=10,054) Prospective Multicentre Study
Robert P. Young, University of Auckland, New Zealand Herbert Decaluwe, University Hospitals Leuven, Belgium
15:00 OA 15.04: Community-Based Lung Cancer Screening, 15:35 OA 16.07: Radiological Feature on TSCT for Predicting
Targeting High-Risk Ever Smokers in Deprived Areas of a Pathological Less-Invasive Lung Cancer According to
Manchester: an NHS Implementation Project. the 8th TNM Classification
Haval Balata, University Hospital of South Manchester, UK Shinya Katsumata, National Cancer Center Hospital East,
Japan
OA 15.04 15:45 OA 16.08: A Modified Pathological N1 Classification
David F. Yankelevitz, Icahn School of Medicine at Mount Strategy Based on Systematic Dissection of N1 Nodes
Sinai, USA from Level 10 to 14 for Non-Small Cell Lung Cancer
Wu Nan, Key laboratory of Carcinogenesis and
15:25 OA 15.06: Management of Nonresolving New Solid Translational Research (Ministry of Education), China
Nodules after Initial Detection in Incidence Rounds of CT
Lung Cancer Screening 15:55 OA 16.09: Discussant – OA 16.06, OA 16.07, OA 16.08
Joan E. Walter, University of Groningen, University Medical Marcin Zielinski, Pulmonary Hospital, Poland
Center Groningen, Netherlands
15:35 OA 15.07: Value of Nodule Characteristics in Risk-

Stratification of New Incident Nodules Detected in CT
Lung Cancer Screening
Joan E. Walter, University of Groningen, University Medical
Center Groningen, Netherlands
14:50 OA 18.03: Genomic Profiling Reveals Hedgehog Pathway
14:30 – 16:15 OA 17: Immunotherapy II Alterations in Vismodegib Sensitive Lung Squamous Cell
Carcinoma
TRACK: ADVANCED NSCLC Siraj M. Ali, Foundation Medicine, USA
IMMUNOLOGY AND IMMUNOTHERAPY
ROOM: 301 + 302 15:00 OA 18.04: Whole Genome Tumor-Normal Sequencing
CHAIRS: ANNE TSAO, USA Reveals Potential False Positives Versus Standard CGP
& YUICHIRO OHE, JAPAN Sequencing in Patients with NSCLC
Sandeep Bobby Reddy, Nant Health, USA
14:30 OA 17.01: Pemetrexed-Carboplatin Plus Pembrolizumab
as First-Line Therapy for Advanced Nonsquamous
OA 18.04
NSCLC: KEYNOTE-021 Cohort G Update
Maria E. Arcila, Memoria Sloan Kettering Cancer Center,
USA
14:40 OA 17.02: Updated Efficacy Results From the BIRCH
15:25 OA 18.06: Three-Dimensional Assessment of Spread
Study: First-Line Atezolizumab Therapy in PD-L1–
Through Air Spaces in Lung Adenocarcinoma: Insights
Selected Patients With Advanced NSCLC
and Implications
Enric Carcereny, Catalan Institute of Oncology Badalona—
Yukako Yagi, Memorial Sloan Kettering Cancer Center, USA
Germans Trias I Pujol Hospital Badalona, Spain
15:35 OA 18.07: 3D Low-Attachment Culture: A Putative Model
14:50 OA 17.03: First-Line Nivolumab plus Platinum-Based
for STAS And “Floating” Cancer Cells
Doublet Chemotherapy for Advanced NSCLC: CheckMate
Toshiro Niki, Jichi Medical University, Japan
012 3-Year Update
Rosalyn J. Juergens, Juravinski Cancer Centre at 15:45 OA 18.08: FLI1 Circular RNAs Promote Metastasis of
McMaster University, Canada Small Cell Lung Cancer Cells by Direct Binding to miR-
584-3p
Jiuwei Cui, The First Hospital of Jilin University, China
Martin Schuler, University Hospital Essen, Germany
15:15 OA 17.05: IFCT-1502 CLINIVO: Real-Life Experience
Alain Borczuk, Albert Einstein College of Medicine/
with Nivolumab in 600 Patients (Pts) with Advanced
Montefiore Medical Center, USA
Non-Small Cell Lung Cancer (NSCLC)
Nicolas Girard, Institut Curie, France
15:25 OA 17.06: Updated Analysis of KEYNOTE-024:

Pembrolizumab vs Platinum-Based Chemotherapy for
Advanced NSCLC With PD-L1 TPS ≥50% 14:30 – 16:15 MA 20: Recent Advances in Pulmonology/
Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Endoscopy
Center at Johns Hopkins, USA TRACK: PULMONOLOGY/ENDOSCOPY
15:35 OA 17.07: Long-Term Survival in Atezolizumab-Treated
Patients with 2L+ NSCLC from Ph III Randomized OAK CHAIRS: CHOON-TAEK LEE, KOREA
& SHINJI SASADA, JAPAN
Study
Miyako Satouchi, Hyogo Cancer Center, Japan
14:30 MA 20.01: Fiducial Marker Placement Using
15:45 OA 17.08: Phase II Study of Pembrolizumab for Electromagnetic Navigation Bronchoscopy in the
Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Prospective, Multicenter NAVIGATE Study
Following Completion of Locally Ablative Therapy (LAT) Mark R. Bowling, East Carolina University, USA
Joshua Michael Bauml, Perelman School of Medicine at
the University of Pennsylvania, USA 14:35 MA 20.02: Pleural Dye Marking of Lung Nodules by
Electromagnetic Navigation Bronchoscopy in the
15:55 OA 17.09: Discussant – OA 17.05, OA 17.06, OA 17.07, Prospective, Multicenter NAVIGATE Study
OA 17.08 Mark R. Bowling, East Carolina University, USA
Penelope Bradbury, University Hospital Network, Princess
Margaret Cancer Centre, Canada 14:40 MA 20.03: Safety of Electromagnetic Navigation
Bronchoscopy in Patients with COPD: Results from the
NAVIGATE Study
Christopher W. Towe, University Hospitals Cleveland
Medical Center and Case Western Reserve School of
14:30 – 16:15 OA 18: Lung Cancer Pathology and Genetics Medicine, USA
TRACK: BIOLOGY/PATHOLOGY 14:45 MA 20.04: Inteligent Biopsy Device for SPN Diagnosis
ROOM: 316 Jiri Votruba, Charles University Hospital, Czech Republic
CHAIRS: GEORGE R. SIMON, USA
& YOON-LA CHOI, KOREA 14:50 MA 20.05: Discussant – MA 20.01, MA 20.02, MA
20.03, MA 20.04
Yoon Soo Chang, Yonsei University College of Medicine,
14:30 OA 18.01: Paired Tumor-Normal Next-Generation
Korea
Sequencing (NGS) to Identify Pathogenic / Likely
Pathogenic Germline Mutations in Lung Cancer Patients 15:05 MA 20.06: Discerning Lung Cancer Cell Patterns with
Rongrong Chen, Geneplus-Beijing, China Confocal Endomicroscopy
Antoni Rosell, Hospital Universitari de Bellvitge, Spain
14:40 OA 18.02: The Landscape of Alteration of DNA Integrity-
Related Genes and Their Association with Tumor
Mutation Burden in Non-Small Cell Lung Cancer
Michael F. Sharpnack, The Ohio State University, USA
15:10 MA 20.07: Endobronchial Ultrasound Elastography:
Mediastinal Staging in Non-Small Cell Lung Cancer and
Technical Factors
Lokesh Yagnik, Fiona Stanley Hospital, Australia
15:15 MA 20.08: Classification of Confocal Endomicroscopy

Patterns for Diagnosis of Lung Cancer
Antoni Rosell, Hospital Universitari de Bellvitge, Spain
15:20 MA 20.09: Accuracy & Utility of Systematic Mediastinal

LN Staging via EBUS-TBNA in cN0/N1 NSCLC:
Systematic Review & Meta-Analysis
Daniel P. Steinfort, Royal Melbourne Hospital, Australia

20.08, MA 20.09
Jitsuo Usuda, Nippon Medical School, Japan
15:40 MA 20.11: Chronic Obstructive Pulmonary Disease

Prevalence in a Lung Cancer Screening Population
John R. Goffin, McMaster University, Canada
15:45 MA 20.12: Longitudinal Evaluation of Pulmonary

Function in Patients with Advanced NSCLC Treated with
Concurrent Chemo-Radiotherapy
Marisol Arroyo Hernandez, Instituto Nacional de
Cancerologia, Mexico
15:50 MA 20.13: etDNA: Tumor-Derived DNA from Pleural

Effusion Supernatant as a Promising Source for NGS-
Based Mutation Profiling in Lung Cancer
Lin Tong, Shanghai Respiratory Research Institute, China
15:55 MA 20.14: Genotyping of Lung Cancer Using Cell-Free

DNA (cfDNA) from Cytologic Supernatant (CSN)
Nicolas Marie Guibert, Dana Farber Cancer Institute, USA

MA 20.14
Virginie Westeel, Jean-Minjoz Hospital, France
16:30 – 17:45 PL 04: Closing Plenary:

Where We Are Now, and Where We
Will Be in 10 Years
ROOM: MAIN HALL

CHAIRS: HARUBUMI KATO, JAPAN & RAFAEL ROSELL, SPAIN
16:30 PL 04.01: Where We Are Now, and Where We Will

Be in 10 Years: From North American Perspective
Paul A. Bunn, Jr., University of Colorado Denver Medical
Campus, USA

Be in 10 Years: From Asian Perspective
Nagahiro Saijo, Tokyo Medical University, Kinki University
School Medicine, Japan

Be in 10 Years: From European Perspective
Giorgio Vittorio Scagliotti, University of Torino, Italy
17:30 PL 04.04: WCLC 2018 – Welcome to Toronto

Andrea Bezjak, Princess Margaret Cancer Centre, Canada,
Gail Elizabeth Darling, University of Toronto, Canada,
Natasha B. Leighl, Princess Margaret Cancer Centre,
Canada,
Canada
NOTES
SECTION 8
POSTER
SESSIONS
Poster Session 1
Monday, October 16
At a Glance 124
In Detail 125
Poster Session 2
Tuesday, October 17
At a Glance 139
In Detail 140
Poster Session 3
At a Glance 154
In Detail 155
POSTER SESSIONS | MONDAY, OCTOBER 16
POSTERS AT A GLANCE
Monday, October 16 | Poster Session 1

P1.01 ADVANCED NSCLC P1.07 IMMUNOLOGY AND IMMUNOTHERAPY
P1.01-001 – P1.01-023 ALK P1.07-001 – P1.07-044a IMMUNOTHERAPY (BIOMARKERS)

P1.01-024 – P1.01-045 BIOMARKERS
P1.01-046 – P1.01-049 EGFR P1.08 LOCALLY ADVANCED NSCLC
P1.01-050 – P1.01-066 IMMUNOTHERAPY
P1.01-067 – P1.01-070 MISCELLANEOUS
P1.09 MESOTHELIOMA
P1.01-071 – P1.01-078a PRECLINICAL
P1.10 NURSING/PALLIATIVE CARE/ETHICS

P1.02 BIOLOGY/PATHOLOGY

P1.11 PATIENT ADVOCACY
P1.02-007 – P1.02-013 MISMATCH REPAIR AND
MUTATION LOADS
P1.02-014 – P1.02-039 MORPHOLOGY
P1.12 PULMONOLOGY/ENDOSCOPY
P1.02-040 – P1.02-059 OTHER MUTATIONS IN
THORACIC MALIGNANCIES P1.12-001 – P1.12-009 THERAPEUTIC ENDOSCOPY
P1.02-060 – P1.02-064 PROTEINS IN LUNG CANCER
AND PROTEOMICS
P1.13 RADIOLOGY/STAGING/SCREENING
P1.02-065 – P1.02-067 STEM CELLS IN LUNG CANCER
P1.02-068 – P1.02-071 TARGETS FOR TREATMENT P1.13-001 – P1.13-011 STAGING
PREDICTION
P1.14 RADIOTHERAPY
P1.03 CHEMOTHERAPY/TARGETED THERAPY
P1.03-001 – P1.03-013 ALK P1.15 SCLC/NEUROENDOCRINE TUMORS

P1.03-014 – P1.03-049 CHEMOTHERAPY
P1.16 SURGERY
P1.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS P1.16-001 – P1.16-028 MINIMAL INVASIVE SURGERY
P1.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/

P1.05 EARLY STAGE NSCLC OTHER THORACIC MALIGNANCIES
P1.05-001 – P1.05-012 MISCELLANEOUS P1.17-001 – P1.17-019 THYMOMA

P1.05-013 – P1.05-015 NEOADJUVANT AND
ADJUVANT CHEMOTHERAPY
P1.05-016 – P1.05-022a RECURRENCE
P1.06 EPIDEMIOLOGY/PRIMARY PREVENTION/

TOBACCO CONTROL AND CESSATION
P1.06-001 – P1.06-024 EPIDEMIOLOGY
MONDAY, OCTOBER 16 | POSTER SESSIONS
POSTERS IN DETAIL
Monday, October 16 | Poster Session 1

P1.01-006: Effect of EML-Alk Fusion Variant P1.01-016: Next-Generation Sequencing
and Fusion Abundance on the Efficacy of Shows Mechanisms of Intrinsic Resistance in
POSTER SETUP TIME Crizotinib in Non-Small Cell Lung Cancer ALK-Positive NSCLC Patients Treated with
Tang Feng Lv, Jinling Hospital, China Crizotinib
Ben J. Solomon, Peter MacCallum Cancer
Monday, October 16 08:00 – 10:00 P1.01-007: ALK Testing Trends and Patterns Centre, Australia
Among Community Practices in the United
States P1.01-017: ALK-Rearranged May Promote
POSTER TAKEDOWN TIME Peter B. Illei, Johns Hopkins University School VTE by Increasing the Expression of TF in
of Medicine, USA Advanced Lung Adenocarcinoma
Qiming Wang, Affiliated Cancer Hospital of
Monday, October 16 15:30 – 18:00 P1.01-008: Real-World Patient Characteris- Zhengzhou University, Henan Cancer Hospital,
tics, Testing and Treatment Patterns of ALK+ China
Posters not taken down by 18:00 NSCLC
will be discarded by management Matthew A. Gubens, University of California, P1.01-018: Acquired Resistance to Crizotinib
USA in Advanced NSCLC with De Novo MET
Overexpression
PRESENTERS IN ATTENDANCE P1.01-009: Clinically Primary and Sec- Anna Li, Guangdong Lung Cancer Institute,
AT THEIR POSTER ondary Resistance to ALK Inhibitors in Guangdong General Hospital & Guangdong
ALK-Positive Advanced Non-Small-Cell Lung Academy of Medical Sciences, China
10:00 – 10:45 and 14:30 – 15:30 Cancer
Jin Kang, Guangdong Lung Cancer Institute, P1.01-019: ALK+ Non-Small Cell Lung
Guangdong General Hospital & Guangdong Cancer Treated with First Line Crizotinib:
Academy of Medical Sciences, China Patient Characteristics, Treatment Patterns,
LOCATION: EXHIBIT HALL (HALL B + C)
and Survival
P1.01-010: Circulating Cell-Free DNA of Claudio Martín, Fleming Institute, Argentina
Cerebrospinal Fluid May Function as Liquid
Biopsy for Leptomeningeal Metastases of P1.01-020: Translocation ALK/EML4+ in
ALK Rearrangement NSCLC Non-Squamous NSCLC Population and
P1.01 ADVANCED NSCLC Yangsi Li, Guangdong Lung Cancer Institute, Crizotinib: What Can We Tell?
Guangdong Provincial Key Laboratory of Ana Barroso, Centro Hospitalar Vila Nova de
Translational Medicine in Lung Cancer, Guang- Gaia/Espinho, Portugal
P1.01-001 – P1.01-023 dong General Hospital & Guangdong Academy
ALK of Medical Sciences, China P1.01-021: FISH and IHC Discordance in ALK
Rearranged Non Small Cell Lung Cancer
P1.01-001: Depth of Target Lesion Response P1.01-011: Pattern of Care and Survival of Akhil Kapoor, Tata Memorial Hospital, India
to Brigatinib and Its Association With Out- ALK Rearranged Non-Small Cell Lung Can-
comes in Patients With ALK+ NSCLC in the cer in Two Australian Referral Centres P1.01-022: Prediction of Central Nervous
ALTA Trial Malinda Itchins, University of Sydney, Australia System Progression During Crizotinib Treat-
D. Ross Camidge, University of Colorado ment in ALK+ NSCLC Among Hispanics
Cancer Center, USA P1.01-012: Ceritinib in Anaplastic Lymphoma Andrés F. Cardona, Foundation for Clinical and
Kinase (ALK)+ NSCLC Patients Pretreated Applied Cancer Research - FICMAC, Colombia
P1.01-002: TP53 Mutations Predict for Poor With Only Crizotinib: ASCEND-1 Subgroup
Survival in ALK Rearrangement Lung Ade- Analysis P1.01-023: ALK-Positive NSCLC: A TMH
nocarcinoma Patients Treated with Crizotinib Alice Shaw, Massachusetts General Hospital, Experience
Gang Chen, Fujian Provincial Cancer Hospital, USA Vikas Talreja, Tata Memorial Hospital, India
China
P1.01-013: Patient-Reported Outcomes and
P1.01-003: Patients Harboring a Novel Safety from the Phase III ALUR Study of P1.01-024 – P1.01-045
PIK3CA Point Mutation after Acquired Resis- Alectinib vs Chemotherapy in Pre-Treated BIOMARKERS
tance to Crizotinib in ROS1 Rearrangement ALK+ NSCLC
Adenocarcinoma: A Case Report Julien Mazieres, Toulouse University Hospital,
P1.01-024: Plasma Circulating cfDNA as a
Wu Zhuang, Fujian Provincial Cancer Hospital, France
Potential Biomarker in Clinical Management
China of NSCLC: Experience of Tata Memorial
P1.01-014: Feasibility of Liquid Biopsy Using
Plasma and Platelets for Detection of ALK Hospital, India
P1.01-004: Hypertension With Brigatinib: Anuradha Choughule, Tata Memorial Hospital,
Experience in ALTA, a Randomized Phase 2 Rearrangements in Non-Small Cell Lung
Cancer India
Trial in Crizotinib-Refractory ALK+ NSCLC
D. Ross Camidge, University of Colorado Cheol-Kyu Park, Chonnam National University
P1.01-025: Biomarker Testing in Advanced
Cancer Center, USA Medical School, Hwasun Hospital, Korea
NSCLC: A Simulation-Based Assessment of
P1.01-015: Crizotinib in ROS1 Rearranged or Medical Oncologists
P1.01-005: Overall Survival (OS) After Tara Herrmann, Medscape Education, USA
Disease Progression (PD) on Brigatinib in MET Deregulated Non-Small-Cell Lung Can-
Patients With Crizotinib-Refractory ALK+ cer (NSCLC): Final Results of the METROS
P1.01-026: Circulating miR-206 in Advanced
NSCLC in ALTA Trial
Stage Lung Cancer Patients and Its Associa-
Corey J. Langer, Abramson Cancer Center, Lorenza Landi, OncoHematology Department,
tion with Cancer Cachexia
University of Pennsylvania, USA AUSL della Romagna, Italy
Noorwati Sutandyo, Dharmais National Cancer
Hospital, Indonesia
P1.01-027: Combination of Biomarker and P1.01-039: Survival Impact of Next-Genera- P1.01-049: Conformity of EGFR Mutation
Clinicopathologic Characters May Circle out tion Sequencing in Lung Cancer Status Between Blood Plasma and Tumor
Beneficiaries through Second-Line Immuno- Smadar Geva, Thoracic Cancer Service, Tissue Samples Among NSCLC Adenocarci-
therapy: A Meta Analyse Davidoff Cancer Center, Rabin Medical Center, noma Patients, at Dr. H. A. Rotinsulu Lung
Si-Yang Liu, Guangdong Lung Cancer Institute; Israel Hospital. A Preliminary Study
Guangdong General Hospita & Guangdong Reza Kurniawan Tanuwihardja, RS Paru Dr. H.
Academy of Medical Sciences, China P1.01-040: Clinical Utility of Plasma-Based A. Rotinsulu, Indonesia
NGS for Advanced-Stage NSCLC Patients
P1.01-028: Characteristics of Cell Free DNA with Insufficient or Unavailable Tumor
in Lung Cancer Patients Tissue P1.01-050 – P1.01-066
Tomonori Abe, Saga University, Japan Pilar Garrido, Hospital Universitario Ramón y IMMUNOTHERAPY
Cajal, Spain
P1.01-029: Lymphocyte Monocyte Ratio as
a Prognostic Factor in Non Small Cell Lung P1.01-041: Role of Re-Biopsy During Disease P1.01-050: Cost-Effectiveness of PDL1
Cancer Progression Non-Small Cell Lung Cancer for Based Test-And-Treat Strategy with Pem-
Tarkan Yetisyigit, Namik Kemal University Acquired Resistance Analysis and Directing brolizumab as the 1st Line Treatment for
Hospital, Turkey Oncology Treatments NSCLC in Hong Kong
Masatoshi Kakihana, Tokyo Medical University, Herbert H. Loong, The Chinese University of
P1.01-030: Predictive Biomarkers in Japan Hong Kong, Hong Kong
Non-SmallCell Carcinoma and Their Clinical
Association P1.01-042: Dynamic ctDNA Assay by Next P1.01-051: Nivolumab Versus Chemotherapy
Anurag Mehta, RGCI&RC, India Generation Sequencing to Guide Targeted as Post-Platinum Therapy for Advanced
Therapy in Advanced Non-Small Cell Lung Non-Small Cell Lung Cancer in a Real-world
P1.01-031: Utilization and Timing of Founda- Cancer Setting
tion Medicine (FMI) Testing in U.S. Advanced Xiaochun Zhang, The Affiliated Hospital of Edward Brian Garon, Santa Monica Hematol-
Non-Small Cell Lung Cancer (aNSCLC) Qingdao University, China ogy Oncology, USA
Patients
Lisa Wang, Genentech, Inc, USA P1.01-043: Molecular Testing for Non-Small P1.01-052: Patient-Reported Outcomes
Cell Lung Cancer in Latin American (PROs) in OAK: A Phase III Study of Atezoli-
P1.01-032: Detection of EGFR, ALK and Ana Caroline Zimmer Gelatti, Grupo Brasileiro zumab vs Docetaxel in Non-Small-Cell Lung
Other Driver Oncogenes from Plasma cfDNA de Oncologia Torácica - GBOT, Brazil Cancer (NSCLC)
by Single Molecule Amplification and Re-se- Rodolfo Bordoni, Georgia Cancer Specialists
quencing Technology (cSMART) P1.01-044: Detection of Circulating Tumor and Northside Hospital Cancer Institute, USA
Tony Mok, The Chinese University of Hong Cells Is Associated with Disease Burden in
Kong, Hong Kong Patients with Advanced Non-Small Cell Lung P1.01-053: Italian Nivolumab Expanded
Cancer Access Programme (EAP): Data from
P1.01-033: Thrombogenic Biomarkers in Kostas Syrigos, University of Athens, Greece Patients with Advanced Non-Squamous
Patients with NSCLC - Associations with NSCLC and Brain Metastases
Thrombosis, Progression, and Survival P1.01-045: Companion Diagnostic Tests for Lucio Crinò, Medical Oncology- Istituto Sci-
Marliese Alexander, Monash University, EGFR, ALK and ROS-1 vs NGS in Advanced entifico Romagnolo per lo Studio e la Cura dei
Australia NSCLC Patients - Which Is the Best in Terms Tumori (IRST) IRCCS, Italy
of Cost and Effective?
P1.01-034: Cerebrospinal Fluid and Plasma Luciene Schluckebier, Fundação do Câncer, P1.01-054: PD-L1 Expression in Patients
Tumor DNA Profiling Reveals Heterogeneity with Non-Small Cell Lung Cancer According
Brazil
of CNS Metastasis in Patients with Non- to Underlying Pulmonary Disease: A Retro-
Small-Cell Lung Cancer spective Study
Panwen Tian, Department of Pulmonary and Sayaka Ohara, NTT Medical Center Tokyo,
P1.01-046 – P1.01-049 Japan
Critical Care Medicine, West China Hospital,
EGFR
Sichuan University, China
P1.01-055: Spectrum of Early Progression
P1.01-035: A Next Generation Sequencing P1.01-046: The Feasibility of Osimertinib in Advanced NSCLC Patients Treated with
and Characteristics Based Model for Predict Treatment on Brain Metastases in NSCLC PD-1 Inhibitors: Identifying Markers for Poor
Clinical Benefit of Advanced NSCLC Patients Patients After 1st Generation EGFR-TKI Outcome
Yongchang Zhang, Hunan Cancer Hospital, Resistance: A Preliminary Study Mizuki Nishino, Dana-Farber Cancer Institute,
China Lucheng Zhu, Hangzhou First People’s Hospi- USA
tal, Nanjing Medical University, China
P1.01-036: Identifying and Addressing Gaps P1.01-056: Quality of Life and Clinical Out-
in Molecular Testing for Patients with Lung P1.01-047: Analysis of EGFR Mutation Status comes of Nivolumab as 2+ Line Treatment
Cancer in CSF and Blood in Lung Adenocarcinoma in Advanced Refractory NSCLC Pts: Interim
Jennifer C. King, Lung Cancer Alliance, USA Patients with EGFR Mutation and CNS Analysis
Metastasis Tatiana I. Ionova, Multinational Center for Qual-
P1.01-037: Circulating Tumor DNA Clearance Qiming Wang, Affiliated Cancer Hospital of ity of Life Research, Russia
During Treatment Associates with Improved Zhengzhou University, Henan Cancer Hospital,
Progression-Free Survival China P1.01-057: Nivolumab in Previously Treated
Shun Lu, Shanghai Chest Hospital, Shanghai Advanced Non-Small-Cell Lung Cancer
Jiao Tong University, China P1.01-048: Clinical Impact of EGFR Mutation (NSCLC)
on Brain Metastasis in NSCLC Patients: José Miguel Sánchez-Torres, Hospital Univer-
P1.01-038: Identification and Character- A Meta-Regression Analysis sitario de La Princesa, Spain
ization of Circulating Tumor Cells from Chien-Chung Lin, National Cheng Kung Univer-
Lung Cancer Patients for Selecting Target sity Hospital, Taiwan P1.01-058: Real World Data with Nivolumab:
Anticancer Drugs for Relapse Experience in Argentina
Bong-Seog Kim, Veterans Health Service Claudio Martin, Department of Clinical Oncol-
Medical Center, Korea ogy, Instituto Alexander Fleming, Argentina
P1.01-059: Combination Pembrolizumab and P1.01-071 – P1.01-078a P1.02-002: Diagnostic Utility of MUC4
Low Dose Weekly Carboplatin/Paclitaxel for PRECLINICAL Expression to Differentiate Epithelioid Meso-
Patients with Recurrent/Metastatic NSCLC thelioma from Lung Adenocarcinoma and
and PS of 2 P1.01-071: High Dose IVAA Synergy with Squamous Cell Carcinoma
Tamjeed Ahmed, Wake Forest Comprehensive mEHT in Patients with Stage III-IV NSCLC: A Vishwa Jeet Amatya, Graduate School of
Cancer Center, USA Phase I Study Biomedical & Health Sciences, Hiroshima
Junwen Ou, Clifford Hospital, China University, Japan
P1.01-060: Nivolumab after Progression to
Platinum- Based Chemotherapy in Advanced P1.01-072: Epithelial-To-Mesenchymal P1.02-003: Prevention of Adriamycin-in-
Non-Small-Cell Lung Cancer (NSCLC) Transition (EMT) in Lung Cancer: Classic duced Cardiac Damage by NAD-Modulation-
Mariana López Flores, Complejo Asistencial Reproduction Prevention of Adriamycin-induced Cardiac
Universitario de León, Spain Huibin Liu, Affiliated Tumor Hospital of Xinji- Damage by NAD-Modulation
ang Medical University, Urumqi, China Sei-Hoon Yang, Wonkwang University Hospi-
P1.01-061: The Efficacy and Safety of tal, Korea
Anti-PD-1 in the Treatment of Non-Small Cell P1.01-073: Over-Expression of GGPPs Con-
Lung Cancer (NSCLC): Systematic Review tributes to Tumor Metastasis and Correlates P1.02-004: Long Non-Coding RNA
Mingyi Di, Peking Union Medical College with Poor Prognosis of Lung Adenocarci- XLOC_000090 Promotes Lung Cancer
Hospital, China noma Migration Through Modulation of miR-4505
Yong Song, Jinling Hospital, China Bin Zhang, Tianjin Medical University Cancer
P1.01-062: KRAS Mutations (KRAS-Mut) Institute and Hospital, China
and antiPD1/PDL1 Therapy in a Cohort of P1.01-074: Exosomal RNA-Profiling of Lung
Lung Cancer (LC) Patients (P). Experience Pleural Effusions Identifies Adenocarci- P1.02-005: Solving the Interfering Problem
from a Single Institution noma Patients through Elevated miR-200 of Tissue Embedding OCT Compound in
Enric Carcereny, Catalan Institute of Oncolo- Expression Activity Based Multiplex Profiling of Tyrosine
gy-Hospital Germans Trias i Pujol, Spain Per Hydbring, Karolinska Institutet, Sweden Kinase Substrates
Sven Hillinger, University Hospital, Switzerland
P1.01-063: Are the Real World Patients with P1.01-075: Simultaneous Multiplex Profiling
Advanced Non-Small Cell Lung Cancer Rep- of Gene Fusions, METe14 Mutations and P1.02-006: Arsenic Promotes Persistent
resented in Phase III Immunotherapy Trials? Immune Genes in Advanced NSCLC by Alterations in the Lung PiRNA Transcriptome
Ana Caroline Zimmer Gelatti, Grupo Brasileiro NCounter Technology to Target Epigenetic Pathways
de Oncologia Toracica (GBOT), Brazil Noemi Reguart, Hospital Clinic, Translational Victor D. Martinez, BC Cancer Research
Genomics and Targeted Therapeutics in Solid Centre, Canada
P1.01-064: Efficacy and Tolerability of Tumors, Institut d’Investigacions Biomèdiques
Nivolumab in Elderly Patients with Advanced August Pi i Sunyer (IDIBAPS), Spain
Non-Small Cell Lung Cancer P1.02-007 – P1.02-013
Kohei Yamane, Tottori University Hospital, P1.01-076: Comparison of PANA Mutyper MISMATCH REPAIR AND MUTATION
Japan and PNA Clamping for Detecting KRAS LOADS
Mutations in Tumor Tissue, Cell Block and
P1.01-065: Treatment Beyond Progression Pleural Effusion from Cancer
with Nivolumab in Patients with Advanced P1.02-007: TP53 and DNA-Repair Gene
Chan Kwon Park, The Catholic University of Polymorphisms as Risk Factors for the
Non-Squamous NSCLC: Results from the Korea, Korea
Italian Expanded Access Program Development of Advanced Lung Adenocarci-
Enrico Cortesi, Policlinico Umberto I, Italy noma in Serbia
P1.01-077: Oncogenic Potential of a Novel
Jelena Spasic, Institute for Oncology and
HER2 755PL In-Frame (HER2PL) Mutation
P1.01-066: PDL-1 Expression of Tumor Cell, Radiology of Serbia, Serbia
in Lung Adenocarcinoma
Macrophage, and Immune Cells on Pleural Anya Maan-Yuh Lin, Institute of Pharmacology,
Effusion P1.02-008: Expression of Mismatch Repair
National Yang-Ming University, Taiwan Proteins Associates with Survival and
Yen-Han Tseng, Taipei Veterans General
Hospital, Taiwan Response to EGFR Tyrosine Kinase Inhibitors
P1.01-078: Longitudinal Studies of Quality of
in Lung Adenocarcinoma Patients
Life in Advanced Non-Small Cell Lung Can-
Hsiang-Ling Ho, Taipei Veterans General
cer Patients Undergoing First-Line Target
Hospital, Taiwan
P1.01-067 – P1.01-070 Therapy
MISCELLANEOUS Lin Zhi Xuan, Chi Mei Medical Center, Liouying, P1.02-009: Accumulation of Mutations in
Taiwan Background Normal Lung Tissue Constitutes
P1.01-067: Characteristics and Survival Rate a Major Lung Cancer Risk
of Non-Small Cell Lung Cancer in Patients P1.01-078a: The Construction and Clinical
Emi Kubo, National Cancer Center Japan,
45 Years of Age or Younger Application of an Integrated Microfluidic
Japan
Noorwati Sutandyo, Dharmais National Cancer Device for CTCs Detection in Patients with
Hospital, Indonesia NSCLC P1.02-010: Novel Role of hSSB2 in the Base
Qi Wang, The Second Affiliated Hospital, Excision Repair Pathway (BER)
P1.01-068: Impact of Case-Based CME on Dalian Medical University, China Mark Adams, Queensland University of Tech-
Physician Performance in the Diagnosis and nology, Australia
Management of NSCLC
Elaine Hamarstrom, Medscape Education, USA P1.02-011: XRCC6BP1: A Key Player in the
DNA Repair of Cisplatin Resistant NSCLC
P1.01-069: Clinical Experience with IBM Cells
Watson for Oncology (WFO) Cognitive Sys- P1.02-001 – P1.02-006 Martin P. Barr, St. James’s Hospital & Trinity
tem for Lung Cancer Treatment in China MISCELLANEOUS College Dublin, Ireland
Xiaochun Zhang, The Affiliated Hospital of
Qingdao University, China P1.02-012: Profiling DNA Repair in Lung
P1.02-001: SLFN11 Expression in Early
Cancer
P1.01-070: BIW-8962, an Anti-GM2 Gangli- Stage Non-Small Cell Lung Cancer Predicts
Alexander Dobrovic, Olivia Newton-John
oside Monoclonal Antibody, in Advanced/ Benefit from Adjuvant Chemotherapy with
Cancer Research Institute, Australia
Recurrent Lung Cancer: A Phase I/II Study Taxane and Platinum
Joo-Hang Kim, Yonsei Cancer Center, Korea Vamsidhar Velcheti, Cleveland Clinic, USA
P1.02-013: ATM Mutation as a Predictor for P1.02-025: A Case of Primary Peripheral P1.02-037: Pulmonary Carcinoid Tumors:
Mutation Burden in NSCLC Epithelial–Myoepithelial Carcinoma of the A Prognostic Implications of Ki-67 Prolifer-
D. Gwyn Bebb, University of Calgary, Canada Lung ative Index
Daisuke Eriguchi, Tokyo Medical University Renata Langfort, National Institute of Tubercu-
Hachioji Medical Center, Japan losis and Lung Diseases, Poland
P1.02-014 – P1.02-039
MORPHOLOGY P1.02-026: The Characteristics of Lymph P1.02-038: Bilateral Combined Lymphan-
Node Metastasis in Resected Adenosqua- gioleiomyomatosis and Diffuse Idiopathic
mous Lung Cancer Pulmonary Neuroendocrine Cell Hyperplasia
P1.02-014: TGFalpha Promotes Growth of Xiuyu Cai, State Key Laboratory of Oncology with Typical Carcinoids
Lung Tumors Carrying EGFR Mutation but in South China, Sun Yat-sen University Cancer Jan Hinrich Von Der Thüsen, Erasmus MC,
not KRAS Mutation in Transgenic Mouse Netherlands
Center, China
Models in Vivo
Koichi Tomoshige, Cincinnati Children’s Hospi- P1.02-027: Minute Pulmonary Meningo- P1.02-039: Main Bronchus Location Is a
tal Medical Center, USA thelial-Like Nodules Presenting as Multiple Predictor for Metastasis and Prognosis in
Ground-Glass Density Nodules (GGNs): A Lung Adenocarcinoma: A Large North Amer-
P1.02-015: Comparison of Study Models of Case Report ican Cohort Analysis
Lung Cancer Yeon Bi Han, Department of Pathology Seoul Lin Yang, National Cancer Center/Cancer Hos-
Yoshito Yamada, University Hospital Zurich, National University Bundang Hospital, Korea pital,Chinese Academy of Medical Sciences,
Switzerland China
P1.02-028: Pathways Involved in Early Stage
P1.02-016: Establishment of Lung Adenocar- Lung Cancers
cinoma Organoid Cultures Vilde D. Haakensen, Oslo University Hospital,
Hirotsugu Notsuda, University Health Network, P1.02-040 – P1.02-059
Norway OTHER MUTATIONS IN
Canada
P1.02-029: Pulmonary Adenofibroma with THORACIC MALIGNANCIES
P1.02-017: Freely Floating Cancer Cells in Cystic Change: A Case Report
Lymph Node Sinuses of Hilar Lymph Node Eunhyang Park, Seoul National University P1.02-040: Genetic Risk Evaluation in Fam-
Positive Lung Cancer Patients Bundang Hospital, Korea ilies with Lung Cancer History in High Lung
Yusuke Nakamura, Tokai University Hachioji Cancer Mortality Region of Xuanwei, China
Hospital, Japan P1.02-030: The Effect of Chronic Obstruc- Madiha Kanwal, Kunming Institute of Zoology,
tive Pulmonary Disease on the Tumor Chinese Academy of Sciences, China
P1.02-018: Number of Cancer Cells in Lung Stroma in Non-Small Cell Lung Cancer
Adenocarcinoma Specimen - Correlation Yasuhiko Ohshio, Shiga University of Medical P1.02-041: Mutation of SWI/SNF Complex
with Noguchi’s Classification, WHO Patho- Genes Is Frequent in Poorly Differentiated,
Science, Japan
logic Type, and Prognosis Mesenchymal-Like Lung Cancer without
Takashi Inoue, Dokkyo Medical University, P1.02-031: Clinicopathological Study of 16 Major Driver Mutation
Japan Cases with Pulmonary Pleomorphic Carci- Taichiro Yoshimoto, Jichi Medical University,
noma Japan
P1.02-019: Dual Role of Notch in Lung Fumi Ohsawa, Maebashi Red Cross Hospital,
Cancer Japan P1.02-042: Circadian Clock Gene Per2
Sara Sinicropi-Yao, The Ohio State University, Over-Expression Inhibits Tumor Progression
USA P1.02-032: Clinicopathological Profile of in Human Non-Small Cell Lung Cancer
Invasive Mucinous Adenocarcinoma Based Li Qiang, Sichuan Cancer Hospital-Institute,Si-
P1.02-020: Acinar-Predominant Pattern on Evaluation of Invasive Components chuan Cancer Center, School of Medicine, Uni-
Correlates with Poorer Prognosis in Invasive Yuichi Mitsui, Osaka General Medical Center, versity of Electronic Science and Technology
Mucinous Adenocarcinoma of the Lung Japan of China, China
Gengpeng Lin, The First Affiliated Hospital of
Sun Yat-sen University, China P1.02-033: Differentiating of Cytomorpho- P1.02-043: A Comparison of Consistency of
logical Characteristics in Non-Small Cell Detecting BRAF Gene Mutations in Periph-
P1.02-021: Can 18F-FDG PET/CT Predict Lung Cancer Predicts Value of Radiologic eral Blood and Tumor Tissue of Non-Small-
the Pathological Necrosis and Microvessel Features Cell Lung Cancer Patients
Density in Lung Adenocarcinomas Ryota Tanaka, Kyorin University School of Gang Chen, Fujian Provincial Cancer Hospital,
Young Wha Koh, Ajou University School of Medicine, Japan China
Medicine, Korea
P1.02-034: Non-Invasive Qualitative Diag- P1.02-044: Relationship between RET
P1.02-022: Spontaneous Regression of nosis of Lung Cancer Enabled by Spectrum Rearrangement and Thymidylate Synthase
Primary Pulmonary Synovial Sarcoma; A Analysis of Ultrasound mRNA Expression in Non-Small Cell Lung
Case Report Takashi Anayama, Kochi Medical School, Kochi Cancer Tissues
Naoko Miyata, Kyoto Prefectural University of University, Japan Gang Chen, Fujian Provincial Cancer Hospital,
Medicine, Japan China
P1.02-035: Human Papillomavirus Infec-
P1.02-023: TGF-β Signaling Mediated by tion in Lung Squamous Cell Carcinoma and P1.02-045: PIK3CA Mutations in Chinese
Fibroblasts is Associated with the Histologi- Correlation to p16 INK4a Expression from an Patients with Non-Small-Cell Lung Cancer
cal Subtypes of Lung Adenocarcinoma Argentine Population Meiyu Fang, Zhejiang Cancer Hospital, China
Ryo Sato, Keio University, Japan Valeria Cecilia Denninghoff, Centro de
Educación Médica e Investigaciones Clínicas P1.02-046: Mutational Subtypes and
P1.02-024: Correlation of Maximal Tumor Prognosis of Non-Small-Cell Lung Cancer
(CEMIC-CONICET), Argentina
Diameter between Pathology Specimen and Harboring HER2 Mutations
CT in Nonsmall Cell Lung Cancer: A Pilot P1.02-036: Fine Needle Aspiration as a Gang Chen, Fujian Provincial Cancer Hospital,
Study Diagnostic Tool in Lung Cancer: Worth China
Heae Surng Park, Gangnam Severance Hos- Pursuing?
pital, Korea Luiz H. Araujo, Instituto Nacional de Câncer P1.02-047: Mutational Features and Progno-
(INCA), Brazil sis of Non-Small-Cell Lung Cancer Harboring
RAS Mutations
Meiyu Fang, Zhejiang Cancer Hospital, China
P1.02-048: Somatic Mutation Analysis of P1.02-060 – P1.02-064 P1.02-069: Pemetrexed-Resistant Non-Small

RB1 Gene in Chinese Non-Small Cell Lung PROTEINS IN LUNG CANCER Cell Lung Cancer Cell Lines Have Novel
Cancer Patients AND PROTEOMICS Drug-Resistant Mechanisms
Meiyu Fang, Zhejiang Cancer Hospital, China Ryosuke Tanino, Shimane University, Japan
P1.02-060: Podoplanin Expression in
P1.02-049: Detection of CDKN2A Gene P1.02-070: Identification of Lung Cancer
Cancer-associated Fibroblasts Predicts Poor
Mutations in Patients with Non-Small Cell Specific Differentially Methylated Regions
Prognosis in Patients with Squamous Cell
Lung Cancer Patients Using Genome-Wide DNA Methylation Study
Carcinoma of the Lung
Meiyu Fang, Zhejiang Cancer Hospital, China Yoonki Hong, Kangwon National University
Yohei Yurugi, Tottori University, Faculty of
Hospital, Korea
P1.02-050: Pan-Can Analysis of miRNAs Medicine, Japan
at the Imprinted Chromosome 14q32 Locus P1.02-071: SFN Stabilizes Oncopro-
P1.02-061: Podoplanin Expression in Can-
Reveals a Unique Pattern of Deregulation in teins through Binding with SKP1 to Block
cer-Associated Fibroblasts Predicts Unfa-
NSCLC SCFFBW7 Ubiquiting Ligase
vourable Prognosis in Patients with Stage IA
Jhon Ralph Enterina, British Columbia Cancer Jeongmin Hong, University of Tsukuba, Japan
Adenocarcinoma
Research Centre, Canada
Yasuaki Kubouchi, Tottori University, Faculty of
P1.02-051: Ultra-Deep Sequencing Depicts Medicine, Japan
the Genomic Landscape of Ground-Glass P1.03 CHEMOTHERAPY/TARGETED
P1.02-062: Ring Finger Protein 38 Promote
Nodules in Early Stage Lung Adenocarci- THERAPY
Non-Small Cell Lung Cancer Progression by
noma
Endowing Cell EMT Phenotype
Hongwei Duan, Beijing Institute of Genomics,
Jian-Yong Ding, Zhongshan Hospital, Fudan P1.03-001 – P1.03-013
Chinese Academy of Sciences, University of
University, China ALK
Chinese Academy of Sciences, China
P1.02-063: Tumor Heterogeneity Analyses
P1.02-052: Identification of DAB2 and P1.03-001: Verification and Implementation
by Integrated Proteo-Genomics of Thoracic
Intelectin-1 as Novel Positive Immunohisto- of the VENTANA Anti-ALK D5F3 Antibody in
Tumors from Sequential Biopsies and Warm
chemical Markers of Epithelioid Mesotheli- Detecting ALK Rearrangement in NSCLC
Autopsies
oma Haider Al-Najjar, Central Manchester Univer-
Udayan Guha, Thoracic and Gastrointestinal
Masatsugu Kuraoka, Hiroshima University sity Hospitals NHS Foundation Trust, UK
Oncology Branch, Center for Cancer Research,
Graduate School of Biomedical and Health
NCI, NIH, USA
Sciences, Japan P1.03-002: Crizotinib-Associated Toxic
P1.02-064: Proteomic Analysis of Exosome Epidermal Necrolysis in an ALK-Positive
P1.02-053: A New Strategy of Adjuvant Advanced NSCLC Patient
Purified Using a Novel Reagent
Chemotherapy for Lung Cancer Based on the Shaoyu Yang, Hangzhou First People’s Hospi-
Ayako Kurimoto, Fujirebio Inc., Japan
Expression of Anti-Aging Gene Klotho tal, China
Kyoshiro Takegahara, Nippon Medical School
Hospital, Japan P1.03-003: Clinical Implications of an Analy-
P1.02-065 – P1.02-067 sis of Crizotinib Pharmacokinetics Co-Ad-
P1.02-054: The Molecular Characterisation STEM CELLS IN LUNG CANCER ministered with Dexamethasone in Patients
of Lung Adenocarcinoma Subgroups with NSCLC
Elizabeth Starren, Imperial College London P1.02-065: Histone Deacetylase Inhibition Swan Lin, University of California, San Diego,
and the Royal Brompton and Harefield NHS Alters Stem Cell Phenotype in Gefitinib-Re- USA
Trust, UK sistant Lung Cancer Cells with EGFR
Mutation P1.03-004: Alectinib for Patients with ALK
P1.02-055: Genotyping Squamous Cell Lung Fariz Nurwidya, Universitas Indonesia, Indo- Rearrangement–Positive Non–Small Cell
Carcinoma Among Hispanics (Geno1.1-CLI- nesia Lung Cancer and a Poor Performance Status
CaP) Hirotsugu Kenmotsu, Shizuoka Cancer Center,
Andrés F. Cardona, Foundation for Clinical and P1.02-066: Cancer Stem Cells in Pulmonary Japan
Applied Cancer Research - FICMAC, Colombia High Grade Neuroendocrine Carcinoma: a
Series of 23 Cases from Eastern India P1.03-005: Phase 2 Study of Ceritinib in
P1.02-056: BRAF Non-V600E Mutations Prasanta Raghab Mohapatra, All India Institute Patients with ALK+ NSCLC with Prior Alec-
Recurrently Found in Non-Small Cell Lung of Medical Sciences, India tinib Treatment in Japan: ASCEND-9
Cancer in Chinese Patients Hidehito Horinouchi, National Cancer Center
Meiyu Fang, Zhejiang Cancer Hospital, China P1.02-067: FGF1 and IGF1 Co-Stimulation Hospital, Japan
Promoted the Amplification and Cancer
P1.02-057: Analysis of C-MET Amplification Stemness of Lung Cancer Cells under 3D P1.03-006: Clinicopathological Features
Non-Small Cell Lung Cancer Cell Blocks Culture Condition and Poor Outcome for ALK Inhibitors of
from Pleural Effusion Rui Zhang, Tianjin Medical University Cancer Squamous Cell Lung Cancer with ALK-Rear-
Gang Chen, Fujian Provincial Cancer Hospital, Institute & Hospital, China rangement
China Hiroaki Motomura, Juntendo University
Faculty of Medicine & Graduate School of
P1.02-058: Molecular Characteristics and Medicine, Japan
P1.02-068 – P1.02-071
Outcome of Chinese Patients with Non-
Small Cell Lung Cancer Harboring NFE2L2 TARGETS FOR TREATMENT
P1.03-007: A Real-World Study of Clinico-
Mutations PREDICTION pathological Characteristics and Survival
Gang Chen, Fujian Provincial Cancer Hospital, Outcome in Advanced ALK-Positive Non-
China P1.02-068: Effects of Pirfenidone Targeting Small-Cell Lung Cancer
EMT and Tumor-Stroma Interaction as Novel Xiao Hu, Zhejiang Cancer Hospital, China
P1.02-059: Molecular Characteristics of Treatment for Non-Small Cell Lung Cancer
SMARCA4 Mutations Detection in Chinese Ayako Fujiwara, Osaka National Hospital, P1.03-008: Analysis of Data on Interstitial
Non-Small Cell Lung Cancer Patients Japan Lung Disease Onset and Its Risk Following
Gang Chen, Fujian Provincial Cancer Hospital, Treatment of ALK-positive NSCLC with
China Xalkori
Akihiko Gemma, Graduate School of Medicine,
Nippon Medical School, Japan
P1.03-009: A Lung Adenocarcinoma with P1.03-020: Detection of Hypoxia Using EF5 P1.03-031: Adherence and Feasibility of
a STRN-ALK Rearrangement Was Poorly PET/CT in 10 Patients with Advanced NSCLC 2 Treatment Schedules of S-1 as Adjuvant
Responsive to Alectinib Treatment Receiving Chemotherapy with and without Chemotherapy in Completely Resected Lung
Yuko Iida, Division of Respiratory Medicine, Bevacizumab Cancer
Department of Internal Medicine, Nihon Uni- Frederic Lacroix-Poisson, BC Cancer Agency, Takaharu Kiribayashi, Division of Chest
versity School of Medicine, Japan Canada Surgery (Ohashi), Toho University School of
Medicine, Japan
P1.03-010: Efficacy and Safety of Anaplastic P1.03-021: A Prospective Observational
Lymphoma Kinase (ALK) Tyrosine Kinase Study to Evaluate Incidence of Thromboem- P1.03-032: Observation of Durative Infusion
Inhibitors in ALK-Positive Non-Small Cell bolic Events during Platinum Based Chemo- Endostar Combined with Chemotherapy
Lung Cancer therapy in Lung Cancer Within Vascular Normalization Period in
Reina Imase, Hiratsuka Kyosai Hospital, Japan Vikas Talreja, Tata Memorial Hospital, India Advanced NSCLC
Jia Chen, Jiangsu Cancer Hospital, China
P1.03-011: Clinical Outcomes Correlated P1.03-022: A Phase 1B Study of TRC105
with Percentage of Positive Anaplastic-Lym- in Combination with Paclitaxel/Carboplatin P1.03-033: Long-Term Outcome of Histocul-
phoma Kinase Cells Tested by FISH Analysis and Bevacizumab in Patients with Stage 4 ture Drug Response Assay Guided Adjuvant
in NSCLC. Non-Squamous Cell Lung Cancer Chemotherapy in Patients with Non-Small
Katy Louise Clarke, Leeds Cancer Centre, UK Francisco Robert, University of Alabama - Cell Lung Cancer
Birmingham, USA Yoshimitsu Hirai, Wakayama Medical Univer-
P1.03-012: Using Computational Modeling to sity, Japan
Simulate Clinical Response of ALK Inhibitors P1.03-023: The Real-World Practice of
to G1202R ALK and Possible Mechanisms of Bevacizumab Plus Chemotherapy in Stage P1.03-034: Therapeutic Effect of Novel
Resistance IV Lung Adenocarcinoma: A Single Institute Leucyl-tRNA Synthetase Inhibitor, B1206, in
Chien-Ting Liu, Kaohsiung Chang Gung Memo- Experience Non-Small Cell Lung Cancer
rial Hospital, Taiwan Yen-Hao Chen, Kaohsiung Chang Gung Memo- Eun Young Kim, Yonsei University College of
rial Hospital, Taiwan Medicine, Korea
P1.03-013: Monitoring of ALK Fusions and
Mutations in Advanced ALK Positive Non- P1.03-024: Efficacy of Carboplatin-Vinorel- P1.03-035: Efficacy of Nintedanib and
Small Cell Lung Cancer (NSCLC) Patients bine in Advanced NSCLC Patients at Persa- Docetaxel in Combination with the Nutraceu-
Laura Mezquita, Gustave Roussy, France habatan Hospital, Jakarta - Indonesia tical Use of Silibinin in Advanced NSCLC
Putu Ayu Diah, Department of Pulmonology Joaquim Bosch Barrera, Catalan Institute
and Respiratory Medicine, Indonesia of Oncology. Hospital Universitari Dr. Josep
P1.03-014 – P1.03-049 Trueta, Spain
CHEMOTHERAPY P1.03-025: Combination Therapy with
Carboplatin and Hyperoxia Synergistically P1.03-036: Adjuvant Chemotherapy with
Enhances Suppression of Benzo[a]Pyrene Uracil-Tegafur for Pathological T1aN0M0
P1.03-014: Saline Alone vs Saline plus Man- Induced Lung Cancer Lung Adenocarcinoma with Lymphatic
nitol Hydration for the Prevention of Acute Sang Haak Lee, St. Paul’s Hospital, Catholic Vessel Invasion
Cisplatin Nephrotoxicity: A Randomized Trial University of Korea, Korea Yoshitaka Kitamura, Hyogo Cancer Center,
Wilfred Dela Cruz, San Antonio Military Medi- Japan
cal Center, USA P1.03-026: Interim Results of a Phase I
Study of Nivolumab plus Nab-Paclitaxel/Car- P1.03-037: A Phase II Study of Adjuvant
P1.03-015: The Relationship between the boplatin in Patients with NSCLC Chemotherapy with Docetaxel plus Nedapla-
UGT1A1*27 and UGT1A1*7 Genetic Polymor- Jonathan W. Goldman, University of California tin for Completely Resected Non-Small Cell
phisms and Irinotecan-Related Toxicities in at Los Angeles, USA Lung Cancer
Patients with Lung Cancer Koji Teramoto, Shiga University of Medical
Minoru Fukuda, Nagasaki University Hospital, P1.03-027: Randomized Phase 2 Study Science, Japan
Japan Comparing CBDCA+PTX+BEV and
CDDP+PEM+BEV in Treatment-Naïve P1.03-038: A Phase I Trial of Afatinib and
P1.03-016: Video-Thoracoscopic Pulmo- Advanced Non-Sq NSCLC (CLEAR Study) Bevacizumab in Untreated Patients with
nary Resection Avoids Delay and Increase Shinji Atagi, National Hospital Organization Advanced NSCLC Harboring EGFR-Muta-
Adjuvant Chemotherapy Compliance for Kinki-chuo Chest Medical Center, Japan tions: OLCSG1404
Non-Small Cell Lung Carcinoma Shoichi Kuyama, NHO Iwakuni Clinical Center,
AkIn Ozturk, Sureyyapasa Thoracic Diseases P1.03-028: A Phase II Trial of Albu- Japan
and Thoracic Surgery Training and Research min-Bound Paclitaxel and Gemcitabine in
Hospital, Turkey Patients with Untreated Stage IV Squamous P1.03-039: Therapeutic Inhibition of the
Cell Lung Cancers Cancer Stem Cell Marker, ALDH1, a Promis-
P1.03-017: Benzyl Isothiocyanate Induces Paul K. Paik, Memorial Sloan Kettering Cancer ing Mechanism by Which Cisplatin Sensitiv-
Protective Autophagy in Human Lung Can- Center, USA ity Can Be Restored in NSCLC
cer Cells through Endoplasmic Reticulum Martin P. Barr, St. James’s Hospital & Trinity
Stress-Mediated Mechanism P1.03-029: Study of Plasma Homocysteine College Dublin, Ireland
Ke Xu, Tianjin Medical University General as a Marker of Toxicity and Depression in
Hospital, China Patients Treated with Pemetrexed-Based P1.03-040: Smokers Having Activating
Chemotherapy EGFR Mutant Non-Small Cell Lung Cancer
P1.03-018: Effectiveness of Supportive Care Mary O’Brien, Royal Marsden Hospital NHS Might Benefit from EGFR-TKI Treatment -
Drugs in Lung Cancer Patients Undergoing Foundation Trust, UK Single Center Experience
1st Line Chemotherapy in a Resource Limited Perran Fulden Yumuk, Marmara University
Setting P1.03-030: Prognostic Impact of the Pres- Medical School, Marmara University Pendik
Digambar Behera, Postgraduate Institute of Medi- ence of COPD in Patients with NSCLC under Training & Research Hospital, Turkey
cal Education and Research (PGIMER), India Conventional Systemic Chemotherapy
Jin Woo Kim, Uijeongbu St. Mary’s Hospital, P1.03-041: Exploitation of the Cancer Stem
P1.03-019: Sophoridine Inhibits Lung Cancer Catholic University of Korea, Korea Cell Marker ALDH1 Within the Vitamin a/
Cell Proliferation through Activating Hippo Retinoic Acid Axis Promotes Re-Sensitisa-
Signaling and P53 Pathway tion of Cisplatin Resistant NSCLC
Jiangping Xiong, The First Affiliated Hospital Martin P. Barr, St. James’s Hospital & Trinity
of Nanchang University, China College Dublin, Ireland
P1.03-042: BBI608, a Small Molecule P1.03-053: Taiwan Real Word Efficacy of 1st P1.04-010: CheckMate 870: An Open-label
Stemness Inhibitor, Circumvents Cisplatin Line EGFR TKIs Treatment in EGFR Mutation Safety Study of Nivolumab in Previously
Resistance in NSCLC Positive Advanced Non Small Cell Lung Treated Patients With Non-Small Cell Lung
Martin P. Barr, St. James’s Hospital & Trinity Cancer Cancer in Asia
College Dublin, Ireland Chih-Yen Tu, China Medical University, Taiwan Shun Lu, Shanghai Lung Cancer Center,
Shanghai Chest Hospital, Shanghai Jiao Tong
P1.03-043: 30-Day Mortality Following University, China
Systemic Anti-Cancer Treatment for NSCLC
at a Single Canadian Cancer Centre P1.04 CLINICAL DESIGN, STATISTICS P1.04-011: Development of Novel Blood-
Gwyn Bebb, Alberta Health Services, Canada AND CLINICAL TRIALS Based Biomarker Assays in 1L Advanced/
Metastatic NSCLC: Blood First Assay
P1.03-044: Exploratory Analysis of Lung Screening Trial (BFAST)
Cancer Patients in a Phase Ib/II Trial of P1.04-001: Osimertinib with Ramucirumab
Tony Mok, Chinese University of Hong Kong,
NC-6004 (Nanoparticle Cisplatin) plus or Necitumumab in Advanced T790M-posi-
Hong Kong
Gemcitabine tive EGFR-Mutant NSCLC: Preliminary Ph1
Lyudmila Bazhenova, University of California Study Results P1.04-012: A Phase 1b Dose-Escalation
San Diego, Moores Cancer Center, USA Helena Yu, Memorial Sloan Kettering Cancer Study of TRC105 in Combination with
Center, USA Nivolumab in Patients with Metastatic Non-
P1.03-045: HER-2 Mutation Is Not a Small Cell Lung Cancer
Prognostic Factor Treated with First-Line P1.04-002: Tolerability of Osimertinib and
Francisco Robert, University of Alabama -
Chemotherapy in NSCLC Patients Its Impact on Quality of Life in Advanced
Birmingham, USA
Tao Jiang, Department of Medical Oncology, Non-Small Cell Lung Cancer Patients: The
Shanghai Pulmonary Hospital, Tongji Univer- ARPA Study P1.04-013: Phase 1b Multi-Indication Study
sity School of Medicine, China Enrica Capelletto, Department of Oncology, of the Antibody Drug Conjugate Anetumab
University of Turin, Italy Ravtansine in Patients with Mesothelin-Ex-
P1.03-046: A Retrospective Analysis of pressing Advanced or Recurrent Malignan-
Correlation Between Cytokines in TME and P1.04-003: The International Lung Screen
cies
Therapeutic Effect of Advanced Lung Cancer Trial: A Multi-Centre Study to Evaluate LDCT
Alex Adjei, Mayo Clinic, USA
Chemotherapy in China Screening Selection Criteria and Nodule
Chunxia Su, Shanghai Pulmonary Hospital, Management
Tongji University School of Medicine, Tongji Kuan Pin Lim, Sir Charles Gairdner Hospital,
University Cancer Institute, China Australia P1.05 EARLY STAGE NSCLC
P1.03-047: Carboplatin/ Weekly Nab-PTX in P1.04-004: Phase I/Ib Study of Nivolumab

Elderly Patients with Previously Untreated and Veliparib in Advanced Solid Tumors and P1.05-001 – P1.05-012
Advanced Squamous NSCLC Selected Based Lymphoma with and without Alterations in MISCELLANEOUS
on MNA-SF Selected DNA Repair Genes
So Takata, Osaka Habikino Medical Center, Wade Thomas Iams, McGaw Medical Center of P1.05-001: Microwave Ablation plus Recom-
Japan Northwestern University, USA binant Human Endostatin (Endostar) versus
Microwave Ablation Alone in Inoperable
P1.03-048: miR-34a and the Micromanage- P1.04-005: Phase 2 Study of Nivolumab and Stage I Non Small Cell Lung Cancer
ment of Cancer Stemness and Resistance in Metformin in Advanced Non-Small Cell Lung Guanghui Huang, Shandong Provincial Hospi-
Cancer with and without Prior Treatment
NSCLC. Does It Hold Therapeutic Benefit? tal Affiliated to Shandong University, China
with PD-1/PD-L1 Inhibitors
Martin P. Barr, St. James’s Hospital & Trinity
Wade Thomas Iams, McGaw Medical Center of P1.05-002: Characteristics and Prognosis
College Dublin, Ireland
Northwestern University, USA of Ground Glass Opacity Predominant Pri-
P1.03-049: Phase II Study of S-1 plus Bev- mary Lung Cancer Larger Than 3.0 Cm on
acizumab Combination Therapy for Patients P1.04-006: Rovalpituzumab Tesirine vs Thin-Section Computed Tomography
Previously Treated for Non-Squamous Non– Topotecan in Patients with Advanced Small Shigeki Suzuki, National Cancer Center Hos-
Cell Lung Cancer Following 1st Line Chemo-
Small Cell Lung Cancer pital, Japan
therapy
Kentaro Masuhiro, Osaka Habikino Medical
Philip Komarnitsky, AbbVie Inc., USA P1.05-003: Impact of Coexisting Pulmo-
Center, Japan
nary Diseases on Oncological Outcomes of
P1.04-007: Rovalpituzumab Tesirine Patients with pStage I Non-Small Cell Lung
Maintenance Therapy Following 1st Line Cancer
P1.03-050 – P1.03-053 Platinum-Based Chemotherapy Small Cell
Hiroyuki Tao, Yamaguchi Ube Medical Center,
MISCELLANEOUS Lung Cancer
Japan
Philip Komarnitsky, AbbVie Inc., USA
P1.03-050: Clinical Consequences, Quality P1.05-004: Adenocarcinoma Subtyping of
of Life, and Management of Neutropenic P1.04-008: POSEIDON: A Phase 3 Study
Early Stage Lung Cancer in a Danish Cohort
NSCLC Patients in the REVEL Trial of First-Line Durvalumab ± Tremelimumab
Petrine laier Sonne, Odense University Hospi-
David S. Ettinger, Sidney Kimmel Comprehen- + Chemotherapy vs Chemotherapy Alone in
tal, Denmark
sive Cancer Center at Johns Hopkins, USA Metastatic NSCLC
Tony Mok, The Chinese University of Hong P1.05-005: Percutaneous Cryoablation for
P1.03-051: Development of a Novel Micro- Kong, Hong Kong Lung Cancer Patients with Idiopathic Pulmo-
fluidic Device for Studying the Chemotaxis nary Fibrosis
Mechanism of Bacterial Cancer Targeting P1.04-009: The First Study of BBSKE in
Takashi Ohtsuka, Keio University, School of
Qi Wang, The Second Affiliated Hospital of Heavy Treated Advanced EGFR Wild Type
Medicine, Japan
Dalian Medical University, China and ALK Negative, Trxr1 High Expression
NSCLC Patients. P1.05-006: Clinicopathological Features of
P1.03-052: Comparing EGFR-TKI with Yongchang Zhang, Hunan Cancer Hospital, Small-Sized Peripheral Squamous Cell Lung
EGFR-TKI plus Chemotherapy as 1st Line China Cancer
Treatment in Advanced NSCLC Patients with Takayuki Kosaka, Gunma University Graduate
Both Mutated EGFR and Bim Polymorphism School of Medicine, Japan
Yayi He, Shanghai Pulmonary Hospital, Tongji
P1.05-007: A Retrospective Study to Com- P1.05-017: Prognostic Significance of Pre- P1.06-005: Sex-Based Disparities in NSCLC:
pare Resection Rate and Survival Rate in operative Plasma D-Dimer Level in Patients An Evidence-Based Study
Operable Stage I to III NSCLC After Introduc- with Surgically Resected Clinical Stage I Noor Asaad Alsaadoun, University Of Cal-
tion of Lung Cancer MDT Non-Small Cell Lung Cancer gary-Arnie Charbonneau Cancer Institute,
Ying Ying Sum, Hospital Umum Sarawak, Kaoru Kaseda, Sagamihara Kyodo Hospital, Canada
Malaysia Japan
P1.06-006: Survival Benefits and Asso-
P1.05-008: A Comparison of the Imaging P1.05-018: Prognostic Impact of Tumor ciated Prognostic Factors among Young
Features of Early Stage Primary Lung Can- Shadow Disappearance Rate in Patients with NSCLC Patients
cer in Patients Treated with Surgery, SABR Clinical IA Lung Adenocarcinoma Gwyn Bebb, Alberta Health Services, Canada
and Microwave Ablation Joji Samejima, Kanagawa Cancer Center,
Ambika Talwar, Oxford University Hospitals Japan P1.06-007: EGFR Status Evaluation and Epi-
NHS Foundation Trust, UK demiological Profile in Patients with NSCLC
P1.05-019: Effects of Tumor Stroma and in a Brazilian Public Health Instituition
P1.05-009: Analysis of Postoperative Prog- Inflammation on Survival of Stage I-IIp Lung Carolina Dutra, CEPON Centro de Pesquisas
nosis in Terms of the Difference Between the Cancer Oncológicas, Brazil
Invasive Growth Area and the Total Tumor Eduard Monsó, Hospital Parc Taulí, CIBERES,
Diameter Universitat Autònoma de Barcelona, Spain P1.06-008: Prevalence of Lung Cancer in
Masaya Yotsukura, Keio University School of Patients with Interstitial Lung Disease is
Medicine, Japan P1.05-020: Clues of Stromal Invasion of Higher than in those with Chronic Obstruc-
Pulmonary Adenocarcinoma on CT, Focusing tive Pulmonary Disease
P1.05-010: Curative Treatment Rates for on Cicatricial Change Wonil Choi, Keimyung University School of
Patients Diagnosed with Early Stage Non- Ye Kyeong Jun, St. Vincent’s Hospital, The Medicine, Korea
Small Cell Lung Cancer (NSCLC) in England Catholic University of Korea, Korea
Neal Navani, Royal College of Physicians of P1.06-009: Barriers to Clinical Trial Par-
London, UK P1.05-021: Are Prognostic Factors Different ticipation in Lung Cancer Patients, a Single
from That Which Predicts Recurrence in Institution Experience
P1.05-011: Comparison of Tumor Measure- Completely Resected Pathological Stage IB Christina S. Baik, University of Washington/
ment Methods in Patients with Clinical Stage Adenocarcinoma? Seattle Cancer Care Alliance, USA
IA Non-Small Cell Lung Cancer Hiroyuki Ito, Kanagawa Cancer Center, Japan
Takuya Nagashima, Kanagawa Cancer Center, P1.06-010: Interaction between Treatment
Japan P1.05-022: Association Between Neutrophil/ Delivery Delay and Stage on the Mortality
Lymphocyte Ratio and Lymphocyte/Mono- from Non-Small Cell Lung Cancer
P1.05-012: Treatment Planning in Non-Small cyte Ratio with Disease Free Survival in Fernando Conrado Abrão, Hospital Santa
Cell Lung Cancer Shows Variable Utilization Operated NSCLC Patients in Peru Marcelina, Brazil
of Multidisciplinary Tumor Board Rodrigo Motta, Edgardo Rebagliati Hospital,
Joshua Robert Rayburn, Swedish Cancer Peru P1.06-011: Hyponatremia - Evaluation of
Institute, USA Prevalence in Hospitalized Lung Cancer
P1.05-022a: Positive Pleural Lavage Cytol- Patients and Its Prognostic Significance
ogy Is the Independent Prognostic Factor Sharif Ahmed, United Hospital Limited, Ban-
P1.05-013 – P1.05-015 in Lung Cancer Patients with Pathological gladesh
Stage I Disease
NEOADJUVANT AND
Tomoko So, Iizuka Hospital, Japan P1.06-012: Non-Small Cell Lung Cancer
ADJUVANT CHEMOTHERAPY (NSCLC) Patient Characteristics and Clinical
Care Insights in Sweden: The SCAN-LEAF
P1.05-013: Induction Chemoradiation Is Study
Associated with Improved Survival in P1.06 EPIDEMIOLOGY/PRIMARY Martin Sandelin, Uppsala University, Sweden
Resected Non-Pancoast Lung Cancer with PREVENTION/TOBACCO
Chest Wall Invasion CONTROL AND CESSATION P1.06-013: Latent Tuberculosis in Newly
Kei Suzuki, Boston Medical Center, USA Diagnosed Lung Cancer Patients. An Spanish
Prospective Study
P1.05-014: Efficacy of Adjuvant Chemo- P1.06-001 – P1.06-024 Ruth Alvarez Cabellos, Hospital Toledo, Spain
therapy for Completely Resected Stage IB EPIDEMIOLOGY
Non-Small Cell Lung Cancer P1.06-014: Higher Body Mass Index Pro-
Seong Kim, Gangnam Severance Hospital, P1.06-001: Does Access to Private Health longs Survival Time in Non-Small Cell Lung
Korea Care Influence Potential Lung Cancer Cure Cancer with Good Performance Status
Rates? Tomohiro Suzumura, Graduate school of Medi-
P1.05-015: Major Pathological Response as Thadathilankal Jess John, Tygerberg Hospital, cine, Osaka City University, Japan
a Predictive Value of Survival in Early-Stage South Africa
NSCLC After Chemotherapy: Cohort of P1.06-015: Analysis of Relationship Between
NATCH Phase III Trial P1.06-002: The Role of Comorbidity in the Non-Small Cell Lung Cancer and Nicotine
Enric Carcereny, Catalan Institute of Oncology Management and Prognosis in Nonsmall Cell Dependence
Badalona—Germans Trias I Pujol Hospital Lung Cancer: A Population-Based Study Yoon Ho Ko, Department of Internal Medicine,
Badalona, Spain Jonas Nilsson, Radiation Sciences, Sweden The Cancer Research Institute, College of
Medicine, The Catholic University of Korea,
P1.06-003: Preoperative Physical Function Korea
P1.05-016 – P1.05-022a and Activity in Elderly Lung Cancer Patients
RECURRENCE Compared to General Elderly P1.06-016: Route to Lung Cancer Diagnosis
Sunga Kong, Sungkyunkwan University, Korea in the UK: How Does This Affect Patient
Outcome?
P1.05-016: The Prognosticator in Synchro-
P1.06-004: Occurrence of Lung Cancer Sher May Ng, Lewisham and Greenwich NHS
nous Multiple Primary Lung Cancer:
A Comprehensive Analysis of 438 Cases among Young Patients Below the Age of 50 - Trust, UK
Yi Liu, Beijing Chao Yang Hospital, China A Retrospective Analysis
Anna Maria Romaszko-Wojtowicz, The Center
for Pulmonary Diseases, Pulmonology Clinic,
Poland
P1.06-017: Lung Cancer Detection Rates for P1.07-004: Predictive Biomarkers of P1.07-015: Interferon-Gamma (INFG) as
National Comprehensive Cancer Network Response to Nivolumab in Non–Small Cell a Biomarker to Guide Immune Checkpoint
Group 2 High Risk Individuals Lung Cancer: A Multicenter Retrospective Blockade (ICB) in Cancer Therapy
Andrea Katalin Borondy Kitts, Lahey Hospital Cohort Study Niki Karachaliou, Instituto Oncológico Dr Rosell
& Medical Center, USA Yuki Kataoka, Hyogo Prefectural Amagasaki (IOR), Hospital Universitario Sagrat Cor, Spain
General Medical Center, Japan
P1.06-018: EGFR Mutations and ALK Gene P1.07-016: Comparison of PD-L1 Immuno-
Rearrangements: Changing Patterns of P1.07-005: A Systematic and Genome-Wide histochemical Staining between EBUS-TBNA
Molecular Testing in Brazil Correlation Analysis of PD-L1 Expression and Resected Non-Small Cell Lung Cancer
Gilberto Lopes, Sylvester Comprehensive Can- and Common NSCLC Driver Genes Specimens
cer Center at the University of Miami, USA Xiaoshun Shi, State Key Laboratory of Respi- Kenneth Kazuto Sakata, Mayo Clinic, USA
ratory Disease, The First Affiliated Hospital
P1.06-019: The Association Between HPV of Guangzhou Medical University, National P1.07-017: Assessment of Cancer Immunity
Presence and EGFR Mutations in Asian Clinical Research Center for Respiratory Status in Each Patient Using Immunogram
Patients with NSCLC: A Meta-Analysis Disease, China Takahiro Karasaki, The University of Tokyo
Hengrui Liang, The First Affiliated Hospital of Hospital, Japan
Guangzhou Medical University, China P1.07-006: Altered Expression of Pro-
grammed Death-1 Receptor (PD-1) and Its P1.07-018: A Meta-Analysis of PD-L1
P1.06-020: Unequal Access to Health Care Ligand PD-L1, PD-L2 after Neo-Adjuvant Expression as a Biomarker of PD-1 Blockade
System Have a Higher Impact in Upgrading Chemotherapy in Lung Cancer in Advanced Non Small Cell Lung Cancer
Staging for 8th TNM Ed Wenyu Sun, The First Hospital of Jinlin Uni- Johnathan Man, Westmead Hospital, Australia
Maria Teresa Ruiz Tsukazan, Hospital São versity, China
Lucas da PUCRS, Brazil P1.07-019: Immune Cell Infiltrates in Non-
P1.07-007: Interleukin-17A Promotes Lung Small Cell Lung Cancer and Interleukin-22
P1.06-021: Lung Cancer Among Women Tumor Progression Through Neutrophil Expression
Assisted in an Argentinean University Attraction to Tumor Sites and Mediating Rudolf M. Huber, Ludwig Maximilian Univer-
Institution Resistance to PD-1 Blockade. sity of Munich and Thoracic Oncology Centre
Carolina Gabay, Instituto de Oncología Angel Esra A. Akbay, University of Texas Southwest- Munich, Germany
H.Roffo, University of Buenos Aires, Argentina ern Medical Center at Dallas, USA
P1.07-020: Autoantibody Profiles of Can-
P1.06-022: Prognostic Value of NLR in P1.07-008: Microbiome & Immunotherapy: cer-Testis Genes in Non-Small Cell Lung
Overall Survival of Patients with Advanced Antibiotic Use Is Associated with Inferior Cancer
Lung Cancer Survival for Lung Cancer Patients Receiving Dijana Djureinovic, Uppsala University, Swe-
Claudio Flores, Oncosalud - AUNA, Peru PD-1 Inhibitors den
Jonathan R. Thompson, Medical College of
P1.06-023: Spatio-Temporal Distribution of Wisconsin, USA P1.07-021: Multiplex Immune Profiling Iden-
Lung Cancer Mortality Rate in Peru: 2005- tifies Prognostic Importance of the Spatial
2014 P1.07-009: PD-L1 Expression in Circulating Co-Localization of Immune Cells in NSCLC
Claudio J. Flores, Oncosalud - AUNA, Peru Tumor Cells and Response to PD-1 Inhibitor Artur Mezheyeuski, Uppsala University,
Treatment in Non-Small Cell Lung Cancer Sweden
P1.06-024: Outcome of Non-Small Cell Lung Patients
Cancer Patients Treated in the Private Health Nicolas Guibert, Centre Hospitalier Universi- P1.07-022: Routine PD-L1 Immunohisto-
Care in Brazil taire, France chemistry Testing by 22C3 in a Canadian
Luiz H. Araujo, Américas Centro de Oncologia Reference Testing Centre
Integrada, Brazil P1.07-010: Peripheral Blood Biomarkers Ming Sound Tsao, University Health Network,
Associated with Clinical Outcome in Non– Canada
Small Cell Lung Cancer Patients Treated
with Nivolumab P1.07-023: The Correlation Between B7-H4
P1.07 IMMUNOLOGY AND Junko Tanizaki, Kindai University Faculty of Expression and Survival of Non-Small
IMMUNOTHERAPY Medicine, Japan Cell Lung Cancer Patients Treated with
Nivolumab
P1.07-011: PD-L1 Expression and CD8+ T Francesco Grossi, Ospedale Policlinico San
P1.07-001 – P1.07-044a Cell Infiltration Associate with the Prognosis Martino, Italy
IMMUNOTHERAPY (BIOMARKERS) of Pulmonary Neuroendocrine Tumor
Haiyue Wang, Peking University Cancer P1.07-024: ISEND May Predict Clinical
P1.07-001: Clinical Value of Expression of Hospital, China Outcomes for Advanced NSCLC Patients on
PD-L1 and CD8 of 58 Cases with NSCLC PD-1/PD-L1 Inhibitors but Not Chemothera-
Hongnian Wu, Fuzhou Lung Hospital, China P1.07-012: Prediction Sensitivity of PD-1 pies or Targeted Kinase Inhibitors
Checkpoint Blockade Using Pathological Wungki Park, University of Miami, Sylvester
P1.07-002: The Expression of PD-L1 Protein Tissues Specimens by Novel Computerized Comprehensive Cancer Center, USA
as a Prognostic Factor in Lung Squamous Analysis System
Cell Carcinoma Akira Saito, Tokyo Medical University, Japan P1.07-025: Correlating ISEND and Tumor
Kazuki Takada, Department of Surgery and Mutation Burden (TMB) with Clinical Out-
Science, Graduate School of Medical Sciences, P1.07-013: Detection of Genomic Alterations comes of Advanced Non-Small Cell Lung
Kyushu University, Japan in Plasma Circulating Tumor DNA in Patients Cancer (ANSCLC) Patients on Nivolumab
with Metabolically Active Lung Cancers Wungki Park, University of Miami, Sylvester
P1.07-003: Cytolitic Tests with Hyperim- Tianhong Li, Veterans Affairs Northern Califor- Comprehensive Cancer Center, USA
mune Patient Sera Is a Good Prognostic nia Health Care System, USA
Tool in Racotumomab Immunotherapy in P1.07-026: Predicting Tumor Mutational
Advanced Non-Small Cell Lung Cancer P1.07-014: Association of Preoperative Burden (TMB) and Tumor Neoantigen Bur-
Necdet Ismail Hakk Uskent, Anadolu Health Serum CRP with PD-L1 Expression in den (TNB) of East Asian ANSCLC Patients
Science Center, Turkey NSCLC: A Comprehensive Analysis of Sys- by a Targeted Genomic Profiling
temic Inflammatory Markers Likun Chen, Sun Yat-Sen University Cancer
Takaki Akamine, Department of Surgery and Center, China
Science, Graduate School of Medical Sciences,
Kyushu University, Japan
P1.07-027: PD-L1 Expression Analysis in P1.07-038: The Potential Clinical Applica- P1.08-004: Adjuvant Chemoradiotherapy
African American (AA) and Hispanic Lung tion of Comprehensive Genomic Profiling vs. Chemotherapy for Completely Resected
Cancer Patients at a Minority-Based Aca- in Targeted Therapy and Immunotherapy of Unsuspected N2-Positive Non-Small Cell
demic Cancer Center Lung Cancer Lung Cancer
Elaine Shum, Montefiore-Einstein Center for Mingwu Chen, The First Affiliated Hospital of Jong-Mu Sun, Samsung Medical Center, Korea
Cancer Care, USA Guangxi Medical University, China
P1.08-005: Preoperative Analysis of 18FDG-
P1.07-028: Determination of Soluble PD-L1 P1.07-039: Blood Biomarkers Correlate PET Features May Predict Loco-Regional
as a Potential Biomaker for Anti-PD(L)1 with Outcome in Advanced Non-Small Cell Invasiveness in NSCLC
Therapy in Non-Small Cell Lung Cancer Lung Cancer Patients Treated with Anti PD-1 Pietro Bertoglio, Sacro Cuore-Don Calabria
(NSCLC) Antibodies Research Hospital and Cancer Care Centre,
Margarita Majem Tarruella, Hospital de la Yanyan Lou, Mayo Clinic, USA Italy
Santa Creu i Sant Pau, Spain
P1.07-040: Prognosis-Relevant Subgroups P1.08-006: Phase I/II Study of Carboplatin,
P1.07-029: Correlation Study Between in NSCLC According to Granulocytic nab-paclitaxel, and Concurrent Radiation
Plasma sPD-L1 and the Efficacy and Prog- Myeloid-Derived Suppressor Cell Frequency Therapy for Patients with Locally Advanced
nosis of Patients with Non-Small Cell Lung and Cytokine Levels NSCLC.
Cancer Oscar Arrieta, Instituto Nacional de Cancero- Yuko Kawano, Research Institute for Diseases
Xiaoyan Kang, Shanxi Cancer Hospital, China logia, Mexico of the Chest, Graduate School of Medical
Sciences, Kyushu University, Japan
P1.07-030: Prognostic Impact of PD-L1 P1.07-041: CD47 Expression and Prognosis
Expression in Correlation with HLA Class in a Cohort of Patients with Lung Adenocar- P1.08-007: Surgery versus Concurrent
I Expression Status in Adenocarcinoma of cinoma (NSCLC) Chemoradiotherapy for Resectable CII-
the Lung Oscar Arrieta, Instituto Nacional de Cancero- IA-N2 NSCLC: A Propensity Score Matched
Kazue Yoneda, University of Occupational and logia, Mexico Analysis
Environmental Health, Japan Xin Sun, National Cancer Center/Cancer
P1.07-042: PD-L1 and CD8 Expression in Hospital, Chinese Academy of Medical Science
P1.07-031: Autoantibodies Associated EGFR-Mutant or ALK-Rearranged Patients and Peking Union Medical College, China
with Risk of Subclinical Autoimmunity with Lung Cancer
and Immune-Related Adverse Events from Yi-Long Wu, Guangdon Lung Cancer Institute, P1.08-008: Chemoradiotherapy in the
Checkpoint Inhibitor Therapy China Regime of Accelerated Fractionation in the
David E. Gerber, UT Southwestern, USA Treatment of Lung Cancer
P1.07-043: Barrier Molecule Overexpression Yury Ragulin, Medical Radiological Research
P1.07-032: 28-Color, 30 Parameter Flow is Associated with Increased CD8 T Cells Center, Russia
Cytometry to Dissect the Complex Hetero- and Decreased B/Treg Cells in Human Lung
geneity of Tumor Infiltrating T Cells in Lung Cancer P1.08-009: Neutrophilia as Prognostic Bio-
Cancer Wooyoung Monica Choi, Robert H Lurie Com- marker in Locally Advanced Stage III Lung
Pierluigi Novellis, Humanitas Clinical and prehensive Cancer Center of Northwestern Cancer
Research Center, Italy University, USA Angela Botticella, Gustave Roussy, France
P1.07-033: Differential Expression of P1.07-044: The Impact of Neutrophil/Lym- P1.08-010: Unsuspected N2 Disease in
Immune Inhibitory Markers in Association phocyte Ratio as the Predictive Marker to Patients Undergoing Surgery for Non-Small
with the Immune Microenvironment in Anti-PD-1 Antibody Treatment in NSCLC Cell Lung Cancer: Role of Extent and Loca-
Resected Lung Adenocarcinomas Patients tion of the Lymph Node Metastasis
Mingjuan Lisa Zhang, Massachusetts General Keiko Tanimura, Kyoto Prefectural University, Saana Andersson, Heart and Lung Center,
Hospital, USA Japan Helsinki University Hospital, Finland
P1.07-034: Pretreatment Neutrophil & P1.07-044a: Comparison of Tumor Muta-

Platelet Count as a Predictor for Unfavorable tional Burden (TMB) Derived from Whole
Clinical Outcome in Non-Small Cell Lung Exome and Large Panel Sequencing in Lung P1.09 MESOTHELIOMA
Cancer (NSCLC) Cancer
Sarita Agte, Northwestern University, USA Gang Cheng, Novogene Co., Ltd, China
P1.09-001: Multiplexed Biomarker Strategies
P1.07-035: Lymphocytes and Neutrophils Based on Targeted Proteomics for Detection
Count After Two Cycles and TTF1 Expres- of Malignant Pleural Mesothelioma in Blood
sion as Early Outcome Predictors During P1.08 LOCALLY ADVANCED NSCLC Ferdinando Cerciello, The Ohio State Univer-
Immunotherapy sity Medical Center, USA
Iosune Baraibar, Clinica Universidad de
P1.08-001: Surgical versus Non-Surgical P1.09-002: Cellular Noise and Positional
Navarra, Spain
Treatments for Resectable Stage III NSCLC: Effects Determine the Cell Stem State in
P1.07-036: LC-HRMS Metabolomics Profiling A Systematic Review and Meta-Analysis Malignant Mesothelioma
in Advanced NSCLC Treated with Anti PD-1 Wee Yao Koh, National University Cancer Walter Blum, UMR-1162, France
Agents. Metabolic Features at Diagnosis and Institute Singapore, Singapore
P1.09-003: Malignant Mesothelioma Versus
at Response Evaluation
P1.08-002: Blood Supply to the Tumor Do Synovial Sarcoma: An Analysis of 19 Cases
Ana Laura Ortega Granados, Complejo Hospi-
Not Predict the Effect of Induction Therapy with Molecular Diagnosis
talario de Jaén, Spain
in Patients with Locally Advanced Lung Sonja Klebe, Flinders University, Australia
P1.07-037: Testing the Positive and Negative Cancer
Koji Kawaguchi, Nagoya University, Japan P1.09-004: YB-1 Suppresses miR-137 via
Immune Checkpoint on PBMCs of Patients
a Feed Forward Loop, Increasing YB-1
from Initiatory to Terminative Treatment of
P1.08-003: Concomitant Chemotherapy and Levels, Migration and Invasion in Malignant
Anti PD-1 Antibody
Radiotherapy with SBRT Boost for Unresect- Mesothelioma
Wushuang Du, Chinese PLA General Hospital,
able, Stage III Non-Small Cell Lung Cancer: Karin Schelch, Asbestos Diseases Research
China
A Phase I Study Institute, Australia
Kristin A. Higgins, Winship Cancer Institute,
Emory University, USA
P1.09-005: Targeting YB-1 Induces Either P1.10-003: Synergy in Motion: Transferring P1.12-002: Nanoparticle Targeted Folate
Drug Sensitisation or Resistance via Distinct Nursing Knowledge from Clinical Trials to Receptor 1 Enhanced Photodynamic Therapy
Mechanisms in Malignant Pleural Mesothe- Standard Therapy to Enhance Care and for Lung Cancer
lioma Communication Tatsuya Kato, Toronto General Hospital, Uni-
Thomas George Johnson, Asbestos Diseases Dianne Zawisza, Princess Margaret Cancer versity Health Network, Canada
Research Institute, Australia Centre, Canada
P1.12-003: Photothermal Ablation of Lung
P1.09-006: JMJ and BRD Domain Family P1.10-004: Testing Efficacy of a Pulmonary Cancer by Low Power Near-Infrared Laser
Members in Malignant Pleural Mesothelioma: Rehabilitation Program for Post Lung Cancer and Topical Injection of Indocyanine Green;
Potential Therapeutic Targets or Not? Resection Surgery A Preliminary Animal Study
Steven G. Gray, Trinity College Dublin/St. Wei Ling Hsiao, National Taiwan University Kentaro Hirohashi, Kochi Medical School,
James’s Hospital, Ireland Hospital, Taiwan Kochi University, Japan
P1.09-007: Targeting MET/TAM Receptors P1.10-005: Generation of Symptom Burden P1.12-004: Therapeutic Rigid Bronchoscopy
in Mesothelioma: Are Multi-TKIs Superior to Patient-Reported Outcomes for Patients with for the Locally Advanced Non-Small Cell
Specific TKI? Lung Cancer Lung Cancer
Steven G. Gray, Trinity College Dublin/St. George R. Simon, The University of Texas MD Hisashi Tsukada, Brigham and Women’s
James’s Hospital, Ireland Anderson Cancer Center, USA Hospital, USA
P1.09-008: A 4-microRNA Signature in P1.10-006: Adverse Events After First-Line P1.12-005: Improvement of Performance
Serum Can Discriminate Between Non- Target Therapy for Non-Small Cell Lung Can- Status After Therapeutic Bronchoscopy in
Small-Cell Lung Cancer and Malignant cer Patients in a Case Management Model Patients with Airway Malignancy: Single
Pleural Mesothelioma Lin Zhi Xuan, Chi Mei Medical Center, Liouying, Center Experience
Michaela B. Kirschner, University Hospital Taiwan Thitiwat Sriprasart, King Chulalongkorn
Zurich, Switzerland Memorial Hospital, Thai Red Cross Society,
P1.10-007: Preparing Mesothelioma Patients Chulalongkorn University, Thailand
P1.09-009: Evaluation of a Combined for Treatment: Providing Psychosocial Sup-
MicroRNA-Clinical Score as Prognostic Fac- port Networks P1.12-006: The Efficacy of Electrocautery
tor for Malignant Pleural Mesothelioma Gleneara Elizabeth Bates, Mesothelioma Using Wire Snare as the Primary Ablation
Michaela B. Kirschner, University Hospital Applied Research Foundation, USA Modality for Malignant and Benign Airway
Zurich, Switzerland Obstruction
P1.10-008: Palliative Care and Hospice Masahiko Harada, Tokyo Metropolitan Cancer
P1.09-010: PD-L1 Reactivity of Tumor Cells Resources are Underutilized in Patients with and Infectious Diseases Center Komagome
Can Successfully Be Determined in Malig- Advanced Non-Small Cell Lung Cancer Hospital, Japan
nant Mesothelioma Effusions Joshua Robert Rayburn, Swedish Cancer
Annika Dejmek, Lund University, Sweden Institute, USA P1.12-007: Outcomes of Radiotherapy and
Endoscopic Airway Stenting for Central
P1.09-011: LUME-Meso Phase II/III Study: Airway Obstruction in Non-Small Cell Lung
Nintedanib + Pemetrexed/Cisplatin in Che- Cancer
mo-Naïve Patients with Malignant Pleural P1.11 PATIENT ADVOCACY Candice Leigh Wilshire, Swedish Cancer
Mesothelioma Institute, USA
Anne Tsao, University of Texas M.D. Anderson
P1.11-001: Economic Impact of Immune
Cancer Center, USA P1.12-008: Photodynamic Therapy for
Checkpoint Inhibitor Therapy in Brazil and
Peripheral Lung Cancers Using Compos-
Strategies to Improve Access
P1.09-012: A Pre-Clinical Investigation ite-Type Optical Fiberscope of 1.0 mm in
of Intrapleural Curcumin Treatments as Pedro Aguiar Jr, Faculdade de Medicina do
Diameter
an Adjunct Therapy for Malignant Pleural ABC, Brazil
Jitsuo Usuda, Nippon Medical School, Japan
Mesothelioma
P1.11-002: Lung Cancer in Nonagenarian
Ashleigh Jean Hocking, Flinders University, P1.12-009: Experience with Fully Covered
Patients
Australia Metallic Stents in Patients with Malignant
Cheng Chieh Hsu, Taipei Veterans General
Airway Obstruction
P1.09-013: Profiling Response to Chemo- Hospital, Taiwan
Antoni Rosell, Hospital Universitari de Bell-
therapy in Malignant Pleural Mesothelioma vitge, Spain
P1.11-003: A Personalized Navigation Pro-
Among Hispanics (MeSO-CLICaP)
gram to Increase Clinical Trial Participation
Andrés F. Cardona, Foundation for Clinical and
of Lung Cancer Patients
Applied Cancer Research - FICMAC, Colombia
Jennifer C. King, Lung Cancer Alliance, USA
P1.13 RADIOLOGY/STAGING/
P1.11-004: Impact of Liquid Biopsy on the SCREENING
Treatment of Low-Income Lung Cancer
P1.10 NURSING/PALLIATIVE CARE/
Patients P1.13-001 – P1.13-011
ETHICS
Jorge Nieva, USC Norris Comprehensive STAGING
Cancer Center, USA
P1.10-001: Hope for People Living with
P1.13-001: T1 Tumor(<<3cm) with Visceral
Metastatic Lung Cancer
Pleural Invasion Should Be Classified as
Aditya Manna, Narikeldaha Prayas, India
P1.12 PULMONOLOGY/ENDOSCOPY T2a in the 8th TNM Classification for Lung
Cancer
P1.10-002: Outcome of Pilot RCT in Lung
Cancer Surgery Patients Receiving Either Jia-Tao Zhang, Guangdong Lung Cancer
P1.12-001 – P1.12-009 Institute, Guangdong General Hospital and
Preop Carbohydrate & Postop Nutritional
Drinks or Water THERAPEUTIC ENDOSCOPY Guangdong Academy of Medical Sciences;
Amy Kerr, Heart of England NHS Foundation Southern Medical University, China
Trust, UK P1.12-001: Flexible Bronchoscopic Cryo-
therapy in Patients with Malignant Central
Airway Obstruction
Sung Kyoung Kim, St. Vincent’s Hospital, The
Catholic University of Korea, Korea
P1.13-002: New Clinical T Classification Is P1.14-002: Comparison Between Stereo- P1.14-013: High Dose Radiotherapy (74Gy)
Associated with Pathological Stage I Invasive tactic and Conventional Radiotherapy for Improved Local Progression Free Survival in
Adenocarcinoma with Solid Histologic Solitary Lung Tumors After Resection of Patients with Inoperable Stage III NSCLC
Subtype Lung Cancer Young Il Kim, Chungnam National University
Yutaka Sawai, The University of Tokyo, Japan Shigeo Takahashi, Kagawa University Hospital, Hospital, Korea
Japan
P1.13-003: Recurrence Dynamics in P1.14-014: Comparative Evaluation of VMAT
Resected Pathological Stage I Lung Adeno- P1.14-003: Anesthesia Allows Safe Adminis- & 3D-CRT in Locally Advanced NSCLC: Is
carcinoma Depend on the IASLC/ATS/ERS tration of SBRT for Early Stage Lung Cancer There Any Radiobiological Advantage?
Histological Subtype Patients with Advanced Cognitive Impair- Iulian Badragan, BC Cancer Agency, Canada
Yusuke Takahashi, Memorial Sloan Kettering ments
Cancer Center, USA Gregory M.M. Videtic, Cleveland Clinic, USA P1.14-015: Local Recurrence Rate and Tim-
ing after Stereotactic Body Radiotherapy for
P1.13-004: The Role of Lymph Node Staging P1.14-004: Outcomes of Stereotactic Body Lung Cancer: Need for Long-term Follow-up
by EBUS-TBNA in Stereotactic Body Radi- Radiotherapy and Surgery in Treating Takashi Shintani, Kyoto University Graduate
ation Therapy for patients with Non-Small Early Stage Non-Small Cell Lung Cancer: A School of Medicine, Japan
Cell Lung Cancer. Meta-Analysis
Kohei Hashimoto, University of Toronto, Liang Wang, Key Laboratory of Carcinogen- P1.14-016: Assessing the Feasibility of FLT-
Canada sis and Translational Research (Ministry of PET for Evaluation of Non-Small Cell Lung
Education), Peking University Cancer Hospital Cancer (NSCLC) Treated with Stereotactic
P1.13-005: Is Tumor Size for the T4 Descrip- and Institute, China Body Radiotherapy (SBRT)
tor in Lung Cancer Staging Appropriate? Meredith Elana Giuliani, University of Toronto
Junji Ichinose, Cancer Institute Hospital, Japa- P1.14-005: Development of a Novel Spacer and Princess Margaret Cancer Center, Canada
nese Foundation for Cancer Research, Japan to Reduce Mediastinal Organ Toxicity from
Stereotactic Body Radiotherapy P1.14-017: Impact of Systematic EBUS-TBNA
P1.13-006: The Value of F-18 FDG PET/ Yusuke Muranishi, Kyoto University, Japan Mediastinal Staging on Radical Radiotherapy
CT-guided EBUS-TBNA in Nodal Staging of Planning in NSCLC
NSCLC. P1.14-006: Carbon-Ion Radiotherapy for Nicholas Hardcastle, Peter MacCallum Cancer
Sung Yong Lee, College of Medicine, Korea Isolated Lymph Node Metastasis from Lung Centre, Australia
University, Korea Cancer Using a Regimen of 12 Fractions
during 3 Weeks P1.14-018: Construction and Evaluation
P1.13-007: Is Central Lung Tumor Location Katsuyuki Shirai, Gunma University Heavy Ion of RapidPlanTM Models for Radical Lung
Really Predictive for Occult Mediastinal Medical Center, Japan Planning
Nodal Disease in (Suspected) NSCLC Staged Timothy Mitchell, Beatson West Of Scotland
cN0 on PET-CT? P1.14-007: Mesenchymal Stem Cells Labeled Cancer Center, UK
Herbert Decaluwe, University Hospitals Leu- with Fluorescent Magnetic Nanoparticles for
ven, Belgium Targeted Imaging and Hyperthermia Therapy
of Lung Cancer
P1.13-008: Evaluation of Clinical Associated Runlei Hu, Hangzhou First People’s Hospital, P1.15 SCLC/NEUROENDOCRINE
Factors for Lung Adenocarcinoma by TNM China TUMORS
8th Edition with Unexpected N2 disease
Yoshiteru Kidokoro, Tottori University, Japan P1.14-008: Elevated Platelet Levels Affect
Prognosis in Patients with NSCLC Treated P1.15-001: Ipilimumab Increases Th1/Th2
P1.13-009: Macroscopic and Microscopic and Inflammatory Cytokines Counteracting
with Curatively Intended Chemoradiotherapy
Lymphatic Remodeling Caused by VEGF-C Chemotherapy Effects in Small Cell Lung
Georg Holgersson, Gävle Hospital, Sweden
Play a Key Role in Lymphatic Metastasis of Cancer
Non-Small Cell Lung Cancer P1.14-009: Comparison of Dosimetric Edurne Arriola, Hospital del Mar, Spain
Hiromitsu Takizawa, Institute of Biomedical Parameters and Outcome in Non-Small Cell
Lung Cancer Patients Having 3D Conformal P1.15-002: A Retrospective Study of
Sciences, Tokushima University Graduate
Amrubicin Monotherapy for the Treatment of
School, Japan or VMAT Plans
Relapsed Small Cell Lung Cancer in Elderly
Nur Abdul Satar, St Bartholomew’s Hospital,
P1.13-010: Is MRI Brain Mandatory in All Patients
UK
Patients with Early Stage NSCLC? Hiroyuki Minemura, Fukushima Medical Uni-
George Karimundackal, Tata Memorial Hospi- P1.14-010: SGA Could Be a Predictive Factor versity, Japan
tal, India for Radiation Pneumonitis in Lung Cancer
Patients Treated by Concurrent Chemoradio- P1.15-003: Survival by Response to
P1.13-011: Prospective Cohort Study of First-line Platinum-Based Therapy Among
therapy
Patterns of Staging and Treatment Selection Patients With Extensive Disease Small Cell
Hui Liu, Sun Yat-sen University Cancer Center,
with or Without Multidisciplinary (MD) Care Lung Cancer
China
Raymond Osarogiagbon, Baptist Cancer Yong Yuan, Bristol-Myers Squibb, USA
Center, USA P1.14-011: An Esophagus-Sparing Technique
P1.15-004: An Open-Label, Multitumor
to Limit Radiation Esophagitis in Locally
Phase II Basket Study of Olaparib and
Advanced NSCLC Treated by SIB-IMRT and
Durvalumab (MEDIOLA): Results in Patients
Concurrent Chemotherapy
P1.14 RADIOTHERAPY with Relapsed SCLC
Matthew G. Krebs, The University of Manches-
China
ter and The Christie NHS Foundation Trust, UK
P1.14-001: The Feasibility of Predicting
P1.14-012: Hypofractionated Simultaneous
Radiation Pneumonitis Using Lung Equivalent P1.15-005: Relationship Between MYC Fam-
Integrated Boost IMRT Concurrent with Che-
Uniform Dose (LEUD) in Volumetric-Modu- ily Status and Sensitivity to Aurora Kinase
motherapy Improved Loco-Regional Control
lated Arc Inhibitors in Neuroendocrine and Other Lung
in Locally Advanced NSCLC
Xiadong Li, Zhejiang University, China Cancer Cell Lines
Tomohiro Haruki, University of Texas South-
China
western Medical Center, USA
P1.15-006: Enriched Environment and P1.15-017: Adoption of Prophylactic Cranial P1.16-011: The Role of 3D-CT in Patients
Anti-Depressants Enhance Platinum Chemo- Irradiation for Extensive Stage Small Cell with Pulmonary Malignancies Undergoing
sensitivity of Small Cell Lung Cancer Lung Cancer: A Population Based Outcomes Segmentectomy
Qiming Wang, Affiliated Cancer Hospital of Study Ali Amiraliev, P. Hertzen Research Institute of
Zhengzhou University, Henan Cancer Hospital, Swee Peng Yap, National Cancer Centre Sin- Oncology, Russia
China gapore, Singapore
P1.16-012: Application of Fluorescent and
P1.15-007: Randomized Phase III Trial Iodized Dual Marker for Pre-Operative
of Enoxaparin in Addition to Standard Localization and Image-Guided Surgery of
Treatment in Small Cell Lung Cancer: The P1.16 SURGERY Pulmonary Nodule
RASTEN Trial Jiyun Rho, Korea University Guro Hospital,
Emelie Gezelius, Lund University Cancer Korea
P1.16-001 – P1.16-028
Center, Sweden
MINIMAL INVASIVE SURGERY P1.16-013: Video-Assisted Thoracoscopic
P1.15-008: Clinical Features and Gene Surgery (VATS) versus Thoracotomy
Mutation Profiling of Pulmonary Carcinoid P1.16-001: Characteristics of Resected Lung in Locally-Advanced Lung Cancers - a
Tumors Cancer in Patients Aged under 60: A Single– Meta-Analysis
Xiongfei Li, Tianjin Medical University General Center Experience Gerald Sng, National Cancer Centre Singapore,
Hospital, China Jeong Su Cho, Pusan National University Singapore
Hospital, Korea
P1.15-009: Safety and Efficacy of Nab-Pa- P1.16-014: The Efficacy of Thoracoscopic
clitaxel Monotherapy as 2nd or Later Line P1.16-002: Management of Local Recurrence Right Upper Lobectomy Using Fissureless
Setting in Pts with Extensive SCLC, a Phase after Segmentectomy for Stage IA Lung Technique in Patients with Dense Fissures
II Single Arm Study (NCT02262897) Cancer Hitoshi Igai, Maebashi Red Cross Hospital,
Shengxiang Ren, Shanghai Pulmonary Hos- Takeshi Mori, Kumamoto University Hospital, Japan
pital, Tongji University School of Medicine, Japan
Tongji University Cancer Institute, China P1.16-015: miMRST Thoracotomy Cures
P1.16-003: Learning Curve for Adoption Aged, Sickly Weak and/or Cardiopulmonary
P1.15-010: Small Cell Lung Cancer: Experi- of Robotic Lobectomy for Early Stage Dysfunction Patients with Lung Cancer
ence of a Portuguese District Hospital Non-Small Cell Lung Cancer by a Thoracic Jun Zhang, China Medical University Lung
Margarida Felizardo, Hospital Beatriz Angelo, Surgeon Experienced in Open Lobectomy Cancer Center, The First Hospital of China
Portugal Shea Gallagher, University of California, USA Medical University, China
P1.15-011: Longitudinal Mutation Monitoring P1.16-004: Intubated Versus Non-intubated P1.16-016: Comparing Safety and Effective-
in Plasma Without Matching Tumor Tissue by Anesthesia for Lung Cancer VATS in Octo- ness of Image-Guided VATS Versus Conven-
Deep Sequencing in Small Cell Lung Cancer generians tional VATS for Small or Deep Pulmonary
(SCLC) Nenad Ilic, University Surgical Hospital, Croatia Nodules
André Rosenthal, Roche Sequencing Solu- Yin Kai Chao, Chang Gung Memorial Hospital,
tions, USA P1.16-005: Comparison Sublobar vs Lobar Taiwan
Resection in Early Stage Lung Cancer in
P1.15-012: Clinical Prognostic Factors of Octagenarian Patients P1.16-017: Middle Term Survival Outcome of
Elderly Patients with Extensive Stage Small Sira Laohathai, Bundang Hospital, Korea Single Port Video Assisted Thoracoscopic
Cell Lung Cancer in Korea Anatomic Lung Resection: Two Center
Jung Sun Kim, Korea University Medical P1.16-006: Less Is More: video Assisted Experience
Center, Korea Thoracic Surgery (VATS) vs Open Thoracot- Ching Feng Wu, Chang Gung Memorial Hospi-
omy in the Management of Resectable Lung tal, Taiwan
P1.15-013: Small Cell Lung Cancer. Meth- Cancer
odology and Preliminary Results from the Shagufta Shaheen, Loma Linda University P1.16-018: Intraoperative Detection of Tumor
Small Cell Study Medical Center, USA Resection Margin via Inhalation of Fluores-
Ángeles Rodríguez, Pontevedra Hospital cent Imaging Agents
Complex, Spain P1.16-007: Mobile Computed Tomography in Yu Hua Quan, Korea University Guro Hospital,
Video-Assisted Thoracoscopic Surgery for Korea
P1.15-014: Can Limited Resection Be Ground-Glass Opacity Lung Nodules
Accepted as an Alternative Treatment Option Kouhei Tajima, Kiryu Kosei General hospital, P1.16-019: Three Dimensional CT
for Patients with Early-Stage Small Cell Japan Angio-Bronchography Doesn’t Contribute
Lung Cancer? to the Shortening of the Operation Time in
Takamasa Koga, National Hospital Organization P1.16-008: Near-Infrared Fluores- Segmentectomy
Minami-kyushu Hospital, Japan cence-Guided Pulmonary Segmentectomy Hirohisa Horinouchi, Saitama-City Hospital,
Following Endobronchial Indocyanine Green Japan
P1.15-015: Prognostic Implication of the Injection
FEV1/FVC Ratio in Limited-Stage Small Cell Hironobu Wada, Chiba University Graduate P1.16-020: Outcomes of Pulmonary Metas-
Lung Cancer School of Medicine, Japan tasectomy in Hepatocellular Carcinoma
Young-Taek Oh, Ajou University School of According to Approach Method-Thoraco-
Medicine, Korea P1.16-009: Comparing Lymph Node Dis- scopic Versus Open Approach
section in VATS versus Open Lung Cancer Hyeong Ryul Kim, Asan Medical Center, Uni-
P1.15-016: The Study of Population Phar- Surgery: How, How Long, and How Does It versity of Ulsan College of Medicine, Korea
macokinetics and Individualized Dosage Matter?
of Lobaplatin-Based Regimens in Elderly Alan D L Sihoe, The University of Hong Kong P1.16-021: Midterm Oncologic Outcomes
Patients with Small Cell Lung Cancer Shenzhen Hospital, China of Single Port Thoracoscopic Lobectomy
Ying Cheng, Jilin Provincial Cancer Hospital, for Lung Cancer by Propensity Matched
China P1.16-010: Development of a Novel Surgical Analysis
Marking Method Using Low Power Laser Kook Nam Han, Korea University Guro Hospi-
Light tal, Korea
Keishi Ohtani, Tokyo Medical University, Japan
P1.16-022: Incorporating Robotics to the P1.17-004: Extrapleural Pneumonectomy for P1.17-016: Immunohistochemical Markers
Surgical Treatment of Thoracic Neoplasms: Patients with Stage IVa Thymoma: Patho- as Prognostic Factors in Malignant Thymic
5-Year Experience at an Academic Center logical Evaluation of Disseminated Pleural Epithelial Tumors
Dao Minh Nguyen, University of Miami, USA Nodules Yoshito Yamada, University Hospital Zürich,
Shota Nakamura, Nagoya University Graduate Switzerland
P1.16-023: A Useful and Safe Method of School of Medicine, Japan
Intraoperative Localization of Small-Sized P1.17-017: Usefulness of FDG-PET for Dif-
Peripheral Pulmonary Lesions P1.17-005: Pure Red Cell Aplasia Associated ferentiating Thymic Epithelial Tumors from
Yujiro Kubo, Iwakuni Clinical Center, Japan with Thymoma: A Report of a Single-Center Malignant Lymphomas
Experience Hiroyuki Sakamaki, Keio University, School of
P1.16-024: A Case of Bronchial Atresia Satoru Moriyama, Nagoya City University Medicine, Japan
Treated with Complete Thoracoscopy-As- Graduate School of Medical Sciences, Japan
sisted Right S6 Segmentectomy Using P1.17-018: Distribution of Ectopic Thymus in
Fluorescence Navigation P1.17-006: Radiographic Assessment for Chinese Patients: A Preliminary Study
Mototsugu Watanabe, Iwakuni Clinical Center, Tumor Responses of Thymic Carcinoma Jian-Yong Ding, Zhongshan Hospital, Fudan
Japan Using the ITMIG Modified Criteria University, China
Taiki Hakozaki, Tokyo Metropolitan Cancer
P1.16-025: Safety of Simultaneous TEVAR and Infectious Diseases Center Komagome P1.17-019: B7-H3 Protein Expression in
and Combined Aortic Wall Resection at the Hospital, Japan Thymic Epithelial Tumour Subtypes and Its
Time of Lung Resection for T4 Lung Cancer Association with PD-L1 and Clinical Charac-
Infiltrating the Aorta P1.17-007: Platinum Based Chemotherapy teristics
Masanori Tsuchida, Niigata University Grad- in Locally Advanced Non-Metastatic Thymic Spyridon Gennatas, Imperial College, London,
uate School of Medical and Dental Sciences, Carcinoma UK
Japan Tahir Mehmood, Northwest General Hospital
and Research Centre, Pakistan
P1.16-026: Multimodal Image-Guided VATS
Resection of Sub-Centimeter Pulmonary P1.17-008: Clinical and Oncological
Nodules by Cone Beam CT and Broncho- Outcomes on Resected Thymomas over a
scopic NIR Fluorescence Marking Decade at the National Cancer Institute at
Takashi Anayama, Kochi Medical School, Kochi Mexico City
University, Japan Francisco Corona Cruz, National Cancer
Institute, Mexico
P1.16-027: Robotic Surgery, VATS, and
Open Surgery for Early Stage Lung Cancer: P1.17-009: Clinical Significance of Preopera-
Comparison of Costs and Outcomes at a tive Neutrophil-Lymphocyte Ratio in Patients
Single Institute with Thymic Epithelial Tumor Undergoing
Pierluigi Novellis, Humanitas Clinical and Surgery
Research Center, Italy Satoru Okada, Kyoto Prefectural University of
Medicine, Japan
P1.16-028: Is Video-Assisted Thoracic
Surgery a Safer Procedure for Lung Cancer P1.17-010: The Diagnostic Value of Serum
Patients? Cytokeratin Fragment 19 (CYFRA21-1) for
Maria Teresa Ruiz Tsukazan, Hospital São Thymic Squamous Cell Carcinoma
Lucas da PUCRS, Brazil Haruhiko Shiiya, Hokkaido University Hospital,
Japan
P1.17-011: Efficacy and Toxicities of Gem-

P1.17 THYMIC MALIGNANCIES/ citabine and Cisplatin Combination Chemo-
ESOPHAGEAL CANCER/OTHER therapy in Advanced Thymoma and Thymic
THORACIC MALIGNANCIES Carcinoma
Jian Fang, Peking University Cancer Hospital
and Institute, China
P1.17-001 – P1.17-019
THYMOMA P1.17-012: Thymic Neoplasms: The Experi-
ence of a Cancer Institute
P1.17-001: The Optimal First-Line Treatment Rita Vitorino, Instituto Português de Oncologia
for Advanced Thymic Carcinomas de Lisboa Francisco Gentil, Portugal
Xue Yang, Peking University Cancer Hospital
and Institute, China P1.17-013: Prognostic Impact of Programmed
Cell Death-1 (PD-1) and PD-Ligand 1 (PD-L1)
P1.17-002: Clinicopathological Significance Expression in Thymic Cancer
of Epithelial Mesenchymal Transition in Soichiro Funaki, Osaka University Graduate
Thymic Cancer School of Medicine, Japan
Yasushi Shintani, Osaka University Graduate
School of Medicine, Japan P1.17-014: Platinum Rechallenge in Advanced
Thymic Epithelial Tumors: Still an Option in
P1.17-003: Identification of Differentially the Age of Target Therapy? A Monocentric
Expressed Genes between Thymoma and Experience
Paraneoplastic Thymic Tissue Margaret Ottaviano, CRTR Rare Tumours
Lei Yu, Beijing Tongren Hospital, Capital Medi- Reference Center, Italy
cal University, China
P1.17-015: Long Acting Octreotide plus
Prednisone in Advanced Thymic Epithelial
Tumors: A Real Life Clinical Experience
Margaret Ottaviano, CRTR Rare Tumours
Reference Center, Italy
TUESDAY, OCTOBER 17 | POSTER SESSIONS
POSTERS AT A GLANCE
Tuesday, October 17 | Poster Session 2

P2.01 ADVANCED NSCLC P2.12 PULMONOLOGY/ENDOSCOPY
P2.01-001 – P2.01-058a CHEMOTHERAPY P2.12-001 – P2.12-006 DIAGNOSTIC ENDOSCOPY

P2.01-059 – P2.01-075a MISCELLANEOUS
P2.13 RADIOLOGY/STAGING/SCREENING
P2.13-001 – P2.13-026a SCREENING
P2.02-001 – P2.02-024 GENOMICS
P2.02-025 – P2.02-049 IMMUNE MECHANISMS IN THORACIC P2.14 RADIOTHERAPY
CANCER AND TARGETED THERAPY
P2.02-050 – P2.02-073 MARKER FOR PROGNOSIS, PREDICTION
P2.15 SCLC/NEUROENDOCRINE TUMORS
P2.16 SURGERY
P2.03-001 – P2.03-058a EGFR
P2.04 CLINICAL DESIGN, STATISTICS P2.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/

AND CLINICAL TRIALS OTHER THORACIC MALIGNANCIES
P2.05 EARLY STAGE NSCLC
P2.05-001 – P2.05-009 SBRT

P2.05-010 – P2.05-021 SURGERY

P2.06-001 – P2.06-011 PREVENTION
P2.07 IMMUNOLOGY AND IMMUNOTHERAPY
P2.07-001 – P2.07-062c IMMUNOTHERAPY (CLINICAL)
P2.08 LOCALLY ADVANCED NSCLC
P2.09 MESOTHELIOMA
POSTER SESSIONS | TUESDAY, OCTOBER 17
POSTERS IN DETAIL
Tuesday, October 17 | Poster Session 2

P2.01-006: Effect of Maintenance Using P2.01-016: Prognostic Impact of a New
Pemetrexed with and without Bevacizumad Score Using Neutrophil-To-Lymphocyte
POSTER SETUP TIME in Patients Advanced Lung Cancer in Non- Ratios in the Serum and Malignant Pleural
Small Cells Effusion in Lung Cancer Patients
Mayra Galeana Hernandez, Hospital Central Hae-Seong Nam, Inha University Hospital,
Tuesday, October 17 08:00 – 10:00 Militar, Mexico Korea
P2.01-007: Molecular Characterization of P2.01-017: Study on the Effect of Apatinib

POSTER TAKEDOWN TIME Non-Small Cell Lung Cancers (NSCLC) in Salvage Treatment of Advanced Non-Small
Young Patients from an Argentine Population Cell Lung Cancer
Valeria Cecilia Denninghoff, Centro de Meiyu Fang, Zhejiang Cancer Hospital, China
Tuesday, October 17 15:30 – 18:00 Educación Médica e Investigaciones Clínicas
(CEMIC-CONICET), Argentina P2.01-018: Risk Factors in Patients with
Posters not taken down by 18:00 Pathological N1 or N2 Non-Small Cell Lung
will be discarded by management P2.01-008: Combination of Bavacizumab Cancer
with Conventional Chemotherapy Shows Yoshimasa Tokunaga, Kochi Health Sciences
Better Prognosis in Patients with Lung Can- Center, Japan
PRESENTERS IN ATTENDANCE
cer with Liver Metastasis
AT THEIR POSTER Kim Ki-Up, Soon Chun Hyang University P2.01-019: The Necessity of Contrast-en-
Hospital, Korea hanced CT before CT-Guided Percutane-
10:00 – 10:45 and 14:30 – 15:30 ous Transthoracic Needle Biopsy for Lung
P2.01-009: The Efficacy of Bevacizumab Lesions
Adding in Standard First Line Chemotherapy Tang Feng Lv, Jinling Hospital, China
and Maintenance Treatment in Advanced
LOCATION: EXHIBIT HALL (HALL B + C) P2.01-020: Continuous Intravenous Infusion
NSCLC: A Network Meta-Analysis
Voralak Vichapat, Mahidol University, Thailand Endostar Combined with Pemetrexed plus
Cisplatin in Chinese Treatment-Naïve Meta-
P2.01-010: Risk Score for Predicting Acute static Non-Squamous NSCLC
Exacerbation after Chemotherapy in Lung Li Chen, The First Affiliated Hospital of Nan-
P2.01 ADVANCED NSCLC Cancer Associated with Interstitial Pneu- chang University, China
monia
Kazutoshi Isobe, Toho University School of P2.01-021: Efficacy of Single-Agent Che-
P2.01-001 – P2.01-058a Medicine, Japan motherapy after Exposure to Nivolumab in
CHEMOTHERAPY Advanced Non-Small Cell Lung Cancer
P2.01-011: The Efficiency and Safety of Apa- Yuto Yasuda, Kyoto University, Japan
P2.01-001: Serum Albumin Level Predicts tinib plus S-1 as Second-Line or Laterline
the Survival Benefit of Chemotherapy in Chemotherapy for Advanced Squamous Cell P2.01-022: Nintedanib/Docetaxel Efficacy
Elderly Advanced NSCLC Patients with Poor Lung Carcinoma in Advanced Lung Adenocarcinoma Treated
Performance Status Qingming Shi, Anhui Chest Hospital, China with 1L Chemotherapy/2L Immunotherapy in
Satoshi Ikeda, Kanagawa Cardiovascular and Nintedanib NPU
Respiratory Center, Japan P2.01-012: Impact of Brain Metastases on Jesus Corral, Hospital Virgen del Rocío-On-
the Humanistic Burden Incurred by Patients coavanze, Spain
P2.01-002: Survival of Patients with with Advanced Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer at (A-NSCLC) P2.01-023: Reasons for Withholding Sys-
Single Institute in Eastern Thailand, 2013- Oana Chirita, Bristol-Myers Squibb, UK temic Therapy in Stage IV NSCLC: Compari-
2016 son of Years 2004 to 2007 and 2010 to 2013
Sitthi Sukauichai, Chonburi Cancer Hospital, P2.01-013: Nab-Paclitaxel/Carboplatin in Gouri Shankar Bhattacharyya, Fortis Hospital,
Elderly Patients with NSCLC (ABOUND.70+): Anandapur, India
Thailand
Analysis of Safety and Quality of Life (QoL)
P2.01-003: Does Astragalus Membranaceus by Cycle P2.01-024: Prognostic Value of Body Fat
Root Extract Have Any Survival Benefit for Corey J. Langer, Abramson Cancer Center, Mass Ratio in Lung Cancer Patients
Metastatic Non-Small Cell Lung Cancer? University of Pennsylvania, USA Abdurrahman Isikdogan, Dicle University
Adnan Aydiner, Istanbul University, Institute of Diyarbakir, Turkey
P2.01-014: ABOUND.PS2: Safety and
Oncology, Turkey
Efficacy of Nab-Paclitaxel–Based Therapy in P2.01-025: Evaluation of Calculating Car-
P2.01-004: Safety and Efficacy of Nab-Pa- Patients with NSCLC and ECOG PS 2 boplatin Dosage in Carboplatin–Pemetrexed
clitaxel plus Carboplatin in Elderly Patients Ajeet Gajra, Upstate Medical University, State Therapy in Chinese Patients with Advanced
with NSCLC (ABOUND.70+) University of New York, USA NSCLC
Corey J. Langer, Abramson Cancer Center, Yixiang Zhu, National Cancer Center/Can-
P2.01-015: Longitudinal Assessment of cer Hospital, Chinese Academy of Medical
University of Pennsylvania, USA
Performance Status (PS) in Patients with Sciences and Peking Union Medical College,
P2.01-005: A Randomized Phase II Trial of NSCLC and ECOG PS 2 on Nab-Paclitaxel– China
Erlotinib vs S-1 in Patients with NSCLC as Based Therapy
Third- or Fourth-Line Therapy (HOT1002) Nagla Abdel Karim, University of Cincinnati P2.01-026: Distribution of Metastatic
Yasutaka Kawai, Oji General Hospital, Japan Medical Center, USA Disease in Survival Outliers with Stage IV
Non-Small Cell Lung Cancer
D. Gwyn Bebb, University of Calgary, Canada
P2.01-027: Clinical Significance of P2.01-038: Determinants of Frailty and P2.01-049: Long Progression Free Survival
Topoisomerase-II Expression in Patients Treatment Toxicity in Non-Small Cell Lung and Overall Survival in Advanced NSCLC
with Non-Small Cell Lung Cancer Treated Cancer Patient Patients with EGFR Mutation and Complete
with Amrubicin Marie-Eve Boucher, Institut Gustave Roussy, Response with TKI Treatment
Reiko Sakurai, Gunma University Hospital, France Omar Macedo-Pérez, Instituto Nacional de
Japan Cancerología, Mexico
P2.01-039: Erythropoiesis-Stimulating
P2.01-028: Clinical Correlation between Agents for Chemotherapy-Induced Anaemia P2.01-050: Predicting Risk of Hospital-
CTCs Enumeration Based on New Detec- in Lung Cancer: Efficacy, Toxicity and Effect ization in Patients with NSCLC Receiving
tion Method and Chemotherapy Efficacy in on Survival Chemotherapy Using the LCSS 3-Item Global
Human Advanced Lung Cancer Kostas Syrigos, University of Athens, Greece Index (3-IGI)
Honglei Chen, Wuhan University, China Richard J. Gralla, Albert Einstein College of
P2.01-040: Pemetrexed plus Platinum Medicine, USA
P2.01-029: Real World Report of Clinical Chemotherapy with or Without Immunother-
Outcomes of Bevacizumab in First-Line apy in Non-Squamous NSCLC: Descriptive P2.01-051: Randomized Study of Peme-
or Later-Line Treatment for Patients with Safety Analysis trexed Versus Erlotinib as Maintenance
Advanced NSCLC Vassiliki A. Papadimitrakopoulou, MD Ander- Therapy in Metastatic/Locally Advanced
Yalei Wang, Cancer Hospital,Chinese Academy son Cancer Center, USA EGFR Mutation Negative NSCLC
of Medical Sciences & Peking Union Medical Vikas Talreja, Tata Memorial Hospital, India
College, China P2.01-041: Pemetrexed plus Platinum
Chemotherapy with or Without ImmunoRe- P2.01-052: Does Radiomics Improves the
P2.01-030: Real World Study of Bevacizum- sponses of Bevacizumab plus Cisplatin for Survival Prediction in Non Small Cell Lung
ab-Contained Regimen as First Line Therapy the Non-Squamous Non-Small-Cell Lung Cancer?
in Chinese Patients with Advanced NSCLC Cancer Patients with Malignant Pleural Ravindra Patil, University of Maastricht,
Yuxin Mu, National Cancer Center/Can- Effusionstherapy in Non-Squamous NSCLC: Netherlands
cer Hospital,Chinese Academy of Medical Descriptive Safety Analysis
Sciences and Peking Union Medical College, Xue Li, National Cancer Center/Cancer Hospi- P2.01-053: Outcome of Clinical Manage-
China tal,Chinese Academy of Medical Sciences and ment of Elderly and Younger Patients with
Peking Union Medical College, China NSCLC Inside a Private Institution (Oncosa-
P2.01-031: Use of Geriatric Assessment lud-AUNA)
(GA) in Clinical Practice for Stage IV Non- P2.01-042: Perioperative Chemotherapy Jose Maria Gutierrez Castañeda, Oncosalud,
Small Cell Lung Cancer (NSCLC). The GIDO with Pemetrexed and Cisplatin for Pulmo- Peru
Experience nary LCNEC: A Case Report and Literature
Regina Gironés, Hospital Lluis Alcanyís, Spain Review P2.01-054: Inclusion of Central Nervous
Hong Tang, Affiliated Cancer Hospital of System Metastasis in Lung Cancer Early
P2.01-032: A Randomized Phase Ii Trial of Zhengzhou University, Henan Cancer Hospital, Phase Clinical Trials
Selumetinib + Platinum-pemetrexed (Pem-c) China Narjust Duma, Mayo Clinic, USA
in Kras Wildtype (Wt)/Unknown NSCLC:
CCTG Ind219 P2.01-043: PD-L1 Expression, EGFR and P2.01-055: Examining Metabolomics as a
Barbara Melosky, British Columbia Cancer KRAS Mutations in First-Line Therapy (1L) Prognostic Marker in Metastatic Non–Small
Agency, Canada for Non-Small Cell Lung Cancer (NSCLC) Cell Lung Cancer Patients Undergoing First-
Patients Line Chemotherapy
P2.01-033: Leptomeningeal Metastasis from James Rigas, AstraZeneca, USA Desiree Hao, University of Calgary & Tom
Non-Small Cell Lung Cancer: A Single Center Baker Cancer Centre, Canada
Experience in Chinese Patients P2.01-044: The Correlation Between One
Junling Li, Cancer Institute and Hospital Year Survival and the Affecting Factors P2.01-056: Use of Cell-Free Circulating RNA
Chinese Academy of Medical Sciences Peking of Lung Cancer Patients at Dr. Moewardi (cfRNA) Expression of PD-L1 and ERCC1 in
Union Medical College, China Hospital Surakarta Plasma to Monitor Response to Therapy in
Ana Rima, Moewardi Hospital, Indonesia NSCLC
P2.01-034: Phase I/II Trial of Weekly Luis E. Raez, Memorial Cancer Institute, USA
Nab-Paclitaxel as 2nd or 3rd Line Treat- P2.01-045: The Efficiency of Apatinib plus
ment in NSCLC Without Driver Mutations. S-1 as Laterline Chemotherapy for Advanced P2.01-057: Activity of Pemetrexed on Wild-
(OLCSG1303) Non-Small-Cell Lung Cancer Type and Unknown Status EGFR Genes with
Kenichiro Kudo, National Hospital Organization Zhiyong Wu, PLA General Hospital, China Brain Metastases from Non-Small Cell Lung
Iwakuni Clinical Center, Japan Cancer
P2.01-046: Clinical Characteristics of Yun Fan, Zhejiang Cancer Hospital, China
P2.01-035: Phase II Study: Weekly Survival with De Novo Versus Relapsed
Docetaxel as First Line Chemotherapy for Metastatic Non-Small Cell Lung Cancer P2.01-058: Pharmacokinetic Parameter
Elderly Patients with Squamous-Cell Non- Gwyn Bebb, Alberta Health Services, Canada Variability of Docetaxel between Individu-
Small-Cell Lung Cancer als and Its Relationship with Hematological
Kyung Ho Kang, College of Medicine, Korea P2.01-047: A Phase 1 Trial of Dose Escalated Toxicity
University, Korea BGB324 in Combination with Docetaxel for Qisen Guo, Shandong Cancer Hospital, China
Previously Treated Advanced NSCLC
P2.01-036: Symptom Trajectories During David E. Gerber, UT Southwestern, USA P2.01-058a: Dose Serum Lactate Dehydro-
Chemotherapy Predict Overall Survival in genase Have a Significant Prognostic Value
Patients with Advanced Non-Small Cell Lung P2.01-048: Early Changes in Body Com- in Lung Cancer?
Cancer position in Metastatic Non-Small Cell Lung Sharareh Seifi, National Institute of Tuberculo-
Qiuling Shi, University of Texas MD Anderson Cancer (NSCLC) Are Predictive for Poor sis and Lung Disease (NRITLD), Iran
Cancer Center, USA Overall Survival
Anne-Marie C. Dingemans, Maastricht Univer-
P2.01-037: Clinical Impact of Interstitial sity Medical Center, Netherlands
Lung Disease on Advanced Non-Small Cell
Lung Cancer
Hajime Oi, Tosei General Hospital, Japan
P2.01-059 – P2.01-075a P2.01-071: Efficacy of Thoracic Radiother- P2.02-005: 13 Cases of Molecular Features
MISCELLANEOUS apy in Oligometastatic Non-Small-Cell Lung Analysis in Pulmonary Mucoepidermoid
Cancer Harboring Wild-Type EGFR After Carcinoma
P2.01-059: Breast Metastasis from Pulmo- First-Line Chemotherapy Gang Chen, Fujian Provincial Cancer Hospital,
nary Cancer: A Case Report. University Hos- Congying Xie, the 1st Affiliated Hospital of China
pital “Shefqet Ndroqi” Tirana Albania 2008 Wenzhou Medical University, China
Fadil Gradica, University Hospital Shefqet P2.02-006: NovoSV: Identify and Parse the
P2.01-072: Local Management of Oligo- Pattern of Chromosomal Structural Variation
Ndroqi, Albania
metastasis in Non-Small Cell Lung Cancer Gang Chen, Fujian Provincial Cancer Hospital,
P2.01-060: Outcomes Following Gamma (NSCLC) China
Knife Radiosurgery in Patients with Non- Margarita Majem Tarruella, Hospital de la
Small Cell Lung Cancer with Brain Metas- Santa Creu i Sant Pau, Spain P2.02-007: Molecular Spectrum of STK11
tases Gene Mutations in Patients with Non-Small-
Oliver Coen, Leeds Cancer Centre, UK P2.01-073: Prognostic Factors Analysis Cell Lung Cancer in Chinese Patients
of Non-Small Cell Lung Cancer with Brain Gang Chen, Fujian Provincial Cancer Hospital,
P2.01-061: Mode of Lung and Airway Metas- Metastases China
tasis of NSCLC: Review of Chest CT Findings Jiancheng Li, Fujian Cancer Hospital, China
Mi Young Kim, Asan Medical Center, Korea P2.02-008: Snai1-Expression Cancer-As-
P2.01-074: Wait and See: A Favorable Alter- sociated Fibroblast Induce Epithelial-Mes-
P2.01-062: Primary Lung Adenocarcinoma native for R-M1a and S-M1a NSCLC Patients enchymal Transition of Lungcancer Cells
in the Young with Multiple Metastases: An Ying Chen, Guangdong Lung Cancer Institute, through miR-33b
Autopsy Report of 2 Cases China Min Li, Xiangya Hospital, The Central South
Randell Santos Arias, Philippine Heart Center, University, China
Philippines P2.01-075: Genomic Changes and Clinical
Characteristics Associated with Wood- P2.02-009: Metabolomic Analysis in Lung
P2.01-063: Outcomes of Patients with Oligo- Smoke Exposure in Patients with Non-Small Cancer
metastatic Non-Small Cell Lung Cancer Who Cell Lung Cancer Naohiro Kajiwara, Tokyo Medical University,
Were Treated with Radical Treatment Norma Yanet Hernandez-Pedro, Instituto Japan
Ahmet Bilici, Istanbul Medipol University, Med- Nacional de Cancerologia, Mexico
ical Faculty, Department of Medical Oncology, P2.02-010: Oncogenic Role of PKP1 in Non-
P2.01-075a: Incidence of Hippocampal Small-Cell Lung Cancer.
Turkey
Metastases in Non-Small Cell Lung Cancer Pedro P. Medina, University of Granada, Spain
P2.01-064: Co-Existing Mutations and Their Sophia Ly, Princess Alexandra Hospital,
Clinical Implications in Non-Small Cell Lung Australia P2.02-011: Clinical and Molecular Features
Cancer: Korean Lung Cancer Consortium of Lung Cancers with Increased FGFR1
(KLCC-13-01) mRNA and/or Gene Copy Number
Bo Mi Ku, Samsung Biomedical Research Terry L. Ng, University of Colorado Cancer
Institute, Samsung Medical Center, Korea P2.02 BIOLOGY/PATHOLOGY Center, USA
P2.01-065: Clinico-Radiological and Patho- P2.02-012: The Epigenetic Role of LSD1+8a

P2.02-001 – P2.02-024 in Small Cell Lung Cancer
logical Evaluation of Lung Adenocarcinoma GENOMICS
with Infiltration on the Computed Tomogra- Aditya Wirawan, Juntendo University Graduate
phy of the Chest School of Medicine, Japan
Asuka Okada, Saiseikai Suita Hospital, Japan P2.02-001: Detection of Gene Fusions in
NSCLC Using NGS Fusion Assay P2.02-013: Investigation of Genomic and
P2.01-066: Targeted Therapy for Lung Can- Yoon-La Choi, Samsung Medical Center, TCR Repertoire Evolution of AAH, AIS, MIA
cer: Liquid Biopsy or Tumor Sampling? Sungkyunkwan University School of Medicine, to Invasive Lung Adenocarcinoma by Multi-
A Case-Control Study Korea region Exome and TCR Sequencing
Zhen-Yu Ding, West China Hospital, Sichuan Jianjun Zhang, The University of Texas MD
University, China P2.02-002: Digital Multiplexed Detection of Anderson Cancer Center, USA
Single Nucleotide Variants (SNV) in Non-
P2.01-067: Treatment of the Patients with Small Cell Lung Cancer Using NanoString P2.02-014: Simultaneous Gene Profiling of
Oncological Emergencies with Massive Pleu- Technology Advanced NSCLC: Single-Molecule Quan-
ral Effusion at the First Hospital Visit Brielle Parris, University of Queensland tification of DNA and RNA by nCounter3D™
Kazuhiro Ito, Kyoto Yamashiro Medical Center, Thoracic Research Centre, The Prince Charles Technology
Japan Hospital, Australia Cristina Teixidó, Hospital Clinic, Translational
Genomics and Targeted Therapeutics in Solid
P2.01-068: Lobectomy Improve the Survival P2.02-003: A Practical Prognostic lncRNA Tumors, Institut d’Investigacions Biomèdiques
of Non-Small Cell Lung Cancer Patients Signature for Lung Squamous Cell Carci- August Pi i Sunyer (IDIBAPS), Spain
with Occult Malignant Pleural Disease First noma
Detected at Thoracotomy Xiaoshun Shi, State Key Laboratory of Respi- P2.02-015: Mutation Patterns in a Swedish
Shaolei Li, Peking University Cancer Hospital ratory Disease, The First Affiliated Hospital Non-Small Cell Lung Cancer Cohort
& Institute, China of Guangzhou Medical University, National Linnea La Fleur, Uppsala University, Sweden
Clinical Research Center for Respiratory
P2.01-069: Radiologists’ Considerations to Disease, China P2.02-016: Pulmonary Sarcomas: A Com-
Determine the Origin of Tumor on Chest CT: prehensive Genomic Profiling Study
Lung vs Mediastinum P2.02-004: Gene Mutational Feature in Lung Jeffrey S. Ross, Albany Medical College, USA
Junghwa Choi, Uijeongbu St. Mary’s Hospital, Enteric Adenocarcinoma by the Next Gener-
ation Sequencing P2.02-017: Aberrant Expression of Long
Korea
Gang Chen, Fujian Provincial Cancer Hospital, Non-Coding RNAs from Pseudogene Loci
P2.01-070: FAACT- Anorexia Cachexia China Highlights Alternative Mechanisms of Cancer
Scale: Cut-Off Value for the Anorexia Diag- Gene Regulation
nosis in NSCLC Patients Greg L. Stewart, BC Cancer Research Centre,
Jenny Turcott, Instituto Nacional de Canada
Cancerología, Mexico
P2.02-018: Genomic Profiling of Driver Gene P2.02-030: Bavituximab in Combination P2.02-042: Clinical Significance of the
Mutations in 498 Chinese NSCLC Patients With Nivolumab Enhances Tumor Immune Tumor Expression of PD-L1 Using Four
Minghui Wang, Sun Yat-Sen Memorial Hospital, Response in a 3D Ex Vivo System of Lung Immunohistochemistry Assays in Non-Small
Sun Yat-Sen University, China Cancer Patients Cell Lung Cancer. Multicentre Study
Joseph Shan, Peregrine Pharmaceuticals, Inc, Cristian Ortiz -Villalón, Karolinska University
P2.02-019: Utility of Circulating Tumor DNA USA Hospital, Sweden
(CtDNA) in Prognostication of Lung Cancer
vs. Other Cancer Types P2.02-031: Relationship between PD-L1 P2.02-043: Multicentre Assessment of
Francisco III Maramara Heralde, University of Expression and EGFR/HER2 Signaling in PD-L1 Immunohistochemistry: Challenges for
the Philippines, Philippines Non-Small-Cell Lung Cancer Establishing the Concordance Between Four
Riki Okita, Kawasaki Medical School, Japan Different Antibodies
P2.02-020: Molecular Characteristics of Cristian Ortiz -Villalón, Karolinska University
Patients with PTEN Mutations in Chinese P2.02-032: Interplaying between Gam- Hospital, Sweden
Non-Small Cell Lung Cancer ma-H2AX and Autophagy in A549 Cells
Meiyu Fang, Zhejiang Cancer Hospital, China Treated with Cisplatin and Etoposide P2.02-044: Pulmonary Findings in 7
Jong Wook Shin, Chung-Ang University Autopsy Cases of Patients Treated with
P2.02-021: Prevalence of PTPRD Gene Hospital, Korea Immune Checkpoint Inhibitors
Mutations in Chinese Non-Small Cell Lung Peter B. Illei, Johns Hopkins University School
Cancer Patients P2.02-033: The Association of PD-L1 Expres- of Medicine, USA
Meiyu Fang, Zhejiang Cancer Hospital, China sion with Clinical Characteristics and EGFR
and ALK Status in Lung Adenocarcinoma P2.02-045: PD-L1 Assessment in Cytology
P2.02-022: Alternative Regulation of Can- Jinghui Wang, Beijing Chest Hospital, China Samples
cer-Associated Genes through Modulation of Peter B. Illei, Johns Hopkins University School
Long Non-Coding RNAs P2.02-034: PD-L1 Expression Can Be a of Medicine, USA
Adam Patrick Sage, British Columbia Cancer Prognostic Marker in EGFR Mutant NSCLC
Research Centre, Canada Patients Treated with Erlotinib P2.02-046: Assessment of PDL1 and
Niki Karachaliou, Instituto Oncológico Dr Rosell Immunoprofiling Using Multiplex Quantita-
P2.02-023: Targeted Gene Expression (IOR), Hospital Universitario Sagrat Cor, Spain tive Immunofluorescence in Lung Cancer:
Profiling to Evaluate Minimal Diagnostic Clinical Implications
FFPE-Biopsies from NSCLC-Patients P2.02-035: PD-L1 IHC Test on Cytological Vera Luiza Capelozzi, Faculdade de Medicina
Johanna Sofia Margareta Mattsson, Uppsala Cell Block Specimen; Potential Utility and da USP, Brazil
University, Sweden Practical Issues
Michiko Sugiyama, National Cancer Center P2.02-047: Comparison of PD-L1 Immu-
P2.02-024: False Positivity Due to Polysomy Hospital, Japan nohistochemistry Assays and Response to
in Fluorescence in Situ Hybridization PD-L1 Inhibitors
Erik Thunnissen, VU University Medical Cen- P2.02-036: The Expression Pattern of Sanja Dacic, University of Pittsburgh Medical
ter, Netherlands CD26/DPP4 in Human Lung Cancer Center, USA
Ignacio Gil-Bazo, Clinica Universidad de
Navarra, Spain P2.02-048: Survival Correlation Between
P2.02-025 – P2.02-049 TP53 Gene and PD-L1 Tumour Expression in
P2.02-037: CD14+ Cell Tumor Microenviron- Resected Non-Small Cell Lung Carcinoma
IMMUNE MECHANISMS IN THORACIC
ment Infiltration Correlates with Poor Overall Jane Sze Yin Sui, St. James’s Hospital, Ireland
CANCER AND TARGETED THERAPY Survival in Patients with Early Stage Lung
Cancer P2.02-049: Immunohistochemical Approach
P2.02-025: Histological Difference of Erin Schenk, Mayo Clinic, USA in Predicting Primary Lung Cancer Outcome:
Tumor-Infiltrate Lymphocytes in Non-Small A Single Center Study
Cell Lung Cancer P2.02-038: Imaging Platform for the Quan- Gulrukh Komiljonovna Botiralieva, National
Naohiro Kobayashi, University of Tsukuba, Japan tification of Cell-Cell Spatial Organization Cancer Research Center, Uzbekistan
within the Tumour-Immune Microenviron-
P2.02-026: Impact of PD-L1 Expression on ment
18F-FDG-PET in Pulmonary Squamous Cell Katey S.S. Enfield, British Columbia Cancer
Carcinoma P2.02-050 – P2.02-073
Research Centre, Canada MARKER FOR PROGNOSIS,
Norimitsu Kasahara, Gunma University Gradu-
ate School of Medicine, Japan P2.02-039: Spatial Heterogeneity of PREDICTION
Immunological Markers Between Cores and
P2.02-027: Are Inflammatory Markers Pre- Complete NSCLC Sections Using Multispec- P2.02-050: Weighted Genes Co-expression
dictive of Nivolumab Efficacy in Advanced tral Fluorescent IHC Network Analysis of Lung Cancers Concern-
Non-Small-Cell Lung Cancer (NSCLC)? Geoffrey Peters, Olivia Newton-John Cancer ing Patients Overall Survival and Cancer
José Miguel Sánchez-Torres, Hospital Univer- Research Institute, Australia Stage
sitario de La Princesa, Spain Haolong Qi, Chinese University of Hong Kong,
P2.02-040: Cytology Cell Block Is Suitable Hong Kong
P2.02-028: Prognostic Value of Cox-2 for Immunohistochemical Testing for PD-L1
Expression Differs Depending on CD8+ in Lung Cancer P2.02-051: Bevacizumab Prevents Growth
T Lymphocytes and PD-L1 Expression in Hangjun Wang, McGill University Health Center of Established Non-Small Cell Lung Cancer
Resected Lung Adenocarcinoma & McGill University, Canada Brain Metastases in Hematogenous Brain
Katsuhiko Shimizu, Kawasaki Medical School, Metastasis Model
Japan P2.02-041: Update on Prospective Immu- Chinami Masuda, Chugai Pharmaceutical Co.,
nogenomic Profiling of Non-Small Cell Lung Ltd., Japan
P2.02-029: Morphologic Features of Lung Cancer (ICON Project)
Adenocarcinoma Expressing PD-L1 Protein Jianjun Zhang, MD Anderson, USA P2.02-052: A Clinically-Validated Universal
in Small Biopsy Specimens Companion Diagnostic Platform for Cancer
Eun Su Park, Incheon St. Mary’s Hospital, Patient Care
College of Medicine, The Catholic University of James Sun, Foundation Medicine, USA
Korea, Korea
P2.02-053: The Prognostic Value of 18 P2.02-064: A Novel 5-miR Signature Shows P2.03-002: Impact of EGFR-Tyrosine Kinase
Circulating Markers of Inflammation, Endo- Potential as a Diagnostic Tool and as a Inhibitors for Postoperative Recurrent Non-
thelial Activation and Extracellular Matrix Predictive Biomarker of Cisplatin Response Small Cell Lung Cancer Harboring EGFR
Remodelling in Non-Small Cell Lung Cancer in NSCLC Mutations
Patients Martin P. Barr, St. James’s Hospital & Trinity Satoshi Igawa, Kitasato University School of
Janna Berg, Vestfold Hospital Trust, Norway College Dublin, Ireland Medicine, Japan
P2.02-054: Thymidylate Synthase Promotes P2.02-065: RanBP9 is a Novel Prognostic P2.03-003: Cost Effectiveness of Gefitinib
Epithelial-To-Mesenchymal Transition and and Predictive Biomarker for NSCLC and for Lung Adenocarcinoma Patients with
Aggressiveness in NSCLC Affects Cellular Response to Cisplatin and Mutant Epidermal Growth Factor Receptor
Paolo Ceppi, IZKF Erlangen, Germany PARP Inhibitors Chun-Ru Chien, China Medical University
Anna Tessari, The Ohio State University, USA Hospital, Taiwan
P2.02-055: Stratifin Regulates Stabilization
of Receptor Tyrosine Kinases via Activation P2.02-066: Identification of Crucial Gene P2.03-004: Recurrent Response to
of Ubiquitin-Specific Protease 8 in Lung Targets in the in Situ Environment of Cancer Advanced NSCLC with Erlotinib Develop-
Adenocarcinoma by Google Network Ranking ing Central Nervous System Failure during
Aya Shiba, Univerysity of Tsukuba, Japan Victor Pontén, Uppsala University, Sweden Gefitinib or Icotinib Treatment
Di Ma, National Cancer Center/Cancer Hospi-
P2.02-056: Regulatory Variants in Can- P2.02-067: LKB1 Loss Is Associated with tal, Chinese Academy of Medical Sciences and
cer-Related Pathway Genes Predict Survival DNA Hypomethylation in Human Lung Ade- Peking Union Medical College, China
of Patients with Surgically Resected Non- nocarcinoma
Small Cell Lung Cancer Michael John Koenig, The Ohio State Univer- P2.03-005: Overall Survival Results from
Eungbae Lee, Kyungpook National University sity, USA a Prospective, Multicenter Phase II Trial
Medical Center, Korea of Low-Dose Erlotinib as Maintenance in
P2.02-068: BRG1 and p53 Expression in NSCLC Harboring EGFR Mutation
P2.02-057: Expression of MGAT4a and Resected Stage I - III Non-Small Cell Lung Satoshi Hirano, Funabashi Municipal Medical
MGAT5 Are Correlated with Poorer Outcome Cancer Center, Japan
in Advanced Lung Adenocarcinoma Gwyn Bebb, University of Calgary and Alberta
Yoko Nakanishi, Nihon University School of Health Services, Canada P2.03-006: How Many Years of Life Have
Medicine, Japan We Lost in Brazil Due to the Lack of Access
P2.02-069: Targeting Neuropilin-1 in NSCLC to Anti-EGFR TKIs in the National Public
P2.02-058: Endogenous Arginase 2 as a Martin P. Barr, St James’s Hospital & Trinity Health System?
Biomarker for PEGylated Arginase 1 Treat- College Dublin, Ireland Pedro Aguiar Jr, Faculdade de Medicina do
ment in Squamous Cell Lung Carcinoma ABC, Brazil
Xenograft Models P2.02-070: C-MET as a Biomarker in
Sze Kwan Lam, The University of Hong Kong, Patients with Surgically Resected Non-Small P2.03-007: Loxoprofen Prevents EGFR-TKI-
Hong Kong Cell Lung Cancer Related Skin Rash in Non-Small Cell Lung
Georgios Tsakonas, Karolinska Institutet, Cancer Patients: A Single-Center Retrospec-
P2.02-059: Genomic Mutation Patterns Sweden tive Study
Detected with Cancer Panel Can Predict Yohei Iimura, Chemotherapy Research Insti-
Postoperative Prognosis in Clinical Stage I P2.02-071: Prospective Molecular Study of tute, Kaken Hospital, Japan
Adenocarcinoma 22 Genes by NGS in Patients with Non-Small
Kwanyong Hyun, Seoul National University Cell Lung Cancer (NSCLC) in Argentina: A P2.03-008: Phase I/II Study of Intermitted
Hospital, Korea Single Institution Experience Erlotinib in Combination with Docetaxel in
Valeria Cecilia Denninghoff, Centro de Patients with Recurrent NSCLC with Wild-
P2.02-060: Prognostic Significance of Educación Médica e Investigaciones Clínicas Type EGFR: WJOG 4708L
EDIL3 Expression and Correlation with (CEMIC-CONICET), Argentina Tatsuo Kimura, Osaka City University, Japan
Mesenchymal Phenotype and Microvessel
Density in Lung Adenocarcinoma P2.02-072: Reliability of Small Biopsy P2.03-009: Clarification of Mechanisms
Young Wha Koh, Ajou University School of Samples for Tumor PD-L1 Expression in of Acquired Resistance for Afatinib Using
Medicine, Korea Non-small-cell Lung Cancer Plasma Samples
Akihito Tsunoda, St. Marianna University Tomomi Nakamura, Saga University, Japan
P2.02-061: Two Novel Protein-Based Prog- School Of Medicine, Japan
nostic Signatures Improve Risk Stratification P2.03-010: Updated Survival Outcomes of
of Early Lung ADC and SCC Patients P2.02-073: Cytoplasmic Mislocalization of NEJ005/TCOG0902, a Randomized PII of
Luis M. Montuenga, CIMA-University of ECT2 Protein Is Associated with Poor Prog- Gefitinib and Chemotherapy in EGFR-Mutant
Navarra, IDISNA, CIBERONC, Spain nosis in Lung Adenocarcinoma NSCLC
Zeinab Kosibaty, Graduate School of Com- Tatsuro Fukuhara, Miyagi Cancer Center,
P2.02-062: The MicroRNAs Associated with prehensive Human Sciences, University of Japan
Recurrence and Metastasis of Stage I Lung Tsukuba, Japan
Adenocarcinoma P2.03-011: Correlation and Problems of
Yanning Gao, Cancer Hospital, Peking Union Re-Biopsy and Liquid Biopsy for Detecting
Medical College, China T790M Mutation
P2.03 CHEMOTHERAPY/ Kazutoshi Komiya, Saga University, Japan
P2.02-063: Oncogenic microRNAs Associ- TARGETED THERAPY
ated with Poor Prognosis Are Up-Regulated P2.03-012: Characterization of the Efficacies
on the Amplicon in Squamous Cell Lung of Osimertinib and Nazartinib against Cells
Carcinoma P2.03-001 – P2.03-058a Expressing Epidermal Growth Factor Recep-
Sana Yokoi, Chiba Cancer Center Research EGFR tor Mutations
Institute, Japan Keita Masuzawa, Keio University, Japan
P2.03-001: Survivors and Adverse
Events After First-Line Target Therapy P2.03-013: Uncommon Mutation Types
for Advanced Non-Small Cell Lung Cancer of EGFR and Response to EGFR Tyrosine
Patients in Taiwan Kinase Inhibitors in Chinese Non-Small Cell
Lin Zhi Xuan, Chi Mei Medical Center, Taiwan Lung Cancer Patients
Yun Fan, Zhejiang Cancer Hospital, China
P2.03-014: A Phase I Study of Afatinib for P2.03-025: Prevalence of EGFR T790M P2.03-035: Osimertinib in Relapsed
Patients Aged 75 or Older with Advanced Mutation in NSCLC Patients after Afati- EGFR-Mutated Non-Small Cell Lung Cancer
NSCLC Harboring EGFR Mutations nib Failure, and Subsequent Response to Patients with Brain Metastases: Results from
Hisashi Tanaka, Hirosaki University, Japan Osimertinib the TREM-Study
Maximilian Johannes Hochmair, Department Inger Johanne Zwicky Eide, Oslo University
P2.03-015: Efficacy of EGFR-TKIs for EGFR of Respiratory and Critical Care Medicine, Hospital, Norway
Mutatnt NSCLC Patients with Central Ner- and Ludwig Boltzmann Institute of COPD
vous System Metastases: A Retrospective and Respiratory Epidemiology, Otto Wagner P2.03-036: Comparing the Efficacy/Toxicity
Analysis Hospital, Austria of Osimertinib and First Line EGFR-TKI by
Kenichi Koyama, Niigata Cancer Center Hos- Individual Patient Analysis
pital, Japan P2.03-026: Managing EGFR T790M Mutation Shoko Narita, National Cancer Center Hospital,
in Advanced Non-Small Cell Lung Cancers Japan
P2.03-016: Clinical Utility of Liquid Biopsy in Thailand
for Detecting EGFR T790M Mutation Is Very Thongbliew Prempree, Chularat Hospital, P2.03-037: Osimertinib in Relapsed
Limited Thailand EGFR-Mutated, T790M-Negative Non-Small
Tomohiro Sakamoto, Tottori University Hospi- Cell Lung Cancer (NSCLC) Patients: Results
tal, Japan P2.03-027: Comparative Longitudinal from the TREM-Study
Toxicity Analysis of EGFR Mutated NSCLC Inger Johanne Zwicky Eide, Oslo University
P2.03-017: Clinical Features and Treatment Treated with Either Pemetrexed Carboplatin Hospital, Norway
with Afatinib in Patients with Squamous Cell or Gefitinib
Lung Cancer with Sensitive EGFR Mutations Mansi Sharma, Tata Memorial Hospital, India P2.03-038: Early Serum Tumor Markers
Yuri Taniguchi, NTT Medical Center Tokyo, Japan After 14 Days of Tyrosine Kinase Inhibi-
P2.03-028: Third Generation EGFR Inhibitor tor Target Therapy Predicts Outcomes in
P2.03-018: Diagnostic Yield of Fine-Nee- AST2818 (Alflutinib) in NSCLC Patients Patients with Lung Adenocarcinoma
dle Aspiration and Core-Needle Biopsy in with EGFR T790M Mutation: A Phase 1/2 Kuo-Yang Huang, Yuanlin Christian Hospital,
Assessment of EGFR and ALK Mutation Multi-Center Clinical Trial Taiwan
Status in Non–Small Cell Lung Cancer Yuankai Shi, National Cancer Center/Can-
Junghoon Kim, Seoul National University cer Hospital, Chinese Academy of Medical P2.03-039: Compassionate Use of Osimerti-
Bundang Hospital, Korea Sciences and Peking Union Medical College, nib: Argentine Experience
China Jose Nicolas Minatta, Hospital Italiano, Argentina
P2.03-019: Sizing Capillary Electrophoresis
with PCR to Detect Various EGFR Exon 19 P2.03-029: A Case of a Patient Harboring an P2.03-040: EGFR T790M Mutation Detec-
Deletions in Non-Small Cell Lung Cancer EGFR Insertion of Exon 20 and Long Lasting tion and Osimertinib Treatment Response
Eiji Nakajima, Tokyo Medical University Ibaraki Clinical Response to Afatinib Evaluation by Liquid Biopsy in Advanced
Medical Center, Japan Ana Caroline Zimmer Gelatti, Hospital do NSCLC Patients
Câncer Mãe de Deus, Brazil Chenguang Li, Tianjin Medical University
P2.03-020: Pemetrexed Continuation Main- Cancer Institute and Hospital, China
tenance versus Conventional Platinum-based P2.03-030: Cumulative Smoking Dose
Doublet Chemotherapy in EGFR-negative Affects the Clinical Outcomes of EGFR-Mu- P2.03-041: The Concentration of Avitinib
Lung Adenocarcinoma: Retrospective tated Lung Adenocarcinoma Patients Treated in Cerebrospinal Fluid and Its Efficacy and
Analysis with EGFR-TKIs Safety in NSCLC Patients with T790M
Seung Hyeun Lee, Kyung Hee University In Ae Kim, Konkuk University Medical Center, Mutation
Medical Center, Korea Korea Hanping Wang, Peking Union Medical College
Hospital, China
P2.03-021: A Phase I Study Evaluating the P2.03-031: Efficacy of Gefitinib and Radio-
Combination of Afatinib, Carboplatin and therapy Combination in Lung Adenocarcinoma P2.03-042: EGFR Mutation and Erlotinib
Pemetrexed after Failure of 1St Generation Elisna Syahruddin, Persahabatan National Efficacy in Turkish Oncoregistry
EGFR-TKIs Respiratory Refferal Hospital, Indonesia Mahmut Gumus, Istanbul Medeniyet University,
Ou Yamaguchi, Saitama Medical University Turkey
International Medical Center, Japan P2.03-032: Efficacy and Safety of Osim-
ertinib as Third-Line or Later Therapy for P2.03-043: A Phase 1b Study of Erlotinib
P2.03-022: Impact of EGFR Mutation T790M-Positive Advanced Non-Small Cell and Momelotinib for TKI-Naïve EGFR-Mu-
on Clinical Outcome of Nintedanib plus Lung Cancer tated Metastatic Non-Small Cell Lung Cancer
Docetaxel in Previously Treated Non- Small Hiroyuki Shimada, Hiratsuka Kyosai Hospital, Sukhmani Kaur Padda, Stanford Cancer Insti-
Cell Lung Cancer (NSCLC) Japan tute/Stanford University School of Medicine,
Jin-Hyoung Kang, Seoul St. Mary’s Hospital, USA
Korea P2.03-033: Propensity Score-Adjusted
Survival Analysis of Non-Small Cell Lung P2.03-044: OSCILLATE - Phase 2 Trial of
P2.03-023: Characteristics of NSCLC Cancer Patients with Acquired Resistance to Alternating Osimertinib with Gefitinib in
Patients Treated in First Line Treatment with EGFR-TKI Patients with EGFR-T790M Mutation Positive
Tyrosine Kinase Inhibitors (TKI) - Real Data Sho Watanabe, National Center for Global Advanced NSCLC
from the Czech Republic Health and Medicine, Japan Ben J. Solomon, Peter MacCallum Cancer
Jana Skrickova, University Hospital Brno Centre, Australia
and Faculty of Medicine, Masaryk University, P2.03-034: EGFR Exon 19 Deletion Is Asso-
Czech Republic ciated with Favorable Overall Survival After P2.03-045: Updated Results of Phase II,
First-Line Icotinib Therapy in Advanced Liquid Biopsy Study in EGFR Mutated NSCLC
P2.03-024: Phase II Trial of AZD9291 in NSCLC Patients Patients Treated with Afatinib (WJOG
Second-Line Treatment after Acquired Xiaochun Zhang, The Affiliated Hospital of 8114LTR)
Resistance with T790M Mutation Detected Qingdao University, China Hidetoshi Hayashi, Kindai University Faculty of
From Circulating Tumor DNA Medicine, Japan
Young-Chul Kim, Chonnam National University
Hwasun Hospital, Korea
P2.03-046: Lymhocyte-To-Monocyte Ratio P2.03-057: Effectiveness of Icotinib on P2.04-008: ATLANTIS: Phase III Study
and Mean Platelet Volume as Prognostic Uncommon EGFR Exon 20 Insert Mutations: of PM01183 with Doxorubicin vs. CAV or
Factor in EGFR Mutant NSCLC Treated with A763_Y 764insFQEA in Non-Small-Cell Lung Topotecan in Small-Cell Lung Cancer After
EGFR TKI Cancer Platinum Therapy
Kousuke Watanabe, University of Tokyo Hos- Meiyu Fang, Zhejiang Cancer Hospital, China Jose Antonio Lopez-Vilariño, PharmaMar,
pital, Japan Spain
P2.03-058: Tiger-3: A Phase 3 Randomized
P2.03-047: The Main Treatment Failure Study of Rociletinib Vs Chemotherapy in P2.04-009: Randomized, Single-Blind Phase
Pattern for Completely Resected Stage II– EGFR-mutated Non-Small Cell Lung Cancer 1 Study of Pharmacokinetic Equivalence of
IIIA (N1–N2) EGFR-Mutation Positive Lung (NSCLC) ABP 215 Relative to Bevacizumab in Japa-
Cancer James Chih-Hsin Yang, National Taiwan Uni- nese Subjects
Songtao Xu, Zhongshan Hospital Fudan Uni- versity Hospital, Taiwan Valdimir Hanes, Amgen, Inc., USA
versity, China
P2.03-058a: T790M-Selective EGFR-TKI P2.04-010: Afatinib in Combination with
P2.03-048: Mixed Response of Non-Small Combined with Dasatinib as an Optimal Pembrolizumab in Patients with Stage IIIB/IV
Cell Lung Cancer Harboring the EGFR Strategy for Overcoming EGFR-TKI Resis- Squamous Cell Carcinoma (SCC) of the Lung
T790M Mutation to Osimertinib tance in T790M-Positive NSCLC Jonathan W. Riess, University of California
Yuki Shinno, National Cancer Center Hospital, Takeshi Yoshida, Kindai University Faculty of Davis Comprehensive Cancer Center, USA
Japan Medicine, Japan
P2.04-011: The Using of LungCare Electro-
P2.03-049: Pulmonary Adenoid Cystic Car- magnetic Navigated Bronchoscopy System in
cinoma with EGFR Activating Mutation and Lung Lesions, a New Project in China
Responds Well with Tyrosine Kinase Inhibitor P2.04 CLINICAL DESIGN, STATISTICS Baohui Han, Shanghai Chest Hospital, China
Jamal Zaini, Faculty of Medicine Universitas AND CLINICAL TRIALS
Indonesia - Persahabatan National Respiratory P2.04-012: First-Line Ensartinib (X396) ver-
Referral Hospital, Indonesia sus Crizotinib in Advanced ALK-Rearranged
P2.04-001: BALTIC: A Phase 2, Open-Label NSCLC (eXalt3): A Randomized, Open-Label,
P2.03-050: The Efficacy of EGFR Tyrosine Study of Novel Combinations of Immunother- Phase 3 Study
Kinase Inhibitors in Advanced Non-Small apies or DDR Inhibitors in Platinum-Refrac- Yi-Long Wu, Guangdong General Hospital &
Cell Lung Cancer Harboring G719X Mutation tory ED-SCLC Guangdong Academy of Medical Sciences,
Hanping Wang, Peking Union Medical College Ihor Vynnychenko, Sumy State University, Ukraine China
Hospital, China
P2.04-002: CASPIAN: Phase 3 Study of P2.04-013: ElevatION:NSCLC-101 - A Phase
First-Line Durvalumab ± Tremelimumab + 1b Study of PDR001 Combined with Che-
P2.03-051: The Impact of EGFR Mutations.
Platinum-Based Chemotherapy vs Chemo- motherapy in PD-L1 Unselected, Metastatic
Treatment with ITKs in Non Small Cell Lung
therapy Alone in ED-SCLC NSCLC Patients
Cancer Patients
Luis Paz-Ares, Hospital Universitario 12 de Enriqueta Felip, Vall d’Hebron University Hos-
Teresa García Manrique, Hospital Virgen
Octubre, Spain pital and Vall d’Hebron Institute of Oncology,
Macarena, Spain
Spain
P2.04-003: Phase II Trial of X-396 (Ensarti-
P2.03-052: Local Ablative Therapy for
nib) for Chinese Patients with ALK (+) Non– P2.04-014: Computing the Impact of
Oligoprogressive, EGFR-Mutant, Non-Small
Small-Cell Lung Cancer Who Progressed on Immunotherapy on NSCLC Landscape: The
Cell Lung Cancer (NSCLC) After Treatment
Crizotinib Advanced Non-Small Cell Lung Cancer
with Osimertinib
Li Zhang, Sun Yat-sen University Cancer Holistic Registry (ANCHoR)
Udayan Guha, Thoracic and Gastrointestinal
Center, China George R. Simon, The University of Texas MD
Oncology Branch, National Cancer Institute,
National Institutes of Health, USA Anderson Cancer Center, USA
P2.04-004: IMpower010: A Phase III Study
of Atezolizumab vs Best Supportive Care
P2.03-053: A Five-Year Audit of EGFR
Following Adjuvant Chemotherapy in Com-
and ALK Testing at a Tertiary Care Centre
pletely Resected NSCLC P2.05 EARLY STAGE NSCLC
in North India: More Sensitive Methods Do
Enriqueta Felip, Vall d’Hebron University
Make a Difference!
Hospital, Spain
Valliappan Muthu, Postgraduate Institute of
P2.05-001 – P2.05-009
Medical Education and Research (PGIMER), India
P2.04-005: GEOMETRY Mono-1: Phase II, SBRT
Multicenter Study of MET Inhibitor Capmati-
P2.03-054: EGFR Mutation with Acquired
nib (INC280) in EGFR Wt, MET-Dysregulated P2.05-001: Does CGA Impact QoL and Over-
C-MET Positive Reveals Potential Immuno-
Advanced NSCLC all Survival in NSCLC Patients Treated with
therapeutic Vulnerabilities
Jürgen Wolf, University of Cologne, Germany SBRT - Results of a Randomized Pilot Study
Shan Su, Guangdong Lung Cancer Insti-
tute,Guangdong General Hospital & Guang- Stefan Starup Jeppesen, Odense University
P2.04-006: ADAURA: PhIII, Double-Blind,
dong Academy of Medical Sciences, China Hospital, Denmark
Randomized Study of Osimertinib vs Placebo
in EGFR Mutation-Positive NSCLC Post-Tu- P2.05-002: A Pilot Study on the Safety and
P2.03-055: Comparison of Afatinib Versus
mor Resection the Efficacy of Dose Escalation in Stereotac-
Erlotinib for Advanced Non-Small-Cell Lung
Roy S. Herbst, Yale Cancer Center, USA tic Body Radiotherapy for Peripheral Lung
Cancer Patients with Resistance to EGFR-TKI
Yuichi Sakamori, Graduate School of Medicine, Tumor
P2.04-007: KEYNOTE-604: Phase 3
Kyoto University, Japan Takamasa Mitsuyoshi, Kyoto University Gradu-
Randomized, Double-Blind Trial of Pembroli-
ate School of Medicine, Japan
zumab/Placebo plus Etoposide/Platinum for
P2.03-056: Primary Double EGFR Muta-
Extensive Stage-SCLC P2.05-003: Stage by Stage Comparison of
tions T790M and Mutation in Exon 19 or
Charles M. Rudin, Memorial Sloan Kettering Radiotherapy versus Surgery in NSCLC: The
21 in Slovakiab NSCLC Patients - Updated
Cancer Center, USA Influence of Prognostic Factors on Survival
Survival Data
Peter Berzinec, Specialised Hospital of St Outcome
Zoerardus Zobor, Slovakia Sara Moore, British Columbia Cancer Agency,
Canada
P2.05-004: Radiotherapy Patterns of Care P2.05-015: Wedge Resection Is Enough for P2.06-003: Retrospective Study of Cerebral
for Stage I and II Non-Small-Cell Lung Can- Curing GGO Patients with Minimally Invasive Thromboembolism Occurring before and
cer in Sydney, Australia Adenocarcinoma (MIA) of the Lung? after Detection of Lung Cancer (Trousseau
Andrew Duy Duc Nguyen, University of NSW, Jun Zhang, China Medical University Lung Syndrome)
Australia Cancer Center, The First Hospital of China Kinnosuke Matsumoto, Osaka General Medical
Medical University, China Center, Japan
P2.05-005: Proton Beam Therapy for Early
Stage Lung Cancer: A Multi-Institutional P2.05-016: Clinical Importance and Appli- P2.06-004: Role of Polymorphic Variants of
Retrospective Study in Japan cation of New T Descriptors in the 8th TNM BER and DSBR Pathway Genes in Modulat-
Kayoko Ohnishi, University of Tsukuba Hospi- Classification for Pathological T0-1 Lung ing Lung Cancer Susceptibility and Progno-
tal, Japan Adenocarcinoma sis of North Indian Population
Masayuki Nakao, The Cancer Institute Hospital, Amrita Singh, Thapar University, India
P2.05-006: Credentialing of Radiotherapy Japanese Foundation for Cancer Research,
Centres in Australasia for a Phase III Clinical Japan P2.06-005: An Exploration of Attitudes and
Trial on SABR (TROG 09.02 CHISEL) Barriers to Uptake of Lung Cancer Screening
Nicholas Hardcastle, Peter MacCallum Cancer P2.05-017: Prognostic Impact of the Clinical in at Risk Adults in the United Kingdom
Centre, Australia T Descriptor in the Eighth Edition of the David Raymond Baldwin, Nottingham Univer-
TNM Staging System of Non-Small Cell Lung sity Hospitals, UK
P2.05-007: Sterotactic-Body-Radiotherapy Cancer
for Early-Lung Cancer: Is FDG-PET/TC a Tatsuro Okamoto, Oita University Faculty of P2.06-006: Screening Values of CEA and
Predictor of Outcome? Medicine, Japan Cyfra 21-1 for Lung Cancer in Combination
Margarita Majem, Hospital de la Santa Creu i with Low Dose CT (LDCT) in High-Risk
Sant Pau, Spain P2.05-018: Video-Assisted Thoracoscopic Populations
Surgery vs Thoracotomy for Early-Stage Natthaya Triphuridet, Chulabhorn Hospital,
P2.05-008: Stereotactic Body Radiotherapy Non-Small Cell Lung Cancer: Short-Term Thailand
(SBRT) for Early Stage I Lung Cancer: A Outcomes of a Randomized Trial
Review from an Oncology Center in Hong Dongrong Situ, Lung Cancer Research Insti- P2.06-007: Demographic Characteristics
Kong tute, Sun Yat-sen University, China of Lung Cancer and Association with Wood
Lim Mei Ying, Princess Margaret Hospital, Smoke in Mexican Population
Hong Kong P2.05-019: Overall Survival (OS) of Patho- Jeronimo Rafael Rodriguez-Cid, Instituto Nacio-
logical T1N0 Non-Small Cell Lung Cancer nal de Enfermedades Respiratorias, Mexico
P2.05-009: Outcome of Stereotactic Body (NSCLC) After Resection.
Radiotherapy for Clinical Stage I Non Small Etienne Bourdages-Pageau, Laval University, P2.06-008: Diagnosis of Incidental Disease
Cell Lung Cancer and CT Findings: Compari- Canada in Medicaid Recipients During Lung Cancer
son with Surgical Resection Screening
Yuho Maki, Shikoku Cancer Center, Japan P2.05-020: Prognostic Factors in Patients Marisa Bittoni, The Ohio State University
with Completely Resected Subsolid Wexner Medical Center, USA
Node-Negative Lung Adenocarcinoma of 3cm
P2.05-010 – P2.05-021 or Smaller P2.06-009: Trace Elements Affect Lung
SURGERY Jung-Jyh Hung, Taipei Veterans General Cancer Subtypes
Hospital and National Yang-Ming University, Ryosuke Chiba, Iwate Medical University, Japan
Taiwan
P2.05-010: Changes between Pre- and P2.06-010: Association of Vitamin D Recep-
Post-Operative AICS (Lung) in NSCLC P2.05-021: Occult Nodal Metastasis Fol- tor BsmI Polymorphism with Lung Cancer
Patients: Predictability of High-Risk Cases lowing Lobectomy for Clinical Stage I Lung Risk: Evidence from a Meta-Analysis
with Recurrence Adenocarcinoma: Implications for Sublobar Minhua Shi, the Second Affiliated Hospital of
Masahiko Higashiyama, Osaka International Resection Soochow University, China
Cancer Institute, Japan Yusuke Takahashi, Memorial Sloan Kettering
Cancer Center, USA P2.06-011: Assessing and Addressing
P2.05-011: Segmentectomy versus Wedge Knowledge Gaps to Improve Lung Cancer
Resection in Patients with Clinical Stage I Screening Rates
Non-Small Cell Lung Cancer Who Were Unfit Lawrence Eric Feldman, The University of
for Lobectomy P2.06 EPIDEMIOLOGY/PRIMARY Illinois Hospital and Health Sciences System,
Yasuhiro Tsutani, Hiroshima University, Japan PREVENTION/TOBACCO UI Cancer Center, USA
P2.05-012: Prognostic Factors for Surgically CONTROL AND CESSATION
Resected Non-Small Cell Lung Cancer with
Cavity Formation P2.06-001 – P2.06-011 P2.07 IMMUNOLOGY AND
Shunsuke Shigefuku, Tokyo Medical University, PREVENTION IMMUNOTHERAPY
Japan
P2.06-001: Circulating Cotinine Concen-
P2.05-013: The Result of Preoperative P2.07-001 – P2.07-062c
Lipiodol Markings for 121 Small Pulmonary trations, Self-Reported Smoking, and Lung
Cancer Risk in the Lung Cancer Cohort
IMMUNOTHERAPY (CLINICAL)
Nodules in 115 Patients
Hirofumi Suzuki, Saiseikai Suita Hospital, Consortium (LC3)
Tricia L. Larose, Norwegian University of P2.07-001: Clinicopathological Characteris-
Japan tics of NSCLC Patients with Nivolumab-In-
Science and Technology, Norway
duced Pneumonitis
P2.05-014: Factors Associated with Recov-
P2.06-002: Tobacco Use and Prevalence Nobuyuki Koyama, Tokyo Medical University
ery Time to Predicted FEV1 in Non-Small-
of Head and Neck Cancers among Malayali Hachioji Medical Center, Japan
Cell Lung Cancer Patients after Lobectomy
Shin Ah Young, Incheon St. Mary’s Hospital, Tribes, Yelagiri Hills, Tamil Nadu, India
Delfin Lovelina Francis, Tagore Dental College P2.07-002: Drug-Related Pneumonitis in
College of Medicine, The Catholic University of Advanced Non-Small-Cell Lung Cancer
Korea, Korea and Hospital, India
(NSCLC) Patients Treated with Commercial
PD-1 Inhibitors
Mizuki Nishino, Dana-Farber Cancer Institute,
USA
P2.07-003: Nivolumab for Patients with EGFR P2.07-015: Reviving Chemotherapy Sensitiv- P2.07-027: Efficacy and Safety of Nivolumab
Mutation-Positive Non-Small Cell Lung Cancer ity after Anti-CCR4 mAb (Mogamulizumab) Therapy for Advanced NSCLC in the Expanded
Hironori Yoshida, Department of Respiratory Treatment in Lung Cancer Patients Access Named Patient Program in Taiwan
Medicine, Graduate School of Medicine, Kyoto Koji Kurose, Kawasaki Medical School, Japan Bin-Chi Liao, National Taiwan University
University, Kyoto, Japan Hospital, Taiwan
P2.07-016: Inmunotherapy: Which Is More
P2.07-004: Immune-Related Adverse Events Important, Choosing Patients Who Will P2.07-028: Efficacy and Safety of
(irAEs) of Nivolumab Predicts Clinical Bene- Respond or Identifying Those Who Will Die Nivolumab in Non-Small Cell Lung Cancer
fit in Advanced Lung Cancer Patients Early? Patients Who Relapse after Thoracic Radio-
Yukihiro Toi, Sendai Kousei Hospital, Japan Inmaculada Ramos García, Hospital Universi- therapy
tario VIrgen de la Victoria, Spain Teppei Yamaguchi, Aichi Cancer Center Hos-
P2.07-005: Impact of Baseline Leptomenin- pital, Japan
geal and Brain Metastases on Immunother- P2.07-017: Association between Thyroid
apy Outcomes in Advanced Non-Small Cell Dysfunction and Progression-Free Survival P2.07-029: CheckMate 169: Safety/Effi-
Lung Cancer (NSCLC) Patients in Patients with Non-Small Cell Lung Cancer cacy of Nivolumab in Canadian Pretreated
Laura Mezquita, Gustave Roussy, France Received Nivolumab Advanced NSCLC (including Elderly and PS
Tomoko Funazo, Kyoto University, Japan 2) Patients
P2.07-006: Irinotecan Augmented Anti-Tu- Rosalyn J. Juergens, Juravinski Cancer
mor Activity of Anti-PD-L1 through Enhanc- P2.07-018: Correlation of Clinical Response Centre, Canada
ing CD8 Proliferation Regardless of Its and XAGE1 Immunity in Lung Adenocarci-
Hematotoxicity noma P2.07-030: Real Life Second-Line
Toshiki Iwai, Chugai Pharmaceutical Co., Ltd., Yoshihiro Ohue, Kawasaki Medical School, Nivolumab in Advanced Non-Small-Cell-Lung
Japan Japan Cancer: A French Observational Multicenter
Study of 259 Patients
P2.07-007: Retrospective Analysis of Antitu- P2.07-019: Role of Anti-Angiogenesis on the Margaux Geier, CHRU Morvan, France
mor Effects and Biomarkers of Nivolumab in Prognosis in Advanced Non-Small Cell Lung
NSCLC Patients with EGFR Mutations Cancer Who Are Treated with Immunother- P2.07-031: Relationship between Clinical
Satoshi Watanabe, Niigata University Graduate apy Factors and the Expression of Programmed
School of Medical and Dental Sciences, Japan Takefumi Komiya, Tulane University School of Death Ligand 1 in Lung Cancer
Medicine, USA Yasuhiro Kato, Tokyo Metropolitan Cancer
P2.07-008: Does PD-L1 Expression of the and Infectious Diseases Center Komagome
Archive Surgical Specimen of Primary P2.07-020: Distinct Immune Status in Hospital, Japan
Tumor Predict the Sensitivity of Recurrence Patients with Adenocarcinoma and Squa-
to Nivolumab in Patients with NSCLC? mous Cell Carcinoma: Implication for Immu- P2.07-032: Outcomes of Nivolumab in
Yuki Shiina, Chiba University Graduate School notherapy of NSCLC Metastatic NSCLC Patients via the Access
of Medicine, Japan Nada Hradilova, Sotio a.s., Czech Republic Program Across Multiple Tertiary Oncology
Centres.
P2.07-009: Monitoring Nivolumab Binding as P2.07-021: A Checkpoint Molecule B7-H3 Kenneth O’byrne, Princess Alexandra Hospital
a Method to Clarify the Residual Therapeutic as a Novel Immune Therapy Target for Non- and Queensland University of Technology,
Effects in Previously Treated Lung Cancer Small Cell Lung Cancer (NSCLC) Australia
Patients Kimio Yonesaka, Kindai University Faculty of
Akio Osa, Osaka University Graduate School Medicine, Japan P2.07-033: Anti-PD1-Induced Rotator Cuff
of Medicine, Japan Injury: A Case Series
P2.07-022: Inflammatory Cytokine Induction Kenneth O’Byrne, Princess Alexandra Hospital
P2.07-010: Impact of Clinicopathological after Anti-PD-1 Ab Administration Relates to and Queensland University of Technology,
Features on the Efficacy of PD-1/PD-L1 the Efficacy and Safety in Patients with Non- Australia
Inhibitors in Patients with Previously Treated Small Cell Lung Cancer
Non-Small Cell Lung Cancer Yuichi Ozawa, Seirei Mikatahara General P2.07-034: Health Status in Patients
Tao Jiang, Shanghai Pulmonary Hospital, Hospital, Japan with Small-Cell Lung Cancer Treated with
Tongji University School of Medicine, China Nivolumab Alone or Combined with Ipilim-
P2.07-023: Safety of Immune Checkpoint umab: CheckMate 032
P2.07-011: Long Follow up from Phase I Study Inhibitors in Patients with Preexisting Auto- D. Ross Camidge, University of Colorado, USA
of Nivolumab and Chemotherapy in Patients immune Disease
with Advanced Non-Small-Cell Lung Cancer Margaux Geier, CHU Brest, France P2.07-035: Correlation Between
Shintaro Kanda, National Cancer Center Immune-Related Adverse Events and Effi-
Hospital, Japan P2.07-024: Real-World Data of Nivolumab cacy in Non-Small Cell Lung Cancer Treated
for Previously Treated Non-Small Cell Lung with Nivolumab
P2.07-012: Patterns of Response to Cancer Patients in Japan: A Multicenter Koichi Sato, Third Department of Internal Med-
Nivolumab in Patients with Non-Small Cell Retrospective Cohort Study icine, Wakayama Medical University, Japan
Lung Cancer (NSCLC) Daichi Fujimoto, Kobe City Medical Center
Martin Früh, Cantonal Hospital St. Gallen, General Hospital, Japan P2.07-036: Appropriate Use of Immune
Switzerland Checkpoint Inhibitors in Advanced NSCLC:
P2.07-025: Increased Antitumor Response Effectiveness of Unique Case-Based Educa-
P2.07-013: Efficacy and Safety of Nivolumab to Chemotherapy Administered after PD-1/ tion on Clinical Decision-Making
in Non-Small Cell Lung Cancer with Preex- PD-L1 Inhibitors in Patients with Non-Small Tara Herrmann, Medscape Education, USA
isting Interstitial Lung Disease Cell Lung Cancer
Osamu Kanai, National Hospital Organization Song Ee Park, Samsung Medical Center, Korea P2.07-037: Developing a Predictive Clinical
Kyoto Medical Center, Japan Outcome Model for Advanced Non-Small Cell
P2.07-026: Nivolumab in Non-Small Cell Lung Cancer Patients Receiving Nivolumab
P2.07-014: Immune Checkpoint Inhibitors Lung Cancer (NSCLC): Facing the Reality Wungki Park, University of Miami, Sylvester
for Brain Metastases of Non-Small-Cell Lung Sivan Shamai, Tel Aviv Medical Center, Israel Comprehensive Cancer Center, USA
Cancer
Hironori Ashinuma, Chiba Cancer Center,
Japan
P2.07-038: Thyroid Dysfunction Arising P2.07-049: Early Clinical Predictors of Pro- P2.07-060: Response Assessment and
During KEYNOTE-001 Associated with gressive Disease or Non-Response to PD-1/ Subgroups Analysis According to the Lung
Improved Efficacy of Pembrolizumab in PD-L1 Inhibitors in Advanced Non-Small Cell Immune Prognostic Index (LIPI) for Immuno-
NSCLC Patients at UCLA Lung Cancer therapy in Advanced NSCLC Patients
Aaron Lisberg, University of California, Los David P. Walder, The Institute of Cancer Laura Mezquita, Gustave Roussy, France
Angeles, USA Research and the Royal Marsden NHS Foun-
dation Trust, UK P2.07-061: Nivolumab for Patients with
P2.07-039: Nivolumab Experience in Non-Small Cell Lung Carcinoma in Patients
Patients with Previously Treated Advanced P2.07-050: Impact of Steroid Use for with Progression to One or More Lines of
Non Small Cell Lung Cancer (NSCLC) in Immune Related Adverse Events on Chemotherapy in Mexican Population
Toledo, Spain Outcomes in Non-Small Cell Lung Cancer Jeronimo Rafael Rodriguez-Cid, Instituto
Antonio Irigoyen Medina, Hospital Toledo, Spain (NSCLC) Treated with Checkpoint Inhibitors Nacional de Enfermedades Respiratorias,
Neil J. Shah, Medstar Georgetown University Mexico
P2.07-040: Pre-Treatment Tumor Volume in Hospital, USA
Non-Small Cell Lung Cancer (NSCLC) as a P2.07-062: PIVOT-02: Phase 1/2 Study of
Predictor of Response to PD-1 Inhibitors P2.07-051: Immune Checkpoint Associated NKTR-214 and Nivolumab in Patients with
Misako Nagasaka, Karmanos Cancer Institute/ Cardiotoxicity: An Update Locally Advanced or Metastatic Solid Tumor
Wayne State University, USA Zin War Mynt, Division of Hematology and Malignancies
Oncology, University of Kentucky, USA Vassiliki A. Papadimitrakopoulou, The Univer-
P2.07-041: Immuno-Related Cutaneous sity of Texas MD Anderson Cancer Center,
Adverse Events (IRcutAEs) in Patients (P) P2.07-052: Detection of KRAS Mutation in USA
with Advanced NSCLC: A Single-Institution Blood Predicts Favorable Response to Immu-
Prospective Study notherapy in NSCLC P2.07-062a: Single Institutional Experience
Enric Carcereny, Catalan Institute of Oncolo- Martin Frederik Dietrich, Memorial Cancer of the Use of PD-1 Inhibitors to Non-Small
gy-Hospital Germans Trias i Pujol, Spain Institute, USA Cell Lung Cancer Patients with Preexisting
Autoimmune Diseases
P2.07-042: Feasibility Study of Nivolumab P2.07-053: A Case of Small Cell Lung Mehmet Altan, MD Anderson Cancer Center,
and Docetaxel in Previously Treated Patients Cancer Complicated During Nivolumab USA
with Advanced Non-Small Cell Lung Cancer Administration as Second Line Treatment for
Tsuneo Shimokawa, Yokohama Municipal Squamous Cell Lung Cancer P2.07-062b: DNA Damage Repair Targeting
Citizen’s Hospital, Japan Tomoki Kimura, Tosei General Hospital, Japan Upregulates PD-L1 Level and Potentiates the
Effect of PD-L1 Blockade in Small Cell Lung
P2.07-043: Efficacy and Safety of Anti-PD-1 P2.07-054: Cost-Effectiveness of Pembroli- Cancer
Antibody as the First Line Treatment in zumab as First-Line Therapy for Advanced Triparna Sen, University of Texas MD Ander-
Elderly Patient with Advanced Lung Squa- Non-Small Cell Lung Cancer son Cancer Center, USA
mous Cell Carcinoma: A Case Report Pedro Aguiar Jr, Faculdade de Medicina do
Hua Min Shi, The Second Affiliated Hospital of ABC, Brazil P2.07-062c: A Phase II Study of BGB324 in
Soochow University, China Combination with Pembrolizumab in Patients
P2.07-055: Indirect Comparison between with Previously Treated Advanced Lung
P2.07-044: Thyroid Disfunction in Advanced Immune-Checkpoint Inhibitors for 2nd Line Adenocarcinoma
NSCLC Patients Treated with Nivolumab out Non-Small Cell Lung Cancer - a Network Murray Yule, BerGenBio ASA, Norway
of Clinical Trial: A Real-World Data Analysis Meta-Analysis
Ramon Palmero, Catalan Institute of Oncology, Pedro Aguiar Jr, Faculdade de Medicina do
Spain ABC, Brazil
P2.07-045: A Retrospective Analysis of P2.07-056: SAKK 16/14 - Perioperative
Nivolumab-Related Pneumonitis in Non- Anti-PD-L1 Antibody Durvalumab in Patients
P2.08-001: Hand Grip Strength Is an Inde-
Small Cell Lung Cancer Patients with Stage IIIA(N2) Non-Small Cell Lung
pendent Prognostic Factor for Mortality in
Shuhei Tsujino, Nagasaki University Hospital, Cancer (NSCLC)
Patients with NSCLC Undergoing Radiother-
Japan Sacha I. Rothschild, University Hospital Basel,
apy
Switzerland
P2.07-046: Nivolumab Exerts Remark- Chris Burtin, Hasselt University, Belgium
able Antitumor Activity in NSCLC After P2.07-057: Anti-PD-1/PD-L1 Antibodies
P2.08-002: A Nomogram for Predicting
an Immune-Modulating Biochemotherapy Combine with Chemotherapy or CTLA4 Anti-
Underlying Beneficiaries for Resectable IIIA/
Regimen bodies for First-Line Treatment of Advanced
N2 NSCLC Patients
Pierpaolo Correale, Unit of Medical Oncology, Lung Cancer
Chao Zhang, Guangdong Lung Cancer Insti-
Grand Metropolitan Hospital “Bianchi-Melacri- Yun Fan, Zhejiang Cancer Hospital, China
tute, China
no-Morelli”, Reggio Calabria, Italy
P2.07-058: First-In-Human Study of JNJ-
P2.08-003: An Audit of Concurrent Chemo-
P2.07-047: Poor Performance Status 64041757, a Live Attenuated Listeria Mono-
radiotherapy for Non-Small Cell Lung Cancer
and BRAF Mutation Predict Grade 3-5 cytogenes Immunotherapy, for Non-Small
at the Leeds Cancer Centre (LCC)
Immune-Related Adverse Events in Pts with Cell Lung Cancer
Katy Louise Clarke, Leeds Cancer Centre, UK
Advanced NSCLC Julie R. Brahmer, Sidney Kimmel Comprehen-
Yan Wang, Shanghai Pulmonary Hospital, sive Cancer Center at Johns Hopkins, USA P2.08-004: Pathologic Complete Response
Tongji University School of Medicine, China as an Independed Prognostic Factor in
P2.07-059: Phase I Trial of Gene Mediated
Patients with Locally Advanced Non-Small
P2.07-048: Immunotherapy vs. Targeted Cytotoxic Immunotherapy (GMCI) for Malig-
Cell Lung Cancer
Therapy - Who Wins? A Case Series nant Pleural Effusion (MPE) and Malignant
Waldemar Schreiner, Friedrich-Alexander-Uni-
Inbar Finkel, Beilinson Medical Center, Israel Pleural Mesothelioma (MPM)
versity, Germany
Daniel H. Sterman, NYU Langone Medical
Center, USA P2.08-005: Salvage Lung Surgery Follow-
ing Definitive Chemoradiation in Locally
Advanced Non-Small Cell Lung Cancer
Waldemar Schreiner, Friedrich-Alexander-Uni-
versity, Germany
P2.08-006: Immunological Biomarkers P2.12-002: Radial Probe Endobronchial

Characterization in Locally Advanced P2.10 NURSING/PALLIATIVE CARE/ Ultrasound (R-EBUS) Guided Transbronchial
Non-Small Cell Lung Cancer Treated with ETHICS Cryobiopsy In The Diagnosis of Peripheral
Concurrent Chemo-Radiotherapy Lung Mass
Ernest Nadal, Department of Medical Oncol- Sze Shyang Kho, Sarawak General Hospital,
P2.10-001: Factors Associated with Quality
ogy, Catalan Institute of Oncology, Hospitalet, Malaysia
of Life among Patients with Lung Cancer
Spain
Yi-Lin Wu, National Cheng Kung University,
P2.12-003: The History of EBUS TBNA
Taiwan
P2.08-007: Five-Year Results of Concurrent Mark Krasnik, Copenhagen University Hospital
Chemotherapy and Isotoxic Radiotherapy Rigshospitalet/Gentofte Hospital, Denmark
P2.10-002: A Study on the Relation between
Dose-Escalation with IMRT in Stage III
Gender and Quality of Life for Lung Cancer
NSCLC (NCT01166204) P2.12-004: Lung Cancer Detection Rate of
Patients
Dirk K. De Ruysscher, Maastricht University Conventional Bronchoscopic Techniques:
Yi-Lin Wu, National Cheng Kung University
Medical Center, Netherlands A Tertiary Hospital Experience June 2011-
Hospital, Taiwan
December 2016
Marlo Pasco Bagano, Perpetual Succour Hos-
P2.10-003: The Deterioration and Prognostic
pital - Cebu Lung Institute, Philippines
Value of Functional Capacity in Patients with
P2.09 MESOTHELIOMA
Lung Cancer: A Systematic Review
P2.12-005: Comparison of Needle Gauge
Laerke Winther, University of Copenhagen,
Used to Obtain Specimens During EBUS-
P2.09-001: Effects of Tumor Burden Denmark
TBNA in Patients with Lung Cancer
Reduction on Survival in Epithelioid Pleural
Goohyeon Hong, Dankook University Hospital,
Mesothelioma P2.10-004: Efficacy and Safety of Viscum
Dankook University College of Medicine, Korea
Aaron S. Mansfield, Mayo Clinic, USA Album (Helixor M) to Treat Malignant Pleural
Effusion in Patients with Advanced Lung
P2.12-006: Evaluation of New 25G Needle in
P2.09-001a: TNM or Tumor Volume for Cancer
EBUS-TBNA Comparing Conventional 22G
Predicting Prognosis in Malignant Pleural Yun-Gyoo Lee, Kangbuk Samsung Hospital,
Needle in Diagnosis for Nodal Metastasis of
Mesothelioma: Still an Open Debate Korea
Lung Cancer
Marina Chiara Garassino, IRCCS Istituto Nazio-
Yuichi Sakairi, Chiba University Graduate
nale dei Tumori, Italy P2.10-005: Overall Survival of Lung Cancer
School of Medicine, Japan
Patients with Brain Metastases in a Develop-
P2.09-002: Prevalence and Survival of ing Country
Malignant Pleural Mesothelioma Patients Tomi Kovacevic, Institute for Pulmonary
Treated in a Single Brazilian Cancer Center Diseases of Vojvodina, Faculty of Medicine, P2.13 RADIOLOGY/STAGING/
João Navarro Reolon, A.C. Camargo Cancer University of Novi Sad, Serbia
SCREENING
Center, Brazil
P2.10-006: Prognostic Factors of Mortality
P2.09-003: Dissecting the Immune Envi- and Recurrence of Malignant Pleural Effusion P2.13-001 – P2.13-026a
ronment in Malignant Pleural Mesothelioma: in High-Risk Tumors According to the LENT SCREENING
Results from a Prospective Assessment Score Study
Silvia Novello, University of Torino, Italy Fernando Conrado Abrão, Hospital Santa
P2.13-001: Herbal Compound as a Potential
Marcelina, Brazil
P2.09-004: PD-L1 Protein Expression Is Lead Targets Lung Cancer Stem Cells
Negative Prognostic Factor in Malignant P2.10-007: Quality of Life across Various Pei-Jung Lee, National Taiwan University,
Pleural Mesothelioma in Central Europe Treatment Lines in Metastatic Lung Cancer College of Medicine, Taiwan
Luka Brcic, Medical University of Graz, Austria Patients
P2.13-002: The LungScreen WA Project:
Aseem Rai Bhatnagar, SMS Hospital, India
P2.09-005: The C-reactive Protein/Albu- Feasibility of LDCT Screening with the
min Ratio is a Novel Significant Prognostic PLCOm2012 Risk Model and PanCan Nodule
Factor in Patients with Malignant Pleural Risk Calculator
Mesothelioma P2.11 PATIENT ADVOCACY Kuan Pin Lim, Sir Charles Gairdner Hospital,
Shinkichi Takamori, Graduate School of Medi- Australia
cal Sciences, Kyushu University, Japan
P2.11-001: Evaluation of a Cultural Note- P2.13-004: Role of Low-Dose Chest
P2.09-005a: Clinical Characteristics of Early book of Self-Expression and Follow-Up Computerized Tomography in Lung Cancer
Stage, Malignant Pleural Mesothelioma Among Patients with Lung Cancer in French Screening among Never-Smokers
Kozo Kuribayashi, Hyogo College of Medicine, Polynesia Hye-Rin Kang, Seoul National University
Japan Eric Parrat, CHPf Taaone, French Polynesia College of Medicine, Korea
P2.09-006: FISH Analysis of p16 and BAP1 P2.11-002: To Live and Work with Lung Can- P2.13-005: Early Results of Lung Cancer
Immunohistochemistry for the Diagnosis of cer: Coping Strategies of a Stage 4 Patient Screening in an African American Population
Mesothelioma Satoko Kono, Japan Cherie Parungo Erkmen, Temple University
Kenzo Hiroshima, Tokyo Women’s Medical Hospital, USA
University, Japan
P2.13-006: Enhanced Shared Decision
P2.12 PULMONOLOGY/ENDOSCOPY Making in Lung Cancer Screening: Address-
P2.09-007: Pleural Biopsy in Patients Sus-
pected of Malignant Pleural Mesothelioma ing Questions of Willingness and Ability to
Consecutive 377 Cases P2.12-001: Early Experience with Radial Undergo Lung Cancer Treatment
Masaki Hashimoto, Hyogo College of Medicine, Endobronchial Ultrasound with Guide Sheath Cherie Parungo Erkmen, Temple University
Japan For Diagnosis of Peripheral Pulmonary Hospital, USA
Lesion
P2.09-008: Usefulness of Immunohisto- P2.13-007: Relationship of Nodule Count
Sze Shyang Kho, Sarawak General Hospital,
chemistry in the Differential Diagnosis of and Lung Cancer Probability in New Nodules
Malaysia
Epithelioid Mesothelioma and Lung Squa- Detected after Baseline in CT Lung Cancer
mous Cell Carcinoma Screening
Kei Kushitani, Hiroshima University, Japan Joan E. Walter, University of Groningen, Uni-
versity Medical Center Groningen, Netherlands
P2.13-008: Lung Cancer Screening Improves P2.13-020: Lung-RADS Used in Lung Cancer P2.14-005: Determination of Optimal Cut off
Mortality: Examining Screening Patterns in Screening: Does Granulomatous Disease SUV Threshold for Auto-Contouring of GTV
an Urban Underserved Community Intereferes with the Results? Initial Findings Using PETCT for Early Stage NSCLC
Haiying Cheng, Albert Einstein College of Med- at a Brazilian Cancer Center Mangesh Babarao Patil, Tata Memorial Hospi-
icine/Montefiore Medical Center, USA Fabio Jose Haddad, A.C.Camargo Cancer tal, India
Center, Brazil
P2.13-009: Results of Low-Dose CT Lung P2.14-006: A Pilot, Randomized Trial of
Cancer Screening at a Non-University Ter- P2.13-021: Community Network Lung Can- Daily Lisinopril vs Placebo to Prevent Radi-
tiary Hospital System in Oregon, USA cer Screening Experience Underrepresents ation-Induced Pulmonary Distress (Alliance
John R. Handy, Providence Cancer Center, USA Medically Underserved and Geographically MC1221)
Remote Individuals Terence Tai Weng Sio, Mayo Clinic Arizona, USA
P2.13-010: Five-Year-Long Follow-Up of the Candice Leigh Wilshire, Swedish Medical
Low-Dose Computed Tomography Screening Center and Cancer Institute, USA P2.14-007: Histological Difference in Out-
Programme in Gdansk, Poland comes of Definitive Chemoradiotherapy for
Marcin Ostrowski, Medical University of P2.13-022: Lung Nodule Survey: One non-small cell Lung Cancer
Gdansk, Poland Pathology, Perspectives from Thoracic Ito Hitoshi, Kyoto Katsura Hospital, Japan
Surgeon, Pulmonologist and Radiology Point
P2.13-011: Optimal Selection Criteria for of View P2.14-008: Partial and Full Arc VMAT in
LDCT Lung Cancer Screening Maria Teresa Ruiz Tsukazan, Hospital São Lung Cancer SBRT with Different Definitions
Renelle L. Myers, British Columbia Cancer Lucas da PUCRS, Brazil of Internal Target Volume Based on 4D CT
Agency, Canada Xiance Jin, The 1st Affiliated Hospital of Wen-
P2.13-023: Lung Cancer Risk and Eligibil- zhou Medical University, China
P2.13-012: Recruitment for Lung Cancer ity for Lung Cancer Screening in Patients
Screening Undergoing Computed Tomography Coronary P2.14-009: Assessing the Value of Radio-
Renelle L. Myers, British Columbia Cancer Angiography therapy for Lung Cancer in the Intensive
Agency, Canada Daniel P. Steinfort, Royal Melbourne Hospital, Care Unit - A Population-based analysis
Australia Alexander Vincent Louie, London Regional
P2.13-013: Determination of the Detection Cancer Program, Canada
Lead Time for Autoantibody Biomarkers in P2.13-025: Selecting the Risk Cut off for the
Early Stage Lung Cancer Using the UKC- LLP Model P2.14-010: The Time-Weighted Mid-Venti-
TOCS Cohort Kevin Ten Haaf, Erasmus MC, Netherlands lation Technique: Reducing Planning Target
Jim Jett, Oncimmune PLC, USA Volumes For Patients Undergoing Lung
P2.13-026: Determining the Effect of Stereotactic Body Radiotherapy.
P2.13-014: Computed Tomography-Based Screening on Lung Cancer Mortality Charlotte Emily Louise Atkinson, St George
Radiomic Classifier Distinguishes Malignant Claudia I. Henschke, Icahn School of Medicine Cancer Centre, Australia
from Benign Pulmonary Nodules in the at Mount Sinai, USA
National Lung Screening Trial P2.14-011: Recombinant Human Endostatin
Tobias Peikert, Mayo Clinic, USA P2.13-026a: A Validated Clinical Lung Can- (Endostar) Combined with Concurrent Inten-
cer Risk-Prediction Model for Light-, Heavy- sity Modulated Radiation Therapy for Elderly
P2.13-015: The Primary Care Provider and Ex-Smokers: the Lung-HUNT Model Local Advanced NSCLC
Role in the US Screening Context: Current Oluf Røe, Norwegian University of Science Qun Chen, Fuzhou Pulmonary Hospital of
Practices and Strategies for Physician and Technology, Norway Fujian, China
Engagement
Angela Meredith Criswell, Lung Cancer Alli- P2.14-012: Clinical Outcomes of the Largest
ance, USA UK Cohort of Cyberknife-Delivered Stereo-
P2.14 RADIOTHERAPY tactic Ablative Body Radiotherapy (SABR)
P2.13-016: Self-Reported Program Barriers for Primary Lung Cancers
to Increasing Lung Cancer Screening Rates Qamar Ghafoor, Queen Elizabeth Hospital, UK
P2.14-001: Mid-Treatment Perfusion PET/
in the US and Implications for the Screening
CT Is More Effective Than Ventilation PET/
Community P2.14-013: Effect of Stereotactic Radio-
CT in Functionally-Adapted Radiotherapy for
Angela Meredith Criswell, Lung Cancer Alli- therapy (SABR) on Pulmonary Function
NSCLC and Quality of Life: Results from a Tertiary
ance, USA
Roshini Thomas, Peter MacCallum Cancer Oncology Unit
P2.13-017: Four Years of Data in an Estab- Centre, Australia Qamar Ghafoor, Queen Elizabeth Hospital, UK
lished Low Dose CT (LDCT) Screening
P2.14-002: Impact of Pre-Existing Cardiac P2.14-014: Does Histological Subtype Affect
Program
Disease and Heart Doses on Survival in Outcomes in Stereotactic Ablative Body
Jacob Sands, Lahey Hospital & Medical
Nsclc Treated with Post-Operative Thoracic
Center, USA Radiotherapy (SABR) for Lung Tumours?
Radiotherapy
Qamar Ghafoor, University Hospitals Birming-
P2.13-018: Clinical Outcomes Stage I/0 Chia Ching Lee, National University Cancer
ham NHS Foundation Trust, UK
Adenocarcinoma Lung Diagnosed by Low Institute Singapore, Singapore
Dose CT (LDCT) Screening vs Incidentally P2.14-015: Outcomes for Stereotactic Abla-
P2.14-003: Clinical Outcomes of SBRT in tive Body Radiotherapy (SABR) for Early
Discovered
Inoperable Elderly Patients with NSCLC: Primary Lung Cancers: Cyberknife Versus
Jacob Sands, Lahey Hospital & Medical
Experience from a Developing Country VMAT Platform
Center, USA
Fabio Y. Moraes, Hospital Sirio Libanes, Brazil Qamar Ghafoor, University Hospitals Birming-
P2.13-019: Attrition Rate in Community-Based ham NHS Foundation Trust, UK
P2.14-004: Comparable Local Controls after
Lung Cancer Screening: One and Done
Twice-Daily and Once-Daily Chest Radio-
Candice L. Wilshire, Swedish Cancer Institute, P2.14-016: Pulomonary Resection After
therapy in Extensive Stage Small Cell Lung
USA Curative Intent Chemoradiation for NSCLC
Cancer
Gamze Cetinkaya, Uludag University, Turkey
Bo Qiu, Sun Yat-sen University Cancer Center,
China
P2.14-017: Postoperative Radiotherapy in P2.15-007: Extensive Stage Small Cell Lung

Completely Resected Stage IIIA-N2 Non- Cancer: Patterns of Care and Outcomes of a P2.16 SURGERY
Small Cell Lung Cancer Single Institution over 15 Years
Sung-Ja Ahn, Chonnam National University Eunji Hwang, Radiation Oncology Prince of P2.16-001: Liposomal Bupivacaine (Exparel)
Hwasun Hospital, Korea Wales Hospital, Australia Reduces Thoracic Surgery Post-Operative
Pain and Reduces Length of Stay, a Retros-
P2.14-018: Treatment Outcome and Lung P2.15-008: Genomic Analysis to Assess a petive Study
Toxicities of Volumetric Modulated Arc Molecular Signature in Japanese Patients
Joseph Aisner, Rutgers Cancer Institute of
Therapy in the Treatment of Inoperable Non- with Pulmonary High Grade Neuroendocrine
New Jersey, USA
Small-Cell Lung Cancer Patients Carcinoma
Congying Xie, The 1st Affiliated Hospital of Hideaki Kojima, Shizuoka Cancer Center, Japan P2.16-002: Adequacy of Lymph Node Sam-
Wenzhou Medical University, China pling during Lobectomy in a Small Commu-
P2.15-009: Linc00173 Modulates Chemo-
nity Teaching Hospital
P2.14-019: Magnetic Resonance (MR)- resistance of Small Cell Lung Cancer by
Mark A. Kryskow, Berkshire Medical Center,
Guided Adaptive Stereotactic Ablative Functioning as a Competing Endogenous
USA
Radiotherapy for Adrenal Metastases RNA to Regulate Etk Expression
Suresh Senan, VU University Medical Center, Fanrui Zeng, Zhujiang Hospital, Southern P2.16-003: Diagnostic Lobectomy for Inde-
Netherlands Medical University, China terminate Pulmonary Tumor
Noritoshi Nishiyama, Osaka City University,
P2.14-020: Clinical Validation of NTCP-Mod- P2.15-010: Etk Interacting with PFKFB4
Japan
els for Esophagus Toxicity in Non-Small Cell Modulates Chemoresistance of Small Cell
Lung Cancer Patients Treated with Concur- Lung Cancer by Regulating Autophagy P2.16-004: Alternative Subpreural Lymph
rent Chemoradiation Qiongyao Wang, Zhujiang Hospital, Southern Flow Pathways in Human Lung - a Hundred
Iris Walraven, The Netherlands Cancer Medical University, China Cases Experience and Analysis
Institute - Antoni van Leeuwenhoek Hospital, Takuya Tokunaga, Kagoshima University,
Netherlands P2.15-011: Therapeutic Strategies and
Japan
Genetic Comparisons in SCLC and LCNEC of
P2.14-020a: Retrospective Research on the Lung Using Next-Generation Sequencing P2.16-005: Is There Any Oncological
Radiofrequency Ablation (RFA) for Liver Masaoki Ito, Hiroshima University Hospital, Japan Concern about Preoperative Biopsy for
Metastasis Due to NSCLC: A Single Institu- Resectable Lung Cancer Patients?
tional Experience P2.15-012: Analysis of Small Cell Lung Can-
Hideyuki Kozuka, Kansai Medical University,
Kentaro Ito, Matsusaka Municipal Hospital, cer with Paraneoplastic Limbic Encephalitis
Japan
Japan Mingyi Di, Peking Union Medical College
Hospital, China P2.16-006: Locking of the Scapula after
Lobectomy with Rib Resection
P2.15-013: Doxorubicin and Topotecan for
Motohiro Nishimura, Saiseikai Suita Hospital,
P2.15 SCLC/NEUROENDOCRINE Relapsed/Refractory Small Cell Lung Cancer
Japan
TUMORS (SCLC): A FPBCC Clinical Trials Network
Phase I Study P2.16-007: Two Cases of VATS Resection
Apar Kishor Ganti, VA Nebraska Western for Endobronchial Protruded Tumors
P2.15-001: NHWD-870, a Novel BET Family Iowa Health Care System and University of
Bromodomain Inhibitor Targeting BRD2/3/4, Kunihiko Terauchi, Nara City Hospital, Japan
Nebraska Medical Center/Fred & Pamela
Proved to Be Effective and Promising for Buffett Cancer Center, USA
Treatment of Small Cell Lung Cancer P2.16-008: Collapsed Lung Index Ten Min-
Yongchang Zhang, Hunan Cancer Hospital, China utes after Thoracotomy and Pre-Operative
P2.15-014: Extensive Stage Small Cell Lung Pulmonary Function Tests
Cancer: Is Primary Growth Factor Support Junichi Shimada, Kyoto Prefectural University
P2.15-002: Pulmonary Large Cell Neuroen- Warranted in Patients Having Doublet Che-
docrine Carcinoma (LCNEC): An Experience of Medicine, Japan
motherapy?
From Eastern Indian Hospital Tasha Mackie, Auckland District Health Board,
Prasanta Raghab Mohapatra, All India Institute P2.16-009: Strategy for Oncologic Emer-
New Zealand gency in Thoracic Disease
of Medical Sciences, India
Ryohei Yoshikawa, Maebashi Red Cross
P2.15-015: Negativity for Thyroid Tran- Hospital, Japan
P2.15-003: A Long Non-Coding RNA HOT- scription Factor 1 Was Correlated with Less
TIP Expression Is Associated with Disease Neuroendocrine Differentiation in Small Cell
Progression and Predicts Outcome in Small P2.16-010: Removing the Chest Tube on the
Lung Cancers First Day after Surgery Does Not Contribute
Cell Lung Cancer Patients Yuko Iida, Nihon University School of Medicine,
Linlang Guo, Zhujiang Hospital, Southern to the Early Discharge from the Hospital
Japan Takuya Ohashi, Wakayama Medical University,
Japan
P2.15-016: Clinical Significance of
P2.15-004: Underrepresentation of Elderly Topoisomerase-II Expression in Patients
Patients with ED-SCLC as Clinical Trial P2.16-011: Unsuspectedly Detected Isolated
with Relapsed HGNEC of the Lung Treated Fibrinogen Deficiency in a Patient with Lung
Candidates (JCOG1201/TORG1528) with Amrubicin
Yuki Misumi, Yokohama Municipal Citizen’s Adenocarcinoma after Surgery
Yosuke Miura, Department of Respiratory Jeong Su Cho, Pusan National University
Hospital, Japan Medicine, Gunma University Graduate School Hospital, Korea
of Medicine, Japan
P2.15-005: Post-Progression Survival
Is Strongly Linked to Overall Survival in P2.16-012: Does Percutaneous Ultrasound
P2.15-016a: Exploiting G2-M Cell Cycle Predict Tumor Site and Internal Tumor
Refractory Small-Cell Lung Cancer Patients Checkpoint Dependency in Small Cell Lung
Who Received Amrubicin Properties?
Cancer (SCLC) by Targeting Checkpoint Gaku Yamaguchi, Chemotherapy Research
Hisao Imai, Gunma Prefectural Cancer Center, Kinase 1 (CHK1)
Japan Institute, Kaken Hospital, Japan
Triparna Sen, University of Texas MD Ander-
son Cancer Center, USA P2.16-013: Peripheral or Central Lung Nod-
P2.15-006: The Effects of Pegylated Argin-
ase on Small Cell Lung Cancer in vitro and ules: How do Thoracic Surgeons Define it?
in vivo Rowena Yip, Icahn School of Medicine at
Shi Xu, The University of Hong Kong, Hong Kong Mount Sinai, USA
P2.16-014: Deconstructing Surgical Decision P2.16-027: Comparison of Single Chest Tube

Making Versus Double Chest Tube Drainage After
Rowena Yip, Icahn School of Medicine at Lung Resection for the Treatment of Non-
Mount Sinai, USA Small Cell Lung Cancer
Tomasz Gil, Jagiellonian University, John Paul
P2.16-015: Log Data of Digital Drainage II Hospital, Poland
System Is a Potential Predictive Factor of
Pleurodesis Efficacy for Postoperative Air P2.16-028: Are We Doing the Right Thing?
Leak After Pulmonary Resection Overall Survival & Intermediate Outcomes
Tomonari Oki, National Cancer Center Hospital Following Lung Metastasectomy
East, Japan Prakash Balakrishnan, Wellington Regional
Hospital, New Zealand
P2.16-016: Surgical Treatment of Indetermi-
nate Lung Nodules
Masashi Yanada, Japanese Red Cross Kyoto
Daini Hospital, Japan P2.17 THYMIC MALIGNANCIES/
ESOPHAGEAL CANCER/OTHER
P2.16-017: Surgical Treatment of Bronchial THORACIC MALIGNANCIES
Carcinoid Tumors: Evaluation of Survival
and Prognostic Factors. A Single-Center
Experience P2.17-001: Pulmonary Inflammatory Myofi-
Piotr Rudzinski, National Institute of Tubercu- broblastic Tumor with TPM4-ALK Translo-
losis and Lung Diseases, Poland cation
Katsuhiro Okuda, Nagoya City University Grad-
P2.16-018: Phrenic Nerve Injury After Lung uate School of Medical Sciences, Japan
Surgery: An Underestimated Problem
Luigi Ventura, University Hospital of Parma, P2.17-002: Pulmonary and Mediastinal Para-
Italy gangliomas: Rare Endothoracic Malignancies
with Challenging Diagnosis and Treatment
P2.16-019: Improving Survival with a Lymph Angela De Palma, University of Bari “Aldo
Node (LN) Collection Kit for Non-Small Cell Moro”, Italy
Lung Cancer (NSCLC) Resections
Raymond U. Osarogiagbon, Baptist Cancer P2.17-003: Is Complete Resection Manda-
Center, USA tory for Mediastinal Germ Cell Tumor Which
Shows Severe Adhesion to Greater Vessels?
P2.16-020: Surgical Strategy for Synchro- Hiroyuki Ito, Kanagawa Cancer Center, Japan
nous Multiple Lung Cancer with Ground
Glass Opacity P2.17-004: Salvage Surgery for Pulmonary
Toshihiko Moroga, Fukuoka University Chikushi Metastases in Patients with Testicular Germ
Hospital, Japan Cell Tumors
Shinji Kikuchi, University of Tsukuba, Japan
P2.16-021: Malignant Melanocytic Neoplasm:
A Rare Presentation of a Large Mediastinal
Mass
Tina Koh, National Cancer Centre, Singapore
P2.16-022: Initiative for Early Lung Cancer

Research on Treatment: Pilot Implementation
Claudia I. Henschke, Icahn School of Medicine
at Mount Sinai, USA
P2.16-023: Changes of the Pulmonary

Artery After Resection of Stage I Lung
Cancer
Michael Chung, Mount Sinai Hospital, USA
P2.16-024: Effect of Resection of Stage 1

Lung Cancer on Lung Volume
Artit Jirapatnakul, Icahn School of Medicine at
Mount Sinai, USA
P2.16-025: Accuracy of Multidisciplinary

Evaluation of Small Solitary Pulmonary Nod-
ules in a Portuguese Private Hospital
Joao Reis, Hospital da Luz, Portugal
P2.16-026: Surgical Treatment for Metastatic

Lung Tumors from Various Sarcomas
Hiromasa Yamamoto, Okayama University
Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences, Japan
POSTER SESSIONS | WEDNESDAY, OCTOBER 18
POSTERS AT A GLANCE
Wednesday, October 18 | Poster Session 3

P3.01 ADVANCED NSCLC P3.13 RADIOLOGY/STAGING/SCREENING
P3.01-001 – P3.01-076a EGFR P3.13-001 – P3.13-038a DIAGNOSTIC RADIOLOGY

P3.01-077 – P3.01-088a OTHER GROUPS AND TARGETS
P3.14 RADIOTHERAPY
P3.02-001 – P3.02-014a ANALYSIS OF BODY FLUIDS IN CANCER P3.15 SCLC/NEUROENDOCRINE TUMORS

P3.02-015 – P3.02-017 APOPTOSIS IN LUNG CANCER
P3.02-018 – P3.02-070 DRIVER GENES IN NSCLC,
P3.16 SURGERY
RESISTANCE, AND OTHER
P3.02-071 – P3.02-097e FUNCTIONAL BIOLOGY P3.16-001 – P3.16-036 RISK ASSESSMENT
IN LUNG CANCER AND PROGNOSTIC FACTORS
P3.16-037 – P3.16-049 SURGERY FOR LOCALLY ADVANCED
AND ADVANCED NSCLC
P3.16-050 – P3.16-053a TRANSLATIONAL STUDIES
P3.04 CLINICAL DESIGN, STATISTICS

P3.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/
AND CLINICAL TRIALS
P3.05 EARLY STAGE NSCLC

P3.07 IMMUNOLOGY AND IMMUNOTHERAPY
P3.09 MESOTHELIOMA
P3.12 PULMONOLOGY/ENDOSCOPY
POSTERS IN DETAIL
Wednesday, October 18 | Poster Session 3

P3.01-006: Osimertinib in Pretreated EGFR P3.01-018: Mutation Abundance Affects the
T790M-Positive Non-Small Cell Lung Cancer Therapeutic Efficacy of EGFR-TKI in Patients
POSTER SETUP TIME Patients with Leptomeningeal Carcinoma- with Advanced Lung Adenocarcinoma: A
tosis Retrospective Analysis
Bin-Chi Liao, National Taiwan University Huijuan Wang, Henan Cancer Hospital, China
Wednesday, October 18 08:00 – 10:00 Hospital, Taiwan
P3.01-019: Canadian Multicentre Validation
P3.01-007: Heterogeneous Resistance Mech- Study of Plasma Circulating Tumour DNA
POSTER TAKEDOWN TIME anisms in Rebiopsies from EGFR-Mutated for Epidermal Growth Factor (EGFR) T790M
NSCLC: Transformation to SCLC; FGFR3 and Testing
T790M Mutations Ming Sound Tsao, University Health Network
Wednesday, October 18 15:30 – 18:00 Edyta Maria Urbanska, University of Copenha- Princess Margaret Cancer Centre, Canada
gen, Rigshospitalet, Finsens Center, Denmark
Posters not taken down by 18:00 P3.01-020: Clinical Features of Patients with
will be discarded by management P3.01-008: Association between Icotinib Non-Small Cell Lung Cancer (NSCLC) Har-
Efficacy and Circulating Tumor Cell Levels in bouring Epidermal Growth Factor Receptor
Advanced Non-Small Cell Lung Cancer (EGFR) Mutations in Brunei
PRESENTERS IN ATTENDANCE
Meiyu Fang, Zhejiang Cancer Hospital, China Shir Kiong Lu, The Brunei Cancer Centre,
AT THEIR POSTER Brunei Darussalam
P3.01-009: Clinical Efficacy of Icotinib in
10:00 – 10:45 and 14:30 – 15:30 Patients with Advanced Non-Small Cell Lung P3.01-021: A Multicenter, Non-Interventional
Cancer Harboring EGFR Exon 18 E709X Study on Real World EGFR Testing and in
Mutations Patients with IIIB/IV NSCLC in Northern
Meiyu Fang, Zhejiang Cancer Hospital, China China
LOCATION: EXHIBIT HALL (HALL B + C)
Ying Cheng, Jilin Provincial Cancer Hospital,
P3.01-010: High Probability and Frequency China
of EGFR Mutations in Non-Small Cell Lung
Cancer with Brain Metastases P3.01-022: Prognostic Value of Clini-
Xiaohua Liang, Huashan Hospital, China cal, Immune and Biochemical Markers in
P3.01 ADVANCED NSCLC EGFR-Mutant NSCLC Patients Treated with
P3.01-011: Comparision of EGFR and First-Line EGFR TKIs
ALK-Driven Lung Adenocarcinoma with Isaac Kah Siang Ng, NUS Yong Loo Lin School
P3.01-001 – P3.01-076a Brain Metastases for Prognostic Factors in of Medicine, Singapore
EGFR Chinese Patients
Fengnan Wang, The First Affiliated Hospital of P3.01-023: First-line Afatinib for Non-Small
P3.01-001: Comparisons of Two Plasma Guangzhou Medical University, China Cell Lung Cancer in Real World Practice
EGFR Platforms (ddPCR and Cobas) in Youjin Kim, Samsung Medical Center, Korea
Patients with Radiological Metastatic Lung P3.01-012: Symptom Impact of First-Line
Cancer Dacomitinib versus Gefitinib in EGFR-Pos- P3.01-024: Characterization of PD-L1
itive NSCLC: Results from a Randomized Expression and Its Predictive and Prog-
Jacky Yu Chung Li, Queen Elizabeth Hospital,
Phase 3 Study nostic Significance in EGFR-Mutant NSCLC
Hong Kong
Rickard Sandin, Pfizer Oncology, Sweden Patients Treated with EGFR-TKIs
P3.01-002: Concurrent EGFR T790M Tao Jiang, Shanghai Pulmonary Hospital,
Secondary Mutation and EMT in a Lung P3.01-013: CNS Metastases in EGFR Tongji University School of Medicine, China
Adenocarcinoma Patient with EGFR TKI Mutation Positive NSCLC: Impact on Health
Drug Resistance Resource Utilization P3.01-025: Treatment Outcomes of
Renwang Liu, Tianjin Medical University Gen- Negar Chooback, British Columbia Cancer Advanced Lung Adenocarcinoma with
Agency, Canada Unknown EGFR Gene Status: A Retrospec-
eral Hospital, China
tive Analysis of 140 Patients
P3.01-003: Study of the Relationship P3.01-015: Differential Outcomes between Cheng Xiao, The First Affiliated Hospital,
between EGFR Mutation Status and Bone First and Second Generation TKIs in Patients School of Medicine, Zhejiang University, China
Metastasis in Advanced Lung Adenocarci- with Activating EGFR Mutations in NSCLC
noma Sally C. Lau, British Columbia Cancer Agency, P3.01-026: Analysis of Long-Term Response
Zhao Bing, Affiliated Tumor Hospital of Xinji- Canada to First-Line Afatinib in the LUX-Lung 3, 6
ang Medical University, China and 7 Trials in Advanced EGFRm+ NSCLC
P3.01-016: Factors Associated with Symp- Martin Schuler, West German Cancer Center,
P3.01-004: The Underestimated Role of toms Improvement and HRQoL for First- University Hospital Essen, University Duis-
Bronchial Washing Fluid in the Detection of Line EGFR-TKIs in NSCLC: A Multicenter burg-Essen, Germany
EGFR Mutation from Lung Cancer Patients Prospective SMILE Study
Jie Hu, Zhongshan Hospital, China Yu-Feng Wei, E-Da Hospital/I-Shou University, P3.01-027: TET2 Mutation as a Novel Mech-
Taiwan anism of Acquired Resistance to EGFR TKIs
P3.01-005: ASTRIS: A Real World Study of Identified by a Mutational Profiling Using
Osimertinib Treatment in Patients with EGFR P3.01-017: Clinical Outcomes of Patients NGS
T790M Positive Advanced NSCLC; Interim with EGFR T790M + NSCLC on Osimertinib Xiao Hu, Zhejiang Cancer Hospital, China
Analysis Wan Ling Tan, National Cancer Centre Singa-
Sang-We Kim, Asan Medical Center, University pore, Singapore P3.01-028: Efficacy of Osimertinib for Brain
of Ulsan College of Medicine, Korea Metastasis in Advanced NSCLC: Data from
Single Center in ASTRIS Trial
Jee Hung Kim, Yonsei Cancer Center, Korea
P3.01-029: Transient Asymptomatic Pulmo- P3.01-041: The Robustness of Allele-Spe- P3.01-052: The Prevalence and Genotype
nary Opacities (TAPOs) during Osimertinib cific qPCR Assays for Detection of EGFR Distribution of Dual in Cis EGFR Mutations
Treatment and Its Clinical Implication Mutations in Plasma Cell-Free DNA from in Chinese Advanced Non-Small Cell Lung
Hansang Lee, Samsung Medical Center, Korea NSCLC Patients Cancer Patients
Joanna Chorostowska-Wynimko, National Min Li, Xiangya Hospital, Central South Univer-
P3.01-030: CNS Metastases in EGFR Institute of Tuberculosis and Lung Diseases, sity, China
Mutation Positive (EGFRm) NSCLC Patients: Poland
The Prognostic Relevance of Presenting P3.01-053: Detection of Common EGFR
Symptoms P3.01-042: Efficacy & Tolerability of Afatinib Mutation in Cytological Smears Using
Negar Chooback, British Columbia Cancer in NSCLC Patients Prior Exposure to 1st Reversed Dot Blot (RDB) Hybridization
Agency, Canada Generation EGFR TKI: Thailand Multicenter Method
Study Najmiatul Masykura, Stem-cell and Cancer
P3.01-031: ctDNA Assessment of EGFR Thanyanan Reungwetwattana, Ramathibodi Institute, Indonesia
Mutation Status in Chinese Patients with Hospital, Thailand
Advanced Non–Small-Cell Lung Cancer in P3.01-054: Urinary ct-DNA Testing of EGFR
Read World Setting P3.01-043: Impact of ErbB Mutations on Common Mutation in Non-Small Cell Lung
Shirong Zhang, Affiliated Hangzhou Hospital of Clinical Outcomes in Afatinib- or Erlo- Cancer Patients
Nanjing Medical University, China tinib-Treated Patients with SCC of the Lung Asep Muhamad Ridwanuloh, Indonesian Insti-
Glenwood Goss, University of Ottawa, Canada tute of Sciences, Indonesia
P3.01-032: Preliminary study of Lung
Cancer Adenocarcinoma with De-novo EGFR P3.01-044: Erlotinib vs Chemotherapy in P3.01-055: The Usefulness of Liquid Biopsy
T790M Mutation in Persahabatan Hospi- EGFR Mut+ NSCLC: OS in Three Phase III for ctDNA in Patients with EGFR-Mutant
tal-Jakarta, Indonesia. Trials Adjusting for Post-Progression Treat- NSCLC During and After Treatment with
Hapsari Dewanti, Faculty of Medicine Uni- ment Crossover EGFR-TKIs
versitas Indonesia - Persahabatan National Yi-Long Wu, Guangdong General Hospital & Takuma Yokoyama, Kyorin University Hospital,
Respiratory Referral Hospital, Indonesia Guangdong Academy of Medical Sciences, Japan
China
P3.01-033: Detection of Epidermal Growth P3.01-056: Intracranial Activity of Osimerti-
Factor Receptor Mutations with Plasma P3.01-045: Correlation of EGFR Mutation nib in Naïve EGFRm T790M(-)And Treated
Sample Compared with Tumor Tissue Biopsy Detection in CtDNA by Two Different Plat- EGFRm T790M(+) NSCLC Patients with
in Advanced Lung Adenocarcinoma forms in Advanced NSCLC Patients from a Asymptomatic Brain Metastases
Taewon Jang, Kosin Univeristy Gosepel Hos- Single Institution Nir Peled, Rabin Medical Center, Davidoff
pital, Korea Noemi Reguart, Hospital Clinic, Translational Cancer Center, Israel
P3.01-034: Liquid Biopsy for EGFR Geno- Tumors, Institut d’Investigacions Biomèdiques P3.01-057: Comparison of EGFR Mutations
typing Using Cell-Free DNA and Extracel- August Pi i Sunyer (IDIBAPS), Spain in Matched Tumor Tissues, Cell Blocks,
lular Vesicular DNA of Pleural Effusion in Pleural Effusions and Bloods with NSCLC, by
Pulmonary Adenocarcinoma Patients P3.01-046: Longitudinal Analysis of Plasma PANA Mutyper and PNA Clamping
Jong Sik Lee, Konkuk University School of CtDNA in EGFR-Mutant NSCLC: SWOG Seung Joon Kim, The Cancer Research
Medicine, Korea S1403 Trial of Afatinib with or Without Institute, College of Medicine, The Catholic
Cetuximab University of Korea, Korea
P3.01-035: Post-Marketing Observational Philip Christopher Mack, UC Davis Compre-
Study of Japanese Patients with EGFR Muta- hensive Cancer Center, USA P3.01-058: Impact of Different Timing of
tion-Positive (EGFRm+) NSCLC Treated with Radiotherapy in Patients with Brain Metasta-
Daily Afatinib (Final Report) P3.01-047: Erlotinib Induced Ectropion Fol- ses from Epidermal Growth Factor Recep-
Nobuyuki Yamamoto, Wakayama Medical lowed by Papulo-Erythemato Skin Rash tor-Mutant NSCLC
University, Japan Abdolali Shahrasbi, Bouali Hospital, Tehran Yaping Xu, Zhejiang Cancer Hospital, China
Medical unit, Azad University, Iran
P3.01-036: A Phase IIIb Open-Label, Sin- P3.01-059: First Experience with Osimerti-
gle-Arm Study of Afatinib in EGFR TKI-Naïve P3.01-048: CBL Mutations as Potential nib in Patients with Newly Developed T790M
Patients with EGFRm+ NSCLC: An Interim Mediators of EGFR TKI Resistance Effec- Mutation Previously Treated with EGFR -
Analysis tively Treated with Sitravatinib TKIs in Croatia
Yi-Long Wu, Guangdon Lung Cancer Institute, Lyudmila A. Bazhenova, University of Califor- Marko Jakopovic, University Hospital Centre
China nia San Diego Moores Cancer Center, USA Zagreb, Croatia
P3.01-037: Understanding Mechanisms of P3.01-049: T790M Mutation Detection, P3.01-060: The Clinical Utility of ctDNA
Resistance to Osimertinib by Circulating Clinical Characteristics and Impact in NSCLC Gene Analysis in Lung Cancer
Tumor DNA Genotyping in Advanced Non- Patients Treated with EGFR Tyrosine Kinase Smadar Geva, Thoracic Cancer Service,
Small-Cell Lung Cancer Inhibitors Davidoff Cancer Center, Rabin Medical Center,
Gang Cheng, Novogene Co., Ltd., China Júlio Oliveira, Instituto Português de Oncologia Israel
do Porto, Portugal
P3.01-038: Impact on OS and PFS of 2nd P3.01-061: Endostar Combined with
and 3rd Generation TKI in EGFR Mt+ and P3.01-050: A Real World Treatment Study of Re-Challenged Gefitinib in Previous Treat-
ALK+ Patients: Results of the NOWEL Osimertinib: ASTRIS Study Korean Subgroup ment Failed NSCLC: A Retrospective Study
Network Analysis Huijuan Wang, Henan Cancer Hospital, China
Julia Roeper, Pius Hospital Oldenburg/Univer- Byoung Chul Cho, Yonsei Cancer Center, Korea
sity of Oldenburg, Germany P3.01-062: The Perceived Value of Avoiding
P3.01-051: Dramatic Response to Afatinib Biopsy: Patients’ Willingness to Pay for
P3.01-040: Real-World Management of in EGFR-Mutant Lung Adenocarcinomas Circulating Tumour DNA T790M Testing
Patients with EGFR Mutation-Positive After Resistance to First-Generation EGFR Tristan Alexandra Barnes, Princess Margaret
NSCLC in the US Inhibitors: A Brief Report Cancer Centre, Canada
Apar Kishor Ganti, VA Nebraska Western Wen -Feng Li, Guangdong Lung Cancer Insti-
Iowa Health Care System and University of tute, Guangdong General Hospital and Guang-
Nebraska Medical Centre, USA dong Academy of Medical Sciences, China
P3.01-063: Concomitant EGFR Mutation and P3.01-074: Genomic Analysis of Tumor and P3.01-083: Clinical Characteristics and
ALK Rearrangement in Non-Small-Cell Lung Plasma in T790M Mutant Positive EGFR Survival Outcomes for Non-Small Cell Lung
Cancer Lung Cancer Patients before and after Osim- Cancer Patients with Epidermal Growth
Rui-Lian Chen, Guangdong Lung Cancer Insti- ertinib Treatment Factor Receptor Double Mutations
tute, Guangdong General Hospital and Guang- James Chih-Hsin Yang, National Taiwan Uni- Min Peng, Renmin Hospital of Wuhan Univer-
dong Academy of Medical Sciences, China versity, Taiwan sity, China
P3.01-064: Detection of EGFR Mutations P3.01-075: Afatinib Dose Adjustment: Effect P3.01-084: Analysis on ALTER0303 Trial:
in Circulating Tumor DNA Using Plasma on Safety, Efficacy and Patient-Reported aCECs Level May Correlate with Metasta-
Samples: Clinical Validation of Cobas EGFR Outcomes in the LUX-Lung 3/6 Trials in ses Burden and Predict PFS of Anlotinib in
Mutation Test V2 EGFRm+ NSCLC Advanced NSCLC
Hidetoshi Itani, Ise Red Cross Hospital, Japan Vera Hirsh, McGill University, Canada Kai Li, Tianjin Medical University Cancer Insti-
tute and Hospital, China
P3.01-065: Advanced NSCLC with EGFR P3.01-076: QTWiST Analysis to Compare
Mutations in Elderly Patients. Single-Centre the Benefit of Gefitinib Versus Pemetrexed P3.01-085: A Phase 2 Trial of Apatinib in
Experience Platinum for Patients with EGFR Mutated Advanced Non-Squamous NSCLC: Updated
Angel Artal Cortes, Hospital Universitario NSCLC Data and Clinical Benefit of Continuing Apa-
Miguel Servet, Spain Vijay Patil, Tata Memorial Hospital, India tinib after Initial Progression
Fengying Wu, Shanghai Pulmonary Hospital,
P3.01-066: CNS Metastases of Pulmonary P3.01-076a: Lung Cancer Stem Cell (LCSC) Tongji University, China
Adenocarcinoma Harboring EGFR-Activating Markers and Epidermal Growth Factor
Mutations: a Multidisciplinary Approach, Receptor (EGFR) Tyrosine Kinase Inhibitors P3.01-086: Biomarker Testing Trends and
Including EGFR-TKis (TKIs) Resistance Treatment Patterns in Advanced Non-Small
Renata Rodrigues da Cunha Colombo Bonadio, Shinnosuke Takemoto, Nagasaki Medical Cell Lung Cancer (NSCLC) Patients in the
Instituto do Cancer do Estado de Sao Paulo, Center, Japan United States
Brazil Laura Chu, Genentech, USA
P3.01-067: TP53 Mutations Could Involved in P3.01-077 – P3.01-088a P3.01-087: Impact Factor Analysis for Effi-
EGFR-TKI Primary Resistance in Advanced OTHER GROUPS AND TARGETS cacy and Prognosis of Anlotinib in NSCLC as
Non-Small Cell Lung Cancer Third-Line Treatment: Data from Trial ALTER
Tao Jiang, Shanghai Pulmonary Hospital, 0303
Tongji University School of Medicine, China P3.01-077: Effectiveness of Methylnaltrex- Kai Li, Tianjin Medical University Cancer Insti-
one Bromide in Opioid-Induced Constipation tute and Hospital, China
P3.01-068: Investigation of Low Plasma/Tis- in Advanced NSCLC Patients
sue EGFR Concordance in Russia: Follow-up Ioannis Dimitroulis, Sotiria Hospital for Tho- P3.01-088: Molecular Testing and First-Line
to the IGNITE Global Diagnostic Study racic Diseases, Greece Treatment of Patients with NSCLC. First
Brian B. Lentrichia, AstraZeneca Pharmaceu- Results from the German CRISP Study (AIO-
ticals, USA P3.01-078: Outcome of Stage IIIb Non-Small TRK-0315)
Cell Lung Cancer (NSCLC) Patients - A Martin Sebastian, University Hospital Frank-
P3.01-069: Three Treatments for EGFR-Mu- Single Tertiary Center Experience furt, Germany
tant Non-Small-Cell Lung Cancer with Brain Tahir Mehmood, Northwest General Hospital
Metastases and Research Centre, Pakistan P3.01-088a: Phase II Study of Nab-Pacl-
Yun Fan, Zhejiang Cancer Hospital, China itaxel in Previously Treated Patients with
P3.01-079: Evaluating the Roles of Neo- Advanced Non-Small Cell Lung Cancer:
P3.01-070: A Phase II Study of Fruquintinib adjuvant and Adjuvant Chemotherapy for SNIPER Study
in Combination with Gefitinib in Stage IIIb/IV Treating Patients with Stage IIIa (N2) Lung Naruo Yoshimura, Graduate School of Medi-
NSCLC Patients Harboring EGFR Activating Cancer cine, Osaka City University, Japan
Mutations Luo-Sheng Yong, National Taiwan University,
Shun Lu, Shanghai Chest Hospital, China Taiwan
P3.01-071: Randomized Phase 1b/3 Study of P3.01-080: Overall Survival (OS) of Patho- P3.02 BIOLOGY/PATHOLOGY
Erlotinib + Ramucirumab in Untreated EGFR logical N2 Non-Small Cell Lung Cancer
Mutation-Positive Stage IV NSCLC: Phase 1b (NSCLC) After Surgical Resection
Outcomes Etienne Bourdages-Pageau, Laval University, P3.02-001 – P3.02-014
Kazuhiko Nakagawa, Kindai University School Canada ANALYSIS OF BODY FLUIDS IN CAN-
of Medicine, Japan CER
P3.01-081: Overall Survival (OS) of Locally
P3.01-072: Dacomitinib Versus Gefitinib for Advanced Non-Small Cell Lung Cancer P3.02-001: Clinical Significance of Plasma
First-Line Treatment of Advanced EGFR+ (NSCLC) After Negative Invasive Mediastinal Epstein-Barr Virus DNA in Pulmonary
NSCLC in Japanese Patients (ARCHER Staging Lymphoepithelioma-Like Carcinoma (LELC)
1050) Arthur Vieira, Institut Universitaire de Cardi- Patients
Kazuhiko Nakagawa, Kindai University Hospi- ologie et de Pneumologie de Québec (IUCPQ), Mian Xie, The First Affiliated Hospital of
tal, Japan Canada Guangzhou Medical University, China
P3.01-073: TPX-0005 with an EGFR Tyro- P3.01-082: Surgical Rebiopsy in Advanced P3.02-002: Liquid and Solid Rebiopsies in
sine Kinase Inhibitor (TKI) Overcomes Innate Non-Small Cell Lung Cancer Resistant to EGFR-Mutated NSCLC Patients
Resistance in EGFR Mutant NSCLC Previous Chemotherapy Alexis B. Cortot, Lille University Hospital,
Rafael Rosell, Catalan Institute of Oncology, Sumin Shin, Samsung Medical Center, France
Germans Trias i Pujol Health Sciences Institute Sungkyunkwan University School of Medicine,
and Hospital, Spain Korea P3.02-003: Tissue and Serum Levels of
Galectin-3 in NSCLC Patients
Yoko Kataoka, Shiga University of Medical
Science, Japan
P3.02-004: Analysis of MET in Liquid P3.02-014: Amplicon-Based Next-Genera- P3.02-022: Protein Tyrosine Phosphatase
Biopsy and Tissue Biopsy in Patients with tion Sequencing (NGS) of Plasma Cell-Free Interacting Protein 51 Might Improve EGFR-
Advanced NSCLC: Incidence and Pattern. DNA (cfDNA) for Detection of Driver and TKI Sensitivity in Non-Small-Cell Lung
Edgardo S. Santos, Thoracic and Head and Resistance Mutations in NSCLC Cancer
Neck Cancer Programs, Eugene M. & Christine Nicolas Marie Guibert, Dana Farber Cancer Xing Wang, Key Laboratory of Carcinogene-
E. Lynn Cancer Institute, Florida Atlantic Uni- Institute, USA sis and Translational Research (Ministry of
versity, Boca Raton, FL, USA Education), China
P3.02-014a: Diagnostic Value of FR + - CTCs
P3.02-005: Applicability of Ion Torrent Detected by LT-PCR for Lung Cancer in SPN P3.02-023: Semaphorin 7A Reduces
Colon and Lung Sequencing Panel on Circu- and Tumor Invasiveness in Adenocarcinoma Response to EGFR-TKI Treatment via Apop-
lating Cell-Free DNA Qianjun Zhou, Shanghai Chest Hospital, tosis in Human Lung Adenocarcinoma
Christina Demuth, Aarhus University Hospital, Shanghai Jiaotong University School of Med- Yuhei Kinehara, Department of Respiratory
Denmark icine, China Medicine, Allergy and Rheumatic Diseases,
Osaka University Graduate School of Medicine,
P3.02-006: Monitoring Genetic Alterations Japan
in Plasma during Anti-Cancer Treatment P3.02-015 – P3.02-017
in Advanced NSCLC (MAGIC1-Validation APOPTOSIS IN LUNG CANCER P3.02-024: Role of FBXW7 in the Mainte-
Cohort: Preliminary Results) nance of Quiescent Cancer Stem Cells Resis-
Laura Bonanno, 1. Medical Oncology 2, Istituto tant to Gefitinib in EGFR Mutation-Positive
Oncologico Veneto IRCCS, Italy P3.02-015: 433MHz Microwave Radia- Non-Small Cell Lung Cancer
tion Induces G2/M Checkpoint Arrest and Moulid Hidayat, Juntendo University Graduate
P3.02-007: Circulating miRNAs as Prog- Promotes Apoptosis under Hyperthermia in School of Medicine, Japan
nostic Biomarkers in Resected Early-Stages Non-Small Cell Lung Cancer Cells
Non-Small-Cell Lung Cancer Yanyan Zhao, Hangzhou First People’s Hospi- P3.02-025: 65 Cases of Molecular Profiling
Lucio Crinò, Medical Oncology- Istituto Sci- tal, Nanjing Medical University, China Anaysis in Surgical Resected Pulmonary
entifico Romagnolo per lo Studio e la Cura dei Neuroendocrine Carcinoma
Tumori (IRST) IRCCS, Italy P3.02-016: Correlation of Programmed Cell Gang Chen, Fujian Provincial Cancer Hospital,
Death Ligand-1 Messenger RNA and Protein China
P3.02-008: Non-Invasive Diagnosis Expression in Non-Small Cell Lung Cancer
of Solitary Pulmonary Nodules Using Hyun Jung Kwon, Seoul National University P3.02-026: The Study of ROS1 Rearrange-
High-Throughput Targeted DNA Methylation Bundang Hospital, Korea ment in Advanced Primary Non-Small Cell
Sequencing of Circulating Tumor DNA Lung Cancer and Associated Metastatic
Wenhua Liang, The First Affiliated Hospital of P3.02-017: Apoptosis-Related Protein in Lesions
Guangzhou Medical University, National Clini- Non Small Cell Lung Cancer: Correlation of Gang Chen, Fujian Provincial Cancer Hospital,
Clinicopathologic, Molecular Characteristics China
cal Research Center for Respiratory Disease,
and Prognosis
China State Key Laboratory of Respiratory
Ping-Li Sun, Jilin University Second Hospital, P3.02-027: Lung Adenocarcinoma Patient
Disease, China
China with EGFR 19 Exon Insert Mutation: I740_
P3.02-009: Mutation Detection in Cell-Free K745insIPVAIK and Its Response to Icotinib:
DNA from Patients with Lung Adenocarci- A Case Report
noma by Next-Generation Sequencing P3.02-018 – P3.02-070 Gang Chen, Fujian Provincial Cancer Hospital,
Hana Khairina Putri Faisal, Natural Science DRIVER GENES IN NSCLC, China
Center for Basic Research Development, RESISTANCE, AND OTHER
Graduate School of Biomedical and Health P3.02-028: 276 Cases of EGFR/ALK Gene
Sciences, Japan Status and Predominant Histologic Subtype
P3.02-018: Patients Harboring ALK Rear-
in Chinese Surgically Resected Lung Adeno-
rangement Adenocarcinoma after Acquired
P3.02-010: Significant Increase of Blood Resistance to Crizotinib and Transformation carcinoma
Extracellular Vesicles in Pulmonary Vein to SCLC: A Case Report Gang Chen, Fujian Provincial Cancer Hospital,
as Potential Prognostic Biomarker for Lung Meiyu Fang, Zhejiang Cancer Hospital, China China
Cancer Patients
Byeon Hyeon Choi, Korea University Guro P3.02-019: Clinical Validation of a Real Time P3.02-029: 218 Cases of EGFR/ALK Gene
Hospital, Korea PCR Assay for the Detection of ROS1 Fusion Status Anaysis in Chinese Lung Squamous
in Chinese Non-Small Cell Lung Cancer Cell Carcinoma
P3.02-011: A Prospective Study of Serial Guanshan Zhu, Amoy Diagnostics Co., Ltd., Gang Chen, Fujian Provincial Cancer Hospital,
Circulating Tumor DNA Assessment in China China
Detecting Recurrence of Resected Ear-
ly-stage Lung Cancer P3.02-020: Comparison of Diagnostic Ability P3.02-030: Inhibitory Effects of Mitochon-
Hong Kwan Kim, Samsung Medical Center, for EGFR Mutation of the Specimen Groups: drial TRAP1 on Gefitinib-Resistance in Non-
Sungkyunkwan University School of Medicine, Histology - Cytology - Plasma Small Lung Cancer Cells
Korea Nguyen Son Lam, Pham Ngoc Thach Hospital, Euntaik Jeong, Wonkwang University Hospital,
Vietnam Korea
P3.02-012: Liquid Based Cytology (LBC)
Specimens Were Useful for EGFR Mutation P3.02-021: Secondary EGFR Exon 20 P3.02-031: Detection of Activating EGFR
Test T790m Mutation for Therapy of Non Small Mutations and Resistant T790M Mutation
Tatsuo Ohira, Tokyo Medical University, Japan Cell Lung Cancer at Phat Ngoc Thach - Ho from cfDNA in Malignant Pleural Effu-
Chi Minh City - Vietnam sion(MPE-DNA)
P3.02-013: Prognostic Role of Circulat- Nguyen Son Lam, Pham Ngoc Thach Hospital, Kirsty Wai Chung Lee, Chinese University of
ing Tumor DNA (ctDNA) and Immune Cell Vietnam Hong Kong, Hong Kong
Biomarkers in Non-Small Cell Lung Cancer
(NSCLC)
Young Kwang Chae, Robert H Lurie Com-
prehensive Cancer Center of Northwestern
University, USA
P3.02-032: Spatial Heterogeneity of EGFR P3.02-045: Prevalence of ALK Gene Abnor- P3.02-057: Comparison of Molecular Testing
and KRAS Variant Allele Frequencies Cor- malities in Routine Diagnostics of Polish Modalities for Detection of ROS1 Rear-
relates with Histological Patterns of Lung NSCLC Patients rangements in a Cohort of Positive Patient
Adenocarcinomas Kamila Wojas-Krawczyk, Medical University of Samples
Steffen Dietz, German Cancer Research Lublin, Poland Kurtis D. Davies, University of Colorado -
Center (DKFZ) and National Center for Tumor Anschutz Medical Campus, USA
Diseases (NCT), Germany P3.02-046: EGFR-Grb2-GEP100 Complex
Promoted Its Invasive and Metastatic Poten- P3.02-058: Detection of ROS1 Rearrange-
P3.02-033: Pathological and Molecular tial via Arf6 Pathway in Lung Adenocarci- ments in 508 Russian Patients with Non-
Alterations after First and Second Gener- noma Small Cell Lung Cancer (NSCLC)
ation EGFR-TKI Therapy in Patients with Toshi Menju, Graduate School of Medicine, Irina Demidova, Moscow Oncological Hospital
EGFR-Mutated Lung Adenocarcinomas Kyoto University, Japan 62, Russia
Hironori Uruga, Toranomon Hospital, Japan
P3.02-047: Testing EGFR and ALK in Large P3.02-059: T790M and C797S as Mecha-
P3.02-034: Acquired Resistance to Osim- Cell Neuroendocrine Carcinoma of the Lung. nisms of Acquired Resistance to Dacomitinib
ertinib by CCDC6-RET Fusion in a Patient Looking for Biological Features in Rare in Cell Models
with EGFR T790M Mutant Metastatic Lung Tumors Yoshihisa Kobayashi, Kindai University Faculty
Adenocarcinoma Teresa García Manrique, Hospital Virgen of Medicine, Japan
Wade Thomas Iams, McGaw Medical Center of Macarena, Spain
Northwestern University, USA P3.02-060: EGFR Mutation Status by Three
P3.02-048: Clinicopathologic Characteristics Sequencing Platforms in 704 Non-Small Cell
P3.02-035: Mutational Signatures and Their of Non-Small Cell Lung Carcinomas Habour- Lung Cancer (NSCLC) Brazilian Patients
Association with Clinicopathological Fea- ing MET Exon 14 Skipping Mutations Helano Carioca Freitas, A.C. Camargo Cancer
tures in Lung Adenocarcinoma of Smokers Takeshi Fujii, Toranomon Hospital, Japan Center, Brazil
Takayuki Honda, National Cancer Center
Research Institute, Japan P3.02-049: The Evaluation of Circulating P3.02-061: An ALK Follow-On Companion
miRNA Expression in Plasma as the Epi- Diagnostic Using CGP for Clinical Care of
P3.02-036: Feasibility Study to Evaluate genetic Marker of EGFR Mutation Status in Patients with NSCLC
Patterns of Metastases and Effect of Surgery NSCLC Patients James Sun, Foundation Medicine, USA
on Lung Cancer Xenografts with Differing Mateusz Florczuk, National Institute of Tuber-
Sensitivity to EGFR TKI culosis and Lung Diseases, Poland P3.02-062: An EGFR Follow-On Companion
Sabita Jiwnani, Tata Memorial Hospital, India Diagnostic for Clinical Care of Patients with
P3.02-050: Mechanisms of Acquired NSCLC
P3.02-038: Diagnosis of Leptomeningeal Resistance to the ALK Inhibitor Lorlatinib in James Sun, Foundation Medicine, USA
Disease and Clonal Heterogeneity with Dig- ALK-Rearranged NSCLC Cell Lines
ital Droplet PCR (ddPCR) in EGFR Mutated Anne Tranberg Madsen, Aarhus University P3.02-063: EGFR Exon 20 Insertions in
NSCLC Hospital, Denmark Lung Adenocarcinomas: Molecular and
Gareth Rivalland, University of Melbourne, Clinicopathologic Characteristics Among
Australia P3.02-051: Low Consistency Between Hispanics (Geno1.2-CLICaP)
FGFR1 Gene Amplification and Protein Oscar Arrieta, Instituto Nacional de Cancero-
P3.02-039: Acquired Resistance to EGFR- Expression in Squamous Cell Lung Cancer logia, Mexico
TKI in the Uncommon EGFR Mutation, G719S (SQCLC)
Atsushi Osoegawa, Oita University Faculty of Joanna Chorostowska-Wynimko, National P3.02-064: Epidermal Growth Factor Recep-
Medicine, Japan Institute of Tuberculosis and Lung Diseases, tor Gene Mutation in Pleural Lavage Cytology
Poland Findings of Primary Lung Adenocarcinoma
P3.02-040: Driver Gene Detection in Chi- Cases
nese NSCLC Patients Using cSMART and P3.02-052: Stability of EGFR Mutations in Takashi Inoue, Dokkyo Medical University,
Prognosis Analysis Whole Blood and Plasma in Patients with Japan
Xueqin Chen, Hangzhou First People’s Hospi- NSCLC
tal, China Johanne Andersen Højbjerg, Aarhus Univer- P3.02-065: Lung Adenocarcinoma Patient
sity Hospital, Denmark with EGFR Kinase Domain Duplication(KDD)
P3.02-041: EGFR Amplification Mediates and Its Response to Icotinib: A Case Report
Resistance to TAS121, A Third-Generation P3.02-053: Optimization and Character- Chunwei Xu, Fujian Provincial Cancer Hospital,
EGFR-TKI, in EGFR T790M-Positive Non- ization of Assays to Identify Met Exon 14 China
Small Cell Lung Cancer Skipping in FFPE Embedded NSCLC Samples
Sho Watanabe, National Cancer Center Hospi- Steven G. Gray, Trinity College Dublin, Ireland P3.02-066: Wild-Type KRAS Mediates
tal, Japan Growth Inhibition and Resistance to MEK
P3.02-054: Prognostic Implications of ROS1 Inhibitors through Dimerization with Mutant
P3.02-042: DS-1205b, a Novel, Selective, Positivity in Non-Small Cell Lung Cancer KRAS in Lung Adenocarcinoma
Inhibitor of AXL, Delays the Onset of Resis- (NSCLC): A Systematic Review of Published Chiara Ambrogio, Dana Farber Cancer Insti-
tance and Overcomes Acquired Resistance Literature tute, USA
to EGFR-TKIs Anchit Khanna, Pfizer Oncology, Australia
Takeshi Jimbo, Daiichi-Sankyo Co., Ltd., Japan P3.02-067: Lung Cancer with Concurrent
P3.02-055: Detecting ALK, ROS1 and RET EGFR Mutation and ROS1 Rearrangement: A
P3.02-043: Clinical and Genetic Features in Gene Translocations in Non-Small Cell Case Report
Lung Adenocarcinoma Without EGFR Muta- Lung Cancer (NSCLC) with the NanoString Meiyu Fang, Zhejiang Cancer Hospital, China
tion and ALK Rearrangement in Taiwan Platform
Tsu-Hui Shiao, Taipei Veterans General Hos- Hangjun Wang, McGill University Health Center P3.02-068: 95 Cases of EGFR/ALK Gene
pital, Taiwan & McGill University, Canada Status Anaysis in Lung Adenosquamous
Carcinoma
P3.02-044: Diagnosis and Monitoring P3.02-056: EGFR Mutation Profile of NSCLC Meiyu Fang, Zhejiang Cancer Hospital, China
of EGFR Mutation Status with cfDNA in Patients Tested at the Lung Center of the
Advanced NSCLC: A Prospective Single Philippines
Institution Study in Asia Maria Teresa Alhambra Barzaga, Lung Center
Teh-Ying Chou, Taipei Veterans General Hos- of the Philippines, Philippines
pital, Taiwan
P3.02-069: 58 Cases of EGFR/ALK Gene P3.02-080: DNMT3A Defines a Unique P3.02-091: Concurrent Aberrations in
Status Anaysis in Pulmonary Sarcomatoid Molecular Class of Chinese Non-Small Cell G2/M-Phase Transcriptional Programs and
Carcinoma Lung Cancer Patients Genomic Gatekeepers Highlight Lung Cancer
Meiyu Fang, Zhejiang Cancer Hospital, China Gang Chen, Fujian Provincial Cancer Hospital, Predisposition in COPD Patients
China Erin Anne Marshall, BC Cancer Research
P3.02-070: Investigation of Whether HIF-1α Centre, Canada
Inhibitors Can Increase EGFR-TKI Effect for P3.02-081: Nutritional Status Assessment in
Non-Small Cell Lung Cancer Cell Lines Treatment Naïve Patients with Lung Cancer P3.02-092: CD151-Integrin-C-Kit Axis Plays
Yung-Hung Luo, Taipei Veterans General Sabita Jiwnani, Tata Memorial Hospital, India an Important Role in the Pathogenesis of
Hospital, Taiwan Non-Small Cell Lung Cancer
P3.02-082: High Mobility Group Box 1 Zeyi Liu, Institute of Respiratory Diseases,
Antagonist Limits Metastatic Seeding in the China
P3.02-071 – P3.02-097e Lungs via Reduction of Cell-Cel Adhesion
Adi Karsch-Bluman, The Institute for Drug P3.02-093: Knockdown of BRM Causes
FUNCTIONAL BIOLOGY IN LUNG CAN-
Research, The School of Pharmacy, Faculty of Epithelial-Mesenchymal Transition in Lung
CER
Medicine, The Hebrew University of Jerusa- Adenocarcinoma Cell Line H1975
lem, Israel Daisuke Matsubara, Jichi Medical University,
P3.02-071: Statins May Improve the Progno- Japan
sis of Patients with Lung Adenocarcinoma by P3.02-083: DKK1 Promotes Migration and
Suppressing Mutant p53-Induced EMT Invasion of Non-Small Cell Lung Cancer via P3.02-094: Identification of Oncofetal piR-
Shigeto Nishikawa, Graduate School of Medi- β-Catenin Signaling Pathway NAs in Lung
cine, Kyoto University, Japan Jinjing Tan, Beijing Chest Hospital, Capital Brenda C. Minatel, British Columbia Cancer
Medical University/Beijing Tuberculosis and Research Centre, Canada
P3.02-072: MiR-33b Inhibits Lung Ade- Thoracic Tumor Research Institute, China
nocarcinoma Cell Epithelial-Mesenchymal P3.02-095: Basic Transcription Factor 3
Transition Through CeRNA Regulatory P3.02-084: FGF9-FGFR Pathway Induce Is Involved in Lung Cancer Growth and
Network Neuroendocrine Differentiation in Lung Progression
Min Li, Xiangya Hospital Central South Univer- Epithelial Cells Xiongfei Li, Tianjin Medical University General
sity, China Kota Ishioka, Keio University School of Medi- Hospital, China
cine, Japan
P3.02-073: Stromal Hedgehog Pathway P3.02-096: The Interaction Between Mast
Activation Suppresses Growth and Metasta- P3.02-085: Sphingosine Kinase 1 (SPHK1) Cells and Lung Cancer Cells Through Extra-
sis of Lung Adenocarcinoma Promotes Proliferation and Survival in Non- cellular Vesicles
James Kim, University of Texas Southwestern, Small Cell Lung Cancer Smadar Geva, Thoracic Cancer Service,
USA Nozomu Motono, Kanazawa Medical Univer- Davidoff Cancer Center, Rabin Medical Center,
sity, Japan Israel
P3.02-074: Podoplanin-Positive CAF Is
Associated with a Higher Number of Single P3.02-086: MGA Suppresses the MYC Path- P3.02-097: Clinicopathological Features and
Nucleotide Variants in Cancer Cells in Lung way in Lung Adeocarcinoma Genetic Landscape of Pulmonary Large Cell
Adenocarcinoma Paula Llabata, Bellvitge Biomedical Research Carcinoma under 2015 WHO Classification
Shoko Nakasone, National Cancer Center Institute, Spain of NSCLC
Hospital East, Japan Renwang Liu, Tianjin Medical University Gen-
P3.02-087: Long Noncoding RNA eral Hospital, China
P3.02-075: Molecular Disorders of the FOXF1-AS1 Regulates Epithelial-Mesen-
Genes of Intracellular Signal Pathways in chymal Transition in Non-Small Cell Lung P3.02-097a: Metabolic Biomarkers in Serum
Patients with Non-Small Cell Lung Cancer Cancer Cells for the Early Diagnosis of Lung Cancer:
Anna Shchayuk, Institute of Genetics and Yongsheng Wang, Nanjing Drum Tower Hospi- First Results from the Cancer-Biomarkers in
Cytology of the National Academy of Sciences tal, Medical School of Nanjing University, China HUNT Initiative
of Belarus, Belarus Oluf Røe, Norwegian University of Science
P3.02-088: Enhanced Glycolysis Is Critical and Technology, Norway
P3.02-076: Glutaminase Inhibitor CB-839 for Maintaining Inactivation of JNK and
Radiosensitizes KRAS-Mutant Lung Cancer Stability of EGFR Leading to the Survival of P3.02-097b: Significance of PAK1/CREB
Cells in a LKB1- and KEAP1/NRF2-Pathway EGFR-Mutant Lung Cancer Cells Pathway in Lung Adenocarcinoma Onco-
Dependent Manner Jae Cheol Lee, Asan Medical Center, Univer- genesis
Piyada Sitthideatphaiboon, The University of sity of Ulsan College of Medicine, Korea Seong Yoon, Pusan National University Yang-
Texas MD Anderson Cancer Center, USA san Hospital, Korea
P3.02-089: Establishment of Highly Meta-
P3.02-077: Platin Sensitivity and ATM-Defi- static Lung Cancer Cell Sublines in Long- P3.02-097c: Detection of the EGFR
ciency in Non-Small Cell Lung Cancer term Three-dimensional Low Attachment P.(T790M) Mutation by Different Methods:
D. Gwyn Bebb, University of Calgary, Canada Cultures A Small Comparison Case Study
Tomoyuki Nakano, Jichi Medical University, Hangjun Wang, McGill University Health Center
P3.02-078: Establishing Malignant Pleural Japan & McGill University, Canada
Mesothelioma Primary Cell Lines Using the
3D Spheroid Method Produces a Model with P3.02-090: Hypoxia-Induced Modifications P3.02-097d: Pulmonary LCNEC Might Be
Better Tumour Architecture of the Small Non-Coding RNA Transcriptome Aggregated With SCC On the Basis of Differ-
Yuen Yee Cheng, The University of Sydney, Delineates Risk of Recurrence in Early-Stage ent Clinical Features, Overall Survival, and
Australia Lung Adenocarcinoma Pathogenesis
Victor D. Martinez, BC Cancer Research Ke Chen, Zhongshan Hospital, China
P3.02-079: A 3D Spheroid Culture Rep- Centre, Canada
resents an Improved in Vitro Model of Malig- P3.02-097e: Prognostic Importance of
nant Plural Mesothelioma (MPM) Tumor Spread Through Air Spaces in Lymph
Yuen Yee Cheng, The University of Sydney, Node Negative Operated Adenocarcinoma
Australia Lung Cancers
Fatih Biricik, Koc University Medicine Faculty,
Turkey
P3.03-012: The Relationship between P3.03-024: Real-Life Experience and

P3.03 CHEMOTHERAPY/ Efficacy of Wee1 Inhibitor AZD1775 and Clinical Characterization of BRAF V600E
TARGETED THERAPY Mutational Status of TP53 in KRAS-Mutant Mutation in Austrian NSCLC Patients
Non-Small Cell Lung Cancer Maximilian Johannes Hochmair, Department
Bo Mi Ku, Samsung Biomedical Research of Respiratory and Critical Care Medicine,
P3.03-001: Immunotherapy Toxicity: Are
Institute, Samsung Medical Center, Korea and Ludwig Boltzmann Institute of COPD
General Practitioner Satisfied About Infor-
mation Transmitted? A Retrospective Survey and Respiratory Epidemiology, Otto Wagner
P3.03-013: Identification of Proteasomal Hospital, Austria
Radj Gervais, Centre Francois Baclesse,
Catalytic Subunit PSMA6 as a Therapeutic
France Target for Lung Cancer through a Pooled P3.03-025: Tumor Biomarkers for the
shRNA Screen Routine Care of Advanced Non-Small-Cell
P3.03-002: Histone Deacetylase Inhibition
Mitsuo Sato, Nagoya University Graduate Lung Cancer: A Decade of Experience in
Enhances the Antitumor Activity of a MEK
Inhibitor in Lung Cancer Cells Harboring
School of Medicine, Japan Implementing Predictive Genomic Events
RAS Mutations Paul Andrew Vanderlaan, Beth Israel Deaconess
P3.03-014: Tumor Cavitation in Patients Medical Center, Harvard Medical School, USA
Tadaaki Yamada, Kyoto Prefectural University
with Primary Lung Cancer Following Apati-
of Medicine, Japan
nib Treatment P3.03-026: Cell-CT® Differential Detection
Man Jiang, The Affiliated Hospital of Qingdao of Dysplastic Bronchial Epithelial Cells from
P3.03-003: ABCB1 3435C&Gt;T Polymor-
phism Influences the Toxicity and Clinical
University, China Patient Explants
Outcome of Patients with Taxane-Based Daniel J. Sussman, VisionGate, USA
P3.03-015: ROS-1 Rearranged Non Small
Chemotherapy
Cell Lung Cancer and Crizotinib: An Indian P3.03-027: LKB1 Loss Is Associated with
Jia Zhong, Peking University Cancer Hospital
Experience Resistance to Anti-Angiogenic Therapy in
& Institute, China
Vikas Talreja, Tata Memorial Hospital, India Non-Small Cell Lung Cancer Mouse Models
P3.03-004: The Frequency and Clinical Irene Guijarro, The University of Texas M. D.
P3.03-016: Morphometric Genotyping Iden- Anderson Cancer Center, USA
Implication of ALK, ROS1, RET and NTRK1
tifies Lung Cancer Cells Harboring Target
Gene Rearrangements in Adenosquamous
Mutations; Cell-CT® Platform Detects Gene P3.03-028: WINTHER - a Study of Can-
Lung Carcinoma Patients
Abnormalities cer Therapy Based on Tumor and Nor-
Xiaohua Shi, Peking Union Medical College
Alan Nelson, VisionGate, USA mal-Matched Biopsies - the Sheba Medical
Hospital, China
Center Lung Cancer Experience
P3.03-017: Blood Samples NGS for Baseline Amir Onn, Sheba Medical Center, Israel
P3.03-005: Diagnosis and Treatment Analy-
Molecular Signature of Anotinib Treated
sis of Lung Enteric Adenocarcinoma: 6 Case
Advanced NSCLC Patients in ALTER0303 P3.03-029: ROS1 Alterations in Lung Adeno-
Report and Review of the Literature
Trial carcinoma: The Prognostic Role of Rear-
Li Lin, Affiliated Hospital Cancer Center, Acad-
Baohui Han, Shanghai Chest Hospital, China rangement and Copy Number Variation
emy of Military Medical Sciences, China
Jun Chen, The Second Affiliated Hospital of
P3.03-018: Tumor Cavitation in Lung Metas- Dalian Medical University, China
P3.03-006: Efficiency of Anlotinib as 3rd tases in Patients with Solid Tumor Treated
Line Treatment in Patients with Different
with Apatinib P3.03-030: TP53 Alteration, a Potential
EGFR Gene Status, an Exploratory Subgroup
Man Jiang, The Affiliated Hospital of Qingdao Primary Cause of Early Progression in
Analysis of ALTER0303 Trial
University, China EGFR-Mutated NSCLC Patients Treated with
Baohui Han, Shanghai Chest Hospital, China
First-Line TKIs
P3.03-019: Activity of PARP Inhibitor in Yun Fan, Zhejiang Cancer Hospital, China
P3.03-007: LCMC2: Expanded Profiling of
NSCLC with Germline and Somatic Mutation
Lung Adenocarcinomas Identifies ROS1 and
and in Silico Chemotherapy Lethality P3.03-031: Response to Crizotinib Can
RET Rearrangements and TP53 Mutations as
Carmelia Maria Noia Barreto, Avancos em Occur in C-MET Overexpression NSCLC
a Negative Prognostic Factor
Medicina Institute, Brazil Independent of MET exon14 Alterations After
Mark G. Kris, Memorial Sloan Kettering Cancer
First-Line EGFR-TKI Resistance
Center, USA P3.03-020: Unique Molecular Profile of Yun Fan, Zhejiang Cancer Hospital, China
NSCLC in Thai Population
P3.03-008: Organoid Cultures of Lung Squa-
Narumol Trachu, Mahidol University, Thailand P3.03-031a: The IGFBP-3 Methylation Sta-
mous Cell Carcinoma for Drug Screening
tus Could Define a New Alternative Schedule
Ruoshi Shi, Ontario Cancer Institute, Canada P3.03-021: In Vitro Pharmacogenomic for NSCLC Treatment
Platform with a High-Purity Patient-Derived Javier De Castro Carpeño, Hospital Universi-
P3.03-009: Concurrent Somatic Mutations
Cell Model tario La Paz, IDIPAZ, Spain
in Driver Genes Were Significantly Cor-
Hyun Chang, Catholic Kwandong University
related with Lymph Node Metastasis and
International St. Mary’s Hospital, Korea P3.03-031b: Results of a Phase II Study
Pathological Types in Solid Tumors
of Stereotactic Radiosurgery Followed by
Yanan Cheng, Tianjin Medical University P3.03-022: Lung Cancer in Young Patients: Erlotinib for Patients with EGFR Mutation
Cancer Institute and Hospital, China Higher Rate of Driver Mutations and Brain and Progression in 5 or Fewer Sites
Involvement but Better Survival Jared Weiss, Lineberger Comprehensive
P3.03-010: Identification of Mechanisms of
Nir Peled, Rabin Medical Center, Israel Cancer Center, USA
Drug Resistance in RET-Rearranged Lung
Cancer P3.03-023: Nintedanib Selectively Inhibits
Takashi Nakaoku, National Cancer Center, the Activation and Tumor-Promoting Effects
Research Institute, Japan of Fibroblasts from Lung Adenocarcinoma P3.04 CLINICAL DESIGN, STATISTICS
Patients AND CLINICAL TRIALS
P3.03-011: A Report of BRAF V600E
Noemi Reguart, Hospital Clinic, Translational
Positive Lung Adenocarcinoma Patient Who
Respond Well to Pemetrexed P3.04-001: Evaluate the Utility of the
Tumors, Institut d’Investigacions Biomèdiques
Yoshiko Nakagawa, Nihon University School of ProLung China Test in the Diagnosis of Lung
August Pi i Sunyer (IDIBAPS), Spain
Medicine, Japan Cancer
Dawei Yang, Zhongshan Hospital Fudan Uni-
versity, China
P3.04-002: A Randomized Phase II Study P3.04-013: Phase 1 Study of the Anti-HER3 P3.05-010: NOTCH 1 and NOTCH 3 Expres-
of Carboplatin plus Nab-Paclitaxel with or Antibody Drug Conjugate U3-1402 in Meta- sions for Early Stage of Non-Small Cell Lung
Without Nintedanib for NSCLC with IPF static or Unresectable EGFR-Mutant NSCLC Cancer
(J-SONIC): Trial in Progress Pasi A. Jänne, Dana-Farber Cancer Institute, Eun Kyung Cho, Gachon University Gil Medical
Kohei Otsubo, Kyushu University, Japan USA Center, Korea
P3.04-003: Phase II Trial of Atezolizumab P3.04-013a: CONFIRM: A Phase III Ran- P3.05-012: Clinicopathological Determinants
Before and After Definitive Chemoradiation for domized Trial to Evaluate the Efficacy of of Circulating Tumor DNA Detection in Ear-
Patients with Unresectable Stage III NSCLC Nivolumab versus Placebo in Relapsed ly-Stage Non-Small Cell Lung Cancer
Helen J. Ross, Mayo Clinic Arizona, USA Mesothelioma Jong Ho Cho, Sungkyunkwan University
Dean Fennell, University of Leicester & School of Medicine, Samsung Medical Center,
P3.04-004: Treatment Rationale and Study Leicester University Hospitals, UK Korea
Design for the TAKUMI Trial
Kentaro Tanaka, Kyushu University Hospital,
Japan
P3.05 EARLY STAGE NSCLC P3.06 EPIDEMIOLOGY/PRIMARY
P3.04-005: PD-L1 and Other Immuno-Mark- PREVENTION/TOBACCO
ers Influenced by Osimertinib Treatment CONTROL AND CESSATION
P3.05-001: Breath Analysis for Early Detec-
in Advanced Non-Small Cell Lung Cancer
tion of Lung Cancer: The LuCID Study
Patients (ATHENE Study)
Marc Phillipe Van Der Schee, Academic P3.06-001: Tobacco Use, Awareness and
Shun Lu, Shanghai Chest Hospital, Shanghai
Medical Center, University of Amsterdam, Oral Health among Kanchipuram Silk Weav-
Jiao Tong University, China
Netherlands ers, Tamil Nadu, India
P3.04-006: SYSTEMS-2: Randomised Phase Delfin Lovelina Francis, Tagore Dental College
II Trial of Standard Versus Dose Escalated P3.05-002: The Effect of Nodule Size on and Hospital, India
Radiotherapy for Pain in Malignant Pleural the Sensitivity of the LuCED® Test for Lung
Mesothelioma Cancer P3.06-002: Tobacco Use, Awareness and
Miranda Jane Ashton, Beatson West of Scot- Michael Meyer, VisionGate, USA Oral Health Status among Seafarers in Voc
land Cancer Centre, UK Port, Tuticorin, Tamilnadu, India
P3.05-003: Serum Thioredoxin Reductase Delfin Lovelina Francis, Tagore Dental College
1 as a Diagnostic Biomarker for Non-Small and Hospital, India
P3.04-007: A Prospective Study of Apatinib
in Advanced Small Cell Lung Cancer Patients Cell Lung Cancer
Failed from Two or More Lines of Chemo- Xiaozheng Kang, Peking University Cancer P3.06-003: What Do the Children Think
therapy Hospital, China about Smoking and How Are They Helped in
Yutao Liu, National Cancer Center/Cancer Prevention?
P3.05-004: The Impact of EGFR Mutations Domenico Galetta, Clinical Cancer Center
Hospital-Chinese Academy of Medical Sci-
on Incidence and Survival of NSCLC Patients “Giovanni Paolo II”, Italy
ences & Peking Union Medical College, China
with Brain Metastasis: a Single Center Retro-
spective Study P3.06-004: Role Models “a Tool for Effec-
P3.04-008: A Phase 1b/2 Study of Atezoli-
zumab With or Without Daratumumab in Wei-Yuan Chang, National Cheng Kung Univer- tive Tobacco Control Campaign”
Advanced or Metastatic Non-Small Cell Lung sity Hospital, Taiwan Seye O. Omiyefa, Youth Action on Tobacco
Cancer (NSCLC) Control and Health, Nigeria
P3.05-005: Hypermethylation of the
Rathi N. Pillai, Winship Cancer Institute, Emory
RASSF1A and SOX1 Genes in Tumor DNA P3.06-005: Informational Needs on Smoking
University, USA
Predicts Unfavorable Overall Survival in Cessation of Cancer Patients
Surgically Resected NSCLC Patients Meredith Elana Giuliani, University of Toronto
P3.04-009: Stereotactic Body Radiotherapy
to All Sites of Oligometastatic Non-Small Milica Kontic, Clinic for Pulmonology, Clinical and Princess Margaret Cancer Center, Canada
Cell Lung Cancer (NSCLC) Combined with Centre of Serbia, Serbia
Durvalumab and Tremelimumab P3.06-006: The Government Willingness to
P3.05-006: Integrated Genomic Analysis to Legislate Tobacco Control and Changes on
Ticiana A. Leal, University of Wisconsin Car-
Assess the Molecular Signature of Japanese Individual Behavior in Brazil
bone Cancer Center, USA
Patients with Non-Small Cell Lung Cancer Ana Paula Leal Teixeira, National Cancer
P3.04-010: Validation of a ctDNA Meth- Mitsuhiro Isaka, Shizuoka Cancer Center, Institute-Ministry of Health, Brazil
ylation Assay to Differentiate Benign and Japan
Malignant Pulmonary Nodules: A Chinese P3.06-007: Level of Awareness of Various
P3.05-007: Potential of CYFRA 21-1 and Aspects of Lung Cancer Among College Stu-
Nationwide Multi-Center Study
CEA to Predict Adjuvant Chemotherapy dents in India: Impact of Cancer Awareness
Wenhua Liang, The First Affiliated Hospital of
Benefit in Early-Stage Squamous Cell Lung Programes
Guangzhou Medical University, National Clini-
Cancer Abhishek Shankar, All India Institute of Medical
cal Research Center for Respiratory Disease,
Achim Escherich, Roche Diagnostics Interna- Sciences, India
China State Key Laboratory of Respiratory
tional Ltd, Switzerland
Disease, China
P3.06-008: Lung Cancer Pathways: A Five-
P3.05-008: Potential of CYFRA 21-1 and Year Program to Reduce Impact Through
P3.04-011: A Prospective Study to Optimize
HE4 to Detect Recurrence in Patients with Epidemiological Modelling and Investment in
the Extent of Pulmonary Resection Accord-
Early-Stage Lung Adenocarcinoma Prioritized Interventions
ing to Decision-Making Algorithm in cStage
Achim Escherich, Roche Diagnostics Interna- Nicole Marion Rankin, The University of Syd-
IA NSCLC
tional Ltd, Switzerland ney, Australia
Hong Kwan Kim, Samsung Medical Center,
Sungkyunkwan University School of Medicine, P3.05-009: Hsa_circ_0044013: A Potential
Korea P3.06-009: How Does Screening for the
Novel Diagnostic Biomarker of Lung Adeno- Early Detection of Lung Cancer Facilitate
carcinoma Smoking Cessation? A Qualitative Study of
P3.04-012: Phase 1 Study of the AXL
Shuzhen Wei, Zhongda Hospital, Southeast Screened Smokers
Inhibitor DS-1205c in Combination with
University, China Ben Young, University of Nottingham, UK
Osimertinib in Subjects with Metastatic or
Unresectable EGFR-Mutant NSCLC
Pasi A. Jänne, Dana-Farber Cancer Institute,
USA
P3.06-009a: Lung Cancer in the Elderly - P3.07-012: Nivolumab Versus Docetaxel in

Histology, Localization and Gender Distribu- Patients With Previously Treated Advanced P3.09 MESOTHELIOMA
tion in North Romania Non-Small Cell Lung Cancer and Liver
Lucian Miron, University of Medicine and Metastases P3.09-001: The Dosimetric Advantages of
Pharmacy, Romania Lucio Crinò, Istituto Scientifico Romagnolo Per Intensity Modulated Proton Therapy (IMPT)
lo Studio e la Cura dei Tumori (IRST) IRCSS, for Mesothelioma after Pleurectomy/Decor-
Italy tication
Jean-Claude M. Rwigema, Mayo Clinic Ari-
P3.07 IMMUNOLOGY AND P3.07-013: Cost-Effectiveness of Immune
zona, USA
IMMUNOTHERAPY Checkpoint Inhibitors in the Treatment of
Advanced Non-Small Cell Lung Cancer P3.09-002: Can We Do Better? Feasibility
Alexander Kuhlmann, Leibniz Universität Dosimetric Study for Upfront Radical Radio-
P3.07-001: Overcoming Resistance to
Hannover, Germany therapy in Mesothelioma
Anti-PD Immunotherapy in a Syngeneic
Mouse Lung Cancer Model Using Adenovi- Timothy Mitchell, Beatson West of Scotland
P3.07-013a: PD-L1 Expression, Using
rus-Mediated Gene Therapy Cancer Center, UK
SP142 and 22C3 Antibody Clones, in NSCLC
Xiang Yan, Chinese PLA General Hospital, Patients with Known Status of EGFR and
China P3.09-003: Heart Radiation Dose as a Risk
ALK Genes Factor for Dyspnea Worsening After Multi-
Pawel Krawczyk, Medical University of Lublin, modality Treatment for NSCLC and MPM: An
P3.07-002: Blocking of ADAM17 Mitigates
Poland Exploratory Analysis
Kras-Induced Lung Adenocarcinoma Possi-
bly via Inhibition of IL-6 Trans-Signaling Angela Botticella, KU Leuven, Belgium
P3.07-013b:The Comparison Analysis of
Mohamed I. Saad, Monash University, Australia PD-1 Status Between 22C3 and 28-8 IHC P3.09-004: Routine Clinical Parameters Can
Assay in Clinical Practice: A Single Institu- Stratify Survival Characteristics in Mesothe-
P3.07-003: Analysis of Dendritic Cell
tional Experience lioma Patients Undergoing Surgery
Derived Exosomes That Suppressed Tumor
Yuki Nakamura, Matsusaka Municipal Hospital, Fraser Brims, Sir Charles Gairdner Hospital,
Growth
Japan Australia
Masakatsu Takanashi, Tokyo Medical Univer-
sity, Japan
P3.09-005: The Results of Trimodality
P3.07-004: GSDMD Is Required for Effector Treatment Strategy for Malignant Pleural
P3.08 LOCALLY ADVANCED NSCLC Mesothelioma
CD8+ T Cell Responses to Lung Cancer Cell
Tang Feng Lv, Jinling Hospital, China Kazunori Okabe, Yamaguchi Ube Medical
P3.08-001: Concurrent Chemoradiotherapy Center, Japan
P3.07-005: Activation of Toll-like Recep- with Weekly Carboplatin-Paclitaxel May
tor-2 Promotes Proliferation in Human Lung Be Feasible Option in inoperable Stage III P3.09-006: Preoperative Six-Minute Walk
Adenocarcinoma Cells NSCLC Distance and Desaturation in Patients with
Patrick Kohtz, University of Colorado - Denver, Fatih Kose, Baskent University, Turkey Malignant Pleural Mesothelioma
USA Motoki Nagaya, Nagoya University Hospital,
P3.08-002: Lymphovascular Invasion Is Not Japan
P3.07-006: Pemetrexed Exerts Intratumor a Postoperative Prognostic Factor for Large-
Immunomodulatory Effects and Enhances Sized Lung Cancer P3.09-007: Thoracic Asymmetry and Its
Efficacy of Immune Checkpoint Blockade in Atsushi Tajima, Saiseikai Utsunomiya Hospital, Impact on Survival after Radiation and Sur-
MC38 Syngeneic Mouse Tumor Model Japan gery for Malignant Pleural Mesothelioma
Ruslan Novosiadly, Eli Lilly, USA John Cho, University Hospital Network, Prin-
P3.08-003: Multimodal Treatment in the cess Margaret Cancer Centre, Canada
P3.07-007: Blockade of the Complement Initially Inoperable Stage III N2 Non-Small
C5a/C5aR1 Axis Impairs Lung Cancer Bone Cell Lung Cancer Patients P3.09-008: Role of Surgery in the Multi-
Metastasis Eun Kyo Joung, Seoul St. Mary’s Hospital, modality Treatment of Malignant Pleural
Ruben Pio, CIMA-University of Navarra, Idisna, College of Medicine, The Catholic University of Mesothelioma
Ciberonc, Spain Korea, Korea Bub-Se Na, Seoul National University Hospital,
Korea
P3.07-008: Development of Immunomoni- P3.08-004: Phase I/II Trial of Nab-Paclitaxel
toring Assays for Dendritic Cell-Based Lung or Paclitaxel Plus Carboplatin with Concur- P3.09-009: Fourteen Cases Study of 5 Year
Cancer Immunotherapy rent Radiation for Inoperable Stage IIIA/B Survivors of Malignant Pleural Mesothelioma
Ondrej Palata, Sotio a.s., Czech Republic NSCLC Following Extrapleural Pneumonectomy
Aaron Laine, UT Southwestern Medical Center, Ayumi Kuroda, Hyogo College of Medicine,
P3.07-009: PI3K/mTOR Pathway Altertions USA Japan
May Mediate PD-1/PD-L1 Blockade Resis-
tance in Non-Small Cell Lung Cancer P3.08-005: Hereditary Familial Overlap P3.09-010: 18 Years Single Center Expe-
Tao Shou, First People’s Hospital of Yunnan Syndrome with Multiple Synchronous Lung rience of Surgical Resection of Malignant
Province, China Tumors Pleural Mesothelioma After Induction
Andrés F. Cardona, Foundation for Clinical and Chemotherapy
P3.07-010: Immunotherapies Evaluation in Applied Cancer Research - FICMAC, Colombia Michaela B. Kirschner, University Hospital
an Ex-Vivo Culture Model of NSCLC Zurich, Switzerland
Jair Bar, Thoracic Cancer Unit, Sheba Cancer P3.08-006: Treatment Response and
Center and Institute of Oncology, Tel HaSho- Survival Outcomes Are Associated with His-
mer, Israel tologic Type in Non-Small Cell Lung Cancer
Treated with Trimodal Treatment
P3.07-011: Investigation of Autologous Hong Kwan Kim, Samsung Medical Center,
Tumor-Killing Effect of Effusion-Associated Sungkyunkwan University School of Medicine,
Lymphocytes in Malignant Pleural Effusion Korea
of Lung Cancer
Yung-Hung Luo, Taipei Veterans General
Hospital, Taiwan
P3.13-006: Correlation between CT Mor-

P3.10 NURSING/PALLIATIVE CARE/ P3.12 PULMONOLOGY/ENDOSCOPY phology at the Diagnosis and EGFR Status in
ETHICS Patients with Adenocarcinoma of the Lung
Manlio Mencoboni, Villa Scassi Hospital, ASL 3
P3.12-001: Lung Cancer in Patients with Genovese, Italy
P3.10-001: Prognostic Factors of Survival in Interstitial Lung Disease: Clinical Character-
Malignant Pleural Effusion istics and Impact on Survival P3.13-007: A Feasible Follow-Up Program
Fernando Conrado Abrão, Hospital Santa Shunsaku Hayai, Tosei General Hospital, Japan Using FDG-PET/CT for Asymptomatic
Marcelina, Brazil Postoperative Non-Small-Cell Lung Cancer
P3.12-002: Patients with Malignant Pleural Patients
P3.10-002: Implementing an Innovative Effusion who Succeeded Pleurodesis have a Hiroaki Toba, Institute of Biomedical Sciences,
Distress/Supportive Care Screening Tool in Longer Survival Rate - a 10-year Follow-up Tokushima University Graduate School, Japan
a Lung Cancer Clinic Li-Han Hsu, Sun Yat-Sen Cancer Center,
Lawrence Eric Feldman, The University of Taiwan P3.13-008: Lung Cancer Associated with
Illinois Hospital and Health Sciences System, Cystic Airspaces: Clinical, Imaging, Histo-
UI Cancer Center, USA P3.12-003: Optimised Inhaler Therapy Is pathological and Molecular Correlation
Superior to Supportive Care Alone for Dys- Annemie Snoeckx, Antwerp University Hospi-
P3.10-003: Assessing and Addressing pnoea in Patients with Coexisting COPD and tal and University of Antwerp, Belgium
Knowledge Gaps to Improve Lung Cancer Lung Cancer
Screening Rates David Peter Walder, Institution for Cancer P3.13-009: Rapid Detection of Lung
Lawrence Eric Feldman, The University of Research, UK Cancer by Fluorescent Imaging using a
Illinois Hospital and Health Sciences System, ɤ-Glutamyltranspeptidase-activatable Fluo-
UI Cancer Center, USA P3.12-004: Maidong on the Prevention and rescent Probe
Treatment of Radiation Pneumonitis in Mice Mingyon Mun, The Cancer Institute Hospital,
P3.10-004: Immunotherapy: Emergency C57BL/6 Japanese Foundation for Cancer Research,
Department Provider Needs Assessment Jiancheng Li, Fujian Cancer Hospital, China Japan
Survey
Lavinia Dobrea, St. Joseph Hospital, USA P3.12-004a: The Demonstration of the Pos- P3.13-010: Correlation between HRCT
sibility of the Mediastinal Mass Diagnosis by Features of Pulmonary Pure Ground-Glass
P3.10-005: National UK Thoracic Surgery Means of the Cryo Biopsy Nodules and the New Pathologic Classifica-
PPI Group Identify Key Questions in Routine Jaroslaw Pierog, Pomeranian Medical Univer- tion of Lung Adenocarcinoma
Clinical Care for Further Research sity, Poland Jindong Guo, Shanghai Chest Hospital, China
Amy Kerr, Heart of England NHS Foundation
Trust, UK P3.13-011: Use of Volume Growth and Flu-
or-Deoxy-Glucose Positron Emission Tomog-
P3.10-006: The Efficacy of Pistacia Terebin- P3.13 RADIOLOGY/STAGING/ raphy in Evaluating Indeterminate Lung
thus Soap in the Treatment of Erlotinib-In- SCREENING Nodules in Lung Cancer Screening
duced Skin Toxicity in Non-Small Cell Lung
Zaigham Saghir, Copenhagen University Hos-
Cancer Patients
P3.13-001: Clinical Significance of Chest pital, Gentofte Hospital, Denmark
Didem Tastekin, Institute of Oncology, Istanbul
University, Turkey Tomography Characteristics in Non Small
Cell Lung Cancer Patients Who Received P3.13-012: Fast Fourier Transform Analysis
Anatomic Resection for the Outline of Pulmonary Nodules on
P3.10-007: Sudden Death of the Patients
Ching-Yang Wu, Chang Gung Memorial Hospi- Computed Tomography Images
with Lung Cancer
tal, Linkou, Taiwan Tatsuya Yoshimasu, Wakayama Medical Uni-
Yasushi Nakano, Kawasaki Municipal Ida
versity, Japan
Hospital, Japan
P3.13-002: Reduced Dose Perfusion CT of
Lung Cancer using a 16-cm Coverage Scan- P3.13-013: Association of Pleural Tags with
ner: Effects of Respiratory Motion Correc- Visceral Pleural Invasion of Peripheral Lung
tion on Perfusion Assessment Cancer
Yeon Joo Jeong, Pusan National University Mayumi Higashi, Yamaguchi University, Japan
Hospital, Korea
P3.11-001: Factors Correlated With Time and P3.13-014: Prediction of Survival with
Cost Diagnostic Lung Cancer P3.13-003: The Lung Cancer Prognostic 18F-FDG-PET/CT Early during Erlotinib
Inggar Pertiwi, Department of Pulmonology Index - a Risk Score to Predict Overall Sur- Treatment in NSCLC Patients - a Comparison
and Respiratory Medicine, Faculty of Medicine, vival after the Diagnosis of Non-Small Cell of Four Evaluation Methods
Universitas Indonesia, Persahabatan National Lung Cancer Joan Fledelius, Herning Hospital, Denmark
Respiratory Refferal Hospital, Indonesia Marliese Alexander, Monash University,
P3.13-015: 18F-FDG-PET/CT after Induction
Australia
P3.11-002: Immunotherapies and Lung Chemotherapy for Prediction of Survival
Cancer: Educating the Global Lung Cancer P3.13-004: Prospective Study of Sequential after Radical Chemo-Radiotherapy in Locally
Community Ultra-Low then Standard Dose 18F-FDG Advanced NSCLC Patients
Maureen Rigney, Lung Cancer Alliance, USA PET/CT Scans for Lung Lesion Detectability Joan Fledelius, Herning Hospital, Denmark
Ivan WK Tham, National University Cancer
P3.11-003: Addario Lung Cancer Foun- P3.13-016: 18F-FDG-PET/CT for Prediction
Institute, Singapore
dation Patient Education Handbooks Fill a of Survival after Induction Chemotherapy in
Health Literacy Void for Patients and Nurse P3.13-005: Characteristics of Primary Lung Locally Advanced NSCLC - a Comparison of
Navigators Cancer on PET/CT Imaging in the South Methods
Danielle Hicks, Addario Lung Cancer Founda- African Population Joan Fledelius, Herning Hospital, Denmark
tion, USA Osayande Evbuomwan, Charlotte Maxeke
P3.13-017: Review of Lung Cancers on the
Johannesburg Academic Hospital, University
Stage and Growth Rate, Matched with Lung
of the Witwatersrand, South Africa
RADs Category, in Previously Treated with
Breast Cancer Patients
Soo-Youn Ham, Korea University Anam Hos-
pital, Korea
P3.13-018: CT-Guided Percutaneous Barium P3.13-030: Metabolic Parameters of FDG

Marking Prior to Video-Assisted Thoraco- PET at Early Evaluation of NSCLC Differ P3.14 RADIOTHERAPY
scopic Surgery (VATS) for the Localization with Histological Subtypes
of Small Pulmonary Nodules Yosef Landman, Thoracic Cancer Service,
P3.14-001 – P3.14-038
Ana Caroline Zimmer Gelatti, Hospital do Davidoff Cancer Center, Rabin Medical Center,
Câncer Mãe de Deus, Brazil
DIAGNOSTIC RADIOLOGY
Israel
P3.13-019: Preoperative Needle Biopsy Does P3.13-031: Predicting Factor for the Dissoci- P3.14-001: Impact of PCI on Prognosis of
Not Increase the Risk of Pleural Recurrence ation of the Diameter Between Radiographi- LD-SCLC Through Pattern of Brain Metasta-
in ≤3cm Lung Adenocarcinoma cal Solid Part and Pathological Invasive Part ses as a First Recurrence Site
Koji Kameda, Memorial Sloan Kettering Cancer in Lung Adenocarcinoma Masaki Nakamura, National Cancer Center
Center, USA Yota Suzuki, Keio University School of Medi- Hospital East, Japan
cine, Japan
P3.13-020: A Pilot Study of the Autoantibod- P3.14-002: Multimodality Management of
ies to Tumor Antigens in Lung Cancer Using P3.13-032: The Impact of Tobacco Exposure Pancoast Tumors; Does Surgical Resection
the EarlyCDT-Lung Test in Hong Kong on Lung Nodules and Emphysema in a Pilot Need to Be Included?
Chu Leuk Lau, Quality HealthCare Medical Silesian Study of Early Lung Cancer with Mojgan Taremi, Princess Margaret Hospital,
Service, Hong Kong LDCT Canada
Mariusz Adamek, Department of Thoracic
P3.13-021: Can Lymph Nodes Visualised on Surgery, School of Medicine with the Division P3.14-003: Patterns of Follow-Up Care After
PET/CT Predict the Outcome of Patients of Dentistry in Zabrze, Medical University of Curative Radiotherapy for Stage I-III Non-
with Lung Cancer? Silesia, Poland Small Cell Lung Cancer
Mboyo Di Tamba Vangu, Charlotte Maxeke Sharanya Mohan, University of NSW, Australia
Johannesburg Academic Hospital, University P3.13-033: DNA Methylation of PTGER4
of the Witwatersrand, South Africa and SHOX2 in Liquid Biopsies Facilitates the P3.14-004: Pathological Study on the Clin-
Diagnosis of Lung Malignancy After Chest ical Target Volume (CTV) in Limited-Stage
P3.13-022: 3D CNNs for Recognition of CT-Scan SCLC for CT-Simulation Based Thoracic
Epidermal Growth Factor Receptor Mutation Lea Maria Schotten, University Medicine Radiotherapy Planning
Status in Patients with Lung Adenocarci- Essen - Ruhrlandklinik, Essen, Germany, Xiao Hu, Zhejiang Cancer Hospital, Zhejiang
noma Germany Key Laboratory of Radiation Oncology, China
Junfeng Xiong, Shanghai Jiao Tong University,
China P3.13-034: Comparison of Cytological P3.14-005: Treatment Response Measured
Smears and Cell Blocks of Pleural Fluid on Conebeam-CT During Concurrent Chemo-
P3.13-023: Clinicopathological Impacts of Diagnosing Malignant Pleural Effusion in radiation for NSCLC Patients
the Small Ground-Glass Opacity Surrounding Lung Cancer Margriet Kwint, The Netherlands Cancer
the Solid Type Lung Adenocarcinoma Giedre Cincileviciute, Center of Pulmonology Institute - Antoni van Leeuwenhoek Hospital,
Kazutoshi Hamanaka, Shinshu University, and Allergology of Vilnius University Hospital Netherlands
Japan Santaros Klinikos, Lithuania
P3.14-006: Slow CT Simulation for GTV
P3.13-024: Is Alveolar Spread May Be Pre- P3.13-035: Automatic Estimation of Mea- Delineation and Planning of Radiotherapy to
dictive with PET CT Scanning? surement Error on CT Imaging Lung Cancer Patients; A Sunshine to Devel-
Nil Molinas Mandel, Koc University Medicine Ricardo S. Avila, Accumetra, LLC, USA oping Countries
Faculty, Turkey Sharif Ahmed, United Hospital Limited, Ban-
P3.13-036: Immunohistochemical and gladesh
P3.13-025: Spinal Cord and Cauda Equina Genetic Characteristics of Lung Cancer
Compression in Lung Cancer Mimicking Organizing Pneumonia P3.14-007: A Functional Equivalent Uniform
Henda Neji, Abderrahmen Mami Hospital, Tomohiro Ichikawa, National Cancer Center Dose Correlates with Radiation Pneumonities
Tunisia Hospital East, Japan in Radiation Therapy
Li Yan Dai, Renji Hospital, Shanghai Jiaotong
P3.13-026: Non-Small Cell Lung Cancer: P3.13-037: Deep Learning System for Lung University School of Medicine, China
Imaging of Recurrences After Surgery Nodule Detection
Henda Neji, Abderrahmen Mami Hospital, Dawei Yang, Zhongshan Hospital Fudan Uni- P3.14-008: Clinical Characteristics Matrix
Tunisia versity, China of Lung Tumor Under Stereotactic Ablative
Body Radiotherapy (SABR)
P3.13-027: Utilization of PET Scan in P3.13-038: The RoaDmaP Study: Feasibility Kaile Li, John R Marsh Cancer Center, USA
Advanced Stage Non-Small Cell Lung Cancer of Implementing a Primary Care Intervention
in the United States for Referral of Potential Lung Cancer Cases P3.14-009: Thoracic Re-Irradiation of Lung
Madhusmita Behera, Winship Cancer Institute to Specialist Care Cancer Using Highly Conformal Radiotherapy
of Emory University, USA Nicole Marion Rankin, Cancer Council NSW, Is Effective as Salvage Treatment Option
Australia Yeon Sil Kim, Seoul St.Mary’s Hospital, Korea
P3.13-028: Controversies on Lung Cancers
Manifesting as Part-Solid Nodules P3.13-038a: Metastases in T1-T2 classed P3.14-010: Magnetic Resonance Imaging
Rowena Yip, Icahn School of Medicine at Lung Cancer (MRI) for Lung Cancer Radiotherapy Plan-
Mount Sinai, USA Henda Neji, Abderrahmen Mami Hospital, ning and Treatment
Tunisia Michael Dubec, The Christie NHS Foundation
P3.13-029: Imaging Guideline-Recommen- Trust, UK
dations Prior to Treatment for Non-Small
Cell Lung Cancer Demonstrates Variable P3.14-011: Mean Heart Dose Is an Indepen-
Compliance dent Risk Factor for Early Mortality After
Joshua Robert Rayburn, Swedish Cancer Chemoradiotherapy Treatment for Lung
Institute, USA Cancer
Dirk K. De Ruysscher, Maastricht University
Medical Centre, Netherlands
P3.14-012: Risk of Developing Pneumonitis P3.15-005: Third Line Chemotherapy in P3.15-016a: Prediction of Potential Biomark-
Increases in Patients Receiving Immunother- SCLC: The West of Scotland Experience ers for Personalized Treatment in Pulmonary
apy with a History of Lung Irradiation Sarah Jane Slater, Beatson West of Scotland Large-Cell Neuroendocrine Carcinoma
Feliciano Barron, Instituto Nacional de Cancer- Cancer Centre, UK Takashi Makino, Toho University School of
ologia, Mexico Medicine, Japan
P3.15-006: Comprehensive Analysis of EMT
P3.14-013: Outcomes According to Marginal Gene Signature in Primary and Metastatic
Tumor Dose Prescription for Small- to Small Cell and Non-Small Cell Carcinomas
Medium-Sized Brain Metastases from Lung of the Lung P3.16 SURGERY
Cancer Tabatha Gutierrez Prieto, Faculdade de
Fabio Y. Moraes, University of Toronto - Prin- Medicina da USP, Brazil
cess Margaret Cancer Center, Canada
P3.16-001 – P3.16-036
P3.15-007: A Retrospective Review of Small RISK ASSESSMENT AND PROGNOSTIC
P3.14-014: Lung Stereotactic Body Radio- Cell Lung Cancer (SCLC) Patients Treated at FACTORS
therapy (SBRT): Patient’s Outcome and Marmara University Hospital
Prognostic Factors Faysal Dane, Marmara University Medical P3.16-001: Feasibility of 20 mL of Saline for
Margarita Majem, Hospital de la Santa Creu i School, Marmara University Pendik Training & Pleural Lavage Cytology in Non-Small Cell
Sant Pau, Spain Research Hospital, Turkey Lung Cancer
Toru Nakamura, Seirei Hamamatsu General
P3.14-015: A Propensity Matched Analysis P3.15-008: [F18]PARPi PET as an In Vivo Hospital, Japan
of SBRT and Sublobar Resection for Stage Pharmacodynamic Biomarker of PARP Inhib-
I Non-Small Cell Lung Cancer in Patients at itor Therapy in Patient-Derived Xenografts P3.16-002: Postoperative Prognostic Factors
High Risk for Lobectomy of Small Cell Lung Cancer in Non-Small Cell Lung Cancer Patients with
Yaping Xu, Zhejiang Cancer Hospital, China Benjamin Lok, Princess Margaret Cancer Lymph Node Metastasis
Centre, Canada Tatsuya Goto, Niigata University, Japan
P3.14-016: Research About Different Admin-
istration Mode of Endostar for Combining P3.15-009: Impact of Interstitial Lung Dis- P3.16-003: The Clinical Significance of
with Concurrent Chemoradiotherapy in Local ease on Clinical Outcomes in Small Cell Lung Immune-Nutritional Parameters in Surgically
Advanced NSCLC Cancer Patients Resected Elderly Patients with Non-Small
Jiancheng Li, Fujian Cancer Hospital, China Kimitaka Akaike, Kumamoto University Hospi- Cell Lung Cancer
tal, Japan Fumihiro Shoji, Kyushu University, Graduate
P3.14-017: Dosimetric Evaluation of Lung School of Medical Sciences, Japan
SBRT Treatment P3.15-010: Diffuse Idiopathic Pulmo-
Margarita Majem, Hospital de la Santa Creu i nary Neuroendocrine Cell Hyperplasia P3.16-004: Surgery for Patients with Lung
Sant Pau, Spain (DIPNECH): Natural History of the Disease Cancer Associated with Interstitial Pneumonia
Progression and Management Yoko Azuma, Toho University School of Med-
P3.14-017a: Extra-Cranial Oligo-Progression Zin Myint, University of Kentucky, USA icine, Japan
upon 1st Line EGFR TKI in Advanced Non-
Small Cell Lung Cancer Patients: Outcomes P3.15-011: Contemporary Treatment and P3.16-005: Outcome, Mortality and Morbid-
of Local Ablative Radiotherapy Prognosis of Non-Metastatic Atypical Bron- ity after Lung Cancer Thoracic Surgery
Florence Siu Ting Mok, Prince of Wales Hospi- chopulmonary Carcinoid Tumors Fadil Gradica, University Hospital Shefqet
tal, Hong Kong Abraham J. Wu, Memorial Sloan Kettering Ndroqi, Albania
Cancer Center, USA
P3.16-006: Impact of Limited Resection or
P3.15-012: Surgical Outcome in Early Stage Omitted Adjuvant Therapy in Patients with
P3.15 SCLC/NEUROENDOCRINE Small Cell Lung Cancer Pathologic Stage II and III Non-Small-Cell
TUMORS Kenji Inafuku, Kanagawa Cancer Center, Japan Lung Cancer
Jeong Su Cho, Pusan National University
P3.15-013: The Addition of Antiangiogenic Hospital, Korea
P3.15-001: The Impact of MET Inhibition Agents to Chemotherapy for Patients with
on Small-Cell Lung Cancer Cells Exhibit- Extensive-Stage Small Cell Lung Cancer: A P3.16-007: Incidence and Outcomes of
ing Aberrant Activation of the HGF/MET Meta-Analysis Positive Parenchymal Margins after Lung
Pathway Min Peng, Renmin Hospital of Wuhan Univer- Resection - an Analysis of 1428 Cases
Hirokazu Taniguchi, Department of Respira- sity, China Patrick James Villeneuve, The Ottawa Hospi-
tory Medicine, Nagasaki University Graduate
tal, Canada
School of Biomedical Sciences, Japan P3.15-014: Case Series of Small Cell Lung
Cancer Transformation as Resistance Mech- P3.16-008: Thymidine Phosphorylase Influ-
P3.15-002: Molecular Profiling and Net- anism to Epidermal Growth Factor Recep- ences Clinical Outcome Following Surgery in
works Relevant to Disease Mechanisms in tor-Tyrosine Kinase Inhibitor Patients with Stage I and II Non-Small Cell
Small Cell Lung Cancer and Lung Carcinoid Chong-Kin Liam, University of Malaya, Malay- Lung Cancer
Tumor sia Naoya Himuro, Showa University School of
Kiyonaga Fujii, St. Marianna University School
Medicine, Japan
of Medicine, Japan P3.15-015: LCNEC Tumor Location, Divided
into Central and Peripheral Type, Has P3.16-009: Reoperation for Hemostasis
P3.15-003: Second Line Chemotherapy in Distinct Clinicopathologic Feature, Genomic within 24 Hours Can Get a Better Short-
SCLC: The West of Scotland Experience Characteristics and Survival Term Outcome When Indicated after Lung
Sarah Jane Slater, Beatson West of Scotland Fei Zhou, Tongji University School of Medicine, Cancer Surgery
Cancer Centre, UK China Qiang Li, Sichuan Cancer Hospital & Institute,
Sichuan Cancer Center, School of Medicine,
P3.15-004: Distinct Role of FAK Kinase and P3.15-016: The Role of Surgery in Combi- University of Electronic Science and Technol-
C-Terminal Domains on Small-Cell Lung nation Treatment of Patients with Small Cell ogy of China, China
Cancer Proliferation Lung Cancer
Sebahat Ocak, Cliniques Universitaires UCL Aleksei Aleksandrovich Aksarin, Surgut Dis-
Mont-Godinne, Belgium trict Clinical Hospital, Russia
P3.16-010: Preoperative Six-Minute Walk P3.16-023: Intrapulmonary Lymph Node P3.16-035: The Unknown: Does Body Mass
Distance Is Associated with Complications of Metastasis of Non-Small Cell Lung Can- Index (BMI) Influence Outcomes Post Lung
Pneumonia after Lung Resection cer: Distribution Pattern and Therapeutic Cancer Resection Surgery?
Keiko Hattori, Nagoya University Hospital, Japan Relevance Prakash Balakrishnan, Wellington Regional
Nan Wu, Key laboratory of Carcinogenesis and Hospital, New Zealand
P3.16-011: Correlation Between Pulmonary Translational Research (Ministry of Education),
Vein Stump Thrombus and Cerebral Infarc- China P3.16-036: Feasibility of Lung Cancer Sur-
tion After Left Upper Lobectomy of the Lung gery in Septuagenarians
Yoshiyuki Yasuura, Shizuoka Cancer Center, P3.16-024: Feasibility of the Fit4Surgery Prakash Balakrishnan, Wellington Regional
Japan App - Can It Replace Conventional Pulmonary Hospital, New Zealand
Rehabilitation in the Surgical Population?
P3.16-012: Lung Cancer: System Approach Nicola Oswald, University of Birmingham, UK
Oleg Kshivets, Roshal Hospital, Russia P3.16-037 – P3.16-049
P3.16-025: Development and Validation of a
SURGERY FOR LOCALLY
P3.16-013: Prognostic Effect of EGFR Gene Survival Nomogram in Elderly Patients with
Mutation for Recurrence in Completely ADVANCED AND ADVANCED NSCLC
Resected Non-Small-Cell Lung Cancer
Resected Lung Adenocarcinoma Xizhao Sui, Peking University People’s Hospi-
In Kyu Park, Seoul National University Hospi- tal, China P3.16-037: Superior Vena Cava Replacement
tal, Korea Combined with Veno-Venous Shunt for Lung
P3.16-026: Clinical Implication of Occult Cancer and Thymoma: Case Series
P3.16-014: Post-Recurrence Survival Lymph Node Metastasis in the Remaining Qiang Li, Sichuan Cancer Hospital & Institute,
Analysis of Stage I Non-Small Cell Lung Lobes After Lobectomy in Non-Small Cell Sichuan Cancer Center, School of Medicine,
Cancer-Prognostic Significance of Local Lung Cancer University of Electronic Science and Technol-
Treatment Young Tae Kim, Seoul National University ogy of China, China
Hyeong Ryul Kim, Asan Medical Center, Uni- Hospital, Korea
versity of Ulsan College of Medicine, Korea P3.16-038: Experience of 180 Bronchial
P3.16-027: Effects of Surgical Waiting Time Sleeve Resections for Malignant Tumors
P3.16-015: Rapid Identification of Micropap- on Prognosis in Patients with Lung Cancer Evgeny Levchenko, N. N. Petrov Research
illary or Solid Component for Early-Stage Yuriko Terada, Japanese Red Cross Medical Institute of Oncology, Russia
Lung Adenocarcinoma Center, Japan
Ze-Rui Zhao, Prince of Wales Hospital, Chi- P3.16-039: Right Upper Lobectomy with SVC
nese University of Hong Kong, Hong Kong P3.16-028: Necrosis Is a Predictor of Recur- Reconstruction after Induction Chemoradio-
rence in Patients with Small Lung Adenocar- therapy for a Patient with Bulky N2 NSCLC
P3.16-016: Prognosis of Patients with cinoma ≤2cm Hideo Ichimura, University of Tsukuba, Hitachi
Remnant Tumor at Bronchial Stump After Yuriko Terada, The University of Tokyo Hospi- Medical Education and Research Center, Japan
Pulmonary Resection for NSCLC: Based on tal, Japan
Case Series Study P3.16-040: Intrapleural Perfusion Ther-
Hye-Seon Kim, Hanyang University Seoul P3.16-029: Recurrence within a Year after mo-Chemotherapy for Pleural Effusion
Hospital, Korea Complete Resection of Primary Lung Cancer Caused by Lung Carcinoma under VATS
Takashi Ibe, Maebashi Red Cross hospital, Runlei Hu, Hangzhou First People’s Hospital,
P3.16-017: The Role of Skip Metastases and Japan China
the Number of Metastac Lymp Nodes in the
Survival of Operated Patients P3.16-030: Venous Thromboembolism After P3.16-041: Pleural Photodynamic Therapy
Mark Krasnik, Copenhagen University Hospital Lung Cancer Surgery and Its Risk Factors: and Surgery for Pleural Metastasis by Non-
Rigshospitalet / Gentofte Hospital, Denmark A Single Center, Retrospective, Cohort Study Small Cell Lung Cancer
from China Ke-Cheng Chen, National Taiwan University
P3.16-018: Null 30-Days Mortality After 72 Bo Tian, Beijing Chao-Yang Hospital, Capital Hospital, Taiwan
Consecutive Left Open Pneumonectomies for Medical University, China
Lung Cancer P3.16-042: Intraoperative Hyper-Thermo-
Veronica Manolache, Oncology Institute P3.16-031: Survival and Prognostic Factors therapy with Distilled Water for StageIV
Bucharest, Romania of Synchronous Multiple Primary NSCLC and Lung Cancer
Further Differentiation from Intrapulmonary Ayumi Suzuki, Kariya Toyota General Hospital,
P3.16-019: Prognostic Factors for Resected Metastasis Japan
Non-Small Cell Lung Cancer in Patients with Fei Xiao, National Clinical Research Center for
Type 2 Diabetes Mellitus Respiratory Diseases, Center for Respiratory P3.16-043: Resection and Reconstruction of
Woo Sik Yu, The Graduate School of Yonsei Diseases, China-Japan Friendship Hospital, Tracheal Carina in Lung Cancer Surgery
University, Korea China Evgeny Levchenko, N. N. Petrov Research
Institute of Oncology, Russia
P3.16-020: Long Term Changes of Pulmo- P3.16-032: Prediction of Postoperative Lung
nary Function After Lobectomy Function in Patients with Lung Cancer by P3.16-044: Feasible Outcome of Radical
Kook Nam Han, Korea University Guro Hospi- Lung Lobe Extended Surgery in T4 Locally Advanced
tal, Korea Kantaro Hara, Osaka City University Hospital, NSCLC; 23-Year Japanese Single Center
Japan Experience
P3.16-021: Thoracic Morbidity and Mortality Ryuichi Waseda, Fukuoka University, Japan
System in Analysis of Postoperative Com- P3.16-033: Significance of Spread through
plications after Pneumonectomy in NSCLC Air Spaces in Resected Pathological Stage I P3.16-045: Evaluation of the Safety and
Patients Lung Adenocarcinoma Efficacy of VATS Pneumonectomy in the
Oleg Pikin, P. Hertzen Research Institute of Gouji Toyokawa, Graduate School of Medical Treatment of Locally Advanced Lung Cancer
Oncology, Russia Sciences, Kyushu University, Japan Joshua Goldblatt, St Vincent’s Hospital,
Australia
P3.16-022: Segmentectomy for Lung Ade- P3.16-034: Impact of Travel Distance to
nocarcinoma: The Impact of EGFR Mutation Treatment Institution on Survival from Stage P3.16-046: Pneumonectomy After Induc-
Status on Recurrence I to III Lung Cancer tion/Neoadjuvant Treatment for NSCLC:
Kwanyong Hyun, Seoul National University Ana Caroline Zimmer Gelatti, Hospital do Morbidity, Mortality and Long-Term Survival
Hospital, Korea Câncer Mãe de Deus, Brazil Cengiz Gebitekin, Uludag University, Turkey
P3.16-047: Salvage Surgery for Locoregional P3.17-003: A Selective Small Molecule

Recurrence or Persistent Residual Tumor Inhibitor of C-Met Kinase, BPI-9016M, Has
After Definitive Chemoradiation Therapy Synergistic Effects with Radiation on Esoph-
Junichiro Osawa, Kanagawa Cancer Center, ageal Squamous Cell Carcinoma
Japan Yaping Xu, Zhejiang Cancer Hospital, China
P3.16-048: The Role of Pulmonary Resec-

tion in Stage IVa Non-Small Cell Carcinoma
Patients
Tomoyuki Igarashi, Shiga University of Medical
Science, Japan
P3.16-049: Surgery with Continued TKI

Therapy After Acquiring Resistance to EGFR
or ALK TKI
Shuta Ohara, Kindai University, Japan
P3.16-050 – P3.16-053a
TRANSLATIONAL STUDIES
P3.16-050: Stromal PDGFR-β Expression

Influences Postoperative Survival of NSCLC
Patients Receiving Preoperative Chemo- or
Chemo-Radiotherapy
Ryu Kanzaki, Osaka University Graduate
School of Medicine, Japan
P3.16-051: Implications of Preoperative

Serum Tumor Levels on Pathological Char-
acteristics in Patients with Lung Adenocar-
cinoma
Terumoto Koike, Niigata University, Japan
P3.16-052: Use of Decellularised Porcine

Intestinal Submucosa Extracellular Matrix in
Airway Reconstruction to Enable Lung-Spar-
ing Oncological Surgery
Michelle Lynne Kim, Barwon Health, Australia
P3.16-053: Genomic Challenges for Lung

Cancers with Multiple Pulmonary Sites of
Involvement
Xiaozheng Kang, Peking University Cancer
Hospital, China
P3.16-053a: Surgical Outcome of Bronchop-

lasty in Non-small Cell Lung Cancer Patients
Katsuyuki Suzuki, Yamagata Prefectural Cen-
tral Hospital, Japan
P3.17 THYMIC MALIGNANCIES/

ESOPHAGEAL CANCER/OTHER
THORACIC MALIGNANCIES
P3.17-001: The Prognostic Analysis of

Postoperative Radiotherapy for Esophageal
Squamous Cell Carcinoma with Different
Status of Lymph Node Metastasis
Xin Xu, Renji Hospital, School of Medicine,
Shanghai Jiao Tong University, China
P3.17-002: Comparison of Single- and

Multi-Incision Minimally Invasive Esophagec-
tomy for Treating Esophageal Cancer: A
Propensity-Matched Study
Mong-Wei Lin, National Taiwan University
Hospital, Taiwan
SECTION 9
AUTHOR
INDEX
Amaladas Nelusha..................................................P3.07-006
AUTHOR INDEX Aman Enrique........................................................... P1.01-058
Amanam Idoroenyi....................................................MS 25.02
Amann Joseph......................................................... P1.02-019
Amann Joseph M...............................P1.09-001, P2.02-065,
..............................................................P2.02-067, P3.03-002
..............................................OA 10.01, OA 14.06, P1.01-001, Amano Hiroyuki...................................................... P2.03-005
.........................................P1.01-004, P1.08-004, P2.01-064, Amano Toraji............................................................ P2.01-005
A ......................................... P2.07-025, P3.01-023, P3.01-029, Amano Yosuke.........................................................P2.03-046
.........................................P3.01-082, P3.03-012, P3.08-006 Amano Yusuke....................................P2.07-022, P3.02-089
Aalbersberg Else......................................................P3.14-005 Ahn Sung-Ja...................P2.03-024, P2.14-017, SH 02.02
Aapro Matti.................................................................MA 08.02 Amato Giovanni..........................................................MA 19.02
Ahn Yong Chan...............ES 10.03, P1.08-004, P3.08-006 Amatya Vishwa J........ P1.02-002, P1.02-052, P2.09-008
Abbattista Antonello..................................................OA 05.06 Ai Xinghao.............................................JCSE 01.28, MA 07.13
Abdel Karim Nagla...............................P2.01-014, P2.01-015 Ambrogio Chiara.....................................................P3.02-066
Aiba Tomoiki.............................................................P2.07-004 Ameratunga Malaka................................................P2.02-039
Abdelmutti Nazek................................................... P3.06-005 Aida Shinji..................................................................P3.10-007
Abdul Satar Nur.......................................................P1.14-009 Amiraliev Ali...........................................P1.16-011, P3.16-021
Aigner Clemens......................................OA 16.06, P3.13-033 Amiri Katayoun I............. P2.01-004, P2.01-013, P2.01-014,
Abe Kanae................................................................ P1.03-006 Ailawadhi Sikander................................OA 06.05, OA 06.07
Abe Miyuki.................................................................P2.05-017 .................................................................................... P2.01-015
Aisner Dara L......................................P3.02-057, P3.03-007 Amjadi Kayvan.............................................................OA 15.01
Abe Takanori............................................................. P1.14-006 Aisner Joseph..........................................................P2.16-001
Abe Tetsuya.............................................................. P2.03-015 Ammari Samy..........................................................P2.07-005
Aix Santiago P............................................................ MA 10.02 Amoyav Benzion.....................................................P3.02-082
Abe Tomonori......................................P1.01-028, P2.03-011 Ajlouni Muntheer........................................................MA 13.08
Abecassis Nuno..........................................................P1.17-012 Ampollini Luca............................................................OA 16.02
Ajona Daniel............................................................. P3.07-007 Amrein Michael............................................................ MA 15.11
Aberle Denise R.......................................OA 06.06, OA 15.03 Akai Masaya..............................................................P2.07-013
Aberrbock Shira......................................................P2.02-047 An Tongtong.................................................................MA 11.03
Akaike Kimitaka....................................................... P3.15-009 Anas Gazzah............................................................ P2.01-038
Able Arnold.............................................................. P3.14-008 Akamatsu Hiroaki......... P1.03-004, P2.03-045, P2.07-035
Abolhoda Amir.......................................................... P1.16-003 Anayama Takashi..........P1.02-034, P1.12-003, P1.16-026,
Akamatsu Keiichiro................................................. P2.07-035 ................................................................................... P2.05-010
Aboubakar Nana Frank........................................... P3.15-004 Akamine Takaki.................OA 13.06, P1.07-002, P1.07-014, Ancevski Katerina....................................................P2.02-047
Abraham Ninan...........................................................MA 05.12 ......................................... P2.09-005, P3.16-003, P3.16-033 Anciano Carlos J....................................MA 20.01, MA 20.02
Abrams Judith.........................................................P2.07-040 Akazawa Rio............................................................... OA 05.03 Andarini Sita...................MA 04.12, P1.02-065, P1.03-024,
Abreu Carlos E.........................................................P2.14-003 Akbay Ahmet.............................................................P2.01-024 .........................................P2.03-031, P2.03-049, P3.01-032,
Abreu Igor..................................................................P1.06-010 Akbay Esra A.......................................................... P1.07-007 ............................................P3.01-053, P3.01-054, P3.11-001
Abreu Igor R.........................................P2.10-006, P3.10-001 Akdeniz Nadiye.........................................................P2.01-024 Andersohn Frank.......................................................MA 12.07
Abrão Fernando C...... P1.06-010, P2.10-006, P3.10-001 Akerley Wallace L....................................................P2.03-058 Anderson Christine............ MA 15.12, OA 07.07, P2.02-022,
Accioly Maria Theresa.............................................P1.02-036 Akhurst Tim.................................................................. MA 17.12 ...................................................................................P3.02-094
Acevedo Angelic...................................................... P2.07-029 Akimoto Tetsuo................. MA 17.06, P2.05-005, P3.14-001 Anderson Eric C.................................. P2.01-004, P2.01-013
Achenbach H. Jost.....................................................OA 10.06 Akimov Mikhail........................................................ P2.04-005 Anderson Harald...................................................... P1.15-007
Ackerstein Aliza.......................................................P3.03-028 Akinbobola Olawale............................... OA 15.08, P2.16-019 Anderson Nigel......................................................... P2.14-001
Acosta Estrella..................................... P2.05-007, P3.14-014 Aksarin Aleksei A.................................................... P3.15-016 Andersson Saana................................................... P1.08-010
Adam Julien.........................MA 05.03, MA 11.01, P1.03-013, Al Freijat Faraj............................................................ OA 16.03 Ando Masahiko....................................................... P3.04-002
.........................................P2.01-038, P2.07-005, P2.07-060 Al-Kaisey Ahmed......................................................P2.13-023 Andrade Perla.......................................................... P1.06-024
Adam Michael J....................................................... P1.03-020 Al-Najjar Haider...................................................... P1.03-001 Andrade Santiago Jesus.................... P1.06-013, P2.07-039
Adam Stacey............................................................... OA 14.07 Alabiso Oscar.............................................................MA 02.05 Andrades Delgado Álvaro...................................... P2.02-010
Adame Carlos.......................................................... P2.07-038 Alaez Carmen...........................................................P2.01-075 Andrés Granyò Marta..............................................P1.07-028
Adamek Mariusz......................................................P3.13-032 Alam Ei Din Mona................................................... P2.02-040 Ang Mei-Kim........................................... OA 09.07, P3.01-017
Adams Hans-Peter....................................................OA 10.06 Alam Naveed.............................................................P3.16-045 Angel Martin.............................................................P2.03-039
Adams Kerry..............................................................MA 08.09 Alama Angela............................................................P1.07-023 Angelats Laura.......................................................... P1.01-062
Adams Mark.............................................................P1.02-010 Alan Ozkan...........................................P1.03-040, P3.15-007 Angell Helen K.......................................................... P1.15-004
Adams Mark N...........................................................MA 03.11 Alanya Enrique........................................................P2.07-044 Angevin Eric................................................................MA 02.10
Adamska Julia............................................................. MA 16.01 Alatan Bolag.............................................................P2.02-026 Anguera Palacios Georgia................. P1.07-028, P2.01-072
Addo Safoa................................................................ P1.01-059 Alatorre Alexander Jorge Arturo.... P2.06-007, P2.07-061 Anker Jonathan...................................... MA 05.11, P1.07-043
Adeline Lau Koh Mei............................................... P1.05-007 Albacker Lee A..........................................................MA 05.02 Anraku Masaki...................P1.07-017, P1.13-002, P3.16-028
Aden James.............................................................. P1.03-014 Albadri Cinaria.........................................................P1.09-006 Anselmo Achille........................................................P1.07-032
Adeni Anika E.......................................P1.01-055, P2.07-002 Albain Kathy................................................................ OA 14.07 Anstee Caitlin............................................................P3.16-007
Adjei Alex............................JTO 01.01, MA 01.06, MA 18.09, Albanell Joan.............................................................P1.15-001 Anthony Lowell B.................................P2.07-051, P3.15-010
.........................................MTE 11.01, P1.04-013, P1.07-039,
Albaqer Tahani..........................................................P1.07-022 Anton Etta.................................................................. P2.16-001
..................................................................P2.01-054, YI 01.07
Albelda Steven......................................................... P2.07-059 Antonelli Paola.............................................................. MA 11.11
Adkins Irena........................................P2.07-020, P3.07-008
Alcaraz Jordi........................................P1.05-019, P3.03-023 Antonia Scott.....................OA 17.03, P2.02-030, P3.07-012
Adler Brendan...........................................................P2.13-002
Alchimowicz Jacek.................................................... MA 14.01 Antonia Scott J...........................................................PL 02.02
Adusumilli Prasad S......... MA 13.14, MA 15.09, MTE 07.01,
.............................................OA 02.08, OA 18.06, P1.13-003, Aldeguer Erika..................................... P1.07-015, P2.02-034 Aoe Keisuke..........MA 07.11, MA 19.01, OA 12.03, P1.03-038
................................................................P2.05-021, P3.13-019 Aldige Carolyn...........................................................MS 04.02 Aoishi Yuka........................ P1.03-033, P2.16-010, P3.13-012
Aerts Joachim G........................................................OA 02.01 Alemayehu Aster.....................................................P2.03-056 Aokage Keiju....OA 16.07, P2.16-015, P3.02-074, P3.13-036
Afar Daniel...................................................................MA 02.10 Alexander Laura..................................................... P3.04-006 Aoki Masahiko........................................ MA 09.06, MS 24.04
Affes Mariem.........................................P3.13-025, P3.13-026 Alexander Marliese........MA 18.12, P1.01-033, P3.13-003 Aoki Masaya............................................................. P2.16-004
Agarwal Jai P........................................................... P2.14-005 Alexandra Curioni....................................................P2.02-036 Aoki Shinichi..............................................................MS 24.04
Agbareya Abed..........................................................MA 02.06 Alexandris Ekaterine........MA 03.06, P1.03-050, P3.01-071 Aoki Shuri................................................................. P3.14-008
Agelaki Sofia.............................................................P1.01-044 Alexandrov Oleg..................................... P1.16-011, P3.16-021 Aoki Takahiro.............................................................P1.02-034
Aggarwal Charu...................OA 14.07, OA 17.08, P2.07-059 Alhayyani Sultan......................................................P3.07-002 Aoyama Akihiro.................................. P3.02-046, P3.02-071
Agorreta Jackeline..............................P2.02-061, P3.07-007 Ali Haythem Y....................................... P2.01-014, P2.01-015 Aparisi Francisco.................................. MA 07.03, P2.01-031
Agostini Paula J....................................................... MA 08.09 Ali Kamran.................................................................. MA 13.12 Appel Wiebke............................................................. OA 02.03
Agte Sarita........................ OA 07.03, P1.07-034, P3.02-013 Ali Siraj M..............................MA 07.07, MA 12.03, MA 15.06, Appiah Adams K.........................................................MA 13.04
Aguiar Jr Pedro..........P1.11-001, P2.03-006, P2.07-054, ..............................................OA 12.08, OA 18.03, P2.02-016 Appius Anita............................................................. P3.01-040
............................................................. P2.07-055, P3.03-019 Alizadeh Ash A........................................................... MA 13.01 Appleton Elizabeth................................................. P2.08-003
Aguilar Alfredo................P1.06-022, P1.06-023, P2.01-053 Allen Britney............................................................. P2.14-009 Aprile Vittorio...............................................................MA 17.01
Aguilar Laura K........................................................ P2.07-059 Allen Pamela K............................................................ MA 01.10 Apthorp Duncan.................................... P3.05-001, WS 01.18
Aguilar-Cordova Estuardo..................................... P2.07-059 Allen Philip................................................................ P1.09-003 Aquino Jose.................................................................OA 11.06
Aguirre Maria L........................................................P3.02-055 Allende-Perez Silvia................................................. MA 08.10 Aragaki Masato....................................... OA 04.02, P1.17-010
Agulnik Jason....................................P2.02-040, P3.02-055 Alley Evan............................................... OA 17.08, P2.07-059 Aragane Naoko....................................OA 10.08, P2.03-009
Ah Young Shin........................................................P2.05-014 Allibhai Zishan..........................................................P3.14-002 Arai Daisuke.............................................................P3.02-084
Ahmad Usman..............................................................MA 17.11 Allison James.............................................................. OA 13.05 Arai Ryosuke.............................................................P3.10-007
Ahmed Ghada......................................... OA 09.03, OA 09.06 Alloisio Marco........................................ P1.07-032, P1.16-027 Arai Sachiko.............................................................. P3.15-001
Ahmed Hegab..........................................................P3.02-084 Allos Beshar.......................P2.14-012, P2.14-014, P2.14-015 Arakawa Kenichi.......................................................P3.10-007
Ahmed Merina...........................................................MA 09.09 Allred Alicia J...........................................................P2.07-058 Araki Kunio........................P1.02-060, P1.02-061, P1.13-008
Ahmed Sharif..................................... P1.06-011, P3.14-006 Allsworth Max........................................ P3.05-001, WS 01.18 Araki Osamu........................................P1.02-018, P3.02-064
Ahmed Sheikh Nisar................................................. P1.14-014 Almodovar Teresa......................................................P1.17-012 Aramaki Nao...............................................................P1.07-012
Ahmed Tamjeed.......................................................P1.01-059 Alpay Levent.............................................................. P1.03-016 Aran Veronica........................................................... P1.01-045
Ahn Beung Chul.......................................................... MA 11.09 Alpert Naomi...............................................................MA 18.07 Aranas John Clifford E............................................P2.12-004
Ahn Hee Kyung........................................................ P3.05-010 Alsaadoun Noor A..................................................P1.06-005 Araujo Luiz H....................................P1.02-036, P1.06-024
Ahn Ho Jung............................................................P2.03-022 Altan Mehmet........................................................ P2.07-061a Arce-Lara Carlos......................................................P1.07-008
Ahn Hyo Yeong.................. P1.16-001, P2.16-011, P3.16-006 Altiok Soner..............................................................P2.02-030 Archila Pilar...................... MA 01.02, P1.02-055, P3.02-063
Ahn Jin Seok....................... MA 17.05, OA 03.04, OA 08.07, Altomonte Maresa......................................................MA 19.02 Archuleta James P.................................................. P3.09-001
.........................................P2.01-064, P2.07-025, P3.01-023, Altorki Nasser................MS 03.01, P2.04-004, WS 02.09 Arcila Maria E........................ OA 10.05, OA 14.05, OA 18.05
.................... P3.01-029, P3.01-082, P3.03-012, P3.08-006 Alvarez Cabellos Ruth.......................P1.06-013, P2.07-039 Arcocha Ainara................P1.01-075, P2.02-014, P3.01-045
Ahn Joong Hyun................................P2.02-029, P2.05-014 Álvarez María........................................................... P3.01-065 Ardissone Francesco.................................................OA 16.02
Ahn Linda..................................................................P1.03-028 Alvarez-Avitia Miguel A..............................................MA 16.12 Ardizoni Andrea......................................................... MA 10.02
Ahn Myung-Ju.......... ISS 02.04, MS 13.05, OA 03.04, OA Alì Greta......................................................................P1.01-015 Ardizzoia Antonio..................................................... P1.01-065
........................................ 05.05, OA 08.07, OA 09.03, Amadori Dino...........................................................P3.02-007 Ardizzoni Andrea............MA 02.05, P2.07-034, P3.01-043
AUTHORS IN BOLD = PRESENTING AUTHORS
Aref Amir R................................................................. MA 07.12 Azzoli Christopher G............................... OA 07.05, OA 12.02 Barnett Todd..............................................................P1.12-007
Arellanes-Herrera Paloma.....................................P2.07-061 Barone Claudia...........................................................MA 18.02
Arellano Monica.......................................................P2.07-044 Barr Martin P...................MA 04.10, P1.02-011, P1.03-039,
Arenberg Douglas.....................................................MA 20.02 ..................................... P1.03-041, P1.03-042, P1.03-048,
B ................ P1.09-007, P2.02-048, P2.02-064, P2.02-069
Arfan Ahmad............................................................P3.02-009
Argjiri Dhimitraq..................................P2.01-059, P3.16-005 Barreiro Esther......................................................... P1.05-019
Baamonde Carlos.......................................................PL 02.04 Barrera Lourdes................................... MA 12.10, P1.07-040
Arias Randell S.......................................................P2.01-062
Baas Paul............................................... OA 02.02, SH 04.01 Barreto Carmelia M.N..........................P1.11-001, P3.03-019
Arima Yoshimi...........................................................P1.02-023
Bab-Dinitz Liza.........................................................P3.07-010 Barrett Carl........................................ P2.02-052, P3.02-062
Arimori Kazuhiko...................................................... P1.03-015
Baba Keisuke............................................................ P2.03-014 Barrie Umaru........................................................... P3.02-073
Arimura Takeshi..................................................... P2.05-005
Babacan Nalan A..................................................... P1.03-040 Barrios Carlos............................................................P3.13-018
Arisaka Yukiko..........................................................P2.02-026
Babington Scott..........................................................MA 13.07 Barrios Pedro............................................................P1.07-041
Arita Masashi...........................................................P2.07-007
Baccouche Ines....................................P3.13-025, P3.13-026 Barrios Rodolfo....................................................... P3.08-005
Arnaiz Mm............................................................... P2.08-006
Backhus Leah............................................................OA 04.06 Barrios-Bernal Pedro..............................................P2.01-075
Arnaoutakis Konstantinos........................................ MA 18.15
Backman Max W...............MA 06.01, P1.07-021, P2.02-023, Barron Feliciano.................................... MA 12.10, P3.14-012
Arni Stephan............................................................ P1.02-005 ...................................................................................P2.02-066
Arnieri Brandon.........................................................P1.01-031 Barroso Ana.............................................................P1.01-020
Bacon Ludwing.......................................MA 20.12, P1.09-013
Arnold Andrew........................................................... MA 10.01 Barrueco José...........................................................P1.09-011
Badawi Ramsey D.....................................................P1.07-013
Arnold Susanne....................................P2.07-051, P3.15-010 Barshack Iris............................................................P3.03-028
Badragan Iulian.........................................................P1.14-014
Arpí Oriol....................................................................P1.15-001 Barthe-Vonsy Poerava.............................................P2.11-001
Badwe Rajendra......................................................P3.02-036
Arrabal Ricardo..........................................................PL 02.04 Bartholmai Brian.......................................................P2.13-014
Bae William H.......................................... MA 05.11, P1.07-043
Arrieta Oscar................... ISS 02.04, MA 01.02, MA 08.10, Bartlett Greg...............................................................MA 13.06
Bae Yeon-Hee...........................................................P3.03-012
..................................................MA 12.10, MA 16.12, MA 20.12, Barve Minal.................................................................MA 02.10
Baena Javier.............................................................P2.07-016
............................................P1.01-019, P1.01-022, P1.02-055, Barzaga Maria Teresa A................... P2.02-019, P3.02-056
........................................P1.03-050, P1.03-054, P1.07-040, Bafunno Daniela..................................................... P3.06-003
Bas Carlos................................................................. P1.01-058
...........................................P1.07-041, P1.09-013, P1.17-008, Bagano Marlo P....................................................... P2.12-004
Basappa Naveen...................................................... P2.01-032
......................................... P2.01-049, P2.01-070, P2.01-075, Baglivo Sara.............................................................P3.02-007
Baschnagel Andrew............................................... P3.04-009
........................................P3.02-063, P3.08-005, P3.14-012 Bagnes Claudia......................................................... P1.01-058
Baselga Jose...............................................................OA 14.05
Arriola Edurne......................................................... P1.15-001 Bahcall Magda............................................................. MA 07.12
Bassetti Michael..................................................... P3.04-009
Arroyo Hernandez Marisol..................MA 20.12, P3.14-012 Bahce Idris............................................MA 05.07, P2.02-024
Bassier-Paltoo Marcia............................................... MA 18.01
Artal Cortes Angel..............MA 10.03, MA 15.01, P2.01-022, Bahl Gaurav................................................................ P1.14-014
Bastos Lilian..............................................................P1.02-036
..................................................................................P3.01-065 Bai Chunxue.......................MA 20.13, P3.04-001, P3.13-037
Batagel Emilio........................................................... P1.01-058
Arulananda Surein..................................................P3.02-038 Bai Yaying..................................................................P3.01-074
Batenchuk Cory.........................................................P1.01-051
Arzumanyan Alla L................................................... P1.01-056 Bai Yongrui.................................................................P3.17-001
Bates Alan..................................................................MA 04.02
Arén Frontera Osvaldo............................................P3.07-012 Baigi Amir..................................................................P1.09-010
Bates Andrew............................................................ OA 02.03
Asahina Hajime.................................. P2.01-005, P3.04-004 Baijal Shobhit.............................................................SS 01.08
Bates Gleneara E.............ES 03.04, MA 04.05, P1.10-007
Asakawa Ayaka......................................................... P1.12-006 Baik Christina S.................................. OA 12.04, P1.06-009
Batista Bernardo......................................................P1.06-010
Asakura Keisuke.................................. P1.05-002, P1.05-017 Bailey Simon.............................................................P1.03-001
Batista Mayara......................................................... P1.06-024
Asamura Hisao...............MA 05.04, MS 03.02, P1.05-005, Bainbridge Hannah................................................. MA 09.09
........................... P1.05-009, P1.17-017, P3.13-031, PL 02.06 Battaglia Giuseppe..................................................P2.07-046
Bains Manpreet....................................................... P2.06-005
Asao Takayuki..........................................................P2.02-026 Bauer Todd M...........................................OA 05.06, OA 12.07
Baird Anne-Marie................................ MA 04.10, P1.09-007
Ashcroft Linda.........................MA 09.11, MA 17.14, OA 02.03 Bauman Jessica........................................................ MA 07.02
Baixeras Nuria.................MA 20.06, P1.01-075, P2.08-006
Ashinuma Hironori................................................. P2.07-014 Bauml Joshua M................................... OA 17.08, P2.07-059
Baker Katie..................................................................MA 10.07
Ashizawa Kazuto...............P1.03-015, WS 01.31, WS 02.17 Baxter Tammy........................................................... P1.16-022
Baker Kelsey............................................................P1.06-009
Ashraf Haseem.......................................................... P3.13-011 Bayliss Richard..........................................................P1.03-011
Bal Amanjit...............................................................P2.03-053
Ashton Miranda J............................ P3.04-006, P3.09-002 Bayman Neil............................................ MA 09.11, OA 02.03
Balaguera Alberto.................................................. P3.08-005
Asmann Yan............................................................... MA 05.01 Bayram Ahmet S................MA 17.08, P2.14-016, P3.16-046
Balakrishnan Prakash......................P2.16-028, P3.16-035,
Assal Amer.................................................................. OA 13.03 Baysungur Volkan S................................................. P1.03-016
.................................................................................. P3.16-036
Asselin Marie-Claude................................................. MA 17.14 Baz David V.................................................................PL 02.02
Balart Josep......................................... P2.05-007, P3.14-014
Atagi Shinji....................P1.03-027, P2.15-004, P3.04-002 Bazhenova Lyudmila A........MA 17.07, OA 14.07, P1.01-004,
Balas Bogdana........................................................... P1.01-013
..................................... P1.03-044, P2.03-058, P3.01-048
Ather Sarim..............................................................P1.05-008 Balasubramanyam Aarthi.........................................OA 10.06
Beal Silvia E.............................................................. P1.06-007
Atherton Pamela J.................................................. P2.14-006 Balata Haval...............................................................OA 15.04
Beale Philip................................................................P3.13-038
Atkar-Khattra Sukhinder.........MA 14.11, MA 20.11, OA 15.01, Baldacci Simon.......................................................... MA 07.06
..................................................................P2.13-011, P2.13-012 Beamer Staci E........................................................ P3.09-001
Baldi Milind.................................................................MA 03.02
Atkinson Charlotte E.L............................................P2.14-010 Beard Sam................................................................. P1.02-010
Baldini Edi E.................................................................. MA 11.11
Atmaca Akin.............................................................P2.07-034 Bearz Alessandra.................MA 01.07, OA 02.01, OA 05.06,
Baldotto Clarissa..................................................... P1.06-024 ..................................................................OA 05.07, P1.01-065
Atmodimedjo Peggy.................................................P1.02-038 Baldwin David R............OA 02.03, P1.05-010, P2.06-005, Beasley Mary Beth....................................................MS 07.01
Atsumi Jun...............................................................P1.05-006 ............................................. P3.05-001, WS 01.09, WS 01.18
Beattie Vanessa.........................................................MA 08.07
Attia Albert.............................................................. P3.08-004 Bale Tejus....................................................................MA 20.14
Beaulieu Juliette.........................................................MA 02.10
Attia Monia.............................................P3.13-025, P3.13-026 Balisan Othaniel Philip R........................................ P2.01-062
Beaumont Hubert.......................................................MA 14.02
Attili Ilaria..................................................................P3.02-006 Balkissoon Jaikrishna............................................. P1.03-044
Bebb D. Gwyn..............P1.02-013, P1.06-005, P2.01-026,
Aubin François......................................................... P2.07-023 Ball David L.......................... MA 04.06, MA 13.07, MA 17.12, ..................................................................................P3.02-077
Aubry Marie Christine............................ OA 13.07, P1.07-016 ........................ MA 18.12, MTE 04.02, P1.01-033, P1.14-017,
Bebb Gwyn................ P1.03-043, P1.06-006, P2.01-046,
Auclin Edouard....................MA 05.03, MA 11.01, P1.03-013, .....................P2.05-006, P2.14-001, P3.13-003, WS 03.06
................................................................................. P2.02-068
.........................................P2.01-038, P2.07-005, P2.07-060 Ballesteros Anabel.............................. P1.01-057, P2.02-027
Beck-Magaña Andres............................................... MA 08.10
Audigier-Valette Clarisse........................MA 05.03, MA 10.11, Ballesteros Isabel.......................................................PL 02.04
Becker Betsy........................................ P2.16-022, P3.13-028
................................................................. OA 17.05, P2.07-060 Ballesteros-Merino Carmen....................................P1.07-019
Becker-Santos Daiana D...................... MA 15.12, P3.02-094
Auewarakul Chirayu............................................... P2.06-006 Ballinger Marcus................... MA 05.09, MA 10.03, OA 17.07,
Beckert Sophie...........................................................P1.15-011
Auger Manon........................................................... P2.02-040 .................................................................................... P1.01-052
Beckett Paul..............................................................P1.05-010
Auger Nathalie.......................................................... P1.03-013 Ballman Karla..............................................................MA 13.02
Bedard Eric..............................................MA 14.03, P2.13-011
Aukrust Pål...............................................................P2.02-053 Balmanoukian Ani.......................................................OA 17.02
Bederski Krzysztof...................................................P2.16-027
Aumann Ines............................................................... OA 15.02 Bamidele Oluwatosin............................ MA 18.08, P1.10-005
Bedford Laura......................................... MA 18.04, OA 06.08
Aung Sandra............................................................P2.07-062 Bancroft Hollie..........................................................P1.10-002
Beelen Roel.................................................................OA 16.06
Aung Zaw Win............................................................OA 09.07 Banerji Shantanu..................................................... P2.07-029
Beer David...................................................................MA 13.02
Avagnina Maria Alejandra................. P1.02-035, P2.01-007, Bang In Yeong.........................................MA 11.09, P3.01-028
....................................................................................P2.02-071 Begin Paul................................................................ P2.07-029
Banks Kimberly C.................................. OA 12.05, P3.01-046
Avdiu Ibrahim........................................................... P2.01-059 Behera Digambar..........MA 03.02, P1.03-018, P2.03-053,
Banno Shigeo........................................................... P1.03-008
.................................................................................. P2.06-004
Avila Kimberly..............................................................MA 15.13 Bao Hairong................................................................MA 20.13
Behera Madhusmita............................. OA 01.06, P3.13-027
Avila Ricardo S.......... P3.13-035, PL 01.02, WS 01.12, WS Bao Jiarong...............................................................P2.15-003
........................................................................02.15 Behrens Carmen....................................OA 13.05, P2.02-061
Bao Yong....................................................................... MA 01.11
Avilés Alejandro.........................................................P1.07-041 Bei Li........................................................MA 07.03, P3.01-049
Bar Jair........................... MA 02.06, P3.03-028, P3.07-010
Avogadri-Connors Francesca.................................. MA 07.12 Belani Chandra P................................... MA 13.08, P3.13-027
Bara Ilze................................................................... P3.04-003
Awad Mark M......................MA 02.03, MA 05.02, OA 17.01, Belderbos José.................... MA 13.09, MA 17.10, P2.14-020,
Baraibar Iosune.......................................................P1.07-035 ....................................................................................P3.14-005
..........................................P1.01-055, P2.07-002, P2.07-058 Baranski Jim.............................................................. MS 19.01
Awais Omar................................................................MA 20.02 Belilovski Rozenblum Anna................MA 02.06, P1.01-039,
Barba Joaquín Andrés....................... P1.07-028, P2.01-072 ................................................................................... P3.01-060
Aydiner Adnan........................................................P2.01-003 Barber Phil..................................................................OA 15.04 Bell Tim.....................................................................P3.03-026
Aye Ralph.......P1.05-012, P1.10-008, P2.13-021, P3.13-029 Barbieri Fausto..........................................................P1.01-015 Bello Rodrigo M.........................................................P3.13-018
Aye Ralph W...............................................................P2.13-019 Barbosa Paula N.......................................................P2.13-020 Belting Mattias.......................................................... P1.15-007
Ayeni Akinwale..........................................................P3.13-021 Barchuk Alexey.........................................................P3.16-043 Ben Hadj Yahia Bechir..............................................MA 03.05
Ayeni Olusegun A.....................................................P3.13-005 Barlesi Fabrice............... ISS 03.02, ISS 03.08, MA 05.09, Ben Miled-M’Rad Khaoula...................P3.13-025, P3.13-026
Ayers Kelsey............................................................... MA 13.01 ...............................................MS 05.02, OA 16.03, OA 17.05, Benard Francois...................................................... P1.03-020
Azad Tej D................................................................... MA 13.01 ...........................................P1.15-004, P2.04-013, P3.07-012
Benchea Iuliana........................................................ P1.05-019
Azarian Reza............................................................... OA 16.03 Barletta Giulia............................................................P1.07-023
Bendahl Pär-Ola....................................................... P1.15-007
Azevedo Isabel..........................................................P3.01-049 Barlow Andrew..................................... P3.05-001, WS 01.18
Bender Joseph......................................................... P1.01-036
Azuma Hisaya...........................................................P3.01-035 Barmin Vitaliy.......................................... P1.16-011, P3.16-021
Benejova Andrea.....................................................P2.03-023
Azuma Koichi........................................OA 05.03, P2.03-045 Barnes Tristan.................................... P3.01-019, P3.01-062
Beneton Nathalie..................................................... P2.07-023
Azuma Yoko.........................................MS 07.04, P3.16-004 Barneto Isidoro...........................................................PL 02.04
Bengala Carmelo.......................................................... MA 11.11
Azzarello Giuseppe.................................................. P1.01-065 Barnett Stephen A...................................................P3.16-052
Bengtson May-Bente..............................................P2.02-053 Bitencourt Almir.......................................................P2.13-020 Bożyk Aleksandra...................................................... OA 08.03
Bennett Bryan..........................................................P2.07-034 Bittoni Marisa.........................................................P2.06-008 Brabletz Thomas.....................................................P2.02-054
Bennett Jonathan.................................. P3.05-001, WS 01.18 Bivona Trever G.........................................................OA 12.05 Bradbury Penelope............MA 10.01, OA 17.09, P2.01-032,
Bennewith Kevin L............................... MA 05.12, P3.02-090 Bizec Jean-Louis.....................................................P2.07-030 ...................................................................................P3.09-007
Bennouna Jaafar............... MA 03.01, MA 03.05, MA 10.02, Blackhall Fiona.... MA 10.07, MA 17.14, OA 14.08, P1.01-016 Brade Anthony............................................................MS 17.01
................................................................................... P2.04-010 Blais Edik................................................................... P1.01-036 Bradley Jeffrey........................................MA 13.08,MA 18.06,
Benny Ofra...............................................................P3.02-082 Blake Cerda Mónica...................................................MA 20.12 ...............................................MS 16.01, OA 14.07, P1.08-003
Bensman Lindsey....................................................... MA 17.07 Blakely Collin............................................................P2.03-058 Brady Lauren............................................................. P1.02-011
Bentebibel Salah E..................................................P2.07-062 Blanchard Ashley..................................................... P1.01-036 Brahmer Julie R..................MA 09.08, MS 18.06, OA 12.01,
Benz Steve..................................................................OA 18.04 Blanco Ana................................................................ P1.05-019 ............................................ OA 17.03, OA 17.06, P2.07-058,
Benzeno Sharon......................................................... OA 13.05 Blanco Remei........................................ P1.07-015, P2.07-041 ................................................................. P3.03-007, YI 01.04
Berardi Rossana....................................................... P1.01-065 Blanke Charles D........................................................ OA 14.07 Braiteh Fadi.................................................................MA 10.03
Berciano Miguel........................................................P2.07-016 Blanshan Stephanie C...............................................P2.13-019 Brambilla Elisabeth................................................MTE 05.01
Berenguer Jordi.......................................................P3.01-073 Blasco Ana................................................................. MA 07.03 Brandao Mariana.....................................................P2.07-049
Berg Christine....................................... P1.04-003, P2.13-011 Blasi Livio...................................................................... MA 11.11 Branden Eva.....MA 05.13, MA 06.01, P1.01-074, P2.02-015
Berg Janna............................................................. P2.02-053 Blum Walter.............................................................P1.09-002 Brao Isabel...............................................................P2.07-044
Bergaglio Marina......................................................P3.13-006 Blumenschein George......... OA 02.01, OA 12.01, P3.07-012 Bratch Jillian.............................................................P3.01-073
Bergamino Sirvén Milana A.................................. P2.08-006 Boada Aram..............................................................P2.07-041 Braunger Juergen......................................................MA 19.03
Berger Michael F......................................OA 10.05, OA 14.05 Boateng Nana........................................... MA 04.01, P1.13-011 Bray Jenkyn Krista.................................................. P2.14-009
Berger Raanan.........................................................P3.03-028 Bobe Iulian................................................................ P1.03-044 Brcic Luka...............................................................P2.09-004
Berger Walter..............................................................MA 19.07 Boccardo Simona.....................................................P1.07-023 Breder Valery V........................................................ P1.01-056
Berglund Anders...................................MA 05.13, P1.06-002 Boerckel Winfield...................................................... P3.11-002 Bregni Marco Bregni................................................ P1.01-053
Bergman Bengt......................................................... P1.15-007 Bogart Jeffrey............................................................. MA 17.07 Brekken Rolf A..........................................................P2.01-047
Bergqvist Michael............P1.06-002, P1.07-020, P1.14-008 Boggio Gaston..........................................................P2.03-039 Brennan Paul...........................................................P2.06-001
Bergsland Christian...................................................P1.07-021 Bogina Giuseppe S..................................................P1.08-005 Breslin Maeve..........................................................P1.09-006
Bergström Stefan................................P1.06-002, P1.14-008 Bohoudi Omar............................................................P2.14-019 Bressel Mathias....................................... MA 17.12, P2.14-001
Berlin Alejandro.........................................................P3.14-013 Bokan Darijo............................................................. P2.10-005 Bria Emilio..................................................MA 01.07, MA 10.11
Bernabe Reyes........................................................ P1.03-054 Bokhoven Adriaan V...................................................MA 13.02 Brianti Annalisa........................................................P3.13-006
Bernal Samuel.........................................................P3.02-056 Boland Jennifer.......................................................P2.02-037 Brilli Lucia....................................................................MA 19.02
Bernal Xana............................................................... P1.01-075 Boldt R. Gabriel............................................................OA 16.01 Brims Fraser.................. OA 02.05, P1.04-003, P2.13-002,
Bernatchez Chantale.............................OA 13.05, P2.07-062 .................................................................................P3.09-004
Bolotina Larisa V....................................................... P1.01-056
Bernier Cyril.............................................................P2.07-030 Brinkmann Kay......................................................... P1.03-013
Bolton Simon..............................................................MA 08.07
Bernstein Hannah....................................................P3.13-030 Brioude Geoffrey........................................................OA 16.06
Bomalaski John..........................................................MA 19.05
Bernstein Mark..........................................................P3.14-013 Brockman J. Michelle............................................ P3.04-003
Bonacorsi Samuel J.................................................MA 05.07
Berruti Alberto...........................................................MA 02.05 Broderick Caitlin.............. MS 14.04, WS 03.02, WS 03.14
Bonadio Renata R.D.C.C........................................P3.01-066
Berry Lynne D..........................................................P3.03-007 Broggini Massimo....................................................P2.02-065
Bonanno Laura.................MA 01.07, P1.01-015, P3.02-006
Berry Tymara............................................................ P2.01-013 Brooks Carol..............................................................P1.11-004
Bondarde Shailesh Arjun........................................P3.01-036
Bertino Erin................................................................MA 06.08 Brosseau Solenn......................................................... MA 10.11
Bonet Mara................................................................P1.06-021
Bertocci Erica.............................................................MA 19.02 Brovsky Kristine.........................................................MA 13.02
Boniecka Anna..........................................................P2.01-047
Bertoglio Pietro..................................... MA 17.01, P1.08-005 Brown Chris............................................................ P2.03-044
Bonilla-Molina Diana.......................... P2.06-007, P2.07-061
Bertran-Alamillo Jordi............................................P2.02-014 Brown Helen............................................................ P3.01-068
Bonnetain Franck......................................................MA 03.05
Berutti Susana.........................................................P2.03-039 Brown Noah................................................................. MA 11.10
Bonomi Lucia.............................................................MA 02.05
Berzinec Peter....................................................... P2.03-056 Brown-Walker Pamela......................... MA 10.01, P2.01-032
Bonomi Marcelo........................................................ P1.01-059
Besen Ayberk........................................................... P3.08-001 Bruha Tomas..............................................................MA 20.04
Bonomi Philip.............................................................. YI 01.03
Besse Benjamin................ISS 12.02, MA 02.02, MA 05.03, Brummell Stephen P.................................................MA 08.03
Boone Erna L..............................................................MA 18.02
................................MA 10.11, MA 11.01, MS 01.01, OA 03.01, Brummelman Jolanda.............................................P1.07-032
Booton Richard...........................................................OA 15.04
..........................OA 05.06, OA 17.05, P1.03-013, P1.08-009, Brun Philippe...............................................................OA 17.05
Bootsma Gerben..................................................... P2.08-007
.........................................P2.01-038, P2.07-005, P2.07-060 Brunelli Alessandro..................................................OA 04.06
Borbolla-Escoboza Jose Rafael................................MA 12.10
Bessho Akihiro..................OA 12.03, P1.03-004, P1.03-038, Brunet Joan..............................................................P1.03-035
Borczuk Alain...........................................OA 13.03, OA 18.09
..............................................................P2.01-034, P2.03-045 Brunet-Possenti Florence...................................... P2.07-023
Bordeaux Jennifer.....................................................MA 13.03
Bessich Jamie L......................................................... MA 10.10 Brunnström Hans.................................. MA 05.13, P2.02-015
Bordenave-Caffre Stéphanie.....................................OA 17.05
Bestvina Christine M............................................... MA 03.09 Bruno Rossella..........................................................P1.01-015
Bordoni Rodolfo......................................OA 17.07, P1.01-052
Bethe Bethina.............................................................OA 16.06 Brustugun Odd Terje........ MA 18.14, P1.02-028, P1.06-012,
Borghaei Hossein......... ISS 03.01, ISS 03.04, ISS 03.06, ........................................P2.02-053, P2.03-035, P2.03-037
Betsuyaku Tomoko.............................P2.03-012, P3.02-084 ..................... ISS 03.07, ISS 03.08, MTE 15.02, OA 14.07,
Betticher Daniel........................................................... MA 15.11 ............................................... OA 17.01, OA 17.03, P2.01-040 Brutsche Martin........................................................... MA 15.11
Bettini Anna Cecilia................................................... OA 05.07 Borkowsky Shane................................................... P3.10-003 Bruun Jarle................................................................P1.07-021
Betzer Catherine......................................................P2.13-009 Bornais Chantal...........................................................OA 11.06 Bruynzeel A................................................................P2.14-019
Beunders Ingeborg.................................................. MS 27.04 Bornazyan Krikor.................................MA 02.07, P2.07-038 Bruzzi Paolo..............................................................P1.07-023
Beydoun Nadine.................................P2.05-004, P3.14-003 Borondy Kitts Andrea K.................... MA 04.08, P1.06-017, Bryl Maciej............................................P3.01-041, P3.02-049
Bezjak Andrea..................... MA 09.02, MA 16.03, P1.14-016, .............................................P2.13-017, WS 01.03, WS 02.17 Brzezniak Christina................................................... MA 07.02
................................................................ PC 02.03, PL 04.04 Boros Angela...........................................................P1.08-009 Bubendorf Lukas................. MA 06.06, MA 15.11, MS 15.04,
Bezuidenhout Jacques...........................................P2.08-001 Borra Gloria................................................................ OA 05.07 ...................................................................................P2.02-024
Bhandari Prasha........................................................OA 04.06 Borregon Rivilla Miguel...................... P1.06-013, P2.07-039 Buczkowski Jarosław.............................................P3.02-045
Bhandari Ruchir....................................................... P2.10-007 Borrisova Svetlana............................ P2.03-035, P2.03-037 Buder Anna........................................P2.03-025, P2.09-004
Bhargava Amit..........................................................P2.13-008 Bortlicek Zbynek......................................................P2.03-023 Bueno Raphael.....................MA 13.02, MA 19.10, MS 08.03,
Bhatia Rick................................. MA 14.11, MA 20.11, OA 15.01 .................................................................................... P1.12-004
Bosch Barrera Joaquim................... P1.03-035, P1.03-054
Bhatnagar Aseem R...............................................P2.10-007 Buevich Natalia N..................................................... P1.01-056
Bosch Joaquim........................................................... MA 15.01
Bhattacharyya Gouri Shankar..............................P2.01-023 Bui Justin L...........................................MA 02.07, P2.07-038
Boschmans Jasper............................... P3.05-001, WS 01.18
Bhattarjee Atanu.....................................................P2.03-027 Bui Khanh.................................................................. P1.15-004
Bosse Dominick..........................................................OA 14.02
Bhora Faiz.................................................................P2.16-023 Bulur Peggy.............................................................P2.02-037
Botiralieva Gulrukh K............................................ P2.02-049
Bhosle Jaishree...............MA 09.09, P1.03-029, P2.07-049, Bulutay Pınar............................................................P3.13-024
Botling Johan...................... MA 05.13, MA 06.01, P2.02-015
....................................................................................P3.12-003 Bunn, Jr. Paul A....................................P3.03-007, PL 04.01
Botta Cirino..............................................................P2.07-046
Bhowmik Angshu...................................................... P2.13-011 Buonocore Darren.....................................................OA 14.05
Botta Laura............................................................. P2.09-001a
Bhuniya Sourin....................................P1.02-066, P2.15-002 Buosi Roberta............................................................P1.01-015
Botticella Angela............................... P1.08-009, P2.01-038,
Biaggi Christine............................................................ MA 15.11 ............................................................P2.07-005, P3.09-003 Burbury Kate....................... MA 18.12, P1.01-033, P3.13-003
Bialous Stella.............................................................MS 09.07 Bottoni Edoardo.........................................................P1.16-027 Burgers Sjaak....................OA 02.01, OA 02.02, P1.09-008,
Bidoli Paolo.............................................MA 02.05, P1.01-053 ...............................................................P2.04-013, P3.14-005
Boubekeur Nadia......................................................P1.07-009
Biello Federica..........................................................P1.07-023 Burgess Joshua.......................................MA 03.11, P1.02-010
Boucher Marie-Eve............MA 10.11, OA 03.01, P2.01-038
Biernat Wojtek........................................................... MA 06.06 Burghuber Otto.................................. P2.03-025, P3.03-024
Boura Vanessa............................................................MA 05.13
Bifulco Carlo B...........................................................P1.07-019 Burgio Marco A.........................................................P3.07-012
Bourdages-Pageau Etienne........... P2.05-019, P3.01-080,
Biglia Carlotta.......................................................... P3.06-003 .................................................................................... P3.01-081 Burgueño Lorenzo Isabel................... P1.06-013, P2.07-039
Bilguun Erkhem-Ochir............................................P2.02-026 Bowcock Anne M....................................OA 03.02, P1.17-019 Burich Rebekah A................................................... P3.01-046
Bilici Ahmet.............................................................P2.01-063 Bowles Sweta........................................................... P1.14-009 Burke Tom............................................P1.01-050, P2.04-014
Billiet Charlotte........................................................P3.09-003 Bowling Mark R................................... MA 20.01, MA 20.02 Burkes Ronald.......................................P3.01-019, P3.01-062
Billingham Lucinda J.................................................MS 17.03 Bowman Alex..............................................................P1.17-019 Burks Eric...................................................................P2.13-018
Bing Zhao................................................................P3.01-003 Bowman Rayleen....................................................P2.02-002 Burlacu Alin................................................................P3.16-018
Binti Hj Mohd Diah Suwarni.................................. P3.01-020 Boyd Alana S.............................................................MS 19.04 Burns Christine..............P2.02-052, P3.02-061, P3.02-062
Biosca Mercedes....................................................... MA 07.03 Boyer Michael.................. MA 10.05, P3.01-039, PL 02.03, Burns Katy...................................................................MA 10.07
Birdas Thomas............................................................MA 13.06 ...................................................................................... YI 01.09 Burns Mark.............................................................. P2.05-006
Biricik Fatih S............................................................P3.13-024 Boyeras Iris...............................................................P1.06-021 Burns Virginia............................................................P1.01-051
Bironzo Paolo.......................................................... P2.09-003 Boyero Corral Laura............................................... P2.02-010 Burrowes Paul......................... MA 14.11, OA 15.01, P2.13-011
Bishay Ehab....................... MA 08.09, P1.10-002, P3.16-024 Boylan Colm.................................................................OA 15.01 Burtin Chris..............................................................P2.08-001
Bissonnette Jean-Pierre.......................................... P1.14-016 Boyle Billy............................................... P3.05-001, WS 01.18 Bushunow Peter........................................................ MA 01.06
Biswas Ghanashyam...............................................P2.01-023 Boyle Peter................................................................MS 22.03 Buttigliero Consuelo............................................... P2.09-003
Biswas Romi.............................................................P1.02-063 Boyle Theresa A.........................................................MA 12.05 Butts Charles A.....................................MA 01.04, OA 13.04
Bitar Lela....................................................................P3.01-059 Bozkurtlar Emine......................................................P3.15-007 Byers Lauren..... MA 01.10, MA 02.09, OA 13.01, P3.03-013
Byrd Tiffany............................................................... P1.03-014 Carr Ryan................................................................. P2.01-054 Chao Heng-Sheng...................................................P3.02-043

Byrne Annette T...................................................... P1.09-007 Carranza Hernán...............P1.01-019, P1.01-022, P1.09-013, Chao Richard C........................................................ P3.01-048
Byun Min Kwang......................................................P1.05-014 ...................................................................................P3.02-063 Chao Yin Kai..............................................................P1.16-016
Büttner Reinhard....................................................... MS 18.01 Carranza Omar......................................................... P1.01-058 Chaoul Alejandro.......................................................MS 21.02
Carraro Dirce M................. MA 01.01, OA 07.08, P3.02-060, Chaput Nathalie.................................... MA 05.03, P2.07-060
................................................................................... P3.15-006 Chara Luis................................................................... MA 07.03
Carrasco Josep........................................................ P1.05-019 Charoenyingwattana Angkana..............................P3.03-020
C Carrasco Pablo.................P2.05-007, P3.14-014, P3.14-017 Charrier Melinda............. MA 05.03, P2.01-038, P2.07-060
Carrillo Rosario.........................................................P2.03-051 Chatterji Abhishek................................................... P2.14-005
Cabanero Michael................................P1.02-016, P3.03-008 Carrillo-Sanchez Karol............................................P2.01-075 Chaudhuri Aadel A..................................................... MA 13.01
Cabanillas Maria E...................................................... OA 12.07 Carroll James.......................................MA 02.07, P2.07-038 Chauhan Aman.....................................P2.07-051, P3.15-010
Cabrera-Miranda Luis...............................................P1.07-041 Carter Brett................................................................MA 05.02 Chauhan Anoop......................................................... OA 02.05
Cacciotti Tiziana...........................................................OA 11.06 Carter Justin............................................................... MA 13.01 Chebotaryova Natalia..............................................P3.02-075
Cacho Juan Diego..................................................... MA 07.03 Carvalhana Ilda........................................................ P3.01-062 Chee Serena........................................... P3.05-001, WS 01.18
Cadranel Jacques........................................................OA 17.05 Carvalho Heloisa A..................................................P2.14-003 Cheema Parneet K.........P2.07-029, P3.01-005, P3.01-019,
Caetano Rosangela................................................... P1.01-045 Carvalho Natália..................................P1.02-036, P1.06-024 ................................................................................... P3.01-062
Caffarra Cristina......................................................P3.02-066 Casadio Caterina........................................................OA 16.02 Chella Antonio............................................................P1.01-015
Caffrey Laura...........................................................P1.04-006 Cascales Almudena................................................ P3.09-002 Chen Allen M............................................................P2.02-003
Caglar Hale Basak................................................... P2.01-063 Cascinu Stefano............................................................ MA 11.11 Chen Baozhi............................................................. P3.02-073
Cai Can...................................................................... P2.04-013 Cascone Tina.............................................................. OA 13.05 Chen Chang.............................................................. P3.04-010
Cai Diana...............................................MA 06.14, P3.02-086 Cases Carla................................................................P3.14-017 Chen Chao-Hsun..................................................... P2.07-027
Cai Kaican................................................................. P3.04-010 Cassidy Adrian......................................................... P3.01-040 Chen Chia-Hung.................................P1.03-053, P2.03-003
Cai Weijing........................P1.03-052, P1.15-009, P3.01-085 Cassivi Stephen......................................................... OA 03.06 Chen Chih-Chieh...................................................... P1.03-012
Cai Xiuyu.................................................................. P1.02-026 Castagneris Nicolas................................................P2.03-039 Chen Chu-Yun...........................................................P3.12-002
Cai Xuwei............. MA 14.12, MA 17.02, MA 17.03, P3.13-022 Castañón Eduardo....................................................P1.07-035 Chen Chun........................JCSE 01.10, OA 16.04, P2.03-047
Cai Xuyu...............................................P3.02-008, P3.04-010 Castañón López Carmen.........................................P1.01-060 Chen Difei..................................................................... MA 12.11
Calabrese Fiorella...................................................P3.02-006 Castedo Carla.............................................................. MA 11.02 Chen Enguo............................................................... P3.01-031
Calabro Luana.........................................MA 19.02, OA 02.01 Castillero Lillibeth D.C.............................................P3.02-004 Chen Feng.................................................................. MA 14.04
Calareso Giuseppina............................................. P2.09-001a Castillo Sergi............................................................. P1.01-075 Chen Gang......................JCSE 01.28, MA 07.13, P1.01-002,
Caldwell Jr Charles.................................................. MA 05.14 Castillo-Fernandez Omar..................... P1.01-019, P1.01-022 .......................................P1.01-003, P1.02-043, P1.02-044,
Califano Raffaele.........................................................MA 10.07 Castrellon Aurelio B................................................ P2.01-056 ........................................ P1.02-045, P1.02-046, P1.02-047,
Calikusu Zuleyha..................................................... P3.08-001 Castro Monica A.......................................................P1.06-021 .........................................P1.02-049, P1.02-056, P1.02-057,
Call Sergi.....................................................................OA 16.06 Castro Uriol Denisse............................................... P1.05-022 ....................................... P1.02-058, P1.02-059, P1.15-008,
Callahan Jason........................................ MA 17.12, P2.14-001 Catarino Ana.............................................................P2.16-025 ......................................P2.01-017, P2.02-004, P2.02-005,
Callejo Perez Ana................................ P1.07-028, P2.01-072 .................................... P2.02-006, P2.02-007, P2.02-020,
Cathomas Richard....................................................... MA 15.11 .........................................P2.02-021, P2.03-057, P3.01-002,
Callister Matthew E............................. ES 02.02, WS 02.09 Catino Annamaria................................. MA 01.07, P3.06-003
Calvert Lori............................................. P3.05-001, WS 01.18 .........................................P3.01-008, P3.01-009, P3.02-018,
Cavalcante Tânia Maria.......................................... P3.06-006 .................................... P3.02-025, P3.02-026, P3.02-027,
Calvete Julio..............................................................P2.03-051 Cavic Milena..............................................................P1.02-007 .....................................P3.02-028, P3.02-029, P3.02-065,
Calvo Emiliano.....................................MA 01.05, P2.07-034 Caviezel Claudio....................................................... P1.02-005 ......................................P3.02-068, P3.02-069, P3.02-080,
Calvo Virginia............................................................. MA 07.03 Cayol Federico.....................................P1.01-058, P2.03-039 ..............................................................P3.02-097, P3.03-005
Calzas Julia................................................................ MA 07.03 Cecchi Fabiola...........................................................P1.02-001 Chen George G....................................P2.02-050, P3.16-015
Camacho Arellano Silvia D.....................................P1.07-028 Cedres Susana.......................................................... P1.05-015 Chen Gong-Yan.......................................................... OA 09.06
Camacho M Del Valle.......................... P2.05-007, P3.14-014 Ceppi Paolo............................................................ P2.02-054 Chen Haiqing.............................................................P3.16-025
Camargo Spencer.................................................... P1.16-028 Cerciello Ferdinando.............................................. P1.09-001 Chen Haiquan..............................................................OA 16.04
Cameron Erin.............................................................. MA 18.01 Ceresoli Giovanni L.................MA 11.11, MA 19.03, OA 02.01, Chen Hanbo.................................................................OA 16.01
Camidge D. Ross.............ES 08.03, ISS 01.01, ISS 01.03, .................................................................................... P1.01-065 Chen Hanxiao..............................................................P1.17-001
............................ISS 01.06,MA 02.10, MA 07.01, OA 05.05, Cerga Gojard............................................................ P2.01-059 Chen Heidi.............................................MA 14.08, P3.03-007
......................OA 12.06, P1.01-001, P1.01-004, P1.01-005,
Cernovska Marketa.................................................P2.03-023 Chen Hongbin...........................................................MA 01.06
..............................................P1.01-012, P1.01-016, P2.02-011
Cerra-Franco Alberto................................................MA 13.06 Chen Honglei...........................................................P2.01-028
Camilleri-Broet Sophie.......................................... P2.02-040
Cetinkaya Gamze.............. MA 17.08, P2.14-016, P3.16-046 Chen Hongxia........................................................... P2.01-028
Camp Aaron............................................................. P1.03-044
Cetnar Jeremy.........................................................P3.03-007 Chen Hsuan-Yu......................................................... P2.13-001
Campaínha Sérgio....................................................P1.01-020
Chabon Jacob J.........................................................MA 13.01 Chen Hua -Jun......................................................... P3.01-051
Campbell Toby......................................MA 02.01, P3.04-009
Chacon Lopez-Muñiz Jose Ignacio.. P1.06-013, P2.07-039 Chen Hua-Jun................ JCSE 01.26, P1.01-009, P1.01-010,
Camps Carlos..........................................MA 15.01, P1.01-040
Chae Yee Soo...........................................................P2.03-022 ................................................................ P1.01-018, P3.01-063
Canfell Karen...................................... P1.04-003, P3.06-008
Chae Young K................ P1.04-004, P1.04-005, P2.07-037, Chen Huei-Wen......................................................... P2.13-001
Cani Alma.............................................P2.01-059, P3.16-005
...................................................................................P3.02-034 Chen Hui....................................................................P2.02-018
Cantero Frederique....................................................MA 12.02
Chae Young Kwang............ MA 05.11, OA 07.03, OA 12.05, Chen Hung-Jen.................................P2.03-003, P2.03-038
Cao Bangwei.............................................................P3.01-087 .......................................... P1.07-024, P1.07-025, P1.07-034, Chen Isan................................................MA 02.01, P3.01-048
Cao Peng....................................................................P3.01-073 ..............................................................P1.07-043, P3.02-013 Chen Jia................................................................... P1.03-032
Cao Xiting..................................................................... OA 13.02 Chaft Jamie E..............................................................OA 10.05 Chen Jingyi................................................................P1.07-005
Cao Yuan.................................................................... P1.03-019 Chagoya-Bello Juan Carlos....................................P2.07-061 Chen Jinliang........................................................... P3.01-084
Caorsi Facundo Z................................ P1.01-043, P1.06-007 Chahine Bachar.......................................................... OA 16.03 Chen Juan................................................................. P1.12-002
Capelletti Marzia......................................................P3.02-066 Chai Chee-Shee.........................................................P3.15-014 Chen Jun.....JCSE 01.11, P1.15-008, P3.01-002, P3.01-021,
Capelletto Enrica..............................P1.04-002, P2.09-003 Chaib Imane...............................................................P3.01-073 ...................P3.01-087, P3.02-095, P3.02-097, P3.03-029
Capelozzi Vera L..............MA 01.01, P2.02-046, P3.15-006 Chaiviboontham Suchira............................................OA 11.04 Chen Junying............................................................. OA 03.07
Capen Andrew.........................................................P3.07-006 Chakrabarti Shaon.....................................................MA 12.06 Chen Kaiyan.........................................JCSE 01.18, P2.03-013
Cappuzzo Frederico........ MA 03.06, MA 10.06, MTE 10.01, Chalise Prabhakar....................................................P2.07-019 Chen Ke-Cheng....................................P3.01-079, P3.16-041
............................................P1.01-015, P1.01-053, P1.03-050 Chalmers Anthony................................................. P3.04-006 Chen Ke-Neng.............. JCSE 01.10, JCSE 01.20, OA 04.03,
Capra William.............................................................P1.01-031 Chambers Emily.......................................MA 07.12, MA 20.14 .........................................P2.03-047, P3.05-003, P3.16-053
Caprioli Alberto...........................................................MA 01.07 Champiat Stephane..................................................... MA 10.11 Chen Kezhong.........................................OA 07.01, P3.16-017
Capuano Marina....................................... P1.17-014, P1.17-015 Chan Alexandre.................................... WS 03.13, WS 03.14 Chen Kuan-Yu.......................................................... P3.01-006
Caramella Caroline.................MA 05.03, MA 10.11, MA 11.01, Chan Allen K.C..........................................................P3.02-031 Chen Li...................................................P1.14-011, P2.01-020
..........................................P1.03-013, P1.08-009, P2.01-038,
Chan Mei-Lin..............................................................OA 02.06 Chen Li-Kun.............................................................. P2.14-004
............................................................. P2.07-005, P2.07-060
Chan Oscar S.H........................................................P3.02-031 Chen Liang................................................................ P3.04-010
Carbajal Walter..........................................................P1.03-035
Chan Swee Kim....................................P2.12-001, P2.12-002 Chen Liang-An............................................................ OA 10.07
Carbone David P.............ES 04.04, ISS 07.04, ISS 07.05,
...........................MA 06.08, MS 17.05, OA 18.02, P1.02-019, Chan Vivian W...........................................................P3.02-031 Chen Lijuan................................................................P1.07-038
.........................................P1.09-001, P2.02-065, P2.02-067, Chan-Diehl Faye W.................................................. P1.03-050 Chen Likun.......................JCSE 01.28, MA 07.13, P1.07-026
............................................................ P2.06-008, P3.03-002 Chandler Jason..........................................................P1.01-051 Chen Liming..............................................................P3.01-087
Carbone Salvatore Francesco...............................P2.07-046 Chandrananda Dineika............................................... MA 11.02 Chen Limo.....................................................................OA 13.01
Carcereny Enric............. OA 17.02, P1.01-062, P1.05-015, Chandrasekharan Arun..........................................P2.03-027 Chen Ling..................................................................P2.03-034
......................................... P2.01-022, P2.07-041, P3.01-073 Chandwani Sheenu.............................P1.01-050, P2.04-014 Chen Lingxiang.........................................................P1.03-032
Cardenal Felipe..................................P2.07-044, P2.08-006 Chang Chih-Cheng................................................... P3.01-016 Chen Meng Y................................................................ MA 01.11
Cardenas Juan David......................... P1.06-013, P2.07-039 Chang Gee-Chen................................. MA 12.02, P1.03-050 Chen Ming........MA 01.11, P1.03-007, P3.01-027, P3.14-004
Cardona Andres........................................................ P1.01-013 Chang Hyun............................................................. P3.03-021 Chen Mingwu......................................P1.07-038, P2.02-018
Cardona Andrés F...........MA 01.02, P1.01-019, P1.01-022, Chang Jianhua.......................................OA 09.06, P3.01-036 Chen Mo...............................................JCSE 01.12, P3.01-070
...................P1.02-055, P1.07-041, P1.09-013, P2.02-034, Chang Joe Y...........................................MA 13.08, MS 03.05 Chen Ning.............................................. P1.16-015, P2.05-015
....................................... P3.01-073, P3.02-063, P3.08-005 Chang Shao-Chun.................................................... P1.15-004 Chen Peng.............................................MA 02.03, P3.01-084
Carey Cassandra......................................................P3.14-002 Chang Shu-Chan...................................................... P1.01-078 Chen Peng-Yu.......................................................... P2.07-027
Carfagno Tommaso.................................................P2.07-046 Chang Wei-Yuan................................P1.01-048, P3.05-004 Chen Qixun..............................................MA 09.01, P3.14-015
Cariboni Umberto......................................................P1.16-027 Chang Yih Leong......................................................P3.01-074 Chen Qun................................................P1.15-016, P2.14-011
Carlson Alexander S.................................................P2.13-019 Chang Yoon Soo..................................MA 20.05, P1.03-034 Chen Qunhui...............................................................MA 14.07
Carlucci Maria C......................................................P3.02-006 Chanprasertpinyo Wandee....................................... OA 11.04 Chen Rongrong..............JCSE 01.28, MA 07.13, OA 18.01,
Carmen Behrens......................................................P2.02-013 Chansky Kari...............................................................PL 02.06 ..................... P1.01-002, P1.02-045, P1.02-046, P1.02-047,
Carney Brandon...................................................... P3.15-008 Chansriwong Phichai..................................................OA 11.04 .....................P1.02-048, P1.02-049, P1.02-056, P1.02-058,
Carp Laurens............................................................P3.13-008 Chantratita Wasan...................................................P3.03-020 .................. P1.02-059, P2.02-004, P2.02-007, P2.02-020,
Carpinelli Marisa...................................................... P3.10-002 .................... P2.02-021, P2.03-057, P3.01-009, P3.02-018,
Chao Bo H.................................................................P1.04-001
..............................................................P3.02-027, P3.02-080
Chen Rui-Lian......................................................... P3.01-063 Chirn Gung-Wei................................... P1.07-038, P2.02-018 Clancy Jill S................................................................OA 05.06
Chen Ruizhe..............................................................P2.02-013 Chisamore Michael J.............................................. P2.04-010 Clark Candice J........................................................P3.02-078
Chen Runzhe............................................................... OA 13.05 Chiu Chao-Hua............... MA 03.07, P3.02-043, P3.02-044 Clark Jeffrey W...........................................................OA 12.06
Chen Ruthia................................................................OA 06.02 Chiyo Masako..................P1.16-008, P2.07-008, P2.12-006 Clark Marcia...............................................................OA 06.08
Chen Shuo-Chueh...................................................P2.03-003 Chlistalla Marijana..................................................... P1.01-013 Clark Travis A.............................................................P1.07-013
Chen Tangbin............................................................ P2.16-018 Chloupkova Renata..................................................P2.03-023 Clarke Jeffrey M.........................................................OA 12.05
Chen Tianlei...............................................................P1.03-026 Cho Byoung Chul................. MA 11.09, MA 12.01, MS 20.04, Clarke Katy L................ P1.03-011, P2.01-060, P2.08-003
Chen Ting....................................................MA 07.12, OA 12.01 ...........................OA 05.07, OA 09.03, OA 14.06, P1.01-070, Clarke Stephen..........................................OA 10.03, P1.01-011
Chen Wan-Jiun......................................................... P2.13-001 ....................P3.01-005, P3.01-028, P3.01-050, P3.03-021 Clay Ryan....................................................................P2.13-014
Chen Wei-Chun................................... P1.03-053, P2.07-027 Cho Charles...............................................................P3.14-002 Clayton Karen J.........................................................MA 08.07
Chen Weiqiang................P3.01-087, P3.03-006, P3.03-017 Cho Daniel C.............................................................P2.07-062 Cleeland Charles S..............MA 18.08, OA 01.07, P1.10-005,
Chen Wucheng...........................................................P3.14-015 Cho Deog Gon.......................................................... P1.05-020 .............................................................. P2.01-036, P2.04-014
Chen Xiaohui...................P1.01-002, P1.02-045, P1.02-059, Cho Eun Kyung........................................................P3.05-010 Clement Michelle S..................................................P3.02-052
..............................................................P2.02-007, P3.01-008 Cho Hyun Ji.............................................MA 11.09, P3.01-028 Clement-Duchene Christelle.....................................OA 03.01
Chen Xiaoxia....................P1.03-045, P1.03-052, P1.15-009, Cho Hyun-Ju.........................................P1.01-014, P2.03-024 Clermont Estelle.......................................................P1.07-009
............................................P3.01-067, P3.01-085, P3.15-015 Cho Jae Hwa............................................................. P2.01-016 Cobo Dols Manuel.................MA 03.01, MA 10.02, OA 17.07,
Chen Xiasong........................................................... P3.02-001 Cho Jae Yong............................................................ P1.05-014 ......................................................................................PL 02.04
Chen Xueqin................. JCSE 01.23, P1.01-046, P1.03-002, Cho Jang Ho..................... OA 03.04, P2.07-025, P3.01-023 Cobo Manuel......................................... OA 05.02, P3.01-043
............................................................. P3.01-031, P3.02-040 Cho Jeong Su................P1.16-001, P2.16-011, P3.16-006 Coco Simona.............................................................P1.07-023
Chen Ya-Fang.......................................................... P3.01-006 Cho Jinhyun..............................................................OA 03.04 Codony Servat Carles..............................................P3.01-073
Chen Yamei.............................................................. P1.03-007 Cho John..........................MA 09.02, P1.14-016, P3.09-007 Codony Servat Jordi................................................P3.01-073
Chen Yan.................................................................. P3.05-009 Cho Jong Ho....................P3.01-082, P3.02-011, P3.04-011, Coen Oliver........................................P2.01-060, P2.08-003
Chen Yang................................................................ P3.05-009 ............................................................P3.05-012, P3.08-006 Cognetti Francesco................................... MA 10.06, MA 11.11
Chen Yanping.................. P1.01-002, P1.01-003, P1.02-043, Cho Ju Hwan..............................................................OA 18.02 Cohen Harvey J......................................................... MA 18.06
..................... P1.02-046, P1.02-047, P1.02-049, P1.02-058, Cho Juhee................................................................ P1.06-003 Cohen Roger B....................................... OA 17.08, P2.07-059
.................. P1.02-059, P2.02-004, P2.02-005, P2.02-007, Cho Moon June......................................................... P1.14-013 Cohen Victor......................................P2.02-040, P3.02-055
................... P2.02-020, P2.02-021, P3.01-008, P3.02-018, Cho Oyeon.................................................................. P1.15-015 Cole Aidan J.............................................. MA 17.12, P1.14-017
...................P3.02-025, P3.02-027, P3.02-028, P3.02-029, Cho Sukki................................................ MA 13.12, P2.02-056
.................. P3.02-065, P3.02-068, P3.02-069, P3.02-080 Coleman Shelley..........................................................OA 17.02
Cho Sungnam..........................................................P3.03-027 Colgan Ruth................................................................MA 09.09
Chen Yaoqi.................................................................P1.07-005
Choh Sumito............................................................. P2.01-065 Collaud Stephane.....................................................P3.16-046
Chen Yen-Hao......................................................... P1.03-023
Choi Byeon Hyeon..................................................P3.02-010 Collier Jenna...............................................................MA 05.12
Chen Ying.......................................... P2.01-074, P2.08-002
Choi Byeong Hyeon............................... P1.16-012, P1.16-018 Collins Karen..............................................................MA 08.03
Chen Yinglan.............................................................P3.01-087
Choi Chang-Min..................................P3.01-034, P3.02-088 Colomer Ramón................................... P1.01-057, P2.02-027
Chen Yuan....JCSE 01.25, MA 03.03, MA 06.09, P1.01-037
Choi Jihyun................................................................. MA 07.12 Colson Yolanda......................................................... P1.12-004
Chen Yuehan............................................................. P1.06-019
Choi Jong Hyun........................................................P2.01-035 Coluzzi Paul................................................................MA 02.07
Chen Yuh-Min...................P1.01-066, P1.11-002, P2.07-027,
.......................................... P3.01-005, P3.02-070, P3.07-011 Choi Junghwa.........................................................P2.01-069 Combest Austin....................................................... P1.03-044
Chen Yuhchyau....................................................... P3.08-004 Choi Meena................................................................P1.09-001 Comin Ana................................................................ P3.01-065
Chen Yusong.............................................................P1.07-005 Choi Peter S.......................................... MA 06.14, P3.02-086 Committee Ests Lung Nets Steering...................... MS 07.05
Chen Zhaoling............................................................ P1.14-010 Choi Se Hoon.............................................................P3.16-014 Conde Sara................................................................P1.01-020
Chen Zhaoyang........................................................P2.02-038 Choi Wonil................................................................P1.06-008 Cong Jing.........................P1.01-042, P2.03-034, P3.03-018
Chen Zhe.................................................................... OA 05.07 Choi Wooyoung M..................................MA 05.11, P1.07-043 Conibear John.......................................................... P1.14-009
Chen Zhengjia.......................................................... P1.08-003 Choi Yeonho.......................................... P1.16-018, P3.02-010 Conkling Paul...............................................................OA 17.07
Chen Zhengming........................................................MA 13.02 Choi Yong Soo.................P2.02-001, P3.01-082, P3.02-011, Connelly Luke........................................................... P1.04-003
P3.04-011, P3.05-012, P3.08-006 Connolly Maureen...................................................P2.03-052
Chen Zhi-Hong.................................... P1.01-018, P2.03-054
Choi Yoo-Duk........................................P1.01-014, P2.03-024 Conrad Tatiana......................................P3.14-002, P3.14-013
Chen Zhiwei...............................................................MA 03.03
Choi Yoon Ji............................................................... P1.15-012 Conron Matthew.......................................................P3.13-003
Cheney Richard........................................................ MA 06.06
Choi Yoon-La......................................P2.02-001, P3.04-011 Constenla Figueiras Manuel.................................... P1.15-013
Cheng Chao.............................................................. P3.04-010
Choi Young Ho.P1.16-012, P1.16-018, P1.16-021, P3.02-010, Conte Pierfranco.....................................................P3.02-006
Cheng Ching-Yuan.....................................................MA 03.07 P3.16-020
Cheng Gang.......................................... MA 11.05, P3.01-037 Conteh Veronica.................................... P3.05-001, WS 01.18
Chomprasert Kittisak.............................................. P2.01-002 Conti Maurizio...........................................................P3.13-004
Cheng Haiying......................MA 08.11, OA 13.03, P1.07-027, Chong Inn-Wen........................................................ P2.07-027
.............................................................P2.01-050, P2.13-008 Cooke Matthew..........................................................P1.07-013
Chooback Negar............P3.01-013, P3.01-015, P3.01-030 Cookson William....................................MA 06.13, P1.02-054
Cheng Michael L.........................................................OA 10.05
Chorostowska-Wynimko Joanna....P3.01-041, P3.02-049, Coolen Johan.............................................................P1.13-007
Cheng Ngan Ching...................................................P3.02-078 .................................................................................. P3.02-051
Cheng Paul Ning-Man........................P2.02-058, P2.15-006 Coolens Catherine.....................................................P3.14-013
Chou Teh-Ying.............. P1.01-066, P1.02-008, P3.02-044 Coombes Kevin.....................................P1.02-019, P3.03-013
Cheng Rebecca........................................................ P1.03-050 Chouaid Christos.......................................................MA 03.05
Cheng Xianping..........................................................P2.01-011 Cooper Wendy A........................................................P1.01-011
Choudhari Pradip....................................................P3.02-036 Copakova Lucia........................................................P2.03-056
Cheng Xin.................................................................P2.03-034 Choughule Anuradha..............................................P1.01-024
Cheng Yanan.......................................................... P3.03-009 Copeland Amy........................................P2.13-015, P2.13-016
Chow Chi-Wan..........................................................P2.02-013 Copin Marie Christine......................... MA 07.06, P3.02-002
Cheng Ying................JCSE 01.10, JCSE 01.11, JCSE 01.24, Chow Helen................................................................. MA 07.14
..........................JCSE 01.25, MA 06.09, MA 11.03,OA 05.01, Coppola Vincenzo....................................................P2.02-065
......................P1.01-032, P1.04-010, P1.15-016, P2.03-047, Chow Laura Q....MA 05.05, OA 17.02, OA 17.03, P1.01-012 Corassa Marcelo......................................................P3.02-060
.....................P3.01-012, P3.01-021, P3.01-036, P3.01-087, Chow Vincent.......................................................... P2.04-009 Corcoran Ryan............................................................OA 07.05
..............................................................P3.03-006, P3.03-017 Chow-Maneval Edna..................................................OA 14.06 Cordeiro De Lima Vladmir C................................. P2.09-002
Cheng Yu-Jen.............................................................MA 16.02 Chowaniecova Gabriela..........................................P2.03-056 Cordero Hernando.................................................. P2.01-050
Cheng Yuen Yee.............MA 19.06, P3.02-078, P3.02-079 Chowbay Balram.......................................................P3.01-017 Cornec Divi............................................................... P2.07-023
Chengbo Han............................................................ JCSE 01.11 Choy Hak.............................MA 13.08, P3.08-004, PC 01.01 Cornelio Gerardo D.H.............................................. MS 12.04
Chern Jin-Yuan......................................................... P1.01-078 Choy Young Bin....................................................... P3.02-010 Cornell Dan............................................................... P3.14-008
Chesson Brent...................................... MA 13.07, P2.05-006 Christensen James G...........................MA 02.01, P3.01-048 Corona Cruz Francisco.......................................... P1.17-008
Cheuk Wah.................................................................P3.01-001 Christie Alana.......................................................... P3.08-004 Corona-Cruz Jose F................................................. MA 16.12
Cheung Carol............................................................P1.07-022 Chu Chang-Yao...........................................................MA 16.02 Corral Jaime Jesus.................................................. P3.01-071
Cheung Winson.............. P1.03-043, P1.06-006, P2.01-046 Chu Laura........................P1.01-007, P1.01-008, P3.01-086 Corral Jesus......................OA 05.01, P2.01-022, P3.01-012
Chewaskulyong Busyamas.................................... P3.01-042 Chu Nei-Min.........................................P2.07-027, P3.12-002 Corrales Leticia........................................................ P3.07-007
Chi Kin Cheng.......................................................... P2.05-008 Chu Quincy............................................................... P2.07-029 Corrales Luis.......................MA 01.02, P1.01-019, P1.01-022,
Chian Chih-Feng....................................................... P3.01-016 Chua Bernard Ji Guang............................................P3.01-017 .......................................... P1.02-055, P1.09-013, P3.02-063
Chiang Chi-Lu.................. MA 03.07, P2.07-027, P3.02-043 Chui Michael H............................................................MA 13.02 Corrao Giulia.......................................................... P2.09-001a
Chiappori Alberto.................................P2.04-008, PL 02.02 Chul Cho Byoung........................................................PL 02.02 Corre Romain...........................................................P2.07-030
Chiari Rita...........MA 02.05, MA 11.11, P1.01-015, P1.01-065, Chulam Thiago C......................................................P2.13-020 Correale Pierpaolo.................................................P2.07-046
............................................................. P2.03-058, P3.02-007 Chun Mison................................................................. P1.15-015 Corsi-Travali Stefani................................................... OA 12.07
Chiarle Roberto........................................................P3.02-066 Chun Stephen G........................................................OA 08.05 Cortesi Enrico...MA 10.06, MA 11.11, P1.01-053, P1.01-065
Chiba Masato........................................P3.02-059, P3.16-049 Chung Jin-Haeng............MS 18.04, P1.02-027, P1.02-029, Cortinovis Diego....................................P1.01-015, P1.01-052
Chiba Ryohei..............................................................OA 04.02 ............................................................... P3.02-016, P3.02-017 Cortot Alexis B..................MA 03.10, MA 07.06, P3.02-002
Chiba Ryosuke.......................................................P2.06-009 Chung Kyukwang......................................................P3.16-032 Cortsen Josefine.....................................................P1.05-004
Chiba Yasutaka.....................................P1.07-010, P2.03-008 Chung Kyung Young..................................................P3.16-019 Corvino Frank A...................................................... P3.01-086
Chida Masayuki....................................P1.02-018, P3.02-064 Chung Michael.......................................P2.16-023, PL 01.02 Costa Alexandre B.A.............................................. P2.09-002
Chien Chun-Ru......................................................P2.03-003 Chung Sang Mi..........................................................P2.01-035 Costa Daniel B......................MA 06.02, MA 12.06, OA 12.02,
Chien Hung-Che........................................................ OA 04.07 Chung Won Sang.......................................................P3.16-016 ...................................................................................P3.03-025
Childs Barrett H......................................OA 02.01, P1.04-013 Chungklay Naree.................................................... P2.06-006 Costa Ricardo......................................P1.04-004, P1.04-005
Chiles Caroline.........................................OA 06.06, OA 15.03 Ciardiello Fortunato................................MA 12.02, P1.01-052 Costardi Lorena...................................................... P2.09-003
Chin Yaw.................................................................... P2.14-010 Ciberes-Rticc-Separ-Plataforma Biobanco Pulmonar Costas Kimberly.........................................................P2.13-021
Chinese Clincal Trial Consortium (Cctc) On Behalf Of......... Collaborative Group In Lung Cancer..................... P1.05-019 Costin Daniel...............................................................MA 12.03
................................................................................... P3.04-010 Cicenas Saulius................................. P2.03-035, P2.03-037 Coudert Mathieu........................................................MA 03.05
Chiricolo Anthony..................................................... P2.16-001 Ciftci Rumeysa......................................................... P2.01-003 Coupkova Helena.....................................................P2.03-023
Chirieac Lucian...........................................................MA 13.02 Cincilevičiūtė Giedrė............................................... P3.13-034 Courau Emmanuel..................................................... OA 16.03
Chirinos Luis..................... P1.01-019, P1.01-022, P1.09-013, Ciuffreda Libero........................................................ P1.01-053 Coutinho Daniel.........................................................P1.01-020
...................................................................................P3.02-063 Ciunci Christine............................................................OA 17.08 Couturaud Francis...................................................P2.07-030
Chirita Oana......MA 18.14, OA 11.01, P1.06-012, P2.01-012 Ciupek Andrew...................................... P1.01-036, P1.11-003 Couture Christian........................................................OA 15.01
Coves Juan................................................................P2.07-041 Dal Bello Maria Giovanna........................................P1.07-023 Del Bianco Paola.....................................................P3.02-006

Cox James D..........................................MS 16.05, PL 02.08 Dal Molin Graziela Z................................................P3.02-060 Del Carpio Huerta Luis P.................... P1.07-028, P2.01-072
Coyne Bethany............................................................ MA 08.11 Dalmau Elsa..............................................................P2.07-041 Del Giglio Auro......................................P1.11-001, P2.03-006
Coëtmeur Daniel..........................................................OA 17.05 Dalvi Tapashi............................................................ P2.01-043 Del Olmo Gil Esteban...............................................P2.07-061
Crain Melissa........................................................... P2.05-006 Daly Benedict............................................................ P1.05-013 Dela Cruz Wilfred....................................................P1.03-014
Craven-Bartle Jordi............................ P2.05-007, P3.14-014 Damiano Vincenzo.................................. P1.17-014, P1.17-015 Delaunay Myriam......................................................P1.07-009
Crawford Jeffrey................ MA 08.04, MA 08.11, MA 19.09, Dane Faysal...................P1.03-040, P2.03-042, P3.15-007 Delgado Maria............................................................ P1.16-017
........................... OA 12.05, OA 14.07, P1.01-068, P2.01-050 Danenberg Kathleen............................................... P2.01-056 Delgado Paula............................................................P3.14-017
Creaney Jenette.......................................................P1.09-001 Danenberg Peter..................................................... P2.01-056 Delgado Sillero Irene................................................P1.01-060
Creelan Benjamin.......................................................MA 12.03 Danese Mark D...................................... P1.01-051, P1.15-003 Deliu Zana................................................................. P3.10-002
Cregan Sian..............................................................P1.09-006 Daniel Davey...............................................................PL 02.02 Delmonte Angelo................. MA 02.05, MA 10.06, OA 10.01,
Crespo Guillermo.......................................................P1.07-015 Daniel-Meshulam Inbal............................................P3.07-010 ............................................P1.01-015, P1.01-053, P3.02-007
Cressman Sonya.........................................................OA 15.01 Danielli Riccardo.........................................................MA 19.02 Delord Jean-Pierre.................................................. P1.15-004
Crinò Lucio..........................ES 09.05, MA 10.06, P1.01-015, Danila Edvardas........................................................P3.13-034 Demidova Irina........................................................P3.02-058
.......................................P1.01-053, P3.02-007, P3.07-012 Danilova Anastasiya S............................................. P1.01-056 Demir Cagri..............................................................P2.03-042
Cristea Mihaela.......................................................... OA 03.03 Dansin Eric......................... MA 07.06, OA 03.01, P3.02-002 Demura Yoshiki....................................P2.03-010, P2.07-013
Criswell Angela M..........MA 04.11, P2.13-015, P2.13-016, Darling Gail E.................. MA 14.14, MTE 16.02, P1.13-004, Demuth Christina..............................P3.02-005, P3.02-050
............................................WS 01.06, WS 01.21, WS 01.39 .................................................................................... PL 04.04 Denby Donna.............................................................MA 08.07
Croce Carlo M..........................................................P2.02-065 Darlison Liz........................MS 08.07, OA 02.03, WS 03.18 Deng Jun................................................................... P1.03-019
Croci Stefania...........................................................P2.07-046 Darwiche Kaid...........................................................P3.13-033 Deng Lamei................................................................. MA 11.05
Cronin-Fenton Deirdre........................................... P2.01-043 Das Majumdar Saroj K............................................ P2.15-002 Deng Qinghua............................................................P1.14-001
Crosbie Phil.......................... OA 15.04, P3.05-001, WS 01.18 Das Nair Roshan............... MA 18.04, OA 06.08, P3.06-009 Deng Qiuhua...............................................................P3.01-011
Crosby Marcus.........................................................P2.07-040 Das Partha M...........................................................P3.02-044 Deng Wei..................................................................... MA 07.09
Crossley Fayre........................................................... MA 04.01 Dastani Zari..............................................................P3.02-055 Deng Xiaowu...............................................................P1.14-011
Crouser Elliott......................................................... P2.06-008 Date Hiroshi..................... P1.14-005, P3.02-046, P3.02-071 Dennie Carole..............................................................OA 11.06
Crowley John.............................................................MS 17.06 Datta Sutirtha............................................OA 10.03, OA 10.05 Denning Warren L.....................................................MA 05.02
Cruickshank Scott...................................................... OA 12.07 Dauth Margaret...................................................................9941 Denninghoff Valeria C..................... P1.02-035, P2.01-007,
Cruz Marcelo........................................... MA 05.11, P1.07-043 Davidescu Mihnea.....................................................P3.16-018 .................................................................................. P2.02-071
Cruz-Rico Graciela...............................P1.07-041, P2.01-049 Davies Kurtis D.......................................................P3.02-057 Dennis Philip A.............P1.04-008, P2.04-001, P2.04-002
Crystal Jessica......................................................... P2.16-001 Davies Marianne................................... MS 14.02, WS 03.15 Dennis Phillip A..........................................................PL 02.02
Cseh Agnieszka..................................P2.03-025, P3.01-043 Davies Michael P........................................................ WS 01.24 Deonaraine Kristina.................................................. OA 03.03
Csőszi Tibor.................................................................OA 17.06 Davies Reece.............................................................P3.16-045 Depypere Lieven........................................................P1.13-007
Cubero Noelia.....................MA 20.06, MA 20.08, P1.12-009 Davis Andrew A..................MA 05.11, OA 07.03, P1.07-034, Deroose Christophe............................ P1.13-007, P3.09-003
Cuello María T..................P1.02-035, P2.01-007, P2.02-071 ............................................................... P1.07-043, P3.02-013 Desai Amrita........................................P1.07-024, P2.07-037
Cuello Mauricio......................................................... P1.09-013 Davis April.................................................................... MA 11.10 Desbiolles Lotus.......................................................P2.07-012
Cuffe Sinead..........................MA 04.10, OA 17.06, P1.02-011, Davì Davide...............................................................P2.07-046 Descarpentries Clotilde...................... MA 07.06, P3.02-002
..................... P1.03-039, P1.03-041, P1.03-042, P1.03-048, Dawson Sarah-Jane.............................................. P2.03-044 Descourt Renaud.....................................................P2.07-030
.................. P1.09-006, P1.09-007, P2.02-048, P2.02-064, Dayyani Farshid.................................P3.05-007, P3.05-008 Deshpande Charuhas............................................. MA 06.03
..............................................................P2.02-069, P3.02-053 Dazzi Claudio.............................................................P1.01-015 Despain Darrin.........................................................P2.03-058
Cui J. Jean............................................ MA 07.09, P3.01-073 De Angelis Flavia..................................................... P2.07-029 Detarkom Supoj..................................P3.01-042, P3.03-020
Cui Jiuwei...................................................................OA 18.08 De Braud Filippo.........................................................OA 14.06 Detry Bruno............................................................. P3.15-004
Cui Xiaoxia................................................................ P2.03-041 De Castro Javier................. P1.01-013, P1.01-040, PL 02.04 Detterbeck Frank............................... MTE 23.01, P2.13-022
Culligan Melissa.............. MS 10.04, WS 03.06, WS 03.18, De Castro Jr Gilberto.............................................. P3.01-066 Deutsch Eric.............................................................P1.08-009
.................................................................................... WS 03.19
De Censi Andrea........................................................MA 02.05 Devanand Anantham.................................................OA 09.07
Cultraro Constance M........................P1.02-063, P2.03-052
De Esteban Julvez Leonardo................................. P1.05-019 Devaraj Anand............................................................MA 09.10
Cumberland Marianne............................................. ES 06.04
De Jong Evelyn E.C................................................. P2.01-048 Devine Matthew..................................................................9941
Cummings Amy....................................MA 02.07, P2.07-038
De Jonge Maja.................................... P1.15-004, P2.04-005 Devriendt Daniel.........................................................MS 13.02
Cunha Edson T..........................................................P1.02-036
De Koning Harry J............... ES 02.01, OA 15.06, OA 15.07, Dewal Ninad.............................................................P2.02-052
Cupit Lisa................................................................... P1.04-013 .......................P2.13-007, P2.13-025, WS 01.02, WS 01.36 Dewanti Hapsari..................................................... P3.01-032
Curigliano Giuseppe...................................................MA 12.02 De La Garza Jaime....................................................P1.17-008 Dhalluin Xavier............................................................MA 03.10
Curotto De Lafaille Maria A....................................... MA 10.10 De La Maza Luis........................................................OA 02.06 Dhanurdhar Yera..................................................... P2.15-002
Curran, Jr. Walter J........ MS 23.04, P1.08-003, P3.13-027 De La Torre Cabrera Capilla...................................P1.07-036 Dholaria Bhagirathbhai.....OA 06.05, OA 06.07, P1.07-039
Currykosky Penny....................................................P2.01-047 De La Torre Mercedes.............................................. P1.16-017 Di Gennaro Francesco.............................................P2.17-002
Curti Brendan D.......................................................P2.07-062 De La Vega Máximo............................ P2.01-007, P2.02-071 Di Giacomo Anna Maria.............................................MA 19.02
Cutler Jr. Richard E.................................................... MA 07.12 De Langen Joop........................................................MA 05.07 Di Mingyi.............................................. P1.01-061, P2.15-012
Cutz Jean-Claude........................................................OA 15.01 De Leyn Paul.......................MS 24.02, OA 16.06, P1.13-007 Diab Adi.....................................................................P2.07-062
Cuyas Elisabet...........................................................P1.03-035 De Los Llanos Gil Maria...................... P1.07-015, P2.02-034 Diab Khalil....................................................................MA 13.06
Cypel Marcelo............................................................ P1.13-004 De Luca Emmanuele...............................................P1.04-002 Diah Putu A.............................................................P1.03-024
Czarnecka Kasia....................................................... P1.13-004 De Luigi Nicoletta.....................................................P3.02-007 Diakos Connie I...........................................................OA 10.03
Czyzewicz Grzegorz................................................ P3.01-041 De Macedo Mariana P.............................................P3.02-060 Diao Lixia......................................................................OA 13.01
Czyżewski Damian...................................................P3.13-032 De Marinis Filippo.............JCSE 01.27, MA 07.01, MA 10.06, Dias Margarida..........................................................P1.01-020
Cárdenas Quesada Nuria........................................P1.07-036 .......................... MA 11.11, P1.01-015, P1.01-053, P2.04-005, Dias-Santagata Dora..................................................OA 07.05
Cé Coelho Juliano................................ P1.01-043, P1.01-063 ...............................................................P3.01-005, P3.01-073 Dibonaventura Marco............................................... MA 01.09
De Mello Ramon Andrade...................P1.11-001, P2.03-006 Dickgreber Nicolas...................................................P3.01-075
De Miguel Fernando............................P2.02-061, P3.07-007 Dickinson Helen.........................................................P1.03-011
D De Palma Angela.....................................................P2.17-002 Dickinson Pete........................................................ P2.08-003
De Paoli Federica.....................................................P1.07-032 Dickinson Rosie........................................................P1.05-010
D’Agostino Ralph...................................................... P1.01-059 De Paula Claudia A.....................................................OA 07.08 Dickson Jennifer.................P2.13-011, P3.05-001, WS 01.18
D’Amico Thomas....................................GR 03.03, MA 19.09 De Perrot Marc..................MS 23.01, OA 02.06, P1.13-004, Dieci Elisa...................................................................P1.16-027
D’Avila Rui..............................................P1.01-063, P3.16-034 ...................................................................................P3.09-007 Diehl Nancy...............................................................P1.07-039
D’Incecco Armida.......................................................MA 19.02 De Petris Luigi.................P1.01-074, P2.02-042, P2.02-043 Diehn Maximilian........................................................ MA 13.01
D’Journo Xavier B......................................................OA 16.06 De Quinana Cristian.................................................P2.01-072 Diem Stefan...............................................................P2.07-012
D’Silva Adrijana.............P1.03-043, P1.06-006, P2.01-026, De Ruysscher Dirk K.........GR 02.07, MA 17.10, P1.13-007, Dienemann Hendrik...... MA 06.06, P3.05-007, P3.05-008
..............................................................P2.01-046, P2.02-068 .................P2.08-001, P2.08-007, P3.09-003, P3.14-011
Dietrich Martin F............. MA 15.02, P2.01-056, P2.07-052
D’Souza Anishka A...................................................P1.11-004 De Sa Vanessa K..................................OA 07.08, P3.02-060
Dietz Allan................................................................P2.02-037
Da Costa Duro.............................................................P1.17-012 De Salvo Gian Luca.................................................P3.02-006
Dietz Steffen............................................................P3.02-032
Da Silva Caroline A.M..............................................P3.16-034 De Sande González Luis.........................................P1.01-060
Diez-Ferrer Marta.............MA 20.06, MA 20.08, P1.12-009
Da Silva Eduardo C.A........................... MA 01.01, P3.15-006 De Stanchina Elisa.................................................. P3.15-008
Digumarthy Subba R..................................................OA 07.05
Da Silva Thiago B......................................................P3.13-018 De Sá Vanessa K................MA 01.01, OA 07.08, P3.15-006
Dilege Şükrü..............................................................P3.13-024
Dacic Sanja..............................................................P2.02-047 De Tursi Michele........................................................MA 02.05
Dimitroulis Ioannis..............................P2.01-039, P3.01-077
Daddi Niccolo............................................................ P1.13-004 De Wever Walter.................................... MS 24.02, P1.13-007
Ding Cuimin.............................................MA 11.03, P3.01-087
Dafni Urania.............................................................. MA 06.06 De Wit Maike...........................................P3.01-088, PL 02.02
Ding Jian-Yong................ MA 16.06, P1.02-062, P1.17-018
Dagogo-Jack Ibiayi.................................................... MA 07.07 Dean Michelle...........................................................P2.02-068
Ding Keyue................................................................ P2.01-055
Dahlberg Suzanne.....................................................OA 08.06 Dearden Simon.......................................................... OA 05.02
Ding Lieming...................................... P2.04-003, P2.04-012
Dai Guanghai............................................................ P2.01-045 Deb Dhruba..................................................................MA 15.13
Ding Ning.....................................................................MA 20.13
Dai Hongshuang......................................................P2.02-062 Debiasi Márcio......................................................... P1.06-007
Ding Ting.....................................................................P3.15-015
Dai Lei................................................... P1.07-038, P2.02-018 Decaluwe Herbert............ MS 24.02, OA 16.06, P1.13-007
Ding Xiao-Jie............................................................ P1.02-040
Dai Li Yan................................................................. P3.14-007 Dechaphunkul Arunee.........................MA 08.02, P3.01-042
Ding Zhen-Yu..........................................................P2.01-066
Dai Liang..........................JCSE 01.20, OA 04.03, P3.16-053 Declerck Jerome.........................................................MA 14.13
Dingemans Anne-Marie C.................ISS 07.03, ISS 07.05,
Dai Pingping.................................................................OA 18.01 Deese Lawrence.................................... OA 15.08, P2.16-019 ...........................................MA 17.10, P2.01-048, P2.08-007
Dai Wei.................................................. P3.16-009, P3.16-037 Defraene Gilles......................................P3.09-003, P3.14-011 Dinjens Winand.........................................................P1.02-038
Dai Zhaoxia........................................... JCSE 01.11, P3.01-021 Degens Juliette H.R.J............................................. P2.01-048 Dipetrillo Thomas A................................................... MA 17.07
Daigo Yataro..............................................................P1.03-037 Deguchi Hiroyuki.................................................... P2.06-009 Disesa Verdi.........................................P2.13-005, P2.13-006
Dakappagari Naveen..................................................MA 13.03 Dehette Stéphanie...................................................... OA 16.03 Disselhorst Maria...................................................... OA 02.02
Dakhil Christopher S.R....................... P2.01-004, P2.01-013 Dejmek Annika........................................................ P1.09-010 Divanon Fabienne.................................................... P3.03-001
Dako Farouk...............................................................MA 04.07 Dekker Andre........................................................... P2.01-052 Dive Caroline..............................................................MS 15.03
Dix Daniel.................................................................. P3.01-046 Dunlop Alex................................................................MA 09.09 Erus Suat...................................................................P3.13-024
Diz Taín Pilar.............................................................P1.01-060 Dupasquier Sebastien............................................ P3.15-004 Escande Alexandre.................................................P1.08-009
Djureinovic Dijana............ MA 05.13, MA 06.01, P1.07-020, Dutra Carolina.........................................................P1.06-007 Escande Fabienne............................... MA 07.06, P3.02-002
...................................................................................P2.02-066 Duval Da Silva Vinicius........................................... P1.06-020 Escherich Achim............................ P3.05-007, P3.05-008
Dmitrovsky Ethan........................................................OA 13.01 Dvir Addie................................................................. P3.01-060 España Sofia............................................................. P1.01-062
Do Hongdo............................................P1.02-012, P3.02-038 Dy Grace K............................................ MA 01.06, MA 02.04 Esteban Antonio........................................................MA 20.08
Doboszyńska Anna.................................................P1.06-004 Dybuncio Anne..........................................................P2.13-012 Esteban Esteban Carmen........................................ P1.06-013
Dobra Katalin.............................................................P1.09-010 Dziadziuszko Rafal......... ES 10.05, JCSE 01.27, MA 06.06, Estival Anna..........................................P1.05-015, P2.07-041
Dobrea Lavinia....................................MS 10.03, P3.10-004 .............................MA 07.01, OA 05.07, P1.01-013, P1.04-011 Estrada-Bernal Adriana.............................................OA 12.01
Dobrovic Alexander...........................P1.02-012, P3.02-038 Dziubinski Juliann..............................P1.04-006, P1.04-007 Eterovic Agda.............................................................. OA 13.05
Dodig-Crnkovic Tea..................................................P1.07-020 Díaz Navarro Caridad..............................................P1.07-036 Etop Lungscape For................................................. MA 06.06
Doebele Robert C.................MS 25.05, OA 12.01, OA 14.06, Díaz-Rico Julian.......................................................P2.07-061 Ettinger David S.................................. MA 09.08, P1.03-050
...................................................................................P3.02-057 Dô Pascal.................................................................. P3.03-001 Euathrongchit Juntima.............................................OA 04.08
Doel Tom......................................................................MA 09.10 Eunice Ong Song-En.............................................. P1.05-007
Doherty Michael...........P2.02-052, P3.02-061, P3.02-062, Evangelista Andrea....................................................OA 16.02
....................................................................................P3.03-016 Evans Sue M....................... MA 18.12, P1.01-033, P3.13-003
Doi Hiroshi................................................................. P1.14-005 E
Evans Tracey.......................................... OA 17.08, P2.07-059
Doig Sarah....................................................................MA 14.14 Evans William K......................................MA 18.01, OA 06.01,
Domachevsky Liran.................................................P3.13-030 Eaby-Sandy Beth................................. MS 10.05, WS 03.14
....................................................................OA 14.03, OA 15.01
Doman Thompson N...............................................P3.07-006 Eary Todd.................................................................... OA 12.07
Evbuomwan Osayande.......................................... P3.13-005
Domas Jean................................................................ OA 16.03 Easty David............................................................... P1.09-007
Everitt Sarah J............................................................. MA 17.12
Domchek Susan M................................................... P1.15-004 Eaton Keith D............................................................P1.06-009
Evison Matthew..........................................................OA 15.04
Dome Balazs......................................... MA 19.07, P2.09-004 Ebata Kevin.................................................................. OA 12.07
Evman Rıza S............................................................ P1.03-016
Domeki Yutaka.........................................................P2.07-004 Eberhardt Wilfried........... ISS 12.04, MS 16.04, P3.01-088
Evrensel Türkkan........................................................MA 17.08
Domine Manuel.................MA 02.02, MA 07.03, P1.03-054, Ebi Noriyuki...............................................................P1.07-004
Ezhil Veni.................................................................... OA 02.03
................................................................................... P2.01-022 Economopoulou Panagiota......................................MA 09.05
Dominguez Maria.....................................................P2.07-016 Edell Eric.....................................................................P1.07-016
Donabedian Patrick................................................. P3.15-008 Edelman Martin.......................................MS 02.03, OA 14.07
Donahoe Laura .......................................................WS 04.05 Edualdo Teresa..........................................................P3.14-017 F
Dong Bai Q................................................................... MA 01.11 Edwards John G.................................... OA 02.03, PL 02.06
Dong Chaoran......................................................... P3.05-003 Edwards Melanie.......................................................OA 04.06 Fabbri Alessandra...................................................P2.02-065
Dong Haidong............................................................. OA 13.07 Ege Olsen Karen......................................................P1.05-004 Fabikan Hannah.......................................................P3.03-024
Dong Ji Fu.................................................................P3.16-037 Egenod Thomas...........................................................OA 17.05 Fabre Aurelie...........................................................P3.02-053
Dong Jian...................................................................P3.01-087 Egile Coumaran......................................................... OA 09.06 Fabre Elizabeth............................................................OA 17.05
Dong Xiaorong.......................................................... P1.01-037 Eguchi Takashi....................... MA 13.14, MA 15.09, OA 18.06, Fadel Elie.................................................................... MS 11.03
Dong Xin...................................................................P2.02-062 ............................................P1.13-003, P2.05-021, P3.13-019 Faghih Amir.............................................................. P2.07-029
Dong Zhong Y..........................................................P2.03-054 Ehrnrooth Eva......................................P3.01-039, P3.01-043 Fahrat Cecília A.......................................................P2.02-046
Dong Zhong-Yi.............JCSE 01.19, JCSE 01.21, P1.01-027, Eichhorn Florian......................................................P3.02-032 Fairclough Stephen....................................................OA 09.01
....................................................................................P1.07-042 Eickhoff Jens.......................................................... P3.04-009 Faisal Hana K.P...................................................... P3.02-009
Donington Jessica....................................................MS 23.02 Eide Inger Johanne Z.....................P2.03-035, P2.03-037 Faivre-Finn Corinne........... MA 09.11, MA 17.14, MTE 04.01,
Donnay Olga......................................... P1.01-057, P2.02-027 Eiji Shimizu................................................................P1.01-064 ...............................................OA 01.05, OA 02.03, P3.14-010
Donnelly David J.......................................................MA 05.07 Einhorn Lawrence................................................. MTE 23.02 Falay Okan.................................................................P3.13-024
Donoho Gregory P...................................................P3.07-006 Eino Daisuke..............................................................P3.16-050 Falch David..................................................................MA 19.07
Dooms Christophe................................. OA 16.06, P1.13-007 Eisen Timothy G......................................................... MA 11.02 Falchero Lionel..........................................................MA 03.05
Dorantes Yuzmiren...................................................P3.14-012 Eisenmann Stephan.................................................P3.13-033 Falk Markus...............................................................P3.01-038
Dorca Jordi........................MA 20.06, MA 20.08, P1.12-009 Ek Lars....................................................................... P1.15-007 Falk-Sörqvist Elin.....................................................P2.02-015
Dornan Linda............................................................. P3.11-002 Ekman Simon.....................MA 18.14, P1.01-074, P1.06-012, Falkmer Ursula......................................................... P1.15-007
Dosaka-Akita Hirotoshi........................................... P2.01-005 ........................................P2.02-070, P2.03-035, P2.03-037 Fallon Padraic G......................................................P2.02-069
Dougherty B................................................................. MA 14.11 El Badri Salma......................................................... P2.01-060 Fan Jean...............................................P3.01-026, P3.01-036
Doughton Gail.............................................................. MA 11.02 El Dinali Mohamed.................................................. P2.07-037 Fan Jianbing........................................P3.02-008, P3.04-010
Dowlati Afshin............................................................. OA 18.03 El Kadi Najwa............................................................... MA 11.10 Fan Liping.................................................................P3.03-003
Downey Robert J......................................................PC 01.02 Elamin Yasir Y....................... MA 05.02, OA 09.05, OA 12.01 Fan Mengying..................JCSE 01.20, OA 04.03, P3.16-053
Dozier Jordan.......................................................... P2.05-021 Elbanna Houda..........................................................P3.13-026 Fan Youhong...........................................OA 13.01, P3.03-027
Draffan Jeanette...................................................... MA 08.07 Elbi Cem...................................................OA 02.01, P1.04-013 Fan Yun.........................JCSE 01.18, MA 03.03, P2.01-057,
Draft Chris................................................................. MS 27.05 Elder Christine............................................................MA 13.07 ................P2.03-013, P2.04-003, P2.07-057, P3.01-069,
Elegbede Anifat A......... P1.03-043, P1.06-006, P2.01-046, ........................................................... P3.03-030, P3.03-031
Dragonieri Silvano................................. P3.05-001, WS 01.18
..............................................................P2.02-068, P3.02-077 Fan Zaiwen............................................JCSE 01.28, MA 07.13
Dranoff Glenn............................................................P1.07-007
Eliadis Paul............................................................... P2.07-033 Fandi Abderrahim................................. MA 02.02, MA 02.03
Draulans Cedric.......................................................P3.09-003
Eliane Jean-Pierre...................................................P1.07-033 Fang Bingliang..........................................................P3.07-001
Dresler Carolyn...........................................................PL 01.01
Elias Roy................................................................... P2.07-037 Fang Hongmin........................................................... P3.01-031
Dri Alejandra............................................................. P1.01-058
Ella Ezra....................................................................P3.02-082 Fang Jian............................. MA 03.03, OA 09.06, P1.17-011
Drilon Alexander.................MS 25.03, OA 12.06, OA 12.07,
......................................................................................OA 14.06 Elliot David................................................................. P1.09-012 Fang Jun................................................................... P3.01-058
Driscoll Brandon........................................................ P1.14-016 Ellis Peter M................................................................ MA 10.01 Fang Meiyu...................... JCSE 01.28, MA 07.13, P1.01-002,
Ellis Stuart.................................................................P3.01-026 ....................P1.01-003, P1.02-043, P1.02-044, P1.02-045,
Dronca Roxana........................................................... OA 13.07
Ellison Kim...................................................................MA 05.14 .................P1.02-046, P1.02-047, P1.02-048, P1.02-049,
Drozdowskyj Ana...........P1.03-054, P1.07-015, P2.02-034, ................... P1.02-056, P1.02-057, P1.02-058, P2.01-017,
....................................................................................P3.01-073 Elvin Julia........................MA 05.02, P2.02-016, P2.02-052,
.............................................................. P3.02-061, P3.02-062 ................P2.02-005, P2.02-007, P2.02-020, P2.02-021,
Du Bo............................................................................ MA 06.11 .............. P2.03-057, P3.01-008, P3.01-009, P3.02-018,
Du Kaiqi........P1.01-003, P1.02-043, P3.02-018, P3.02-067 Embrione Valerio.....................................................P2.02-065
.................. P3.02-025, P3.02-026, P3.02-027, P3.02-028,
Du Min....................................................................... P3.01-004 Emerich Carolina D.S.M......................................... P1.06-007 ................P3.02-029, P3.02-065, P3.02-067, P3.02-068,
Du Wushuang...........................................................P1.07-037 Emerson Ryan............................................................ OA 13.05 ............................................................ P3.02-069, P3.02-080
Du Xiaohui............................................................... P1.01-078a Emery Jon.................................................................P3.13-038 Fang Min....................................................................... MA 01.11
Du Xinmiao................................................................ P1.01-034 Emoto Katsura..................................... P3.02-084, P3.13-031 Fang Wentao.........................................MS 06.02, P2.16-018
Du Yingying...............................................................P3.01-037 Endo Katsuhiko.........................................................P3.16-042 Farago Anna F................. OA 07.05, P2.04-008, P2.07-034
Duan Fenghai....................... OA 06.06, OA 15.03, P2.13-014 Endo Makoto.................................................................MA 13.13 Farella Magali............................................................P1.07-009
Duan Hongwei.........................................................P1.02-051 Endo Shun............................................P1.03-010, P2.03-032 Farez-Vidal Esther.................................................. P2.02-010
Duan Huanli............................................................. P3.03-004 Endo Shunsuke...................................... OA 18.07, P3.02-089 Faris Nicholas R.................... MA 04.01, OA 15.08, P1.13-011,
Duan Rong-Yan........................................................ P2.14-004 Endo Yutaka............................................................. P1.03-008 .....................................................................................P2.16-019
Dubbink Erik-Jan......................................................P1.02-038 Endris Volker............................................................P3.02-032 Farivar Alexander S.........P1.05-012, P1.10-008, P2.13-019,
Dubec Michael.........................................................P3.14-010 Enfield Katey S.S..................MA 10.09, MA 15.14, OA 07.07, ................................................................ P2.13-021, P3.13-029
........................................P2.02-017, P2.02-022, P2.02-038 Farkasova Anna.......................................................P2.03-056
Dubinina Tatiana.......................................................P3.16-038
Eng Juliana................................................................P1.03-028 Farny Michel................................................................ OA 16.03
Duboff Mariel...............................................................OA 10.03
Eng Lawson............................................................. P3.06-005 Farouque Omar........................................................P2.13-023
Dubos Arvis Catherine........................................... P3.03-001
Engelman Jeffrey A................................................... OA 14.07 Farrell Elongia............................................................ MA 01.06
Duchemann Boris....................................................... MA 10.11
English John C.....................MA 05.12, OA 15.01, P2.02-038 Farrell Robert............................................................. P1.02-011
Dudek Wojciech................................ P2.08-004, P2.08-005
Enterina Jhon R......................................................P1.02-050 Farré Núria...P2.01-072, P2.05-007, P3.14-014, P3.14-017
Dudnik Elizabeth.............MA 02.06, P1.01-039, P3.01-056,
...............................................................P3.01-060, P3.13-030 Enwere Emeka.........................................................P2.02-068 Fasola Gianpiero.................. MA 01.07, MA 03.01, P1.01-065
Dueñas Cid Núria......................................................P1.07-028 Epifanov Nikolay.........................................................P1.16-011 Fassan Matteo..........................................................P2.02-065
Dueñas García Rosario............................................P1.07-036 Erasmus Jeremy.......................................................MA 05.02 Fathi Joelle T.....................P2.13-019, P2.13-021, WS 02.20
Duff Eimear................................................................ MA 04.10 Erasun Carlos........................................................... P1.01-062 Fattah Farjana....................................... P1.07-031, P2.01-047
Duffy Mary........................MA 04.06, MS 10.01, WS 03.05 Ercelep Ozlem.......................................................... P1.03-040 Fauchon Eric................................................................OA 17.05
Dufrane Carter........................................................ P3.04-003 Erdogan Alper..........................................................P2.03-042 Favaretto Adolfo.........................................................MA 01.07
Duhamel Jean-Paul................................................... OA 16.03 Ergnyan Stepan................................... P3.16-038, P3.16-043 Favre Gilles................................................................P1.07-009
Duk Katarzyna......................................P3.01-041, P3.02-049 Eriguchi Daisuke..................................................... P1.02-025 Faye Nathalie...............................................................MA 14.02
Dukart Gary........................................... MA 07.02, P2.04-012 Eriko Murakami........................................................ P2.07-035 Federico Lorenzo....................................................... OA 13.05
Duma Narjust...................................... MA 18.09, P2.01-054 Eriş Aslı......................................................................P3.15-007 Fedorchak Kyle........................................................... OA 18.03
Duncan Francesca................................................. P2.06-008 Erkmen Cherie P.......... MA 04.07, P2.13-005, P2.13-006 Feeney Nora...........................................OA 09.02, P3.02-014
Ernani Vinicius.......................................MA 13.04, P2.15-013 Fehnel Carrie........................ OA 15.08, P1.13-011, P2.16-019
Fehrenbacher Louis................................. MA 10.03, OA 17.07 Florescu Marie......................................................... P2.01-032 Fujiwara Yutaka............. MA 16.04, P2.03-036, P2.03-048,
Fei Ke...................................................JCSE 01.10, P2.03-047 Florou Vaia............................................P1.07-024, P1.07-025 ................................................................ P2.07-011, P3.02-041
Feigenberg Steven J.................................................. MA 17.07 Flynt Frederick.......................................................... P1.03-014 Fukayama Masashi...................................................P3.16-028
Feldkamp Mirjam........................................................OA 10.06 Fogg Carole................................................................ OA 02.05 Fukazawa Takahiro.................................................P3.02-009
Feldman Lawrence E...................... P2.06-011, P3.10-002, Foglia Silvia............................................................... P1.01-058 Fukazawa Takuya..................................................... P1.02-014
..................................................................................P3.10-003 Folador Juliana B.....................................................P2.13-020 Fukuda Akihiro...................................P2.09-007, P3.09-009
Felices Pilar.............................................................. P3.01-065 Folch Erik E......................... MA 20.01, MA 20.02, MA 20.03 Fukuda Akihito..........................................................P2.07-031
Feliciano Josephine L...............................................MA 09.08 Foley Emma............................................................... P1.02-011 Fukuda Koji................................................................ P3.15-001
Felip Enriqueta....................ES 08.04, MA 02.02, MA 15.01, Follador Alessandro...................................................MA 01.07 Fukuda Minoru............... P1.03-015, P2.07-018, P2.07-045
........................... OA 05.06, OA 17.02, P1.01-012, P1.05-015, Fong Geoffrey...........................................................MS 09.02 Fukuda Takanori........................................................MA 09.06
....................................P2.04-004, P2.04-005, P2.04-013, Fong Kam Weng......................................................... P1.15-017 Fukuda Yasushi........................................................ P2.07-024
............................................................... P3.01-043, P3.07-012 Fong Kwun M.............. MTE 22.01, P1.04-003, P2.02-002, Fukuhara Tatsuro...................................................P2.03-010
Felizardo M Margarida.............................................P2.16-025 ........................................... P2.13-011, P3.06-008, WS 01.16, Fukui Eriko................................................................ P1.02-068
Felizardo Margarida................................................ P1.15-010 ................................................................WS 01.32, WS 01.43 Fukui Keisuke..............................................................MA 14.06
Felizzi Federico......................................................... P1.01-052 Font Carme................................................................. MA 07.03 Fukui Motonari......................................................... P2.07-024
Felley-Bosco Emanuela..........................................P1.09-001 Fontanini Gabriella....................................................P1.01-015 Fukui Takayuki................ P1.08-002, P1.17-004, P3.03-013,
Feng An-Chen...........................................................P3.12-002 Fontela Antoinette....................................................P3.02-031 .............................................................. P3.09-006, P3.16-010
Feng Fenglan............................................................P1.07-005 Foray Claudia...........................................................P2.02-065 Fukui Tomoya.......................................................... P2.03-002
Feng Jia-Yih...............................................................MA 03.07 Forbes Karen............................................................. OA 02.05 Fukumoto Kento.................MA 05.06, P1.07-017, P2.16-005
Feng Jian................................................................... P2.16-018 Forbes Leta................................................................. OA 14.03 Fukuoka Junya................................... P2.02-042, P2.02-043
Feng Jianguo...........................................MA 16.14, P3.17-003 Force Seth................................................................ P1.08-003 Fukuoka Masahiro..................................................... OA 05.03
Feng Jifeng....................P2.04-003, P3.01-026, P3.01-036, Forde Patrick M.................................. MA 09.08, MTE 28.01 Fuller Carson.............................................................P2.13-021
....................................................................................P3.01-075 Forget Marie-Andrée................................................. OA 13.05 Fuller Clifton D...........................................................OA 08.05
Feng Leying................................................................P1.07-031 Forino Carmen......................................... P1.17-014, P1.17-015 Fuller Liz................................................. P3.05-001, WS 01.18
Feng Wen..................................................MA 17.02, MA 17.03 Forster Martin............................................................ MA 01.05 Fullerton David.........................................................P3.07-005
Feng Yin-Hsun......................................................... P2.07-027 Fortoul Aurélien........................................................P1.07-009 Funaki Soichiro................. MA 16.08, P1.02-068, P1.17-002,
Feng Yuejuan............................................................ P3.01-031 Fortson Ben G............................................................MA 18.02 ................................................................P1.17-013, P3.16-050
Feng Zipei...................................................................P1.07-019 Fortunato Gustavo................................P1.16-028, P2.13-022 Funakoshi Yasunobu..........................P1.02-032, P2.06-003
Fengshi Chen...................................... P3.02-046, P3.02-071 Foser Stefan...............................................................P1.01-031 Funasaki Aika...........................................................P3.02-085
Fennell Dean A.......................................MA 02.12, OA 02.01 Fossella Frank.........................................................P2.07-061a Funazo Tomoko.............P2.01-021, P2.03-055, P2.07-003,
Fenor De La Maza María Dolores..... P1.01-057, P2.02-027 Foucher Pascal........................................................... OA 16.03 ...................................................................................P2.07-017
Fernandes Maria Otilia............................................P2.16-025 Foust Courtney........................................ MA 04.01, P1.13-011 Fung Andrea............................................................ P2.01-026
Fernandez Cristina............................ P2.02-042, P2.02-043 Foweraker Karen......................................................P1.05-010 Fung Ron..................................................................... OA 14.03
Fernandez Esther..................................................... P1.05-019 Fox Bernard A...........................................................P1.07-019 Fung Sherwood Y.H.................................................P3.02-031
Fernandez Felix....................................................... P1.08-003 Fox Jesme................................................................. MS 04.01 Fung-Kee-Fung Michael.............................................OA 11.06
Fernandez Ricardo.................................................... P1.16-017 Fox Roy..................................................... MA 04.01, P1.13-011 Furuhata Yoshiaki.....................................................P3.16-027
Fernandez-Banet Julio.............................................P1.01-016 Fradette Jared J..........................................................OA 13.01 Furukawa Kinya........................................................P2.03-019
Fernandez-Cubelo Irina............................................ OA 13.05 Frampton Garrett M..................................................P1.07-013 Furukawa Masashi............................ P1.05-003, P3.09-005
Fernando Hiran..........................................................PC 01.03 Francini Guido............................................................MA 02.05 Furukawa Ryutaro................................P1.01-054, P2.03-017
Fernández Alejandro.......................... P2.05-007, P3.14-014 Francis Delfin Lovelina..................P2.06-002, P3.06-001, Furumoto Hideyuki....................................................P1.16-010
Fernández Franco Lourdes..................................... MA 07.03 ................................................................................. P3.06-002 Furuta Hiromi........................................................... P2.07-028
Fernández Navarro Mónica....................................P1.07-036 Franklin Patricia L......................................................MA 18.02 Furuya Naoki............................................................P2.02-072
Fernández Plata Rosario...........................................MA 20.12 Franklin Wilbur A...................................MA 13.02, P2.03-019 Furuya Tatsuo.......................................P1.02-022, P1.17-009
Ferrara Roberto.................MA 05.03, MA 10.11, P2.01-038, Franks Elizabeth.........................................................MA 05.12 Fusamoto Aya.......................................P1.03-033, P3.13-012
............................................................. P2.07-005, P2.07-060 Franks Kevin N....................MA 09.11, P1.03-011, P2.01-060, Fushimi Hiroaki...................................P1.02-032, P2.06-003
Ferraresi Federica................................................. P3.06-003 .................................................................................. P2.08-003 Futami Shinji............................................................ P1.03-049
Ferreira Carlos Gil............................... P1.01-045, P1.02-036 Fraser Anne.............................................................. WS 03.18 Futreal Andrew.....................MA 01.03, OA 09.05, OA 13.05,
Ferreira Elisa N.E....................................................P3.02-060 Frassoldati Antonio.............................. P1.01-053, P1.01-065 ....................................................................................P2.02-013
Ferreira Paula.............................................................P1.17-012 Freeman Molly T....................................................... P1.14-003 Fülop Andrea........................................................... P2.04-008
Ferrer Marta.............................................................P2.07-044 Frega Stefano...........................................................P3.02-006 Fülöp Andrea................................................................OA 17.06
Ferris Matthew J.......................................................OA 01.06 Freimark Bruce........................................................P2.02-030
Fertè Charles............................................................... MA 10.11 Freitag Lutz...............................................................P3.13-033
Feyereislova Andrea.......................... P3.01-040, P3.01-044 Freitas Helano C.............OA 07.08, P2.09-002, P3.01-005, G
Ffrench Brendan............P1.03-041, P1.03-048, P2.02-064 ................................................................................. P3.02-060
Fidias Panos.............................................................. P1.01-025 Friboulet Luc............................................ MA 11.01, P1.03-013
Gaafar Rabab M.........................................................P1.09-011
Fieira Eva.................................................................... P1.16-017 Friedman Nethanel..................................................P3.02-082
Gabarroca Christine...................................................MA 12.02
Field John K...................... OA 15.09, P2.13-025, WS 01.01, Friess Martina..................................... P1.09-009, P3.09-010
...................... WS 01.02, WS 01.24, WS 01.38, WS 02.09 Gabasa Marta...........................................................P3.03-023
Frigault Mealnie M..................................................... OA 09.03
Fietkau Rainer................................... P2.08-004, P2.08-005 Gabay Carolina.........................................................P1.06-021
Frigault Melanie M..................................................... OA 09.06
Figueiredo Pinto Jose.........................P1.06-020, P3.16-034 Gaber Rania............................................. MA 15.09, P3.13-019
Fritz Richard.............................................................P2.03-025
Filiberti Rosa A.........................................................P3.13-006 Gadgeel Shirish M........... JCSE 01.27, MA 05.09, MA 07.01,
Frleta Ilic Nives......................................................... P1.16-004 ..............................................MA 10.03, MTE 13.02, OA 17.01,
Filipits Martin...............MTE 07.02, P2.03-025, P2.09-004 Froehler Sebastian...................................OA 10.06, P1.15-011 ................................................................ P1.04-011, P3.01-043
Filippova Elena A...................................................... P1.01-056 Fryzek Jon............................................................... P2.01-043 Gadia Rafael..............................................................P2.14-003
Filosso Pier Luigi................MS 07.05, MTE 17.02, OA 16.02 Frøkiær Jørgen...................P3.13-014, P3.13-015, P3.13-016 Gaga Mina............................................... P3.05-001, WS 01.18
Fine Leah...............................MA 04.03, OA 11.07, P3.11-003 Früh Martin..............................................MA 15.11, P2.07-012 Gai Fei........................................................................P3.01-037
Finkel Inbar..............................................................P2.07-048 Ftanou Maria..............................................................MS 21.03 Gai Wanxia.................................................................P3.02-031
Finley Richard J...........................................................OA 15.01 Fu Hao..............................JCSE 01.20, OA 04.03, P3.16-053 Gainor Justin F.............. ISS 08.03, ISS 08.04, MA 05.02,
Finn Nicholas........................................................... P2.07-029 Fu Jianhua.................................................................. OA 03.07 .............................MA 07.07, MA 11.08, OA 07.05, OA 12.02,
Finn Stephen P....................MA 04.10, MA 06.06, P1.02-011, Fu Jui-Ying................................................................ P3.13-001 ................................................................P1.07-033, P3.07-012
..................... P1.03-039, P1.03-041, P1.03-042, P1.03-048, Fu Ling.......................................................................P3.13-022 Gajra Ajeet............................................P2.01-014, P2.01-015
...................P1.09-006, P1.09-007, P2.02-024, P2.02-048, Fu Xiangning............................................................P3.02-008 Galanternik Fernando......................... P2.01-007, P2.02-071
.....................P2.02-064, P2.02-069, P3.02-053, SS 01.06
Fu Xiaolong.............MA 01.11, MA 14.12, MA 17.02, MA 17.03, Gale Davina.................................................................. MA 11.02
Fintelmann Florian.....................................................OA 07.05 ................................................................ P3.13-010, P3.13-022 Galeana Hernandez Mayra...................................P2.01-006
Fiore John.................................................................P1.03-028 Fu Xiayu...................................................................... OA 03.07 Galetta Domenico.............. MA 01.07, MA 02.05, MA 10.06,
Fiore Joseph................................................................ OA 17.01 Fu Xiujun......................................................................OA 18.06 ..............................................MA 11.11, P1.01-015, P3.06-003
Fiorella Angela..........................................................P2.17-002 Fujii Kazuhiko.......................................P1.02-023, P3.15-009 Gallagher David J...................................................... MA 04.10
Fioretto Luisa............................................................ P1.01-065 Fujii Kiyonaga.......................................................... P3.15-002 Gallagher Michael...........P1.03-041, P1.03-048, P2.02-064
Firmino Natalie.........................................................P3.02-090 Fujii Takeshi....................................... P3.02-033, P3.02-048 Gallagher Paul..........................................................P2.02-038
Fischer Jurgen R.....................................MA 03.01, MA 10.02 Fujimori Fumio......................................................... P2.03-015 Gallagher Shea........................................................P1.16-003
Fiset Pierre-Olivier................................................ P2.02-040 Fujimori Maiko............................................................ES 06.01 Gallego Iria.................................................................. MA 07.03
Fisher Mark............................................................... P1.02-010 Fujimoto Daichi............ P1.07-004, P2.03-045, P2.07-024 Galli Giulia............................................................... P2.09-001a
Fishleder Sarah......................................................... MA 04.10 Fujimoto Junya................................... P2.02-013, P3.03-007 Galvez Christian....................................................... P2.16-002
Fiste Oraianthi...........................................................P1.01-044 Fujimoto Kosuke......................................................P2.07-009 Galvez Laura.............................................................P2.07-016
Fitzgerald Natalie........................................................OA 06.01 Fujimoto Nobukazu..............MA 19.01, OA 12.03, P1.03-038 Galvin Sean......................P2.16-028, P3.16-035, P3.16-036
Flacke Sebastian....................................................... P1.06-017 Fujimoto Shota.........................................................P2.03-033 Galvis Diego............................................................. P3.08-005
Flanagan William.........................................................OA 06.01 Fujino Toshio........................................P3.02-059, P3.16-049 Galván Patricia..........................................................P2.02-014
Flanagan Yvonne....................................................... P1.14-018 Fujita Kohei................................................................P2.07-013 Gamble Greg D......................OA 06.03, OA 06.06, OA 15.03
Flatz Lukas................................................................P2.07-012 Fujita Tetsuro.......................................................... P2.03-005 Gamblin Kathleen A..............................WS 03.07, WS 03.18
Fledelius Joan................ P3.13-014, P3.13-015, P3.13-016 Fujita Tomonobu........................................................MA 05.04 Gamucci Teresa............................................................ MA 11.11
Fleitz Annette........................................................... P3.01-088 Fujita Yuka..........................................P1.03-004, P1.08-006, Gandara David R................ISS 02.02, MA 02.11, MA 05.09,
Flinspach Claudia..................................................... P1.03-013 ...............................................................P2.03-010, P3.01-072 ...........................MA 07.14, MA 13.02, MS 05.05, OA 12.05,
Florczuk Mateusz...................................................P3.02-049 Fujitaka Kazunori........................................................ OA 12.03 .................................................OA 14.07, OA 17.07, P3.01-046
Flores Claudio.................................... P1.06-022, P2.01-053 Fujiwara Ayako....................................................... P1.02-068 Gandhi Leena............................................................... OA 17.01
Flores Claudio J......................................................P1.06-023 Fujiwara Masachika.................................................P1.02-033 Gandhi Mayank....................MA 10.03, OA 17.07, P3.04-003
Flores Raja......MA 18.07, P2.13-026, P2.16-022, P2.16-024 Fujiwara Taiki..................P1.16-008, P2.07-008, P2.12-006 Gandolfo Nicoletta....................................................P3.13-006
Flores Thaís C.M...................................................... P1.06-007 Fujiwara Wakako...............P1.02-060, P1.02-061, P1.13-008 Gandossi Eric..............................................................MA 12.02
Flores-Estrada Diana...........................P2.01-070, P3.14-012
Gang Wu...............................................JCSE 01.25, MA 03.03 Gergel Ivan...............................................................P2.07-062 Gomila Pons Paula...................................................P1.07-028
Gangadharan Bharath............................................... P1.13-010 Gerry Stephen........................................................... OA 02.05 Gon Yasuhiro.........................................P1.03-009, P2.15-015
Gangadharan Sidhartha P......................................P3.03-025 Gerson-Cwilich Raquel.......................................... P2.06-007 Gondi Sudershan.....................................................P3.02-066
Ganti Apar Kishor.............MA 13.04, MA 18.06, P2.14-006, Gerstmayr Jasmin......................................................MA 19.07 Gong Dianxia............................................................P2.03-034
.............................................................P2.15-013, P3.01-040 Gervais Radj............................................................P3.03-001 Gong Jay..................................................MA 15.08, P1.07-013
Ganzinelli Monica.............................P2.02-065, P2.09-001a Gettinger Scott N................GR 02.05, OA 05.05, OA 09.01, Gong Lei...............................................JCSE 01.18, P2.03-013
Gao Boning...................................................................MA 15.13 ............................. OA 14.07, OA 17.03, P1.01-001, P3.07-012 Gong Yuhua............................................MA 01.03, P3.16-053
Gao Dexiang.............................................................. P2.02-011 Geva Smadar................ MA 02.06, P1.01-039, P3.01-060, Gong Ziying.............................................................. P3.01-004
Gao E Mei.....................................................................P1.17-001 ..................................................................................P3.02-096 Goniewicz Maciej L.................................................. MA 18.03
Gao Feng...................................................................P3.07-009 Gey Thomas................................................................MA 03.10 Gonzales-Nogales José E...................................... P2.01-049
Gao Guanghui.................. P1.03-052, P1.15-009, P2.07-047, Gezelius Emelie.......................................................P1.15-007 Gonzalez Michel.......................................................P2.07-056
............................................................... P3.01-067, P3.01-085 Ghafoor Qamar.............P2.14-012, P2.14-013, P2.14-014, Gonzalez Velez Miguel..........................MA 18.09, P2.01-054
Gao Hongjun.......................JCSE 01.11, MA 11.03, P3.01-021 ...................................................................................P2.14-015 Gonzalez-Castro Mª Angeles................................. P1.05-019
Gao Hongwen...........................................................P3.02-017 Gharei Radhamohan............................................... P1.02-066 Gonzalez-Rivas Diego............................................... P1.16-017
Gao Jianjun................................................................. OA 13.05 Ghdes Ons.................................................................P3.13-026 González Cao Maria............................ P1.07-015, P2.02-034
Gao Lianju.................................................................... MA 11.05 Ghiorghiu Dana.......................................................... OA 09.03 González De Aledo Jose Manuel.......................... P3.01-045
Gao Liuwei................................................................ P1.02-004 Ghosh Moumita........................................................P3.03-026 González Lisde...................P1.01-019, P1.01-022, P1.09-013,
Gao Shaojian.......................................P1.02-063, P2.03-052 Ghosh Sunita...............................................................MA 14.03 ...................................................................................P3.02-063
Gao Yangbin.............................................................P3.02-008 Giacchero Damien................................................... P2.07-023 González Luna Josué A......................... MA 16.12, P1.17-008
Gao Yanning........................................................... P2.02-062 Giaccone Giuseppe..........MA 02.02, MA 06.05, MS 01.03, González-Larriba José Luis...................MA 15.01, PL 02.04
Gao Yun.....................................................................P1.09-006 ...................................................................................P2.07-050 Gonçalves Vinícius Knackfuss........... P2.03-029, P3.13-018
Garassino Marina C............ MA 02.02, MA 11.11, P1.01-053, Gianetta Martina......................................................P1.04-002 Goo Jin Mo............................................ MTE 27.02, OA 14.01
......................................P2.02-065, P2.09-001a, P3.07-012 Giannarelli Diana....................MA 01.07, MA 10.06, MA 19.02 Goodman Christopher D............................................OA 16.01
Garay Osvaldo U....................................................... P1.01-045 Giannicola Rocco.....................................................P2.07-046 Gooi Julian H.............................................................P3.16-052
Garber Judy E...........................................................OA 06.02 Giannini Fabio.............................................................MA 19.02 Goparaju Chandra...................................................... MA 10.10
Garbers Christoph...................................................P3.07-002 Giannone Luciana.......................................................MA 01.07 Goparju Chandra M................................................. P1.09-007
Garces Yolanda I...................................................... P2.14-006 Gibbons Don L......................................MA 02.09, OA 13.01, Gopaul Darindra.........................................................MA 13.08
Garcia Alejandro Jorge............................................P1.02-035 ..................................................................OA 13.05, P2.02-041 Gorden Jed A....................P1.05-012, P1.10-008, P1.12-007,
Garcia-Balaña Natalia.............................................. P1.01-062 Gibson Amanda J.W..... P1.03-043, P1.06-006, P2.01-046, .............................................P2.13-019, P2.13-021, P3.13-029
García Campelo Rosario....................... MA 15.01, P1.01-040, ...................................................................................P2.02-068 Gordon Ana.............................................................. P3.10-002
............................................................. P1.03-054, P3.01-073 Gibson Neil................................................................P3.01-043 Gorohov Leonid................................... P3.16-038, P3.16-043
García Casabal Florencia........................................P1.01-060 Gierada David............................................................WS 01.22 Gorzalczany Yaara..................................................P3.02-096
García Del Barrio María Ángeles...........................P1.07-035 Gikalo Marina...........................................................P3.02-058 Goss Glenwood................ ISS 06.03, ISS 06.05, MA 20.11,
García Escobar Ignacio............................................. MA 07.03 Gil Debora...................................................................MA 20.08 .................................................MS 12.01, OA 14.02, OA 15.01,
García Escudero Antonio.......................................P3.02-047 Gil Tomasz............................................. OA 04.01, P2.16-027 ............................................................. P2.01-032, P3.01-043
García Falcone María Monica............P1.02-035, P2.01-007 Gil-Bazo Ignacio.............MS 05.06, P1.07-035, P2.02-036 Gosálvez Javier S.....................................................P1.07-019
García Inmaculada R.............................................. P2.07-016 Gilbert Christopher R.......P1.05-012, P1.10-008, P1.12-007, Goto Daiki...................................................................P3.03-013
García Jose............................................................... P2.01-031 .............................................P2.13-019, P2.13-021, P3.13-029 Goto Koichi......................... ISS 12.01, ISS 12.05, MA 17.06,
García Manrique Teresa..................P2.03-051, P3.02-047 Gilbert Houston..............P2.02-052, P3.02-061, P3.02-062 .........................................MTE 21.01, P1.03-027, P2.15-004,
García Palomo Andrés.............................................P1.01-060 Gilbert Sebastien......................................................P3.16-007 ............................................................... P3.02-074, P3.14-001
García Verdejo Francisco José..............................P1.07-036 Gildersleeve Jane.................................. MA 08.11, P2.01-050 Goto Taichiro.......................MA 05.08, MA 13.15, MA 15.03
García Yolanda.....................................P2.01-022, P2.07-041 Giles Francis J....................MA 05.11, OA 07.03, P1.04-004, Goto Tatsuya....................P1.16-025, P3.16-002, P3.16-051
García-Morillo Marcial.............................................. MA 07.03 ...............................................................P1.04-005, P1.07-043 Goto Yasushi....................ISS 08.01, ISS 08.04, MA 16.04,
García-Sancho Cecilia...............................................MA 20.12 Gilham Louise R........................................................MA 08.01 ....................MA 19.01, P1.03-004, P2.03-036, P2.03-046,
Gardner Faithlore.......................................................MA 15.06 Gill Anthony J..............................................................P1.01-011 .......................................... P2.03-048, P2.07-011, P3.02-041
Gareeboo Shafick.....................................................P1.06-016 Gill Ritu R................................................ MA 19.10, P1.12-004 Goto Yukinobu.................P2.02-025, P2.17-004, P3.16-039
Garg Kavita................................................................ ES 02.03 Gilligan David.............................................................. OA 02.03 Gottfried Maya........................................ ISS 12.03, OA 17.06
Garner Chad P.............................................................OA 18.04 Giménez Ana........................................ P2.05-007, P3.14-014 Goud Supriya.......................................P2.01-051, P2.03-027
Garofalo Giuseppe....................................................P2.17-002 Giménez-Capitán Ana..... P1.01-075, P1.07-015, P2.02-014, Gough Karla............................................................... MA 04.06
.............................................................. P2.02-034, P3.01-073 Goulart Bernardo....................................................P1.06-009
Garon Edward B...........ISS 03.03, ISS 03.05, ISS 03.08,
.....................MA 02.07, MA 03.06, MTE 28.02, P1.01-051, Gingras Michel............................................ MA 14.11, OA 15.01 Govindan Ramaswamy.....MA 03.01, MA 10.02, MA 13.02,
................... P1.04-008, P2.04-005, P2.07-038, P3.01-071, Ginsberg Michelle S................................ OA 03.03, OA 14.05 ............................................................... MS 02.01, P2.01-040
...................................................................................P3.03-007 Giordano Laura..........................................................P1.16-027 Govindbabu K............................................................P2.01-023
Garrido Pilar.....................MA 02.02, MA 15.01, P1.01-040, Giordano Monica.......................................................MA 02.05 Gowen Kyle............................................ MA 07.07, P2.02-052
.............................................................. P1.04-001, P2.07-060 Giovannini Monica.................................................. P2.04-005 Gradica Fadil..................................... P2.01-059, P3.16-005
Garzón Juan C........................................................ P3.08-005 Girard Luc.............................................P3.02-073, P3.03-013 Gradica Flora............................................................ P3.16-005
Gasch Claudia.................P1.03-041, P1.03-048, P2.02-064 Girard Nicolas................. ISS 08.02, ISS 08.04, MA 11.12, Graf Von Der Schulenburg J.-Matthias................. OA 15.02,
Gaspar Laurie E........................................................GR 03.06 .............................OA 03.01, OA 03.08, OA 16.03, OA 17.05 ....................................................................................P3.07-013
Gaspe Nilupa............................................................ P2.01-050 Girard Philippe............................................................ OA 16.03 Grafino Mónica..........................................................P2.16-025
Gasser Stefan..........................................................P3.03-024 Giri Uma.................................................................... P3.02-076 Gralla Richard J..............MA 08.11, MTE 09.01, P2.01-050
Gately Kathy....................................... P2.02-048, P2.02-069 Gironés Regina.........................................................P2.01-031 Granato Lorenzo........................................................P1.16-027
Gauler Thomas C........................................................MS 16.04 Giroud Mathilde..........................................................P2.11-001 Granger Catherine L................................................ ES 03.02
Gausdal Gro...............................................................P2.01-047 Gittelman Rachel........................................................ OA 13.05 Grant Burkeen...........................................................P2.07-051
Gauthier Sanja......................................................... P1.04-007 Giuliani Meredith E...........MA 09.02, MA 13.09, MA 18.01, Grant Cliona................................................................ MA 04.10
Gautschi Oliver............................................................ MA 15.11 .........................................P1.13-004, P1.14-016, P3.06-005 Grant Stefan C.......................................................... P1.01-059
Gauvreau Cindy..........................................................OA 06.01 Giusti Sabrina............................................................ P1.01-065 Grapsa Dimitra..................................... P1.01-044, P2.01-039
Gay Laurie..........................MA 05.02, P1.01-031, P2.02-016 Gkiozos Ioannis.........................................................P2.01-039 Grau Juan Francisco................................................ MA 07.03
Gazdar Adi F..........................................P1.02-039, P1.15-005 Gleeson Fergus.......................................MA 14.13, P1.05-008 Grauslund Morten................................................... P3.01-007
Gazzah Anas.......................MA 11.01, P1.03-013, P2.07-005 Gleeson Michelle.................................... P1.01-051, P1.15-003 Gray Christine M.N....................................................P2.14-013
Ge Mengxi.................................................................. P3.01-010 Glisson Bonnie......................................MA 01.03, P3.03-007 Gray Jhanelle E...................MA 12.05, OA 05.02, PL 02.02
Gearey Brayden......................................................... P1.14-017 Glushko Vladimir....................................................... P3.16-021 Gray Steven G................. P1.03-039, P1.03-041, P1.03-042,
Geater Sarayut L.............. OA 05.07, P3.01-026, P3.01-075 Go Ronald....................................................................MA 18.09 ................ P1.03-048, P1.09-006, P1.09-007, P2.02-048,
Gebitekin Cengiz............... MA 17.08, P2.14-016, P3.16-046 Go Tetsuhiko.............................................................. P1.14-002 .......................................P2.02-064, P2.02-069, P3.02-053
Gebski Val...................................................................P1.07-018 Goarant Eric.............................................................P2.07-030 Greco Erin................................................OA 06.06, OA 15.03
Gedvilaite Erika...........................................................OA 10.05 Gochicoa-Rangel Laura.............................................MA 20.12 Greco Francesca Gabriella.................................. P2.09-001a
Geeganage Sandaruwan........................................P3.07-006 Gocyk Wojciech........................................................P2.16-027 Greco Martín........................................ P2.01-007, P2.02-071
Geese William J...................................... OA 17.03, P3.07-012 Godal Robert............................................................P2.03-056 Gree-Renner Dan................................................... P2.06-007
Geib Guilherme......................................................... P1.01-063 Godoy Ana.................................................................P2.07-016 Green Emma................................................................ MA 11.01
Geier Margaux................................. P2.07-023, P2.07-030 Goel Alok...........................P1.01-023, P2.03-027, P3.01-076 Green Matt...................................................................MA 12.07
Geiger Christopher L..............................................P1.06-009 Goffin John R.......MA 10.01, MA 20.11, OA 06.01, OA 15.01, Gregg Jeffrey P..........................................................P1.07-013
Geisinger Kim..........................................................MTE 24.01 ................................................................................... P2.01-032 Greillier Laurent..........................................................MA 19.03
Gelatti Ana C.Z............P1.01-043, P1.01-063, P2.03-029, Gogna Apoorva....................................... OA 09.07, P3.01-017 Grenda Anna.........................................OA 08.03, P3.02-045
............................................................. P3.13-018, P3.16-034 Gogolin Danil............................................................P1.08-008 Gresty Christopher................................................... P1.15-004
Gemba Kenichi....................................... OA 12.03, P2.01-034 Gold Edward J............................................................ MA 11.06 Greystoke Alastair......................................................OA 02.01
Gemma Akihiko............. P1.03-008, P2.03-010, P3.01-035 Goldberg Michael E...................................................MA 05.02 Gridelli Cesare...........................................................P1.01-015
Gennatas Spyridon...............................OA 03.02, P1.17-019 Goldberg Sarah B.................................................... P3.01-046 Griffin Katie.................................................................. OA 14.07
Genova Carlo.......................................... MA 13.02, P1.07-023 Goldblatt Joshua.................................................... P3.16-045 Griggs K....................................................................P1.09-006
Gentile Antonia..........................................................P2.17-002 Goldman Jonathan W........ MA 02.07, MA 02.10, OA 17.03, Grignani Francesco.................................................P3.02-007
Gentzler Ryan D........................................................... OA 17.01 ....................P1.03-026, P2.01-004, P2.01-013, P2.07-038 Grilley-Olson Juneko E.......................................... P1.03-044
Genzler Ryan.......................................... MA 08.11, P2.01-050 Goldman Lisa.............................................................MS 19.03 Grills Inga.....................................................................MA 13.09
Geoghegan Orla.......................................................P3.02-053 Goldstraw Peter........................................................ ES 06.05 Grivaux Michel............................................................ OA 16.03
George Ben...............................................................P1.03-026 Golpon Heiko...........................................OA 15.02, P3.07-013 Grochowski Zbigniew........................... OA 04.01, P2.16-027
Georgieva Mina........................................................P2.07-054 Golsorkhi Tony.........................................................P2.03-058 Grodzki Tomasz.......................................................... MA 14.01
Georgoulias Vassilis.................................................P3.01-043 Gomes Fabio............................................................. MA 10.07 Groen Harry J.......................MA 17.10, OA 05.05, P1.01-001,
Geraedts Wiel.......................................................... P2.08-007 Gomez Alejandro........................................................ MA 16.01 .................................................................................. P2.04-005
Gerber David E...................MA 02.09, MA 10.05, MA 10.12, Gomez Bradley Dolores.........................................P2.03-039 Groman Adrienne...................................................... MA 01.06
......................OA 17.03, P1.07-031, P2.01-047, P3.08-004 Gomez Gregoria...................................................... P2.07-059 Groom Nichola.......................................... MA 09.11, OA 01.05
Groshar David...........................................................P3.13-030 Hakozaki Taiki........................................................... P1.17-006 Haris Mohammed.................................. P3.05-001, WS 01.18

Gross Jefferson L..............................P2.09-002, P2.13-020 Hales Russell..............................................................MA 09.08 Hariyatun Hariyatun................................................ P3.01-054
Grossi Francesco..................MA 01.07, MA 10.06, MA 11.11, Halil Suleyman.....................................P1.03-040, P3.15-007 Harms Alexander....................................................P3.02-032
....................... P1.01-015, P1.01-053, P1.01-065, P1.07-023 Hall Gerald E............................................................P3.07-006 Harms Emmy............................................................. OA 02.02
Grosso Federica.........................................................MA 19.03 Hall Richard............................................ MA 08.11, P2.01-050 Harpole David.....................MA 13.02, MA 19.09, MS 24.03
Grundy Seamus..................................... P3.05-001, WS 01.18 Hallas Cora................................................................P3.01-038 Harris Catherine.........................................MA 09.11, MA 17.14
Grunenwald Dominique H.....................................MTE 03.01 Halmos Balazs....................OA 07.04, OA 13.03, P1.07-027, Harris Edward....................................P2.13-002, P3.09-004
Grusch Michael....................................MA 19.07, P2.09-004 ....................................................................................P2.13-008 Harris Jade................................................................P1.03-001
Grygarkova Ivona....................................................P2.03-023 Halpenny Darragh F..................................................MA 05.02 Harrold Emily............................................................. MA 04.10
Grégoire Valérie................................... MA 07.06, P3.02-002 Halperin Sharon......................................................P3.03-028 Harrow Kimberly.................................. MA 07.02, P2.04-012
Grønberg Bjørn Henning.................. P2.03-035, P2.03-037 Halverson David....................................................... P1.01-036 Harrow Stephen....................................MA 09.11, P3.09-002
Gu Feiying.................................................................. P3.17-003 Halvorsen Ann Rita.................................................P2.02-053 Hartigan Phillip......................................................... P1.12-004
Gu Jiale.......................................................................P1.14-001 Halvorsen Bente......................................................P2.02-053 Haruki Tomohiro.............P1.02-060, P1.13-008, P1.15-005
Gu Yingying...........................................JCSE 01.15, OA 08.01 Halvorsen Elizabeth...................................................MA 05.12 Hasanov Rahib.....................................P1.03-040, P3.15-007
Gu Zhitao....................................................................MS 06.02 Ham Soo-Youn......................................................... P3.13-017 Hase Tetsunari..........................................................P3.03-013
Guan Yanfang....................JCSE 01.28, MA 01.03, MA 07.13, Ham Yun Hee............................................................ ES 03.05 Hasegawa Hirotsugu..............................................P2.07-022
........................ OA 18.01, P1.01-002, P1.02-045, P1.02-046, Hamada Akinobu..................................................... P1.03-004 Hasegawa Kazuo...................................MA 04.09, OA 11.08
..................... P1.02-047, P1.02-048, P1.02-049, P1.02-056, Hamada Keniti.............................................................P1.17-017 Hasegawa Seiki..........P1.14-005, P2.09-005a, P2.09-007,
................... P1.02-058, P1.02-059, P2.02-004, P2.02-007, Hamaji Masatsugu.............................. P3.02-046, P3.02-071 .................................................................................. P3.09-009
................... P2.02-020, P2.02-021, P2.03-057, P3.01-009, Hamamoto Junko...............................P2.03-012, P3.02-084 Hasegawa Yoshikazu............................................... P1.07-010
......................................... P3.02-027, P3.02-080, P3.16-053
Hamanaka Kazutoshi..............................................P3.13-023 Hasegawa Yoshinori......P3.03-013, P3.09-006, P3.16-010
Guarino Michael J...................................................... MA 17.07
Hamarstrom Elaine........P1.01-025, P1.01-068, P2.07-036 Hasegawa Yukihiro................................................. P2.03-014
Gubens Matthew A............OA 17.01, P1.01-007, P1.01-008
Hamatake Daisuke....................................................P2.16-020 Hasegawa Yuzo........................................................P2.07-014
Gucalp Rasim A....................................P1.07-027, P2.13-008
Hameed Meera...........................................................OA 18.06 Hashimoto Kana........................................................P2.07-031
Guckenberger Matthias.............................................MA 13.09
Hamel Sénécal Léa................................................. P3.03-001 Hashimoto Kohei......................................................P1.13-004
Guclu Salih................................................................P3.01-043
Hamilton Celeste................................. P3.03-016, P3.03-026 Hashimoto Masaki............................P2.09-007, P3.09-009
Guerrera Francesco...............................MS 07.05, OA 16.02
Hamilton-Dutoit Stephen........................................ P2.01-043 Hashimoto Masayuki.......P1.02-030, P1.03-037, P3.16-048
Guevara Ferdinand...................................................P3.04-013
Hams Emily..............................................................P2.02-069 Hashimoto Shu...............P1.03-009, P2.02-057, P2.15-015,
Guha Udayan.................................... P1.02-063, P2.03-052 .................................................................................... P3.03-011
Han Baohui......................MA 14.07, P2.04-011, P3.01-087,
Guibert Nicolas....................................................... P1.07-009 ........................................................... P3.03-006, P3.03-017 Hashimoto Taiki.......................................................P2.02-035
Guibert Nicolas M................................MA 20.14, P3.02-014 Han Chengbo............................................................. P3.01-021 Hashimoto Takafumi...........................P2.05-017, P3.02-039
Guida Florence.........................................................P2.06-001 Han Guang................................................................ P3.01-083 Haslett Kate..............................................MA 09.11, MA 17.14
Guijarro Irene..........................................................P3.03-027 Han Ji-Youn.........................GR 02.03, MA 10.03, OA 09.03, Hassan Khaled A........................................................MA 11.10
Guillaud Martial........................................................P2.02-038 ................................................OA 10.01, OA 17.07, P2.04-005 Hassan Md. M............................................................P1.06-011
Guimaraes Marcos D...............................................P2.13-020 Han Jing..................................................................... P1.01-072 Hassan Raffit.....................OA 02.01, P1.02-063, P2.07-058
Guirado Maria.......................................................... P1.03-054 Han Joungho........................................................... P3.08-006 Hastings Willeen........................................................ MA 04.01
Gulbranson Scott....................................................P1.04-006 Han Jung Min........................................................... P1.03-034 Hata Aaron N...........................................MA 07.07, OA 07.05
Gulidov Igor..............................................................P1.08-008 Han Kook Nam.................P1.16-012, P1.16-021, P3.16-020 Hata Atsushi......................................... P1.16-008, P2.12-006
Gumbs Curtis..........................................OA 13.05, P2.02-013 Han Lei......................................................................P3.03-009 Hata Yoshinobu......................................................... P1.03-031
Gumus Mahmut..................................................... P2.03-042 Han Shu-Hua.......................................................... P3.05-009 Hatabu Hiroto.......................................P1.01-055, P2.07-002
Gunapala Ranga................................... P1.03-029, P3.12-003 Han Shuiyun...... MA 16.13, MA 16.14, P3.01-058, P3.17-003 Hataji Osamu.............................................................P1.03-027
Gunatilake Sam.......................................................... OA 02.05 Han Xiaohong...........................................................P2.03-028 Hatano Ben............................................................... P1.03-005
Gunuganti Vijay..........................................................P1.01-051 Han Xiaoying.............................................................P1.05-001 Hatfield Paul............................................................. P2.01-060
Guo Jin-Yu................................................................ P2.14-004 Han Yeon Bi.........................................P1.02-027, P1.02-029 Hatton Matthew........................................MA 09.11, OA 02.03
Guo Jindong.............................................................P3.13-010 Han-Zhang Han........................................................ P1.01-037 Hattori Keiko.............................................................P3.16-010
Guo Linghong..............................................................MA 14.03 Hanada Shigeo.........................................................P3.02-033 Hattori Noboru.........................................................P3.02-009
Guo Linlang.................... P2.15-003, P2.15-009, P2.15-010 Hanaki Hideaki.......................................................... P2.05-011 Hatz Rudolf.................................................................P1.07-019
Guo Qian...................................................................P3.03-029 Hanaoka Jun..................P1.02-030, P1.03-037, P3.02-003, Hau Eric..................................................................... P2.14-010
Guo Qisen........................................... P2.01-058, P2.02-018 ....................................................................................P3.16-048 Hauer Jolanta.............................................................OA 04.01
Guo Suping................................................................. P1.14-010 Hanawa Ryutaro..................................................... P3.08-002 Hauer Łukasz..............................................................OA 04.01
Guo Xinglai.................................................................P2.01-011 Handa Hiroshi..........................................................P2.02-072 Hauptmann-Repitz Elisabeth.................................P3.03-024
Guo Ye..................................................JCSE 01.16, P1.07-006 Handy John R.................. P1.07-019, P2.13-009, P2.13-021 Haura Eric................................................................P3.03-007
Guo Zihan.................................................................P3.03-003 Handzel Amir A......................................................... OA 09.06 Havel Libor...............................................................P2.03-023
Gupta Nalini..............................................................P2.03-053 Haneda Hiroshi.................... MA 16.10, P1.17-005, P2.17-001 Hawkes David.............................................................MA 09.10
Gurruchaga Ibon...................................................... P3.01-065 Hanes Valdimir.......................................................P2.04-009 Haworth Jacob J........................................................ MA 07.12
Gutierres Barbara......................................................P1.11-001 Hangiri Takeshi.........................................................P1.07-030 Hayai Shunsaku.......................................................P3.12-001
Gutierrez Castañeda Jose Maria....P1.06-022, P2.01-053 Hann Christine L........................................................MA 09.08 Hayakawa Daisuke............................. P2.02-012, P3.02-024
Guzmán-Barragán Abigail........................................MA 20.12 Hanna Gerard G...................................... MA 09.11, MA 09.07 Hayakawa Kazushige................................................MS 16.03
Gyoba Jennifer E...................................................... MA 14.03 Hansen Hanh........................................................... P2.01-043 Hayama Noriko....................................................... P2.03-005
Gyotoku Hiroshi........................................................ P1.03-015 Hansen Karin H.......................................OA 05.05, P1.01-001 Hayasaka Kazuki..........................................................MA 13.13
Gyoutoku Hiroshi.....................................................P2.07-045 Hansen Olfred................... MA 17.15, OA 01.02, P2.05-001, Hayase Momoko....................................................... P2.03-011
Gómez Rueda Ana................................MA 07.03, P1.01-040 ................................................................. P3.13-015, P3.13-016 Hayashi Hidetoshi............OA 05.03, P1.07-010, P2.03-008,
Göker Erdem.............................................................P3.01-043 Hantous-Zannad Saoussen................P3.13-025, P3.13-026 .............................................................P2.03-045, P2.07-021
Görtz Anna Lena.....................................................P2.02-024 Hao Chenxing............................................................ P1.01-042 Hayashi Kazuki.................P1.02-030, P1.03-037, P3.16-048
Gúrpide Alfonso........................................................P1.07-035 Hao Desiree..........................................MA 10.01, P1.06-005, Hayashi Masataro.............................. P1.05-003, P3.09-005
............................................................. P2.01-032, P2.01-055 Hayashi Shoko........................................................... P3.16-011
Hao Xishan...............................................................P3.03-009 Hayashi Takashi........................................................ MA 14.02
Hao Xuezhi.....................P2.01-029, P2.01-030, P3.04-007 Hayashi Takuo.......................................................... P1.03-006
H
Haouari Mohamed Amine.......................................P3.13-025 Hayashi Yuichiro............ MA 05.04, P1.05-009, P3.02-084,
Haque Mohammad..................................................... MA 18.01 .....................................................................................P3.13-031
Ha Jick Hwan........................................................... P2.05-014
Hara Akio............................................ P1.05-003, P3.09-005 Hayata Atsushi......................................................... P2.07-035
Ha Seung Yeon........................................................ P3.05-010
Hara Kantaro.......................................P2.16-003, P3.16-032 Hayes Sarah A............................................................P1.01-011
Haager Benedikt.........................................................OA 16.06
Hara Satoshi........................................ P1.07-004, P2.07-024 Hayes Wendy.............................................................MA 05.07
Haakensen Vilde D................................................. P1.02-028
Hara Tetsu............................................P1.03-010, P2.03-032 Haymaker Cara L...................................OA 13.05, P2.07-062
Haaland Benjamin..............................P2.07-054, P2.07-055
Harada Daijiro.................. MA 07.11, P1.03-038, P2.01-034, Hayman Jonathan.....................................................MA 09.08
Haas Andrew R....................................................... P2.07-059
.................................................................................. P2.05-009 Hazell Sarah Z...........................................................MA 09.08
Haba Reiji................................................................. P2.09-006
Harada Guilherme................................................... P3.01-066 He Hua.................................................JCSE 01.16, P1.07-006
Habaue Cheryl......................................................... P2.01-056
Harada Hideyuki..................................................... P2.05-005 He Huijuan................................................................. P3.01-031
Haberecker Martina................................................P2.02-036
Harada Mamoru........................................................P1.02-069 He Jiankui....................................................................MA 15.07
Haddad Cecilia K.......................................................P2.14-003
Harada Masahiko.....................................................P1.12-006 He Jianxing........MA 12.11, OA 09.06, P1.06-019, P3.01-087,
Haddad Fabio J....................................................... P2.13-020
Harada Masao....................................... OA 05.08, P2.03-010 ....................P3.02-008, P3.03-006, P3.03-017, P3.04-010
Haddad Vincent......................................................... OA 09.03
Harada Shinya........................................................ P2.03-002 He Jiao...................................................JCSE 01.17, OA 08.02
Haddox Candace.........................................................MA 18.09
Harada Taishi........................................................... P1.03-004 He Jie........................................................................P2.02-052
Hager Henrik............................................................P1.05-004
Harada Toshiyuki..................................................... P2.03-010 He Kai...................................MA 06.08, OA 18.02, P3.13-033
Hager Thomas..........................................................P3.13-033
Haraguchi Mizuki.....................................................P3.02-024 He Minwei.................................................................P3.02-022
Haggstrom Daniel E............................ P2.01-004, P2.01-013
Haramati Linda B......................................................P2.13-008 He Pei..................................... MA 10.03, OA 17.07, P1.01-052
Haginoya Noriyasu..................................................P3.02-042
Harashima Nanae.....................................................P1.02-069 He Shuang........................P1.04-001, P2.01-040, P3.01-071
Hagiwara Koichi....................................................... P2.03-010
Haratake Naoki................... OA 13.06, P1.07-002, P1.07-014, He Xian........................................................................P1.04-011
Hagiwara Masaru.............P1.01-041, P1.16-010, P2.02-009, ......................................... P2.09-005, P3.16-003, P3.16-033
...............................................................P2.05-012, P3.02-012 He Yayi.....................................................................P1.03-052
Haratani Koji..........................................P1.07-010, P2.07-021 He Ying................................................P3.05-007, P3.05-008
Hahn Seokyung...........................................................OA 14.01
Hardcastle Nicholas..........................P1.14-017, P2.05-006 He Yong.........................................................................OA 10.01
Hahn Stephen M........................................................OA 08.05
Hardcastle Nick......................................................... P2.14-001 He Yuexi...................................................................... P1.02-011
Haider Ehsan................................................................OA 15.01
Harden Susan V.....................MA 09.11, MA 11.02, P1.05-010 He Yuting..................................................................P2.02-052
Haigentz Jr. Missak..................................................P1.07-027
Hardy-Werbin Max....................................................P1.15-001 He Zhen..................................................................... P1.01-047
Haitjema Tjeerd...........................................................MA 17.10
Hariani Ririn.............................................................. P1.01-026 Healey Diane.............................................................P3.07-012
Hajder Piotr...............................................................P2.16-027
Hariniv Vidya............................................................. P1.01-024 Healey Graham..........................................................P2.13-013
Hakiri Shuhei.........................................P1.08-002, P1.17-004
Heasley Lynn............................................................. P2.02-011 Hirata Kazuto..........................................MS 02.02, P1.06-014 Houzawa Hiroyuki................................................... P1.03-008
Hedgeman Elizabeth............................................... P2.01-043 Hirata Taizo...................................................................MA 07.11 Hovig Eivind..............................................................P1.02-028
Hegde Priti..................................................................MA 05.09 Hirohashi Kentaro............P1.02-034, P1.12-003, P1.16-026 Howarth Karen.........................................................P3.02-014
Hegedus Balazs...................................................... P2.09-004 Hirohata Ryosuke..................................................... P2.05-011 Howell Viive M............................................................P1.01-011
Heider Katrin............................................................... MA 11.02 Hiroishi Takuma...................................................... P2.03-005 Hoyle Christopher.................................................... MA 12.07
Heist Rebecca.......................MA 02.10, OA 07.05, OA 12.02, Hiroshima Kenzo...............................P2.09-006, SH 04.03 Hradilova Nada................................. P2.07-020, P3.07-008
.............................................. OA 12.06, OA 17.02, P2.04-005 Hirsch Fred R.......................MA 05.14, MA 13.02, MS 18.02, Hrnciarik Michal.......................................................P2.03-023
Heitzer Ellen................................................................OA 10.05 .......................... OA 07.06, OA 14.07, P1.03-052, P2.02-011, Hsia Te-Chun................... OA 10.01, P1.03-053, P2.03-003,
Hejduk Karel.............................................................P2.03-023 ............................................ P2.02-070, P2.03-019, PL 03.03 ..........................................P2.03-058, P2.07-027, P3.01-016
Helland Åslaug................ P1.01-013, P1.02-028, P2.02-053, Hirschmann Meita................................................... P2.04-014 Hsiao Wei Ling........................................................ P1.10-004
............................................................. P2.03-035, P2.03-037 Hirsh Vera........................MS 20.01, P2.07-029, P3.01-026, Hsieh Chih-Cheng..................................................... OA 04.07
Hellmann Matthew D.............................. MA 05.02, OA 17.03 ..............................................................P3.01-039, P3.01-075 Hsieh Ming-Ju.........................................P1.16-017, P3.13-001
Hellström Cecilia.......................................................P1.07-020 Hisada Takeshi................. P2.01-027, P2.15-005, P2.15-016 Hsieh Wen Son...........................................................MA 12.03
Hembrough Todd......................................................P1.02-001 Hisamatsu Yasushi..................................................P1.08-006 Hsieh Wen-Yu........................................................... P1.02-008
Henderson Douglas................................................ P1.09-003 Hishida Tomoyuki............ P1.05-005, P1.05-009, P1.17-017, Hsu Cheng Chieh......................................................P1.11-002
Henderson Samantha................................................OA 10.03 .....................................................................................P3.13-031 Hsu Li-Han.............................................................. P3.12-002
Hendrikse Nh.............................................................MA 05.07 Hishima Tsunekazu.................................................. P1.12-006 Hsu Po-Kuei............................................................... OA 04.07
Heng Jennifer C........................................................OA 06.02 Hitoshi Ito................................................................. P2.14-007 Hsu Wen-Hu............................................................ P2.05-020
Hennedige Tiffany Priyanthi....................................P3.01-017 Hiura Toru................................................................. P2.03-015 Hsu Wu-Huei.............................................................P1.03-053
Hennessy Bryan......................................................P2.02-048 Hiyama Eiso.............................................................P3.02-009 Hsu Ying-Han............................................................. OA 03.06
Henon Clémence.....................................................P2.07-005 Hjorthaug Karin..................P3.13-014, P3.13-015, P3.13-016 Hu Beibei..................................................................... MA 17.07
Henrique Rui.............................................................P3.01-049 Hlavcak Peter...........................................................P2.03-056 Hu Bin........................................................................P3.16-009
Henschke Claudia I......... P2.13-026, P2.16-013, P2.16-014, Ho Chao-Chi.....................P2.13-001, P3.01-006, P3.01-074 Hu Chen......................................................................MA 09.08
....................P2.16-022, P2.16-023, P2.16-024, P3.13-028, Ho Cheryl........................MA 04.02, P1.03-020, P2.05-003, Hu Cheng P.................................................................MA 03.03
..........................P3.13-035, PL 01.02, WS 01.12, WS 02.01, ............................................P3.01-013, P3.01-015, P3.01-030 Hu Cheng-Ping....................................P3.01-026, P3.01-075
........................................... WS 02.03, WS 02.08, WS 02.15 Ho Ching-Liang....................................P2.07-027, P3.01-036 Hu Chengping................ P2.02-008, P3.01-052, P3.02-072
Heo Jae-Sung............................................................ P1.15-015 Ho Hsiang-Ling................................. P1.02-008, P3.02-044 Hu Hsin-Pei............................................................... P1.12-002
Heo Su Jin................................................................... MA 11.09 Ho James Chung-Man.......................P2.02-058, P2.15-006 Hu Huan..................................................................... P2.01-019
Heralde Francisco Iii M.....................P2.02-019, P3.02-056 Ho Shaun.................................................................... P1.15-017 Hu Jian............................. P1.07-038, P2.02-018, P3.04-010
Herbolsheimer Pia................................................... P1.15-004 Ho Steffan N...............................................................P1.01-016 Hu Jie........JCSE 01.06, MA 20.13, P1.01-037, P3.01-004,
Herbst Cameron......................................................P2.02-047 Hoang Chuong D.....................................................P2.03-052 .......................................... P3.01-052, P3.04-001, P3.13-037
Herbst Roy S................ JCSE 01.03, MA 07.14, MTE 15.01, Hoch Ute...................................................................P2.07-062 Hu Jifan........................................................................OA 18.08
..............................................................OA 14.07, P2.04-006 Hochmair Maximilian J.........................OA 05.05, P1.01-001, Hu Jingwen...............................................................P1.03-032
Herder Judith...............................................................MA 17.10 .....................................P2.03-025, P2.04-005, P3.03-024 Hu Jinlin................................................... MA 16.13, P2.02-013
Hernan Cristina.........................................................P2.02-014 Hocking Ashleigh J............................P1.09-003, P1.09-012 Hu Jinwei.............................................. P1.07-038, P2.02-018
Hernandez Martinez Juan M................MA 12.10, P1.07-040 Hoda Mir A........................ MA 16.05, MA 19.07, P2.09-004 Hu Qin....................................................................... P3.01-004
Hernandez-Pedro Norma Y...............P1.07-041, P2.01-075 Hodge David........................ OA 06.05, OA 06.07, P1.07-039 Hu Qiong................................................................... P1.03-052
Hernando Jorge...................................................... P3.01-065 Hodge Rachel............................................................. OA 05.02 Hu Runlei............................................P1.14-007, P3.16-040
Hernández Alejandro...............................................P1.03-035 Hodi F. Stephen...................................P1.01-055, P2.07-002 Hu Weijian...................................................................P2.01-011
Hernández Berta....................................................... MA 07.03 Hodkinson Chris.................................... P3.05-001, WS 01.18 Hu Xiao.......MA 01.11, P1.03-007, P3.01-027, P3.14-004
Herrmann Tara............. P1.01-025, P1.01-068, P2.07-036 Hoffman Philip C......................................MA 03.09, OA 14.07 Hu Xin.........................................................................P2.02-013
Herschtal Alan............................................................MA 13.07 Hoffmann Hans......................................................... ES 05.06 Hu Xingsheng.................. JCSE 01.28, MA 07.13, P2.01-029,
Herth Felix J......................................P3.05-007, P3.05-008 Hofman Michael........................................................ P2.14-001 ........................................P2.01-030, P2.03-028, P3.04-007
Herth Felix Jf..............................................................P1.15-011 Hojo Hidehiro............................................................ P3.14-001 Hu Yan-Ping........................................JCSE 01.25, MA 06.09
Hesdorffer Mary...............ES 03.04, MA 04.05, P1.10-007, Hojo Masayuki........................................................... P1.01-054 Hu Yanping...................................................................MA 11.03
.................................................................................... WS 03.17 Hojou Masafumi........................................................P2.03-017 Hu Yi...............MA 11.03, P1.07-037, P2.04-003, P3.01-036
Heukamp Lukas C....................................................P3.01-038 Holgado Esther.........................................................P3.07-012 Hu Yonghong...............................................................P1.14-011
Heuvelmans Marjolein A.........................OA 15.06, OA 15.07, Holgersson Georg.............................. P1.07-020, P1.14-008 Hu Yuebi.................................................OA 09.02, P3.02-014
...................................................................P2.13-007, WS 01.11 Hollen Patricia J...................................MA 08.11, P2.01-050 Hua Jin....................................................................... P1.09-012
Hewitt Stephen.........................................................P1.02-063 Hollenberg Morley...................................................P1.06-005 Hua Ye..................................................JCSE 01.12, P3.01-070
Heymach John V............. MA 01.03, MA 05.02, MTE 31.01, Holynskyj Ariadna.................................................... P1.04-013
.............................OA 07.02, OA 09.05, OA 12.01, OA 12.05, Huan Jiaojiao...............................................................OA 18.01
Homma Sakae................... MS 07.04, P2.01-010, P3.16-004 Huang Anfei..................................................................OA 13.01
...........................OA 13.01, OA 13.05, P2.02-013, P2.04-014, Honda Takayuki.......................................................P3.02-035
...................P2.07-061a, P3.02-076, P3.03-013, P3.03-027 Huang Chao H...........................................................P2.07-019
Honda Yoshihiro......................................................P2.07-004 Huang Cheng....................JCSE 01.10, MA 11.03, P2.03-047,
Hickes William..........................................................P1.05-008
Hong Goohyeon...................................................... P2.12-005 ....................................................................................P3.01-087
Hicks Danielle................. MA 04.03, MS 22.02, P3.11-003
Hong Jeongmin.......................................................P1.02-071 Huang Chun.............................................................. P3.01-084
Hicks James K............................................................MA 12.05
Hong Jihyun..............................................................P3.14-009 Huang Daniel............................................................P2.03-043
Hicks Jonathan....................................P3.15-003, P3.15-005
Hong Ju-Young.........................................................P3.14-009 Huang Derek.............................................................P3.01-074
Hicks Rodney............................................................ P2.14-001
Hong Mi Jeong.........................................................P2.02-056 Huang Gemu.............................................................P3.02-019
Hida Tomoyuki.........................................................P2.07-002
Hong Min Hee......................MA 11.09, MA 12.01, P3.01-028 Huang Guanghui..................................................... P1.05-001
Hida Toyoaki...........................MA 12.02, MA 17.06, MA 19.01,
.............................OA 05.08, OA 10.01, OA 17.07, P1.03-005, Hong Qunying........................................MA 20.13, P3.01-004 Huang Han-Yao........................................MA 18.14, P1.06-012
.............................................................. P2.07-028, P2.15-004 Hong Shan-Huei.................................. P3.02-070, P3.07-011 Huang Hsu-Ching............................... MA 03.07, P3.02-043
Hida Yasuhiro......................................... OA 04.02, P1.17-010 Hong Sook-Hee.................................P2.03-022, P3.08-003 Huang Hui..................................................................P1.01-005
Hidayat Moulid.............. P1.02-065, P2.02-012, P3.02-024 Hong Waun K............................................................P2.02-013 Huang James............................................................OA 03.03
Higashi Mayumi....................................................... P3.13-013 Hong Wu................................................................... P1.02-042 Huang Jia.................................................................P3.02-014a
Higashiguchi Masayoshi......................................... P1.03-049 Hong Yoonki............................................................ P1.02-070 Huang Jian-An........................................................... OA 09.06
Higashiyama Masahiko..........................................P2.05-010 Hong Zhihai................................................................ MA 14.04 Huang Jianjin............................................................P3.01-087
Higashiyama Shigeaki..............................................P3.16-032 Honjo Tasuku.............................................................. PL 03.01 Huang Jie..................................................................P3.02-040
Higginbottom Karen.................................................. MA 01.09 Hooper Jody E.........................................................P2.02-044 Huang Jun..................................................................P3.01-011
Higgins Catherine.....................................................P1.03-001 Hope Andrew J...................MA 09.02, MA 13.09, MA 16.03, Huang Kailing...........................................................P2.02-003
Higgins Kristin A.............. OA 01.06, P1.08-003, P3.13-027 ............................................P1.13-004, P1.14-016, P3.09-007 Huang Kun...................................................................OA 18.02
Higuachi Tetsuya.....................................................P2.02-026 Hopkins Raewyn J..............OA 06.03, OA 06.06, OA 15.03 Huang Kuo-Yang.................................................... P2.03-038
Hilberg Frank...........................................................P3.03-023 Horgan Denis.......................................WS 01.33, WS 02.05 Huang Miao.............................................................. P2.01-068
Hilgers Werner.............................................................OA 17.05 Hori Testuo................................................................P1.03-037 Huang Min.................................................................P1.01-050
Hillinger Sven..........................................................P1.02-005 Horiike Atsushi...................................... MA 16.04, P1.08-006 Huang Pei-Ming....................................P3.01-079, P3.17-002
Hillmer Axel.................................................................OA 09.07 Horimasu Yasushi...................................................P3.02-009 Huang Ruofan........................................................... P3.01-010
Hilton John.................................................................. MA 10.01 Horinouchi Hidehito........ISS 02.04, MA 10.08, MA 16.04, Huang Shanshan...................................................... P1.03-019
................. MS 23.03, P1.03-005, P2.03-036, P2.03-048, Huang Tzu-Yen.......................................................... P3.13-001
Himuro Naoya......................................................... P3.16-008 .......................................... P2.07-011, P3.02-041, P3.04-002
Hinotsu Shiro...............................................................MA 07.11 Huang Weimei.......................................................... P2.15-009
Horinouchi Hirohisa.................................................P1.16-019
Hinton Ivora................................................................. MA 08.11 Huang Weizhe..........................................................P3.02-008
Horio Hirotoshi......................................................... P1.12-006
Hinzmann Bernd........................................................P1.15-011 Huang Wen-Tsung.................................................... P3.01-016
Horio Yoshitsugu..................................................... P2.07-028
Hipper Annette........................................................ P3.01-088 Huang Yan...................................................................P1.14-011
Horn Leora...........................MA 07.02, MA 14.08, OA 09.03,
Hirabayashi Masataka............................................. P2.07-024 ...............................................................P2.04-012, P3.07-012 Huang Yifan........................................P2.04-001, P2.04-002
Hirai Ayako................................................................P1.07-030 Horvat Teodor............................................................P3.16-018 Huang Yu-Jing......................................................... P1.03-050
Hirai Fumihiko....................OA 13.06, P1.03-005, P1.07-014, Hosoi Akihiro..............................................................P1.07-017 Huang Yunchao...................................P3.01-026, P3.01-075
..............................................................P2.09-005, P3.16-033 Hosokawa Shinobu..............................OA 12.03, P1.08-006 Huang Yunjian.................P1.01-002, P3.01-008, P3.02-069
Hirai Toyohiro.................P2.01-021, P2.03-055, P2.07-003, Hosomi Yukio.....................MA 16.04, P1.17-006, P2.15-004 Huang Zhangzhou.........P1.02-046, P3.01-008, P3.02-028
...........................................P2.07-013, P2.07-017, P2.07-024 Huang Zhiyu................. JCSE 01.18, P2.03-013, P3.03-030,
Hosoya Keiko........................................ P1.02-060, P1.13-008
Hirai Yoshimitsu...............P1.03-033, P2.16-010, P3.13-012 ....................................................................................P3.03-031
Hosoya Miki.............................................................. WS 03.04
Hiraiwa Shinichiro.....................................................P1.02-017 Huang Zhongdong..................................................... MA 07.09
Hotta Katsuyuki....................... MA 07.11, OA 12.03, OA 17.06,
Hirakawa Haruki....................................................... P2.03-011 .............................................................. P1.03-005, P2.01-034 Hubbard Richard B............................P1.05-010, P2.06-005
Hirano Katsuya................................... P1.07-004, P1.08-006 Hou Helei.....P1.01-042, P1.01-069, P2.03-034, P3.03-018 Huber Rudolf M.................OA 05.05, P1.01-001, P1.01-004,
Hirano Satoshi.......................................................P2.03-005 ................................................................................... P1.07-019
Hou Likun....................................................................P3.15-015
Hirano Shoko........................................P2.15-011, P3.02-009 Huberman Kety...........................................................OA 10.05
Hou Yingyong........................................................... P3.01-004
Hirashima Tomonori........................... P1.03-047, P1.03-049 Huberman Mark.....................................OA 12.02, P3.03-025
Houston-Harris Cheryl........ OA 15.08, P1.13-011, P2.16-019
Hirata Haruhiko........................................................P2.07-009 Hout-Siloni Goni......................................................P3.03-028
Hudoyo Achmad............P1.03-024, P2.03-031, P2.03-049, Illiano Alfonso.........................................MA 02.05, P1.01-053 Iwai Toshiki............................................................. P2.07-006
..........................................P3.01-032, P3.01-053, P3.01-054 Ilonen Ilkka.................................................................P1.08-010 Iwama Eiji................................................................. P1.03-004
Huemer Florian........................................................P3.03-024 Ilouze Maya......................P1.01-039, P3.01-056, P3.01-060, Iwamoto Keisuke...................................................... P3.01-064
Huffman Kenneth.........................................................MA 15.13 ............................................................. P3.02-096, P3.03-022 Iwasaki Akinori....................................P2.16-020, P3.16-044
Hughes Brett.....................MA 19.03, P2.07-032, P2.07-033 Im Sun-Wha.........................................MA 06.04, P2.02-059 Iwasaki Teruo..............................................................MA 17.04
Hughes Suzanne.................................................... P3.06-008 Imai Hisao............................................P1.15-002, P2.15-005 Iwasaki Yasushi....................................................... P2.16-008
Hui Rina................................. OA 17.06, P1.07-018, PL 02.02 Imai Kentaro...............................................................P1.16-010 Iwasawa Shunichiro...............................................P2.07-042
Hui Zhouguang....................................P1.08-007, P2.14-004 Imaizumi Kazuyoshi................................................ P2.07-028 Iwata Hiromitsu...................................................... P2.05-005
Huisman Marc C........................................................MA 05.07 Imamura Fumio.................. MA 19.01, OA 05.02, P2.05-010 Iwazaki Masayuki......................................................P1.02-017
Hukins Craig........................................................................9941 Imanaka Keiko..........................................................P2.03-007 Iyama Shinji...............................................................P3.15-009
Hullinger Naomi........................................................ P1.03-014 Imase Reina........................................P1.03-010, P2.03-032 Iyengar Puneeth...................................MA 13.08, P3.08-004
Hung Jamie.................................................................MA 15.08 Imaz-Olguín Victoria.............................................. P2.06-007 Iyer Gopal....................................................................OA 09.07
Hung Jen-Yu............................................................ P2.07-027 Imber Brandon........................................................... P3.15-011 Iyoda Akira....MS 07.04, P1.03-031, P2.01-010, P3.16-004
Hung Jung-Jyh......................................................P2.05-020 Imbimbo Martina.................................................... P2.09-001a Izevbaye Iyare........................................................... P3.01-019
Hunis Brian....................... MA 15.02, P2.01-056, P2.07-052 Imperiale Michael....................................................P2.07-062 Izquierdo Angel.........................................................P1.03-035
Hunt Jaime............................................MA 02.07, P2.07-038 In Gino.........................................................................P1.11-004 Izumi Hiroki.......................................... P1.01-064, P2.03-016
Hunter John C.........................................................P3.02-066 Inafuku Kenji......................P1.05-011, P1.05-018, P1.05-021, Izumi Nobuhiro....................................P2.16-003, P3.16-032
Hur Gyu Young.........................................................P2.01-035 ...........................................P2.17-003, P3.15-012, P3.16-047 Izumo Takehiro.......................................ES 07.02, WS 04.04
Hur Jae Young......................................................... P3.01-034 Inai Kouki.............................................P1.02-052, P2.09-008
Hureaux José...............................................................OA 17.05 Inaki Koichiro............................................................P3.02-042
Hurley James.........................................P1.01-074, P1.03-013 Inamura Saki..............................................................OA 05.08
Inase Naohiko...........................................................P3.02-035 J
Hurwitz Michael E...................................................P2.07-062
Husain Hatim.............................................................OA 09.04 Inbar Edna................................................................ P3.01-056
Incharoen Pimpin....................................................P3.03-020 Jabo Brice................................................................. P1.16-006
Hussein Maen............................................................P1.01-051
Inci Ilhan.................................................................... P3.09-010 Jackson Alan................................................................ MA 17.14
Huswatun Aida L..................................................... P2.03-031
Indraccolo Stefano..................................................P3.02-006 Jackson Bianca........................................ MA 04.01, P1.13-011
Huynh Tiffany............................................................P1.07-033
Inoue Akira.........................OA 05.03, OA 05.08, P2.03-010 Jackson Edwin........................................................ P2.06-008
Hwang David H...........................................................MA 20.14
Inoue Kouji..............................................OA 12.03, P1.08-006 Jacobs Carmel.......................................................... P2.15-014
Hwang David M...................................... OA 15.01, P1.07-022
Inoue Masaaki............................................................. OA 12.03 Jacobs Colin................................................................. MA 14.11
Hwang Eunji............................................................ P2.15-007
Inoue Masayoshi.............. P1.02-022, P1.17-009, P2.01-067, Jagaty Suman K...................................................... P2.15-002
Hwang In Kyoung....................................................P2.03-020
.................................................................................... P2.16-016 Jaggi Rolf...................................................................... MA 15.11
Hwang Kieun............................................................P3.02-030
Inoue Takashi.................................... P1.02-018, P3.02-064 Jahanzeb Mohammad....P1.07-024, P1.07-025, P2.07-037
Hwang Moon Hee.................................................... P2.07-024
Inoue Takayuki.................................... P3.09-006, P3.16-010 Jaimes Yolanda........................................................ P2.01-056
Hwang Yoohwa........................................................ MA 06.04
Inoue Takeo..............................................................P2.02-072 Jain Amit................................................. OA 09.07, P3.01-017
Hwangbo Bin..........................................................MTE 08.02
Inoue Tatsuya........................................P1.02-053, P1.12-008 Jain Deepali...................................................................YI 01.13
Hwu Patrick..............................................................P2.07-062
Inoue Teppei.............................................................P2.02-072 Jain Pooja........................................... P2.01-060, P2.08-003
Hydbring Per............................................................ P1.01-074
Inoue Tetsuya.............................................................MA 09.06 Jain Prantesh............................................. MA 15.06, MA 17.11
Hyman David M..........................................................OA 14.05
Insa Amelia..............................................MA 15.01, P1.03-054 Jain Vikram.............................................................. P2.07-032
Hyun Kwanyong........... MA 06.04, P2.02-059, P3.09-008,
.......................................... P3.16-013, P3.16-022, P3.16-026 Inuzuka Tatsutoshi................................................... P1.02-064 Jakobsen Kristine R................................................P3.02-050
Hååg Petra..................................................................P1.01-074 Ionescu Diana..............................................................OA 15.01 Jakopovic Marko............................... P2.09-004, P3.01-059
Højbjerg Johanne A...............................................P3.02-052 Ionova Tatiana I........................................................P1.01-056 Jalal Shadia I................................................................ OA 17.01
Iqbal Afsheen............................................................P1.03-028 Jalali Ali........................................................................ OA 13.05
Iqbal Mussawar....................................P3.01-019, P3.01-062 James Leonard P.......................................................OA 05.06
Iravani Amir.................................................................. MA 17.12 Jamme Philippe........................................................MA 07.06
I Janakiram Murali........................................................ OA 13.03
Irigoyen Antonio....................................................... P1.06-013
Irigoyen Medina Antonio........................................P2.07-039 Janchompoo Pareena............................................P3.03-020
I Cheon Park.............................................................P2.03-022 Janes Sam M........................................P2.13-011, P3.05-001,
Iriki Toyohisa.............................................................P3.15-009
I Hoseok.............................. P1.16-001, P2.16-011, P3.16-006 ...................................................................WS 01.18, WS 01.41
Irisuna Fumiko......................................P2.15-011, P3.02-009
Iafrate Anthony J................................... MA 07.07, P1.07-033 Jang Jae-Hwi......................................P1.02-015, P2.02-036
Irusen Elvis................................................................P1.06-001
Iams Wade T...................MA 05.11, P1.04-004, P1.04-005, Jang Seung Hun...................................................... P3.01-050
Irving Louis B......................MA 20.09, P1.14-017, P2.13-023
............................................................. P1.07-043, P3.02-034 Jang Tae Won..........................................................P2.03-022
Isaka Mitsuhiro............... P2.15-008, P3.05-006, P3.16-011
Iannessi Antoine.........................................................MA 14.02 Jang Taewon........................................................... P3.01-033
Isaksson Johan...................................... MA 05.13, P2.02-015
Ibe Takashi....P1.02-031, P1.16-014, P2.16-009, P3.16-029 Janker Florian......................................P1.02-015, P2.02-036
Isbell James............................MA 13.14, OA 10.03, P3.15-011
Ichihara Eiki............................................................. P3.04-002 Jankovic Radmila.....................................................P1.02-007
Ishibashi Fumihiro.....................................................OA 04.05
Ichikado Kazuya...................................................... P3.04-002 Janssen Tomas.........................................................P2.14-020
Ishida Hiroo...............................................................P3.01-055
Ichikawa Kosuke................................. P2.03-015, P2.07-007 Jantus-Lewintre Eloisa...........................................P1.01-040
Ishida Kazuyuki....................................................... P2.06-009
Ichikawa Tomohiro.............................P3.02-074, P3.13-036 Janu Amit.......................... P1.01-021, P1.01-023, P2.01-051,
Ishida Keiko................................................................P1.03-037
Ichimura Hideo................. MA 14.06, P2.17-004, P3.16-039 ............................................................... P3.01-076, P3.03-015
Ishida Mitsuaki...........................................................MA 05.06
Ichinose Junji................. P1.13-005, P2.05-016, P3.13-009 Jares Pedro...........................................P1.01-075, P3.01-045
Ishida Tadashi......................................P2.01-001, P2.07-024
Ichinose Yukito........................................................ P2.09-005 Jarkowski Anthony.................................................P1.04-008
Ishihara Shunta.....................................P1.02-022, P1.17-009
Ichiyasu Hidenori.................................P1.02-023, P3.15-009 Jarosz Bożena.........................................................P3.02-045
Ishii Genichirou.................. OA 16.07, P3.02-074, P3.13-036
Icon Team Icon Project............................................P2.02-041 Jarzabek Monika..................................................... P1.09-007
Ishikawa Hiroyuki............................... P3.02-046, P3.02-071
Idris Ahmad F............................................................. MA 04.10 Jassem Jacek.........................................................MTE 25.01
Ishikawa Hitoshi...................................................... P2.05-005
Iemwimangsa Nareenart........................................P3.03-020 Jaén Morago Ana.....................................................P1.07-036
Ishikawa Narumi...................................P1.02-022, P1.17-009
Igai Hitoshi....P1.02-031, P1.16-014, P2.16-009, P3.16-029 Jean Didier............................................................... P1.09-002
Ishikawa Nobuhisa..................................................... OA 12.03
Igarashi Tomoyuki.........P1.02-030, P1.03-037, P3.02-003, Jeffs Yvonne..............................................................MA 08.07
.................................................................................. P3.16-048 Ishikawa Yuichi...............MTE 17.01, P2.05-016, P3.13-009
Jen Jin........................................................MA 13.01, OA 13.07
Igawa Satoshi.........................................................P2.03-002 Ishimaru Chisako......................................................P2.02-051
Jenkins Brendan J..................................................P3.07-002
Igishi Tadashi........................................ P1.01-064, P2.03-016 Ishimoto Osamu....................................................... P2.03-021
Jenkins Sarah............................................................ OA 03.06
Ignatius Ou Sai-Hong............................ MA 07.01, P3.01-073 Ishioka Kota............................................................ P3.02-084
Jenkins Suzanne..............OA 10.01, P2.02-052, P3.02-062
Ihara Hiroaki.............................................................P3.02-024 Ishioka Yoshiko......................................................... P2.03-014
Jenko Nathan...........................................................P1.05-008
Ihara Rie.....................................................................P1.02-034 Ishitoko Manabu....................................................... P2.07-024
Jennens Ross.............................................................OA 02.01
Iida Yuko..............................................P1.03-009, P2.15-015 Ishiyama Hiromichi...................................................MS 24.04
Jennings Barton R.................................................... P1.14-017
Iijima Yuki.................................................................. MA 05.08 Ishkanian Adrian..............P1.07-024, P1.07-025, P2.07-037
Jeon Jihyoun..............................................................WS 01.07
Iikura Motoyasu....................................................... P2.03-005 Isikdogan Abdurrahman........................................P2.01-024
Jeon Sang-Hoon...................................................... P2.01-016
Iimura Yohei........................................................... P2.03-007 Isla Dolores.......MA 15.01, P1.01-040, P3.01-043, PL 02.04
Jeong Dongjun....................................................... P2.02-060
Iizasa Toshihiko........................................................P2.02-063 Isobe Hiroshi....................................... P2.01-005, P2.03-010
Jeong Euntaik........................................................ P3.02-030
Iizuka Yusuke........................................ P1.14-015, P2.05-002 Isobe Kazutoshi................MS 07.04, P2.01-010, P3.16-004
Jeong Yeon Joo...................................................... P3.13-002
Ikeda Atsuko............................................................. P2.05-010 Isobe Midori.......................................... P2.07-015, P2.07-018
Jeppesen Stefan S.............................. OA 01.02, P2.05-001
Ikeda Koei................................................ P1.15-014, P1.16-002 Isobe Takeshi.............................................................P1.02-069
Jerez Ignacio............................................................. P1.01-058
Ikeda Norihiko.....................ES 05.03, MA 15.13, OA 06.09, Isoyama Takeshi......................................................P3.02-042
Jerome Mary....................................... P1.03-022, P1.04-012
.........................P1.01-041, P1.02-025, P1.07-012, P1.16-010, Itani Hidetoshi.........................................................P3.01-064
Jessop Nicholas A.................................................... MA 07.07
.....................P2.02-009, P2.03-019, P2.05-012, P2.16-012, Itchins Malinda.......................................................... P1.01-011
Jett Jim..........MTE 27.01, P1.07-016, P2.13-013, YI 01.08
.............................................................. P3.02-012, P3.07-003 Ito Hiroyuki...................... P1.05-011, P1.05-018, P1.05-021,
...........................................P2.17-003, P3.15-012, P3.16-047 Jeung Hei-Cheul....................................................... P1.05-014
Ikeda Satoshi........................................................... P2.01-001
Ito Kazuhiko.............................................................. P2.03-010 Jha Ashish................................................................ P2.14-005
Ikeda Shingo.............................................................. P1.03-031
Ito Kazuhiro.........................................P2.01-067, P2.16-008 Jheon Sanghoon.........................................................MA 13.12
Ikeda Takaya.........................................P1.03-015, P2.07-045
Ito Masaoki.................................................................P2.15-011 Ji Chunyu................................................................... P2.16-018
Ikemori Rafael..........................................................P3.03-023
Ito Ryo....................................................................... P2.03-015 Ji Qiao....................................................................... P2.01-020
Ikeo Satoshi...............................................................P2.01-001
Ito Satoru............................................. P3.09-006, P3.16-010 Jia Hongyan................................................................MA 01.03
Ikezawa Yasuyuki.................................................... P2.01-005
Ito Yuhei.................................................................... P3.01-064 Jia Tianying............................................MA 14.12, P3.13-022
Ikpeazu Chukwuemeka........................................... P2.07-037
Itoga Masamichi....................................................... P2.03-014 Jia Yijun........................................................................MA 11.07
Ilic Darko.................................................................... P1.16-004
Iuchi Toshihiko..........................................................P2.07-014 Jian Hong..........................................P3.02-014a, P3.04-005
Ilic Nenad..................................................................P1.16-004
Ivanova Elena.............................................................MA 07.12 Jiang Benyuan................ JCSE 01.26, OA 10.02, P1.01-010
Ill Mark......................................................................... MA 04.01
Ivanova Irina.............................................................P1.08-008 Jiang Chenxue.......................MA 16.13, MA 16.14, P3.17-003
Ill Toni.......................................................................... MA 04.01
Ivimey Beth...................... MA 08.08, WS 03.03, WS 03.14 Jiang Gening....................................... P2.05-018, P3.04-010
Illei Peter B...................P1.01-007, P1.01-008, P2.02-044,
................................................................................. P2.02-045 Iwai Moe.................................................................... P1.03-006 Jiang Haiping............................................................P3.01-025
Jiang Haiyi..........................................P2.04-001, P2.04-002 Jurisica Igor.... MA 15.12, OA 07.07, P1.02-006, P3.02-094 Kanzaki Ryu..... MA 16.08, MA 17.04, P1.02-068, P1.17-002,
Jiang Jianing........................................................... P1.01-078a Jusuf Anwar............................................................ P2.03-031 ................................................................P1.17-013, P3.16-050
Jiang John..................................................................OA 10.06 Jänicke Martina....................................................... P3.01-088 Kao Shu-Huei............................................................P3.12-002
Jiang Jun..................................................................P3.04-007 Jänne Pasi A........................MA 05.02, MA 07.08, MA 07.12, Kao Steven.......................... MA 19.06, P1.01-011, P3.09-004
Jiang Man........................P1.01-042, P1.01-069, P2.03-034, ....................... MS 25.01, OA 09.02, P1.01-055, P3.02-066, Kapfhammer Irene..................................................P3.03-024
............................................................P3.03-014, P3.03-018 ............................................................P3.04-012, P3.04-013 Kaplan Muhammed Ali.............................................P2.01-024
Jiang Mei..................................................................P3.02-083 Jørgensen Lars H....................................................P1.02-028 Kapoor Akhil..................... P1.01-021, P1.01-023, P3.01-076
Jiang Renjian...........................................OA 01.06, P3.13-027 Jørgensen Leif.........................................MA 18.14, P1.06-012 Kapoor Rakesh...........................................................MA 03.02
Jiang Richeng.......................................................... P3.01-084 Kar Madhabananda................................................. P2.15-002
Jiang Tao............................MA 06.11, MA 11.07, P1.03-045, Kara Volkan..................................................................OA 16.06
..................P1.03-052, P2.07-010, P3.01-024, P3.01-067 Karachaliou Niki............P1.07-015, P2.02-034, P3.01-073
K
Jiang Wei...................................................................P3.16-025 Karagiannis Thomas................................................ P1.01-052
Jiang Xiangli............................................................. P3.01-084 Karagiannis Tom........................................................ P1.01-013
Kaburagi Takayuki.................................................... P1.15-002
Jiang Zhi.................................................MA 11.05, P2.02-006 Karapetis Chris...........................................................OA 14.06
Kaburaki Kyohei........................................................P2.01-010
Jiayuan Sun..............................................................P2.04-011 Karasaki Takahiro................ P1.07-017, P3.16-028, YI 01.11
Kadir Timor........................................... MA 14.13, P1.05-008
Jie Ma......................................................................... P3.01-018 Karaseva Nina A...................................................... P1.03-050
Kadiri Salma.....................P1.10-002, P3.10-005, P3.16-024
Jie Zhang.................................................................. JCSE 01.11 Karatas Aysun.......................................................... P3.01-088
Kadkhoda Haleh.......................................................P2.07-036
Jimbo Takeshi.........................................................P3.02-042 Karches Clara.............................................................P1.07-019
Kadokura Mitsutaka..............................P1.03-031, P3.16-008
Jiménez Fuentes Edgardo.......................................P1.17-008 Kariatsumari Kota.................................................... P2.16-004
Kadoya Koutaro........................................................ P1.03-006
Jin Cheng S............................................................... P1.12-002 Karimundackal George..................... P1.13-010, P3.02-036,
Kaga Kichizo.........................OA 04.02, P1.12-002, P1.17-010
Jin Chun..................................................P1.02-062, P1.17-018 ....................................................................................P3.02-081
Kagamu Hiroshi.........................................................OA 13.08
Jin Faguang......................................... P3.01-087, P3.03-006 Karlsson Mikael...........................................................MA 05.13
Kagawa Yusuke........................................................ P2.07-028
Jin Jian-Yue................................................................MA 13.06 Karnam Sameer.......................................................P3.13-003
Kage Hidenori...........................................................P2.03-046
Jin Meiling................................................................. P1.01-037 Karpe Ashay P..........................................................P2.03-027
Kagyo Junko..............................................................P3.10-007
Jin Xiance........................ P2.01-071, P2.14-008, P2.14-018 Karsan Aly............................................... OA 07.07, P3.01-019
Kahatt Carmen..................................... MA 01.05, P2.04-008
Jin Yasuto.............................................P1.03-010, P2.03-032 Karsch-Bluman Adi................................................P3.02-082
Kai Yuichiro............................................................... P1.02-002
Jin Ying................................ MA 01.11, P1.03-007, P3.01-027 Karube Yoko.........................................P1.02-018, P3.02-064
Kaiho Daisuke.............................................................OA 04.05
Jinawat Artit............................................................P3.03-020 Karwoski Ronald........................................................P2.13-014
Kaiho Taisuke....................................... P1.16-008, P2.12-006
Jingu Keiichi...............................................................MA 09.06 Kasahara Kazuo......................................................... OA 05.02
Kaira Kyoichi....................P1.15-002, P2.01-027, P2.02-026,
Jirapatnakul Artit.......... P2.16-022, P2.16-023, P2.16-024, ................................................................P2.15-005, P2.15-016 Kasahara Norimitsu...... P2.01-027, P2.02-026, P2.15-016
.................................................................. P3.13-035, PL 01.02 Kasai Takashi....................................... P1.15-002, P2.03-008
Kais-Prial Thomas...................................................... OA 14.03
Jiwnani Sabita..................................P3.02-036, P3.02-081 Kasan Peter..............................................................P2.03-056
Kaiser Larry R......................................P2.13-005, P2.13-006
Jobim De Azevedo Sergio...................................... P1.01-063 Kaseda Kaoru..................................... P1.05-005, P1.05-009,
Kaji Mitsuhito............................................................. P1.12-002
Jochum Wolfram......................................................P2.07-012 ..............................................P1.05-017, P1.17-017, P3.13-031
Kajiwara Naohiro.................ES 05.03, P1.01-041, P1.16-010,
Jodai Takayuki..........................................................P3.15-009 ........................................P2.02-009, P2.05-012, P3.02-012 Kashima Jumpei.......................................................P2.07-031
Joerger Markus.......................................................P3.02-053 Kakihana Masatoshi........P1.01-041, P1.16-010, P2.02-009, Kasiri Sahba............................................................. P3.02-073
Johansson Mattias..................................................P2.06-001 ...............................................................P2.05-012, P3.02-012 Kassapian Marie....................................................... MA 06.06
Joharatnam Nalinie.................................................P2.07-049 Kakimi Kazuhiro.........................................................P1.07-017 Kasymjanova Goulnar.......................P2.02-040, P3.02-055
John Thadathilankal Jess..................................... P1.06-001 Kakinuma Ryutaro.................................................... MS 24.01 Katagiri Masato....................................................... P2.03-002
John Thomas......................MA 19.03, OA 14.06, P2.02-039, Kakizaki Yumiko.........................................................MA 05.08 Kataoka Daisuke....................................................... P3.16-008
...................................................................................P3.02-038 Kaku Ryosuke...................P1.02-030, P1.03-037, P3.16-048 Kataoka Kazuhiko...................................P1.16-023, P1.16-024
Johnson Adrienne...................................................P2.02-052 Kakuhara Hisao..........................................................MA 09.06 Kataoka Kensuke..............P2.01-037, P2.07-053, P3.12-001
Johnson Ann D...........................................................OA 14.06 Kakumu Tomohiko....................................................P3.03-013 Kataoka Masaaki..................................................... P2.05-009
Johnson Bruce E....................................................P3.03-007 Kakutani Takuya.......................................................P2.07-022 Kataoka Yoko.................P1.02-030, P3.02-003, P3.16-048
Johnson Douglas F..................................................P2.13-023 Kalatardi Shana........................................................P3.07-005 Kataoka Yuki.......................................P1.07-004, P2.07-024
Johnson Elizabeth..................................................... OA 06.07 Kalemkerian Gregory.................................................. MA 11.10 Katayama Kumiko.................................................... P2.01-065
Johnson Eric F............................................................ MA 17.07 Kalenja Astrit............................................................ P2.01-059 Katayama Yuya....................................................... P2.09-008
Johnson Margaret..................................................... OA 06.07 Kalkat Mainder.................. MA 08.09, P1.10-002, P3.16-024 Katdare Rahul................ P3.03-016, P3.03-026, P3.05-002
Johnson Matthew................................................... MA 08.03 Kallinteris Nikoletta L...........................MA 10.05, P2.02-030 Kate Shruti................................................................. P1.03-021
Johnson Melissa L........P1.04-008, P2.07-036, P2.07-058 Kalos Michael D.......................................................P3.07-006 Kato Daishiro.....................P1.02-022, P1.17-009, P2.01-067
Johnson Thomas G...........................P1.09-004, P1.09-005 Kamata Toshiko..........................................................OA 04.05 Kato Motoyasu.................P1.02-065, P2.02-012, P3.02-024
Johnston Michael...................................... MA 20.11, OA 15.01 Kameda Koji.......................................... MA 15.09, P3.13-019 Kato Ryoji...................................................................P2.07-021
Jones David......... MA 13.14, MA 15.09, OA 03.03, OA 10.03, Kamel-Reid Suzanne............................................... P3.01-019 Kato Shunsuke......................................................... P1.03-006
............................................P1.13-003, P2.05-021, P3.13-019 Kato Taketo............................................P1.08-002, P1.17-004
Kamer Iris..................................................................P3.07-010
Jones Greg................................................................P3.02-014 Kato Tatsuya..................... OA 04.02, P1.12-002, P1.12-003,
Kamikonya Norihiko.................................................. P1.14-005
Jones Philippa......................................................... WS 03.08 ......................................................................................P1.17-010
Kamimura Go........................................................... P2.16-004
Jongco Robert.......................................................... P2.16-001 Kato Terufumi.................GR 02.06, ISS 06.02, ISS 06.05,
Kamiyoshihara Mitsuhiro......................P1.02-031, P1.16-014,
Jonker Derek..............................................................OA 14.02 ............................................................... P2.16-009, P3.16-029 ............................................... MA 19.01, OA 10.01, P2.15-004,
Joo Min Young..........................................................P3.01-043 ..............................................................P3.01-072, P3.04-002
Kamma Hiroshi.........................................................P1.02-033
Jordan Karin..............................................................MA 08.02 Kato Toshio................................................................P3.03-013
Kammler Roswitha................................................... MA 06.06
Jornet Nuria...............................................................P3.14-017 Kato Yasuhiro.......................................................... P2.07-031
Kamsu-Kom Nyam.....................................................MA 12.02
Joseph Ajith M...........................................................P1.01-015 Katsui Kuniaki.............................................................MA 09.06
Kan Chan Siang........................................................ P1.05-007
Joseph Richard.......................................................... OA 06.07 Katsumata Shinya......................................................OA 16.07
Kan Tsunehiko............................................................MA 09.06
Joseph-Pietras Debprah..........................................P1.15-001 Katsura Masakazu...............................P1.07-002, P3.16-003
Kan Zhengyan............................................................P1.01-016
Joshi Alaknanda..................................................... P2.04-005 Kaufman Andrew J....................................................MA 18.07
Kanai Kuninobu.......................................MA 19.01, P2.07-035
Joshi Amit......................... P1.01-021, P1.01-023, P1.01-024, Kaufman Jacob M....................................................P2.02-067
Kanai Makiko..............................................................P2.07-013
.......................................... P1.03-021, P2.01-051, P2.03-027, Kaur Jyotdeep............................................................MA 03.02
Kanai Osamu............................................................P2.07-013
............................................................... P3.01-076, P3.03-015 Kaur Manmeet........................................................... P1.16-006
Kanai Yoshihiko...................................... OA 18.07, P3.02-089
Joshi Marybeth........................................ MA 13.02, MA 19.09 Kaurah Pardeep....................................................... P2.01-032
Kanamori Koichiro.............................. P2.02-012, P3.02-024
Joshi Subodh............................................................P2.13-023 Kaushal Rajiv..................... P1.01-021, P2.01-051, P3.03-015
Kanazawa Kenya...................................................... P1.15-002
Joshua Thomas V........................................................OA 11.03 Kawa Yoshitaka.........................................................P1.03-027
Kanda Shintaro.............. MA 16.04, P2.03-036, P2.03-048,
Jotte Robert...............................................................P1.01-051 Kawabe Joji...............................................................P3.16-032
...............................................................P2.07-011, P3.02-041
Jotte Robert M..................................... P2.01-004, P2.01-013 Kawada Ichiro.....................................P2.03-012, P3.02-084
Kaneda Hiroyasu..............P1.07-010, P2.07-021, P3.01-072
Joung Eun Kyo....................................................... P3.08-003 Kawada Manabu....................................................... P3.15-001
Kaneko Yoshiko.........................................................P1.07-044
Jovanovic Dragana................................................ P3.05-005 Kawago Mitsumasa.......... P1.03-033, P2.16-010, P3.13-012
Kaneko Yuichiro......................................................... OA 05.03
Jove Maria................................................................P2.07-044 Kawaguchi Koji............. P1.08-002, P1.17-004, P3.09-006,
Kanemaru Ryota................................. P2.02-012, P3.02-024
Jovelet Cecile........................................... MA 11.01, P1.03-013 .................................................................................... P3.16-010
Kanematsu Sotaro...................................................P2.02-063
Ju Sang Kim.............................................................. P1.06-015 Kawaguchi Tomoya....... MS 02.02, P1.06-014, P2.03-008
Kanemori Koichiro................................................... P1.02-065
Ju Young Seok............................................................MA 06.12 Kawaguchi Yo...................P1.02-030, P1.03-037, P3.16-048
Kanesvaran Ravindran.......................... OA 09.07, P3.01-017
Juan Li...................................................................... P1.02-042 Kawaguchi Yohei......................................................P2.03-019
Kang Chang Hyun.............MA 06.04, MA 16.15, P2.02-059,
Juan Vidal Oscar...................................................... P3.01-071 ......................P3.09-008, P3.16-013, P3.16-022, P3.16-026 Kawai Haruyuki........................................................... OA 12.03
Juan Óscar.......MA 07.03, MA 15.01, P1.01-040, P2.01-031 Kang Eun Joo............................................................. P1.15-012 Kawai Koji..................................................................P2.17-004
Juarez-Garcia Ariadna...........................MA 18.14, P1.06-012 Kang Hye-Rin..........................................................P2.13-004 Kawai Yasutaka.......................................................P2.01-005
Juergens Rosalyn J............................OA 17.03, P2.07-029 Kang Jin................................................................... P1.01-009 Kawakami Yutaka......................................................MA 05.04
Juergens* Rosalyn A................................................. MA 10.01 Kang Jin-Hyoung............OA 05.03, P1.01-070, P2.03-022, Kawakita Naoya........................................................P3.13-007
Jun Ye Kyeong........................................................P1.05-020 ..............................................................P3.01-050, P3.08-003 Kawamoto Hironori.................................................P2.03-033
Jung Eward.............................................................. P3.14-008 Kang Jingjing............................................................ P1.08-007 Kawamoto Nobutaka.................................................P1.16-026
Jung Hye Won.........................................MA 11.09, P3.01-028 Kang Kyu Hyuck..........................................................MA 06.12 Kawamura Masafumi................................................SH 01.02
Jung Inha.................................................................. P2.10-004 Kang Kyung Ho........................................................P2.01-035 Kawamura Tomohiro....... MA 16.08, P1.02-068, P1.17-002,
Jung Ki Hwan............................................................ P1.13-006 Kang Shin Myung..................................................... P3.05-010 ................................................................. P1.17-013, P3.16-050
Jung Manhong..........................................................P3.01-033 Kang Xiaoyan...........................................................P1.07-029 Kawamura Tomoyuki.......................... P2.17-004, P3.16-039
Jung Sung Hwan..................................................... P3.05-010 Kang Xiaozheng...............................JCSE 01.20, OA 04.03, Kawana Sachiko......................................................P2.07-004
Jung Yoo Jin........................................MA 06.04, P2.02-059 ........................................................... P3.05-003, P3.16-053 Kawano Osamu.................... MA 16.10, P1.17-005, P2.17-001
Jungraithmayr Wolfgang......................P1.02-015, P1.17-016, Kanter Lena................................................................P1.01-074 Kawano Yuko...........................................................P1.08-006
...................................................................................P2.02-036 Kanwal Madiha........................................................P1.02-040 Kawasaki Norihito....................................................P2.03-007
Juricic Josko............................................................. P1.16-004 Kawashima Jun.......................................................P2.03-043
Kawashima Yosuke............................P2.03-021, P2.07-004 Kim Hoon-Gu............................................................. OA 08.07 Kinoshita Fumihiko...........OA 13.06, P1.07-014, P2.09-005,
Kawatani Natsuko............................... P1.05-006, P2.16-009 Kim Hwan..................................................................P3.03-021 ....................................................................................P3.16-033
Kaya Handan............................................................ P1.03-040 Kim Hye Ryun........................MA 11.04, MA 11.09, MA 12.01, Kinoshita Ichiro........................................................ P2.03-010
Kaya Serap............................................................... P1.03-040 ...............................................................P3.01-028, P3.03-021 Kinoshita Mari...........................................................P2.02-051
Kayata Hiroyuki.......................................................... P3.16-011 Kim Hye-Seon.......................................................... P3.16-016 Kinoshita Tomonari................................................. MA 05.04
Kazakov Jordan......................................................... MA 20.01 Kim Hyejung............................................MA 11.09, P3.01-028 Kinoshita Toshifumi.................................................. P1.14-002
Kazama Akio............................................................. P1.05-017 Kim Hyeong Ryul............P1.16-020, P2.01-061, P3.16-014 Kipp Benjamin............................................................ OA 03.06
Kazdal Daniel............................................................P3.02-032 Kim Hyerim..............................................MA 11.09, P3.01-028 Kiribayashi Takaharu...............................................P1.03-031
Kazerooni Ella...........................................................WS 01.35 Kim Hyojin.........................P1.02-027, P1.02-029, P3.02-016 Kirita Keisuke............................................................. P3.14-001
Kearns Dianne......................................................... P3.09-002 Kim Hyuck..................................................................P3.16-016 Kirkpatrick Vincent................................................... P1.16-003
Keef Jennifer........................................ P1.03-022, P1.04-012 Kim Hyun K................................................................. P1.16-018 Kirschner Michaela B.... MA 19.06, P1.09-006, P1.09-008,
Keegan Niamh M........................................................ MA 04.10 Kim Hyun Koo....................P1.16-012, P1.16-021, P3.02-010, ............................................................P1.09-009, P3.09-010
Kefyalew Sylvia..........................................................MA 08.07 ....................................................................................P3.16-020 Kis Lorand........................................... P2.02-042, P2.02-043
Kehl Kenneth...............................................................MA 18.08 Kim Hyung Woo....................................................... P2.05-014 Kishi Kazuma...................P1.03-031, P3.01-055, P3.02-033,
Keiko Ohgino............................................................P3.02-084 Kim Hyung-Jin......................................................... P1.02-003 ...................................................................................P3.02-048
Kelly Karen............................. MA 02.10, MA 02.11, MA 18.06, Kim Il-Jin......................................................................OA 18.02 Kishima Kyoko............................................................P1.02-017
..........................MS 17.04, OA 14.07, P1.03-026, P3.01-046 Kim In Ae........................................... P2.03-030, P3.01-034 Kishimoto Junji............ P1.08-006, P3.04-002, P3.04-004
Kelly Ronan J.............................................................MA 09.08 Kim In-Ho................................................................. P3.08-003 Kishimoto Takumi...............................P1.02-052, P2.09-008
Kelly William J..........................................................P2.07-050 Kim James...............................................................P3.02-073 Kita Yusuke................................................................ P2.01-018
Kelso Paul................................................................... P1.14-018 Kim Jee Hung........................................MA 11.09, P3.01-028 Kitahara Akihiko................ P1.16-025, P3.16-002, P3.16-051
Kem Marina...............................................................P1.07-033 Kim Jhingook.................MS 23.05, P1.08-004, P2.02-001, Kitamura Shoji..........................................................P1.03-037
Kempen Leon V......................................................... P3.01-019 ...........................................P3.01-082, P3.02-011, P3.04-011, Kitamura Yoshitaka.................................................P1.03-036
Kendrick Denise................ MA 18.04, OA 06.08, P3.06-009 ..............................................................P3.05-012, P3.08-006 Kitano Kentaro....................P1.07-017, P1.13-002, P3.16-028
Kenmotsu Hirotsugu........................P1.03-004, P3.04-002 Kim Jihang................................................................ P2.03-018 Kitazono Satoru......................................................... MA 16.04
Kennedy John............................................................ MA 04.10 Kim Jihye.....................................................................OA 07.06 Kitchen Simon........................................ P3.05-001, WS 01.18
Kent Michael S.........................................................P3.03-025 Kim Jin Hee................................................................OA 01.04 Kitzing Thomas...........................................................MA 19.03
Kerjouan Mallorie........................................................OA 03.01 Kim Jin Woo....................................... P1.03-025, P1.03-030 Kiura Katsuyuki...MA 07.11, OA 05.03, OA 05.08, OA 12.03,
Kern Izidor............................................................... P2.09-004 Kim Jisung............................................................... P3.09-008 ...........................................P1.03-038, P2.01-034, P3.01-071
Kern Jens................................................................. P3.01-088 Kim Jong Seok......................................................... P2.01-040 Klaisuban Wipawi....................................................P3.03-020
Kern Ryan M...............................................................P1.07-016 Kim Joo-Hang..................................... P1.01-070, P1.04-001 Klebe Sonja....................P1.09-003, P1.09-006, P1.09-012,
Kernstine Kemp..........................................................PL 02.07 Kim Ju Sang........................................P2.02-029, P2.05-014 ...................................................................................P3.02-078
Kerr Amy.......................P1.10-002, P3.10-005, P3.16-024 Kim Ju Y.......................................................................MA 13.03 Kleiner David.............................................................P1.02-063
Kerr Keith M........................ MA 06.06, PC 03.04, PL 03.03 Kim Jun Sang............................................................. P1.14-013 Klempner Samuel J...................................................MA 12.03
Kerstein David........................................OA 05.05, P1.01-001, Kim Jung Soo............................................................ P2.01-016 Klepetko Walter................... MA 19.07, OA 16.06, P2.09-004
................................................................P1.01-004, P1.01-005 Kim Jung Sun...........................................................P1.15-012 Klikovits Thomas...................................OA 16.06, P2.09-004
Kesarwala Aparna H...............................................P2.03-052 Kim Junghoon.........................................................P2.03-018 Klingbiel Dirk.............................................................P2.07-012
Keshavjee Shaf.................MA 16.03, P1.13-004, P3.09-007 Kim Ki Hwan.............................................................P2.03-022 Kluger Harriet M......................................................P2.07-062
Kessinger Margaret A...............................................P2.15-013 Kim Kwhanmien...........................................................MA 13.12 Knepley Christina.........................................................OA 17.08
Ketcham Marsha........................................................P2.15-013 Kim Mi Soon............................................................. P2.01-064 Knepper Todd C..........................................................MA 12.05
Ketzler-Henkel Sandra........................................... P3.01-088 Kim Mi Young...........................................................P2.01-061 Knight Simon R....................................P2.02-039, P3.16-052
Khadeir Ramsay..........................................................MA 19.05 Kim Mi-Hyun.............................................................P3.13-002 Knightly Eileen......................................................... P3.10-002
Khadka Dipendra..................................................... P1.02-003 Kim Michelle L......................................................... P3.16-052 Knoblauch Roland E................................................P2.07-058
Khakwani Aamir.......................................................P1.05-010 Kim Ruru..................................................MA 11.09, P3.01-028 Knowles Ross.......................................................... P2.16-002
Khalil Azza Ahmed.............P3.13-014, P3.13-015, P3.13-016 Kim Sang-We.......................OA 05.03, OA 05.05, OA 05.07, Knutson Keith......................................... MA 05.01, P1.07-039
Khalimon Alexander...................................................P1.16-011 ............................OA 09.03, OA 10.01, P1.01-001, P1.01-070, Ko Jen-Chung........................................................... P3.01-016
Khan Javed..........................................P1.02-063, P2.03-052 .........................................P1.15-004, P3.01-005, P3.01-050 Ko Jen-Sheng...........................................................P3.12-002
Khan Saad..................................................................P1.07-031 Kim Seok...................................................................P2.03-024 Ko Jeong Min........................................................... P1.05-020
Khan Sahara................................................................ MA 18.01 Kim Seok-Young.......................................................P3.03-021 Ko Nai-Ying...........................................P2.10-001, P2.10-002
Khan Shaheen............................................................P1.07-031 Kim Seung Joon..............P1.01-076, P1.03-025, P1.06-015, Ko Ryo.......................................................................P3.02-024
............................................................. P2.02-001, P3.01-057 Ko Stephen................................................................. OA 06.07
Khan Zanobia............................................................P1.07-022
Kim Shin Young......................................................... P1.12-001 Ko Yoon Ho...............................................................P1.06-015
Khandhar Sandeep J......... MA 20.01, MA 20.02, MA 20.03
Kim Sub....................................................................... P1.14-013 Ko Yu Mi...................................................................... P1.12-001
Khanna Anchit........................................................ P3.02-054
Kim Sung Kyoung...........P1.03-025, P1.03-030, P1.12-001 Koba Taro.................................................................. P1.03-049
Kherrouche Zoulika...................................................MA 07.06
Kim Sungeun............................................................. P1.13-006 Kobayashi Akiko...................................P1.03-010, P2.03-032
Kho Sze Shyang................................P2.12-001, P2.12-002
Kim Tae Hoon............................................................P1.02-024 Kobayashi Hiroko.....................................................P2.02-057
Khorrami Mohammadhahi..........................................MA 17.11
Kim Tae Jung............................................................ ES 02.04 Kobayashi Hiroshi.....................................................P2.01-010
Khorshid Mohsen......................................................P1.01-031
Kim Tae Min............................................................. P2.04-005 Kobayashi Isao.....................................P1.02-065, P2.02-012
Khunger Monica..........................................................MA 13.03
Kim Wan Seop.......................................................... P3.01-034 Kobayashi Keisuke....................................................P3.16-039
Khuri Fadlo R............................................................P3.13-027
Kim Yeol Hong............................................................P3.13-017 Kobayashi Kleber......................................................P3.03-019
Ki-Up Kim.................................................................P2.01-008
Kim Yeon Sil............................................................ P3.14-009 Kobayashi Kunihiko.........MS 14.03, P2.03-010, P2.03-021
Kida Hiroshi..........................................P1.03-027, P2.07-009
Kim Yong-Hee........................................P1.16-020, P3.16-014 Kobayashi Masashi..................................................P3.02-035
Kida Hirotaka............................................................P2.02-072
Kim Youjin............................................. OA 03.04, P2.07-025, Kobayashi Mitsuru.....................................................MA 09.06
Kidokoro Yoshiteru......... P1.02-060, P1.02-061, P1.13-008 ..............................................................P3.01-023, P3.01-029
Kiedrowski Leslie........................................................MA 15.02 Kobayashi Naohiro........P2.02-025, P2.17-004, P3.16-039
Kim Youn Seup.........................................................P2.12-005 Kobayashi Ryoji....................................P2.05-017, P3.02-039
Kiefer Gauri J.............................................................. OA 14.07 Kim Young Dae....................................... P1.16-001, P2.16-011,
Kiertsman Flavia...................................................... P2.04-013 Kobayashi Satoru................................P1.02-018, P3.02-064
...............................................................P3.13-002, P3.16-006 Kobayashi Susumu S..............................................P3.03-025
Kijima Takashi..........................................MA 19.01, P1.03-047, Kim Young H........................................ P1.03-005, P2.01-021,
.................P1.03-049, P2.03-008, P2.07-009, P2.09-005a Kobayashi Yoichi........................................................MA 05.08
...........................................P2.07-013, P2.07-017, P2.07-024
Kikuchi Shinji..................P2.02-025, P2.17-004, P3.16-039 Kobayashi Yoshihisa.......................... P3.02-059, P3.16-049
Kim Young Hak................................... P2.03-055, P2.07-003
Kikuchi Shinya.......................................................... P2.05-010 Kobold Sebastian.......................................................P1.07-019
Kim Young Il...............................................................P1.14-013
Kikuchi Toshiaki.................................. P2.03-015, P2.07-007 Kocakaya Derya........................................................P3.15-007
Kim Young Kyoon..................................P1.01-076, P3.01-057
Kikuchi Yasuhiro..................................................... P2.05-005 Kocon Piotr..................................................................OA 04.01
Kim Young T........................................ MA 06.04, P2.02-059,
Kikuyama Ayano.......................................................P1.02-032 ......................................... P3.09-008, P3.16-013, P3.16-022, Kocoń Piotr................................................................P2.16-027
Kim Anthony..............................................................OA 04.09 ............................................................... P3.16-026, PC 01.04 Koczywas Marianna................................................P2.03-043
Kim Arum.................................................................. P1.03-034 Kim Young Tae............................................................MA 06.12 Koda Yuichi............................................................ P2.09-005a
Kim Bong-Seog..................................... OA 08.07, P1.01-038 Kim Young-Chul............P1.01-014, P2.03-024, P2.03-058, Kodama Ken................................................................MA 17.04
Kim Changhwan........................................................ P2.01-016 ................................................................P2.14-017, P3.01-050 Koebel Martin...........................................................P2.02-068
Kim Cheol Hyeon..................................................... P3.01-050 Kim Yu Jin................................................................. P3.05-010 Koegelenberg Coenie...............................................P1.06-001
Kim Chi Hong........................................ P1.05-020, P1.12-001 Kim Yun Ho...........................................MA 06.04, P2.02-059 Koeller Diane R..........................................................OA 06.02
Kim Chul...............................................P1.02-063, P2.03-052 Kim Yun-Jung......................................P1.02-071, P2.02-055 Koenig Michael............................................................OA 18.02
Kim Dae Joon.............................................................P3.16-019 Kimura Kenji...........................................MA 16.08, P1.17-002 Koenig Michael J....................................................P2.02-067
Kim Dae Won............................................................ P2.07-037 Kimura Shingo......................................P2.15-011, P3.02-009 Koenig Thomas.........................................................P3.13-033
Kim Dai-Jin................................................................ P1.06-015 Kimura Shinya..................P1.01-028, P2.03-009, P2.03-011 Koeppen Hartmut......................................................MA 05.09
Kim Doh Hyung.........................................................P2.12-005 Kimura Takuya..........................................................P3.16-032 Koezuka Satoshi................................... MS 07.04, P3.16-004
Kim Dong Kwan.....................................P1.16-020, P3.16-014 Kimura Tatsuo....................................P1.06-014, P2.03-008 Koga Takamasa.........................................................P1.15-014
Kim Dong-Gyu........................................................... P2.01-016 Kimura Tomoki.................MS 24.04, P1.08-006, P2.01-037, Koger Renate............................................................P2.03-025
Kim Dong-Wan..................JCSE 01.27, MA 07.01, OA 05.05, ..............................................................P2.07-053, P3.12-001 Koguchi Nobuo......................................................... P2.01-065
............................OA 05.07, OA 14.01, P1.01-001, P1.01-004, Kimura Yuichiro.......................................................P2.07-004 Kogure Yoshihito..................................................... P2.03-008
........................P1.01-012, P1.01-016, P3.01-005, P3.01-050 Kindler Hedy Lee..................................MS 08.06, OA 02.01 Koh Eitetsu............................................OA 04.05, P2.09-006
Kim Edward.......................................... P2.01-004, P2.01-013 Kinehara Yuhei........................................................P3.02-023 Koh Jiae.....................................................................P3.03-012
Kim Edward S.........................................OA 05.05, P1.01-001 King Bridget...............................................................P2.13-023 Koh Mariko..................................................................P3.01-017
Kim Eun Young........................................................P1.03-034 King Bronwyn...........................................................MS 22.04 Koh Pek K..................................................................... MA 17.14
Kim Hee Joung...................................P2.03-030, P3.01-034 King Jennifer C............... MA 08.06, MS 27.02, P1.01-036, Koh Tina..................................................OA 09.07, P2.16-021
Kim Hee Kyung................. OA 03.04, P2.07-025, P3.01-023 ....................................................................................P1.11-003 Koh Wee Yao.................... P1.08-001, P1.15-017, P2.14-002
Kim Hojoong...........................................ES 07.03, P3.04-011 King Melissa.............................................................. P1.03-014 Koh Yasuhiro...................................... P2.03-045, P2.07-035
Kim Hong Kwan............ P1.08-004, P3.01-082, P3.02-011, Kinio Anna E..............................................................P3.16-007 Koh Young Wha.................................P1.02-021, P2.02-060
.......................................P3.04-011, P3.05-012, P3.08-006 Kohashi Kenichi........................................................... OA 13.06
Kohler Jens..............................................................P3.02-066 Krimsky William S...................................................... MA 20.01 Kwon Kunyoung.......................................................P2.02-036
Kohno Mikihiro..........................................................OA 02.06 Kris Mark G..........................OA 03.03, OA 05.04, OA 14.05, Kwon Nak-Jung........................................................ MA 06.04
Kohno Nobuoki.........................................................P3.02-009 .............................................................P1.03-028, P3.03-007 Kyheng Maeva............................................................MA 07.06
Kohno Tadasu...........................................................P3.02-048 Krishnasamy Mei...................................................... MA 04.06 Kyung Sun Young.................................................... P3.05-010
Kohno Takashi................. ES 04.01, P3.02-035, P3.02-041, Kristiansen Charlotte.................................................OA 01.02 Kıral Hakan................................................................ P1.03-016
................................................................................... P3.03-010 Krivokuca Ana...........................................................P1.02-007
Kohtz Patrick...........................................................P3.07-005 Krnic Dragan............................................................. P1.16-004
Koike Terumoto................P1.16-025, P3.16-002, P3.16-051 Kron Tomas.....MA 13.07, P1.14-017, P2.05-006, P2.14-001
L
Koinuma Yoshika............P1.02-065, P2.02-012, P3.02-024 Krouse Michael........................................................P2.02-002
Koivunen Jussi.................................. P2.03-035, P2.03-037 Krupnova Evelina.....................................................P3.02-075
La Fleur Linnea.................MA 05.13, MA 06.01, P2.02-015
Koizumi Hirotaka.......................................................P3.15-002 Kryskow Mark A.....................................................P2.16-002
La Perle Krista.........................................................P2.02-065
Kojima Hideaki................ P2.15-008, P3.05-006, P3.16-011 Krystal Gerry...............................................................MA 05.12
Laba Joanna M............................................................OA 16.01
Kojima Takahiro.........................................................P2.17-004 Krämer Nicole...........................................................P3.01-043
Labbé Catherine..............P2.05-019, P3.01-080, P3.01-081
Kok Peey-Sei........................................................... P2.03-044 Krügel Rainer..............................................................OA 10.06
Laberge Francis...........................................................OA 15.01
Kokici Fahri............................................................... P2.01-059 Kshivets Oleg............................................................ P3.16-012
Labreuche Julien........................................................MA 03.10
Kokiqi Fahri............................................................... P3.16-005 Ku Bo Mi.............................................P2.01-064, P3.03-012
Labrune Sylvie............................................................ OA 16.03
Kolbanov Konstantin................................................. P3.16-021 Kubisa Bartosz...........................................................MA 14.01
Labuc Pippa.............................................................. WS 03.09
Kolbaş Ilker................................................................ P1.03-016 Kubo Emi..................................................................P1.02-009
Lacerda Landry Lara........................P2.04-014, P2.07-061a
Kolek Vitezslav...................................P2.03-023, P2.09-004 Kubo Yujiro........................................... P1.16-023, P1.16-024
Lacroix Ludovic....................................... MA 11.01, P1.03-013
Kollmannsberger Christian.................. MA 10.01, P2.01-032 Kubota Ichiro.............................................................. P1.15-014
Lacroix-Poisson Frederic.....................................P1.03-020
Komaki Ritsuko.....................MA 01.10, MA 13.08, OA 08.05, Kubota Masaru........................................................ P2.03-002
.....................................................................................PC 02.01 Ladanyi Marc...................... MTE 21.02, OA 10.05, OA 14.05
Kubota Reiko N............................................................P1.17-010
Komarnitsky Philip........................... P1.04-006, P1.04-007 Ladjemi Maha Zohra............................................... P3.15-004
Kubota Seiji.................................................................MA 09.06
Komatsu Hiroaki..................................P2.16-003, P3.16-032 Lafitte Jean-Jacques................................................. OA 16.03
Kubouchi Yasuaki........... P1.02-060, P1.02-061, P1.13-008
Komatsu Takahiro....................................................P3.02-042 Lagerwaard Frank J............................... MA 17.10, P2.14-019
Kucharczyk Tomasz................................................P3.02-045
Komiya Kazutoshi.........P1.08-006, P2.03-009, P2.03-011 Lago Leonardo......................................................... P1.06-020
Kucma Martin...........................................................P2.03-056
Komiya Takefumi......................................................P2.07-019 Lahmar Jihene....................MA 05.03, MA 10.11, P2.07-005,
Kudo Keita.................................................................. P1.07-010
...................................................................................P2.07-060
Komiyama Takafumi............................. MA 09.03, MS 24.04 Kudo Kenichiro................................... P1.03-038, P2.01-034
Lai Chiung-Ru...........................................................P1.01-066
Komorowski Michal.................................................P3.02-049 Kudo Yujin................................................................. P2.05-012
Lai Chun-Liang......................................................... P2.07-027
Komuta Kiyoshi.................................... P1.03-047, P1.03-049 Kudoh Keita................................................................P2.07-021
Lai Gillianne............................................................... OA 09.07
Konaka Chimori.................................... P2.03-007, P2.16-012 Kudoh Shinzoh........................................................ P2.03-008
Lai Jennifer................................................................ MA 10.05
Kondo Haruhiko........................................................P1.02-033 Kugler Kelly...............................................................P3.03-007
Lai Sunny...................................................................P1.02-039
Kondo Kazuya...........................................................P3.13-007 Kuhlmann Alexander........................... OA 15.02, P3.07-013
Laine Aaron............................................................P3.08-004
Kondo Masashi..........................................................P3.03-013 Kukulj Suzana............................................................P3.01-059
Laird Barry.............................................................. P3.04-006
Kondo Nobuyuki........... P2.09-007, P3.09-004, P3.09-009 Kumanogoh Atsushi...... P1.03-047, P2.07-009, P3.02-023
Laird James............................................................. P3.15-008
Kondo Rie............................................. P2.03-015, P2.07-007 Kumar Rajiv.....................P1.01-023, P1.03-029, P2.07-049,
Laird Peter................................................................P3.02-008
Kondo Shigeto.......................................................... P3.01-064 ...........................................P2.14-005, P3.01-076, P3.12-003
Lakers Frances................................... P3.03-016, P3.03-026
Kondoh Yasuhiro................................P2.01-037, P2.07-053, Kumarakulasinghe Nesaretnam B........................ P3.01-022
...............................................................P3.04-002, P3.12-001 Lakhani Nehal............................................................. OA 12.07
Kumazawa Jun.........................................................P3.01-035
Konduri Kartik...................................... P2.01-004, P2.01-013 Laktionov Konstantin K............................................ P1.01-056
Kumazawa Kentaro.................................................P3.02-042
Kong Feng-Ming (Spring)........................................ MA 13.06 Lala Aishe................................................................. P2.01-059
Kumbhaj Prashant................................................... P2.10-007
Kong Shengchun.....................................................P2.03-043 Lala Donika............................................................... P3.16-005
Kume Motohiko..........................................................P1.16-026
Kong Sunga.............................................................P1.06-003 Lalani Alshad S........................................................... MA 07.12
Kung Sonia H.Y...................................... MA 10.09, P2.02-038
Kongkarnka Sarawut................................................OA 04.08 Lam Chi Leung..........................................................P3.01-036
Kunihiro Yoshie..........................................................P3.13-013
Kongkham Paul..........................................................P3.14-013 Lam Kit S.....................................................................MA 15.08
Kunikane Hiroshi........................................................MS 20.03
Konishi Eiichi.............................................................P1.02-022 Lam Kwok Chi...........................................................P3.01-036
Kunitoh Hideo......................................... MS 11.01, P3.01-055
Konmun Jitprapa.........................................................OA 11.04 Lam Nguyen S..................................P3.02-020, P3.02-021
Kuno Kika.............................................P1.02-032, P2.06-003
Kono Satoko......................................... MA 04.09, P2.11-002 Lam Stephen..........................ES 07.04, MA 05.12, MA 14.11,
Kuo David...................................................................P3.01-036
............................MA 20.11, OA 07.07, OA 15.01, P1.04-003,
Kontic Milica...........................................................P3.05-005 Kuo Shuenn-Wen.....................................................P3.01-079 ....................... P2.02-017, P2.02-038, P2.13-011, P2.13-012,
Koo Hyun Jung......................................................... P2.01-061 Kuo Yu-Hsuan.......................................................... P2.07-027 .............................................................. P3.02-091, WS 02.09
Koo Ji Hae.................................................................P2.12-005 Kupis Wlodzimierz...............................P3.01-041, P3.02-049 Lam Sze Kwan...................................P2.02-058, P2.15-006
Kooski Mitra............................................................... P1.01-059 Kuraguchi Mari............................................................ MA 07.12 Lam Vincent K....................... MA 01.03, OA 07.02, OA 12.01
Kopciuk Karen..........................................................P1.06-005 Kurahayashi Shintaro............................................. P2.03-002 Lam Vivian...................................................................MA 05.12
Kopecka Joanna..................................................... P2.09-003 Kuraoka Masatsugu................................................ P1.02-052 Lam Wan L..............................MA 05.12, MA 10.09, MA 15.12,
Kornietskaya Anna L................................................ P1.01-056 Kurasawa Mitsue................................ P2.02-051, P2.07-006 ..........................MA 15.14, OA 07.07, P1.02-006, P1.02-050,
Korse Tiny................................................................. P1.09-008 Kurata Takayasu.....................MA 05.06, MA 17.06, OA 17.02 ...................P2.02-017, P2.02-022, P2.02-038, P3.02-090,
Korytowsky Beata................................. P1.01-051, P1.15-003 Kuribayashi Kozo.................................................P2.09-005a .............................................................. P3.02-091, P3.02-094
Kos Gábor................................................................ P2.04-008 Kurie Jonathan.............................................................OA 12.01 Lambe Mats..............................................................P1.06-002
Kosaka Takayuki......................................................P1.05-006 Kurihara Minoru....................................................... P2.03-010 Lambert Mickael...................................................... P2.07-023
Kose Fatih................................................................P3.08-001 Kurihara Yasuyuki................................................... P1.03-008 Lambert Peter............................................................P1.01-031
Kosibaty Zeinab......................................................P2.02-073 Kuriki Hiroshi..............................................................OA 05.08 Lambkin Helen......................................................... P1.09-007
Kosmacek Elizabeth..................................................P2.15-013 Kurimoto Ayako.......................................................P1.02-064 Lamblin Catherine...................................................P3.02-002
Kossatz Susanne..................................................... P3.15-008 Kuriyama Kengo.........................................................MS 24.04 Lambrecht Maarten................................P1.13-007, P3.14-011
Kostine Marie........................................................... P2.07-023 Kuriyama Shoji.........................................P1.17-017, P3.13-031 Lamlertthon Wisut................................................... P3.01-042
Kosuke Fujino..................... P1.12-002, P1.15-014, P1.16-002 Kuroda Ayumi...................................P2.09-007, P3.09-009 Lamy Regine.............................................................P2.07-030
Koubkova Leona.......................................................P2.03-023 Kuroda Koji................................................................P1.07-030 Landau David..............................................................MA 09.10
Kovacevic Tomi.......................................................P2.10-005 Kuroda Masahiko................................. P1.07-012, P3.07-003 Landi Lorenza.......................................MA 02.05, P1.01-015
Kow Ken-Siong..........................................................P3.15-014 Kurokawa Eiji...............................................................MA 17.04 Landman Yosef....................................................... P3.13-030
Kowalyzyn Ruben..................................................... P1.01-058 Kurono Yuri.............................................................. P2.01-065 Lang Elisabeth.............................................................MA 19.07
Kowanetz Marcin.................................... MA 05.09, OA 17.07 Kurosaki Takeshi.......................................................P2.16-026 Lang Joshua............................................................ P3.04-009
Koya Toshiyuki.........................................................P2.07-007 Kurose Koji........................................... P2.07-015, P2.07-018 Lange Maria...............................................OA 10.06, P1.15-011
Koyama Kenichi.......................................................P2.03-015 Kurppa Pinja............................................................... MA 06.01 Langenfeld John....................................................... P2.16-001
Koyama Nobuyuki................................................... P2.07-001 Kurtz David M............................................................. MA 13.01 Langer Corey J.................MTE 22.02, OA 05.05, OA 14.07,
Koyama Ryo.............................................................P3.02-024 Kusachi Shinya......................................................... P1.03-031 ............................. OA 17.01, OA 17.08, P1.01-001, P1.01-004,
Koyama Shohei...............P1.07-007, P2.07-009, P3.02-023 Kusel Jessica............................................................P3.16-035 ................. P1.01-005, P2.01-004, P2.01-013, P2.07-059
Koyauchi Takafumi..................................................P2.07-022 Kushitani Kei.................P1.02-002, P1.02-052, P2.09-008, Langer Mark................................................................MA 13.06
Koyi Hirsh.............................MA 05.13, MA 06.01, P1.01-074, ..................................................................................... P2.15-011 Langfort Renata...............P1.02-037, P2.16-017, P3.02-051
....................................................................................P2.02-015 Kushniruk Eugenia K................................................ P1.01-056 Lanman Richard........................................................P1.11-004
Kozono David.........................................MA 17.07, P3.04-003 Kusuhara Masatoshi.......................... P2.15-008, P3.05-006 Lanman Richard B.................OA 07.02, OA 09.01, OA 12.05,
Kozuka Hideyuki.....................................................P2.16-005 Kusuhara Seiichiro................................................. P2.03-002 .............................................................. P3.01-046, P3.01-060
Kozuki Toshiyuki....................................... MA 07.11, OA 12.03, Kusumi Yoshiaki................................... P2.02-057, P3.03-011 Lanuti Michael.............................................................OA 07.05
............................................................. P2.01-034, P2.05-009 Kusumoto Masahiko.....MTE 14.01, P1.03-008, P3.04-002 Lanzarotti Corinna.....................................................MA 08.02
Kozuma Yuka.....................OA 13.06, P1.07-002, P1.07-014, Kuwano Hiroyuki............P1.05-006, P1.16-007, P2.02-026 Laohathai Sira..........................................................P1.16-005
......................................... P2.09-005, P3.16-003, P3.16-033 Kuyama Shoichi............... OA 12.03, P1.03-038, P2.01-034 Laohavinij Sudsawat............................................... P3.01-042
Kołb-Sielecki Jarosław...........................................P3.02-045 Kuzdzal Jaroslaw................................. OA 04.01, SH 03.02 Lapadula Vittoria.................................................... P3.06-003
Kołodziejczyk Bartosz.............................................P2.16-027 Kuznetsov Teodor......................................................MA 02.06 Laperriere Normand.................................................P3.14-013
Kramchaninov Mikhail M......................................... P1.01-056 Kuźniar-Kamińska Barbara....................................P3.02-045 Lara Primo............................. MA 02.11, MS 07.03, OA 14.07
Kramkimel Norah..................................................... P2.07-023 Kużdżał Jarosław.....................................................P2.16-027 Larner James M......................................................... MA 17.07
Krapf Mirjam..............................................................P2.07-012 Kwang Diannita A.....................................................P3.01-053 Larose Tricia L........................................................P2.06-001
Krasnik Mark...................................... P2.12-003, P3.16-017 Kwang Xue-Lin...........................................................OA 09.07 Lasham Annette.................................P1.09-004, P1.09-005
Krawczyk Pawel...................................OA 08.03, P3.02-045 Kwiatkowski David J...............................................P3.03-007 Laskar Sarbani G..................................................... P2.14-005
Kreahling Jenny.......................................................P2.02-030 Kwint Margriet.................................... P2.14-020, P3.14-005 Laskin Janessa.................. MA 04.02, OA 10.01, P1.03-020,
Krebs Matthew G.................................. OA 14.06, P1.15-004 Kwon Deukoo...................P1.07-024, P1.07-025, P2.07-037 ................................................................P3.01-019, P3.01-062
Krejci Jana................................................................P2.03-023 Kwon Hyun Jung............P1.02-027, P1.02-029, P3.02-016 Lastilla Gaetano........................................................P2.17-002
Krenbek Dagmar......................................................P3.03-024 Kwon Ji Eun.............................................................P2.02-029 Lastiri Jose M..........................................................P2.03-039
Kriegsmann Mark....................................................P3.02-032 Kwon Kang-Beom................................................... P1.02-003 Laszlo Viktoria....................................... MA 19.07, P2.09-004
Latipova Dilorom H.................................................. P1.01-056 ......................................... P3.01-023, P3.01-029, P3.01-082, Li Jin....................................................... P1.07-005, P1.07-013
Latorre-Musoll Artur................................................P3.14-017 .....................P3.02-011, P3.03-012, P3.05-012, P3.08-006 Li Jun.......................................................OA 13.05, P2.02-013
Lau Anthea.................................................................MA 09.02 Lee Seung Hyeun.................................................. P2.03-020 Li Junling...... JCSE 01.11, MA 11.05, P2.01-025, P2.01-029,
Lau Chu Leuk.......................................................... P3.13-020 Lee Seung Sei..........................................................P2.03-022 ............................................................ P2.01-030, P2.01-033,
Lau Dawn P.................................................................OA 09.07 Lee Seung-Hoon..................................................... P1.02-003 ........................................P2.01-041, P2.03-004, P2.04-003,
Lau Kelvin....................................................................MA 19.05 Lee Seung-Sei......................................................... P2.10-004 ...............................................................P3.01-021, P3.04-007
Lau Rainbow W.H......................................................P3.16-015 Lee Shin Yup............................................................P2.02-056 Li Kai..............................P3.01-036, P3.01-084, P3.01-087,
Lau Sally C....................... P3.01-013, P3.01-015, P3.01-030 Lee Sinae................................................................... P1.13-006 ..............................................................P3.03-006, P3.03-017
Lau W H.....................................................................P3.01-001 Lee Su Jin.................................................................. P1.02-021 Li Kaile...................................................................... P3.14-008
Lau Yvonne Y........................................................... P2.04-013 Lee Su-Bin............................................................... P1.02-003 Li Kunwei........................... P2.16-013, P2.16-014, P3.13-028
Lauk Olivia................................................................ P3.09-010 Lee Sung Soo............................................................ P1.05-014 Li Lei.....................................MA 11.05, P1.01-034, P3.01-037
Laurence David........................................................ P3.01-062 Lee Sung Yong............... P1.13-006, P2.01-035, P3.01-050 Li Lequn....................................................................P3.02-008
Laurie Scott A........................ MA 10.01, OA 05.07, OA 17.03, Lee Sungsoo.............................................................P1.02-024 Li Lerong......................................................................OA 07.02
................................................................................... P2.01-032 Lee Victor..................................................................P3.01-036 Li Lihua...................................................................... P2.14-009
Lautenschlaeger Tim.................................................MA 13.06 Lee Won-Chul............................................................. OA 13.05 Li Lin..........................................................................P2.02-062
Law Adeline Y.Y........................................................P1.01-050 Lee Yong Seok.......................................................... P2.01-016 Li Lingyu......................................................................OA 18.08
Lawrence David....................................................... P2.01-043 Lee Young Seok........................................................P2.01-035 Li Mark.........................................................................OA 10.03
Lawrie Iain.................................................................. OA 02.05 Lee Yu-Sheng......................................... OA 15.08, P2.16-019 Li Min.......P1.01-037, P2.02-008, P3.01-052, P3.02-072
Layton Andrew J........................................................ MA 11.06 Lee Yun Gyoo...........................................................P2.03-022 Li Ming........................................................................ P1.02-016
Layton Deborah........................................................ P1.06-012 Lee Yun-Gyoo.........................................................P2.10-004 Li Mingbiao................................................................ P1.15-008
Le Anh T...................................................OA 12.01, P3.02-057 Leedy Scott............................................................... P2.02-011 Li Peng....................................................................... P3.01-061
Le Bruchec Yvan.......................................................MA 02.03 Lees Michael.............................................OA 11.01, P2.01-012 Li Qi-Wen.................................................................. P2.14-004
Le Ken........................................................................P3.14-002 Lefebvre Corentin........................................................ MA 10.11 Li Qiang............................ OA 16.04, P3.16-009, P3.16-037
Le Lisa.....................................................MA 09.02, P1.13-004 Lefresne Shilo.......................................P3.01-013, P3.01-030 Li Qiwen....................................................P1.14-010, P1.14-011
Le Moulec Sylvestre.................................................... MA 10.11 Lehman Margot...................................................................9941 Li Qiyu....................................................... MA 15.11, P2.07-012
Le Pechoux Cecile..........MA 09.12, P1.08-009, P2.01-038, Leiber Nathalie......................................................... P3.03-001 Li Quan Z....................................................................P1.07-031
...................................................................................P2.07-005 Leighl Natasha B................ ES 06.06, MA 19.03, MS 22.01, Li Shaolei....JCSE 01.22, OA 16.08, P1.14-004, P2.01-068
Le Xiaobing...............................................................P2.02-003 ........................... OA 05.05, OA 15.01, P1.01-001, P1.01-004, Li Shaomei................................................................. P1.01-047
Le Xiuning.............................................MA 12.06, P3.03-025 .......................................... P2.01-032, P2.01-055, P3.01-019, Li Sherry.....................................................................P1.01-016
Leal Ticiana A....................................MA 02.01, P3.04-009 .......................................... P3.01-062, P3.09-007, PL 04.04 Li Shuai................................................... OA 12.01, P3.02-066
Lebargy François........................................................ OA 16.03 Leisibach Priska..........................................................P1.17-016 Li Tianhong........................................... MA 15.08, P1.07-013
Lecanda Fernando.................................................. P3.07-007 Lele Shashikant...........................................................MA 13.08 Li Tianjun...........................P1.01-042, P1.01-069, P3.03-014
Lecocq Marylène..................................................... P3.15-004 Lema Mauricio....................................... P1.01-019, P1.01-022 Li Wei................OA 09.06, OA 18.08, P1.03-052, P1.15-009,
Ledezma Blanca........................................................MA 02.07 Lemense Gregory...................................................... MA 20.01 .................... P2.03-028, P2.07-047, P3.01-043, P3.01-067,
Ledson Martin....................P3.05-001, WS 01.05, WS 01.18 ................................................................P3.01-085, P3.15-015
Lemos Flávio............................................................ P1.06-024
Leduc David............................................................... MS 27.03 Li Weimin................................................................... P1.01-034
Lena Herve................................................................. MA 10.05
Lee Adrian...................................................................OA 10.03 Li Weiying.................................................................P3.02-083
Lennes Inga T........................................... OA 07.05, OA 12.02
Lee Chang Hun.........................................................P3.13-002 Li Wen -Feng.........................................P1.13-001, P3.01-051
Lentrichia Brian B...............................OA 05.02, P3.01-068
Lee Chang Young.......................................................P3.16-019 Li Wenhong................................................................P1.05-001
Lenz Gabriel.........................................P1.06-020, P3.16-034
Lee Chee K................................................................P3.02-031 Li Xiadong................................................................. P1.14-001
Leo Silvana.............................................................. P3.06-003
Lee Chia Ching........................................................P2.14-002 Li Xiang......................................................................P1.04-010
Leonard Niamh............... P1.02-011, P1.03-039, P2.02-064,
Lee Choon-Taek....................................................... P2.13-004 ...................................................................................P3.02-053 Li Xiaofei......JCSE 01.10, OA 16.04, P2.03-047, P3.04-010
Lee Dae Ho........................MA 12.08, P1.01-070, P1.04-001 Leonardi Giulia C.......................................................MA 05.02 Li Xiaohua....................................................................MA 15.07
Lee Daehee............................................................... P1.13-006 Leong Cheng Nang............P1.08-001, P1.15-017, P2.14-002 Li Xiaoling............................................. JCSE 01.11, P3.01-021
Lee Daiyoon............................................................... P1.12-002 Leong Chie Hui......................................................... P3.01-020 Li Xiaoxiang........................MA 16.11, P2.02-003, P3.02-001
Lee Dongwoon......................................................... P1.06-003 Leong Tracy L............................................................MA 20.09 Li Xiaoyang.............................................. MA 14.12, P3.13-022
Lee Eungbae........................................................... P2.02-056 Lerner Andrew........................................................P2.02-045 Li Xin............................................................................ MA 14.04
Lee Geewon..............................................................P3.13-002 Leroy Laura.............................................MA 10.11, P2.07-060 Li Xinzhong.................................................................P2.01-011
Lee Han Pil................................................................ P1.16-020 Leroy Vincent............................................................ MA 03.10 Li Xiongfei.................... P1.15-008, P3.01-002, P3.02-095,
...................................................................................P3.02-097
Lee Hansang....................OA 03.04, P2.07-025, P3.01-023, Lertprasertsuke Nirush............................................OA 04.08
.................................................................................. P3.01-029 Li Xue........................................................................P2.01-041
Leschka Sebastian...................................................P2.07-012
Lee Ho Yun................................................................ P3.04-011 Li Xuefei............................. MA 11.07, P1.03-045, P1.03-046,
Lesimple Thierry..................................................... P2.07-023 ...........................................P1.03-052, P3.01-067, P3.01-073
Lee Ho-Jin...........................................P1.04-006, P1.04-007 Lesser Martin......................................... MA 08.11, P2.01-050 Li Xuemei......................................................................OA 17.03
Lee Hoyun.................................................................P3.01-029 Leung Bonnie................. MA 04.02, MA 08.12, P2.05-003 Li Yali...............................P2.02-052, P3.02-061, P3.02-062
Lee Hyun Joo..................MA 06.04, P2.02-059, P3.16-022, Leung Linda K.S........................................................P1.01-050
....................................................................................P3.16-026 Li Yan............................................................................ MA 11.05
Leung Yuki.................................................................P1.07-022 Li Yang-Si....................................................................OA 10.02
Lee Hyun Kyung........................................................P2.01-035 Levchenko Evgeny.............................P3.16-038, P3.16-043
Lee Jack............MS 01.02, OA 07.02, OA 13.05, P2.04-014 Li Yangsi............................................JCSE 01.26, P1.01-010
Levchenko Nikita.................................. P3.16-038, P3.16-043 Li Yanli...........................................................................OA 13.01
Lee Jae Cheol................P2.01-061, P3.01-034, P3.02-088 Leveiller Guillaume..................................................P2.07-030
Lee Jae Wook............................................................. P1.16-012 Li Ying................................................... P1.07-013, P3.02-095
Leventakos Konstantinos........................................ P2.01-054 Li Yinyin................................................ JCSE 01.11, P3.01-021
Lee Jae-Ik................................................................. P3.05-010 Levi Michael...............................................................P3.01-053
Lee Jaekyung........................................................... P1.06-003 Li Yishan..................................................................... MA 07.09
Levin Pavel................................................................P2.01-047 Li Yulin....................................................................... P3.01-040
Lee Jang-Ming..................P3.01-079, P3.16-041, P3.17-002 Levy Benjamin......................................................... P2.04-010
Lee Jeeyun................................................................ P3.02-011 Li Yuping.................................................................... P3.01-031
Levy Benjamin P........................................................MA 02.02 Li Zhongwu................................................................ P1.07-011
Lee Ji Won.................................................................P3.13-002 Levy Paul................................................. OA 15.08, P2.16-019
Lee Ji Yun................................................................. P3.05-012 Liam Chong-Kin................................... MS 13.04, P3.15-014
Lewanski Conrad.....................................MA 10.02, MA 10.03 Lianes Pilar............................................................... P1.03-054
Lee Jieun................................................................. P3.08-003 Lewensohn Rolf................................... P1.01-074, P2.02-042
Lee Jih-Hsiang.....................................P3.01-006, P3.01-074 Liang Chaoyang........................................MA 13.11, P3.16-031
Lewis Craig R............................................................P2.15-007 Liang Chris............................................. MA 07.02, P2.04-012
Lee Jin Gu..................................................................P3.16-019 Lewis Debbie...............................................................MA 15.08
Lee Jin Soo.................................................................OA 11.05 Liang Hengrui........................................ MA 12.11, P1.06-019
Lewis Erik..................................................................P2.16-023 Liang Li..........................................................................MA 11.03
Lee Jong Seok........................................ OA 05.02, OA 09.03 Lewis Jeff............................OA 07.02, OA 09.05, P2.04-014
Lee Jong Sik...................................... P2.03-030, P3.01-034 Liang Wenhua....................MA 12.11, P1.06-019, P3.02-008,
Lewis Jennifer.......................................................... MA 14.08 ..................................................................................P3.04-010
Lee Jong-Seok...............P1.01-070, P1.15-004, P2.03-058, Leygo Catherine....................................................... P1.09-008
.............................................................. P3.01-005, P3.01-050 Liang Xiaohua..........................................................P3.01-010
Li Aiqin....................................................................... P1.01-069 Liang Ying............................................P2.02-003, P2.14-004
Lee June-Koo.............................................................MA 06.12 Li An -Na.................................................................... P3.01-051
Lee Junehawk............................................................MA 06.12 Liang Zhen.......................JCSE 01.20, OA 04.03, P3.16-053
Li Ang....................................................P2.07-029, P3.07-012 Liang Zhi-Yong....................................JCSE 01.25, MA 06.09
Lee Jung Mo............................................................ P1.03-034 Li Anna...................................................................... P1.01-018
Lee Kang-Yun............................................................. OA 09.03 Liang Zhiyong........................................MA 12.09, P3.03-004
Li Baolan.............................................. P3.01-087, P3.03-006 Liang Zong-An....................................JCSE 01.25, MA 06.09
Lee Kanghoon............................................................P3.16-014 Li Bing................................................... JCSE 01.11, P3.01-021
Lee Kenneth.............................................................P3.02-078 Liao Bin-Chi.......................................P2.07-027, P3.01-006
Li Bob T...........JCSE 01.14, OA 10.03, OA 10.05, OA 14.05 Liao Mei Lin.............................................................P3.02-014a
Lee Ki Hyeong.....................OA 05.01, OA 08.07, P1.04-001, Li Chenguang....................................P1.02-004, P2.03-040
............................................. P3.01-012, P3.01-043, PL 02.02 Liao Wei-Chih......................................P1.03-053, P2.03-003
Li Chia-Hsiang..........................................................P2.03-003 Liao Wei-Yu................................................................P3.01-074
Lee Kirsty W.C......................................................... P3.02-031 Li ChiaChin................................................................P2.03-003
Lee Kye Yonng.........................................................P2.03-030 Liao Xin-Ming............................................................P1.01-048
Li Chun....................................................MA 20.13, P3.01-004 Liao Xinghui..................... P1.01-003, P1.02-043, P1.02-047,
Lee Kye Young......................................................... P3.01-034 Li Chun-Sun................................................................ OA 10.07
Lee Kyungjong.......................................................... P3.04-011 ...............................................................P3.02-018, P3.02-067
Li Encheng............................................................... P1.01-078a Liao Zhongxing........................................ MA 01.03, OA 01.07
Lee Min Ki..................................................................P3.13-002 Li Gaofeng..................................................................P1.07-038
Lee Na Lim................................................................ P2.01-064 Licht Peter................................................................P1.05-004
Li Haocheng...................P1.03-043, P1.06-006, P2.01-026, Lieberman Sivan......................................................P3.03-028
Lee Nathanael.......................................................... P3.14-008 ..............................................................P2.01-046, P2.02-068
Lee Pablo................................................MA 03.06, P3.01-071 Lieberman-Cribbin Wil.............................................P2.13-026
Li Hui............................... P1.02-020, P3.03-009, P3.16-030 Lien Huang-Chun.................................................... P3.01-006
Lee Pei-Jung............................................................P2.13-001 Li Jack....................................................................... P3.04-012
Lee Sae Bom........................................MA 06.04, P2.02-059 Liew Perry J.R............................................................OA 09.07
Li Jacky Y.C..............................................................P3.01-001 Lim Adeline..................................................................MA 13.07
Lee Sang Eun...........................................................P2.02-032 Li Jiamin......................................................................MA 20.13
Lee Sang Haak............... P1.03-025, P1.03-030, P1.06-015 Lim Alvin S..................................................................OA 09.07
Li Jian..................................................JCSE 01.10, P2.03-047 Lim Eric..................................................GR 03.04, OA 02.07
Lee Se-Hoon.......................ES 09.04, OA 03.04, OA 08.07, Li Jiancheng................. P2.01-073, P3.12-004, P3.14-016
........................................P1.08-004, P2.01-064, P2.07-025, Lim Ji-Young.............................................................. P1.16-018
Li Jiayu.................................MA 11.07, P1.03-052, P3.01-067 Lim John...................................................MA 07.09, OA 09.07
Lim Jun Hyeok.......................................................... P2.01-016 Liu Qianwen.............................................................. OA 03.07 Lu Shir Kiong...........................................................P3.01-020
Lim Jung-Hwan....................................P1.01-014, P2.03-024 Liu Renwang.................P1.15-008, P3.01-002, P3.02-095, Lu Shun.......................GR 03.05, JCSE 01.12, JCSE 01.24,
Lim Kuan Pin.....................................P1.04-003, P2.13-002 ..................................................................................P3.02-097 ..................... MA 03.03, MA 07.04, MA 08.02, P1.01-032,
Lim Lee........................................................................OA 10.03 Liu Rui........................................................................P1.01-003 ................... P1.01-037, P1.04-010, P3.01-026, P3.01-043,
Lim Sean-Tee............................................................. MA 04.10 Liu Shengu...................................................................OA 12.01 ................. P3.01-052, P3.01-070, P3.01-075, P3.02-014a,
Lim Sung Won.................. OA 03.04, P2.07-025, P3.01-023 Liu Shuang................................................................P2.16-024 .................................................................................P3.04-005
Lim Tony K...................................................................OA 09.07 Liu Si-Yang.......................................JCSE 01.21, P1.01-027, Lu Tao....................................................................... P2.03-050
Lim Tony Kiat Hon.....................................................P3.01-017 .................................................................P1.07-042, P1.13-001 Lu Xuemei.................................................................. P1.02-051
Lim Tse-Hui.................................................................OA 09.07 Liu Stephen V...........................................................P2.07-050 Lu Yimin...................................................................... P1.01-071
Lim Wan-Teck...................... MA 10.04, MA 12.02, OA 09.07, Liu Tao...........................................................................OA 18.01 Lu You............................. JCSE 01.25, MA 06.09, P3.01-052
.....................................................................................P3.01-017 Liu Ting..................................................JCSE 01.27, MA 07.01 Lu Zhao H.................................................................P3.07-006
Lima João Paulo......................................................P2.07-054 Liu Tu-Chen............................................................... P3.01-016 Lu Zhihui................................................................... P2.01-020
Lima Vladmir C.C.D.................................................P3.02-060 Liu Wei................................OA 16.04, P1.02-046, P3.09-001 Lubeck Deborah.................................... P1.01-051, P1.15-003
Lin Anya Maan-Yuh.................................................P1.01-077 Liu Wei-Ping........................................JCSE 01.25, MA 06.09 Lucchi Marco................................................................MA 17.01
Lin Baochai................................................................ P2.01-071 Liu Xi..............................................................................OA 13.01 Ludovini Vienna.......................................................P3.02-007
Lin Chia-Chi......................... MA 07.15, MA 12.02, OA 05.06, Liu Xia........................................................................ P3.01-002 Lueers Anne C..........................................................P3.01-038
...............................................................P3.01-006, P3.01-074 Liu Xiaoqing............................................ OA 09.06, P1.15-016, Lueng David K............................................................MA 05.07
Lin Chia-Mo............................................................... P3.01-016 ..............................................................P2.04-003, P3.01-036 Lugg Sebastian T.......................................................MA 08.09
Lin Chien-Chung.............MA 16.02, P1.01-048, P3.05-004 Liu Xiaoting..................................................................MA 12.09 Lugli Enrico................................................................P1.07-032
Lin Chih-Bin............................................................. P2.07-027 Liu Xiaozhen............................................................... MA 11.07 Lukrak Somthawin..................................................P3.03-020
Lin Ching-Chan........................................................P2.03-003 Liu Yan-Hui............................................JCSE 01.17, OA 08.02 Luna Ana María.......................................................... MA 07.03
Lin Ching-Hsiung................................... MA 03.07, P3.01-016 Liu Yanhui.................................................................P2.02-003 Luo Dong-Lan.......................................JCSE 01.17, OA 08.02
Lin Dongmei.........................MA 15.04, MA 18.13, P1.07-011 Liu Yi..........................................................................P1.05-016 Luo Guangyu.............................................................. P1.14-010
Lin Gang....................................................MA 16.14, P3.17-003 Liu Yingmin..........................................JCSE 01.16, P1.07-006 Luo Jun...........................P2.02-052, P3.02-061, P3.02-062
Lin Gen............................. JCSE 01.28, MA 07.13, P1.01-002, Liu Yongmei.................................................................MA 13.06 Luo Qing Q..........................................P2.05-018, P3.02-014a
.............................................................. P1.02-045, P3.01-008 Liu Yongyu........................JCSE 01.10, OA 16.04, P2.03-047 Luo Qingquan........................................................... P3.04-010
Lin Gengpeng..........................................................P1.02-020 Liu Yuan....................................................OA 12.06, P1.01-016 Luo Qingwei............................................................ P3.06-008
Lin Jessica J.............................................................MA 07.07 Liu Yuanyuan....................MA 12.09, P2.02-033, P3.03-004 Luo Shuang..............................................................P3.07-006
Lin Jia -Xin................................................................ P3.01-051 Liu Yun-Hen............................................P1.16-017, P3.13-001 Luo Viola Y................................................................P2.02-003
Lin Jing-Heng........................................................... P1.01-077 Liu Yunde................................................................... P1.03-017 Luo Xin........................................................................P1.07-031
Lin Jinlan..................................................................P3.02-025 Liu Yunpeng.......................................... JCSE 01.11, P3.01-021 Luo Yan......................................................................P1.07-039
Lin Juan....................................................................... OA 13.03 Liu Yuping...................................................................P2.01-011 Luo Yi...............................P3.01-087, P3.03-006, P3.03-017
Lin Jun-Tao................................................................ P1.13-001 Liu Yutao........................P2.01-029, P2.01-030, P3.04-007 Luo Yung-Hung............. P1.11-002, P3.02-043, P3.02-070,
Lin Li............................. P2.02-004, P3.01-084, P3.03-005 Liu Zeyi.....................................................................P3.02-092 ................................................................................... P3.07-011
Lin Maosheng..............................................................P1.14-011 Liu Zhe........................................................................MA 03.03 Lupinacci Lorena.............. P1.01-019, P1.01-022, P1.01-058,
Lin Meng-Chih.......................................................... P2.07-027 Liu Zhidong.........................................JCSE 01.10, P2.03-047 ...................................................................................P2.03-039
Lin Mong-Wei...................................... P3.01-079, P3.17-002 Liu Zhujun................................................................. P3.01-084 Luque Caro Natalia...................................................P1.07-036
Lin Qingren.........MA 09.01, MA 16.13, MA 16.14, P3.01-058, Liv Per........................................................................ P1.14-008 Lusque Amelie..........................................................P1.07-009
................................................................ P3.14-015, P3.17-003 Livi Lorenzo............................................MA 02.05, P1.01-065 Lustgarten Stephanie...............................................P1.01-005
Lin Sheng-Hao...........................................................MA 03.07 Livingstone Ann...................................................... P2.03-044 Lutringer-Magnin Delphine......................................P2.11-001
Lin Steven H................................................................ MA 01.10 Lizondo María.............................................................P3.14-017 Lv Chao........................................................................OA 16.08
Lin Swan..................................................................P1.03-003 Llabata Paula...........................................................P3.02-086 Lv Hongying....................P1.01-042, P1.01-069, P2.03-034,
Lin Yao..............................JCSE 01.20, OA 04.03, P3.16-053 Llorente Mar............................................................. P2.01-022 ....................................................................................P3.03-014
Lin Yung-Feng...........................................................P3.12-002 Lo Russo Giuseppe............................................... P2.09-001a Lv Qi...........................................................................P3.02-066
Lindeman Neal........................................................... MS 15.01 Lo Shir Kiong............................................................ P1.02-054 Lv Tang F..........................P1.01-002, P1.01-006, P1.01-073,
Linden Philip A........................................MA 20.01, MA 20.03 .................... P1.02-043, P1.02-044, P1.02-045, P1.02-046,
Lo Simon................................................................... P3.14-008 ..................... P1.02-047, P1.02-048, P1.02-049, P1.02-056,
Lingampalli Nithya...................................................... MA 16.01 Locke Imogen.............................................................MA 09.09 .......................P1.02-057, P1.02-058, P1.02-059, P2.01-017,
Lingjærde Ole Christian...........................................P1.02-028 Locke Matthew............................................................MA 19.05 ....................................... P2.01-019, P2.02-005, P2.02-007,
Linke Rolf............................ OA 05.01, P3.01-012, P3.01-072 Lockwood William W..............................MA 05.12, OA 07.07 ................... P2.02-020, P2.02-021, P2.03-057, P3.01-009,
Lipatova Daria A....................................................... P1.01-056 Lococo Filippo.............................................................OA 16.02 .................. P3.02-025, P3.02-026, P3.02-027, P3.02-028,
Lipson Doron..................P2.02-052, P3.02-061, P3.02-062 Loewenthal Cristina.................................................P2.16-025 ..................P3.02-029, P3.02-065, P3.02-068, P3.02-069,
Lira Maruja E............................................................ P2.02-001 Loftin Isabell..........................................JCSE 01.27, MA 07.01 ............................................................P3.02-080, P3.07-004
Lisberg Aaron.................................... MA 02.07, P2.07-038 Logroscino Antonio Fabio..................................... P3.06-003 Lwin Zarnie.............................................................. P2.07-032
Lischke Robert....................................P2.07-020, P3.07-008 Loizzi Michele............................................................P2.17-002 Ly Sophia............................................................................ 9941
Lisha Lutfi.............................................P2.01-059, P3.16-005 Lok Benjamin.......................................................... P3.15-008 Lybeck Lind Charlotte............................................. P2.04-010
Litle Virginia R........................................................... P1.05-013 Lome Katie.................................................................P1.09-001 Lyberis Paraskevas...............................MS 07.05, MTE 17.02
Little Latasha............................................................... OA 13.05 Long Hao.............................................. P2.05-018, P2.14-004 Lydon Christine A.............MA 07.08, P1.01-055, P2.07-002
Litzky Leslie................................................................MA 06.03 Long Niamh................................................................MA 05.02 Lynch Sophie............................................................ P1.14-009
Liu Anwen.................................................................P3.01-087 Longmate Jeffrey........................................................MA 02.11 Lyons Gustavo.........................................................MTE 30.01
Liu Baoxin.................................................................P2.02-003 Longuespée Remi....................................................P3.02-032 Lyra-González Iván................................................. P2.01-049
Liu Bian....................................................MA 18.07, P2.13-026 Loo Billy.....................................................ES 10.01, MA 13.01 Lyu Chao................................................................JCSE 01.22
Liu Bing........................................................................ MA 11.05 Looney Stephen...........................................................OA 11.03 López Castro Rafael.................................................. MA 07.03
Liu Boning.................................................................. P1.03-017 Loong Herbert H.................................................... P1.01-050 López Flores Mariana............................................ P1.01-060
Liu Changhong..........................................................P1.07-038 Lopes Gilberto................ P1.06-018, P1.07-024, P1.07-025, López González Ana................................................P1.01-060
Liu Chao-Yu...............................................................OA 04.07 ...........................................P1.11-001, P2.03-006, P2.07-037, López Picazo Jose María....................................... P2.01-022
Liu Chaoyu...................................................................MA 15.07 ..............................................................P2.07-054, P2.07-055 López Rafael................................................................PL 02.04
Liu Chien-Ting..........................................................P1.03-012 Lopez Criado Maria Pilar......................MA 01.05, P2.01-022 López Saucedo Raúl A........................... MA 16.12, P1.17-008
Liu Chih Long.............................................................. MA 13.01 Lopez Maria...............................................................P1.03-035 López-Brea Marta...................................................... MA 15.01
Liu Chunling................................................................ P1.15-016 Lopez-Lisbona Rosa.........MA 20.06, MA 20.08, P1.12-009 López-Picazo José María.......................................P1.07-035
Liu Dan....................................................................... P1.01-034 Lopez-Padres Sandra.............................................P2.02-014 López-Vivanco Guillermo................. P2.02-034, P3.01-073,
Liu Deruo...................................................MA 13.11, P3.16-031 Lopez-Vilariño Jose A.......................MA 01.05, P2.04-008 ......................................................................................PL 02.04
Liu Dong.......P1.01-042, P1.01-069, P2.03-034, P3.03-018 Lora David.................................................................. MA 07.03
Liu Frank X.................................................................. OA 13.02 Lorandi Vinicius................................... P2.03-029, P3.13-018
Liu Geoffrey......... MA 16.03, MA 20.11, OA 15.01, P3.01-019, Lorens James....................................... MA 02.09, P2.01-047 M
..............................................................P3.01-062, P3.06-005 Lorenzi Matthew V..................................................P2.07-058
Liu Guangwei............................................................ P1.01-069 Lorusso Mariagrazia................................................P2.17-002 M Geetha................................................................... P2.01-052
Liu Hailin.................................................................. P2.03-040 Losem Christoph..................................................... P3.01-088 Ma Barbara...............................................................P2.07-050
Liu Haixin..................................................................P2.03-034 Losonczy Gyorgy...................................................... MA 10.05 Ma Daniel J............................................................... P2.14-006
Liu Hao....................................................................... P1.01-037 Lothe Ragnhild A.......................................................P1.07-021 Ma Di..................................................... MA 11.05, P2.03-004
Liu Hongbing........................................P2.01-019, P3.07-004 Lou Jiatao................................................................P3.02-014a Ma Grace X...........................................P2.13-005, P2.13-006
Liu Hongyu...............................................................P3.02-095 Lou Yanyan........................ MA 05.01, OA 06.05, OA 06.07, Ma Haitao..........................JCSE 01.10, OA 16.04, P2.03-047
Liu Hua Li.................................................................. P3.01-083 ...................................................................................P1.07-039 Ma Hong L.................................................................... MA 01.11
Liu Hui.......... P1.14-010, P1.14-011, P1.14-012, P2.14-004 Louie Alexander V.................................OA 16.01, P2.14-009 Ma Jingchen.................................................................MA 14.12
Liu Huibin..................................................................P1.01-072 Louie Brian E.....................P1.05-012, P1.10-008, P2.13-019, Ma Kewei.......................JCSE 01.11, JCSE 01.16, P1.07-006,
Liu Jin-Shi................................................................ P3.14-004 ................................................................ P2.13-021, P3.13-029 .................................................................................... P3.01-021
Liu Jing....................................................P2.13-011, P2.13-012 Loveland Paula..........................................................MA 20.09 Ma Li.....................................P1.14-010, P1.14-011, P3.02-083
Liu Jinshi.................................................MA 09.01, P3.14-015 Lovell Janaka............................................................P3.16-045 Ma Rui...............................JCSE 01.11, P3.01-021, P3.01-087
Liu Jiwei................................................ JCSE 01.11, P3.01-021 Lovly Christine............................................................MA 15.06 Ma Shenglin.................. JCSE 01.23, P1.01-046, P1.03-002,
Liu Junfeng.............................................OA 16.04, P3.04-010 Lozano Maria D.........................................................P2.02-061 .......................P1.14-001, P3.01-031, P3.02-015, P3.02-040
Liu Kewei.........................P1.01-042, P1.01-069, P2.03-034, Lozano-Ruiz Francisco..............................................MA 20.12 Ma Weijie..................................................MA 15.08, P1.07-013
....................................................................................P3.03-014 Lu Charles....................................................................OA 12.01 Ma Xiu Mei.................................................................P3.14-007
Liu Li...............JCSE 01.28, MA 07.13, P1.01-037, P3.13-028 Lu Fangliang........................................................... JCSE 01.22 Ma Xiumei...................................................................P3.17-001
Liu Lunxu....................... JCSE 01.10, P2.03-047, P3.04-010 Lu Henry................................................MA 02.07, P2.07-038 Ma Yuanyuan................JCSE 01.22, P2.01-068, P3.02-022
Liu Mengzhong...........................................................P1.14-011 Lu Hongyang............................................................P3.03-030 Ma Zhiyong............................................ P3.01-018, P3.01-061
Liu Peng....................................................................P3.04-007 Lu Kaihua.................................................................. P3.01-052 Maanaoui Sarah....................................................... P2.07-023
Liu Pengpeng...........................................................P3.03-009 Lu Shaohua.......................................... P2.05-021, P3.13-037
Mac Donagh Lauren....... P1.03-039, P1.03-041, P1.03-042, Mansard Sandrine................................................... P2.07-023 Martínez Stella........................................................ P3.08-005
..............................................................P1.03-048, P2.02-064 Manser Renee....................MA 14.09, P1.01-033, P1.04-003 Martínez-Barreda Luis...................... P2.06-007, P2.07-061
Mac Manus Michael P................................................. MA 17.12 Mansfield Aaron S................ MA 13.01, MA 18.09, OA 13.07, Maruoka Shuichiro................................................... P2.15-015
Macaulay Calum E.............. MA 10.09, OA 07.07, P2.02-038 .............................................................P2.01-054, P2.09-001 Mas Lopez Luis Alberto.....................P1.06-022, P1.06-023,
Macdonagh Lauren............................ P1.09-006, P1.09-007 Mansour Mohammed...............................................P1.09-010 ................................................................................... P2.01-053
Macdonald Isabel.......................................................P2.13-013 Mansy Talal................................................................. OA 02.03 Mas Luis..................................................................... P1.09-013
Maceachern Paul......................................OA 15.01, P2.13-011 Mantel Frederick.........................................................MA 13.09 Masada Atsuhiro...................................................... P1.03-044
Macedo Gabriel D.S................................................P2.03-029 Manzanera Andrea.................................................. P2.07-059 Masai Kyohei................. P1.05-002, P1.05-005, P1.05-009,
Macedo-Perez Eleazar Omar....................................MA 12.10 Manzano Aranzazu................................................... MA 07.03 ............................................. P1.17-017, P3.02-035, P3.13-031
Macedo-Pérez Omar..........................P2.01-049, P3.14-012 Mao Chenyu..............................................................P3.01-025 Mascall Sophie...................P2.14-012, P2.14-014, P2.14-015
Macerelli Marianna....................................................... MA 11.11 Mao Weimin...JCSE 01.10, MA 09.01, OA 16.04, P2.03-047, Mascarenhas Francisco..........................................P2.16-025
Macias Jose Antonio............................................... P1.03-054 ................................................................P3.14-004, P3.14-015 Mashadi-Hossein Afshin...................P2.02-002, P2.02-014
Mack Philip C......MA 02.11, MS 02.02, MS 15.05, OA 14.07, Mao Xinru.......................... P1.01-035, P1.01-037, P3.01-052 Maskell Nick................................................................ OA 02.05
..................................................................................P3.01-046 Mao Xizeng................................................................P2.02-013 Mason Kimberly........................................................ P1.01-036
Mackenzie Regina......................................................MA 04.02 Mao Yousheng..........................................................P2.02-062 Mason Robert........................................................... P2.07-032
Mackie Tasha............................................................P2.15-014 Mapes Abigail............................................................. MA 02.01 Massard Gilbert..........................................................OA 03.01
Maclaren Vivienne...............................P3.15-003, P3.15-005 Marc Cucurull............................................................ P1.01-062 Massey Dan...............................................................P3.01-075
Macleod Nick........................................................... P3.04-006 Marchese Valentina....................................................OA 16.02 Massie Charlie E......................................................... MA 11.02
Macmanus Michael P.........MA 18.12, P1.01-033, P2.14-001, Marchetti Paolo......................................................... P1.01-065 Massion Pierre P................ MA 14.08, MA 14.13, P3.15-004,
....................................................................................P3.13-003 Marchiò Caterina.................................................... P2.09-003 .................................................................................... WS 02.12
Madabhushi Anant.......................................................MA 17.11 Marciano Carolina................................................... P2.10-006 Massuti Bartomeu..............MA 15.01, P1.03-054, PL 02.04
Madhavan Subha...................................................... P1.01-036 Marcos Flores........................................................... P1.01-058 Masters Elizabeth T...................................................OA 05.06
Madrigal John.......................................MA 02.07, P2.07-038 Marcoux Nicolas.........................................................OA 09.01 Mastrangelo Randy..................................................P3.03-016
Madsen Anne T........... P3.02-005, P3.02-050, P3.02-052 Marcq Marie............................................................. P2.07-023 Masuda Chinami..................................................... P2.02-051
Maeda Ai.............................................. P2.02-028, P2.02-031 Marczyk Michal......................................................... P2.13-010 Masuda Munetaka................................. P1.05-018, P3.15-012
Maeda Junichi..................P1.01-041, P2.02-009, P3.02-012 Mardynsky Yury.......................................................P1.08-008 Masuda Noriyuki................................ P1.03-008, P2.03-002
Maeda Kohki............................................................. P2.16-004 Marghadi Jamila...................................................... P2.01-038 Masuda Shinobu.................................P1.03-009, P2.02-057,
Maeda Naoyuki........................................................P3.02-042 Marginet Marta......................................................... P1.01-075 .................................................................P2.15-015, P3.03-011
Maeda Ryo................................................................P3.02-085 Marin Juan Antonio.................................................P2.07-044 Masuda Tomomi................................... P2.01-027, P2.15-016
Maeda Sumiko.....................................P1.02-018, P3.02-064 Marin Julian...............................................................P1.07-039 Masuhiro Kentaro...................................................P1.03-049
Maeda Yutaka............................................................ P1.02-014 Marino Kan.................................................................MS 24.04 Masumoto Ai............................................................ P2.03-021
Maehara Sachio................P1.01-041, P1.16-010, P2.02-009, Mariotti Veronica..................................................... P2.01-054 Masuzawa Keita................................ P2.03-012, P3.02-084
....................................................................................P3.02-012 Marisi Giorgia...........................................................P3.02-007 Masykura Najmiatul........................... P3.01-053, P3.01-054
Maehara Yoshihiko............ OA 13.06, P1.07-002, P1.07-014, Marjanski Tomasz..................................................... P2.13-010 Matano Elide................................................................P1.17-015
.....................P2.05-017, P2.09-005, P3.16-003, P3.16-033 Markelewicz Robert..................................................MA 02.03 Mate Jose Luís.......................................................... P1.05-015
Maekawa Takafumi...................................................P2.16-020 Markin Leslie............................................................ P3.01-062 Mates Mihaela............................................................. MA 10.01
Maemondo Makoto.............OA 05.08, OA 10.01, P1.03-005, Markovets Aleksandra................................................OA 10.01 Matheny Christina.................................... MA 10.03, OA 17.07
.................................................................................. P2.06-009 Markovic Svetomir N................................................. OA 13.07 Mathias Clarissa................GR 02.04, MA 17.09, P1.01-043
Maenishi Osamu.......................................................P2.07-021 Markus Richard....................................................... P2.04-009 Mathiot Nathalie.........................................................MA 07.06
Maeno Yuri............................................................... P2.03-021 Marotti Marcelo....................................................... P2.04-006 Mathisen Michael.......................................................P1.04-011
Magallanes Maciel Manuel..................................... P2.01-006 Marquis Katerine..................................................... P2.07-029 Matkowskyj Kristina............................................... P3.04-009
Mager Ulrich..............................................................P1.09-010 Marr Alissa..............................................MA 13.04, P2.15-013 Matos Claudia G.P......................................................P1.15-010
Magri Ignacio............................................................. P1.01-058 Marrades Ramon.......................................................SS 01.02 Matrana Marc R.................................... P2.01-014, P2.01-015
Mahadevan Navin R.................................................. MA 07.08 Marri Shashikanth.................................................... P1.09-012 Matsangou Maria.................................... MA 05.11, P1.07-043
Mahajan Abhishek............ P1.01-021, P1.01-023, P2.01-051, Marriam Ummay...................................................... P3.02-073 Matsubara Daisuke............OA 18.07, P1.02-041, P3.02-089,
............................................................... P3.01-076, P3.03-015 ..................................................................................P3.02-093
Marrone Kristen A.....................................................MA 09.08
Mahavongtrakul Angelique......................................P1.07-013 Matsubara Eri............................................................ P1.16-002
Marroquín-Flores Diana B..................................... P2.01-049
Mahmood Alam........................................................P3.02-054 Matsubara Osamu...............................P1.03-010, P2.03-032
Marschner Norbert................................................. P3.01-088
Mahon Barry.............................................................P3.16-035 Matsubara Taichi............... OA 13.06, P1.07-002, P1.07-014,
Marshall Erin A... MA 10.09, MA 15.12, MA 15.14, OA 07.07,
Mai Tao...............................................................9941, MA 13.07 .........................................P1.02-006, P2.02-017, P2.02-022, ......................................... P2.09-005, P3.16-003, P3.16-033
Mainwaring Paul........................................................ MA 10.05 ....................................... P3.02-090, P3.02-091, P3.02-094 Matsubayashi Jun............P1.01-041, P1.07-012, P2.05-012,
Maio Michele...............................................................MA 19.02 Marshall Henry M.................................................... P1.04-003 ....................................................................................P3.02-012
Maiolino Elena...........................................................P2.17-002 Marshall Laura........................................................... OA 02.05 Matsuda Toshiaki............ P2.01-037, P2.07-053, P3.12-001,
Maione Paolo..............................................................P1.01-015 Marshall Scott...........................................................P2.14-020 .................................................................................... P3.16-010
Maitani Fumio............................................................. P1.16-019 Marsé Raquel............................................................P2.07-041 Matsui Hiroshi.......................................................... P2.16-005
Maity Tapan K............................................................P1.02-063 Marta Guilherme N.................................................. P3.01-066 Matsui Hirsoshi..........................................................MA 05.06
Majem Margarita...............MA 15.01, P1.03-054, P2.01-022, Martel Simon.............................................. MA 20.11, OA 15.01 Matsui Takashi.........................................................P2.07-022
................... P2.05-007, P2.07-041, P3.14-014, P3.14-017 Martelo Fernando.....................................................P2.16-025 Matsui Takuma.........................................................P3.02-085
Majem Tarruella Margarita.............. P1.07-028, P2.01-072 Marti Nesa................................................................. MA 06.06 Matsui Yoshiro.....................OA 04.02, P1.12-002, P1.17-010
Majercakova Katarina.......................... P2.05-007, P3.14-014 Martin Claudio..................MA 01.02, P1.01-022, P1.01-058, Matsumoto Kinnosuke..................... P1.02-032, P2.06-003
Majid Adnan..............................................................P3.03-025 .......................................... P1.02-055, P1.09-013, P3.02-063 Matsumoto Naohisa.......P1.02-065, P2.02-012, P3.02-024
Majima Hidetaka..................................P1.03-010, P2.03-032 Martin Mike G.............................................................MA 06.07 Matsumoto Naoya.................................................... P2.03-015
Makhnin Alex...............................................................OA 10.05 Martin Sarah...............................................................MA 19.05 Matsumoto Seiji.................................P2.09-007, P3.09-009
Maki Yuho...............................................................P2.05-009 Martin Spencer D................................. MA 10.09, P2.02-038 Matsumoto Shingo.............................. P1.03-005, P3.14-001
Makino Haruhiko...................................................... P2.03-016 Martin-Padron Joel................................................. P2.02-010 Matsumoto Tsuneo....................................................P3.13-013
Makino Takashi.................. MS 07.04, P2.01-010, P3.16-004 Martinengo Gaston................................................... P1.01-058 Matsumoto Yasuo.................................. MA 09.06, MS 24.04
Makino Yojiro........................................ P1.07-012, P3.07-003 Martinez Alex............................................................ P1.05-015 Matsumoto Yoko...................................P1.01-054, P2.03-017
Maksymiuk Beata......................................................P1.02-037 Martinez Anabel....................................................... P1.05-019 Matsumoto Yoshiya..................................................P1.06-014
Maldonado Fabien.....................................................P2.13-014 Martinez Andres.........................................................OA 10.03 Matsumoto Yuji....................................P2.03-048, P2.07-011
Maldonado Federico.............................. MA 20.12, P3.14-012 Martinez Barroso Katherin................ P1.06-013, P2.07-039 Matsuo Yukinori..................MS 24.04, OA 01.08, P1.14-015,
Malet Isabelle.............................................................P1.01-012 Martinez Daniel......................................................... P1.01-075 ..............................................................P2.05-002, P2.14-007
Malhotra Hemant......................................................P2.01-023 Martinez De Castro A.............................................. P1.05-015 Matsuoka Yoshisuke..................................................MA 09.06
Malik Shakun............................................................... OA 14.07 Martinez Debora.......................................................P2.02-014 Matsushita Haruo......................................................MS 24.04
Mallone Sandra...................................................... P2.09-001a Martinez Gala.............................................................MA 05.03 Matsushita Hirokazu.................................................P1.07-017
Malova Olga A........................................................... P1.01-056 Martinez Moreno Elia.......................... P1.06-013, P2.07-039 Matsuura Yoshiaki.................................................... P2.16-016
Mambetsariev Isa......................................................MS 25.02 Martinez Pablo..........................................................MA 07.08 Matsuura Yosuke..................................P1.13-005, P3.13-009
Man Johnathan........................................................ P1.07-018 Martinez Stephanie................................................. P2.07-023 Mattsson Johanna S.M......MA 05.13, MA 06.01, P2.02-015,
Manabe Yoshihiko......................................................MA 09.06 ............................................................P2.02-023, P2.02-066
Martinez Victor D...............MA 15.12, MA 15.14, P1.02-006,
Mandal Amit.............................................OA 03.02, P1.17-019 ........................................ P2.02-017, P2.02-022, P2.02-038, Matzen Lars..............................................................P2.05-001
Mandel Nil M.............................................................P3.13-024 ....................................... P3.02-090, P3.02-091, P3.02-094 Mavroudis Dimitris...................................................P1.01-044
Mando Pablo.............................................................. P1.01-058 Martinez-Bernal Gala............................MA 10.11, P2.07-005 Mawas Amany S............P1.02-002, P1.02-052, P2.09-008
Manegold Christian K................................................ MS 14.01 Martinez-Cedillo Jorge...............................................MA 16.12 May Tracy.................................................................P3.02-052
Manfrivato Maria Flavia G.......................................P3.03-019 Martinez-Hernandez Jorge-Negueb...................... MA 08.10 Mayasari Hesti N..................................................... P2.01-044
Mangalick Keshav....................................................... MA 10.10 Martinez-Terroba Elena......................P2.02-061, P3.07-007 Mayo John R.........MA 14.11, OA 15.01, P2.13-011, P2.13-012
Manikkam Umakanthan Jayadev............................P2.15-013 Martini Jean-Francois..............................................OA 05.06 Maziak Donna.......................................... OA 11.06, P3.16-007
Maniwa Tomohiro......................................................MA 17.04 Martins Frederico K..................................................P3.13-018 Mazieres Julien...................... MA 10.03, MA 10.11, MA 19.03,
Manley Daumont Melinda.......................MA 18.14, P1.06-012 Martins Renato G.................................... OA 17.01, P1.06-009 .........................OA 03.01, OA 12.09, P1.01-013, P1.07-009,
Mann Helen...........................................MA 12.07, P2.04-006 ...................................................................................P2.07-060
Martos-Ramírez Guillermo................................... P2.06-007
Manna Aditya........................................................... P1.10-001 Mccall Amber...............................................................OA 11.03
Martín Algarra Salvador...........................................P1.07-015
Manners David...................MA 14.09, P2.13-002, P2.13-023 Mccall Bretta M..........................................................P2.13-021
Martín Claudio...........................................................P1.01-019
Manochakian Rami.................................................... OA 06.07 Mccaughan Brian.......................................................MA 19.06
Martínez Briseño David.............................................MA 20.12
Manoharan Prakash.................................................... MA 17.14 Mccleland Mark..........................................................MA 05.09
Martínez De Castro Eva............................................ MA 07.03
Manolache Veronica................................................ P3.16-018 Mcclelland Jamie R....................................................MA 09.10
Martínez Elisabeth.......... P2.01-072, P2.05-007, P3.14-014
Manos Daria................................................ MA 14.11, OA 15.01 Mccleod Michael........................................................ MA 10.05
Martínez Julia............................................................ MA 07.03
Manro Jason R........................................................P3.07-006 Mccloskey Paula..........................................................MA 09.11
Martínez Maite........................................................... MA 07.03
Mans Nicole Z.............................................................MA 15.08 Mcculloch Tracey..................................................... P2.04-013
Martínez Ortega Esther...........................................P1.07-036
Mccuthchen Yvonne G..............................................P1.07-031
Mcdonald Fiona....................................... MA 09.09, MA 09.11 Mikami Koji............................................................. P2.09-005a Miyashita Yoshihiro...................................................MA 05.08
Mcdonough John........................................................MA 06.13 Mikami Tetuo.............................................................. MS 07.04 Miyata Naoko........................................P1.02-022, P1.17-009
Mcdonough Shannon................................................. OA 14.07 Mikhalenka Alena.....................................................P3.02-075 Miyata Ryo........................................... P3.02-046, P3.02-071
Mcfadden Julia........................................................P2.02-048 Milanowski Janusz...............................OA 08.03, P3.02-045 Miyata Yoshihiro.............P1.02-002, P1.02-052, P2.05-011,
Mcfarland Daniel......................................................P1.03-028 Milbury Coren................P2.02-052, P3.02-061, P3.02-062 ............................................................... P2.09-008, P2.15-011
Mcgarry Ronald..........................................................MA 13.08 Mileham Kathryn F.................................................... OA 09.02 Miyata Yuka...............................................................P3.15-002
Mcgary Eric................................................................. OA 14.07 Mileshkin Linda......................................................... MA 04.06 Miyawaki Michiyo................................P2.05-017, P3.02-039
Mcgill Joseph........................................................... P3.04-012 Miley Debi................................................................. P1.03-022 Miyazaki Kazuhito....................................................P2.07-042
Mchugh Laura.......................................... MA 04.01, P1.13-011 Milite Nicola..............................................................P3.02-006 Miyazaki Ryohei..............P1.02-034, P1.05-003, P1.16-026,
Mckay Stephen....................................P3.15-003, P3.15-005 Millar Barbara-Ann...................................................P3.14-013 .................................................................................. P3.09-005
Mckee Andrea B.................................... P1.06-017, P2.13-017 Millares Laura.......................................P1.05-019, P2.02-061 Miyazawa Masaaki...................................................P2.07-021
Mckee Brady J....................................... P1.06-017, P2.13-017 Miller Anthony.............................................................OA 06.01 Miyazawa Teruomi..................................................P2.02-072
Mckee Mark D............................................................. MA 17.07 Miller Austin............................................................... MA 01.06 Miyoshi Tomohiro.............. OA 16.07, P2.16-015, P3.02-074,
Mckeever Tricia....................................................... P2.06-005 Miller Beth....................................................................MA 14.14 ....................................................................................P3.13-036
Mcleod Louise..........................................................P3.07-002 Miller Linda...................................................................OA 17.08 Mizoe Jun-Estu...................................................... P2.05-005
Mcloone Philip......................................P3.15-003, P3.15-005 Miller Robert C.......................................OA 06.07, P2.14-006 Mizoue Tetsuya...........................................................MA 14.06
Mcnamara Aoife...................................................... MS 04.05 Miller Vincent A...................MA 05.02, MA 07.07, MA 12.03, Mizowaki Takashi.............P1.14-015, P2.05-002, P2.14-007
Mcphelim John......................................MA 08.07, WS 03.14 .................................................MA 15.06, OA 12.08, OA 14.07, Mizuguchi Hiroyuki.................................................. P1.03-006
Mcquaid Dualta..........................................................MA 09.09 ...........................................OA 18.03, P2.02-016, P2.02-052, Mizumura Kenji......................................................... P2.15-015
Mcwilliams Annette............MA 20.07, OA 15.01, P1.04-003, .............................................................. P3.02-061, P3.02-062 Mizuno Kiyomichi...................................................... P3.16-011
....................................................................................P2.13-002 Miller York E.............................................................P3.03-026 Mizuno Takafumi...................................................... P1.03-006
Meadows Meghan................................... MA 04.01, P1.13-011 Milne Katey................................................................. MA 10.09 Mizuno Yota......................................... P3.09-006, P3.16-010
Mecca Caterina...........................................................GR 01.05 Milne Katy.................................................................P2.02-038 Mizushima Masaya...................................................P3.01-035
Mediavilla-Varela Melanie......................................P2.02-030 Milner Alvin.............................................................. P3.01-005 Mo Hongnan.............................................................P2.03-028
Medina Pedro P.......................................................P2.02-010 Milner-Watts Charlotte............................................P2.07-049 Mocci Simonetta...................................... OA 17.02, P1.04-011
Medvedeva Kira.......................................................P1.08-008 Mimaki Sachiyo...................................P3.02-035, P3.02-074 Mochizuki Sayaka....................................................P3.02-033
Meerang Mayura................................. P1.09-009, P3.09-010 Min Kyung Hoon.......................................................P2.01-035 Mochizuki Yumiko..............................MS 09.05, MTE 25.02
Mehmood Tahir...................................P1.17-007, P3.01-078 Min Young Joo........................................................... OA 08.07 Mody Kabir................................................................. OA 06.07
Mehra Ranee..............................................................P1.01-012 Minakata Takao........................................................ P3.16-008 Moens Lotte...............................................................P2.02-015
Mehta Anurag..........................................................P1.01-030 Minami Daisuke.........................................................P1.03-038 Moezi Mehdi...............................................................P1.01-051
Mehta Vivek................................................................P1.12-007 Minami Kazuhiro.......................................................P1.03-036 Moffatt Miriam........................................MA 06.13, P1.02-054
Mei Lijiang................................................................. P3.01-004 Minami Masato.................. MA 16.08, P1.02-068, P1.17-002, Moghal Nadeem...................................................... P3.03-008
Mei Ying Lim...........................................................P2.05-008 ................................................................. P1.17-013, P3.16-050 Mogi Akira........................P1.05-006, P1.16-007, P2.02-026
Meirelles Gustavo.....................................................P2.13-022 Minami Seigo........................................ P1.03-047, P1.03-049 Mogielnicka Katarzyna............................................P1.06-004
Meister Michael................P1.15-011, P3.05-007, P3.05-008 Minami Toshiyuki.................................................. P2.09-005a Mohakud Sudipta..................................................... P2.15-002
Mekhail Tareck............................................................MA 15.02 Minami Yuko.................... P2.02-073, P2.17-004, SH 02.03 Mohammed Abdallah S.R........................................OA 08.05
Melchior Linea C...................................................... P3.01-007 Minatel Brenda C............MA 15.12, P1.02-006, P3.02-090, Mohan Sharanya.............................. P2.05-004, P3.14-003
Melchor Rosario....................................................... P1.05-019 ..................................................................................P3.02-094 Mohankudo Siladitya............................................... P2.15-002
Meldgaard Peter.............P3.02-005, P3.02-052, P3.13-014 Minato Koichi................... P1.15-002, P2.03-010, P2.15-005 Mohapatra Prasanta R.....................P1.02-066, P2.15-002
Melek Huseyin................... MA 17.08, P2.14-016, P3.16-046 Minatta Jose N................................... P1.01-058, P2.03-039 Mohindra Nisha................ OA 07.03, P1.04-004, P1.04-005
Melesse Etienne..........................................................MA 05.12 Minchole Elisa....................MA 20.06, MA 20.08, P1.12-009 Mohindra Nisha A................................ P1.07-034, P3.02-013
Mellemgaard Anders............................P2.01-043, P3.16-017 Minchom Anna R............ P1.03-029, P2.07-049, P3.12-003 Mohorcic Katja........................................................ P2.09-004
Mellender Scott........................................................ P2.16-001 Minegishi Yuji.......................................................... P3.04-002 Moiseenko Fedor V................................................... P1.01-056
Melnick Mary Ann C................................................ P3.01-046 Minehart Janna........................................................... MA 10.10 Moizumi Sanae........................................................ P1.03-005
Melosky Barbara............ MA 02.08, P2.01-032, P3.01-015 Minelli Mauro..............................................................MA 02.05 Mok Tony.......................................................................OA 10.01
Melovic Martin.......................................................... P1.09-007 Minemura Hiroyuki..................................................P1.15-002 Mok Tony S...................... ISS 01.01, ISS 01.02, ISS 01.06,
Melsom Stephen.......................................................P2.13-002 Minenza Elisa............................................................ P1.01-053 ................. JCSE 01.24, JCSE 01.27, MA 07.01, MA 07.14,
Memon Saima.............................................................OA 06.01 Mineshita Masamiti..................................................P2.02-072 ........................... MA 12.07, MS 05.03, OA 05.01, P1.01-016,
Mini Enrico..................................................................... MA 11.11 ................. P1.01-032, P1.04-008, P1.04-011, P2.04-012,
Mencoboni Manlio.................................................. P3.13-006 ......................P3.01-012, P3.01-026, P3.01-039, P3.01-072,
Mendenhall Melody...................................................MA 02.07 Minna John.....MA 15.13, P1.15-005, P3.03-007, P3.03-013
Minnich Doug.............................................................MA 20.02 ........................................... P3.01-075, P3.02-031, P3.16-015
Mendoza Tito R......................................MA 18.08, P2.01-036 Molassiotis Alex.......................................................MTE 12.01
Menefee Michael E.................................................... OA 06.07 Mino Barbara...........................................................P3.03-027
Mino-Kenudson Mari..... MTE 02.02, OA 07.05, P1.07-033 Molina Julian............................................................ P2.01-054
Menendez Javier A..................................................P1.03-035 Molina Rafael......................................... P3.01-045, SS 01.03
Meng Min...................................................................P1.05-001 Minuti Gabriele...........................................................P1.01-015
Minzhe Guo............................................................... P1.02-014 Molina Romero Camilo...............................................MA 12.10
Meng Xianzhong......................................................P3.07-005 Molina-Vila Miguel-Angel................... MA 12.04, P1.01-075,
Meng Zhaoting......................................................... P3.01-084 Mio Tadashi................................................................P2.07-013
Miranda Fabiana A...................................................P2.14-003 ......................P1.07-015, P2.02-014, P2.02-034, P3.01-073
Menju Toshi........................................P3.02-046, P3.02-071 Molinier Olivier.............................................................OA 17.05
Menon Smitha...........................................................P1.07-008 Miranda Jesús........................................................... MA 07.03
Mirando-Devora Gerardo...........................................MA 16.12 Molins Laureano.........................................................OA 16.06
Meredith Gavin....................................P2.02-002, P2.02-014 Molmen Michael.........................................................P1.07-013
Merghli Adel..............................................................P3.13-026 Mirshahidi Hamid R.................................................. P1.16-006
Mirshahidi Saied....................................................... P1.16-006 Moloczij Natasha....................................................... MA 04.06
Merimsky Ofer......................................................... P2.07-026 Molto Valiente Consolación.....................................P1.07-028
Merrick Daniel T..........................................................MA 13.02 Misery Laurent......................................................... P2.07-023
Mishina Yuko....................................... P2.03-015, P2.07-007 Mondragon Mirna P..................................................MS 04.03
Merriott David............................................................. MA 13.01 Mondéjar Rebeca.............. MA 07.03, P1.01-057, P2.02-027
Mertsoylu Huseyin.................................................. P3.08-001 Mishra Pritinanda................................P1.02-066, P2.15-002
Misic Marija................................................................P3.01-059 Monkhorst Kim........................................................... OA 02.02
Mesa-Guzman Miguel..............................................P2.02-061 Monnai Makoto..........................................................P2.02-051
Mesia Carles.......................................P2.07-044, P2.08-006 Misino Andrea....................................... MA 01.07, P3.06-003
Misra Shagun........................................................... P2.14-005 Monnet Isabelle............................................................OA 17.05
Metzenmacher Martin............................................ P3.01-088 Mons Muriel.............................................................. P2.01-038
Metzger Susan......................................................... P2.07-059 Missy Pascale..............................................................OA 17.05
Misumi Yuki.............................................................P2.15-004 Monsó Eduard..................................... P1.05-019, P2.02-061
Meyer Catalina M.....................................................P3.07-006 Montagna Elisabetta Sara..................................... P3.06-003
Meyer Michael..............P3.03-016, P3.03-026, P3.05-002 Mitchell Jenny.......................................................... MA 08.05
Mitchell Mark........................................P2.13-005, P2.13-006 Montecalvo Joseph...................................MA 17.13, OA 18.06
Meyerson Matthew............ ES 08.05, MA 06.14, MA 12.06, Montero Angeles............................... P2.02-042, P2.02-043
...................................................................................P3.02-086 Mitchell Paul........................................P2.02-039, P3.02-038
Mitchell Timothy................................P1.14-018, P3.09-002 Montes Servin Elizabeth.........................................P1.07-040
Meza Rafael...............................................................WS 01.07 Montes-Servin Edgar.......... MA 08.10, MA 12.10, P1.07-040
Mezheyeuski Artur.................................................. P1.07-021 Mitsudomi Tetsuya......... ES 08.01, ISS 06.01, ISS 06.05,
..........................ISS 06.06, MA 05.04, MA 12.07, OA 07.06, Montorsi Marco..........................................................P1.16-027
Mezquita Laura.................... MA 05.03, MA 10.11, MA 11.01, Montuenga Luis M.......... P2.02-061, P3.07-007, WS 02.11
........................................ P1.03-013, P1.08-009, P2.01-038, ..........................................P1.03-005, P3.02-059, P3.16-049
Mitsufuji Hisashi..................................................... P2.03-002 Moon Hwa Sik......................................P1.03-025, P1.03-030
...........................................................P2.07-005, P2.07-060
Mitsuhashi Atsushi...................................................P2.07-031 Moon James............................................................. P3.01-046
Mi Gu......................................................................... P1.03-050
Mitsui Yuichi...................................... P1.02-032, P2.06-003 Moons Johnny........................................ OA 16.06, P1.13-007
Miao Jieling.............................................OA 14.07, P3.01-046
Mitsuishi Yoichiro....................................................P3.02-086 Mooradian Meghan J............................ OA 07.05, P1.07-033
Miao Liyun................................................................P3.02-087
Mitsuoka Shigeki.......................................................P1.06-014 Moorcraft Sing Yu...................................................P2.07-049
Miccianza Annamaria............................................ P3.06-003
Mitsuyoshi Takamasa.........................P1.14-015, P2.05-002 Moore Elizabeth H..................................MA 15.08, P1.07-013
Michael Epstein.........................................................P3.02-014
Mittman Nicole............................................................MA 16.03 Moore Jarrett........................................................... P3.02-077
Michael Michael........................................................ P1.09-012
Miura Jun...................................................................P1.02-033 Moore Ryan F.......................................P2.13-005, P2.13-006
Michaud Gaetane C.................................................... MA 10.10
Miura Naoko..............................................................P3.16-003 Moore Sara.............................................................P2.05-003
Michel-Tello David..................................................... MA 08.10
Miura Satoru............................................................ P2.03-015 Mora Marco...............................................................P1.07-023
Michor Franziska........................................................MA 12.06
Miura Yosuke........................................P2.01-027, P2.15-016 Morabito Alessandro............................ P1.01-015, P3.01-043
Michálek Pavel...........................................................MA 20.04
Miwa Crystal............................................................... OA 14.07 Moraes Fabio Y..................................P2.14-003, P3.14-013
Mick Rosemarie...........................................................OA 17.08
Miwa Ken...........................P1.02-060, P1.02-061, P1.13-008 Morales Arturo......................................................... P1.12-009
Micke Patrick..................... MA 05.13, MA 06.01, P1.07-020,
.....................P1.07-021, P2.02-015, P2.02-023, P2.02-066 Miya Toshimichi........................................................P1.02-033 More Sucheta B.......................................................P2.03-027
Micklem David............................................................MA 02.09 Miyabayashi Takahiro.............................................. P2.03-015 More Suchita............................................................. P2.01-051
Midthun David............................................................P1.07-016 Miyabe Shingo............................................................ P1.16-019 Moreira Andre L.................................MTE 06.01, P3.03-007
Miedema Jelle...........................................................P1.02-038 Miyakawa Akifumi.....................................................MS 24.04 Moreno Haritz.......................................................... P3.07-007
Mielgo Xabier............................................................. MA 07.03 Miyamoto Atsushi....................................................P3.02-033 Moreno Jiménez Miguel Ángel...............................P1.07-036
Migliorino Maria Rita........... MA 10.06, OA 05.01, P1.01-013, Miyamoto Hikaru.................................P2.16-003, P3.16-032 Moreno Victor............................................................ MA 01.05
............................................................... P3.01-005, P3.01-012 Miyasaka Miwako.............. P1.03-033, P2.16-010, P3.13-012 Morgan R. H...............................................................OA 06.02
Morgan Shethah........................................................ OA 09.06 Muranishi Yusuke....................................................P1.14-005 Nakai Tokiko.............................................................. P2.01-065

Morgensztern Daniel........... MA 02.10, MA 03.01, MA 10.02, Murase Ryoko..........................................................P3.02-033 Nakaji Hitoshi........................................................... P2.07-024
................................................................................... P2.04-013 Murata Yoshihiko.....................................................P2.02-073 Nakajima Eiji....................................... P1.02-025, P2.03-019
Mori Keita.................................................................. P2.15-005 Murayama Sadayuki............................................... WS 02.09 Nakajima Hiroki......................................................... P3.16-010
Mori Masahide.........................................................P2.07-009 Murayama Shigeyuki............................................. P2.05-005 Nakajima Jun...................MTE 01.01, P1.07-017, P1.13-002,
Mori Mio..................................................................... P1.03-015 Murer Bruno............................................................ P1.09-007 ....................................................................................P3.16-028
Mori Takeshi..........................................P1.15-014, P1.16-002 Murillo Boris A........................................................... MA 20.01 Nakajima Takahiro........ MTE 08.01, P1.02-034, P1.16-008,
Mori Yoshiaki............................................................ P1.03-004 Murphy Danielle A......................................................OA 12.06 .........................................P2.07-008, P2.12-006, WS 04.03
Moriguchi Satoshi................................................... P2.06-009 Murphy David...............................................................MA 19.10 Nakamichi Toru..................................P2.09-007, P3.09-009
Moriguchi Shuhei....................................................P3.02-033 Murphy Michelle.................................................................9941 Nakamura Akifumi.................................................. P3.09-009
Morihara Nagisa......................................................P3.02-009 Murray Andrea...........................................................P2.13-013 Nakamura Akihiro.................................P1.16-025, P3.16-002
Morikawa Kei............................................................P2.02-072 Murthy Sudish...............................................................MA 17.11 Nakamura Atsushi...................................................P2.07-004
Morikawa Naoto...................................................... P2.06-009 Murthy Vivek............................................................... MA 10.10 Nakamura Daisuke................................................... P1.03-015
Morikawa Sayako.................................................... P2.07-028 Musallam Lina.......................................................... P2.07-029 Nakamura Haruhiko.................................................P3.15-002
Morimoto Takeshi.................................................... P2.03-014 Mussi Alfredo...............................................................MA 17.01 Nakamura Hiroshige........P1.02-060, P1.02-061, P1.13-008
Morin Franck........................... OA 03.01, OA 16.03, OA 17.05 Mutale Faith..................................................................OA 17.08 Nakamura Makoto................................................... P2.03-005
Morin Paul E...............................................................MA 05.07 Muthu Valliappan............................... P1.03-018, P2.03-053 Nakamura Masaki....................................................P3.14-001
Morinaga Ryotaro...............................P1.03-004, P1.08-006 Mutrie Chris............................................. OA 15.08, P2.16-019 Nakamura Naoki................................. P2.05-005, P3.14-001
Morise Masahiro.......................................................P3.03-013 Mutti Luciano............................................................ P1.09-007 Nakamura Nobuyuki................................................P3.02-048
Morita Mitsunori.......................................................P2.01-001 Muzikansky Alona....................................................... OA 12.02 Nakamura Ryo..........................................................P2.02-051
Morita Ryo..................... P2.03-036, P2.03-048, P3.02-041 Muñoz Andrés J........................................................ MA 07.03 Nakamura Shinichiro............................................. P2.03-008
Morita Satoshi..................OA 05.03, P2.03-010, P2.03-045 Muñoz Miguel...........................................................P2.03-039 Nakamura Shota........... P1.08-002, P1.17-004, P3.09-006
Morita Shigeki...........................................................P3.16-028 Muñoz Miguel Angel...................................................PL 02.04 Nakamura Sukeyuki............................................... P2.03-005
Moriya Yasumitsu....................................................P2.02-063 Muñoz Nerea.............................................................. MA 07.03 Nakamura Tatsuo..................................................... P1.14-005
Moriyama Satoru................MA 16.10, P1.17-005, P2.17-001 Muñoz Platón Enriqueta.......................................... P1.06-013 Nakamura Tomomi............................ P2.03-009, P2.03-011
Mornex Francoise..................................................... ES 10.02 Muñoz Silvia.............................................................. P1.01-075 Nakamura Toru........................................................P3.16-001
Moro-Sibilot Denis.................................... OA 17.05, OA 17.07 Mv Chandrakanth.....................................................P3.03-015 Nakamura Yoshihiro................................................ P2.16-004
Moroga Toshihiko................................................... P2.16-020 Myers Renelle L..................MA 14.11, P2.13-011, P2.13-012 Nakamura Yukiko.....................................................P2.07-042
Morokawa Nasa.......................................................P3.02-033 Myint Zin...................................................................P3.15-010 Nakamura Yusuke................................................... P1.02-017
Moron Asensio Sara................................................P1.07-028 Mylliemngap Badari................................................. P1.03-018 Nakanishi Masanori................................................. P2.07-035
Morra Aldo...................................................................MA 19.02 Mynt Zin W............................................................... P2.07-051 Nakanishi Ryoichi................ MA 16.10, P1.17-005, P2.17-001
Morris Brett............................................................. P3.04-009 Myojin Miyako.............................................................MA 09.06 Nakanishi Yoichi...............ES 09.02, P1.03-004, P1.07-014,
Morris Clive.................................................................. MA 11.01 Myšíková Dagmar...............................P2.07-020, P3.07-008 ........................................P1.08-006, P2.03-008, P3.01-035,
Morris Lindsay K.......................................................MA 06.07 Márquez Diego......................................................... P3.01-065 ............................................................ P3.04-002, P3.04-004
Morris Steve............................................................... OA 02.05 Márquez Lobo Bélgica.............................................P1.07-036 Nakanishi Yoko...............P1.03-009, P2.02-057, P2.15-015,
Morris Zachary....................................................... P3.04-009 .................................................................................... P3.03-011
Márquez-Rodas Iván.................................................P1.07-015
Morrison Carl D.......................................................... MA 11.06 Nakano Takashi................P1.09-011, P1.14-006, P3.09-004
Märten Angela..................P3.01-026, P3.01-039, P3.01-075
Morsli Nassim............................................................P1.09-011 Nakano Tomoyuki.................................OA 18.07, P3.02-089
Mælandsmo Gunhild...............................................P2.02-053
Mortensen Jann........................................................ P3.13-011 Nakano Yasushi......................................................P3.10-007
Mortimer Stefanie................................P3.02-011, P3.05-012 Nakao Masayuki............. P1.13-005, P2.05-016, P3.13-009
Morán Teresa..................... MA 15.01, P1.01-062, P1.05-015, Nakaoka Koujiro........................................................P3.16-039
................................................................. P2.07-041, PL 02.04 N Nakaoku Takashi.....................................................P3.03-010
Moscoso Fernández Salvador Miguel....................P1.17-008 Nakashima Chiho.............P1.01-028, P2.03-009, P2.03-011
Moseley Ellen.............................................................. MA 11.02 Na Bub-Se.............................................................. P3.09-008 Nakasone Shoko.....................................................P3.02-074
Moskovitz Mor.............................................................MA 16.03 Na Kook-Joo......................................... P2.03-024, P2.14-017 Nakata Kensei.............................................................MS 24.04
Mostel Jadmin....................................... MA 04.05, P1.10-007 Nabeshima Kazuki.................................................. P2.09-006 Nakata Masao...................................... P2.02-028, P2.02-031
Motas Natalia..............................................................P3.16-018 Nackaerts Kristiaan...........OA 02.01, P1.13-007, P3.09-003 Nakatani Yukio..........................................................P2.07-008
Motegi Atsushi.......................................................... P3.14-001 Nadal Ernest..................MA 07.03, P2.07-044, P2.08-006, Nakatomi Katsumi................................P1.03-015, P2.07-045
.................................................................................... P3.01-071 Nakatsuka Seishi.....................................................P1.05-005
Motoi Noriko.................. P1.02-009, P1.05-002, P2.02-035,
..........................................P3.02-035, P3.02-041, P3.13-009 Nadira Narine............................................................P1.03-001 Nakayama Eiichi.................................. P2.07-015, P2.07-018
Motoishi Makoto........................................................P1.03-037 Nafteux Philippe.......................................................P3.09-003 Nakayama Haruhiko.........P1.05-011, P1.05-018, P1.05-021,
Motomura Hiroaki...................................................P1.03-006 Nagai Hiroki................... P2.01-021, P2.03-055, P2.07-003, ............................................P2.17-003, P3.15-012, P3.16-047
....................................................................................P2.07-017 Nakayama Takefumi................................................. P1.03-031
Motono Nozomu.....................................................P3.02-085
Nagao Toshitaka................P1.01-041, P2.05-012, P3.02-012 Nakayama Tomio........................................................MA 14.06
Motooka Yamato.................................... P1.15-014, P1.16-002
Nagaoka Tetsutaro.................................................. P1.03-006 Nakayama Yuko.........................................................ES 10.04
Motoyama Hideki................................ P3.02-046, P3.02-071
Nagasaka Misako................................................... P2.07-040 Nakazato Yoshimasa................................................ P1.02-018
Motta Rodrigo..........................................................P1.05-022
Nagase Takahide......................................................P2.03-046 Nakazawa Seshiru..................................................P1.05-006
Motwani Monica................................... MA 02.10, P1.04-006
Nagashima Makoto................................................... P1.03-031 Nakazono Chiaki...................................P1.02-022, P1.17-009
Mountzios Giannis................................................... MA 09.05
Nagashima Takeshi............................ P2.15-008, P3.05-006 Nam Arin.....................................................................MS 25.02
Mourlanette Pierre......................................................OA 17.05
Nagashima Takuya......... P1.05-011, P1.05-018, P1.05-021, Nam Hae-Seong......................................................P2.01-016
Mousli Alia................................................................ P3.14-008
............................................P2.17-003, P3.15-012, P3.16-047 Namba Kei..................................................................P2.16-026
Mrazkova Hana...................................P2.07-020, P3.07-008
Nagashima Yasushi..................................................P1.02-033 Namba Yukiko.......................................................... P1.03-006
Mu Shuo.....................................................................P1.07-038
Nagata Kenji................................................................MA 09.06 Namura Yuki..............................................................P1.03-037
Mu Yuxin............................................. P2.01-029, P2.01-030
Nagata Toshiyuki..................................................... P2.16-004 Nan Kejun.........................P3.01-087, P3.03-006, P3.03-017
Mudad Raja.......................P1.06-018, P1.07-024, P1.07-025,
Nagata Yasushi....................................................... MTE 29.01 Nan Wu....................................................OA 16.08, P1.02-051
................................................................................... P2.07-037
Nagatomo Izumi..................................P2.07-009, P3.02-023 Naoki Katsuhiko..................................P2.03-012, P3.02-084
Muggeri Alejandro...................................................P2.03-039
Nagaya Motoki.................................... P3.09-006, P3.16-010 Naomoto Yoshio........................................................ P1.02-014
Mughal Tariq I.............................................................P1.01-031
Nagayama Kazuhiro..........P1.07-017, P1.13-002, P3.16-028 Napoli Francesca.....................................................P2.02-054
Muhammad Natisha....................................................OA 17.08
Nagayasu Takeshi..................................................... P1.02-014 Naqi Ali....................................................................... P1.02-010
Muir Jean-François................................................... OA 16.03
Nagy Andrew..............................................................MA 18.02 Narabayashi Tomoko...............................................P1.07-004
Mukae Hiroshi..................P1.03-015, P2.07-045, P3.15-001
Nagy Rebecca J..................... MA 15.02, OA 09.01, OA 12.05 Naraki Lucimeire M..................................................P3.03-019
Mukai Masaya.............................................................P1.02-017
Nahar Rahul................................................................OA 09.07 Nardi-Agmon Inbar..................................................... MA 18.11
Mulawarman Achmad..........................P1.01-026, P1.01-067
Naidoo Anestasia.......................................................P3.13-021 Nardo Giorgia...........................................................P3.02-006
Muley Thomas..................P1.15-011, P3.05-007, P3.05-008
Naidoo Jarushka...................................................... MA 09.08 Nardone Valerio.......................................................P2.07-046
Mulford Deborah A............................... P2.01-014, P2.01-015
Naidu Babu.......................MA 08.09, P1.10-002, P3.10-005, Narita Shoko........................................................... P2.03-036
Mullan Damian............................................................. MA 17.14
....................................................................................P3.16-024 Naronha Vanita......................................................... P1.01-024
Mullon John J............................................................P1.07-016
Naik Hiten................................................MA 04.02, MA 16.03 Narukami Eri.............................................................P1.02-034
Mulshine James L............WS 01.01, WS 01.34, WS 01.38
Naik Suprava............................................................ P2.15-002 Naruke Masao...........................................................P3.10-007
Multani Pratik S..........................................................OA 14.06
Nair Viswam S............................................................ MA 13.01 Nashed Andrew..........................................................MA 15.02
Mulvey Arthur............................................................P1.07-018
Naito Hisamichi.........................................................P3.16-050 Nasser Elias..............................................................P3.14-003
Mummudi Naveen................................................... P2.14-005
Naito Yujiro...............................................................P2.07-009 Nasute Fauerbach Paola V........................................OA 15.01
Mun Mingyon.................. P1.13-005, P2.05-016, P3.13-009
Naka Go.......................... P2.03-005, P2.03-033, P3.01-055 Natale Ronald............................................................. MA 10.05
Munden Reginald.........................................................MA 14.13
Nakada-Kubota Reiko................................................OA 04.02 Naumovski Louie........................................................MA 02.10
Munhoz Felipe...........................................................P1.06-010
Nakagaki Noriaki...................................................... P1.03-004 Naunheim Keith..........................................................OA 04.06
Munoz-Largacha Juan A........................................ P1.05-013
Nakagawa Hideyuki................................................. P2.03-014 Navani Neal............................................................. P1.05-010
Muntham Dittapol.................................................... P3.01-042
Nakagawa Kazuhiko.. ISS 02.01, ISS 02.06, MA 19.01, OA Navarrete Constanza............................................. P3.08-005
Murakami Daigo................................. P1.05-003, P3.09-005 ..................................05.01, OA 05.03, OA 05.08, P1.07-010,
Murakami Haruyasu............ MA 12.02, OA 05.03, OA 05.08 Navarro Alejandro.................................................... P1.05-015
...................P2.03-008, P2.03-045, P2.07-021, P2.15-004,
Murakami Isao.............................................................OA 07.06 .....................P3.01-012, P3.01-071, P3.01-072, PC 03.02 Navarro-Martin Arturo.......................................... P2.08-006
Murakami Kotaro......................................................P1.02-025 Nakagawa Kazuo..................................................... P1.05-002 Nawa Takeshi........................................MA 14.06, P3.16-039
Murakami Naoya........................................................MS 24.04 Nakagawa Ken.................P1.13-005, P2.05-016, P3.13-009 Nawrocki Sergiusz...................................................P3.13-032
Murakami Shuji..............P2.03-036, P2.03-048, P2.07-011, Nakagawa Tohru.........................................................MA 14.06 Nayak Mamita........................................................... P1.02-066
......................................................................................PL 02.02 Nakagawa Tomoki..................................................... OA 05.03 Nead Michael A.......................................MA 20.01, MA 20.03
Murakami Sinsuke................................................... P2.01-065 Nakagawa Yoshiko.......... P1.03-009, P2.15-015, P3.03-011 Neal Joel W........................................JCSE 01.13, MA 07.02,
Murakami Toshi.......................................................... OA 12.03 .................................................................MA 13.01, P2.03-043
Nakagomi Takahiro....................................................MA 05.08
Murakami Yoshitaka................................................. P1.03-031 Nechushatan Hovav................................................P3.03-028
Nakahara Hirofumi....................................................MA 04.09
Murakawa Tomohiro............................MA 05.06, P2.16-005 Nechushtan Hovav...............................MA 02.06, P3.01-056
Nakahara Yoshiro.................................MA 16.04, P2.03-002
Neemann Nicole.......................................................P3.01-038 Nishiyama Noritoshi...........................P2.16-003, P3.16-032 Ognjanovic Simona................................................ P3.05-005
Negi Yoshiki........................................................... P2.09-005a Nishizawa Tsukasa.................................................. P1.03-009 Ogura Takashi...........................................................P2.01-001
Neji Henda..........................................P3.13-025, P3.13-026 Nitadori Jun-Ichi................P1.07-017, P1.13-002, P3.16-028 Oguri Tetsuya.......................................................... P2.03-008
Nelson Alan..................P3.03-016, P3.03-026, P3.05-002 Nito Madoka.......................P1.05-011, P1.05-018, P1.05-021, Ogusu Shinsuke........................................................ P2.03-011
Nelson Darlene R......................................................P1.07-016 ............................................P2.17-003, P3.15-012, P3.16-047 Oh Gi-Su................................................................... P1.02-003
Nelson Doug.............................................................. P1.03-014 Niu Tianye...................................................................P1.14-001 Oh In-Jae........P1.01-013, P1.01-014, P2.03-024, P2.14-017
Nelson Heather....................................................... P3.05-005 Niu Xiaomin.........................................JCSE 01.12, P3.01-070 Oh Jee Youn..............................................................P2.01-035
Nematollahi Massey................................................. WS 03.12 Niwa Hiroshi.............................................................P2.07-022 Oh Min Hee..................................................................MA 05.12
Nemoyer Rachel....................................................... P2.16-001 Niwa Takashi....................................... P2.01-001, P2.03-008 Oh Ryooong-Jin.........................................................MA 09.06
Netchaeva Maria.......................................................P3.01-038 Nochang Julia...........................................................P2.13-020 Oh Young-Taek..........................................................P1.15-015
Neuberger Manfred...................................................MA 18.10 Noe Johannes..................JCSE 01.27, MA 07.01, P3.02-061 Ohara Sayaka...................................... P1.01-054, P2.03-017
Neumann Jens...........................................................P1.07-019 Noerholm Mikkel....................................................... P1.03-013 Ohara Shuta....................................... P3.02-059, P3.16-049
Neupane Prakash.....................................................P2.07-019 Nogami Naoyuki................. MA 07.11, OA 05.08, P2.05-009, Ohashi Kadoaki......................................MA 07.11, P2.04-005
Neuteboom Saskia T............................................... P3.01-048 ....................................................................................P3.01-072 Ohashi Kota.......................................... P1.16-008, P2.12-006
Nevala Wendy............................................................. OA 13.07 Noguchi Masayuki.........P1.02-071, P2.02-025, P2.02-055, Ohashi Shizuko..........................................................MA 09.06
Newman Edward.........................................................MA 02.11 ...............................................................P2.02-073, P3.16-039 Ohashi Takuya..................P1.03-033, P2.16-010, P3.13-012
Newton Jared.......................................................... P3.14-008 Noguerón Esther....................................................... MA 07.03 Ohashi Yasuo............................................................P3.01-055
Nex Giulia...................................................................P2.17-002 Noh Jae Myoung..................................................... P3.08-006 Ohbayashi Chiho...................................................... P2.01-065
Ng Calvin S.H.............................................................P3.16-015 Noh O Kyu................................................................... P1.15-015 Ohde Yasuhisa................ P2.15-008, P3.05-006, P3.16-011
Ng Christine..........................................P1.02-016, P3.03-008 Nojima Yuji........................................... P2.02-028, P2.02-031 Ohe Yuichiro...... MA 16.04, MA 17.06, MA 19.01, MS 05.04,
Ng Colin....................................................................... P1.16-013 Nokihara Hiroshi................. MA 16.04, OA 05.03, P2.07-011, ......................................... OA 05.08, P2.02-035, P2.03-036,
Ng Isaac K.S............................................................ P3.01-022 ....................................................................................P3.02-041 ..................... P2.03-048, P2.07-011, P2.15-004, P3.02-041
Ng Kenneth................................................................P1.03-028 Nomiya Takuma.........................................................MS 24.04 Oheda Hodaka........................................................... P1.16-008
Ng Kevin.................................................. OA 07.07, P1.02-006 Nomizo Takashi..............P2.01-021, P2.03-055, P2.07-003, Ohira Tatsuo........................ES 05.03, P1.01-041, P1.07-012,
....................................................................................P2.07-017 ..................... P1.16-010, P2.02-009, P2.03-019, P2.05-012,
Ng Kevin W...........................MA 10.09, MA 15.12, P3.02-094
Nonaka Daisuke....................................................... P1.09-007 .............................................................P3.02-012, P3.07-003
Ng Quan Sing.......................................... OA 09.07, P3.01-017
Nong Jingying.............................................................MA 01.03 Ohki Emiko................................................................ P1.03-008
Ng Raymond T..........................................................P3.02-091
Noor Zorawar.......................................MA 02.07, P2.07-038 Ohnami Shumpei............................... P2.15-008, P3.05-006
Ng Sher May............................................................P1.06-016
Norgaard Mette........................................................ P2.01-043 Ohnishi Kayoko......................................................P2.05-005
Ng Terry L................................................................P2.02-011
Normanno Nicola..................................................... P3.01-068 Ohno Takashi.....................P1.02-060, P1.02-061, P1.13-008
Ngamphaiboon Nuttapong.........................................OA 11.04
Noronha Vanita................. P1.01-021, P1.01-023, P1.03-021, Ohno Tatsuya............................................................ P1.14-006
Ngocamus Maud.......................................................... MA 11.01 ...................... P2.01-051, P2.03-027, P3.01-076, P3.03-015
Ngodnbamthaweesuk Montien..............................P3.03-020 Ohno Yoshiharu........................................................ ES 02.05
Nosaka Kanae.......................................................... P1.02-060 Ohri Nitin....................................................................P2.13-008
Nguyen Andrew D.D........................ P2.05-004, P3.14-003 Notsuda Hirotsugu..................................................P1.02-016
Nguyen Dao M..........................................................P1.16-022 Ohsawa Fumi...................................... P1.02-031, P3.16-029
Nouriany Nazanin..................................................... P1.10-003 Ohshima Keiichi................................. P2.15-008, P3.05-006
Nguyen Enza E........................................................ P3.10-004 Novak Metka...............................................................P1.01-074
Nguyen Michelle......................................................... OA 12.07 Ohshio Mayumi........................................................ P1.02-030
Novellis Pierluigi................................ P1.07-032, P1.16-027 Ohshio Yasuhiko...........P1.02-030, P1.03-037, P3.02-003,
Nguyen Tom............................................................... MA 07.08 Novello Silvia..................... GR 01.05, ISS 02.03, MA 19.03, ....................................................................................P3.16-048
Ni Ai..............................................................................OA 14.05 ..........................OA 02.01, P1.01-013, P1.01-015, P1.04-002, Ohta Mitsunori............................................................MA 17.04
Ni Andy........................................................................OA 10.03 .................... P2.03-058, P2.09-003, P3.06-003, YI 01.01 Ohtani Keishi.............................................................P1.16-010
Ni Yang.......................................................................P1.05-001 Novoa Nuria................................................................OA 04.06 Ohtani Shinji..............................................................P2.16-026
Nicholas Garth...................... MA 20.11, OA 15.01, P2.01-032 Novosiadly Ruslan..................................................P3.07-006 Ohtsu Syuji................................................................P2.14-007
Nicholson Andrew G...........ES 01.04, MA 06.13, OA 03.02, Nowak Anna......................MA 19.03, MS 08.04, P1.09-011,
.................................................................P1.02-054, P1.17-019 Ohtsuka Takashi............. MA 05.04, MA 16.09, P1.05-005,
.................................................................................. P3.09-004 ................................................................P1.05-009, P3.13-031
Nicholson Siobhan......... P1.02-011, P1.03-039, P2.02-064, Nozaki Koichiro................................... P2.03-015, P2.07-007
...................................................................................P3.02-053 Ohue Yoshihiro...................................P2.07-015, P2.07-018
Nueesch Eveline...................................JCSE 01.27, MA 07.01 Ohyanagi Fumiyoshi.............................MA 16.04, P3.01-072
Nickens Dana........................................................... P1.03-003 Nukiwa Toshihiro............P2.03-010, P2.03-021, P3.01-035
Nicotra Claudio.......................................................... P1.03-013 Oi Hajime................................................................. P2.01-037
Numico Gianmauro.................................................. P1.01-053 Oizumi Satoshi..................MA 19.01, P2.01-005, P2.03-010,
Nicoś Marcin.............................................................OA 08.03 Nunes David.............................................................P3.02-002 .................................................................................. P3.04-004
Nidam Meital..............................................................P3.13-030 Nunes Filho Paulo Ricardo.....................................P3.16-034 Ojeabulu Philip........................................ OA 15.08, P2.16-019
Nielsen Morten............................................................OA 01.02 Nurwidya Fariz..................................P1.02-065, P3.02-024 Oka Mikio.............................................. P2.07-015, P2.07-018
Nielsen Tine Bjørn......................................................OA 01.02 Nusch Arnd.............................................................. P3.01-088 Okabe Kazunori.............P1.05-003, P3.09-005, P3.13-013
Niemeijer Anna-Larissa N......................................MA 05.07 Nuthalapati Silpa......................................................... MA 17.07 Okada Asuka...........................................................P2.01-065
Nieto Mangudo Beatriz............................................P1.01-060 Nuño Ana.................................................................. P3.01-065 Okada Hironobu.........................................................P1.16-026
Nieva Jorge........................................... MA 07.02, P1.11-004 Nygaard Vegard........................................................P1.02-028 Okada Morihito.................. MA 19.01, P1.02-002, P1.02-052,
Nihei Keiji....................................................................MS 24.04 Nygårad Ståle............................................................P1.02-028 ........................................... P2.05-011, P2.09-008, P2.15-011
Niho Seiji...............................MA 17.06, MS 07.02, OA 05.01, Nævdal Eline M.........................................................P2.01-047 Okada Satoru.......................................P1.02-022, P1.17-009
............................................P3.01-012, P3.01-072, P3.14-001
Okada Satoshi.........................................OA 16.07, P3.02-074
Niibe Yuzuru............................................................. MA 09.06
Okada Yasuko.......................................................... P2.09-008
Niimi Akio...................................................................P1.03-027
O Okajima Masaaki...................................................... P2.03-015
Niiya Yumiko............................................................. P3.16-008
Okami Jiro..............................................MA 17.04, P2.05-010
Niki Toshiro....................... OA 18.07, P1.02-041, P3.02-089,
...................................................................................P3.02-093 O’Brien Cathal P.................................... MA 04.10, P3.02-053 Okamoto Hiroaki...............MA 17.06, MS 20.03, P2.07-042,
................................................................................... P2.15-004
Nikitina Tatiana P....................................................... P1.01-056 O’Brien Mary................................................................OA 17.06
Okamoto Isamu.................OA 05.02, P1.03-004, P1.07-014,
Nilsson Jonas.....................................P1.06-002, P1.14-008 O’Connell Rachel........................................................P1.01-011
...................P1.08-006, P2.03-045, P2.15-004, P3.01-075,
Nilsson Mats..............................................................P2.02-015 O’Donnell Dearbhaile M........................MA 04.10, P1.09-007 ............................................................ P3.04-002, P3.04-004
Nilsson Monique.....................................OA 12.01, P3.03-027 O’Donnell Martin........................................................ MA 04.10 Okamoto Keigo.................P1.02-030, P1.03-037, P3.16-048
Ninomiya Hironori...............................P2.05-016, P3.13-009 O’Dowd Emma L.................................................... P2.06-005 Okamoto Mariko.......................................................P2.02-072
Ninomiya Kiichiro.......................................MA 07.11, OA 12.03 O’Dwyer Peter J.......................................................P1.03-026 Okamoto Norio..........................................................P1.03-047
Ninomiya Takashi......................................................P1.03-038 O’Hanrahan Emer................................................... P3.01-005 Okamoto Taku........................................................... P2.01-018
Nishi Tatsuya.............................................................P1.03-038 O’Kelly Patrick............................................................ MA 04.10 Okamoto Tatsuro............P1.07-002, P1.07-014, P2.05-017,
Nishida Yoshihiro................................ P3.09-006, P3.16-010 O’Rourke Noelle...................................................... P3.04-006 ...............................................................P3.02-039, P3.16-003
Nishiguchi Haruka................................P1.03-033, P3.13-012 Oak Chulho................................................................P3.01-033 Okano Tetsuya..................P1.01-041, P1.16-010, P2.02-009,
Nishihira Morimichi.............................P1.02-018, P3.02-064 Oakes Christopher...................................................P2.02-067 ...............................................................P2.05-012, P3.02-012
Nishii Kai.................................................................... P1.16-008 Obayashi Kai.............................................................P1.05-006 Okazaki Akihito........................................................ P1.03-004
Nishijima-Futami Yu................................................ P1.03-049 Obermannová Radka................................................ OA 05.07 Oki Tomonari............................................................P2.16-015
Nishikawa Atsushi...............................MA 09.06, P2.05-009 Obholz Kevin............................................................... MA 07.14 Okimoto Tomoaki.................................................... P2.05-005
Nishikawa Shigeto.............................P3.02-046, P3.02-071 Obilade Sandra........................................................ P3.10-002 Okita Riki.............................................P2.02-028, P2.02-031
Nishimaki Haruna............P1.03-009, P2.02-057, P2.15-015 Obispo Berta..................... MA 07.03, P1.01-057, P2.02-027 Okubo Kenichi..........................................................P3.02-035
Nishimura Masaharu............................................... P2.01-005 Oblitas George.................. P1.01-019, P1.01-022, P1.09-013, Okuda Katsuhiro.................MA 16.10, P1.17-005, P2.17-001
Nishimura Motohiro...... P2.05-013, P2.16-006, P2.16-008 ...................................................................................P3.02-063 Okui Masayuki........................................................... P1.12-006
Nishimura Toshihide................................................P3.15-002 Ocak Sebahat..................................... P3.15-004, P3.15-004 Okuma Hiromichi......................................................P1.03-036
Nishimura Yoshiharu....... P1.03-033, P2.16-010, P3.13-012 Ocana Alberto.............................................................OA 14.02 Okuma Yuriko.......................................................... P2.03-002
Nishine Hiroki...........................................................P2.02-072 Ochoa M. Pilar........................................................... MA 07.03 Okuma Yusuke........................................MA 16.04, P1.17-006
Nishino Masaya....................................P3.02-059, P3.16-049 Ochsenbein Adrian...................................................... MA 15.11 Okumura Manabu..................................................... P1.03-015
Nishino Mizuki...................................P1.01-055, P2.07-002 Oda Risa................................ MA 16.10, P1.17-005, P2.17-001 Okumura Meinoshin............MA 16.08, MA 17.04, MS 06.01,
Nishino-Habatu Mizuki.............................................MA 05.02 Oda Yoshinao..................... OA 13.06, P1.07-002, P1.07-014, .........................P1.02-068, P1.17-002, P1.17-013, P3.16-050
Nishio Kazumi...........................................................P3.10-007 ....................................................................................P3.16-033 Okumura Sakae...............P1.13-005, P2.05-016, P3.13-009
Nishio Kazuto....................................... MS 25.04, P2.07-021 Odegaard Justin...................................P3.02-011, P3.05-012 Okuno Motoyasu......................................................P1.08-006
Nishio Makoto.....MA 12.02, MA 16.04, MA 17.06, OA 05.03, Oellers Michel......................................................... P2.08-007 Olah Zachary T...........................................................OA 14.05
.........................................OA 05.08, P1.03-005, P2.04-005 Oertel Vance............................................................. P2.04-012 Oliaro Alberto..........................................MTE 17.02, OA 16.02
Nishio Wataru............................................................P1.03-036 Oezkan Filiz.............................................OA 18.02, P3.13-033 Oliveira Cristina........................................................P3.01-049
Nishioka Kiyonori........................................................MA 17.04 Officer Ann.............................................. MA 18.12, P3.13-003 Oliveira Humberto.................................................... P1.16-028
Nishisaka Takashi.....................................................P1.02-052 Offin Michael...........................OA 10.03, OA 10.05, OA 14.05 Oliveira Júlio........................................................... P3.01-049
Nishiyama Akihiro....................................................P2.01-001 Ogawa Kazumasa....................................................P3.02-033 Oliveira Mariana C.D...........................P2.10-006, P3.10-001
Nishiyama Hiroyuki..................................................P2.17-004 Ogi Takahiro............................................................. P2.01-005 Oliver Georgia............................................................ MA 04.01
Nishiyama Masahiko...............................................P2.02-026 Ogino Takashi.......................................................... P2.05-005 Olivera Julio............................................................... MA 07.03
Olivier Kenneth...........................................................MA 13.08 Oyama Tetsunari.....................................................P2.02-026 Papari-Zareei Mahboubeh...................................... P1.15-005

Olivieri Eloisa H.R................MA 01.01, OA 07.08, P3.15-006 Ozaki Daisuke.......................................................... P2.09-006 Papi Maximilian...........................................................MA 01.07
Olmedo Maria Eugenia........................... MA 01.05, MA 07.03 Ozaki Mari.................................................................P3.02-084 Papiewski Wojciech.................................................P3.02-045
Olmez Omer Fatih................................................... P2.01-063 Ozaki Masatoki...........................................................MA 09.06 Paradela Marina........................................................ P1.16-017
Omiyefa Seye O.....................................................P3.06-004 Ozasa Hiroaki.................P2.01-021, P2.03-055, P2.07-003, Parajian Armen...........................................................MA 16.03
Omura Seiji..................................................................P1.17-017 ....................................................................................P2.07-017 Paranal Raymond....................................................P3.02-066
Onaitis Mark W............................................................MA 19.09 Ozawa Takahiro...................................P1.03-010, P2.03-032 Parbhoo Kareesma.................................................P2.02-065
Ong Boon Hean..........................................................OA 09.07 Ozawa Yuichi...........................................................P2.07-022 Pardo Nuria............................................................... P1.05-015
Ong Teng Jin......................MA 03.01, MA 10.02, P2.01-004, Ozawa Yukihiko......................................................... P1.05-017 Paredes Alfredo..................................... MA 15.01, P3.01-005
............................................ P2.01-013, P2.01-014, P2.01-015 Oze Isao.................................................................... P2.01-034 Parikh Mihir S..........................................................P3.03-025
Onishi Hiroshi........................................ MA 09.06, MS 24.04 Ozeki Naoki........................P1.08-002, P1.17-004, P3.16-010 Parizel Paul M...........................................................P3.13-008
Onizuka Masataka................................ P2.17-004, P3.16-039 Ozeki Yuichi............................................................... P1.03-031 Park Chan Kwon.............P1.01-076, P1.03-025, P3.01-057
Onn Amir........................ MA 02.06, P3.03-028, P3.07-010 Özer Erhan.............................................. MA 17.08, P2.14-016 Park Cheol-Kyu............... P1.01-014, P2.03-024, P2.14-017
Ono Akira........................ MA 17.06, P2.03-008, P2.15-008, Ozer Rachel..................................................................OA 11.06 Park Chul Hwan........................................................P1.02-024
.................................................................................. P3.05-006 Özgüroğlu Mustafa.....................................................PL 02.02 Park Elyse....................................................................MA 14.09
Ono Hirotaka............................................................P2.07-004 Özkan Berker........................................P2.14-016, P3.16-046 Park Eun Su............................................................P2.02-029
Ono Manabu............................................................. P1.03-004 Ozkan Metin..............................................................P2.03-042 Park Eunhyang................P1.02-027, P1.02-029, P3.02-016
Onoda Hideko........................................P1.05-003, P3.13-013 Ozturk Akın...............................................................P1.03-016 Park Ha-Young......................................P1.01-014, P2.03-024
Onozawa Masakatsu................................................ P3.14-001 Ozturk Mehmet A................................P1.03-040, P3.15-007 Park Hae Jin...............................................................P3.16-016
Ooijen Peter M......................OA 15.06, OA 15.07, P2.13-007 O´donnell Patrick.....................................................P3.02-052 Park Heae Surng................................ P1.02-024, P1.05-014
Opalka Petr...............................................................P2.03-023 Oñate-Ocaña Luis F.................................................P2.01-070 Park Hye Jung.......................................................... P1.05-014
Opitz Isabelle...................P1.09-009, P3.09-010, P3.16-046 O’Brien Mary................... MA 03.12, MA 09.09, P1.03-029, Park Hyeyun............................................................. P1.06-003
Orihashi Kazumasa......... P1.02-034, P1.12-003, P1.16-026, ...............................................................P2.07-049, P3.12-003 Park Hyun Jin.......................................................... P1.05-020
................................................................................... P2.05-010 O’Brien Odharnaith.................................................P3.02-053 Park Hyunsil.................................................................MA 15.13
Orlov Sergey.............................................................. OA 05.07 O’Byrne Kenneth.................MA 03.11, MA 12.12, P1.02-010, Park In Kyu.......................MA 06.04, OA 16.05, P2.02-059,
Orlov Sergey V.......................................................... P1.01-056 ..................... P1.03-039, P1.03-041, P1.03-042, P1.03-048, .................... P3.09-008, P3.16-013, P3.16-022, P3.16-026
Orlova Rashida V...................................................... P1.01-056 .................. P1.09-006, P1.09-007, P2.02-048, P2.02-064, Park Jae Kil............................................................. P3.08-003
Orlowski Tadeusz............. P1.02-037, P2.16-017, P3.01-041, .................P2.02-069, P2.07-032, P2.07-033, P3.01-026, Park Jae Suk.............................................................P2.12-005
.............................................................. P3.02-049, P3.02-051 ............................................................... P3.01-039, P3.01-075
Park Jae Yong..........................................................P2.02-056
Orlowski Vanessa.................................................... P3.09-010 Park Ji Soo.................................................................MA 12.01
Orozco Morales Mario.............................................P1.07-040 Park Ji-Ho............................................. P1.16-018, P3.02-010
Orozco-Morales Mario..............................................P1.07-041 P Park Jinho................................................................ P2.05-012
Orsulic Duje............................................................... P1.16-004 Park Jung Woong.................................................... P3.05-010
Ortega Granados Ana Laura.............P1.03-054, P1.07-036 Pacchiana Maria Vittoria.................. P1.04-002, P3.06-003 Park Keunchil................. ISS 06.04, ISS 06.05, MA 03.06,
Ortiz -Villalón Cristian.................... P2.02-042, P2.02-043 Pacheco Patricia.......................................................P3.16-034 .......................... MA 05.09, MA 10.03, MA 12.02, OA 03.04,
Ortiz Carlos............................................................... P1.01-022 Pacheco-Barcia Vilma........................ P1.01-057, P2.02-027 .............................OA 05.03, OA 05.07, OA 08.07, OA 17.07,
Ortiz Comino Rosa María.....................MA 20.08, P1.12-009 Paci Massimiliano.......................................................OA 16.02 .....................P1.01-070, P1.04-001, P1.08-004, P2.01-064,
Ortiz De Juana M.Angeles......................................P1.07-028 Packer Stuart H....................................P1.07-027, P2.13-008 ....................P2.07-025, P3.01-005, P3.01-023, P3.01-026,
Ortiz Rosa Maria........................................................MA 20.06 .................... P3.01-029, P3.01-039, P3.01-050, P3.01-071,
Padda Sukhmani K.............................MA 16.01, P2.03-043
Ortiz-Espinosa Sergio............................................ P3.07-007 .........................................P3.01-082, P3.03-012, P3.08-006
Padhi Somanath...................................................... P1.02-066
Ortmann Christine-Elke............................................P1.01-012 Park Kwon-Sik..........................................................MS 26.05
Padiernos Emerson...........................P1.02-063, P2.03-052
Ortíz Carlos................................................................ P1.01-019 Park Myung Jae.......................................................P2.03-020
Padoan Mônica........................................................ P1.06-024
Oruc Zeynep.............................................................P2.01-024 Park Samina...................MA 06.04, P2.02-059, P3.09-008,
Padro Jonathan........................................................P2.01-047 ............................................P3.16-013, P3.16-022, P3.16-026
Osa Akio.................................................................. P2.07-009 Padrones Susana................................................... P2.08-006
Osada Atsushi.......................................................... P1.03-044 Park Sean.................................................................... OA 13.07
Padua Tiago C.D.......................................................P3.03-019 Park Seong Yong...................................P1.02-021, P3.16-019
Osarogiagbon Raymond...........................................P1.13-011 Page Damian..............................................................P1.01-031
Osarogiagbon Raymond U......................MA 04.01, OA 11.07, Park Seongyeol........................................................ MA 06.12
Page Melba Marie....................................................P2.02-030 Park Seung-Ill........................................P1.16-020, P3.16-014
.................................................................OA 15.08, P2.16-019 Pai Sachin............................................P1.04-004, P1.04-005
Osawa Fumi.......................................... P1.16-014, P2.16-009 Park Song Ee................. OA 03.04, P2.07-025, P3.01-023,
Paik Paul K....................... MTE 18.01, OA 12.06, P1.03-028 ....................................................................................P3.01-029
Osawa Junichiro..............P1.05-011, P1.05-018, P1.05-021, Paik Seung Sook.....................................................P2.03-020
...........................................P2.17-003, P3.15-012, P3.16-047 Park Soo Young........................................................P3.02-016
Paik Soo-Hyun.......................................................... P1.06-015 Park Wungki.................P1.07-024, P1.07-025, P2.07-037
Osbaugh Stacy......................................................... P1.04-007
Pairoj Wantanit.........................................................P3.03-020 Parker William.............................................................MA 13.08
Osborne Jackie.......................................................... MA 04.01
Paiva Heitor...............................................................P1.02-036 Parmigiani Raphael..................................................P3.03-019
Osborne Karen........................................................... OA 05.07
Pajares Maria J....................................P2.02-061, P3.07-007 Parra Cuentas Edwin R..................... MA 05.02, P2.02-046,
Osborne Orion........................................................... MA 04.01
Pajares Virginia............... P2.01-072, P2.05-007, P3.14-014 ...................................................................................P3.03-027
Ose Naoko........MA 16.08, P1.17-002, P1.17-013, P3.16-050
Pakkala Suchita....................................................... P1.08-003 Parra Edwin................................................................ OA 13.05
Oshima Yutaka......................................................... P3.16-008
Pal Prodipto...............................................................P1.07-022 Parra Edwin Roger...................................................P2.02-013
Osoegawa Atsushi............................ P2.05-017, P3.02-039
Palacio Sofia.............................................................P1.06-018 Parrat Eric................................................................ P2.11-001
Ostojic Helene.......................................................... P1.03-050
Palacios José.............................................................. MA 15.01 Parris Brielle.......................................................... P2.02-002
Ostroff Jamie....................WS 01.04, WS 01.25, WS 02.19
Palacios Miguel..........................................................P2.14-019 Parris Russell......................................... P3.05-001, WS 01.18
Ostrowski Marcin....................................................P2.13-010
Palata Ondřej..................................... P2.07-020, P3.07-008 Parsy-Kowalska Celine.............................................P2.13-013
Osumi Hironobu....................................................... P1.16-002
Palazón Carrión Natalia...........................................P2.03-051 Pasa Marcelo B..........................................................P3.13-018
Oswald Nicola..................................... P1.10-002, P3.16-024
Palka Magda..............................................................P1.01-040 Pasello Giulia............................................................P3.02-006
Ota Masahiro............................................................P3.02-042
Palma David A........................................OA 16.01, P2.14-009 Pasetto Stefano.......................................................P1.08-005
Ota Masayuki............................................................P2.07-008
Palma John F............................................OA 10.06, P1.15-011 Pasian Sergio.............................................. MA 14.11, OA 15.01
Ota Satoshi...............................................................P2.07-008
Palmer Michael.........................................................P3.01-075 Pasquale Raffaella................................................... P3.01-068
Ota Takeshi............................................................... P2.03-015
Palmero Ramon............ P1.01-075, P1.03-054, P2.07-044, Pasquinelli Mary............. P2.06-011, P3.10-002, P3.10-003
Otani Sakiko............................................................ P2.03-002 .................................................................................. P2.08-006
Otero Jorge........................ P1.01-019, P1.01-022, P1.09-013 Pass Harvey I.....................MA 10.10, MS 03.04, P1.09-001,
Palmieri Dario..........................................................P2.02-065 ................................................................................... P1.09-007
Oto Takahiro..............................................................P2.16-026 Palmieri Giovannella............................... P1.17-014, P1.17-015 Passaro Antonio.......................................................P3.01-073
Otsubo Kohei..........................................................P3.04-002 Palmiotti Gennaro..................................................... P1.01-065 Passlick Bernward.....................................................OA 16.06
Otsuka Hajime....................MS 07.04, P1.03-031, P3.16-004 Paludo Jonas..............................................................MA 18.09 Passos Coelho Jose.................................................P1.15-010
Otsuka Shannon............P1.03-043, P1.06-006, P2.01-026, Pan Alan.............................OA 07.03, P1.07-034, P3.02-013
..............................................................P2.01-046, P2.02-068 Passos Vanessa Q..................................................... OA 05.07
Pan Chunxia......................................... JCSE 01.11, P3.01-021 Pastina Pierpaolo....................................................P2.07-046
Otsuka Takashi............................................................P1.17-017
Pan Jean.................................................................. P2.04-009 Pastorino Ugo..................................... MA 14.15, P2.09-001a
Otsuka Tsunayuki.................................................... P2.16-004
Pan Jiliu.....................................................................P1.06-016 Patel Anita................................................ MA 04.01, P1.13-011
Ottaviano Margaret.............................. P1.17-014, P1.17-015
Pan Zhenhua............................................................. P1.03-017 Patel Jyoti................................................. MA 03.09, OA 17.02
Ottensmeier Christian...............................................P1.15-001
Pande Nikhil.............................................................P2.03-027 Patel Ketan..................................................................MA 06.03
Otterson Gregory................ MA 06.08, OA 12.06, OA 18.02,
Pandit Arpana.......................................................... P1.02-003 Patel Maulik.............................................................. P1.03-003
...................................................................................P3.03-007
Pang Clifford L.K........................................................ P1.01-071 Patel Monika............................................................. P3.09-001
Otto Geoff.......................P2.02-052, P3.02-061, P3.02-062
Pang Herbert............................................................. MA 18.06 Patel Neal.................................................................... OA 06.07
Ou Junwen............................................................... P1.01-071
Pang Kaimin..............................................................P3.01-036 Patel Pretesh............................................................ P1.08-003
Ou Sai-Hong I.....................MA 07.07, MA 12.03, OA 05.06,
............................................... OA 12.06, OA 12.08, PC 03.01 Pang Peipei................................................................. MA 14.04 Patel Sandipkumar.................................................. MA 06.08
Ou Sai-Hong Ignatius.............................................JCSE 01.27 Pang Yong-Kek....................................... OA 05.02, P3.15-014 Patel Suchit H.............................................................. MA 17.13
Oudkerk Matthijs.................. OA 15.06, OA 15.07, P2.13-007, Pangua Cristina.......................................................... MA 07.03 Patil Mangesh B......................................................P2.14-005
.............................................WS 01.09, WS 01.11, WS 01.40 Panigrahi Manoj K...............................P1.02-066, P2.15-002 Patil Prachi................................................................P3.02-081
Oura Shoji.......................... P1.03-033, P2.16-010, P3.13-012 Pankowski Juliusz...................................................P3.02-045 Patil Ravindra..........................................................P2.01-052
Overbeck Tobias R................................................. P2.04-005 Pantarotto Jason........................................................OA 11.06 Patil Vijay....... P1.01-021, P1.01-023, P1.01-024, P1.03-021,
Owen Ed.................................................. OA 15.08, P2.16-019 Pantarotto Marcos....................................................P2.16-025 .....................P2.01-051, P2.03-027, P3.01-076, P3.03-015
Owen Scott............................................P3.01-019, P3.01-062 Panvichien Ravat.....................................................P3.03-020 Patnaik Amita............................................................... OA 17.01
Owonikoko Taofeek K.......OA 08.06, OA 09.01, P1.08-003, Panwalkar Amit........................................................... OA 17.01 Patnaik Ravi S.......................................................... P3.01-020
....................................................................................P3.13-027 Papadakos Janet.................................................... P3.06-005 Patra Susama......................................P1.02-066, P2.15-002
Oxnard Geoffrey R........... ISS 04.02, MA 07.08, MA 20.14, Papadakos Tina...................................................... P3.06-005 Patria Fadillah P....................................................... P3.01-054
.....................MTE 20.02, OA 06.02, OA 09.02, OA 09.03, Papadimitrakopoulou Vassiliki A.............................MA 01.03, Patsios Demetris.....................................................P3.09-007
................................................OA 12.02, OA 12.07, P3.02-014 .............................. MA 05.02, OA 07.02, OA 13.01, OA 14.07, Pattipaka Thirupathi................................................ P3.01-040
Oya Yuko................................................................... P2.07-028 .......................................... OA 17.01, P2.01-040, P2.07-062 Patumanond Jayanton........................................... P2.06-006
Patwardhan Pallavi D................................................ OA 13.02 Pikin Oleg................................................P1.16-011, P3.16-021 Puma Francesco........................................................OA 16.02
Patz Edward F........................................................... MA 14.05 Pilette Charles......................................P3.15-004, P3.15-004 Pun Yat W....................................................................PL 02.04
Paul Sarah M..............................................................P1.04-011 Pillai Rathi N..................P1.08-003, P3.04-008, P3.13-027 Punwani Ravi............................................................P3.12-003
Paulus Rebecca.......................................MA 13.08, MA 18.06 Pilnik Norma.............................................................. P1.01-058 Puparelli Carmen............... P1.01-019, P1.01-022, P1.01-058
Pauwels Patrick........................................................P3.13-008 Pilotto Sara................................................................ MA 01.07 Puppo Gianfranco...............MA 02.05, MA 10.06, P1.01-065
Pavan Alberto..........................................................P3.02-006 Pimenta Joana..........................................................P1.01-020 Purandare Nilendu.................................................. P2.14-005
Pavlakis Nick.........................MA 19.03, MS 27.01, OA 10.03, Pineda Sandra...........................................................MA 09.02 Purbhoo Khushica....................................................P3.13-005
................................................................P1.01-011, P2.03-044 Pinheiro Manuela......................................................P3.01-049 Puri Sonam............................................................... MA 12.05
Pavlick Dean................................................................OA 12.08 Pinillos-Ashton Luis........................... P1.06-022, P2.01-053 Purkait Suvendu..................................P1.02-066, P2.15-002
Paweletz Cloud P.................. MA 07.12, MA 20.14, OA 09.02, Pinotti Graziella......................................................... P1.01-053 Puthiamadathil Jeevan...........................................P2.07-050
....................................................................................P3.02-014 Pintille Melania........................................................ P3.03-008 Putnam Joe B............................................................ES 05.01
Pawlikowski Meghan..............................................P2.02-065 Pinto Carmine............................................................... MA 11.11 Putra Andika C..........................................................P3.01-032
Paz-Ares Luis...................MA 02.02, MA 05.03, MA 07.03, Pinto Filho Darcy...................................................... P1.16-028 Puzanov Igor............................................................P2.07-062
...........................MA 12.02, MA 15.01, MS 02.04, OA 05.05, Pio Ruben.......................MS 26.02, P2.02-061, P3.07-007 Puértolas Teresa.......................................................P1.07-015
..........................OA 17.02, P1.01-001, P1.01-040, P1.04-001, Piotrowska Zofia................ OA 07.05, OA 09.01, OA 12.02 Pyo Hong Ryull....................................................... P3.08-006
....................................P2.04-002, P2.04-005, P2.04-008,
................... P2.04-010, P2.04-013, P2.07-060, P3.01-026, Piperdi Bilal................................................................MA 02.02 Pérez Chica Gerardo...............................................P1.07-036
..........................................P3.01-039, P3.01-071, P3.04-008 Pirker Christine...........................................................MA 19.07 Pérez Del Palacio José...........................................P1.07-036
Peacock Stuart J.........................................................OA 15.01 Pirker Robert...................MS 20.02, P2.09-004, SH 02.01 Pérez Gago Coral.....................................................P2.03-051
Peake Michael D........................................................ OA 02.03 Pirtoli Luigi................................................................P2.07-046 Pérez Lidia.................................................................P2.07-016
Pealing Jessica........................................................P2.07-049 Pitz Cordula............................................................. P2.08-007 Pérez María Angelina........P1.01-019, P1.01-022, P1.09-013,
Pecze Laszlo............................................................ P1.09-002 Pizzutilo Pamela..................................................... P3.06-003 ...................................................................................P3.02-063
Pedersen Jesper H............................... P3.13-011, WS 01.27 Pizzuto Ondina..........................................................P2.17-002 Pérez-Ruiz Elizabeth................................................P1.07-015
Pedraza Lorenzo Manuela......................................P1.01-060 Plagnol Vincent............................................................ MA 11.01 Pérol Maurice.....................ISS 01.04, MA 03.06, MS 13.01
Peek Laura.................................................................P2.13-013 Planchard David................................ISS 09.04, ISS 09.05, Późniewska Karolina...............................................P1.06-004
Peeters Stephanie...................................................P3.09-003 ................................MA 05.03, MA 10.11, MA 11.01, MA 19.03,
..................... P1.03-013, P1.04-001, P1.08-009, P2.01-038,
Peguero Julio.............................................................MA 02.09 ............................................................. P2.07-005, P2.07-060
Pei Yuquan................................................................ P1.14-004 Planck Maria.............................................MA 18.14, P1.06-012 Q
Peikert Tobias.....................................P2.09-001, P2.13-014 Plank Lukas..............................................................P2.03-056
Peiro Inma................................................................P2.07-044 Plekker Dante............................................................P1.06-001 Qi Haolong.............................................................. P2.02-050
Peixoto Ana...............................................................P3.01-049 Pless Miklos............................................. MA 15.11, P2.07-056 Qi Lihong.....................................................................P1.07-013
Peled Nir.........................ISS 04.04, ISS 04.05, MA 02.06, Plestina Sanja...........................................................P3.01-059 Qi-Tao Yu....................................................................MA 03.03
............................MA 18.11, OA 17.06, P1.01-039, P2.07-048, Qian Fangfei................................................................MA 14.07
................P3.01-056, P3.01-060, P3.02-096, P3.03-022, Plodkowski Andrew.............................MA 05.02, P1.03-028
Plumridge Nikki......................................................... P2.14-001 Qian Jiong..................................................................P3.01-025
.........................P3.13-030, WS 01.16, WS 02.11, WS 02.13 Qian Wendi.................................................................. MA 11.02
Peltz Gerson...............................................................OA 05.06 Pluzanski Adam......................................OA 05.01, P3.01-012
Poder Joel................................................................. P2.14-010 Qiang Li.................................................................... P1.02-042
Pemberton Laura...................................................... OA 02.03 Qiao Meng..............................ES 09.03, MA 11.07, P2.07-010
Peng David...................................................................OA 13.01 Poh Mau-Ern..............................................................P3.15-014
Poirier John..........................................MS 26.04, OA 08.06, Qiao Wenbin.............................................................. P1.01-072
Peng Di..........................................................................OA 13.01 Qin Xiao-Feng..............................................................OA 13.01
Peng Feng.....................................................................MA 11.03 ............................................................... P1.02-001, P3.15-008
Poisl Fay André........................................................P3.16-034 Qin Ziling.....................................................................P2.13-014
Peng Ling.................................................................... MA 14.04 Qiong Zhao.............................................MA 03.03, P3.01-031
Peng Min.............................................P3.01-083, P3.15-013 Pokharel Saraswati.................................................. MA 06.06
Polanska Joanna...................................................... P2.13-010 Qiu Bo...............P1.14-010, P1.14-011, P1.14-012, P2.14-004
Pennaforte Sylvie.......................................................MA 12.02 Qiu Jiaheng..................................................................OA 17.02
Pennell Nathan............................................................MA 13.03 Politaki Eleni..............................................................P1.01-044
Politi Katerina.................... OA 12.01, P3.01-046, P3.03-007 Qiu Qianqian.............................................................. P2.15-010
Penrod John R.................. MA 01.09, P1.15-003, P2.07-034 Qiu Xueshan.......................................... P1.16-015, P2.05-015
Pepe Carmela....................................P2.02-040, P3.02-055 Polo Valentina..........................................................P3.02-006
Pompili Cecilia............................................................OA 04.06 Qiu Yuan......................................................................P3.01-011
Perazzo Florencia.................................................... P1.01-058 Qiu Zidan....................................................................P3.14-016
Pereira Marta...........................................MA 18.14, P1.06-012 Ponce Aix Santiago............. MA 02.02, MA 03.01, PL 02.04
Ponce Santiago..................MA 05.03, MA 07.03, P1.01-040, Qu Zhuohui........................................... JCSE 01.11, P3.01-021
Pereira Nuno C.........................................................P1.01-020 Quaife Samantha....................................................... P2.13-011
...............................................................P2.07-060, P3.01-071
Perera Nisal K...........................................................P3.16-052 Quan Yu Hua.....................P1.16-012, P1.16-018, P3.02-010
Pond Gregory...............................................................MA 20.11
Perera-Low Nicole.................................................. P3.01-062 Quantin Xavier............................................................OA 03.01
Ponten Fredrik.......................................MA 06.01, P1.07-020
Peres Pereira Rodrigo............................................. P1.01-063 Quartey Naa Kwarley............................................. P3.06-005
Pontén Victor....................................P2.02-023, P2.02-066
Perez Omar.............................................................. P2.02-001 Quek Kelly.................................................................... OA 13.05
Poole Lynne.................................................................PL 02.02
Perez-Gracia Jose Luis...................... P1.07-035, P2.02-061 Quero Cristina...........................................................P2.07-016
Poon Wai-Yan.......................................................... P3.09-002
Perez-Soler Roman...........OA 13.03, P1.07-027, P2.13-008 Quevedo Rene......................................................... P3.03-008
Poot Alex....................................................................MA 05.07
Perin Branislav.........................................................P1.02-007 Quezada Sergio..........................................................MA 19.05
Poovorawan Nattaya............................................... P3.01-042
Peristeris Panagiotis................................................P3.01-077 Quill Timothy A........................................................... MA 07.14
Popat Sanjay....................MA 09.09, MA 19.03, MTE 09.02,
Perloff Tara............................................. P1.01-036, P1.11-003 .......................... OA 03.02, P1.03-029, P1.09-011, P1.17-019, Quinn Leah...............................................................P1.09-006
Perrone Pasqualina................................. P1.17-014, P1.17-015 ......................................... P2.03-058, P2.07-049, P3.12-003 Quispel-Janssen Josine........................................... OA 02.02
Perry Yaron................................................................MA 20.03 Postel-Vinay Sophie................................................. P1.15-004 Quist Morten..........................................OA 11.02, P2.10-003
Persson Johan........................................MA 05.13, MA 06.01 Postmus Pieter E............... MA 03.01, MA 10.02, MS 24.05, Quoix Elisabeth............................................................OA 17.05
Pertiwi Inggar...........................................................P3.11-001 ..................................................................................... OA 05.07 Quéré Gilles.........................................P2.07-023, P2.07-030
Perurena Naiara...................................................... P3.07-007 Poteete Alissa..........................................................P3.03-027
Pesek Milos..............................................................P2.03-023 Potter Danielle......................................................... P2.01-043
Peter Alice................................................................... MA 18.01 Pousa Inés.................................................................P3.01-049
Peters Eric......................P2.02-052, P3.02-061, P3.02-062 Powell Charles A...................................................... P3.13-037
R
Peters Geoffrey.......................................................P2.02-039 Powell Steven F........................................................... OA 17.01
Peters Solange...................................ISS 09.01, ISS 09.03, Rabin Michael S........................................................ P1.12-004
Praag John...................................................................MA 17.10
................ISS 09.05, JCSE 01.09, JCSE 01.27, MA 06.06, Rabizadeh Shahrooz.............................OA 18.04, P2.01-056
Prabhakaran Sarita................................................. P1.09-003
..........................MA 07.01, MS 12.02, P1.04-008, P1.04-011 Prabhash Kumar............... P1.01-021, P1.01-023, P1.01-024,
Rachiglio Anna Maria.............................................. P3.01-068
Petersen Iver............................................................. OA 07.09 .......................................... P1.03-021, P2.01-051, P2.03-027, Radniecki Sarah.........................................................P2.15-013
Petersen Lars.......................................................... P2.01-043 ............................................................... P3.01-076, P3.03-015 Radosavljevic Davorin.............................................P1.02-007
Petersen Lars F................................... P1.02-013, P3.02-077 Prabowo Ari............................................................. P2.03-031 Radulovic Sinisa.......................................................P1.02-007
Petracci Elisabetta...................................................P3.02-007 Pradines Anne..........................................................P1.07-009 Radulovich Nikolina.............................P1.02-016, P3.03-008
Petricoin Emanuel.................................................... P1.01-036 Prado Edna................................................................P1.06-018 Raeppel Stephane................................................... P1.09-007
Petrillo Patrizia........................................................ P3.06-003 Pradotto Monica..................................................... P2.09-003 Raez Luis E........................ISS 04.03, MA 15.02, OA 11.07,
Petro Daniel................................................................. OA 14.07 Pramesh Conjeevaram S................. P2.14-005, P3.02-036, .............................................................P2.01-056, P2.07-052
Petty William............................................MA 17.07, P1.01-059 ....................................................................................P3.02-081 Rafee Shereen.........................................................P2.02-048
Peulen Heike...............................................................MA 13.09 Prasad Anjani......................................... P3.05-001, WS 01.18 Rafique Norman M..................................................... OA 14.07
Pezzi Todd A..............................................................OA 08.05 Prasad Kuruswamy T......................... MA 03.02, P2.03-053 Raftopoulos Harry....................................................... OA 17.01
Pham Hoa H.N................................... P2.02-042, P2.02-043 Prasad Ram............................................................... P1.01-024 Raghavan Vibha...................................................... P3.03-008
Pham Nhu-An........................................................... P1.02-016 Prasongsook Naiyarat............................................P3.03-020 Ragulin Yury............................................................P1.08-008
Pham-Ledard Anne................................................ P2.07-023 Prat Aleix..........................P1.01-075, P2.02-014, P3.01-045 Rahmadi Agus........................................................... P1.01-026
Pheeley Ashley....................................P3.15-003, P3.15-005 Preiss Jordan.............................................................. MA 16.01 Rahman Najib........................................OA 02.05, P1.05-008
Piantedosi Francovito.......................... P1.01-053, P1.01-065 Prempree Thongbliew -....................................... P2.03-026 Rahmati Sara..............................................................OA 07.07
Piao Hongmei....................................... JCSE 01.11, P3.01-021 Presley Chris................. P3.03-016, P3.03-026, P3.05-002 Rajagopalan Srinivasan............................................P2.13-014
Piccoli Rafaela...................................... P2.03-029, P3.13-018 Prieto Tabatha G............MA 01.01, P2.02-046, P3.15-006 Rajan Arun......................P1.02-063, P2.03-052, P2.07-058
Piccolo Francesco......................................................MA 14.09 Pritchett Michael........................................................MA 20.02 Rajappa Senthil.........................................................P3.01-036
Pichon Eric..................................................................OA 03.01 Pro Barbara.........................................P1.04-004, P1.04-005 Rajer Mirjana........................................................... P2.09-004
Pickup Lyndsey.......................................MA 14.13, P1.05-008 Proietti Agnese..........................................................P1.01-015 Rajesh Pala.............................................MA 08.09, P1.10-002
Pidgeon Graham......................................................P2.02-069 Prosch Helmut...........................................................MA 14.10 Ramalingam Suresh S....ISS 10.01, ISS 10.03, ISS 10.06,
Pierre Andrew.......................................................... P1.13-004 Proto Claudia.......................................................... P2.09-001a ............................ ISS 10.07, MA 07.14, MA 18.06, OA 01.06,
Pieróg Jarosław......................................................... MA 14.01 ..........................OA 05.02, OA 08.06, OA 09.01, P1.08-003,
Protsenko Svetlana A.............................................. P1.01-056
...................... P3.03-007, P3.04-008, P3.13-027, SH 01.01
Pietanza M Catherine............................................. P2.04-007 Provencio Mariano..............................P3.01-005, P3.01-073
Raman Srinivas..........................................................MA 09.02
Pietanza M. Catherine.................................................OA 17.06 Pugh Trevor............................................................. P3.03-008
Ramaswamy Anant.................................................P2.03-027
Pieters Anne............................................................P2.07-034 Puig-Butille Joan Anton......................................... P3.01-045
Pietzko Kerstin............................................................MA 19.03 Puksa Serge............................................... MA 20.11, OA 15.01
Rami-Porta Ramon.............ES 01.01, OA 16.06, P1.05-019, Reyes Roxana........................................................... P3.01-045 Rodriguez Jaime........................................................ OA 13.05
......................................................................................PL 02.06 Reymen Bart........................................................... P2.08-007 Rodriguez Jenny...................................MA 01.02, P1.02-055
Ramirez-Tirado Laura-Alejandra.........MA 08.10, P1.01-019, Reyna Jonus............................................................P3.03-026 Rodriguez July................. MA 01.02, P1.02-055, P3.02-063
................................................................P2.01-070, P3.14-012 Reyntiens Pieter.......................................................P3.13-008 Rodriguez Lara Maria Isabel.................................. P2.02-010
Ramkissoon Shakti...................................................P2.02-016 Rezo Angela................................................................MA 13.07 Rodriguez Sonia.......................................................P2.02-014
Ramli Ramadhan...................................................... P1.01-026 Rho Jin Kyung..........................................................P3.02-088 Rodriguez Zarco Enrique.......................................P3.02-047
Ramos Inmaculada...................................................P1.01-040 Rho Jiyun...........................P1.16-012, P1.16-018, P3.02-010 Rodriguez-Canales Jaime......................MA 05.02, OA 13.01,
Ramos Oriol................................................................MA 20.08 Riabowol Karl...........................................................P1.06-005 .........................................P2.02-013, P2.02-046, P3.03-027
Ramírez-Tirado Laura A......................................... P2.01-049 Ribas Montserrat.......................................................P3.14-017 Rodriguez-Cid Jeronimo R.............P2.06-007, P2.07-061
Rana Durgesh...........................................................P1.03-001 Ricci Donata............................................................ P3.06-003 Rodriguez-Paniagua Manuel....................................PL 02.04
Randhawa Simran K................................................P2.13-005 Ricci Veronica..........................................................P2.07-046 Rodríguez Sánchez Ángel.......................................P1.01-060
Rangachari Deepa............................... MA 06.02, P3.03-025 Ricciardi Sara............................................................. MA 17.01 Rodríguez Ángeles...................................................P1.15-013
Ranganathan Priya...................................................P3.02-081 Riccio Antonio..............................................................OA 17.06 Rodríguez-Abreu Delvys......................OA 17.06, P1.03-054,
Rangrajan Venkatesh.............................................. P2.14-005 Rice David..................................................................MS 06.03 ................................................................P1.07-015, P2.01-022
Rankin Nicole M............................... P3.06-008, P3.13-038 Ricevuto Enrico......................................MA 02.05, P1.01-065 Roels Steve...............................................................P2.02-052
Rao Chuangzhou...................................................... P1.01-037 Richard Derek..........................................MA 03.11, P1.02-010 Roeper Julia............................................................ P3.01-038
Rao Sowmya R......................................................... P1.05-013 Richardet Eduardo............................... MS 12.05, P1.01-058 Roesmargono Hanny............................................... P1.01-049
Rao Suman...................................................................OA 17.06 Richards Donald........................................................P1.01-051 Rogado Jacobo.................................... P1.01-057, P2.02-027
Rapa Ida....................................................................P2.02-054 Richards William G................................... MA 13.02, MA 19.10 Rogers Evan............................................................... MA 07.09
Rapetti Simonetta Grazia...................................... P3.06-003 Richeimer Kristin.......................................................MS 19.02 Rogé Christophe...................................................... P2.07-023
Rapoport Bernardo L................................................P3.13-021 Rickman Otis B...................................... MA 20.02, MA 20.03 Rohan Kimberly A.....................................................ES 03.01
Rasmussen Torben................................................. P2.01-043 Ridwanuloh Asep M...............................................P3.01-054 Roila Fausto................................................................ MA 10.06
Rassl Doris M.............................................................. MA 11.02 Riedel Bernhard........................................................ P1.01-033 Roisman Laila C............... MA 02.06, P1.01-039, P3.01-060,
Ratcliffe Marianne.................................................... P3.01-068 Riehl Todd...................................................................P1.04-011 ...................................................................................P3.02-096
Rath Goura K............................................................P3.06-007 Riely Gregory J....................GR 01.04, OA 03.03, OA 10.03, Roitberg Felipe........................................................ P2.03-006
Rau Kun-Ming.......................................................... P2.07-027 .................................................OA 12.06, OA 14.05, P1.01-012 Rojas Bilbao Erica................................................... P2.01-007
Rauch Daniel................................................................ MA 15.11 Riera Paula................................................................P2.07-041 Rojas Leonardo...................MA 01.02, P1.01-019, P1.01-022,
Rauch Erica...............................................................P2.13-009 Riess Jonathan W........JCSE 01.14, MA 02.11, P2.04-010 .................... P1.02-055, P1.09-013, P3.02-063, P3.08-005
Rauma Ville................................................................P1.08-010 Riether Carsten............................................................ MA 15.11 Rolfe Lindsey............................................................P2.03-058
Ray Meredith A..................... MA 04.01, OA 15.08, P1.13-011, Riganti Chiara.......................................................... P2.09-003 Rolfo Christian....................................... MS 18.05, P1.07-035
.....................................................................................P2.16-019 Rigas James............................................................P2.01-043 Rolny Vinzent.....................................P3.05-007, P3.05-008
Rayburn Joshua R.........P1.05-012, P1.10-008, P2.13-019, Rigas James R......................................................... P3.01-005 Rolska-Kopińska Anna.............................................. OA 08.03
...................................................................................P3.13-029 Righi Luisella........................................................... P2.09-003 Roman Moreno Marta..............................................P1.07-035
Raymond Chris...........................................................OA 10.03 Rigney Maureen................ MA 04.11, MA 08.06, P3.11-002 Romani Alessandra..................................................P3.13-006
Raymond Victoria M...........OA 12.05, P1.11-004, P3.01-046 Rijavec Erika............................................MA 01.07, P1.07-023 Romano Gianpiero......................................................MA 01.07
Raz Dan J................................................................... OA 03.03 Rijk Anke F................................................................P3.02-055 Romano Vanesa................................... P2.01-007, P2.02-071
Raziee Hamid..........................................P1.14-016, P3.14-013 Rima Ana.................................................................P2.01-044 Romaszko-Wojtowicz Anna M..............................P1.06-004
Ready Neal............................................MA 07.05, P3.07-012 Rimm David..........................MA 05.10, MA 13.03, MA 15.15 Romero Vielva Laura............................................... P1.05-015
Reale Maria Lucia....................................................P1.04-002 Rimner Andreas...................MA 17.13, MS 06.05, OA 10.03, Ronden Merle Ilona...................................................OA 01.03
Rebelato Taiane......................................................... P1.01-063 ..................................................................................... P3.15-011 Rong Tiehua...........................................OA 03.07, P2.05-018
Reck Martin...................... ISS 11.03, ISS 11.06, MA 03.06, Rinsurnogkawong Waree....................................... P2.04-014 Rong Yi........................................................................P1.07-013
...............................MA 10.02, MA 19.03, OA 17.02, OA 17.06, Rinsurongkawong Waree.......................OA 07.02, OA 09.05 Roper Nitin...........................................P1.02-063, P2.03-052
......................P2.04-012, P3.01-071, P3.04-008, PL 03.04 Rintoul Robert C...............MA 11.02, OA 02.03, P3.05-001, Rosa Mahira..............................................................P3.16-034
Reckamp Karen L............... MA 02.11, OA 05.05, OA 08.08, ...................................................................................... WS 01.18 Rose-John Stefan...................................................P3.07-002
..................... P1.01-001, P1.01-004, P2.03-043, P2.03-058 Rios Jayme...........................................P1.06-020, P3.16-034 Rosell Antoni.................MA 20.06, MA 20.08, MTE 19.02,
Recondo Gonzalo........... P1.01-058, P1.02-035, P2.01-007, Ritchie Alexander J..................................................... MA 14.11 ...................................................................................P1.12-009
.............................................................. P2.02-071, P2.03-039 Rosell Rafael........................ISS 04.01, MA 01.02, OA 05.01,
Rittmeyer Achim................ MA 05.09, MA 10.03, P1.01-052,
Recondo Gonzalo (...................................................P1.02-035 ................................................................................... P1.03-050 ...................... P1.02-055, P1.03-054, P1.07-015, P1.09-013,
Recondo Gonzalo J............................. P2.01-007, P2.02-071 Riudavets Melia Mariona.................... P1.07-028, P2.01-072 ........................................P2.02-034, P3.01-012, P3.01-073,
Reddy Chandana.......................................................MA 09.04 Rivalland Gareth.....................................................P3.02-038 ................................................................ P3.02-063, PL 02.04
Reddy Sandeep B......................................................OA 18.04 Rivard Christopher J.............MA 05.14, MA 13.02, OA 07.06 Rosen Lisa.............................................. MA 08.11, P2.01-050
Redig Amanda J......................................................... MA 07.12 Rivas De Andrés Juan Jose.....................................PL 02.04 Rosenbaum Eli............................................................. MA 18.11
Redman Mary...................MTE 26.01, OA 14.07, P1.06-009, Rivera Noelia.............................................................P2.07-041 Rosenberg David..................................................... P3.10-002
................................................................................... P3.01-046 Rosenbrock Carlos..................................................P2.03-039
Rivera Veronica....................................................... P2.16-002
Redondo Tamara......................................................P2.07-016 Rosenfeld Nitzan......................................................... MA 11.02
Rizvi Hira....................................................................MA 05.02
Redzepi Gzim............................................................P3.01-059 Rosenlund Mats.......................................MA 18.14, P1.06-012
Rizvi Naiyer................................................................PL 03.02
Rees Patricia..............................................................MA 08.07 Rosenthal André.....................................OA 10.06, P1.15-011
Rizzo Coleen................................................................OA 07.05
Reese Nicholas..........................................................MA 02.07 Rosenwinkel Lindsey................................................. MA 17.07
Rizzo Manglio............................................................ P1.01-058
Reeves Anthony..............P2.16-022, P2.16-023, P2.16-024, Ross Camidge D.............................. JCSE 01.27, P2.07-034
..................................................................WS 01.17, WS 02.03 Roa Diana...................................................................P1.03-035
Roa Martin................................................................. P1.01-058 Ross Helen J.....................................P3.04-003, P3.09-001
Regis Shawn M...................................... P1.06-017, P2.13-017 Ross Jeffrey S.....................MA 05.02, MA 07.07, MA 12.03,
Reguart Noemi...............P1.01-075, P1.03-054, P2.02-014, Roa Wilson...................................................................MA 14.03
.......................... MA 15.06, OA 12.08, OA 18.03, P2.02-016,
.................P2.04-005, P3.01-045, P3.01-073, P3.03-023 Roark Kristi............................................... MA 04.01, P1.13-011 .........................................P2.02-052, P3.02-061, P3.02-062
Reichmann William............OA 05.05, P1.01-001, P1.01-004, Roarty Emily....................... OA 09.05, OA 13.05, P2.04-014, Ross Kirsty................................................................ P1.15-004
....................................................................................P1.01-005 .............................................................P2.07-061a, P3.03-027
Ross P. Martin.....................................P2.02-002, P2.02-014
Reid Glen............................MA 19.04, MA 19.06, P1.09-004, Robb Richard..............................................................P2.13-014
Rossell Rafael........................................................... P3.01-044
...................P1.09-005, P1.09-006, P1.09-008, P1.09-009, Robbins Edward T................ MA 04.01, OA 15.08, P1.13-011,
.....................................................................................P2.16-019 Rossi Giovanni..........................................................P1.07-023
..............................................................P3.02-078, P3.02-079 Rossi Maddalena M.G...............................................P3.14-005
Reid Mary.................................................................... PL 01.03 Robert Francisco.............OA 14.07, P1.03-022, P1.04-012
Roberts Heidi...............................................................MA 20.11 Rossi Michael...........................................................P3.03-007
Reiger-Christ Kimberly M..P1.06-017, P2.13-017, P2.13-018 Roth Jack......................... OA 07.02, P2.04-014, P2.07-061a
Reiman Anthony...................................................... P2.01-032 Roberts Josianne......................................................MA 08.07
Roberts Kate E....................................P2.07-032, P2.07-033 Rothenberg Stephen.................................................. OA 12.07
Reiner Thomas........................................................ P3.15-008 Rothenstein Jeffrey.........P2.07-029, P3.01-019, P3.01-062
Reis Joao................................................................. P2.16-025 Robertson John................ MA 18.04, OA 06.08, P3.06-009
Robertus Jan L...........................................................P1.17-019 Rotherstein Jeff....................................................... P2.01-032
Reis Madalena.............................................................P1.17-012 Rothschild Sacha I................................MA 15.11, P2.07-056
Reis Rui M............................................... MA 01.01, P3.15-006 Robichaux Jacqulyne P..........................OA 09.05, OA 12.01
Robinet Gilles...........................................................P2.07-030 Rotikova Livia...........................................................P2.03-056
Reiser Marcel........................................................... P3.01-088 Roubec Jaromir.......................................................P2.03-023
Reisman Arlene........................................................ P3.01-012 Robins Harlan............................................................. OA 13.05
Robinson Andrew G..................................MA 10.01, OA 17.06 Rouquette Isabelle....................................................P1.07-009
Reitsma Dirk J......................................................... P1.03-044 Rovira Ana..................................................................P1.15-001
Rekhtman Natasha.............. MA 15.10, OA 18.06, P3.13-019 Robinson Bruce........................................................P1.09-001
Robinson Clifford........................................................MA 13.08 Rowbotham David A...............................................P2.02-022
Remon Jordi.... MA 05.03, MA 11.01, P1.03-013, P2.07-060 Rowe Valerie..............................................................MA 09.08
Ren Hongzheng.........................................MA 13.01, OA 13.07 Robinson Wendy P................................. MA 15.12, P3.02-094
Robinson William........................................................ MA 16.01 Roy Shubham...........................................................P3.06-007
Ren Shengxiang.............P1.03-045, P1.03-052, P1.15-009, Roy Soumyajit............................................................ P1.14-014
...........................................P2.07-047, P3.01-067, P3.01-085 Robles Marta.............................................................P2.07-016
Rocha Patrícia...........................................................P3.01-049 Royo Maria Angeles..................................................P1.07-015
Ren Xiaoxin.................................................................. OA 13.03
Rocha Pedro...............................................................P1.15-001 Rozeboom Leslie.....................................MA 05.14, OA 07.06
Ren Xiubao...............................................................P3.03-009
Rocha Roberto..........................................................P1.06-010 Rozy Adriana.............................................................P3.02-051
Ren Yacheng................................................................MA 14.12
Roche Gerard...........................................................P1.09-006 Ruano-Ravina Alberto.............................................. P1.15-013
Ren Yao.......................................................................P1.14-001
Rockberg Julia.........................................MA 18.14, P1.06-012 Ruben Jeremy D.........................................................MA 13.07
Rena Ottavio................................................................OA 16.02
Roden Anja C......................................OA 03.06, P2.02-042, Rubini Liedke Pedro E............................................. P1.01-063
Reolon João N.......................................................P2.09-002
...............................................................P2.02-043, SH 03.03 Rubtsova Natalia.........................................................P1.16-011
Resta Leonardo.........................................................P2.17-002
Rodrigues Ana..........................................................P3.01-049 Rudin Charles M................ ES 09.01, MA 05.02, OA 08.06,
Reszka Katarzyna....................................................P3.02-045 .............................OA 10.03, OA 10.05, OA 14.05, P1.02-001,
Reu Simone................................................................P1.07-019 Rodrigues Fabiana...................................................P1.02-036
........................................P1.03-028, P2.04-007, P3.15-008
Reuben Alexandre................................ OA 13.05, P2.02-013 Rodrigues George B................................................ P2.14-009
Rudzinski Piotr.................P1.02-037, P2.16-017, P3.01-041,
Reungwetwattana Thanyanan............ OA 11.04, P2.01-009, Rodrigues João.........................................................P1.06-010 .............................................................. P3.02-049, P3.02-051
............................................................ P3.01-042, P3.03-020 Rodriguez B. Leticia....................................................OA 13.01 Ruffinelli Jose Carlos.....MA 07.03, P2.07-044, P2.08-006
Rexha Valbona......................................................... P3.16-005 Rodriguez Erika.......................................................P2.02-044 Ruffini Enrico.................. MTE 17.02, OA 16.02, P2.09-003
Reyes Oscar I.......................................................... P3.08-005 Rodriguez Estelamari................................................MA 15.02 Rugless Fedoria E................................... MA 04.01, P1.13-011
Ruiz Jimmy................................................................ P1.01-059 Sakamoto Takashi....................................................P2.14-007 Sato Seijiro........................ P1.16-025, P3.16-002, P3.16-051
Ruiz Mendoza Rossana.P1.06-022, P1.06-023, P2.01-053 Sakamoto Tomohiro...........................P1.01-064, P2.03-016 Sato Toshihiko................. P1.14-005, P3.02-046, P3.02-071
Ruiz Patino Alejandro.............................................. P1.01-022 Sakamoto Yasumiko.................................................P3.15-009 Sato Yoshiko.............................................................P2.07-022
Ruiz Sanjuan María..................................................P1.07-036 Sakane Tadashi................... MA 16.10, P1.17-005, P2.17-001 Sato Yoshitaka........................................................ P2.05-005
Ruiz Tsukazan Maria Teresa...........P1.06-020, P1.16-028, Sakao Yukinori..........................................................P3.13-009 Sato Yuichi............................................................... P2.03-002
..............................................................P2.13-022, P3.16-034 Sakasegawa Koichi................................................. P2.16-004 Sato Yukio........................P2.02-025, P2.17-004, P3.16-039
Ruiz-Martinez Agustín..............................................P3.14-017 Sakashita Hiroyuki..............................P1.03-004, P3.02-035 Satokata Mariko....................................................... P2.03-015
Ruiz-Patiño Alejandro..... MA 01.02, P1.02-055, P3.02-063 Sakashita Shingo................................P2.02-025, P2.02-073 Satouchi Miyako.................. MA 17.06, MS 06.06, OA 17.07,
Ruiz-Valdepenas Andrea........................................... MA 11.02 Sakata Akiko..............................................................P3.16-039 ...................................................................................P1.08-006
Rukazenkov Yuri..................................................... P2.04-006 Sakata Kenneth K...............................MTE 19.01, P1.07-016 Sauciuc Delia........................................................... P2.07-029
Rullan Antoni........................................................... P2.08-006 Sakata Shinya...........................................................P3.15-009 Sauleda Jaume......................................................... P1.05-019
Rulli Eliana................................................................P2.02-065 Sakr Lama..........................................P2.02-040, P3.02-055 Sauter Jennifer L......................................................MA 05.02
Run Xiang................................................................. P1.02-042 Sakurai Fuminori..................................................... P1.03-006 Savelov Nikita...........................................................P3.02-058
Ruparel Mamta.....................P2.13-011, P3.05-001, WS 01.18 Sakurai Hideyuki..................................................... P2.05-005 Savic Spasenija................ MA 15.11, MTE 24.02, P2.07-056
Rusch Valerie W................... ES 05.02, OA 03.03, OA 10.03 Sakurai Hiroyuki...................................................... P1.05-002 Sawa Kenji..............................................MS 02.02, P1.06-014
Rushton Alison...........................................................MA 08.09 Sakurai Reiko.......................................P2.01-027, P2.15-016 Sawa Toshiyuki........................................................ MS 04.04
Russell Prudence............................. MTE 06.01, P2.02-039 Sala Marian.............................................................. P1.03-054 Sawada Toru.............................................................P3.13-007
Rusterholz Corinne.................................................P2.07-056 Salajka Frantisek.....................................................P2.03-023 Sawai Satoru............................................................P1.03-037
Ruwanpura Saleela.................................................P3.07-002 Salama Joseph K....................................................... MA 17.07 Sawai Yutaka....................................... P1.13-002, P3.16-028
Rwigema Jean-Claude M......................................P3.09-001 Salamonsen Matthew...............................................MA 20.07 Sawczak Magdalena............................................... P3.01-062
Ryabov Andrey....................................... P1.16-011, P3.16-021 Saleh Mansoor N...................................................... P1.04-012 Saya Hideyuki.......................................MS 26.01, P1.02-023
Ryan Michael.............................................................P3.14-002 Sales Diogo B.......................................................... P2.09-002 Sbar Eric I........................... OA 05.01, P3.01-012, P3.01-072
Ryan Ronan......................P1.02-011, P1.03-039, P2.02-064 Salgarello Matteo.....................................................P1.08-005 Scagliotti Giorgio V............. ISS 11.05, ISS 11.06, MA 07.14,
Ryan Sally.................................................................P3.02-054 Salgia Ravi.................................................................MS 25.02 ......................... MA 19.03, P1.09-011, P2.09-003, PL 04.03
Ryder David J..........................MA 09.11, MA 17.14, OA 02.03 Salnikov Alexey...........................................................MA 19.03 Scalbert Camille...................................................... P2.07-023
Rydén Anna.................................................................PL 02.02 Salo Jarmo................................................................P1.08-010 Scaltriti Maurizio.........................................................OA 14.05
Ryota Hironori............................................................MA 05.06 Saltarski Jessica.......................................................P1.07-031 Schaefferkoetter Joshua D.....................................P3.13-004
Ryu Eunjung.............................................................. MS 14.05 Salvador-Coloma Carmen....................................... MA 07.03 Schaer David A........................................................P3.07-006
Ryu Jeong-Seon...................................................... P2.01-016 Samanez Cesar A................................................... P1.06-023 Schaff Hartzell........................................................... OA 03.06
Rzazade Rashad...................................................... P2.01-063 Samaritani Riccardo................................................ P1.01-053 Schalper Kurt A.......................................MA 13.03, MA 15.06
Rzyman Witold.......................................................... P2.13-010 Samarzija Miroslav...................................................P3.01-059 Schelch Karin.....................................P1.09-004, P1.09-005
Räsänen Jari.............................................................P1.08-010 Samejima Joji................. P1.05-011, P1.05-018, P1.05-021, Schenk Erin........................................P2.01-054, P2.02-037
............................................P2.17-003, P3.15-012, P3.16-047 Schernberg Antoine................................................P1.08-009
Samuelsen Carl...................................P3.01-026, P3.01-075 Scherpereel Arnaud..................................................MA 03.10
Sanada Mune............................................................. P1.15-014 Schettini Daria..........................................................P3.13-006
S
Sanborn J. Zachary...................................................OA 18.04 Schiavone Marcella..................................................P2.17-002
Sanborn Rachel E.............. MA 07.02, MA 10.05, P1.07-019, Schild Steven E........................................................ P2.14-006
Saad Mohamed I.....................................................P3.07-002
....................................................................................P2.13-009 Schiller Joan........................................ P3.03-007, PL 02.05
Saavedra Omar.........................................................P2.03-051
Sanchez Carles..........................................................MA 20.08 Schlegel Anne...........................................................P3.13-033
Sabari Joshua K........................................................OA 10.03
Sanchez De Cos Julio............................................. P1.05-019 Schleifman Erica............ P1.04-011, P2.02-052, P3.02-061,
Sabir Sarah................................................................P1.03-011 ...................................................................................P3.02-062
Sanchez-Cespedes Montse..............MA 15.05, P2.08-006,
Sable Mukund.......................................................... P1.02-066 ...................................................................................P3.02-086 Schluckebier Luciene..............................................P1.01-045
Sachdev Veerachai.....................................................OA 11.04 Sanchez-Gil Rosa..................................................... P1.05-019 Schmid Sabine..........................................................P2.07-012
Sachdev Vishal....................................... OA 15.08, P2.16-019 Sanchez-Lorente David.............................................OA 16.06 Schmidt Heidi C.........................MA 14.11, MA 14.14, OA 15.01
Sacher Adrian G...................................................... MA 03.04 Sancho Gemma................................... P2.05-007, P3.14-014 Schmidt Lauren........................................................P2.13-005
Sackmann Sandra....................................................P3.01-038 Sandelin Martin...................................... MA 18.14, P1.06-012 Schmidt Sebastian....................................................WS 01.13
Sacramento Vania.....................................................P1.15-010 Sanders Karin J.C................................................... P2.01-048 Schmidt Timothy................................. P2.06-011, P3.10-003
Sadilova Lenka.........................................................P2.07-020 Sandin Rickard.........................................................P3.01-012 Schmidt Torben........................................................P3.07-013
Sadique Ahmad....................................................... P3.15-008 Sandler Alan........MA 05.09, MA 10.03, OA 17.02, OA 17.07, Schmitt-Opitz Isabelle............................................ P1.09-007
Sadrolhefazi Behbood............................................ P2.04-010 .............................................................. P1.01-052, P2.04-004 Schneider Jeffrey G................................................. MA 15.06
Sadílková Lenka.......................................................P3.07-008 Sandler Kim.................................................................MA 14.08 Schneider Kasey........................................................ MA 02.01
Saeki Sho...................................................................P3.15-009 Sands Jacob....................................... P2.13-017, P2.13-018 Schneider Marc..........................................................P1.15-011
Saeki Yusuke.............................................................P2.17-004 Sands Jacob M......................................................... P1.06-017 Schneider Marc A.............................P3.05-007, P3.05-008
Saeteng Somcharoen...............................................OA 04.08 Sanford Alexandra......... P2.01-004, P2.01-013, P2.01-014, Schneider Martina....................................................... MA 15.11
Saffarzadeh Areo..................................................... P1.16-003 .................................................................................... P2.01-015 Schneiter Didier..........................................................P1.17-016
Sagawa Motoyasu......................................................MA 14.06 Sang Yaxiong............................................................P3.01-037 Schols Annemie M.W.J........................................... P2.01-048
Sage Adam P.......................MA 15.12, MA 15.14, P1.02-006, Sangha Randeep..................................JCSE 01.27, MA 07.01 Schott Roland............................................................MA 03.05
........................................P2.02-017, P2.02-022, P3.02-094 Sanghera Calvin.......................................................... MA 14.11 Schotten Lea M........................................................P3.13-033
Sage Julien..............................................................MTE 10.02 Sano Go.....................................................................P2.01-010 Schreiner Waldemar......................P2.08-004, P2.08-005
Saghir Zaigham........................................................P3.13-011 Sansano J.................................................................. P1.05-015 Schrock Alexa B..................MA 05.02, MA 07.07, MA 12.03,
Sagi-Eisenberg Ronit..............................................P3.02-096 Santamaría David....................................................P3.02-066 .............................MA 15.06, OA 12.08, OA 18.03, P2.02-016
Sahlmann Jörg........................................................ P3.01-088 Santiago Rex C..........................................................P1.07-022 Schroers Martin Joseph........................................... MA 13.01
Sahoo Nibedita......................................................... P1.02-066 Santo Antonio....................MA 01.07, P1.01-053, P3.01-005 Schuler Martin................. OA 17.04, P1.01-012, P3.01-026,
Sahoo Satyajeet...................................................... P2.15-002 Santoni-Rugiu Eric.................................................. P3.01-007 ............................................................... P3.01-039, P3.01-075
Saida Yu.................................................................... P2.03-015 Santoro Armando...................................................... MA 10.06 Schulze Katja................... P1.01-007, P1.01-008, P3.04-003
Saigi Maria............................................................... P2.08-006 Santoro Ilka...............................................................P2.13-022 Schulze Sylvie.............................................................OA 10.06
Saihara Aya...........................................P1.01-054, P2.03-017 Santos Ana Karina................................................... P1.06-013 Schuster Nathalie........................................................ MA 15.11
Saijo Nagahiro........................................................... PL 04.02 Santos Edgardo S......... P2.01-014, P2.01-015, P3.02-004 Schwab Annemarie................................................P2.02-054
Sais Elia.....................................................................P1.03-035 Saraf Sanatan.............................................................. OA 17.01 Schwab Sophia.................................. P2.03-025, P3.03-024
Saisho Shinsuke................................. P2.02-028, P2.02-031 Sarantseva Ksenia A................................................ P1.01-056 Schwaller Beat........................................................ P1.09-002
Saito Akira................................................................ P1.07-012 Saravia Diana.......................................P1.07-024, P2.07-037 Schwartz David L......................................................OA 08.05
Saito Augusto O.......................................................P3.02-060 Sari Lenny..................................................................P1.01-067 Schwartz Naomi......................................................... MA 18.01
Saito Heisuke.......................................................... P2.06-009 Sarobba Maria Giuseppina...................................... P1.01-053 Schwartz Rebecca...................................................P2.16-022
Saito Rhohei.............................................................P2.07-004 Sarun Kadir H..................MA 19.06, P1.09-004, P1.09-005, Schwartz Sarit..........................................................P1.02-001
Saito Ryusei.......................................... P2.01-027, P2.15-016 ...................................................................................P3.02-078 Schwenk Jochen M.................................................P1.07-020
Saito Tomohito.................................... MA 05.06, P2.16-005 Saruwatari Koichi.....................................................P3.15-009 Schytte Tine................................................................OA 01.02
Saitoh Jun-Ichi......................................................... P1.14-006 Sarıhan Sureyya....................................................... P2.14-016 Scoppola Alessandro................................................ MA 10.06
Saji Hisashi...........................................P2.05-012, P3.15-002 Sasahara Yukiko..................................P1.03-010, P2.03-032 Scott Jeffrey............................................................ P2.04-013
Sakabe Tomohiko.................................................... P1.02-060 Sasaki Jiichiro......................................................... P2.03-002 Sebaste Lucio...........................................................P2.07-046
Sakagami Takuro.....................................................P2.07-007 Sasaki Shinichi......................................................... P1.03-006 Sebastian Martin..................................P3.01-075, P3.01-088
Sakaguchi Yasuto..................................................... P1.14-005 Sasaki Tomonari......................................................P1.08-006 Seber Selcuk............................................................. P1.01-029
Sakai Hitomi..............................................................P2.07-021 Sasano Hajime......................................................... P3.01-064 Secouard-Faure M.-C................................................MA 12.02
Sakai Naoki............................................................... P2.07-024 Sashegyi Andreas.....................................................MA 03.06 Sedef Ali Murat........................................................ P3.08-001
Sakai Shuji.................................................................WS 01.29 Sata Yuki............................................... P1.16-008, P2.12-006 See Katharine........................................MA 14.09, P2.13-023
Sakai Takashi...........................................OA 16.07, P3.02-074 Satankova Monika...................................................P2.03-023 Seely Andrew J........................................................P3.16-007
Sakaida Tsukasa.......................................................P2.07-014 Sato Akemi................................................................ P1.01-028 Seely Jean M.............................................. MA 14.11, OA 15.01
Sakairi Yuichi.................P1.16-008, P2.07-008, P2.12-006 Sato Akira..............................................P1.01-054, P2.03-017 Seethamraju Ravi........................................................MA 19.10
Sakaki Seigo............................................................. P2.07-035 Sato Jun......................... P2.03-036, P2.03-048, P3.02-041 Seevanayagam Siven..............................................P3.16-052
Sakakibara Yumi..................................P1.03-010, P2.03-032 Sato Katsuaki............................................................. P3.16-011 Seidal Tomas.............................................................P1.09-010
Sakamaki Hiroyuki................................. P1.17-017, P3.13-031 Sato Ko...................................................................... P2.03-015 Seijo Luis................................................................... P1.05-019
Sakamaki Kentaro.......................................................MA 17.06 Sato Koichi...............................................................P2.07-035 Seike Masahiro........................................................ P1.03-004
Sakamaki Yasushi.......................................................MA 17.04 Sato Masaaki......................P1.07-017, P1.13-002, P3.16-028 Seiwerth Fran...........................................................P3.01-059
Sakamori Yuichi........... P2.01-021, P2.03-055, P2.07-003, Sato Masami............................................................. P2.16-004 Seiwerth Sven....................................P2.09-004, P3.01-059
....................................................................................P2.07-017 Sato Mitsuo.............................................................. P3.03-013 Sekhon Harmanjatinder S..........................................OA 15.01
Sakamoto Shuichi.................................................... P3.15-001 Sato Miyuki...............................................................P2.07-007 Sekido Yoshitaka.............. MA 19.08, MS 08.05, P3.03-013
Sakamoto Susumu.............................. P2.01-010, P3.16-004 Sato Ryo..............................................P1.02-023, P3.15-009 Sekihara Keigo........................................OA 16.07, P3.02-074
Sekimura Atsushi....................................................P3.02-085 Shen Hui...................................................................P3.02-008 Shintani Takashi.............. MA 09.06, P1.14-015, P2.05-002

Sekine Akimasa........................................................P2.01-001 Shen Jianfei..............................................................P1.02-026 Shintani Yasushi.................MA 16.08, MA 17.04, P1.02-068,
Sekine Ikuo...........................................MA 03.08, OA 08.04 Shen Jiqiao............................................................... P1.03-046 ............................................ P1.17-002, P1.17-013, P3.16-050
Sekine Yasuharu.......................................................P2.17-004 Shen Lan.....................................................................MA 07.04 Shiomi Tatsushi....................................................... P1.02-060
Sekine Yasuo.......................................OA 04.05, P2.09-006 Shen Liji................................................................... P2.04-007 Shiono Hiroyuki..........................................................MA 17.04
Sekino Yuta............................................................. P2.05-005 Shen Ronglai...............................................................OA 14.05 Shiono Satoshi........................................................... MA 13.13
Selcukbiricik Fatih................................................... P2.01-063 Shen Wen-Tong....................................................... P2.14-004 Shiotani Toshio..........................................................P1.16-024
Selcuklu Duygu S.......................................................OA 10.05 Shen Yi..............................JCSE 01.10, OA 16.04, P2.03-047 Shioyama Yoshiyuki..................................................MS 24.04
Sella Tal.....................................................................P3.03-028 Shen Yi-Cheng......................................................... P2.07-027 Shipitofsky Nicole................................P3.04-012, P3.04-013
Sellappan Shankar...................................................P1.02-001 Shepherd Frances A.............................ISS 11.01, ISS 11.02, Shirai Katsuyuki................................... MA 09.06, P1.14-006
Selvaggi Giovanni....................................................P2.07-034 .............................................ISS 11.06, ISS 11.07, MA 03.06, Shirai Yuya..........................................P1.02-032, P2.06-003
Semba Takashi..........................................................P1.02-023 ..............................MA 13.02, MS 05.01, OA 15.01, OA 17.02, Shiraishi Kenji........................................ P1.15-014, P1.16-002
Semsarn Siriporn........................................................OA 11.04 ......................... OA 17.03, P2.01-055, P2.04-013, PL 04.04 Shiraishi Kouya........................................................P3.02-035
Sen Yang..................................................P1.01-017, P1.01-047 Shepherd Paula.........................................................MA 08.07 Shiraishi Norihiko..................................................... P1.01-070
Sena Susana........................................P1.01-058, P2.03-039 Sheren Jamie...........................................................P3.02-057 Shiraishi Takeshi.......................................................P3.16-044
Senan Suresh.....MS 11.04, OA 16.01, P2.14-019, YI 01.12 Sheridan Simon...................................................... P3.04-006 Shiraki Akira............................................................ P3.04-002
Sengupta Arjun........................................................ P2.01-055 Sherman Eric J.......................................................... OA 12.07 Shirasawa Masayuki.............................................. P2.03-002
Senju Hiroaki........................................P1.03-015, P2.07-045 Shewade Ashwini.....................................................P1.01-031 Shire Norah.............................................................. P2.01-043
Senson Insee...........................................................P3.03-020 Shi Hua M................................................................P2.07-043 Shiroyama Takayuki.................................................P1.03-047
Senthil Maheswari.................................................... P1.16-006 Shi Jianhua.....................P3.01-087, P3.03-006, P3.03-017 Shiue Kevin..................................................................MA 13.06
Seo Hong Gwan........................................................MS 09.03 Shi Jinpeng.............................................MA 11.07, P2.07-047 Shoji Fumihiro.....................................P1.07-002, P3.16-003
Seo Yuji.......................................................................MS 24.04 Shi Junping..............................................................P3.07-009 Shoji Satoshi....................................... P2.03-015, P2.07-007
Sepesi Boris............................................OA 13.05, P2.02-041 Shi Meiqi....................................................................P3.01-036 Sholl Lynette M................... MA 05.02, MA 07.08, MA 20.14,
Sequist Lecia V................ GR 01.02, ISS 10.05, ISS 10.07, Shi Mingwei............................................................... P2.01-017 ................................................................OA 09.02, P3.03-007
..............................OA 07.05, OA 09.01, OA 09.03, OA 12.02, Shi Minhua...............................................................P2.06-010 Shou Tao..................................................................P3.07-009
............................................. OA 17.01, P3.01-026, P3.01-039, Shi Qin......................................................................... P2.14-011 Shoval Hila................................................................P3.02-082
.............................................................. P3.01-075, P3.03-007 Shi Qingming............................................................ P2.01-011 Shrager Joseph B...................................................... MA 13.01
Sera Koichiro........................................................... P2.06-009 Shi Qiuling.......................OA 01.07, P2.01-036, P2.04-014 Shu Yong-Qian........................................................... OA 09.06
Sereno María.............................................................. MA 07.03 Shi Ruoshi.............................................................. P3.03-008 Shu-Chan Chang.................................P1.10-006, P2.03-001
Serin Meltem............................................................ P3.08-001 Shi Tao............................P3.01-002, P3.02-095, P3.02-097 Shukuya Takehito................................MA 06.08, P3.03-002
Serizawa Masakuni........................... P2.15-008, P3.05-006 Shi Xiaohua...................MA 12.09, P2.02-033, P3.03-004 Shultz David B...........................................................P3.14-013
Serna Adriana......................................................... P3.08-005 Shi Xiaoshun.................................... P1.07-005, P2.02-003 Shum Elaine.............................................................P1.07-027
Serra José María................................. P1.01-057, P2.02-027 Shi Xin Mei................................................................P3.13-004 Shutov Vitaly.............................................................P3.16-043
Serra Mireia.............................................................. P1.05-019 Shi Xun...................................................................... P1.03-007 Shyr Yu.................................................MS 01.04, P3.03-007
Serzan Michael T.....................................................P2.07-050 Shi Yuankai...................... MA 11.03, P2.03-028, P3.01-087, Si Xiaoyan............................................P2.03-041, P2.03-050
Seshan Venkatraman.................................................OA 10.05 .............................................................. P3.03-017, P3.04-007 Sia Michael................................................................. P1.14-014
Sesumi Yuichi......................................P3.02-059, P3.16-049 Shi Yunfei...................................................................P2.02-018 Sibille Yves...........................................P3.15-004, P3.15-004
Sethy Madhusmita................................................... P1.02-066 Shiao Tsu-Hui........................................................ P3.02-043 Sica Gabriel L.............................................................OA 08.06
Setinek Ulrike..................................... P2.03-025, P3.03-024 Shiba Aya.............................................P1.02-071, P2.02-055 Sicks Jorean..............................................................P2.13-014
Seto Takashi.........................MA 07.10, MA 17.06, OA 05.03, Shibahara Junji.........................................................P1.02-033 Siddiqui Aarif...........................................................P2.02-054
............................................OA 05.06, OA 05.08, P1.03-005, Shibano Tomoki..................................... OA 18.07, P3.02-089 Siegel Jonathan......................................OA 02.01, P1.04-013
..............................................................P2.04-005, PC 02.04 Shibata Toru.............................................................. P1.14-002 Siemann Sandra.........................................................OA 10.06
Setoguchi Taiki..........................................................P2.07-014 Shibayama Rina.......................................................P3.02-024 Siemiątkowska Krystyna........................................P3.02-045
Sevinç Tolga............................................ MA 17.08, P2.14-016 Shibayama Takuo....................................................... OA 12.03 Siena Salvatore...........................................................OA 14.06
Seymour Lesley.................MA 10.01, P2.01-032, P2.01-055 Shibuki Yasuo...........................................................P2.02-035 Siewiera Katarzyna..................................................P3.02-051
Sferra Shelby R...................................P2.13-005, P2.13-006 Shibuya Kazutoshi................................ MS 07.04, P3.16-004 Sigal Ellen V................................................................. OA 14.07
Sgnaolin Valeria........................................................P3.16-034 Shieh Jiunn-Min....................................................... P3.01-016 Signore Raymond S............. MA 04.01, OA 15.08, P1.13-011,
Shady Maha.................................................................OA 10.05 Shiels Liam............................................................... P1.09-007 .....................................................................................P2.16-019
Shafiq Jesmin.....................................P2.05-004, P3.14-003 Shien Kazuhiko.........................................................P2.16-026 Signorelli Diego................................... MA 10.06, P2.09-001a
Shah Aakash............................................................ P3.10-002 Shigeeda Wataru.................................................... P2.06-009 Sihoe Alan D.L.........................................................P1.16-009
Shah Chirag D...........................................................P2.13-008 Shigefuku Shunsuke..............................................P2.05-012 Silva Cecilia F............................................................P1.02-036
Shah Manan........................................P1.04-006, P1.04-007 Shigenobu Takao.................................................... P3.08-002 Silva Fernando M.....................................................P3.03-019
Shah Manisha H......................................................... OA 12.07 Shih Danny...............................................................P2.03-058 Silverio Flavio S........................................................P3.03-019
Shah Neil J............................................................. P2.07-050 Shih Jin-Yuan................... MA 03.06, P3.01-006, P3.01-074 Simizu Eiji................................................................. P2.03-016
Shah Nisargbhai...................................................... P3.15-008 Shih Min-Shu............................................................P3.01-074 Simon George R................. MA 18.08, OA 01.07, OA 14.04,
Shah Riyaz..............................................MA 08.01, P3.01-075 Shiina Yuki..........................................P2.07-008, P2.12-006 ....................................... P1.10-005, P2.01-036, P2.04-014
Shah Srushti............................................................. P2.01-051 Shiiya Haruhiko.........................................................P1.17-010 Simon Nicholas I.......................................................P3.02-013
Shaheen Shagufta...................................................P1.16-006 Shikano Kohei......................................................... P2.03-005 Simpronio Jacqueline................................................OA 10.03
Shahid Tanweer........................................................P2.01-023 Shilo Konstantin.........................................................MA 06.08 Simsek Eda T............................................................ P1.03-040
Shahrasbi Abdolali................................................. P3.01-047 Shim Jae Jeong........................................................P2.01-035 Simundza Ivan.......................................................... P1.16-004
Shakeel Shahbano................................................. P3.08-004 Shim Young Mog...........P1.08-004, P2.02-001, P3.01-082, Sin Don.........................................................................OA 15.01
Shakik Sharara...........................................................MA 16.03 ...........................................P3.02-011, P3.04-011, P3.05-012, Singh Amrita..........................................................P2.06-004
Shamai Sivan..........................................................P2.07-026 .................................................................................. P3.08-006 Singh Anand S.........................................................P1.09-006
Shames David S.................................... MA 05.09, P1.04-011 Shimada Hiroyuki.............................. P1.03-010, P2.03-032 Singh Anurag..............................................................MA 13.08
Shamji Farid..............................................................P3.16-007 Shimada Junichi.............. P1.02-022, P1.17-009, P2.01-067, Singh Jasmeet..........................................................P3.04-013
Shan Jidong................................................................MA 15.08 ............................................................. P2.05-013, P2.16-008 Singh Jorawur........................................................... P1.14-014
Shan Joseph....................................... MA 10.05, P2.02-030 Shimada Midori....................................P1.03-015, P2.07-045 Singh Navneet................MA 03.02, P1.03-018, P2.03-053,
Shane-Carson Kate............................... MA 06.08, OA 06.02 Shimada Naoko...............P1.02-065, P2.02-012, P3.02-024 ................................................................ P2.06-004, YI 01.02
Shang Yanhong................................... P2.02-018, P3.07-009 Shimada Tadashi.......................................................OA 05.08 Singh Saravjeet......................................................... P1.02-011
Shankar Abhishek................................................. P3.06-007 Shimada Yoshihisa................................MA 15.13, P2.05-012 Sinha Arvind.............................................................P3.13-004
Shao Yang..................................................................P3.01-067 Shimajiri Shohei.......................................................P1.07-030 Sinicropi-Yao Sara..................................................P1.02-019
Shao Yang W...............................................................MA 20.13 Shimamoto Shigetoshi........................................... P2.06-003 Sio Terence T.W.................................P2.14-006, P3.09-001
Shao Yun............................................P2.02-004, P3.03-005 Shimamura Mie........................................................P2.02-057 Siqueira Gabriela S..................................................P2.14-003
Shapetska Mikhail....................................................P3.02-075 Shimazaki Masashi.................................................... OA 05.03 Sirachainan Ekaphop..............................................P3.03-020
Shapiro Geoffrey I......................................................OA 12.06 Shimazu Kohki....................................P1.02-032, P2.06-003 Sirbu Horia........................................ P2.08-004, P2.08-005
Shariff Salimah........................................................ P2.14-009 Shimizu Hisashi.......................................................P2.07-004 Sirisinha Dejthevaporn Thitiya..............................P3.03-020
Sharma Mansi.....................................P2.01-051, P2.03-027 Shimizu Junichi....................................................... P2.07-028 Sitthideatphaiboon Piyada....................................P3.02-076
Sharma Neelesh...................................................... P1.03-044 Shimizu Katsuhiko.............................P2.02-028, P2.02-031 Situ Dongrong.........................................................P2.05-018
Sharma Padmanee.................................................... OA 13.05 Shimizu Kimihiro................................P1.05-006, P2.02-026 Siva Shankar..........................MA 17.12, P1.14-017, P2.14-001
Sharma Rameshwaram......................................... P2.10-007 Shimizu Reiko...........................................................P1.02-033 Siwachat Sophon......................................................OA 04.08
Sharma Siddharth.................................................. P2.06-004 Shimizu Tetsuo.................P1.03-009, P2.15-015, P3.03-011 Sixtova Dimka..........................................................P2.03-023
Sharpnack Michael F.................................................OA 18.02 Shimoji Masaki.....................................P3.02-059, P3.16-049 Sjoberg Ayla.............................................................P3.07-005
Shaw Alice........................ JCSE 01.27, MA 05.02, MA 07.01, Shimokawa Mototsugu...........................OA 13.06, P1.07-014 Sjöblom Tobias...........................................................P1.07-021
........................... MA 07.07, MS 13.03, OA 05.06, OA 07.05, Shimokawa Tsuneo...........................P2.07-042, P2.15-004 Skala Marketa..............................................................MA 13.07
...........................OA 12.02, P1.01-012, P1.01-016, SS 01.07 Shimomura Hitoshi.................................................P2.03-007 Skenduli Ilir............................................................... P3.16-005
Shaw Mark.............................................. MA 13.07, P2.14-001 Shimose Takayuki.................................................... P1.03-004 Skog Johan.............................................P1.01-074, P1.03-013
Shaw Tim..................................................................P3.13-038 Shin Ah Young.........................................................P2.02-029 Skokan Michael D.....................................................P2.13-009
Shchayuk Anna.......................................................P3.02-075 Shin Jong Wook......................................................P2.02-032 Skoletsky Joel................P2.02-052, P3.02-061, P3.02-062
She Jun........................................................................MA 20.13 Shin Kyung Min........................................................P2.02-056 Skoulidis Ferdinandos............................................ MA 05.02
Sheaff Michael............................................................MA 19.05 Shin Sang Won..........................................................P3.13-017 Skowron François................................................... P2.07-023
Shehaj Eljana........................................................... P3.16-005 Shin Sumin....................P1.06-003, P3.01-082, P3.04-011, Skrickova Jana...................................................... P2.03-023
Shelton David............................................................P1.03-001 .................................................................................. P3.08-006 Skupinska Monika M................................................P3.02-051
Shelton David K.........................................................P1.07-013 Shina Yuki.................................................................. P1.16-008 Slater Sarah J...................................P3.15-003, P3.15-005
Shelton Joseph........................................................ P1.08-003 Shingyoji Masato......................................................P2.07-014 Slavikova Monika.....................................................P2.03-056
Shemanski Lynn.........................................................PL 02.06 Shinmura Takuya.................................P1.03-010, P2.03-032 Slepetis Ruta..............................................................MA 02.02
Shemesh Rachel......................................................P3.02-096 Shinno Yuki............................................................ P2.03-048 Slotman Berend.........................................................P2.14-019
Slugin Evgeny...........................................................P3.16-038 Souquet Pierre Jean.................................................. OA 16.03 Su Weiguo............................................JCSE 01.12, P3.01-070
Small David........................................P2.02-040, P3.02-055 Souquet Pierre-Jean............................................. P2.04-005 Su Wu-Chou........................MA 16.02, OA 09.03, P1.01-048,
Small Isabele.............................................................P1.02-036 Sousa Aureliano M.C...............................................P1.02-036 ..........................................P2.03-058, P2.10-001, P3.01-036
Smeal Tod.................................................................P3.07-006 Sousa Carlos Augusto M.........................................P1.02-036 Su Xiaoxing..........................................JCSE 01.24, P1.01-032
Smeds Patrik.............................................................P2.02-015 Soussan-Gutman Lior............................................ P3.01-060 Su Yanjun................................................................. P2.03-040
Smeltzer Matthew P...........MA 04.01, OA 15.08, P1.13-011, Souza Eunice C.........................................................P3.03-019 Suarez Cruzat Claudio............................................. ES 05.05
.....................................................................................P2.16-019 Soyano Aixa E..................... OA 06.05, OA 06.07, P1.07-039 Subbiah Vivek.........................................OA 12.07, P1.03-044
Smit Egbert F........................MA 05.07, MA 17.10, OA 05.05, Spada Manoela A.....................................................P3.03-019 Subia Laarnie C....................................................... P2.01-062
............................................P1.01-001, P2.03-058, PC 01.05 Spasic Jelena.......................................................... P1.02-007 Subramaniam Deepa..............................................P2.07-050
Smit Terasa................................................................P3.13-021 Spatz Alan...................... P2.02-040, P3.01-019, P3.02-055 Suda Kenichi............................................................. OA 07.06
Smith Christopher G.................................................. MA 11.02 Speicher Paul J..........................................................MA 19.09 Suda Takafumi.........................................................P2.07-022
Smith David A...................................... P2.01-004, P2.01-013 Spencer Kathryn.......................................................P1.03-011 Sueda Taijiro..............................................................P1.02-052
Smith Gary...................................................................MA 14.13 Sperandi Francesca.................................................. MA 10.06 Suenaga Yusuke......................................................P2.02-063
Smith Irma............................................................... P3.08-004 Spicer James..............................................................OA 02.01 Sueoka Eisaburo...................................................... P1.01-028
Smith Lynette M......................................MA 13.04, P2.15-013 Spiegel Marshall........................................................MA 02.07 Sueoka-Aragane Naoko...................... P1.01-028, P2.03-011
Smith Michelle............................................................MA 12.05 Spigel David R.................... MA 10.05, P1.01-051, P2.01-014, Sugai Kazuto.............................................................P2.17-004
Smith Ralph A............................................................MA 05.07 ..........................................P2.01-015, P3.07-012, P3.08-004 Sugai Tamotsu........................................................ P2.06-009
Smith Rob............................................... P3.05-001, WS 01.18 Spinhoven Maarten J...............................................P3.13-008 Sugawara Shunichi.......P2.03-010, P2.03-021, P2.07-004
Smith Robert........................................WS 01.29, WS 02.02 Spira Alexander.........................................................MA 02.03 Sugimoto Ai............................................................. P2.03-002
Smith Steven............................................................... OA 12.07 Spira Avrum.............................................................. WS 02.14 Sugimoto Masahiro.................................................P2.02-009
Smith Suzanne.............. P1.14-018, P3.04-006, P3.09-002 Špíšek Radek.......................................P2.07-020, P3.07-008 Sugimoto Masamichi.......................... P2.02-051, P2.07-006
Smith Tom..................................................................MA 08.09 Spitaleri Gianluca......................................................P1.01-015 Sugimoto Ryujiro.................................................... P2.05-009
Smoljanovic Vlatka.................................................... P1.01-013 Sporchia Andrea F.....................................................OA 02.01 Sugimoto Seiichiro...................................................P2.16-026
Smylie Jennifer...........................................................OA 11.06 Sporn Thomas............................................................MA 13.02 Sugino Keishi.............................................................P2.01-010
Smęder Tomasz.........................................................OA 04.01 Spring Lisa............................................................... P3.01-088 Sugino Takashi................................... P2.15-008, P3.05-006
Snee Mike........................................... P2.01-060, P2.08-003 Spruit Martijn A.......................................................P2.08-001 Sugio Kenji......................P1.03-004, P2.05-017, P3.02-039,
Sng Gerald.................................................................P1.16-013 Srichunrusami Chutatip.........................................P3.03-020 .................................................................................. P3.04-004
Snoeckx Annemie.................................................. P3.13-008 Srikakulum Aparajita................................................P1.03-028 Sugisaka Jun............................................................P2.07-004
So Hong-Seob......................................................... P1.02-003 Srimuninnimit Vichien............................................ P3.01-042 Sugita Keisuke......................................................... P2.03-002
So-Mye Koo.............................................................. P2.01-008 Srinivasa Bj...............................................................P3.01-036 Sugita Michio.............................................................P2.03-019
Soares Marta............................................................P3.01-049 Sriprasart Thitiwat..................................................P1.12-005 Sugiyama Eri.............................................................P1.03-027
Soawa Terumasa.....................................................P3.02-071 Sriuranpong Virote............................... OA 05.02, P3.01-042 Sugiyama Haruhito...........................P2.03-005, P2.03-033
Soca-Chafre Giovanny... P1.07-041, P2.01-070, P2.01-075 Staab Mary Jane....................................................... MA 02.01 Sugiyama Michiko...................................................P2.02-035
Socci Nicholas D.........................................................OA 10.05 Stahel Rolf A....................ISS 10.02, ISS 10.07, MA 06.06, Sugiyama Tomohide................................................ P1.15-002
Socinski Mark..............................................................MA 19.03 ............................................... MA 15.11, MS 18.03, P1.09-001 Sugiyama Tomoko.....................................................P1.02-017
Socinski Mark A.....................................OA 14.07, P3.08-004 Stam Barbara............................................................P3.14-005 Suh James................................................................P2.02-016
Soejima Kenzo................MA 06.10, P2.03-012, P3.02-084 Stamatis Georgios..................................................... MS 11.02 Suh Jee Won..............................................................P3.16-019
Soeratman Eddy........................................................P1.01-067 Stambolic Vuk......................................................... P3.03-008 Sui Jane S.Y........................................................... P2.02-048
Soghrati Kam...............................................................OA 15.01 Stanczak Aleksandra...............................................P3.02-051 Sui Xizhao................................................................ P3.16-025
Soh Junichi...............................................................P2.16-026 Stanfill Bryan........................................................... P1.09-007 Suidan Anna M........................................................P3.03-022
Solberg Steinar.........................................................P1.02-028 Staniec Bartek..........................................................P2.16-027 Suina Kentaro........................................................... P1.03-006
Solca Flavio...............................................................P3.01-043 Stanzi Alessia.............................................................P1.13-007 Sukari Ammar..........................................................P2.07-040
Soldera Sara V.......................................................... MA 16.03 Starr Amelia............................................................... OA 03.03 Sukauichai Sitthi.....................................................P2.01-002
Solit David B..............................................OA 10.05, OA 14.05 Starren Elizabeth................................ MA 06.13, P1.02-054 Sukor Sue................................................................... MA 04.10
Solomon Ben J.............. ISS 09.02, ISS 09.05, MA 04.06, Stastny Victor........................................................... P1.15-005 Sukov William............................................................. OA 03.06
............................MA 18.12, OA 05.06, OA 12.06, P1.01-012, Steele Nicola......................MA 19.03, P3.15-003, P3.15-005 Sukumaran Babu..................................................... P3.01-020
....................P1.01-016, P1.01-033, P2.03-044, P3.13-003 Stefani Stephen D....................................................P2.03-029 Sullivan Ivana............................................................ P1.01-075
Solomon Josie........................................................ P2.06-005 Stehr Henning............................................................. MA 13.01 Sullivan Ivana G................................... P1.07-028, P2.01-072
Solomon Stephen B..................................................P3.13-019 Stein Matthew K...................................................... MA 06.07 Sullivan Travis............................................................P2.13-018
Soltermann Alex...............P1.09-007, P1.17-016, P2.02-036 Steinberg Seth M.....................................................P2.03-052 Sum Ying Ying........................................................P1.05-007
Son Jaekyung..........................................................P3.02-088 Steinfort Daniel P................MA 14.09, MA 20.09, P1.14-017, Sumiyoshi Issei........................................................ P1.03-006
Son Joohyung.................... P1.16-001, P2.16-011, P3.16-006 .............................................................. P2.13-023, P2.14-001 Summers Yvonne.......................................................MA 10.07
Sone Naoyuki............................................................P2.01-001 Steliga Matthew A................................MA 18.02, MS 09.04 Sun Alexander........................................MA 09.02, P1.14-016
Song Chunfeng.........................................................P3.16-030 Stenzinger Albrecht................................................P3.02-032 Sun Fei..................................................................... P2.08-003
Song Jianzhong........................................................ P1.01-072 Stephans Kevin.......................MA 09.04, MA 13.08, MA 17.11 Sun Fuming..................JCSE 01.24, JCSE 01.24, P1.01-032
Song Jing................................................................... P1.03-051 Stephens Dennis......................................OA 10.03, OA 10.05 Sun Guoping..............................................................P3.01-037
Song Qi Bin...........................................P3.01-083, P3.15-013 Stephens Philip J.................MA 05.02, MA 07.07, MA 12.03, Sun James.................P2.02-052, P3.02-061, P3.02-062
Song Qingtao............................................................P3.02-019 ...........................OA 12.08, OA 18.03, P1.07-013, P2.02-016, Sun Jong-Mu..................OA 03.04, OA 08.07, P1.08-004,
Song Sang-Yun.................................... P2.03-024, P2.14-017 .........................................P2.02-052, P3.02-061, P3.02-062 .................... P2.01-064, P2.07-025, P3.01-023, P3.01-029,
Song So Hyang.......................................................... P1.12-001 Stephens-Mcdonough Joy A.................................. P1.16-022 .........................................P3.01-082, P3.03-012, P3.08-006
Song Sunhwa........................................................... P2.01-069 Sterman Daniel H........... MA 10.10, OA 02.04, P2.07-059 Sun Ping-Li...............................................................P3.02-017
Song Wei......................................................................OA 18.08 Steuer Conor............................................................ P1.08-003 Sun Tao....................................................................... P1.15-016
Song Xia.....................................................................P1.07-029 Stevenson James P...................................MA 13.03, OA 17.01 Sun Wei....................................................................... P1.07-011
Song Xingzhi.............................................................P2.02-013 Stevenson Robert..............P2.14-012, P2.14-014, P2.14-015 Sun Wen-Yong......................................................... P3.14-004
Song Yong...........................MA 03.03, MA 11.03, P1.01-002, Stewart David J.................... MA 03.01, MA 10.02, OA 11.06, Sun Wenyong............................................................P2.02-013
.......................................... P1.01-006, P1.01-037, P1.01-073, .....................................................................................OA 14.02 Sun Wenyu.......................................JCSE 01.16, P1.07-006
.................... P1.02-043, P1.02-044, P1.02-045, P1.02-046, Stewart Greg L.................MA 15.14, P2.02-017, P2.02-022 Sun Xiaojiang..................... MA 09.01, P3.01-058, P3.14-015
..................... P1.02-047, P1.02-048, P1.02-049, P1.02-056, Stewart Lori................................................ MA 14.11, OA 15.01 Sun Xin.....................................................................P1.08-007
.......................P1.02-057, P1.02-058, P1.02-059, P2.01-017, Steyn Richard.................... MA 08.09, P1.10-002, P3.16-024 Sun Yajun................................................................... P1.15-009
................... P2.01-019, P2.02-005, P2.02-007, P2.02-020, Stigt Jos........................................................................MA 17.10 Sun Yan.....................................................................P2.03-028
....................P2.02-021, P2.03-057, P3.01-009, P3.02-025, Stinchcombe Thomas E...MA 17.07, MA 18.06, P3.04-003
...................P3.02-026, P3.02-027, P3.02-028, P3.02-029, Sun Yanqin............................................P2.15-003, P2.15-010
Stirling Kevin...............................................................OA 07.05 Sun Yun.........................................................................MA 11.03
..................P3.02-065, P3.02-068, P3.02-069, P3.02-080,
...................................................................................P3.07-004 Stirling Rob.............................................. MA 18.12, P3.13-003 Sunaga Noriaki.................P2.01-027, P2.02-026, P2.15-016
Song Zhengbo................P1.02-044, P1.02-045, P1.02-046, Stockler Martin....................................................... P2.03-044 Sunami Kuniko........................................................... MA 16.04
..................... P1.02-047, P1.02-048, P1.02-049, P1.02-056, Stolp Christa.......................................P3.05-007, P3.05-008 Sunarso Samuel...................................................... P2.01-044
.....................P1.02-058, P1.02-059, P2.01-017, P2.02-005, Stone Amanda............................................................ MA 11.02 Sundaresan Purmina...............................................P3.13-038
...................P2.02-007, P2.02-020, P2.02-021, P2.03-057, Stone Emily...................... MA 18.05, MS 09.01, P1.04-003 Sundaresan Sudhir..................................................P3.16-007
...................P3.01-008, P3.01-009, P3.02-025, P3.02-028, Stoupis Ioannis.........................................................P1.01-044 Sundberg Jan........................................................... P1.15-007
..................P3.02-029, P3.02-065, P3.02-068, P3.02-069, Strasser Florian........................................................ ES 06.02 Sundström Magnus..................................................P2.02-015
...................................................................................P3.02-080 Strickler John.............................................................MA 02.10 Sung Jun Choo........................................................ P2.01-008
Sonke Jan-Jakob.................................. MA 13.09, P3.14-005 Strout Vincent........................................................... P1.01-070 Sung Sook-Whan.................................................... P3.08-003
Sonne Petrine L......................................................P1.05-004 Stroyakovsky Daniil L.............................................. P1.01-056 Surico Giammarco.....................................................MA 01.07
Sonobe Makoto................................... P3.02-046, P3.02-071 Studts Jamie L............................................................ MA 04.11 Sussman Daniel J.............................P3.03-016, P3.03-026
Sonokawa Takumi....................................................P1.02-053 Stump Julia................................................................P1.07-019 Sutandyo Noorwati............................P1.01-026, P1.01-067
Soo Ross...............................................P3.01-022, P3.13-004 Stuschke Martin..........................................................MS 16.04 Sutanto Yusup S...................................................... P2.01-044
Soo Ross A.................................................................OA 05.06 Su Christopher..........................................................P1.07-027 Sutor Shari.................................................................. OA 13.07
Soon Sing Yang....................................................... P1.05-007 Su Christopher T......................................................P2.13-008 Suzuki Ayumi.......................................................... P3.16-042
Soon Yu Yang.....................P1.08-001, P1.15-017, P2.14-002 Su Chunxia................... P1.03-045, P1.03-046, P1.03-052, Suzuki Hidekazu.................................. P1.03-047, P1.03-049
Soon-Shiong Patrick..................................................OA 18.04 ............................................P1.15-009, P3.01-067, P3.01-085 Suzuki Hidemi.................P1.16-008, P2.07-008, P2.12-006
Soong Thomas C......................................................P3.12-002 Su Dan........................................................................P2.02-013 Suzuki Hirofumi............ P2.05-013, P2.16-006, P2.16-008
Sorensen Henrik..................................................... P2.01-043 Su Jian.............................P1.01-018, P1.07-042, P2.03-054, Suzuki Hiroyuki......................................................... MA 05.15
Soria Jean-Charles................MA 05.03, MA 10.11, MA 11.01, ................................................................P3.01-051, P3.01-063 Suzuki Kana..............................................................P2.07-004
...................... P1.01-016, P1.03-013, P1.04-008, P2.01-038, Su Kang-Yi.................................................................P3.01-074
.........................................P2.07-005, P2.07-060, P3.01-043 Suzuki Katsuyuki.........................................................MA 13.13
Su Po-Lan.................................................................P1.01-048 Suzuki Kei.................................................................P1.05-013
Sostruznik Maria Helena....................P1.06-020, P3.16-034 Su Shan.................................................................. P2.03-054
Soto Parra Hector J................................. MA 10.06, MA 11.11 Suzuki Makoto........................................ P1.15-014, P1.16-002
Su Wei-Juin................................................................MA 03.07 Suzuki Mayumi...................................P1.02-032, P2.06-003
Soto-Matos Arturo.............................. MA 01.05, P2.04-008
Suzuki Mikito...............................................................P1.17-017 Takahashi Mai...........................................................P3.02-093 Tan Min Han...............................................................P3.01-017

Suzuki Osamu............................................................MA 09.06 Takahashi Motomi....................................................P3.02-024 Tan Ming....................................................................P2.07-050
Suzuki Ryoko..............................................................MA 01.10 Takahashi Noriaki...........P1.03-009, P2.02-057, P2.15-015, Tan Pui......................................................................P2.07-055
Suzuki Satoshi..........................................................P3.16-032 .................................................................................... P3.03-011 Tan Qinghe................................................................P3.02-065
Suzuki Shigeki.........................................................P1.05-002 Takahashi Shigeo.....................................................P1.14-002 Tan Qunyou.............................................................. P2.05-018
Suzuki Soichi........................................................... P2.16-004 Takahashi Shoji............... P2.15-008, P3.05-006, P3.16-011 Tan Seng Chuen.......................................................P1.01-050
Suzuki Susumu.........................................................P2.07-015 Takahashi Tiago K.................................................... P3.01-066 Tan Sze Huey.............................................................P3.01-017
Suzuki Takashi....................................P3.02-042, P3.16-008 Takahashi Toshiaki..............MA 17.06, MA 19.01, P2.15-008, Tan Wan C.....................................................................OA 15.01
Suzuki Yota........................ P1.05-009, P1.17-017, P3.13-031 ..............................................................P3.01-072, P3.05-006 Tan Wan Ling..........................................OA 09.07, P3.01-017
Suzumura Tomohiro...............................................P1.06-014 Takahashi Tsuyoshi..............................P1.13-002, P3.16-028 Tan Weiwei............................................................... P1.03-003
Suzumura Yuji...........................................................P1.03-037 Takahashi Yui...........................................................P3.02-033 Tan Yun -...................................................................P3.02-072
Svara Erin.....................................................................MA 14.14 Takahashi Yusuke...........MA 13.14, P1.13-003, P2.05-021 Tan Zhi..........................................................................OA 12.01
Svärd Jenny.............................................MA 18.14, P1.06-012 Takahasi Kazuhiro................................................... P1.03-044 Tan-Liu Nelia....................................... P2.02-019, P3.02-056
Swaminath Anand..................................................... MA 01.12 Takahira Asuka......................................................... P1.03-015 Tanahashi Masayuki................................................P2.07-022
Swanson Scott....................................MTE 13.01, P1.12-004 Takai Daiya................................................................P2.03-046 Tanaka Fumihiro.............. P1.03-027, P1.07-030, SH 04.02
Swisher Stephen..................OA 07.02, OA 09.05, OA 13.05, Takai Yujiro................................................................P2.01-010 Tanaka Hiroki.............................................................P1.03-036
.............................................................P2.04-014, P2.07-061a Takakura Nobuyuki...................................................P3.16-050 Tanaka Hiroshi................. MA 19.01, P2.03-008, P2.03-015,
Swisher Stephen G..................................................P2.02-013 Takami Kouji................................................................MA 17.04 .............................................................. P2.07-007, P2.15-004
Syahruddin Elisna....... P1.03-024, P2.03-031, P2.03-049, Takamori Shinkichi............ OA 13.06, P1.07-002, P1.07-014, Tanaka Hiroto..............................................................P1.17-017
............................................P3.01-032, P3.01-053, P3.11-001 ........................................P2.09-005, P3.16-003, P3.16-033 Tanaka Hisashi........................................................P2.03-014
Symanowski James................................................ P2.09-001 Takamura Shiki.........................................................P2.07-021 Tanaka Kaoru........................................P1.07-010, P2.07-021
Syn Nicholas............................................................ P3.01-022 Takanaka Tsuyoshi....................................................MS 24.04 Tanaka Keiko.............................................................. ES 06.03
Syrigos Konstantinos...............................................P3.01-043 Takanashi Masakatsu.............................................P3.07-003 Tanaka Kentaro..................................OA 05.09, P3.04-004
Syrigos Konstantios............................................... P2.04-008 Takanashi Shingo..................................................... P2.03-014 Tanaka Natsumi................................... P1.01-064, P2.03-016
Syrigos Kostas.................................. P1.01-044, P2.01-039 Takano Angela.............................................................OA 09.07 Tanaka Ryota........................................................... P1.02-033
Szabo Aniko..............................................................P1.07-008 Takashi Kijima.......................................................... P3.09-009 Tanaka Tae.............................................. OA 12.03, P1.07-004
Szabo Eva.................................................................P2.03-052 Takata Minoru.............................................................. OA 12.03 Tanaka Takehiko........................................................P1.02-025
Szabłowska-Siwik Sylwia.......................................P3.13-032 Takata So................................................................. P1.03-047 Tanaka Tomohiro..................................................... P2.03-015
Szczepulska Ewa..................................P1.02-037, P3.02-051 Takaya Hisashi.........................................................P3.02-033 Tanaka Yoshihito...................................................... P2.03-014
Szczyrek Michał........................................................ OA 08.03 Takayama Kenji..........................................................MS 24.04 Tanatip Narumon.......................................................OA 04.08
Szczęsna Aleksandra.............................................P3.02-045 Takayama Koichi.................................P1.07-044, P3.03-002 Tandon Nidhi.............................................OA 10.03, OA 10.05
Szlosarek Peter........................................................ MA 19.05 Takayama Tomoyuki.................................................P3.01-035 Tane Kenta.......OA 16.07, P2.16-015, P3.02-074, P3.13-036
Szlubowski Artur....................................................P3.02-045 Takeda Atsuya............................................................MS 24.04 Tang Hong.....P1.01-017, P1.01-047, P1.15-006, P2.01-042
Sznol Mario..............................................................P2.07-062 Takeda Aya H........................................................... P2.16-004 Tang Hua R................................................................... MA 01.11
Szolkowska Malgorzata........................P1.02-037, P2.16-017 Takeda Ikuko....................P1.02-065, P2.02-012, P3.02-024 Tang Min...................................................................... MA 10.05
Szpechcinski Adam.............................P3.01-041, P3.02-049 Takeda Kenichi..................................... P1.01-064, P2.03-016 Tang Wenbo...............................................................P3.01-039
Sztejman Eric.............................................................MA 20.02 Takeda Koji.................................................................. OA 05.03 Tang Xiao Yang........................................................P2.02-057
Sáez Maria Isabel.....................................................P2.07-016 Takeda Masayuki.............P1.03-005, P1.07-010, P2.07-021 Tangsujaritvijit Viratch................................................OA 11.04
Sánchez Alfredo....................................................... P2.01-031 Takeda Yoshito.........................................................P2.07-009 Tanigawa Motoaki.................................................... P3.01-064
Sánchez Cabrero Darío............................................ MA 07.03 Takeda Yuichiro................ MA 19.01, P2.03-005, P2.03-033 Taniguchi Hirokazu........P1.03-015, P2.07-045, P3.03-002,
Sánchez Cousido Luis.............................................P1.01-060 Takeda Yuji................................................................. P2.03-011 ...................................................................................P3.15-001
Sánchez Cánovas Manuel........................................ MA 07.03 Takegahara Kyoshiro.......................... P1.02-053, P1.12-008 Taniguchi Hiroyuki................................ P2.01-037, P3.12-001
Sánchez Paya José...................................................PL 02.04 Takei Hidefumi..........................................................P1.02-033 Taniguchi Yohei.....................................MA 05.06, P2.16-005
Sánchez Rovira Pedro.............................................P1.07-036 Takemoto Toshiki.................................P3.02-059, P3.16-049 Taniguchi Yuji....................P1.02-060, P1.02-061, P1.13-008
Sánchez-Torres José Miguel...............MA 15.01, P1.01-057, Takenaka Hideaki..................................................... P2.01-065 Taniguchi Yuri..................................... P1.01-054, P2.03-017
..................... P2.02-027, P2.02-034, P3.01-073, PL 02.04 Takenaka Tomoyoshi................................................P3.16-003 Tanimoto Azusa.......................................................P3.03-002
Sørensen Boe S...........P3.02-005, P3.02-050, P3.02-052 Takenoyama Mitsuhiro.....MA 19.01, P1.08-006, P2.09-005 Tanimura Keiko....................................................... P1.07-044
Sørensen Jens Benn.......... MA 18.14, MA 19.03, P1.06-012, Takeo Sadanori.........................................................P3.16-003 Tanino Ryosuke....................................................... P1.02-069
................................................................................... P3.01-007 Takeshima Hideyuki................................................ P1.02-009 Tanio Yoshiro........................................................... P2.06-003
Sültmann Holger......................................................P3.02-032 Takeshima Yukio...........P1.02-002, P1.02-052, P2.09-008, Tanio Yoshirou..........................................................P1.02-032
..................................................................................... P2.15-011 Tanita Tatsuo........................................................... P2.06-009
Takeuchi Hideya...................................P2.05-017, P3.02-039 Tanizaki Junko.........................................................P1.07-010
Takeuchi Kengo..........................................................OA 05.08 Tanju Serhan.............................................................P3.13-024
T
Takeuchi Shinji.......................................................... P3.15-001 Tannir Nizar M.........................................................P2.07-062
Takeuchi Yukiyasu......................................................MA 17.04 Tano Zachary...................... MA 15.09, P1.13-003, P3.13-019
Tabares-Nañez Arianna......................................... P2.01-049
Takeyasu Yuki.............................................................MA 05.06 Tanooka Masao......................................................... P1.14-005
Tabata Kazuhiro..........................................................OA 18.06
Takigawa Nagio........................................................ P2.01-034 Tanrıkulu Eda............................................................P3.15-007
Tabeta Hiroshi......................................................... P2.03-005
Takiguchi Yuichi................................... P2.07-042, SH 01.03 Tantraworasin Apichat........................ MA 18.07, OA 04.08
Tachibana Keisei.......................................................P1.02-033
Takimoto Takayuki...................................................P2.07-009 Tanuwihardja Reza K..............................................P1.01-049
Tadigotla Vasisht........................................................P1.01-074
Takizawa Hiromitsu.............................P1.13-009, P3.13-007 Tanwani Poonam.....................................................P1.04-006
Tadokoro Hakaru..................................P1.11-001, P2.03-006
Takumi Yohei........................................P2.05-017, P3.02-039 Tao Hiroyuki...................P1.05-003, P3.09-005, P3.13-013
Tafreshi Ali....................................................................OA 17.06
Takuwa Teruhisa...............................P2.09-007, P3.09-009 Taremi Mojgan........................................................ P3.14-002
Tagawa Tetsuzo................. OA 13.06, P1.07-014, P2.05-017,
..............................................................P2.09-005, P3.16-033 Talbot Denis................................................................ MA 10.02 Tasaka Sadatomo.................................................... P2.03-014
Taghizadeh Niloofer.................................................. P2.13-011 Talreja Vikas.................P1.01-023, P1.03-021, P2.01-051, Tasaki Takuro............................................................ P2.05-011
.........................................P2.03-027, P3.01-076, P3.03-015 Taskén Kristin A.......................................................P2.02-053
Tagliaferri Mary A....................................................P2.07-062
Talwar Ambika........................................................P1.05-008 Tassinari Davide.................................... MA 10.06, P1.01-065
Tagliaferri Pierosandro...........................................P2.07-046
Tam John...................................................................P3.13-004 Tastekin Didem........................................................P3.10-006
Tagliamento Marco...................................................P1.07-023
Tam Kathleen........................................ P2.16-022, P3.13-028 Tateyama Hsashi.......................................................P1.17-004
Taguchi Manato.........................................................P3.16-039
Tam Wai-Leong...........................................................OA 09.07 Taube Christian.........................................................P3.13-033
Tai Yanhong........................................P2.02-004, P3.03-005
Tamaki Nobuyuki.................................................... P2.06-003 Taube Janis M..........................................................P2.02-044
Taima Kageaki.......................................................... P2.03-014
Tamamura Hiroyasu............................................... P2.05-005 Taus Luke..................................................................... MA 07.12
Taioli Emanuela...................MA 18.07, OA 04.08, P2.13-026,
............................................................... P2.16-022, P3.13-028 Tamblyn Laura.....................................P1.02-016, P3.03-008 Taus Álvaro.................................................................P1.15-001
Taira Tomoe..............................................................P3.02-042 Tambo Yuichi.............................................................. MA 16.04 Taveggia Paola A......................................................P3.13-006
Tajima Atsushi........................................................ P3.08-002 Tamiya Motohiro.................................. P1.03-047, P1.03-049 Taxter Timothy....................................P1.04-004, P1.04-005
Tajima Ken.......................P1.02-065, P2.02-012, P3.02-024 Tamiya Nobuyo.........................................................P1.07-044 Taylor Fiona..............................................................P2.07-034
Tajima Kouhei...........................................................P1.16-007 Tammemägi Martin................. MA 14.11, MA 14.14, MA 20.11, Taylor Joanne......................................P1.10-002, P3.10-005
........................... OA 15.01, P1.04-003, P2.13-011, P2.13-012 Taylor Leanne..............................................................OA 11.06
Tajima Manabu................P1.02-065, P2.02-012, P3.02-024
Tamura Hajime................P1.16-008, P2.07-008, P2.12-006 Taylor Marcus B.......................................................... MA 17.14
Tajiri Takuma..............................................................P1.02-017
Tamura Kazuo...........................................................P3.01-035 Taylor Paul................................................OA 02.01, OA 02.03
Takabatake Hiroyuki...........................P1.02-032, P2.06-003
Tamura Paula............................................................P3.03-019
Takada Kazuki...................OA 13.06, P1.07-002, P1.07-014, Taylor-Stokes Gavin.................................OA 11.01, P2.01-012
............................................................... P3.16-003, P3.16-033 Tamura Tomohide.................................. OA 05.08, P2.07-011 Teba Catalina.............................................................. MA 20.01
Takada Yu...................................................................MA 09.06 Tamura Tomohiro..................................................... P1.15-002 Techasurungkul Sarunporn...................................P3.03-020
Takagaki Tereza..................................P2.02-046, P3.01-066 Tamura Tomoki.........................................................P1.03-038 Tehfe Mustapha.......................................................... MA 10.01
Takagi Keigo............................................................... P1.03-031 Tan Aik-Choon............................................................OA 07.06 Tei Keikou...................................................................P2.16-003
Takagi Masayuki........................................................P3.15-002 Tan Ann..................................................................... P2.01-032 Teich Nelson............................................................. P1.06-024
Takagi Yui................................................................... P3.16-010 Tan Bien Soo...............................................................OA 09.07 Teixeira Ana Paula L.............................................P3.06-006
Takagi Yuzo........................P1.02-060, P1.02-061, P1.13-008 Tan Daniel S....................ISS 07.01, ISS 07.02, ISS 07.05, Teixeira Manuel R.....................................................P3.01-049
........................................... MTE 20.01, OA 09.07, P1.01-012,
Takahama Takayuki..................................................P2.07-021 Teixido Cristina.....................................P1.07-015, P3.01-045
.............................................P2.04-005, P3.01-017, YI 01.05
Takahashi Fumiyuki........P1.02-065, P2.02-012, P3.02-024 Teixidor Eduard........................................................P1.03-035
Tan Eng Huat........................................... OA 09.07, P3.01-017
Takahashi Hidenobu............................P1.02-025, P2.03-019 Teixidó Cristina................................... P1.01-075, P2.02-014
Tan Eng-Huat..................P3.01-026, P3.01-036, P3.01-039,
Takahashi Ikuya.........................................................P3.15-002 ....................................................................................P3.01-075 Tekin Salim Basol....................................................P2.03-042
Takahashi Katsuhito.................................................P2.16-026 Tan Fenlai........................ MA 07.02, P2.04-003, P2.04-012 Telli Tugba A.........................................P1.03-040, P3.15-007
Takahashi Kazuhisa.......P1.02-065, P1.03-006, P2.02-012, Tan Jinjing...............................................................P3.02-083 Tello Furtado Sofia....................................................P1.15-010
...................................................................................P3.02-024 Temel Jennifer............................................................OA 07.05
Tan Jiunn-Liang.........................................................P3.15-014
Takahashi Koichiro................................................... P2.03-011 Templo, Jr. Felipe S................................................. P2.01-062
Tan Kay See......MA 13.14, OA 03.03, P1.13-003, P2.05-021
Takahashi Koji..................................... P3.02-046, P3.02-071 Ten Haaf Kevin........................................................ P2.13-025
Teng Jiajun..................................................................MA 14.07 Tolwin Yaakov.............................................................MA 18.11 Tsuboi Masahiro...............OA 16.07, P2.04-006, P2.16-015,
Teng Rebecca S.Y.................................................... P3.01-022 Tomii Keisuke...................................... P1.07-004, P2.07-024 ...............................................................P3.02-074, P3.13-036
Teng Yu.....................................................................P3.02-083 Tomita Yusuke...........................................................P3.15-009 Tsuboi Mitsuhiro.......................................................P3.13-007
Teo Min Yuen............................................................P2.02-048 Tomizawa Kenji....................................P3.02-059, P3.16-049 Tsuchida Masanori........ OA 03.05, P1.16-025, P3.16-002,
Ter-Ovanesov Michail D...........................................P3.15-016 Tomizawa Yoshio.................................. P2.01-027, P2.15-016 .....................................................................................P3.16-051
Terada Yukinobu........................................................ P3.16-011 Tomoshige Koichi.....................................................P1.02-014 Tsuchihara Katsuya............................P3.02-035, P3.02-074
Terada Yuriko..................................... P3.16-027, P3.16-028 Tomoyasu Makoto................................................... P2.06-009 Tsuchiya Tomoshi................................. P1.02-014, P1.03-015
Terahara Atsuro.........................................................MA 09.06 Tong Betty C................................................................MA 19.09 Tsui Dana W.Y...........................................OA 10.05, OA 14.05
Teramoto Koji................P1.02-030, P1.03-037, P3.02-003, Tong Gangling........................................................... P1.01-037 Tsuji Ann.........................P2.02-052, P3.02-061, P3.02-062
....................................................................................P3.16-048 Tong Jing..................................................................P2.02-052 Tsuji Fumito........................ OA 05.01, P3.01-012, P3.01-072
Terauchi Kunihiko................................................... P2.16-007 Tong Lin......................................................................MA 20.13 Tsuji Takahiro.................P2.01-021, P2.03-055, P2.07-003,
Terayama Keisuke...................................................P2.07-004 Tong Macy............................................................... P2.05-008 ....................................................................................P2.07-017
Terce Gaelle.................................................................MA 03.10 Tong Pan..................................................OA 13.01, P3.03-027 Tsujimura Tohru.......... P2.09-006, P2.09-007, P3.09-009
Terra Ricardo M....................................P1.16-028, P2.13-022 Tong Yi-Zhen............................................................ P3.14-004 Tsujino Ichiro........................................ P2.02-057, P3.03-011
Terrasa Josefa..........................................................P2.07-041 Tonge Janet.................................................................OA 15.04 Tsujino Shuhei........................................................P2.07-045
Terrazzino Sandra.................................................... P1.03-014 Tonini Giuseppe..................................... MA 10.06, P1.01-053 Tsukada Hisashi.................................... MA 20.14, P1.12-004
Teruel Iris................................................................... P1.01-062 Too Chow Wei.............................................................OA 09.07 Tsukagoshi Yusuke............................... P2.01-027, P2.15-016
Terzi Alberto C.........................................................P1.08-005 Toquero Patricia.................................. P1.01-057, P2.02-027 Tsukioka Takuma.................................P2.16-003, P3.16-032
Tessari Anna.......................................................... P2.02-065 Torlakovic Emina......................................................P1.07-022 Tsumura Shinsuke................................................... P1.03-004
Tessonnier Laurent..................................MA 05.03, MA 10.11 Torous Vanda.............................................................MA 06.02 Tsunezuka Hiroaki................................P1.02-022, P1.17-009
Testori Alberto...........................................................P1.16-027 Torre Bouscoulet Luis...............................................MA 20.12 Tsunoda Akihito......................................................P2.02-072
Texier Matthieu............................................................ MA 10.11 Torrego Alfons................ P2.01-072, P2.05-007, P3.14-014 Tsurumi Kyouji.........................................................P2.07-004
Tey Jeremy.............................................P1.15-017, P2.14-002 Torrejon Benjamin.....................................................MA 20.06 Tsuta Koji.............................................. MA 05.06, P3.02-035
Tezel Çağatay S........................................................ P1.03-016 Torres Duran Maria................................................... P1.15-013 Tsutani Yasuhiro...................................P2.05-011, P2.15-011
Thakkinstian Ammarin............................................ P2.01-009 Torres Irene.............................................................. P3.01-065 Tsutsui Toshiharu......................................................MA 05.08
Tham Ivan W.....................P1.08-001, P1.15-017, P2.14-002, Torres-Diz Manuel..................................................P3.02-086 Tu Chih-Yen....................................... P1.03-053, P2.03-003
.................................................................................. P3.13-004 Torres-Mora Jorge.................................................... OA 03.06 Tu Dongsheng........................................ MA 10.01, P2.01-032
Thanh Tran D...........................................................P3.02-020 Torres-Roman Junior S......................................... P1.06-023 Tu Hai -Yan................................................................ P3.01-051
Thatcher Nick...................................... ISS 02.01, ISS 02.06 Torrezan Giovana T....................................................OA 07.08 Tu Hai-Yan...................... JCSE 01.26, P1.01-009, P1.01-010,
Thayu Meena........................................................... P3.04-008 Tortora Giampaolo.....................................MA 01.07, MA 10.11 ................................................................ P1.01-018, P3.01-063
Thein May.................................................................. P1.16-003 Tortora Marianna..................................... P1.17-014, P1.17-015 Tu Haiyan...................................................................P3.01-036
Theuer Charles.................................... P1.03-022, P1.04-012 Toschi Luca................................................................MA 02.05 Tu Xiaonian..................................................................MA 15.07
Thiberville Luc............................................................OA 03.01 Totoki Yusuke...........................................................P3.02-042 Tuch Brian B............................................................... OA 12.07
Thillays François........................................................OA 03.01 Toumbis Michalis......................................................P3.01-077 Tudor Roxana A............ P1.03-043, P1.06-006, P2.01-046,
Thiryayi Sakinah.......................................................P1.03-001 ...................................................................................P2.02-068
Tournoy Kurt...............................................................OA 16.06
Thng Choon Hua........................................................P3.01-017 Tufman Amanda........................................................P1.07-019
Tovanabutra Chokaew............................................ P2.01-002
Thomas Anish...........................................................P1.02-063 Tumin Dmitry.......................................................... P2.06-008
Towe Christopher W.............................MA 20.01, MA 20.03
Thomas Mathew..................................... MA 05.01, OA 06.07 Tuminello Stephanie.................................................P2.13-026
Townsend David.......................................................P3.13-004
Thomas Michael.............. P1.15-011, P2.04-005, P3.01-088 Turci Daniele...........................MA 02.05, MA 10.06, MA 11.11
Toyabe Shin-Ichi........................................................P3.16-051
Thomas Pascal.........................................OA 03.01, OA 16.06 Turcott Jenny....................................... MA 08.10, P2.01-070
Toyoda Takahide............... OA 04.05, P1.16-008, P2.12-006
Thomas Roshini.................................... P1.14-017, P2.14-001 Turgeon Guy-Anne.............. MA 17.12, P1.14-017, P2.14-001
Toyokawa Gouji.................. OA 13.06, P1.07-002, P1.07-014,
Thompson Elizabeth D...........................................P2.02-044 ........................................ P2.05-017, P2.09-005, P3.16-003, Turkes Fiona.............................................................P2.07-049
Thompson Jonathan R.......................................... P1.07-008 .................................................................................. P3.16-033 Turna Akif....................................................................OA 16.06
Thompson Luis A.....................................................P1.06-021 Toyooka Shinichi..................MA 07.11, MA 13.05, P2.16-026 Tutuka Dani...............................................................P2.02-039
Thongprasert Sumitra.............................................MS 07.06 Trachoo Objoon.......................................................P3.03-020 Twito Tal.................................................................... P3.01-060
Thorbinson Catherine................................................ MA 11.02 Trachu Narumol..................................................... P3.03-020 Twomey Sinead.......................................................P2.02-048
Threlfall Anthony........................................................OA 15.04 Tracy Philip................................................................. OA 09.02 Tykodi Scott S..........................................................P2.07-062
Thress Kenneth S...............OA 09.02, OA 10.01, P2.02-052, Tradonsky Alison........................................................ MA 11.06 Tyng Chiang J...........................................................P2.13-020
.............................................................. P3.01-074, P3.02-062 Trama Annalisa...................................................... P2.09-001a
Thummala Nithin.....................................................P2.07-040 Tran Hai T.................................................OA 07.02, OA 09.05
Thunnissen Erik.............MA 05.07, MA 06.06, MTE 02.01, Tran Nguyen Tuan Anh.............................................P3.01-017 U
................................................................................. P2.02-024 Tran Quan................................................................. P2.07-033
Thurer Richard J...................................................... P1.16-022 Tran Richard H......................................................... P1.03-044 Ubbels Fred..................................................................MA 17.10
Thurm Holger.............................................................OA 05.06 Travancinha Catarina.................................................P1.17-012 Uchida Junji........................................P1.02-032, P2.06-003
Tian Bo..................................................................... P3.16-030 Travis William D.....................ES 01.02, MA 15.09, MA 17.13, Uchida Osamu...........................................................P1.02-025
Tian Geng................................................................... MA 15.07 .............................................. OA 03.03, OA 18.06, P1.13-003, Uchida Yoshinori........................................................MA 05.08
Tian Hui..................................................................... P3.04-010 ................................................................P2.05-021, P3.13-019 Uchino Junji..............................................................P1.07-044
Tian Jing.................................................................. P1.01-078a Traynor Anne........................................MA 02.01, P3.04-009 Udagawa Hibiki.....................................P1.03-027, P3.14-001
Tian Panwen............................................................P1.01-034 Treister Victoria...........................................................MA 14.14 Ueda Hiroki............................................................... P2.07-035
Tian Yuan...................................................................P1.02-001 Tremblay Alain........................ MA 20.11, OA 15.01, P2.13-011 Ueda Keiko.................................................................P1.03-037
Tian Yuwang...................P1.02-044, P1.02-057, P3.02-026 Treskova Marina.....................................OA 15.02, P3.07-013 Ueda Masahide........................................................ P2.01-065
Tibdewal Anil........................................................... P2.14-005 Trevena Lyndal..........................................................P3.13-038 Ueda Ryuzo...............................................................P2.07-015
Tie Siew Teck........................................P2.12-001, P2.12-002 Trialists Mars2........................................................... OA 02.07 Ueda Sho...................................................................P2.17-004
Tiemann Markus.......................................................P3.01-038 Trigo Manuel........................MA 15.01, P1.01-040, P2.07-016 Ueda Yoshimichi......................................................P3.02-085
Tienchainaanda Piyawan.......................................P3.03-020 Triozzi Pierre............................................................. P1.01-059 Ueda Yutaka................................................................ OA 12.03
Tijerina Jolene M.......................................................P2.15-013 Triphuridet Natthaya.............................................P2.06-006 Ueki Nami................................................................ P2.05-002
Tikoo Nalin...................................................................OA 10.06 Truesdell John...............P2.02-052, P3.02-061, P3.02-062 Uekusa Toshimasa.................................................. P1.03-006
Tillyashaykhov Mirzagolib N..................................P2.02-049 Truini Anna..............................................OA 12.01, P3.01-046 Ueland Thor.............................................................P2.02-053
Timlin Thomas.............................................................OA 11.06 Trujillo Alba Blanca............................. P1.06-013, P2.07-039 Uemura Takehiro..................................................... P2.07-028
Timmerman Robert D................................................MA 13.08 Trujillo Joan Carles..................................................P2.01-072 Uenami Takeshi....................................P1.03-047, P2.07-009
Timmons Brenda.........................................................MA 15.13 Trujillo Juan Carlos...........OA 16.06, P2.05-007, P3.14-014 Ueno Kiyonobu....................................P1.02-032, P2.06-003
Tinawi Georges.................................... P2.16-028, P3.16-036 Truman Matt............................................................. P3.01-044 Ueno Naomi.............................................................. P1.03-008
Tindle Hilary................................................................MA 14.08 Trunova Nataliya.......................................................P1.03-026 Ueno Tsuyoshi........................................................ P2.05-009
Tingen Martha..............................................................OA 11.03 Truscott Rebecca....................................................... MA 18.01 Ugalde Figueroa Paula A..................P2.05-019, P3.01-080,
Tini Paolo..................................................................P2.07-046 Trybalski Łukasz.........................................................OA 04.01 .................................................................................... P3.01-081
Tipton Christopher..................................................... OA 13.05 Trédaniel Jean............................................................ OA 16.03 Ugurluer Gamze...................................................... P3.08-001
Tiseo Marcello.....................MA 10.06, OA 05.05, P1.01-001, Tsai Chun-Ming..................OA 05.03, OA 09.03, P3.02-044 Ujhazy Peter.............................................................. ES 09.06
................................................................P1.01-015, P3.01-005 Tsai Chung-Ming..........................................................OA 10.01 Ujiie Hideki................................................................. P1.12-002
Tison Alice................................................................ P2.07-023 Tsai Scott..................................................... MA 14.11, OA 15.01 Ukena Dieter..............................................................P3.01-038
Tissing-Tan Caroline...................................................MA 17.10 Tsai Tzu-Hsiu............................................................P3.01-074 Ulaner Gary.................................................................OA 14.05
Tjulandin Sergei.......................................................P3.02-058 Tsai Ying-Huang...................................................... P2.07-027 Ulivi Paola.............................................P1.01-053, P3.02-007
Toba Hiroaki............................................................ P3.13-007 Tsakonas Georgios................................................ P2.02-070 Ullrich Stephen............................................................OA 13.01
Tochigi Naobumi............... MS 07.04, P2.01-010, P3.16-004 Tsao Anne............................MA 01.08, OA 12.01, P1.09-011 Ulrich Bryan................................................................MA 20.14
Tod Angela M.........................................MA 08.03, MS 10.02 Tsao Chao-Jung...................................................... P2.07-027 Ulz Peter......................................................................OA 10.05
Toda Michihito......................................P2.16-003, P3.16-032 Tsao Ming S............ MA 13.02, MA 14.11, MA 20.11, OA 15.01, Umehara Tadashi.................................................... P2.16-004
Togo Shinsaku.......................................................... P1.03-006 ....................P1.02-016, P1.07-022, P3.01-019, P3.01-062, Umekita Yoshihisa................................P1.02-060, P1.02-061
Toh Chee Keong...................................... OA 09.07, P3.01-017 ...............................................................P3.03-008, PL 03.03
Umemura Shigeki..................................................... P3.14-001
Toi Yukihiro............................................................. P2.07-004 Tsao Shih-Ming........................................................ P2.07-027
Underwood Malcolm J.............................................P3.16-015
Toker Alper............................................P2.14-016, P3.16-046 Tsao Thomas Chang-Yao....................................... P2.07-027
Ung Jane.................................................................... MA 07.09
Tokudome Nahomi.................................................. P2.07-035 Tsay Jun-Chieh J....................................................... MA 10.10
Ungewiss Christin.......................................................OA 13.01
Tokumaru Sunao.................................................... P2.05-005 Tseng Yau-Lin.............................................................MA 16.02
Unni Arun....................................................................MA 05.12
Tokunaga Shoji......................................................... P1.03-004 Tseng Yen-Chiang....................................................P1.01-066
Uno Makiko...............................................................P3.02-042
Tokunaga Takuya....................................................P2.16-004 Tseng Yen-Han........................................................P1.01-066
Uno Takashi................................................................MS 24.04
Tokunaga Toshiteru................................................. P2.05-010 Tsimafeyeu Ilya........................................................P3.02-058
Urakami Kenichi................................. P2.15-008, P3.05-006
Tokunaga Yoshimasa..............................................P2.01-018 Tsou Florencia.......................................................... P1.01-058
Uramoto Hidetaka....................................................P3.02-085
Tokushige Kota......................................................... P1.03-005 Tsubata Yukari..........................................................P1.02-069
Urano Yasuteru.........................................................P3.13-009
Urata Yasuo.............................................................. P1.03-006 Verghese Eldo............................................................P1.03-011 Walder David.............................................................P1.03-029

Urban Patrick.............................................................P1.01-012 Vergilio Jo-Anne.......................................................P2.02-016 Walder David P.................................. P2.07-049, P3.12-003
Urbanic James.....................................MA 13.08, P3.04-003 Vergnenegre Alain....................................................P3.01-073 Walia Guneet..............................................................MS 22.02
Urbanska Edyta M..................................................P3.01-007 Verheij Marcel...........................................................P2.14-020 Walker Jill................................................................. P2.01-043
Urbanski Stefan...........................................................OA 15.01 Verma Sunil............................................................... P1.15-007 Walkiewicz Marzena...............................................P2.02-039
Uruga Hironori.................................. P3.02-033, P3.02-048 Veronesi Giulia..................ES 05.04, P1.07-032, P1.16-027, Wallace Andrew........................................................P1.03-001
Usari Tiziana...............................................................OA 12.06 ......................................... WS 02.01, WS 02.02, WS 02.04 Wallberg Martin......................................................... P1.15-007
Usher Joshua........................................................... P2.01-056 Verusio Claudio......................................................... P1.01-065 Waller Cornelius...................................................... P3.01-088
Ushijima Shinichiro................................................. P1.03-004 Verza Martina...........................................................P3.02-006 Waller David............................................................. MS 06.04
Ushijima Toshikazu.................................................. P1.02-009 Vethencourt Casado Andrea C...............................P1.07-028 Waloszczyk Piotr........................................................ MA 14.01
Ushijima Yo.................................................................MA 09.06 Viale Agnes..................................................................OA 10.05 Walraven Iris...................................... P2.14-020, P3.14-005
Ushiku Aya.................................................................P3.16-028 Viana Geisa G.......................................P2.10-006, P3.10-001 Walter Annette........................................OA 02.01, P1.04-013
Uskent Necdet I.H................................................... P1.07-003 Vicent Silvestre........................................................ P3.07-007 Walter Joan E....................OA 15.06, OA 15.07, P2.13-007
Usuda Jitsuo................... MA 20.10, P1.02-053, P1.12-008 Vicente Baz David......... P1.03-054, P2.03-051, P3.02-047 Wan Kippo..................................................................P3.01-001
Usuda Katsuo...........................................................P3.02-085 Vicente David........................................................... P3.01-005 Wan Yung-Liang....................................................... P3.13-001
Usui Kazuhiro........................................P1.01-054, P2.03-017 Vicente Pérez Francisca.........................................P1.07-036 Wanders Rinus........................................................ P2.08-007
Utomo Ahmad R.H..............................P3.01-053, P3.01-054 Vichapat Voralak.....................................................P2.01-009 Wang Anna Y......................................P2.02-040, P3.02-055
Uwatsu Kotaro........................................................ P2.05-009 Victoria Ivan............................................................. P3.01-045 Wang Aodi........................................... P2.02-018, P3.07-009
Vidal Alcorisa Silvia..................................................P1.07-028 Wang Bin..............................P1.14-010, P1.14-011, P2.14-004
Vidal Oscar J............................................MA 03.01, MA 10.02 Wang Bin-Chao...................................JCSE 01.26, P1.01-010
Videtic Gregory M.M......MA 09.04, MA 13.08, P1.14-003 Wang Bing.................................................................P3.07-009
V
Vidhyarkorn Sirachat............................................. P2.06-006 Wang Buhai........................................JCSE 01.10, P2.03-047
Vieira Arthur.................. P2.05-019, P3.01-080, P3.01-081 Wang Changli....................OA 16.04, P1.02-004, P1.04-010,
Vagenas Dimitrios................................................... P2.07-032
Vietz Christine................P2.02-052, P3.02-061, P3.02-062 .................................................................................. P2.03-040
Vaghani Viralkumar B............................................. P2.04-014
Vigliotti Michele....................................P3.04-012, P3.04-013 Wang Cheng...............................................................P1.14-001
Vaghjiani Raj.................................................................MA 13.14
Vignali Marissa............................................................ OA 13.05 Wang Chin-Chou.......................................................P1.03-023
Valdez-Rojas Leonora............................................. P2.01-049
Vigo Alvaro........................................... P1.06-020, P1.16-028 Wang Chun............................................................... P2.01-066
Valdivia García Francisco J.....................................P2.03-051
Viktorsson Kristina....................................................P1.01-074 Wang Donglin............................................................P3.01-087
Valdivia Javier............................................................ MA 07.03
Vila Laia..................................................P1.01-062, P2.07-041 Wang Fang................................................................ P3.02-001
Valentine Ronan................................ P3.04-006, P3.09-002
Vilariño Noelia..................P1.01-075, P2.02-014, P3.01-045 Wang Fangqing..........................................................P2.01-011
Vallejo Benítez Ana María......................................P3.02-047
Vile Douglas.................................................................MA 13.06 Wang Fengnan..........................................................P3.01-011
Vallejos Carlos.................P1.06-022, P1.06-023, P2.01-053
Villaflor Victoria...............OA 07.03, P1.04-004, P1.04-005, Wang Genhe..............................................................P3.01-037
Vallieres Eric...................MTE 16.01, P1.05-012, P1.10-008, ............................................................... P1.07-034, P3.02-013 Wang Haiyang................JCSE 01.18, P2.03-013, P3.01-069
.......................P2.04-004, P2.13-019, P2.13-021, P3.13-029
Villalobos Pamela.................................... MA 05.02, OA 13.01 Wang Haiyue.............................................................P1.07-011
Vallone Stefania.........................................................MS 19.05
Villamizar Nestor R.................................................. P1.16-022 Wang Haiyun............................................................P3.02-066
Van Baardwijk Angela............................................ P2.08-007
Villaruz Liza..............................................................P2.02-047 Wang Hangjun..................................P2.02-040, P3.02-055
Van Den Broek Daan............................................... P1.09-008
Villaruz Liza C..................OA 12.06, P3.03-007, P3.08-004 Wang Hanping..................................P2.03-041, P2.03-050
Van Der Noort Vincent...............................................MA 17.10
Villeneuve Patrick J..............................OA 11.06, P3.16-007 Wang Hao....................................................................MA 16.06
Van Der Schee Marc P....................... P3.05-001, WS 01.18
Vines Douglass.......................................................... P1.14-016 Wang Hongbing.........................................................P3.01-087
Van Der Veen Sonja................................................ P2.14-006
Vinod Shalini K.................MA 13.07, P2.05-004, P3.13-038, Wang Hongyu.......................................P2.01-029, P2.01-030
Van Der Wekken Anthonie......................................OA 06.04 ....................................................................................P3.14-003 Wang Hsiang-Tsui..................................................... P1.01-077
Van Dongen Guus A..................................................MA 05.07 Virally Jérôme............................................................. OA 16.03 Wang Hui Ping.......................................................... P2.10-002
Van Eeden Ronwyn...................................................P3.13-021 Virgili Manrique Anna C...........................................P1.07-028 Wang Huijuan......................................P3.01-018, P3.01-061
Van Elmpt Wouter.................................P2.08-007, P3.14-011 Vitali Milena............................................................ P2.09-001a Wang Huimin...............................................................MA 14.07
Van Ginneken Bram.................................................... MA 14.11 Vitek Olga...................................................................P1.09-001 Wang Jia......................................................................OA 16.08
Van Herk Marcel....................................................... P3.14-010 Viteri Santiago.....................MA 12.02, P1.07-015, P3.01-073 Wang Jialei................................................................P3.01-036
Van Houtte Paul.........................................................MS 13.02 Viti Andrea................................................................P1.08-005 Wang Jiao..................................................................P1.05-001
Van Kempen Leon C................................................P3.02-055 Vitorino Rita............................................................... P1.17-012 Wang Jie...................... JCSE 01.24, JCSE 01.25, MA 06.09,
Van Loon Judith...................................................... P2.08-007 Viviers Louis................................................................PL 02.02 .............................................MA 11.03, P1.01-032, P1.04-010
Van Meerbeeck Jan P.......................... P1.09-011, P3.13-008 Viñaras Ana.............................................................. P3.01-065 Wang Jin....................................................................... MA 01.11
Van Raemdonck Dirk................................................P1.13-007 Viñolas Nuria.......................MA 15.01, P1.01-075, P3.01-045 Wang Jing..........OA 07.02, OA 13.01, P2.01-011, P3.01-084,
Van Schil Paul E................MS 03.03, P3.13-008, PL 02.06 Vliegenthart Rozemarijn......OA 15.06, OA 15.07, P2.13-007 ...........................................P3.01-087, P3.03-017, P3.03-027
Van Tinteren Harm...................................MA 17.10, OA 02.02 Vogel-Claussen Jens................................................. OA 15.02 Wang Jinghui........................................MA 01.03, P2.02-033
Van Zandwijk Nico...........MA 19.06, P1.09-004, P1.09-005, Vogelzang Nicholas..............................P1.09-011, P2.09-001 Wang Jun......JCSE 01.10, OA 07.01, P2.03-047, P3.16-025
........................................ P1.09-008, P1.09-009, P3.02-078,
Voigt Soraya L.............................................................MA 19.09 Wang Jung-Der........................................................P2.10-001
................................................................P3.02-079, SH 03.01
Vokes Everett E.....................MA 03.09, MA 17.07, MA 18.06, Wang Kai........MA 11.03, P1.07-038, P2.02-018, P3.07-009
Vanderlaan Paul A.............................MA 06.02, P3.03-025
............................................................... MS 11.05, P3.04-003 Wang Kyrie................................................................P3.02-055
Vanevski Marijana.......................................................MA 13.07
Volante Marco..........................................................P2.02-054 Wang Lei....................................................................P1.07-038
Vangu Mboyo D.T.................................P3.13-005, P3.13-021
Von Der Thüsen Jan H.......................................... P1.02-038 Wang Liang...............................................................P1.14-004
Vanness Katelynd.......................................................OA 10.05
Von Pawel Joachim...........OA 17.07, P1.01-052, P2.04-001 Wang Lien Tu.....................JCSE 01.24, OA 07.01, P1.01-032
Vanni Elena.................................................................P1.16-027
Voon Pei Jye............................................................ P1.05-007 Wang Lin............................................ P3.02-014a, P3.02-026
Vanni Irene................................................................P1.07-023
Voong Khin Ranh.......................................................MA 09.08 Wang Lisa................................................................. P1.01-031
Vannucci Jacopo........................................................OA 16.02
Vora Amish................................................................P2.01-023 Wang Liuchun.......................................................... P3.01-084
Vansteenkiste Johan F....... MA 10.03, MS 17.02, OA 05.02,
Vora Chakor............................................................... P2.01-051 Wang Lu...............................................P1.04-008, P3.02-022
..........................................P1.13-007, P2.04-005, P2.04-013
Votruba Jiri............................................................... MA 20.04 Wang Luo...................................................................... MA 11.10
Vančurová Irena.......................................................P3.07-008
Voulaz Emanuele.......................................................P1.16-027 Wang Mengzhao............ P1.04-010, P2.03-041, P2.03-050
Varea Rocio.............................................................. P1.03-050
Vreugdenhil Margriet........P2.14-012, P2.14-014, P2.14-015 Wang Ming.................................................................P1.07-038
Varela Mirta............................................................... P1.01-058
Vrugt Bart................................................................. P1.09-009 Wang Minghui.......................................................... P2.02-018
Varella-Garcia Marileila..........................................P3.02-057
Vu Nguyen N....................................... P3.02-020, P3.02-021 Wang Ningfang.....................................P3.04-001, P3.13-037
Vargas Carlos.P1.01-019, P1.01-022, P1.09-013, P3.02-063
Vucic Emily A............................................................P3.02-091 Wang Ping................................................................. P1.02-040
Vargas Fernando..................................................... P2.07-037
Vugts Danielle J.........................................................MA 05.07 Wang Qi............................................. P1.01-078a, P1.03-051
Vasile Enrico.................................................................. MA 11.11
Vursol Dmitry..............................................................P1.16-011 Wang Qiming..................P1.01-017, P1.01-047, P1.15-006,
Vasovcak Peter........................................................P2.03-056
Vynnychenko Ihor...................................................P2.04-001 ..........................................P3.01-087, P3.03-006, P3.03-017
Vazakidou Maria Eleni.............................................P2.02-054
Wang Qiongyao.............. P2.15-003, P2.15-009, P2.15-010
Vazquez Sergio........................................................ P1.03-054
Wang Qun.....JCSE 01.10, OA 16.04, P2.03-047, P3.16-025
Vedhara Kavita.................. MA 18.04, OA 06.08, P3.06-009
Wang Shaojing.........................................................P3.03-009
Veiga Catarina........................................................... MA 09.10 W
Wang Shengye.....................................P1.02-049, P2.02-021
Veiga Isabel................................................................P3.01-049
Wang Sherry C...........................................................OA 12.06
Veillon Remi.................................................................. MA 10.11 Wachuła Ewa............................................................P3.13-032
Wang Shidan.............................................................P1.02-039
Velarde Jose María.................................................. P1.01-062 Wada Chisa...............................................................P3.02-042
Wang Shuyu............................................................. P2.15-009
Velastegui Karen........................................................ MA 02.01 Wada Hironobu................ P1.02-034, P1.12-002, P1.12-003,
.........................................P1.16-008, P2.07-008, P2.12-006 Wang Tao............................ OA 05.01, P3.01-012, P3.01-072
Velcheti Vamsidhar.............. MA 13.03, MA 15.06, MA 17.11,
............................................ OA 12.07, OA 13.02, P1.02-001 Wada Hisashi.............................................................P2.07-015 Wang Tianyang.....................................JCSE 01.24, OA 07.01
Vellayappan Balamurugan...................P1.15-017, P2.14-002 Wada Hitoshi........................................................... P2.05-005 Wang Tianyang,......................................................... P1.01-032
Vence Luis................................................................... OA 13.05 Waddell Thomas K.................................................... P1.13-004 Wang Tina...................................................................MA 02.07
Venious George...................................................... P2.06-008 Wade James................................................................ OA 14.07 Wang Wei..................................................................P3.02-008
Ventura Luigi..........................................OA 16.02, P2.16-018 Wade Stephen......................................................... P3.06-008 Wang Wei Ming......................................................... P2.10-002
Venturi Gabriela...................................................... P2.09-002 Wainsztein Vanina............................... P2.01-007, P2.02-071 Wang Weifeng...........................................................P1.07-038
Venugopalan Abhilash.............................................P1.02-063 Wakahara Makoto.............P1.02-060, P1.02-061, P1.13-008 Wang Weili...................................................................MA 13.06
Vera Aguilera Jesus...................................................MA 18.09 Wakeland Ward..........................................................P1.07-031 Wang Wenxian................. JCSE 01.28, MA 07.13, P1.01-002,
.....................P1.01-003, P1.02-043, P1.02-044, P1.02-045,
Vera Beatriz.......................................... P1.01-057, P2.02-027 Wakelee Heather A......... ISS 10.04, ISS 10.07, MA 07.02,
.....................P1.02-046, P1.02-047, P1.02-048, P1.02-049,
Vera Karina................................................................ P1.01-058 .........................MA 13.01, MA 16.01, P2.03-043, P2.03-058,
..................... P1.02-056, P1.02-057, P1.02-058, P1.02-059,
Vera Luis................................................................... P1.05-022 ........................ P2.04-004, P2.04-012, PC 03.03, YI 01.10
...................P2.01-017, P2.02-004, P2.02-005, P2.02-006,
Verastegui Emma...................................................... MA 08.10 Wakelin Sandra.......................................................... MA 08.01 ...................P2.02-007, P2.02-020, P2.02-021, P2.03-057,
Verdu Ana................................................................. P1.03-054 Wakimoto Joeji........................................................... P1.15-014 ....................P3.01-008, P3.01-009, P3.02-018, P3.02-025,
Verdura Sara.............................................................P1.03-035 Wakita Daiko.............................................................P2.07-006 ...................P3.02-026, P3.02-027, P3.02-028, P3.02-029,
Vergara Edgar.............................................................MA 20.12 Wald Ori....................................................................P3.02-082 ...................P3.02-065, P3.02-067, P3.02-068, P3.02-069,
.............................................................P3.02-080, P3.03-005 Weiss Geoffrey............................................................ MA 08.11 Wolfe Rory........................... MA 18.12, P1.01-033, P3.13-003
Wang Wenxiang.......................................................P3.07-009 Weiss Jared......................... MA 17.07, OA 12.06, P2.01-004, Wolff Katharina..........................................................P1.04-001
Wang Xi-Yong.......................................................... P3.05-009 ............................................................... P2.01-013, P2.07-036 Wolfram Jochum.....................................................P3.02-053
Wang Xiang................................................................P3.16-009 Welborn Jeanna..........................................................MA 15.08 Wolfsteiner Marianne..............................MA 03.01, MA 10.02
Wang Xiaodan.............................................................MA 20.13 Weldon Christine..................................................... P3.10-002 Wollner Mira...............................................................MA 02.06
Wang Xiaofei..........................................MA 18.06, P3.04-003 Weljie Aalim.............................................................. P2.01-055 Won Helen H...............................................................OA 14.05
Wang Xiaohui........................................................... P2.01-020 Wells Paula................................................................ P1.14-009 Wong Ashley C.Y.......................................................P3.02-031
Wang Xiaopu.............................................................. P1.01-071 Welsh James W....................................... MA 01.10, OA 08.05 Wong Carlos K.H......................................................P1.01-050
Wang Xiaoxia............................................................. P1.01-073 Welte Tobias............................................OA 15.02, P3.07-013 Wong Chee-Kuan.......................................................P3.15-014
Wang Xiaoying..........................................................P3.12-004 Welter Stefan.............................................................P3.13-033 Wong David T.W.......................................................P2.03-052
Wang Xin..................................................................... OA 03.07 Wen Fugang.......................................... JCSE 01.11, P3.01-021 Wong Kwan Hung.....................................................P3.02-031
Wang Xin S..............................................OA 01.07, P2.01-036 Wen Shuai..................................................................P1.07-005 Wong Kwok-Kin.....................MA 05.02, MA 07.12, MA 10.10,
Wang Xing.........................OA 16.08, P3.02-022, P3.16-023 Wen Yi...................................................P2.01-029, P2.01-030 .............................................. MS 26.03, OA 12.01, P1.07-007
Wang Xingxing......................................................... P3.01-004 Wen-Tsung Huang...........P1.01-078, P1.10-006, P2.03-001 Wong Linda............................................................... P3.01-062
Wang Xinyue............................................................ P3.01-084 Weng Yi Ming........................................P3.01-083, P3.15-013 Wong Michael K.K....................................................P2.07-062
Wang Xiuwen..................P3.01-087, P3.03-006, P3.03-017 Wennstedt Sigrid.....................................................P1.09-006 Wong Shekman...................................P1.04-006, P1.04-007
Wang Xu...............................................JCSE 01.16, P1.07-006 Werneck Isabela D.C...............................................P3.02-060 Wong Stephen......................................................... P2.03-044
Wang Yalei.......................................... P2.01-029, P2.01-030 Werner-Wasik Maria..................................................MA 13.09 Wong Wenchang.................................P2.05-004, P2.15-007
Wang Yan........................JCSE 01.11, JCSE 01.11, P2.01-029, Werutsky Gustavo............P1.01-043, P1.01-063, P3.16-034 Wong William.................... P1.01-007, P1.01-008, P3.01-086
....................P2.01-030, P2.07-047, P3.01-002, P3.01-021, Wesseler Claas.........................................................P3.01-038 Wood Robert.............................................OA 11.01, P2.01-012
...............................................................P3.01-021, P3.04-007 West Doug.................................................................P1.05-010 Woodhouse Samuel.................................................P3.02-014
Wang Yang....................................................................P1.17-011 West Howard L..................OA 05.05, OA 09.08, P1.01-001, Woody Neil..............................................MA 09.04, P1.14-003
Wang Yanrong.......................................................... P2.01-045 ....................................................................................P1.01-004 Woolley Sharon...........................................................MA 10.07
Wang Yaqi................................................OA 16.08, P3.16-023 West Robert B............................................................. MA 13.01 Wormanns Dag...........................................................MA 14.02
Wang Ye..................................................................... P1.01-034 Westeel Virginie.....................MA 10.11, MA 20.15, OA 03.01, Wright Gavin..........................................P1.02-012, P3.16-045
Wang Yin..............................................JCSE 01.24, P1.01-032 .....................................................................................OA 16.03 Wright Mark..............................................................P3.02-053
Wang Yina................................................................... MA 14.04 Westerman David..................................................... P1.01-033 Wrona Anna..............................................................MS 08.02
Wang Yinpeng............................................................ MA 18.06 Westover Kenneth D.........................P3.02-066, P3.08-004 Wu Abraham J....................................... MA 17.13, P3.15-011
Wang Yiwei...............................................................P3.02-079 Westphal Glenn.................................... P2.06-011, P3.10-003 Wu Biao............................ P1.01-002, P1.02-045, P3.01-008
Wang Yongsheng....................................................P3.02-087 Weyant Michael........................................................P3.07-005 Wu Bin....................................................................... P3.14-008
Wang Yongyong.......................................................P3.07-009 Whang-Peng Jacqueline.................... P3.02-070, P3.07-011 Wu Bor-Wen................................................................MA 19.05
Wang Yu.....................................................................P3.01-036 Wheatley-Price Paul............MA 10.01, OA 11.06, P2.01-032 Wu Chang-Jiun.......................................OA 13.05, P2.02-013
Wang Yuyan...............................................................P3.01-036 Wheeler Greg..............................................................MA 13.07 Wu Charlie......................P2.02-052, P3.02-061, P3.02-062
Wang Yuzhao...............................................................OA 16.08 White Jane Liang...................................................... P3.01-012 Wu Chengguang....................................................... P1.09-007
Wang Zhehai.................P2.04-003, P3.01-087, P3.03-006, White Jared..............................................................P2.02-052 Wu Ching Feng..........................................................P1.16-017
....................................................................................P3.03-017 White Kahren............................................................. ES 03.03 Wu Ching-Feng......................................................... P3.13-001
Wang Zhen.......................JCSE 01.26, P1.01-010, P1.01-018 Whitten Jeffrey.......................................................... MA 07.09 Wu Ching-Yang...................................... P1.16-017, P3.13-001
Wang Zheng........................................ P2.05-018, P3.04-010 Widau Ryan C............................................................ P3.01-071 Wu Chunyan...............................................................P3.15-015
Wang Zhexin.............................................................. P2.16-018 Widjajahakim Grace..................................................P3.01-053 Wu Dafei..................................................................... P1.02-051
Wang Zian...................................................................P2.01-011 Wieczorek Maciej......................................................P3.02-051 Wu Di........................................................................ P2.09-006
Wanglikitkoon Sirentra............................................ P2.01-002 Wiesner Georgia L.....................................................OA 06.02 Wu Fengying.................. P1.03-052, P1.15-009, P3.01-085
Wannasopha Yutthaphan.........................................OA 04.08 Wiest Gunther...........................................................P3.01-038 Wu Gang................................................MA 06.09, P2.04-003
Waqar Saiama N.................MA 07.02, OA 14.07, P3.03-007 Wiggins H L............................................. OA 15.08, P2.16-019 Wu He............................................................................MA 16.13
Ward Kenneth D......................................................... MA 04.01 Wiggins Lianne.........................................................P2.07-036 Wu Hong-Gyun.......................................................... MA 13.10
Ward Kevin...............................................OA 01.06, P3.13-027 Wight Andrew........................................ P3.05-001, WS 01.18 Wu Hongnian............................................................P1.07-001
Wargo Jennifer........................................................... OA 13.05 Wilbur David........................................P3.03-016, P3.05-002 Wu Jianyu................................................................. P2.01-045
Waris Maryam..........................................................P2.03-052 Wild Peter................................................................. P1.09-009 Wu Jonn................................................MA 04.02, P2.05-003
Warmus Janusz..................................... OA 04.01, P2.16-027 Wilks Sharon..............................................................P1.01-051 Wu Licun.....................................................................OA 02.06
Warner Andrew....................................................... P2.14-009 Willaime Julien.........................................................P1.05-008 Wu Lin..............................JCSE 01.10, P1.15-016, P2.03-047
Warsch Jessica...............P1.07-024, P1.07-025, P2.07-037 Willemin Marie Capucine...........................................MA 03.10 Wu Meijuan.............................................................. P2.02-004
Warsch Sean............................................................ P2.07-037 Williams Crystal....................................JCSE 01.27, MA 07.01 Wu Ming-Fang.......................................P2.07-027, P3.01-016
Warth Arne........................ MA 06.06, P1.15-011, P3.02-032, Williams Janet...........................................................P2.15-007 Wu Nan..................................................................... P3.16-023
.............................................................P3.05-007, P3.05-008 Williams Loretta A............MA 18.08, P1.10-005, P2.01-036, Wu Ning..............................P1.01-007, P1.01-008, WS 01.09
Waseda Ryuichi...................................................... P3.16-044 ................................................................................... P2.04-014 Wu Qingchen............................................................ P3.04-010
Washimi Kota........................................................... P2.09-006 Williams Lovoria B......................................................OA 11.03 Wu Qiong...................................................................P1.04-010
Wasielewski Eric...................................MA 03.10, P3.02-002 Williams Marissa....................................................... MA 19.06 Wu Shafei..........................MA 12.09, P2.02-033, P3.03-004
Watanabe Hideo.......................................................P3.02-084 Williams Terence.................................................... P3.04-003 Wu Sheng-Cheng.................................................... P2.07-027
Watanabe Junko...................................................... P1.03-006 Williamson Christina.................................................P2.13-018 Wu Sipei.....................................................................P1.07-042
Watanabe Kageaki....................................................P2.07-031 Willis-Owen Saffron................................................ P1.02-054 Wu Xi..........................................................................P2.01-033
Watanabe Katsuya.................................................. P2.03-008 Wills Beatriz.............................................................. P1.09-013 Wu Xiang.................................................................... P1.03-017
Watanabe Kousuke................................................ P2.03-046 Wilner Keith.............................................................. P1.03-003 Wu Xiaojun....... JCSE 01.15, MA 16.11, OA 08.01, P3.02-001
Watanabe Masahiro................................................. P2.01-005 Wilner Keith D.............................................................OA 12.06 Wu Xiaoling.................................................................MA 02.02
Watanabe Mototsugu.......................... P1.16-023, P1.16-024 Wilshire Candice L.......... P1.05-012, P1.10-008, P1.12-007, Wu Xifeng..................................................................... OA 13.05
Watanabe Naohiro................................................... P2.07-028 ..........................................P2.13-019, P2.13-021, P3.13-029 Wu Xu........................................................................P3.07-009
Watanabe Satoshi..........P2.03-010, P2.03-015, P2.03-021, Wilson Alexandra..................................................... P3.02-073 Wu Yi-Cheng............................................................. P3.13-001
..................................................................................P2.07-007 Wilson Brian C.......................................................... P1.12-002 Wu Yi-Lin......................P1.01-048, P2.10-001, P2.10-002,
Watanabe Sho.................................. P2.03-033, P3.02-041 Wilson Don............................................................... P1.03-020 .................................................................................. P3.05-004
Watanabe Shun-Ichi..........................P1.05-002, P2.02-035, Wilson Elena...............................................................OA 01.05 Wu Yi-Long..................JCSE 01.10, JCSE 01.19, JCSE 01.21,
................................................................P3.02-035, PL 01.04 Wilson Linda M...........................................................MA 05.07 ...................................JCSE 01.24, JCSE 01.25, JCSE 01.26,
Watanabe Takuya................. MA 16.10, P1.17-005, P2.17-001 Wilson Samuel.......................................................... P1.16-003 ...........................MA 06.09, MA 11.03, MS 12.03, OA 05.01,
Watanabe Yui............................................................ P2.16-004 Windhorst A.D............................................................MA 05.07 ...........................OA 09.06, OA 10.02, P1.01-009, P1.01-010,
Watase Nodoka........................................................ P2.15-005 Winfree Katherine B.............................MA 03.06, P1.03-050 ........................ P1.01-018, P1.01-027, P1.01-032, P1.04-010,
Waterhouse David............ P1.01-051, P1.03-026, P3.07-012 Wingate Emma...........................................................P2.14-013 ....................P1.07-042, P1.13-001, P2.03-047, P2.03-054,
Watkins Steve.....................P2.14-012, P2.14-014, P2.14-015 Winter Hauke..............................................................P1.07-019 ................P2.04-006, P2.04-012, P2.08-002, P3.01-005,
Watson Gordon...........................................................MA 13.06 Winter Jeff D..............................................................P3.14-013 .................... P3.01-012, P3.01-026, P3.01-036, P3.01-039,
Watson Mark...............................................................MA 13.02 .....................P3.01-044, P3.01-051, P3.01-063, P3.01-075
Winther Laerke.......................................................P2.10-003
Watson Patricia....................................................... P3.04-008 Wu Ying.................................................................... P3.05-009
Winther-Larsen Anne.........................P3.02-005, P3.13-014
Watzka Stefan B.......................................................P3.03-024 Wu Yufeng..............................................P1.01-047, P1.15-006
Wirawan Aditya............P1.02-065, P2.02-012, P3.02-024
Weaver Jerry...........................................MA 03.01, MA 10.02 Wu Zhen......................................................................OA 10.07
Wirth Andrew..............................................................MA 13.07
Weaver Kathryn E......................................................MA 14.08 Wu Zhibing.................................................................P3.02-015
Wirth Lori J................................................................. OA 12.07
Webb Joanne............................................................P1.10-002 Wu Zhiyong.............................................................P2.01-045
Wirtz Hubert................................................................ WS 01.18
Weber Kathy............................................................. MA 04.04 Wu Zhuolin...............................................................P2.02-003
Wislez Marie.............................................MA 07.06, OA 16.03
Weber Marianne..................................................... P3.06-008 Wuyung Puspita E.................................................... P1.01-026
Wistuba Ignacio I............... MA 01.03, MA 05.02, MS 15.02,
Weber Wolfgang..........................................................OA 14.05 ..........................OA 13.01, OA 13.05, P2.02-013, P2.02-046, Wójcik Janusz............................................................. MA 14.01
Weder Walter..................... MA 19.11, MS 08.01, P1.02-005, ......................................... P2.02-061, P3.03-007, P3.03-027 Wójcik Norbert............................................................ MA 14.01
.......................P1.02-015, P1.09-009, P1.17-016, P2.02-036, Withers Sarah..........................................................P2.02-037 Włodarczyk Janusz............................... OA 04.01, P2.16-027
......................................... P2.07-056, P3.09-010, P3.16-046 Witte Birgit................................................................P2.02-024
Wee Leonard............................................................ P2.01-052 Wnuk-Lipinska Katarzyna........................................P2.01-047
Weersink Robert....................................................... P1.12-002 Woestmann Corinna...................................................P1.15-011 X
Wehnl Birgit......................P1.15-011, P3.05-007, P3.05-008 Wojas-Krawczyk Kamila....................................... P3.02-045
Wei Sen.................................................P1.15-008, P3.02-097 Wojcik Piotr................................................................ P3.01-041 Xi Guangmin.............................................................P3.07-004
Wei Shuzhen..........................................................P3.05-009 Wojtyś Małgorzata...................................................... MA 14.01 Xia Bing.............................. JCSE 01.23, MA 01.11, P1.01-046
Wei Xiong..................................................................... MA 01.10 Wolchok Jedd D.........................................................MA 05.02 Xia Endi.....................................................................P2.02-063
Wei Yu-Feng......................MA 16.02, P2.07-027, P3.01-016 Wolf Brad................................................. OA 15.08, P2.16-019 Xia Fan..................................................................... P2.04-004
Wei Zhigang...............................................................P1.05-001 Wolf Jürgen........................ES 04.02, GR 01.06, P1.01-013, Xia Liming...................................................................P2.01-011
Weichert Wilko......................................................... P3.01-088 .................................................................................P2.04-005 Xia Xuefeng...... JCSE 01.28, MA 01.03, MA 07.13, OA 18.01
Xia Yunfei.....................................................................P1.14-011 Yamada Kouzo..................P1.05-011, P1.05-018, P1.05-021, Yang Liu............................... OA 09.03, OA 09.06, P1.07-039
Xiao Cheng.............................................................. P3.01-025 ............................................P2.17-003, P3.15-012, P3.16-047 Yang Nong........................ OA 09.06, P1.01-035, P1.04-009,
Xiao Fei...................................................MA 13.11, P3.16-031 Yamada Shunsuke.....................................................P1.02-017 ...............................................................P2.03-028, P2.15-001
Xiao Guanghua..........................................................P1.02-039 Yamada Tadaaki.............P1.07-044, P3.03-002, P3.15-001 Yang Pan-Chyr.......................................................... P2.13-001
Xiao Ping....................................................................P3.16-009 Yamada Takeshi........................................................P3.16-042 Yang Pei-Wen............................................................P3.17-002
Xiao Qu...................................................................... P3.02-076 Yamada Tatsuya........................................................ P1.16-002 Yang Ping..............................................P1.05-016, P3.03-029
Xiao Wenwu................................................................MA 15.08 Yamada Yoshito...................................P1.02-015, P1.17-016 Yang Sei-Hoon........................................................P1.02-003
Xiaoye Ai................................................................... P3.01-003 Yamada Yuichi...........................................................P3.16-033 Yang Shaoyu.....................................P1.03-002, P3.02-040
Xie Canmao.............................................................. P1.02-020 Yamaguchi Gaku.................................P2.03-007, P2.16-012 Yang Szu-Chun...................................P1.01-048, P3.05-004
Xie Congying..................P2.01-071, P2.14-008, P2.14-018 Yamaguchi Hiroyuki........................... P1.03-015, P1.08-006, Yang Wenjia.................................................................MA 14.07
Xie Mian......JCSE 01.15, MA 16.11, OA 08.01, P3.02-001 ...............................................................P2.07-045, P3.15-001 Yang Xia.....................................................................P1.05-001
Xie Qiang..................................................................... P2.14-011 Yamaguchi Ken.................................. P2.15-008, P3.05-006 Yang Xiao-Jun..................................... P3.16-009, P3.16-037
Xie Tian Peng............................................................P3.16-037 Yamaguchi Kosuke.............................. P1.01-064, P2.03-016 Yang Xin...................................................................... P1.07-011
Xie Tianpeng.............................................................P3.16-009 Yamaguchi Nanae......................................................MA 09.06 Yang Xue....................................................................P1.17-001
Xie Wei-Hao............................................................. P2.14-004 Yamaguchi Nise................................... MS 09.06, P3.03-019 Yang Xue-Ning....................OA 10.02, P1.07-042, P1.13-001,
Xie Yang................................................. P1.02-039, P1.07-031 Yamaguchi Ou.........................................................P2.03-021 .................................................................................. P2.08-002
Xie Yiting....................................................................P2.16-024 Yamaguchi Teppei..................................................P2.07-028 Yang Xuening.....................................JCSE 01.10, P2.03-047
Xie Yuancai..................................................................MA 15.07 Yamaki Ei................................................................... P1.16-007 Yang Yan B................................................................P2.01-033
Xie Zhanhong............................................................ P1.01-037 Yamamichi Takashi................................................... P1.12-006 Yang Yikun................................................................P2.02-062
Xie Zhi..........P1.01-018, P1.07-042, P2.03-054, P3.01-063 Yamamoto Gaku.......................................................P3.02-033 Yang Yongbin................................................................OA 13.01
Xin Hua................................................. JCSE 01.11, P3.01-021 Yamamoto Hiromasa............................................. P2.16-026 Yang Yongbo....................JCSE 01.20, OA 04.03, P3.16-053
Xin Jin...................................................................... P2.02-006 Yamamoto Hiroshi................................................... P2.05-010 Yang Yue........JCSE 01.22, OA 16.04, OA 16.08, P1.14-004,
Xin Yan......................................................................P2.03-043 Yamamoto Kaname............................ P2.02-051, P2.07-006 .................... P2.01-068, P3.02-022, P3.04-010, P3.16-023
Xin-Ling Ren..............................................................MA 03.03 Yamamoto Kentaro....................................................MA 09.06 Yang Zane.....................................................................OA 12.01
Xing Fei Y..................................................................P2.07-043 Yamamoto Marino.....................................................P1.16-026 Yang Zhen.................................................................... OA 10.07
Xing Lei.......................................................................P1.14-001 Yamamoto Noboru............ MA 16.04, MA 17.06, P2.02-035, Yankelevitz David F........ MTE 14.02, OA 15.05, P2.13-026,
Xing Puyuan...................P2.01-025, P2.01-030, P2.03-004 .........................................P2.03-036, P2.03-048, P2.07-011, .......................P2.16-013, P2.16-014, P2.16-022, P2.16-023,
...............................................................P3.01-072, P3.02-041 .........................P2.16-024, P3.13-028, P3.13-035, PL 01.02,
Xing Rui...................................................................... P1.02-051 .......................... WS 01.10, WS 01.12, WS 01.21, WS 01.23,
Xiong Anwen............................................................ P1.03-046 Yamamoto Nobuyuki.....MS 16.02, P1.03-004, P2.03-008,
........................................P2.03-045, P2.07-035, P2.15-004, .........................WS 01.42, WS 02.03, WS 02.09, WS 02.15
Xiong Dian................................................................ P1.02-062 ........................................ P3.01-026, P3.01-035, P3.01-039, Yano Motoki................................................................P1.17-005
Xiong Hongchao.............JCSE 01.20, OA 04.03, P3.16-053 ..............................................................P3.01-075, P3.04-002 Yano Seiji........................P2.03-008, P3.03-002, P3.15-001
Xiong Jiangping.......................................................P1.03-019 Yamamoto Shigeru.................................................. P3.16-008 Yao Huan.....................................................................MA 13.06
Xiong Junfeng........................................MA 14.12, P3.13-022 Yamamoto Takanori..................................................P2.07-011 Yao Jicheng...............................................................P2.02-018
Xiong Lei...................................................................P3.02-065 Yamamoto Takaya.....................................................MA 09.06 Yao Lijing......................................................................OA 10.06
Xirou Vassiliki............................................................P2.01-039 Yamamoto Yoko.........................................................P1.17-002 Yao Ming....... P1.07-038, P1.17-018, P2.02-018, P3.07-009
Xu Chong-Rui...................JCSE 01.26, P1.01-010, P1.01-018 Yamanaka Kazuki.................................P1.03-010, P2.03-032 Yao Xumei....................................................................MA 15.07
Xu Chunwei..................... JCSE 01.28, MA 07.13, P1.01-002, Yamanaka Takeharu..........MA 17.06, P1.03-027, P2.07-042 Yao Yan.......................................................................OA 02.06
.....................P1.01-003, P1.02-043, P1.02-044, P1.02-045, Yamanda Shinsuke..................................................P2.07-004 Yao Yi..........................................................................P3.15-013
.....................P1.02-046, P1.02-047, P1.02-048, P1.02-049,
..................... P1.02-056, P1.02-057, P1.02-058, P1.02-059, Yamane Kohei.....................................P1.01-064, P2.03-016 Yap Swee Peng.........................................................P1.15-017
...................P2.01-017, P2.02-004, P2.02-005, P2.02-006, Yamane Masaomi.....................................................P2.16-026 Yapp Donald............................................................. P1.03-020
...................P2.02-007, P2.02-020, P2.02-021, P2.03-057, Yamaoka Tetsuya...................................MA 04.09, P2.11-002 Yarimizu Kei..................................................................MA 13.13
....................P3.01-008, P3.01-009, P3.02-018, P3.02-025, Yamasaki Akira.................................... P1.01-064, P2.03-016 Yarmus Lonny..........................................................P2.02-045
...................P3.02-026, P3.02-027, P3.02-028, P3.02-029, Yamasaki Masahiro.................................................... OA 12.03 Yarnell Laura...............................................................OA 15.04
................. P3.02-065, P3.02-067, P3.02-068, P3.02-069, Yamashita Hideomi............................... MA 09.06, MS 24.04 Yasheng Adalat........................................................ P3.01-003
.............................................................P3.02-080, P3.03-005 Yamashita Motohiro............................................... P2.05-009 Yasuda Hiroyuki..................................P2.03-012, P3.02-084
Xu Dongming.............................................................P3.13-028 Yamashita Satoshi................................................... P1.02-009 Yasuda Yuto..................P2.01-021, P2.03-055, P2.07-003,
Xu Fangyun............................................................... P1.03-019 Yamashita Shinichi...................................................P3.16-044 ....................................................................................P2.07-017
Xu Feiyue.....................................................................MA 15.07 Yamato Michiko.........................................................P2.07-021 Yasufuku Kazuhiro................ES 07.01, MA 05.04, OA 15.01,
Xu Guobing.............................................................. P3.05-003 Yamauchi Kohei...................................................... P2.06-009 ....................... P1.02-034, P1.12-002, P1.12-003, P1.13-004,
Xu Haiyan.................................................................. P1.01-037 Yamauchi Shuta...................................P1.03-010, P2.03-032 ...............................................................WS 04.01, WS 04.02
Xu Jianping................................................................P1.02-057 Yamazaki Keiichi..................................P1.03-010, P2.03-032 Yasutaka Kimura....................................................... WS 03.16
Xu Jianqing............................................................JCSE 01.05 Yamazaki Koji............................................................P3.16-003 Yasuura Yoshiyuki....................................................P3.16-011
Xu Ke.........................................................................P1.03-017 Yan Dexi......................................................................P1.07-013 Yata Yumi........................... P1.03-033, P2.16-010, P3.13-012
Xu Lin............................. JCSE 01.10, P1.03-032, P2.03-047 Yan Hong-Hong.........................................................P1.01-018 Yatabe Yasushi.........................................ES 01.03, PL 03.03
Xu Man......................................................................... MA 07.12 Yan Honghong....................................JCSE 01.10, P2.03-047 Yates Patsy..............................................................MTE 12.02
Xu Nong.....................................................................P3.01-025 Yan Li-Xu............................................JCSE 01.17, OA 08.02 Yau Vivian K.Y.............................................................MA 09.02
Xu Qian............................. P1.02-056, P2.01-017, P3.02-068 Yan Mengli...................................................................MA 12.09 Yaung Stephanie.........................................................OA 10.06
Xu Rong............................... P1.16-012, P1.16-018, P3.02-010 Yan Shi.................................OA 16.08, P1.02-051, P3.16-023 Ye Hong........................................................................MA 13.09
Xu Shanchao...............................................................MA 20.13 Yan Wanpu.......................JCSE 01.20, OA 04.03, P3.16-053 Ye Jianding..................................................................MA 14.07
Xu Shi................................................. P2.02-058, P2.15-006 Yan Xiang................................................................. P3.07-001 Ye Junyi..................................................P1.01-035, P1.01-037
Xu Shidong..JCSE 01.10, OA 16.04, P2.03-047, P3.04-010 Yan Xiangtao......................................... P3.01-018, P3.01-061 Ye Maosong............................................MA 20.13, P3.01-004
Xu Shun..............................................JCSE 01.10, P2.03-047 Yanada Masashi.......................................................P2.16-016 Ye Ming.......................................................................P3.14-007
Xu Song......P1.15-008, P3.01-002, P3.02-095, P3.02-097 Yanagawa Naoki..........................................................MA 13.13 Ye Wenfeng.................................................................P1.14-010
Xu Songtao......................................JCSE 01.10, P2.03-047 Yanagi Masakazu..................................................... P2.16-004 Ye Xianghua................................................................ MA 14.04
Xu Tu............................................................................ MA 17.07 Yanagimoto Hiroaki...................................................MA 05.06 Ye Xin.......................................................MA 11.03, P1.05-001
Xu Wei..........................................................................MA 16.03 Yanagisawa Asako................................................. P2.03-005 Ye Yuanqing................................................................. OA 13.05
Xu Weihong..............................................................P3.02-008 Yanagitani Noriko....................................................... MA 16.04 Yeap Beow Y.............................................................. MA 07.07
Xu Wujian................................................................... P1.01-073 Yanai Hiroyuki............................................................. OA 12.03 Yee John........... OA 15.01, P1.04-003, P2.13-011, P2.13-012
Xu Xiao-Ling............................................................. P2.07-057 Yanai Masaaki...................................... P1.01-064, P2.03-016 Yeh Yi-Chen............................................................. P1.02-008
Xu Xiaobo.....................................................................MA 20.13 Yanase Takafumi.......................................................P1.02-032 Yen Yi-Ting................................................................ MA 16.02
Xu Xin..................................................... P3.01-011, P3.17-001 Yanase Takahumi.................................................... P2.06-003 Yenerall Paul................................................................MA 15.13
Xu Yanjun...................... JCSE 01.18, P2.03-013, P3.03-030, Yang Cheng-Ta..........................................................P3.01-036 Yentürk Eylem......................................... MA 17.08, P2.14-016
....................................................................................P3.03-031 Yang Chun-Hsiang................................................... P1.01-077 Yeo Chang Dong....................................................... P1.06-015
Xu Yaping.......MA 09.01, MA 16.13, MA 16.14, P3.01-058, Yang Dawei........................................ P3.04-001, P3.13-037 Yetisyigit Tarkan.......................................................P1.01-029
..............................................................P3.14-015, P3.17-003 Yang Fan......... JCSE 01.11, OA 07.01, P3.01-021, P3.16-025 Yeung Enoch............................................................. P1.16-009
Xu Yu J.......................................................................... MA 01.11 Yang Haibo........................................... JCSE 01.11, P3.01-021 Yi Cao........................................................................ P1.02-040
Xu Yuqing.............................................. JCSE 01.11, P3.01-021 Yang Haihong.............................................................P3.01-011 Yi Jingbo................................................................... P3.01-086
Xu Zhaolin.....................................................................OA 15.01 Yang Heli..........................JCSE 01.20, OA 04.03, P3.16-053 Yi Kijong.......................................................................MA 06.12
Xu Zhenwu...................... P1.02-056, P2.01-017, P3.02-068 Yang Huei-Ting.................................... P3.02-070, P3.07-011 Yi Seong Yoon............................................................ OA 08.07
Xu Zhiyong.............................................. MA 14.12, P3.13-022 Yang Ian....................................................................P2.02-002 Yi Xiaohui......................................................................OA 13.01
Xuan Tao....................................................................P3.16-053 Yang James Chih-Hsin...................... ES 08.02, ISS 02.05, Yi Xin.................JCSE 01.28, MA 01.03, MA 07.13, OA 18.01,
Xue Yanping..............................................................P2.01-073 ...............................MA 12.07, OA 05.03, OA 09.03, OA 17.01, ..................... P1.01-002, P1.02-045, P1.02-046, P1.02-047,
Xyrafas Alexandros.................................................P2.07-056 ....................P1.01-077, P1.04-001, P2.03-058, P2.07-027, .....................P1.02-048, P1.02-049, P1.02-056, P1.02-058,
......................................... P3.01-006, P3.01-026, P3.01-039, .................. P1.02-059, P2.02-004, P2.02-007, P2.02-020,
..............................................................P3.01-074, P3.01-075 ....................P2.02-021, P2.03-057, P3.01-009, P3.02-027,
Yang Ji-Hyun.......................................................... P3.08-003 .............................................................. P3.02-080, P3.16-053
Y Yi Yuting.....................................................MA 01.03, OA 18.01
Yang Jie.....................................................................P3.01-073
Yang Jin -Ji.....................JCSE 01.26, OA 09.06, OA 10.02, Yildiz Ozcan.............................................................. P2.01-063
Yagi Yukako................................................................OA 18.06 Yilmaz Ulku...............................................................P2.03-042
........................ P1.01-009, P1.01-010, P1.01-018, P1.07-042,
Yagi Yuki......................................................................OA 04.02 ...........................................P1.13-001, P2.03-054, P3.01-051, Yin Hanwei.............................................................. P3.05-003
Yagnik Lokesh...........................................................MA 20.07 ...............................................................P3.01-052, P3.01-063 Yin Rong.....................................................................P1.03-032
Yahara Katsuya..........................................................MA 09.06 Yang Jing......................................................................OA 17.06 Yin Xia....................................................................... P3.01-004
Yajima Toshiki...........................................................P1.05-006 Yang Julie L.................................................................OA 10.05 Ying Jian-Ming..................JCSE 01.25, MA 06.09, MA 11.05
Yaksic Mateo S..........................................................P3.03-019 Yang Lin................................................................... P1.02-039 Ying Lisha..................................................................P2.02-013
Yalçınkaya Irfan......................................................... P1.03-016 Yang Ling..........JCSE 01.28, MA 01.03, MA 07.13, OA 18.01, Ying Xiaozhen.......................................................... P3.01-058
Yamada Kazunari.......................................................MA 09.06 .............................................................. P2.03-034, P3.16-053 Yip Connie Siew Poh................................................P3.01-017
Yip Kent...................................................................... P1.14-009 Yu Ping................................................JCSE 01.10, P2.03-047 Zhang Daxin......................................... JCSE 01.11, P3.01-021
Yip Rowena................... P2.16-013, P2.16-014, P2.16-022, Yu Tiffany M...............................................................MA 11.06 Zhang Fan............................................P1.04-006, P1.04-007
.........................................P2.16-023, P2.16-024, P3.13-028, Yu Wei.................................... MA 10.03, OA 17.07, P1.01-052 Zhang Fang..............................................................P3.07-004
.................................................................. P3.13-035, PL 01.02 Yu Woo Sik................................................................ P3.16-019 Zhang Gu.................................................... MA 16.13, MA 16.14
Yip Sonia.................................................................. P2.03-044 Yu Xiaoqing.....................JCSE 01.18, P2.01-057, P2.03-013, Zhang Guangxin..................................................... P2.02-006
Yip Wai-Ki.......................P2.02-052, P3.02-061, P3.02-062 ....................................................................................P3.01-069 Zhang Guoqing.......................................................... P1.01-069
Yndestad Arne.........................................................P2.02-053 Yu Xinmin.............................................. P1.03-007, P3.01-027 Zhang Guowei....................................... P3.01-018, P3.01-061
Yoda Satoshi.............................................................. MA 07.07 Yu Yan........................................................................P3.01-087 Zhang Han.................................................................. MA 07.09
Yogo Naoyuki.............................................................P3.03-013 Yu Yang................................................P2.02-006, P3.01-037 Zhang Hanhan......................................P1.01-035, P3.01-052
Yoh Kiyotaka.............................................................. P3.14-001 Yu Yongfeng............................................................ P3.04-005 Zhang He-Long...................................JCSE 01.25, MA 06.09
Yokoba Masanori.................................................... P2.03-002 Yu Zhuang.................................................................P3.01-087 Zhang Hong.................................................................MA 13.06
Yokobori Takehiko....................................................P2.02-026 Yuan Ju........................................................................OA 09.07 Zhang Hong Wei.......................................................P3.16-037
Yokoi Kohei...................... P1.08-002, P1.17-004, P3.03-013, Yuan Ren......................................................................MA 14.11 Zhang Hongyu........................................................... P1.01-071
.............................................................. P3.09-006, P3.16-010 Yuan Yong........................MA 01.09, P1.15-003, P2.07-034 Zhang Hua................................................................ P1.02-004
Yokoi Sana.............................................................. P2.02-063 Yuan Zilong.................................................................P1.07-013 Zhang Hui............................................... OA 05.01, P3.01-072
Yokoi Takashi...................MA 05.06, P2.09-005a, PL 02.02 Yuankai Shi.............................................................. P3.03-006 Zhang Huijun...............................................................MA 20.13
Yokomakura Naoya.................................................. P2.16-004 Yue Cui...................................................................... P1.02-042 Zhang Jia-Tao...........................................................P1.13-001
Yokomise Hiroyasu...............................OA 04.04, P1.14-002 Yue Dongsheng.....................................OA 16.04, P1.02-004 Zhang Jian................................................................. P2.15-010
Yokomura Koshi.......................................................P2.07-022 Yue Huibin...................................................................MA 02.10 Zhang Jianhua........................................OA 13.05, P2.02-013
Yokose Tomoyuki..............P1.05-011, P1.05-018, P1.05-021, Yue Wentao...............................................................P3.02-083 Zhang Jianjun...................ES 04.03, MA 01.03, MA 05.02,
............................................P2.17-003, P3.15-012, P3.16-047 Yuen Johnson........................................................... P2.14-010 ..........................OA 07.02, OA 09.05, OA 13.05, P2.02-013,
Yokota Nanrei............................................................. MS 21.01 Yuh Young Jin..........................................................P2.03-022 .......................................P2.02-041, P2.04-014, P2.07-061a
Yokouchi Hideoki........................................................MA 17.04 Yule Murray........................................... MA 02.09, P2.01-047 Zhang Jianzhi..........................................................P3.02-022
Yokouchi Hiroshi....................................................... P1.15-002 Yumuk Perran F................................. P1.03-040, P3.15-007 Zhang Jie..............................MA 14.12, MA 17.02, P1.03-052,
Yokoyama Takuma.................................................. P3.01-055 Yun Hwan Jung......................................................... OA 08.07 ............................................ P3.01-021, P3.13-022, P3.15-015
Yokoyama Toshihide................................................P2.01-001 Yun John................................................................... P2.07-029 Zhang Jiexia.............................................................P2.02-003
Yokoyama Toshiki............P2.01-037, P2.07-053, P3.12-001 Yun Ju Sik................................................................P2.03-024 Zhang Jiexin................................................................ OA 13.05
Yom Sue S...............................................MA 13.08, PC 02.02 Yun Takamasa............................................................OA 04.05 Zhang Jing................................................................P3.02-083
Yoneda Kazue......................................................... P1.07-030 Yun Zhihong...............................................................OA 02.06 Zhang Jingjing..........................................................P3.02-015
Yonemori Yoko..........................................................P2.12-006 Yun-Chao Huang..................................................... P1.02-040 Zhang Jinjun............................................MA 16.11, P3.02-001
Yonesaka Kimio....................................P1.07-010, P2.07-021 Yunaiyama Daisuke................................................. P2.05-012 Zhang Jun.......................................... P1.16-015, P2.05-015
Yoneshima Yasuto.....................................................P1.07-014 Yung Rex................................................................... P3.04-001 Zhang Junping.........................................................P3.02-026
Yong Hwan Seok....................................................... P1.16-012 Yung Tony.......................JCSE 01.24, P1.01-032, P3.02-031 Zhang Lanjun..............................................................OA 16.04
Yong Luo-Sheng..................................................... P3.01-079 Yunus Faisal............................................................. P1.02-065 Zhang Li............. GR 01.03, MA 08.02, MA 11.03, MA 12.09,
Yong Mei Ching.....................................P2.12-001, P2.12-002 Yura Renee.............................................................. P2.04-005 .......................P1.04-010, P1.14-011, P2.03-041, P2.03-050,
Yoo Kwai Han............................................................. OA 03.04 Yurcan Marta................................................................MA 14.14 ...................P2.04-003, P2.14-004, P3.01-039, P3.01-087,
Yoo Seung Soo........................................................ P3.01-050 ..............................................................P3.03-006, P3.03-017
Yurugi Yohei.................... P1.02-060, P1.02-061, P1.13-008
Yoon Hyoung-Kyu.................................................... P3.01-050 Zhang Lichuan........................................................ P1.01-078a
Yusa Toshikazu....................................................... P2.09-006
Yoon Jeong-Hwa.........................................................OA 14.01 Zhang Limin..................................................................MA 11.07
Yusko Erik.................................................................... OA 13.05
Yoon Nara.................................................................P2.02-029 Zhang Lina................................................................P3.02-083
Yusupbekov Abrorbek A........................................P2.02-049
Yoon Soon Ho............................................................ OA 14.01 Zhang Liyi............................................................... JCSE 01.22
Yutaka Yojiro.............................................................. P1.14-005
York Emily.................................................................. P2.02-011 Zhang Lu.................................................P1.01-035, P1.01-037
York Sarah.................................................................P3.13-038 Zhang Mengmeng..................................................... P1.01-072
Yorke Janelle...............................................................MA 10.07 Zhang Mina............................................ P3.01-018, P3.01-061
Yorozu Keigo....................................... P2.02-051, P2.07-006 Z Zhang Mingjuan L....................................................P1.07-033
Yoshida Akihiko......................................................... MA 06.15 Zhang Na...............................................P1.01-035, P3.01-052
Yoshida Atsushi........................................................P3.16-032 Zablockis Rolandas..................................................P3.13-034 Zhang Qicheng.......................................................... P1.03-017
Yoshida Hironori.......... P2.01-021, P2.03-055, P2.07-003, Zadeh Gelareh...........................................................P3.14-013 Zhang Qin.................................................MA 17.02, MA 17.03
................................................................P2.07-013, P2.07-017 Zadok Oranit..............................................................P3.07-010 Zhang Qiong.............................................................. P1.07-001
Yoshida Kazuhiro.....................................................P2.02-035 Zaffaroni Facundo....................................................P3.16-034 Zhang Rui.................................................................P1.02-067
Yoshida Koichi...........................................................P3.02-012 Zago Giulia................................................................P3.02-006 Zhang Shanyuan................................. P1.14-004, P2.01-068
Yoshida Tatsuya..........................................................MA 17.06 Zaheer Salman......................................................... P1.16-006 Zhang Shijia.............................................................. P3.01-085
Yoshida Yasushi........................................................P2.07-014 Zahn Mark-Oliver.................................................... P3.01-088 Zhang Shirong.............JCSE 01.23, P1.01-046, P3.01-031,
Yoshikawa Akira................................ P2.02-042, P2.02-043 Zaini Jamal................... P1.03-024, P2.03-031, P2.03-049, ..............................................................P3.02-015, P3.02-040
Yoshikawa Ryohei...........P1.02-031, P1.16-014, P2.16-009, .......................P3.01-032, P3.01-053, P3.01-054, P3.11-001 Zhang Shucai.................. JCSE 01.11, MA 01.03, P2.03-028,
....................................................................................P3.16-029 Zalcman Gerard.................. MA 05.03, MA 10.11, P2.07-060 .................................................................................... P3.01-021
Yoshimasu Tatsuya.........P1.03-033, P2.16-010, P3.13-012 Zalevsky Jonathan..................................................P2.07-062 Zhang Shuxing.............................................................OA 12.01
Yoshimoto Kentaro.................................................... P1.15-014 Zamora Atenza Carlos.............................................P1.07-028 Zhang Tao................................................................... P1.01-071
Yoshimoto Naoki....................................MS 02.02, P1.06-014 Zander Thilo................................................................. MA 15.11 Zhang Tong................................................................ P3.01-019
Yoshimoto Taichiro.......... OA 18.07, P1.02-041, P3.02-089, Zandueta Carolina................................................... P3.07-007 Zhang Wei.................................................................. P1.15-005
...................................................................................P3.02-093 Zang Wanchun..........................................................P3.01-037 Zhang Xian..................................................................MA 20.13
Yoshimura Akinobu................................................. P1.03-008 Zang Xingxing............................................................. OA 13.03 Zhang Xiaochun..........P1.01-042, P1.01-069, P2.03-034,
Yoshimura Masahiro................................................P1.03-036 Zanoria Martiniano C...............................................P2.12-004 ...............................................................P3.03-014, P3.03-018
Yoshimura Naruo................................ P1.06-014, P2.03-008 Zapata Luciana L......................................................P3.03-019 Zhang Xiaojuan..................................... P3.01-018, P3.01-061
Yoshino Ichiro............... P1.16-008, P2.02-063, P2.07-008, Zaric Bojan...........................................P1.02-007, P2.10-005 Zhang Xiaoling......................................................... P3.01-084
....................................................................................P2.12-006 Zatarain-Barron Zyanya L...................MA 01.02, P1.01-022, Zhang Xiaotong....................................................... P2.03-050
Yoshioka Hiroshige.......... OA 05.08, P1.07-004, P2.01-001, ..............................................................P1.02-055, P2.01-070, Zhang Xiaoyang.......................................................P3.02-086
........................................ P2.01-034, P2.03-008, P2.07-024 .............................................................P3.02-063, P3.08-005 Zhang Xin............................MA 07.09, MA 20.13, P3.01-004
Yoshizawa Hirohisa................................................. P2.03-021 Zaw Shane................................................................P2.13-023 Zhang Xinting............................................................. P1.01-071
Yotsukura Masaya......... P1.05-009, P1.17-017, P3.08-002, Zawisza Dianne.......................................................P1.10-003 Zhang Xinyu............................................................. P3.01-004
.....................................................................................P3.13-031 Zeaiter Ali.......................... JCSE 01.27, MA 07.01, P1.01-013 Zhang Xu....................................................................P1.02-063
Yotsumoto Takuma...................................................P3.16-028 Zehou Ouidad........................................................... P2.07-023 Zhang Xu -Chao........................................................ P3.01-051
You Jia..................................................................... P2.02-008 Zemanová Milada....................................................P2.03-023 Zhang Xu C.................................................................P1.01-018
You Jin Young.......................................................... P1.05-020 Zenda Sadamoto...................................................... P3.14-001 Zhang Xu-Chao........ JCSE 01.25, JCSE 01.26, MA 06.09,
Younes Riad..........................................P2.10-006, P3.10-001 Zeng Fanrui.................... P2.15-003, P2.15-009, P2.15-010 ..............................................OA 10.02, P1.01-009, P1.01-010,
Young Ben......................MA 18.04, OA 06.08, P3.06-009 Zeng Hui................................................................... P3.01-052 ..............................................................P2.03-054, P3.01-063
Young Robert P.................. OA 06.03, OA 06.06, OA 15.03 Zeng Huihui............................................................. P3.05-003 Zhang Yakun.............................................................P2.03-034
Young Tina C................................................................OA 17.03 Zeng Xuan........................MA 12.09, P2.02-033, P3.03-004 Zhang Yanhong...........................................................MA 15.08
Young Vincent..................P1.02-011, P1.03-039, P2.02-064 Zeng Zhiqun.............................................................P3.02-073 Zhang Yanwei.............................................................MA 14.07
Yousaf Nadia....................MA 09.09, P1.03-029, P2.07-049, Zeniou Anthi............................................................ P2.08-003 Zhang Yifan..............................................................P2.03-028
....................................................................................P3.12-003 Zenzola Victor............................................................ MA 07.03 Zhang Yiping.......................................P2.04-003, P3.01-036
Youssef Jacqueline.................................................P3.02-054 Zer Alona..........................MA 02.06, P1.01-039, P3.01-060, Zhang Yong.................................................................MA 20.13
Youssef Oulkhouir......................................................OA 03.01 ....................................................................................P3.13-030 Zhang Yongchang........P1.01-035, P1.04-009, P2.15-001
Yu Cecilia.....................................................................MA 18.09 Zeren Handan...........................................................P3.13-024 Zhang Yongxing.................................JCSE 01.10, P2.03-047
Yu Chang................................................................... P3.14-004 Zeron-Medina J...................................P1.05-015, P2.07-060 Zhang Yu.................................................................... P1.03-051
Yu Channing.........................................P3.04-012, P3.04-013 Zhai Dayong............................................................... MA 07.09 Zhang Yu-An............................................................. P1.15-005
Yu Chong-Jen................. P2.07-027, P3.01-006, P3.01-074 Zhai Hao-Ran.......................................................... P2.08-002 Zhang Zhen..............................................................P3.07-009
Yu Dan..........................................................................MA 15.07 Zhai Weiwei.................................................................OA 09.07 Zhang Zhenfa..................................... P1.02-004, P2.03-040
Yu Fenglei................................................................. P3.04-010 Zhan Qiong................................................................ P3.01-010 Zhang Zhou.........................................JCSE 01.26, P1.01-010
Yu Helena.............................................. OA 09.03, P1.04-001 Zhang Bin..........................................P1.02-004, P2.03-040 Zhanshan Ma............................................................ P1.02-040
Yu Helena A..........................................P3.04-012, P3.04-013 Zhang Chao....................JCSE 01.21, P1.01-027, P1.08-003, Zhao Changlin............................................................ P1.01-071
Yu Hongsheng..........................................................P2.03-034 .................................................................................P2.08-002 Zhao Chao......MA 11.07, P1.03-045, P1.03-052, P3.01-067
Yu Hui...................................MA 05.14, MA 13.02, P2.02-011 Zhang Chuantao.............P1.01-042, P1.01-069, P2.03-034, Zhao Chen................................................................ P2.01-028
Yu Jia......................................................................... P3.01-085 ...............................................................P3.03-014, P3.03-018 Zhao Fengde..............................................................P2.01-011
Yu Jinpu....................................................................P3.03-009 Zhang Chufeng........................................................ P2.01-058 Zhao Heng................................................. OA 07.01, OA 16.04
Yu Lei................................. MA 16.07, P1.17-003, P2.01-033 Zhang Cuigui............................................................ P3.01-084 Zhao Hui.................................................................. P1.01-078a
Yu Pan........................................................................P3.01-037 Zhang Daoyun.......................................................... P3.01-004 Zhao Jing........ MA 11.07, P1.03-046, P1.03-052, P1.15-009
Zhao Jun..........................JCSE 01.11, JCSE 01.28, MA 07.13, Zhou Di........................................................................P3.17-001 ................... P2.02-007, P2.02-020, P2.02-021, P3.02-018,
...........................MA 14.12, P1.17-001, P3.01-021, P3.01-036, Zhou Fei..........MA 11.07, P1.03-052, P3.01-067, P3.15-015 ..............................................................P3.02-067, P3.02-080
.............................................................. P3.03-003, P3.13-022 Zhou Haitao.....................JCSE 01.20, OA 04.03, P3.16-053 Zhu Zhengfei............................................................. P1.01-037
Zhao Meiru...................................................................OA 18.01 Zhou Jian.....................................................................MA 20.13 Zhu Zhenhua...............................................................MA 20.13
Zhao Qiang...................................................................OA 13.01 Zhou Jianying.............. JCSE 01.12, P2.04-003, P3.01-070, Zhu Zhitu.............................................. JCSE 01.11, P3.01-021
Zhao Qiong................................................................ MA 14.04 ....................................................................................P3.01-087 Zhuang Wu...................... JCSE 01.28, MA 07.13, P1.01-002,
Zhao Sha......................................................................MA 11.07 Zhou Jiebai..................................................................MA 20.13 ................... P1.01-003, P1.02-043, P1.02-044, P1.02-045,
Zhao Wei...................................................................... OA 10.07 Zhou Lijuan...............................................................P2.02-033 .....................P1.02-046, P1.02-047, P1.02-048, P1.02-049,
Zhao Weigang........................................................... P2.16-018 Zhou Lixin................................................................... P1.07-011 ..................... P1.02-056, P1.02-057, P1.02-058, P1.02-059,
Zhao Weixin............................................................... P1.01-037 Zhou Na...........................P1.01-042, P1.01-069, P2.03-034, ....................P2.01-017, P2.02-004,P2.02-005, P2.02-006,
Zhao Xiaoting...........................................................P3.02-083 ...............................................................P3.03-014, P3.03-018 ...................P2.02-007, P2.02-020, P2.02-021, P2.03-057,
....................P3.01-008, P3.01-009, P3.02-018, P3.02-025,
Zhao Yanqiu......................................... P1.15-016, P2.04-003 Zhou Qianjun.........................................................P3.02-014a ...................P3.02-026, P3.02-027, P3.02-028, P3.02-029,
Zhao Yanyan............................................................ P3.02-015 Zhou Qing.....................JCSE 01.07, JCSE 01.26, MA 11.03, ...................P3.02-065, P3.02-067, P3.02-068, P3.02-069,
Zhao Yi Z.........................P3.01-087, P3.03-006, P3.03-017 .......................... OA 10.02, P1.01-009, P1.01-010, P1.01-018, .............................................................P3.02-080, P3.03-005
Zhao Yidan.................................................................OA 02.06 ...............................................................P1.03-032, P3.01-063 Zhuang Xiang............................................................P3.16-009
Zhao Yue...................................................................P3.02-008 Zhou Shengyu.........................................................P3.04-007 Zhuang Yongzhi................................... JCSE 01.11, P3.01-021
Zhao Ze-Rui............................................................. P3.16-015 Zhou Xiangdong......................................OA 05.01, P3.01-012 Zhuo Minglei................................................................P1.17-001
Zhegu Lutfi............................................................... P2.01-059 Zhou Xin....................................................................P3.01-087 Zielinski Marcin..........................................................OA 16.09
Zhen W. K................................................................. P2.14-006 Zhou Xinli................................................................... P3.01-010 Zielinski Robert.........................................................P3.13-038
Zheng Aimin..............................................................P1.05-001 Zhou Yang.................................................................... OA 14.07 Zilembo Nicoletta................................................... P2.09-001a
Zheng Di................................................P1.01-037, P3.01-052 Zhou Yin.................................................................... P2.14-004 Zinck Steven..............................................................P2.13-009
Zheng Gang............................................................... P1.12-002 Zhou Yizhao.............................................................P2.07-050 Zinkovskaya Anna V................................................. P1.01-056
Zheng Huili.............................................P1.15-017, P2.14-002 Zhou Yunyun.............................................................P1.02-039 Zippelius Alfred....................................... MA 15.11, P2.07-056
Zheng Long Y............................................................P3.01-025 Zhou Zhiwei.............................................................P3.02-066 Zirafa Carmelina Cristina...........................................MA 17.01
Zheng Qingshan......................................................... P1.15-016 Zhu Changcheng......................................................P1.07-027 Zivkovic Marko......................................................... P3.01-086
Zheng Xiaobing...................................P1.02-045, P2.02-020 Zhu Chenchen..............................................................OA 18.01 Zo Jae Ill..........................P1.08-004, P3.01-082, P3.02-011,
Zheng Xiaoxuan........................................................P2.04-011 Zhu Guanshan......................................................... P3.02-019 ......................................... P3.04-011, P3.05-012, P3.08-006
Zheng Xin................................................................. P2.03-041 Zhu Hua.....................................................................P3.03-014 Zou Qian....................................................................P1.01-006
Zheng Zhendong................................. JCSE 01.11, P3.01-021 Zhu Hui-Neng.......................................................... P3.14-004 Zou Wei.......................................................................MA 05.09
Zhi Xiuyi.................................................................... P3.04-010 Zhu Jing.....................................................................P3.01-036 Zudaire Enrique.......................................................P2.07-058
Zhi Xuan Lin.................P1.01-078, P1.10-006, P2.03-001 Zhu Jingjuan...................P1.01-042, P1.01-069, P2.03-034, Zugazagoitia Jon..................................MA 07.03, P1.01-040
Zhi-Yong Ma...............................................................MA 03.03 ....................................................................................P3.03-014 Zukin Mauro............................................................. P1.06-024
Zhong Anyuan......................................................... P2.06-010 Zhu Liang.................................................................. P3.14-004 Zulato Elisabetta......................................................P3.02-006
Zhong Diansheng.................................................... P3.01-002 Zhu Lingling............................................................... P1.03-019 Zulueta Javier J............P2.02-061, P3.03-026, P3.05-002,
Zhong Jia................................................................ P3.03-003 Zhu Lucheng............... JCSE 01.23, P1.01-046, P3.01-031 ...........................................WS 01.26, WS 02.08, WS 02.18
Zhong Min............................................. JCSE 01.11, P3.01-021 Zhu Meng.................................................................. P2.14-004 Zuo Yunxia............................................................... P2.04-004
Zhong Wei................................................................ P2.04-003 Zhu Ming-Hui.............................................................. OA 10.07
Zhong Wen-Zhao........JCSE 01.10, JCSE 01.19, JCSE 01.21, Zhu Viola.................................................MA 07.07, MS 02.05
...........................OA 10.02, P1.01-010, P1.01-018, P1.01-027, Zhu Wenyong...........................................................P2.03-034
..................... P1.13-001, P2.03-047, P2.08-002, P3.01-063 Zhu Xiang.....................................................................MA 16.14
Zhou Caicun.........ES 09.03, MA 06.11, MA 11.03, MA 11.07, Zhu Xiaodan................................................................MA 20.13
......................OA 09.06, P1.03-045, P1.03-052, P1.04-008, Zhu Xiaoli................................................................. P3.05-009
.................... P1.15-009, P2.04-004, P2.07-010, P2.07-047, Zhu Xinyu................................................................... P1.01-071
.....................P3.01-024, P3.01-026, P3.01-036, P3.01-039, Zhu Yan.....................................................................P2.03-034
..........................................P3.01-044, P3.01-067, P3.01-075, Zhu Yixiang......................................... P2.01-025, P2.01-029
................................................................P3.01-085, P3.15-015 Zhu Youcai...JCSE 01.28, MA 07.13, P1.01-003, P1.02-043,
Zhou Cathy.................................................................P1.07-013 ..........................................P1.02-047, P1.02-048, P1.02-049,
Zhou Chengzhi......................................................... P3.01-052 ......................P1.02-056, P1.02-058, P1.02-059, P2.01-017,
Join the
conversation!
Get social at the

IASLC 18th Remember to use
the official hashtag:
World Conference #WCLC2017
on Lung Cancer
SECTION 10
MAPS AND
FLOOR PLANS
MAPS AND FLOOR PLANS
PACIFICO YOKOHAMA CONVENTION CENTER COMPLEX
PEDESTRIAN DECK NATIONAL

CONVENTION HALL
YOKOHAMA GRAND
INTERCONTINENTAL
HOTEL
EXHIBITION HALL
ANNEX HALL PLAZA CONFERENCE

CENTER
QUEENS MALL BRIDGE

YOKOHAMA BAY
HOTEL TOKYU
CONFERENCE CENTER
1F TO INTERCONTINENTAL HOTEL
STREET
ENTRANCE
MAIN HALL
SESSION ROOM
CONFERENCE CENTER
2F TO INTERCONTINENTAL HOTEL
ENTRANCE
FROM QUEENS
MALL BRIDGE
DELEGATE BAG PICK UP

CONFERENCE CENTER
3F
SE
SS 31
IO 5
N
RO
OM
SES
314 N RO
SIO
+ 3 OM
13 SES
312 N RO
SIO
+ 3 OM
11
SOCIAL
MEDIA
CORNER
301 + 302 303 + 304

SESSION ROOM SESSION ROOM
316 317 318

SESSION SESSION OVERFLOW
ROOM ROOM ROOM
CONFERENCE CENTER
4F
IASLC BOARDROOM
PRESS CONFERENCES
419
418
MEDIA INTERVIEW ROOM 2
MEDIA INTERVIEW ROOM 1
417
DAILY NEWSPAPER OFFICE
416
IASLC COMMITTEE ROOM 3
415
414
LOCAL ORGANIZING
COMMITTEE ROOM
IASLC COMMITTEE ROOM 2 413
IASLC COMMITTEE ROOM 1

412
411
421 422 423 424
MEETING ROOMS
MEDIA ROOM
CONFERENCE CENTER
5F
SESSION ROOM
511 + 512
502
SESSION ROOM
503
SESSION ROOM
501
SESSION ROOM
Resource Guide
Adverse Event Treatment
Visit the IASLC Membership Booth to learn more about this new IASLC clinical
resource, developed by the IASLC Nurse & Allied Health Professionals Committee.
Or visit IASLC.org for more information.
EXHIBITION HALL
LEVEL
1F
HALL D HALL B + C
PLENARY HALL EXHIBIT HALL & POSTERS
MEZZANINE
LEVEL
M2F
ANNEX HALL
LEVEL
2F
Fifth AACR-IASLC International Joint Conference on
LUNG CANCER
TRANSLATIONAL SCIENCE
FROM THE BENCH TO THE CLINIC
January 8-11, 2018 | Hard Rock Hotel | San Diego, CA
Submit an Abstract/Apply for an Award By: Tuesday, October 31, 2017

Register and Save By: Monday, November 27, 2017
CONFERENCE CHAIRS CONFERENCE COCHAIRS

Charles M. Rudin Tony S.K. Mok
Memorial Sloan Kettering Cancer Center, Chinese University of Hong Kong, Shatin,
New York, NY Hong Kong
Charles Swanton Lecia V. Sequist
The Francis Crick Institute and UCL Cancer Massachusetts General Hospital
Institute, London, United Kingdom Cancer Center, Boston, MA
Monte M. Winslow
Stanford University School of Medicine,
Stanford, CA
ABOUT THIS CONFERENCE

Under the leadership of Margaret Foti, PhD, MD (h.c.), CEO of the American basic, translational, and clinical lung cancer research) and provided a
Association for Cancer Research (AACR), and Fred R. Hirsch, MD, PhD, venue to discuss recent advances and establish new collaborations. As
CEO of the International Association for the Study of Lung Cancer in our past successful conferences, sessions will range in topics spanning
(IASLC), we are thrilled to join in our fifth biennial conference on lung immunotherapy, molecular targets, genetics, drug resistance, clinical
cancer research and treatment. The translational science featured at this trials, patient advocacy, and more. This conference is not only a dynamic
conference will include basic research foundation at the bench to patient collaboration of the AACR and the IASLC, two organizations committed
care in the clinic. This conference has historically attracted a diverse to the study of cancer, but also a dynamic collaboration of the many
group of attendees (physicians, patient advocates, and scientists in individuals charged with the study and treatment of this disease.
Continuing Medical Education (CME) Activity–AMA PRA Category 1 CreditsTM available
Learn more and register at

AACR.org/Lung18
#LUNG18
Neo-Adjuvant Workshop
For Lung Cancer
March 2, 2018 Washington, D.C.
For more information please visit www.iaslc.org
Immunotherapy
2018 March 22-25
Madrid, Spain
Tangier
Morocco
2018 April 29-May 1

Tangier, Morocco
For more information please visit www.iaslc.org
WCLC 2017 INDUSTRY SATELLITE SYMPOSIUM
The Evolving I-O Treatment

Landscape in Thoracic Cancers:
Clinical Updates and Future Directions
Monday, October 16, 2017 | 17:45–19:15
PACIFICO Yokohama Conference Center
Room 1F, Main Hall
Yokohama, Japan
Program:
Current and Evolving Research Landscape in NSCLC
Daniel SW Tan, BSc, MBBS, MRCP, PhD
National Cancer Centre Singapore
Genome Institute of Singapore
Singapore
Meeting Chair
Emerging Data in SCLC and Mesothelioma

Anne-Marie Dingemans, MD, PhD
Maastricht University Medical Center
Maastricht, The Netherlands
The Role of Emerging Biomarkers in Lung Cancer

David P. Carbone, MD, PhD
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Panel discussion and audience Q&A to follow presentations

This program was approved by the IASLC 18th World Conference on Lung Cancer Program
Committee as an independent activity held in conjunction with the IASLC 18th World Conference
on Lung Cancer. This program is not sponsored or endorsed by IASLC.
17A822 08/17 © 2017 Bristol-Myers Squibb Company

EGFR M+ NSCLC
OPTIMISING THE SEQUENCE

WITH GIOTRIF®
VISIT BOEHRINGER INGELHEIM AT

BOOTH 1300 TO LEARN MORE
WWW.GIOTRIF.COM
GIOTRIF®: Irreversible ErbB family blocker. Active substance: Afatinib. Indications: GIOTRIF is indicated as monotherapy for (1) patients
with locally advanced or metastatic NSCLC with activating EGFR mutations not previously treated with EGFR TKIs, (2) patients with
NSCLC of squamous histology progressing on or after platinum-based chemotherapy. Posology: The recommended dose is 40 mg once
daily, orally. Not recommended in patients with an eGFR <15ml/min and severe hepatic impairment. Contraindications: Hypersensitivity
to afatinib or any of the excipients. Interactions: Potent P-gp inhibitors may lead to increased afatinib exposure, concomitant treatment
with potent P-gp inducers may lead to a reduction in afatinib exposure. Afatinib is not an inhibitor or inducer of CYP enzymes.
Undesirable effects: Paronychia, cystitis, decreased appetite, dehydration, hypokalaemia, dysgeusia, conjunctivitis, dry eye, epistaxis,
rhinorrhoea, diarrhoea, stomatitis, nausea, vomiting, cheilitis, dyspepsia, alanine aminotransferase increased, aspartate aminotransferase
increased, rash, acneiform dermatitis, pruritus, dry skin, palmar-plantar erythrodysaesthesia syndrome, nail disorders, Stevens-Johnson
syndrome, toxic epidermal necrolysis, muscle spasms, renal impairment/renal failure, pyrexia, weight decreased, interstitial lung disease,
keratitis, pancreatitis. Presentations: 20 mg, 30 mg, 40 mg, and 50 mg film-coated tablets. For detailed information, please refer to the
published Prescribing Information.
Supply classification: POM. EGFR M+=epidermal growth factor receptor mutation positive;
This medicine is subject to additional monitoring. NSCLC=non-small cell lung cancer; TKI=tyrosine kinase inhibitor.
Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
Copyright © 2017 Boehringer Ingelheim International GmbH.

All rights are reserved. Procedure ID: 5991 – August 2017.

WCLC 2017 Program PDF

Încărcat de

Informații document

Titlu original

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

WCLC 2017 Program PDF

Încărcat de

Drepturi de autor:

Formate disponibile

Onsite Program

IASLC 18TH WORLD CONFERENCEON LUNG CANCER

Immuno-Oncology (I-O) research is the investigation of

© 2017 Bristol-Myers Squibb Company. All rights reserved. 17A719

1 | WELCOME 2 | IASLC AND WCLC 3 | GENERAL

Regional Organizing CME Accreditation Information 28

4 | EXHIBIT 5 | IASLC AND 6 | CONFERENCE

WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 1

7 | DAILY SCIENTIFIC 8 | POSTER 9 | AUTHOR INDEX

International Conference Services Ltd. (ICS)

Suite 300, 1201 West Pender Street

Phone +1 604 681 2153

2 IASLC 18th World Conference on Lung Cancer / Onsite Program WWW.IASLC.ORG

WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 3

WELCOME MESSAGE FROM YOUR IASLC WCLC 2017 CO-PRESIDENTS

Industry Supported Symposia

Dr. Hisao Asamura, MD and Dr. Keunchil Park, MD, PhD

4 IASLC 18th World Conference on Lung Cancer / Onsite Program WWW.IASLC.ORG

WELCOME MESSAGE FROM THE MAYOR OF YOKOHAMA

WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 5

IASLC AND THE 18TH WORLD CONFERENCE ON LUNG CANCER

6 IASLC 18th World Conference on Lung Cancer / Onsite Program WWW.IASLC.ORG

ONSITE REGISTRATION SPEAKER PREVIEW CENTER MEDIA ROOM

PACIFICO CONFERENCE CENTER, PACIFICO CONFERENCE CENTER, PACIFICO CONFERENCE CENTER,

EXHIBIT HALL COAT AND BAGGAGE CHECK POSTER PICK UP

PACIFICO EXHIBITION HALL, PACIFICO CONFERENCE CENTER, PACIFICO EXHIBITION HALL,

PACIFICO ANNEX HALL, F201 + F202,

Monday, October 16 14:30 – 15:30

Light Refreshments will be provided.

WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 7

WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 9

13100 East Colfax Avenue, Unit 10

Pia Hirsch Karen Muth

10 IASLC 18th World Conference on Lung Cancer / Onsite Program WWW.IASLC.ORG

President David P. Carbone, USA

President Elect Giorgio Scagliotti, Italy

Past President Tony Mok, Hong Kong

Chief Executive Officer Fred R. Hirsch, USA

Treasurer David R. Gandara, USA

BOARD OF DIRECTORS IASLC FOUNDATION BOARD

Michael Boyer, Solange Peters, Marc Braunstein, Tony Mok,

Support the IASLC Foundation by attending

WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 11

THE TOK YO CIT Y PHILH A R MONIC ORCHESTR A

JOINT IASLC FOUNDATION

MONDAY, OCTOBER 16, 2017

Minatomirai Hall, Yokohama

Join us for a benefit concert in

Ticket Price: 50 USD

12 IASLC 18th World Conference on Lung Cancer / Onsite Program WWW.IASLC.ORG

REGIONAL ORGANIZING COMMITTEE

Shuji Sakai, Japan

Gabor Kovacs, Hungary Helmut Prosch, Austria

CHAIR EARLY STAGE NSCLC

Takashi Kohno, Japan CHAIR

WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 13

INTERNATIONAL PROGRAM COMMITTEE (CONTINUED)

LOCALLY ADVANCED NSCLC SCLC/NEUROENDOCRINE THYMIC MALIGNANCIES/ RADIOTHERAPY

14 IASLC 18th World Conference on Lung Cancer / Onsite Program WWW.IASLC.ORG

Miyako Satouchi, Japan

WWW.IASLC.ORG Onsite Program / IASLC 18th World Conference on Lung Cancer 15

16 IASLC 18th World Conference on Lung Cancer / Onsite Program WWW.IASLC.ORG

AGENDA | MAIN HALL, LEVEL 1F